"text","relation"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and <e1>hydroxyflutamide</e1>, to the mutated androgen receptor (m-<e2>AR</e2>) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Regulator"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, <e1>bicalutamide</e1>, and hydroxyflutamide, to the mutated <e2>androgen receptor</e2> (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Regulator"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and <e1>hydroxyflutamide</e1>, to the mutated <e2>androgen receptor</e2> (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Regulator"
"Androgen antagonistic effect of <e1>estramustine phosphate</e1> (EMP) metabolites on wild-type and mutated <e2>androgen receptor</e2>.","Regulator"
"Binding of <e1>hydroxyflutamide</e1> to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of <e2>PSA</e2> expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.","Upregulator"
"Down-regulation of <e2>prostate-specific antigen</e2> (PSA) expression, an AR-target gene, by <e1>estramustine</e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor.","Downregulator"
"Down-regulation of prostate-specific antigen (<e2>PSA</e2>) expression, an AR-target gene, by <e1>estramustine</e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor.","Downregulator"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of <e1>estramustine</e1> phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-<e2>AR</e2>) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Downregulator"
"Down-regulation of <e2>prostate-specific antigen</e2> (PSA) expression, an AR-target gene, by estramustine and <e1>bicalutamide</e1> was accompanied by the blockade of the mutated androgen receptor.","Downregulator"
"Down-regulation of prostate-specific antigen (<e2>PSA</e2>) expression, an AR-target gene, by estramustine and <e1>bicalutamide</e1> was accompanied by the blockade of the mutated androgen receptor.","Downregulator"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, <e1>bicalutamide</e1>, and hydroxyflutamide, to the mutated androgen receptor (m-<e2>AR</e2>) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Downregulator"
"Down-regulation of prostate-specific antigen (<e2>PSA</e2>) expression, an AR-target gene, by <e1>estramustine</e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor.","Downregulator"
"Androgen antagonistic effect of <e1>estramustine</e1> phosphate (EMP) metabolites on wild-type and mutated <e2>androgen receptor</e2>.","Downregulator"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, <e1>bicalutamide</e1>, and hydroxyflutamide, to the mutated <e2>androgen receptor</e2> (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Downregulator"
"Down-regulation of prostate-specific antigen (<e2>PSA</e2>) expression, an AR-target gene, by <e1>estramustine</e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor.","Downregulator"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and <e1>hydroxyflutamide</e1>, to the mutated androgen receptor (m-<e2>AR</e2>) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Agonist"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of <e1>estramustine phosphate</e1> and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-<e2>AR</e2>) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Antagonist"
"We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other anti<e1>androgen</e1> agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-<e2>AR</e2>) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.","Antagonist"
"<e1>Androgen</e1> antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated <e2>androgen receptor</e2>.","Antagonist"
"Androgen antagonistic effect of <e1>estramustine phosphate</e1> (EMP) metabolites on wild-type and mutated <e2>androgen receptor</e2>.","Antagonist"
"Androgen antagonistic effect of estramustine phosphate (<e1>EMP</e1>) metabolites on wild-type and mutated <e2>androgen receptor</e2>.","Antagonist"
"In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of <e2>Torpedo californica AChE</e2> soaked with the reversible inhibitor <e1>edrophonium</e1>, using a total X-ray exposure time of 24 ms. Electron-density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features.","Downregulator"
"The current study evaluates the effects of a selective <e2>COX-2</e2> inhibitor (<e1>SC-236</e1>) on renal function in cirrhotic rats with ascites.","Downregulator"
"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective <e2>COX-1</e2>/COX-2 inhibitor, <e1>ketorolac</e1>, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.","Downregulator"
"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/<e2>COX-2</e2> inhibitor, <e1>ketorolac</e1>, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.","Downregulator"
"Selective inhibition of <e2>cyclooxygenase 2</e2> spares renal function and <e1>prostaglandin</e1> synthesis in cirrhotic rats with ascites.","Substrate"
"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective <e2>COX-1</e2>/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of <e1>prostaglandins</e1>, and glomerular filtration rate and in a significant impairment in renal water metabolism.","Substrate"
"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/<e2>COX-2</e2> inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of <e1>prostaglandins</e1>, and glomerular filtration rate and in a significant impairment in renal water metabolism.","Substrate"
"By contrast, membrane expression of <e2>annexin-1</e2>, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M <e1>FP</e1>, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA).","Regulator"
"<e1>FMLP</e1>/CB-stimulated translocation of <e2>cPLA2</e2> to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP.","Regulator"
"FMLP/<e1>CB</e1>-stimulated translocation of <e2>cPLA2</e2> to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP.","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M <e1>FP</e1> in the presence of 10 pg/ml <e2>human recombinant interleukin-5</e2> (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M <e1>FP</e1> in the presence of 10 pg/ml human recombinant interleukin-5 (<e2>rhIL-5</e2>) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml <e2>human recombinant interleukin-5</e2> (rhIL-5) and activated with <e1>formyl-met-leu-phe</e1> (FMLP) + cytochalasin B (CB).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (<e2>rhIL-5</e2>) and activated with <e1>formyl-met-leu-phe</e1> (FMLP) + cytochalasin B (CB).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml <e2>human recombinant interleukin-5</e2> (rhIL-5) and activated with formyl-met-leu-phe (<e1>FMLP</e1>) + cytochalasin B (CB).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (<e2>rhIL-5</e2>) and activated with formyl-met-leu-phe (<e1>FMLP</e1>) + cytochalasin B (CB).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml <e2>human recombinant interleukin-5</e2> (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + <e1>cytochalasin B</e1> (CB).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (<e2>rhIL-5</e2>) and activated with formyl-met-leu-phe (FMLP) + <e1>cytochalasin B</e1> (CB).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml <e2>human recombinant interleukin-5</e2> (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (<e1>CB</e1>).","Regulator"
"Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (<e2>rhIL-5</e2>) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (<e1>CB</e1>).","Regulator"
"By contrast, membrane expression of <e2>annexin-1</e2>, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M <e1>FP</e1>, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA).","Upregulator"
"We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (<e1>FP</e1>), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (<e2>cPLA2</e2>), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro.","Downregulator"
"Inhibition of <e2>cPLA2</e2> translocation and leukotriene C4 secretion by <e1>fluticasone propionate</e1> in exogenously activated human eosinophils.","Downregulator"
"We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (<e1>FP</e1>), in causing (1) inhibition of nuclear translocation of cytosolic <e2>phospholipase A2</e2> (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro.","Downregulator"
"We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic <e2>phospholipase A2</e2> (cPLA2), and (2) blockade of leukotriene C4 (<e1>LTC4</e1>) synthesis in isolated human eosinophils in vitro.","Substrate"
"We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (c<e2>PLA2</e2>), and (2) blockade of leukotriene C4 (<e1>LTC4</e1>) synthesis in isolated human eosinophils in vitro.","Substrate"
"Desipramine treatment decreases <e1>3H-nisoxetine</e1> binding and <e2>norepinephrine transporter</e2> mRNA in SK-N-SHSY5Y cells.","Regulator"
"The antidepressant <e1>desipramine</e1> has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (<e2>NET</e2>) in vivo and in vitro, on both an acute and a chronic basis.","Downregulator"
"The antidepressant <e1>desipramine</e1> has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (<e2>NET</e2>) in vivo and in vitro, on both an acute and a chronic basis.","Downregulator"
"The antidepressant <e1>desipramine</e1> has been shown to decrease synaptic membrane concentrations of the <e2>norepinephrine re-uptake transporter</e2> (NET) in vivo and in vitro, on both an acute and a chronic basis.","Downregulator"
"<e1>Desipramine</e1> treatment decreases 3H-nisoxetine binding and <e2>norepinephrine transporter</e2> mRNA in SK-N-SHSY5Y cells.","Downregulator"
"Inhibition of the human ether-a-go-go-related gene (<e2>HERG</e2>) <e1>potassium</e1> channel by cisapride: affinity for open and inactivated states.","Regulator"
"Inhibition of the <e2>human ether-a-go-go-related gene (HERG) potassium channel</e2> by <e1>cisapride</e1>: affinity for open and inactivated states.","Downregulator"
"Inhibition of the human ether-a-go-go-related gene (<e2>HERG</e2>) potassium channel by <e1>cisapride</e1>: affinity for open and inactivated states.","Downregulator"
"Inhibition of the human ether-a-go-go-related gene (<e2>HERG</e2>) potassium channel by <e1>cisapride</e1>: affinity for open and inactivated states.","Downregulator"
"<e1>Ziprasidone</e1> is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to <e2>5-HT1D</e2>, 5-HT2, and D2 sites.","Regulator"
"<e1>Ziprasidone</e1> is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, <e2>5-HT2</e2>, and D2 sites.","Regulator"
"<e1>Ziprasidone</e1> is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and <e2>D2</e2> sites.","Regulator"
"<e1>Ziprasidone</e1> is a novel antipsychotic agent which binds with high affinity to <e2>5-HT1A receptors</e2> (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and D2 sites.","Regulator"
"Comparison of the novel antipsychotic <e1>ziprasidone</e1> with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A</e2> receptor activation.","Regulator"
"Comparison of the novel antipsychotic <e1>ziprasidone</e1> with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A</e2> receptor activation.","Regulator"
"Comparison of the novel antipsychotic ziprasidone with <e1>clozapine</e1> and olanzapine: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A</e2> receptor activation.","Regulator"
"Comparison of the novel antipsychotic ziprasidone with clozapine and <e1>olanzapine</e1>: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A</e2> receptor activation.","Regulator"
"Comparison of the novel antipsychotic <e1>ziprasidone</e1> with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A receptor</e2> activation.","Regulator"
"Comparison of the novel antipsychotic ziprasidone with <e1>clozapine</e1> and olanzapine: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A receptor</e2> activation.","Regulator"
"Comparison of the novel antipsychotic ziprasidone with clozapine and <e1>olanzapine</e1>: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A receptor</e2> activation.","Regulator"
"Comparison of the novel antipsychotic <e1>ziprasidone</e1> with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A</e2> receptor activation.","Agonist"
"Comparison of the novel antipsychotic <e1>ziprasidone</e1> with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A</e2> receptor activation.","Agonist"
"Comparison of the novel antipsychotic <e1>ziprasidone</e1> with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of <e2>5-HT1A</e2> receptor activation.","Agonist"
"Pretreatment with the <e2>5-HT1A</e2> antagonist <e1>WAY-100,635</e1> (10 micrograms/kg i.v.)","Antagonist"
"Pretreatment with the <e2>5-HT1A</e2> antagonist <e1>WAY-100,635</e1> (10 micrograms/kg i.v.)","Antagonist"
"The nonselective and irreversible <e2>MAO</e2> inhibitors, <e1>phenelzine</e1> (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.","Downregulator"
"The nonselective and irreversible <e2>MAO</e2> inhibitors, phenelzine (3-10 mg/kg), <e1>tranylcypromine</e1> (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.","Downregulator"
"The nonselective and irreversible <e2>MAO</e2> inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and <e1>nialamide</e1> (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.","Downregulator"
"The irreversible <e2>MAO-B</e2> inhibitors, <e1>pargyline</e1> (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.","Downregulator"
"The reversible <e2>MAO-A</e2> inhibitor, <e1>befloxatone</e1> (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration.","Downregulator"
"The reversible <e2>MAO-A</e2> inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, <e1>clorgyline</e1> (10-30 mg/kg), also reduced ethanol self-administration.","Downregulator"
"The irreversible <e2>MAO-B</e2> inhibitors, pargyline (30 mg/kg) and <e1>l-deprenyl</e1> (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.","Downregulator"
"<e1>Dicumarol</e1>, a potent inhibitor of <e2>quinone oxidoreductase</e2>, at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.","Downregulator"
"A novel missense mutation, <e2>G663A</e2>, in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) was identified in a Japanese male with <e1>pyridoxine</e1>-responsive sideroblastic anemia.","Regulator"
"A novel missense mutation, G663A, in exon 5 of the <e2>erythroid-specific delta-aminolevulinate synthase</e2> gene (ALAS2) was identified in a Japanese male with <e1>pyridoxine</e1>-responsive sideroblastic anemia.","Regulator"
"A novel missense mutation, G663A, in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene (<e2>ALAS2</e2>) was identified in a Japanese male with <e1>pyridoxine</e1>-responsive sideroblastic anemia.","Regulator"
"A novel missense mutation, G663A, in exon 5 of the erythroid-specific <e2>delta-aminolevulinate synthase</e2> gene (ALAS2) was identified in a Japanese male with <e1>pyridoxine</e1>-responsive sideroblastic anemia.","Regulator"
"A novel mutation of the <e2>erythroid-specific gamma-Aminolevulinate synthase</e2> gene in a patient with non-inherited <e1>pyridoxine</e1>-responsive sideroblastic anemia.","Regulator"
"Activity of the mutant <e2>delta-aminolevulinate synthase</e2> protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of <e1>pyridoxal 5'-phosphate</e1>, consistent with the clinical response of the patient to pyridoxine treatment.","Upregulator"
"Preferential cerebrospinal fluid <e2>acetylcholinesterase</e2> inhibition by <e1>rivastigmine</e1> in humans.","Downregulator"
"This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (<e2>AChE</e2>) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that <e1>rivastigmine</e1> (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.","Downregulator"
"CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for <e1>rivastigmine</e1> and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (<e2>BuChE</e2>) activity.","Downregulator"
"CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for <e1>rivastigmine</e1> and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (<e2>BuChE</e2>) activity.","Downregulator"
"This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (<e2>AChE</e2>) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that <e1>rivastigmine</e1> (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.","Downregulator"
"This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (<e2>AChE</e2>) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that <e1>rivastigmine</e1> (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.","Downregulator"
"This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (<e2>AChE</e2>) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that <e1>rivastigmine</e1> (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.","Downregulator"
"CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for <e1>rivastigmine</e1> and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (<e2>BuChE</e2>) activity.","Downregulator"
"<e1>Amino acids</e1> between Ile(183) and Val(191) are necessary for proper <e2>factor IX</e2> activation, but additional sequence between Ser(195) and Ile(197) or between Phe(260) and Ser(265) is required for complete restoration of activation.","Part_of"
"Identification of <e1>amino acids</e1> in the factor XI apple 3 domain required for activation of <e2>factor IX</e2>.","Part_of"
"To identify key amino acids involved in factor IX activation, recombinant <e2>factor XIa</e2> proteins containing <e1>alanine</e1> substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.","Part_of"
"Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the <e1>N</e1> terminus and for Ser(258)-Ser(264) at the C terminus of the <e2>A3 domain</e2> markedly decreased factor XI coagulant activity.","Part_of"
"Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the <e1>C</e1> terminus of the <e2>A3 domain</e2> markedly decreased factor XI coagulant activity.","Part_of"
"Identification of <e1>amino acids</e1> in the <e2>factor XI apple 3 domain</e2> required for activation of factor IX.","Part_of"
"Identification of <e1>amino acids</e1> in the factor XI apple 3 domain required for activation of <e2>factor IX</e2>.","Part_of"
"<e1>Yohimbine</e1> displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for <e2>h5-HT(1A)</e2>, h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors.","Regulator"
"<e1>Yohimbine</e1> displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), <e2>h5-HT(1B)</e2>, h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors.","Regulator"
"<e1>Yohimbine</e1> displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), <e2>h5-HT(1D)</e2>, and hD(2) receptors and weak affinity for hD(3) receptors.","Regulator"
"<e1>Yohimbine</e1> displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and <e2>hD(2) receptors</e2> and weak affinity for hD(3) receptors.","Regulator"
"<e1>Yohimbine</e1> displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for <e2>hD(3) receptors</e2>.","Regulator"
"In [<e1>(35)S</e1>]GTPgammaS binding protocols, yohimbine exerts antagonist actions at <e2>halpha(2A)-AR</e2>, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.","Regulator"
"In [<e1>(35)S</e1>]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, <e2>h5-HT(1B)</e2>, h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.","Regulator"
"In [<e1>(35)S</e1>]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), <e2>h5-HT(1D)</e2>, and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.","Regulator"
"In [<e1>(35)S</e1>]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and <e2>hD(2)</e2> sites, yet partial agonist actions at h5-HT(1A) sites.","Regulator"
"In [<e1>(35)S</e1>]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at <e2>h5-HT(1A)</e2> sites.","Regulator"
"Herein, we evaluate the interaction of the alpha(2)-AR antagonist, <e1>yohimbine</e1>, as compared to fluparoxan, at multiple <e2>monoaminergic receptors</e2> and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.","Regulator"
"Herein, we evaluate the interaction of the alpha(2)-AR antagonist, yohimbine, as compared to <e1>fluparoxan</e1>, at multiple <e2>monoaminergic receptors</e2> and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.","Regulator"
"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine</e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h<e2>5-HT(1A)</e2> sites.","Agonist"
"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine</e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at <e2>h5-HT(1A)</e2> sites.","Agonist"
"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine</e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h<e2>5-HT(1A)</e2> sites.","Agonist"
"In guinea pigs, antagonist actions of yohimbine at <e2>5-HT(1B)</e2> receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, <e1>GR46,611</e1>.","Agonist"
"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine</e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at <e2>h5-HT(1A)</e2> sites.","Agonist"
"In distinction to yohimbine, <e1>fluparoxan</e1> shows only modest partial agonist actions at <e2>h5-HT(1A)</e2> sites versus marked antagonist actions at halpha(2)-ARs.","Agonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors <e2>(AR)s</e2>, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Agonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin <e2>(5-HT)(1A)</e2>, 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Agonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <e2>5-HT(1B)</e2>, 5-HT(1D) and dopamine D(2) and D(3) receptors.","Agonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), <e2>5-HT(1D)</e2> and dopamine D(2) and D(3) receptors.","Agonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at <e2>alpha(2)-adrenergic receptors</e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Agonist"
"Agonist and antagonist actions of yohimbine as compared to <e1>fluparoxan</e1> at alpha(2)-adrenergic receptors <e2>(AR)s</e2>, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Agonist"
"Agonist and antagonist actions of yohimbine as compared to <e1>fluparoxan</e1> at <e2>alpha(2)-adrenergic receptors</e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Agonist"
"Herein, we evaluate the interaction of the <e2>alpha(2)-AR</e2> antagonist, <e1>yohimbine</e1>, as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.","Antagonist"
"Herein, we evaluate the interaction of the <e2>alpha(2)-AR</e2> antagonist, yohimbine, as compared to <e1>fluparoxan</e1>, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.","Antagonist"
"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine</e1> exerts antagonist actions at <e2>halpha(2A)-AR</e2>, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.","Antagonist"
"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine</e1> exerts antagonist actions at halpha(2A)-AR, <e2>h5-HT(1B)</e2>, h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.","Antagonist"
"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine</e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), <e2>h5-HT(1D)</e2>, and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.","Antagonist"
"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine</e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and <e2>hD(2)</e2> sites, yet partial agonist actions at h5-HT(1A) sites.","Antagonist"
"Herein, we evaluate the interaction of the <e2>alpha(2)-AR antagonist</e2>, <e1>yohimbine</e1>, as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.","Antagonist"
"In vivo, agonist actions of yohimbine at <e2>5-HT(1A)</e2> sites are revealed by <e1>WAY100,635</e1>-reversible induction of hypothermia in the rat.","Antagonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <e2>5-HT(1B)</e2>, 5-HT(1D) and dopamine D(2) and D(3) receptors.","Antagonist"
"Herein, we evaluate the interaction of the <e2>alpha(2)-AR antagonist</e2>, yohimbine, as compared to <e1>fluparoxan</e1>, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.","Antagonist"
"In distinction to <e1>yohimbine</e1>, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at <e2>halpha(2)-ARs</e2>.","Antagonist"
"In distinction to yohimbine, <e1>fluparoxan</e1> shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at <e2>halpha(2)-ARs</e2>.","Antagonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors <e2>(AR)s</e2>, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Antagonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin <e2>(5-HT)(1A)</e2>, 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Antagonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <e2>5-HT(1B)</e2>, 5-HT(1D) and dopamine D(2) and D(3) receptors.","Antagonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), <e2>5-HT(1D)</e2> and dopamine D(2) and D(3) receptors.","Antagonist"
"Agonist and antagonist actions of <e1>yohimbine</e1> as compared to fluparoxan at <e2>alpha(2)-adrenergic receptors</e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Antagonist"
"Agonist and antagonist actions of yohimbine as compared to <e1>fluparoxan</e1> at alpha(2)-adrenergic receptors <e2>(AR)s</e2>, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Antagonist"
"Agonist and antagonist actions of yohimbine as compared to <e1>fluparoxan</e1> at <e2>alpha(2)-adrenergic receptors</e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.","Antagonist"
"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and <e2>kappa-opioid receptor</e2> (<e1>BRL 52974</e1>) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.","Agonist"
"Parenteral administration of selective agonists of the delta-<e2>opioid receptor</e2> (SB 227122), mu-opioid receptor (<e1>codeine</e1> and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.","Agonist"
"Parenteral administration of selective agonists of the delta-<e2>opioid receptor</e2> (SB 227122), mu-opioid receptor (<e1>codeine</e1> and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.","Agonist"
"In this study, the activity of the delta-<e2>opioid receptor</e2> subtype-selective agonist, <e1>SB 227122</e1>, was investigated in a guinea pig model of citric acid-induced cough.","Agonist"
"In this study, the activity of the delta-<e2>opioid receptor</e2> subtype-selective agonist, <e1>SB 227122</e1>, was investigated in a guinea pig model of citric acid-induced cough.","Agonist"
"In this study, the activity of the <e2>delta-opioid receptor</e2> subtype-selective agonist, <e1>SB 227122</e1>, was investigated in a guinea pig model of citric acid-induced cough.","Agonist"
"In this study, the activity of the <e2>delta-opioid receptor</e2> subtype-selective agonist, <e1>SB 227122</e1>, was investigated in a guinea pig model of citric acid-induced cough.","Agonist"
"In this study, the activity of the <e2>delta-opioid receptor</e2> subtype-selective agonist, <e1>SB 227122</e1>, was investigated in a guinea pig model of citric acid-induced cough.","Agonist"
"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), <e2>mu-opioid receptor</e2> (<e1>codeine</e1> and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.","Agonist"
"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), <e2>mu-opioid receptor</e2> (codeine and <e1>hydrocodone</e1>), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.","Agonist"
"The nonselective <e2>opioid receptor</e2> antagonist, <e1>naloxone</e1> (3 mg/kg, i.m.","Antagonist"
"The <e2>delta-receptor</e2> antagonist, <e1>SB 244525</e1> (10 mg/kg, i.p.","Antagonist"
"In contrast, combined pretreatment with <e1>beta-funaltrexamine</e1> (<e2>mu-receptor</e2> antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).","Antagonist"
"In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and <e1>norbinaltorphimine</e1> (<e2>kappa-receptor</e2> antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).","Antagonist"
"The <e2>sigma-receptor</e2> antagonist <e1>rimcazole</e1> (3 mg/kg, i.p.)","Antagonist"
"New modes of therapy have recently been introduced, and data on the <e2>cyclooxygenase-2</e2> (COX-2)-specific inhibitors <e1>celecoxib</e1> and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","Downregulator"
"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (<e2>COX-2</e2>)-specific inhibitors <e1>celecoxib</e1> and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","Downregulator"
"New modes of therapy have recently been introduced, and data on the <e2>cyclooxygenase-2</e2> (COX-2)-specific inhibitors celecoxib and <e1>rofecoxib</e1> suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","Downregulator"
"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (<e2>COX-2</e2>)-specific inhibitors celecoxib and <e1>rofecoxib</e1> suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","Downregulator"
"<e1>Dichloroally]-lawsone</e1> was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for <e2>mammalian dihydroorotate dehydrogenases</e2>.","Downregulator"
"Another inhibitor, <e1>brequinar</e1> was previously reported to be a slow-binding inhibitor of the <e2>human dihydroorotate dehydrogenase</e2> [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.","Downregulator"
"Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of <e2>human and rat dihyroorotate dehydrogenase</e2> by immunosuppressive <e1>isoxazol</e1> and cinchoninic acid derivatives, Biochem.","Downregulator"
"Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of <e2>human and rat dihyroorotate dehydrogenase</e2> by immunosuppressive isoxazol and <e1>cinchoninic acid</e1> derivatives, Biochem.","Downregulator"
"With respect to the quinone co-substrate of the <e1>dihydroorotate</e1> dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of <e2>human dihydroorotate dehydrogenase</e2>.","Downregulator"
"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, <e1>atovaquone</e1> (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of <e2>human dihydroorotate dehydrogenase</e2>.","Downregulator"
"Kinetics of inhibition of <e2>human and rat dihydroorotate dehydrogenase</e2> by atovaquone, lawsone derivatives, <e1>brequinar sodium</e1> and polyporic acid.","Downregulator"
"Kinetics of inhibition of <e2>human and rat dihydroorotate dehydrogenase</e2> by atovaquone, lawsone derivatives, brequinar sodium and <e1>polyporic acid</e1>.","Downregulator"
"Kinetics of inhibition of <e2>human and rat dihydroorotate dehydrogenase</e2> by <e1>atovaquone</e1>, lawsone derivatives, brequinar sodium and polyporic acid.","Downregulator"
"Kinetics of inhibition of <e2>human and rat dihydroorotate dehydrogenase</e2> by atovaquone, <e1>lawsone</e1> derivatives, brequinar sodium and polyporic acid.","Downregulator"
"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, <e1>atovaquone</e1> (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of <e2>human dihydroorotate dehydrogenase</e2>.","Downregulator"
"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and <e1>dichloroally-lawsone</e1> (Kic = 9.8 nM) were shown to be competitive inhibitors of <e2>human dihydroorotate dehydrogenase</e2>.","Downregulator"
"Mitochondrially-bound <e2>dihydroorotate dehydrogenase</e2> (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of <e1>uridine monophosphate</e1>.","Substrate"
"Mitochondrially-bound dihydroorotate dehydrogenase (<e2>EC 1.3.99.11</e2>) catalyzes the fourth sequential step in the de novo synthesis of <e1>uridine monophosphate</e1>.","Substrate"
"With respect to the <e1>quinone</e1> co-substrate of the <e2>dihydroorotate dehydrogenase</e2>, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.","Substrate"
"METHODS AND RESULTS: The effect of intravenous <e1>ajmaline</e1> (1 mg/kg), procainamide (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a <e2>SCN5A</e2> mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).","Regulator"
"METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), <e1>procainamide</e1> (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a <e2>SCN5A</e2> mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).","Regulator"
"METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), procainamide (10 mg/kg), or <e1>flecainide</e1> (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a <e2>SCN5A</e2> mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).","Regulator"
"<e1>Mibefradil</e1> (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type <e2>Ca2+ channel</e2>s.","Regulator"
"Determinants of voltage-dependent inactivation affect <e1>Mibefradil</e1> block of <e2>calcium channel</e2>s.","Regulator"
"<e1>Mibefradil</e1> blocked alpha1A and alpha1E with a Kd comparable to that reported for <e2>T-type channels</e2>, but had a lower affinity (approximately 30-fold) for alpha1C.","Downregulator"
"<e1>Mibefradil</e1> (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block <e2>T-type Ca2+ channels</e2>.","Downregulator"
"Determinants of voltage-dependent inactivation affect <e1>Mibefradil</e1> block of <e2>calcium channels</e2>.","Downregulator"
"Mibefradil (<e1>Ro 40-5967</e1>) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block <e2>T-type Ca2+ channels</e2>.","Downregulator"
"Postoperative concentrations of <e2>plasminogen</e2> were decreased significantly in the <e1>tranexamic acid</e1> group (P < 0.001).","Downregulator"
"Iontophoresis of <e1>+/- propranolol</e1>, whose serotonergic actions include antagonism and partial agonism at <e2>5-HT1</e2> receptors, also increased serotonin and decreased firing (n=4).","Agonist"
"<e1>Methiothepin</e1> (intravenous, 1 mg/kg), whose serotonergic actions include <e2>5-HT1</e2> and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).","Antagonist"
"<e1>Methiothepin</e1> (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and <e2>5-HT2</e2> antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).","Antagonist"
"Iontophoresis of <e1>+/- propranolol</e1>, whose serotonergic actions include antagonism and partial agonism at <e2>5-HT1</e2> receptors, also increased serotonin and decreased firing (n=4).","Antagonist"
"Treatment with <e1>geldanamycin</e1>, however, does not affect the activation of <e2>lysophosphatide acyltransferase</e2>, which is a plasma membrane enzyme coupled to the T-cell receptor after T-cell stimulation.","Not"
"In this study, we demonstrate that <e1>geldanamycin</e1> treatment blocks <e2>interleukin (IL)-2</e2> secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes.","Downregulator"
"In this study, we demonstrate that <e1>geldanamycin</e1> treatment blocks interleukin (IL)-2 secretion, <e2>IL-2 receptor</e2> expression, and proliferation of stimulated T-lymphocytes.","Downregulator"
"Moreover, <e1>geldanamycin</e1> decreases the amount and phosphorylation of <e2>Lck</e2> and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.","Downregulator"
"Moreover, <e1>geldanamycin</e1> decreases the amount and phosphorylation of Lck and <e2>Raf-1</e2> kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.","Downregulator"
"Moreover, <e1>geldanamycin</e1> decreases the amount and phosphorylation of Lck and Raf-1 <e2>kinases</e2> and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.","Downregulator"
"The Hsp90-specific inhibitor <e1>geldanamycin</e1> selectively disrupts <e2>kinase</e2>-mediated signaling events of T-lymphocyte activation.","Downregulator"
"Improper function of these proteins can be induced by selective disruption of their complexes with <e2>Hsp90</e2> using the <e1>benzoquinonoid ansamycin</e1> geldanamycin.","Downregulator"
"The <e2>Hsp90</e2>-specific inhibitor <e1>geldanamycin</e1> selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.","Downregulator"
"Moreover, <e1>geldanamycin</e1> decreases the amount and phosphorylation of <e2>Lck</e2> and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.","Downregulator"
"Moreover, <e1>geldanamycin</e1> decreases the amount and phosphorylation of Lck and <e2>Raf-1</e2> kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.","Downregulator"
"Moreover, <e1>geldanamycin</e1> decreases the amount and phosphorylation of Lck and Raf-1 <e2>kinases</e2> and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.","Downregulator"
"Moreover, <e1>geldanamycin</e1> decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the <e2>extracellular signal regulated kinase (ERK)-2</e2> kinase.","Downregulator"
"The Hsp90-specific inhibitor <e1>geldanamycin</e1> selectively disrupts <e2>kinase</e2>-mediated signaling events of T-lymphocyte activation.","Downregulator"
"<e1>Geldanamycin</e1> also disrupts the <e2>T-cell receptor</e2>-mediated activation of nuclear factor of activated T-cells (NF-AT).","Downregulator"
"<e1>Geldanamycin</e1> also disrupts the T-cell receptor-mediated activation of <e2>nuclear factor of activated T-cells</e2> (NF-AT).","Downregulator"
"<e1>Geldanamycin</e1> also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (<e2>NF-AT</e2>).","Downregulator"
"The <e2>Hsp90</e2>-specific inhibitor <e1>geldanamycin</e1> selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.","Downregulator"
"The Hsp90-specific inhibitor <e1>geldanamycin</e1> selectively disrupts <e2>kinase</e2>-mediated signaling events of T-lymphocyte activation.","Downregulator"
"<e2>gamma-Butyrobetaine hydroxylase</e2> catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on <e1>Fe2+</e1>, alpha-ketoglutarate, ascorbate and oxygen.","Regulator"
"<e2>gamma-Butyrobetaine hydroxylase</e2> catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, <e1>alpha-ketoglutarate</e1>, ascorbate and oxygen.","Regulator"
"<e2>gamma-Butyrobetaine hydroxylase</e2> catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, <e1>ascorbate</e1> and oxygen.","Regulator"
"<e2>gamma-Butyrobetaine hydroxylase</e2> catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and <e1>oxygen</e1>.","Regulator"
"<e2>gamma-Butyrobetaine hydroxylase</e2> catalyse the last step in <e1>carnitine</e1> biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.","Substrate"
"<e2>gamma-Butyrobetaine hydroxylase</e2> catalyse the last step in carnitine biosynthesis, the formation of <e1>L-carnitine</e1> from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.","Substrate"
"<e2>gamma-Butyrobetaine hydroxylase</e2> catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from <e1>gamma-butyrobetaine</e1>, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.","Substrate"
"<e1>Salicylates</e1> inhibit (125)I-<e2>ET-1</e2> binding to recombinant rat ETA receptors.","Not"
"<e1>Salicylates</e1> do not promote dissociation of (125)I-ET-1 <e2>ETB receptor</e2> complexes.","Not"
"<e1>Salicylic acid</e1> promotes dissociation of (125)I-<e2>ET-1</e2> ETA receptor complexes both in the absence and the presence of unlabeled ET-1.","Regulator"
"<e1>Salicylic acid</e1> promotes dissociation of (125)I-ET-1 <e2>ETA receptor</e2> complexes both in the absence and the presence of unlabeled ET-1.","Regulator"
"Salicylates inhibit <e1>(125)I</e1>-<e2>ET-1</e2> binding to recombinant rat ETA receptors.","Regulator"
"Salicylates inhibit <e1>(125)I</e1>-ET-1 binding to recombinant rat <e2>ETA receptor</e2>s.","Regulator"
"Salicylates inhibit <e1>(125)I</e1>-<e2>ET-1</e2> binding to recombinant rat ETA receptors.","Regulator"
"Salicylates inhibit <e1>(125)I</e1>-ET-1 binding to recombinant rat <e2>ETA receptors</e2>.","Regulator"
"Salicylates inhibit <e1>(125)I</e1>-<e2>ET-1</e2> binding to recombinant rat ETA receptors.","Regulator"
"Salicylates do not promote dissociation of <e1>(125)I</e1>-ET-1 <e2>ETB receptor</e2> complexes.","Regulator"
"<e1>Salicylates</e1> inhibit (125)I-<e2>ET-1</e2> binding to recombinant rat ETA receptors.","Regulator"
"<e1>Salicylates</e1> inhibit (125)I-ET-1 binding to recombinant <e2>rat ETA receptors</e2>.","Regulator"
"Salicylates inhibit <e1>(125)I</e1>-<e2>ET-1</e2> binding to recombinant rat ETA receptors.","Regulator"
"This study shows that <e1>aspirin</e1> and sodium salicylate, its major blood metabolite, reverse contractile actions of <e2>endothelin-1</e2> (ET-1) in isolated rat aorta and human mammary arteries.","Regulator"
"This study shows that <e1>aspirin</e1> and sodium salicylate, its major blood metabolite, reverse contractile actions of endothelin-1 (<e2>ET-1</e2>) in isolated rat aorta and human mammary arteries.","Regulator"
"This study shows that aspirin and <e1>sodium salicylate</e1>, its major blood metabolite, reverse contractile actions of <e2>endothelin-1</e2> (ET-1) in isolated rat aorta and human mammary arteries.","Regulator"
"This study shows that aspirin and <e1>sodium salicylate</e1>, its major blood metabolite, reverse contractile actions of endothelin-1 (<e2>ET-1</e2>) in isolated rat aorta and human mammary arteries.","Regulator"
"<e1>Salicylic acid</e1> promotes dissociation of (125)I-<e2>ET-1</e2> ETA receptor complexes both in the absence and the presence of unlabeled ET-1.","Regulator"
"Salicylates inhibit <e1>(125)I</e1>-<e2>ET-1</e2> binding to recombinant rat ETA receptors.","Regulator"
"Inhibition of the actions of <e2>ET-1</e2> by <e1>salicylates</e1> is apparently competitive.","Regulator"
"Inhibition of the actions of <e2>ET-1</e2> by <e1>salicylates</e1> is apparently competitive.","Downregulator"
"<e1>Aspirin</e1> and sodium salicylate inhibit endothelin <e2>ETA receptors</e2> by an allosteric type of mechanism.","Modulator"
"Aspirin and <e1>sodium salicylate</e1> inhibit endothelin <e2>ETA receptors</e2> by an allosteric type of mechanism.","Modulator"
"It is concluded that <e1>salicylates</e1> are allosteric inhibitors of <e2>ETA receptors</e2>.","Modulator"
"A unique cytosolic activity related but distinct from <e2>NQO1</e2> catalyses metabolic activation of mitomycin C.
Mitomycin C (<e1>MMC</e1>) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer.","Regulator"
"Among the various enzymes, <e1>dicoumarol</e1> inhibitable cytosolic <e2>NAD(P)H:quinone oxidoreductase1</e2> (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.","Downregulator"
"Among the various enzymes, <e1>dicoumarol</e1> inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (<e2>NQO1</e2>) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.","Downregulator"
"Among the various enzymes, <e1>dicoumarol</e1> inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (<e2>NQO1</e2>) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.","Downregulator"
"Among the various enzymes, dicoumarol inhibitable cytosolic <e2>NAD(P)H:quinone oxidoreductase1</e2> (NQO1) was shown to catalyse bioreductive activation of <e1>MMC</e1> leading to cross-linking of the DNA and cytotoxicity.","Substrate"
"A unique cytosolic activity related but distinct from <e2>NQO1</e2> catalyses metabolic activation of mitomycin C.
Mitomycin C (<e1>MMC</e1>) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer.","Substrate"
"A unique cytosolic activity related but distinct from <e2>NQO1</e2> catalyses metabolic activation of mitomycin C.
Mitomycin C (<e1>MMC</e1>) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer.","Substrate"
"A unique cytosolic activity related but distinct from <e2>NQO1</e2> catalyses metabolic activation of mitomycin C.
Mitomycin C (<e1>MMC</e1>) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer.","Substrate"
"A unique cytosolic activity related but distinct from <e2>NQO1</e2> catalyses metabolic activation of <e1>mitomycin C</e1>.
Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer.","Substrate"
"In this study, we investigated the effect of <e1>troglitazone</e1>, a ligand of the <e2>nuclear receptor</e2> peroxisome proliferator activated receptor-gamma, on PAI-1 expression and secretion in human adipocytes.","Regulator"
"In this study, we investigated the effect of <e1>troglitazone</e1>, a ligand of the nuclear receptor <e2>peroxisome proliferator activated receptor-gamma</e2>, on PAI-1 expression and secretion in human adipocytes.","Regulator"
"In this study, we investigated the effect of <e1>troglitazone</e1>, a ligand of the nuclear receptor peroxisome proliferator activated receptor-gamma, on <e2>PAI-1</e2> expression and secretion in human adipocytes.","Downregulator"
"In this study, we investigated the effect of <e1>troglitazone</e1>, a ligand of the nuclear receptor peroxisome proliferator activated receptor-gamma, on <e2>PAI-1</e2> expression and secretion in human adipocytes.","Downregulator"
"In this study, we investigated the effect of <e1>troglitazone</e1>, a ligand of the nuclear receptor peroxisome proliferator activated receptor-gamma, on <e2>PAI-1</e2> expression and secretion in human adipocytes.","Downregulator"
"In this study, we investigated the effect of <e1>troglitazone</e1>, a ligand of the nuclear receptor peroxisome proliferator activated receptor-gamma, on <e2>PAI-1</e2> expression and secretion in human adipocytes.","Downregulator"
"In this study, we investigated the effect of <e1>troglitazone</e1>, a ligand of the nuclear receptor peroxisome proliferator activated receptor-gamma, on <e2>PAI-1</e2> expression and secretion in human adipocytes.","Downregulator"
"<e1>Troglitazone</e1> reduces <e2>plasminogen activator inhibitor-1</e2> expression and secretion in cultured human adipocytes.","Downregulator"
"Effect of <e1>JTH-601</e1>, a novel <e2>alpha(1)-adrenoceptor</e2> antagonist, on prostate function in dogs.","Antagonist"
"In these tissues, JTH-601, <e1>prazosin</e1> (a non-selective <e2>alpha(1)-adrenoceptor</e2> antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.","Antagonist"
"In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and <e1>tamsulosin</e1> (an <e2>alpha(1A)-adrenoceptor</e2> antagonist) competitively antagonized contraction in a concentration-dependent manner.","Antagonist"
"We examined the effect of JTH-601 (3- inverted question mark<e1>N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom</e1> ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <e2>alpha(1L)-adrenoceptor</e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.","Antagonist"
"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-m<e1>ethyl</e1>phenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <e2>alpha(1L)-adrenoceptor</e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.","Antagonist"
"Effect of <e1>JTH-601</e1>, a novel <e2>alpha(1)-adrenoceptor</e2> antagonist, on prostate function in dogs.","Antagonist"
"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-<e1>4-methoxy-2,5,6-trimethylphenol hemifumarate</e1>), a new <e2>alpha(1L)-adrenoceptor</e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.","Antagonist"
"We examined the effect of <e1>JTH-601</e1> (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <e2>alpha(1L)-adrenoceptor</e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.","Antagonist"
"Consistent with defective <e1>Cl(-)</e1> uptake, a loss of bumetanide-sensitive Cl(-) influx was observed in parotid acinar cells from mice lacking <e2>NKCC1</e2>.","Substrate"
"The salivary fluid secretory mechanism is thought to require Na(+)/K(+)/2<e1>Cl(-)</e1> cotransporter-mediated Cl(-) uptake.","Substrate"
"UNLABELLED: Apparent <e2>muscarinic acetylcholine (mAch) receptor</e2> occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (<e1>3H-NMPB</e1>) and 3H-quinuclidinyl benzilate (3H-QNB).","Regulator"
"UNLABELLED: Apparent <e2>muscarinic acetylcholine (mAch) receptor</e2> occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and <e1>3H-quinuclidinyl benzilate</e1> (3H-QNB).","Regulator"
"UNLABELLED: Apparent <e2>muscarinic acetylcholine (mAch) receptor</e2> occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (<e1>3H-QNB</e1>).","Regulator"
"Both radioligands labeled <e2>mAch receptors</e2> in these brain regions, and the relative regional distributions of the specific binding of <e1>3H-NMPB</e1> in vivo paralleled the distribution of mAch receptors.","Regulator"
"Both radioligands labeled <e2>mAch receptors</e2> in these brain regions, and the relative regional distributions of the specific binding of <e1>3H-NMPB</e1> in vivo paralleled the distribution of mAch receptors.","Regulator"
"Both radioligands labeled <e2>mAch receptor</e2>s in these brain regions, and the relative regional distributions of the specific binding of <e1>3H-NMPB</e1> in vivo paralleled the distribution of mAch receptors.","Regulator"
"A similar discrepancy in sensitivity to competitors between 3H-NMPB and <e1>3H-QNB</e1> was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the <e2>mAch receptor</e2> could not account for the observed differences in sensitivity to competition.","Regulator"
"A similar discrepancy in sensitivity to competitors between 3H-NMPB and 3H-QNB was also observed when <e1>biperiden</e1> was used as a competitor, indicating that binding to different subtypes of the <e2>mAch receptor</e2> could not account for the observed differences in sensitivity to competition.","Regulator"
"Both radioligands labeled <e2>mAch receptor</e2>s in these brain regions, and the relative regional distributions of the specific binding of <e1>3H-NMPB</e1> in vivo paralleled the distribution of mAch receptors.","Regulator"
"UNLABELLED: Apparent <e2>muscarinic acetylcholine (mAch) receptor</e2> occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: <e1>3H-N-methyl piperidyl benzilate</e1> (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).","Regulator"
"UNLABELLED: Apparent <e2>muscarinic acetylcholine (mAch) receptor</e2> occupancy in mouse cerebral cortex, hippocampus, and striatum by <e1>scopolamine</e1>, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).","Antagonist"
"UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and <e1>biperiden</e1>, a relatively selective <e2>M1</e2> antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).","Antagonist"
"Treatment of lactating mice with a single injection of <e1>bezafibrate</e1>, an activator of the peroxisome proliferator-activated receptor (PPAR), raises <e2>UCP-3</e2> mRNA in skeletal muscle to levels similar to those in virgin mice.","Not"
"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (<e1>WY-14,643</e1>), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>UCP-3</e2> mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","Not"
"<e1>4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid</e1> (WY-14,643), a specific ligand of the <e2>PPAR-alpha</e2> subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","Regulator"
"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (<e1>WY-14,643</e1>), a specific ligand of the <e2>PPAR-alpha</e2> subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","Regulator"
"Changes in <e2>UCP-3</e2> mRNA occur in parallel with modifications in the levels of free <e1>fatty acids</e1>, which are reduced in lactation and are upregulated due to weaning or fasting.","Regulator"
"Changes in <e2>UCP-3</e2> mRNA occur in parallel with modifications in the levels of free <e1>fatty acid</e1>s, which are reduced in lactation and are upregulated due to weaning or fasting.","Regulator"
"Changes in <e2>UCP-3</e2> mRNA occur in parallel with modifications in the levels of free <e1>fatty acid</e1>s, which are reduced in lactation and are upregulated due to weaning or fasting.","Regulator"
"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>UCP-3</e2> mRNA, whereas <e1>troglitazone</e1>, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","Regulator"
"Changes in <e2>UCP-3</e2> mRNA occur in parallel with modifications in the levels of free <e1>fatty acids</e1>, which are reduced in lactation and are upregulated due to weaning or fasting.","Regulator"
"Changes in <e2>UCP-3</e2> mRNA occur in parallel with modifications in the levels of free <e1>fatty acids</e1>, which are reduced in lactation and are upregulated due to weaning or fasting.","Regulator"
"Changes in <e2>UCP-3</e2> mRNA occur in parallel with modifications in the levels of free <e1>fatty acids</e1>, which are reduced in lactation and are upregulated due to weaning or fasting.","Regulator"
"Treatment of lactating mice with a single injection of <e1>bezafibrate</e1>, an activator of the <e2>peroxisome proliferator-activated receptor</e2> (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.","Upregulator"
"Treatment of lactating mice with a single injection of <e1>bezafibrate</e1>, an activator of the peroxisome proliferator-activated receptor (<e2>PPAR</e2>), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.","Upregulator"
"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas <e1>troglitazone</e1>, a specific activator of <e2>PPAR-gamma</e2>, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","Upregulator"
"It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free <e1>fatty acids</e1> by mechanisms involving activation of <e2>PPARs</e2>.","Upregulator"
"Impaired expression of the <e2>uncoupling protein-3</e2> gene in skeletal muscle during lactation: fibrates and <e1>troglitazone</e1> reverse lactation-induced downregulation of the uncoupling protein-3 gene.","Upregulator"
"Treatment of lactating mice with a single injection of <e1>bezafibrate</e1>, an activator of the peroxisome proliferator-activated receptor (PPAR), raises <e2>UCP-3</e2> mRNA in skeletal muscle to levels similar to those in virgin mice.","Upregulator"
"<e1>4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid</e1> (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>UCP-3</e2> mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","Upregulator"
"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (<e1>WY-14,643</e1>), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>UCP-3</e2> mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","Upregulator"
"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>UCP-3</e2> mRNA, whereas <e1>troglitazone</e1>, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.","Upregulator"
"<e1>Retigabine</e1>, a novel anti-convulsant, enhances activation of KCNQ2/Q3 <e2>potassium channels</e2>.","Upregulator"
"Serotonin transporter gene regulatory region polymorphism (<e2>5-HTTLPR</e2>), <e1>[3H]paroxetine</e1> binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.","Regulator"
"Serotonin transporter gene regulatory region polymorphism (<e2>5-HTTLPR</e2>), <e1>[3H]paroxetine</e1> binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.","Regulator"
"Serotonin transporter gene regulatory region polymorphism (<e2>5-HTTLPR</e2>), <e1>[3H]paroxetine</e1> binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.","Regulator"
"<e2>Serotonin transporter</e2> gene regulatory region polymorphism (5-HTTLPR), <e1>[3H]paroxetine</e1> binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.","Regulator"
"Serotonin transporter gene regulatory region polymorphism (<e2>5-HTTLPR</e2>), <e1>[3H]paroxetine</e1> binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.","Regulator"
"By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of <e1>arachidonic acid</e1> and nonsteroidal anti-inflammatory drugs induces conformational changes in the <e2>human prostaglandin endoperoxide H(2) synthase enzyme</e2> (PGHS-2).","Regulator"
"By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of <e1>arachidonic acid</e1> and nonsteroidal anti-inflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H(2) synthase enzyme (<e2>PGHS-2</e2>).","Regulator"
"By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and non<e1>steroidal</e1> anti-inflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H(2) synthase enzyme (<e2>PGHS</e2>-2).","Regulator"
"The finding that <e1>arachidonate</e1> can also induce a conformational change in <e2>PGHS-2</e2> was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the cyclooxygenase catalytic mechanism.","Regulator"
"The finding that <e1>arachidonate</e1> can also induce a conformational change in PGHS-2 was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the <e2>cyclooxygenase</e2> catalytic mechanism.","Regulator"
"Line shape broadening resulting from spin-spin coupling of <e1>nitroxide</e1> pairs introduced into the membrane-binding helices of <e2>PGHS-2</e2> was used to calculate the inter-helical distances and changes in these distances that occur in response to binding various ligands.","Regulator"
"By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of <e1>arachidonic acid</e1> and nonsteroidal anti-inflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H(2) synthase enzyme (<e2>PGHS-2</e2>).","Regulator"
"However, inter-helical distances calculated and determined by EPR for <e2>PGHS-2</e2> complexed with arachidonic acid, <e1>flurbiprofen</e1>, and SC-58125 were in close agreement with those obtained from the cognate crystal structures.","Regulator"
"However, inter-helical distances calculated and determined by EPR for <e2>PGHS-2</e2> complexed with arachidonic acid, flurbiprofen, and <e1>SC-58125</e1> were in close agreement with those obtained from the cognate crystal structures.","Regulator"
"<e1>Arachidonic acid</e1> and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (<e2>cyclooxygenase-2</e2>).","Regulator"
"<e1>Arachidonic acid</e1> and nonsteroidal anti-inflammatory drugs induce conformational changes in the <e2>human prostaglandin endoperoxide H2 synthase-2</e2> (cyclooxygenase-2).","Regulator"
"Activation of extracellular signal-related kinase (ERK) 1 and 2, <e2>c-Jun-N-terminal kinase (JNK) 1</e2>, and p38 was unaffected by <e1>sulfasalazine</e1>.","Not"
"Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun-N-terminal kinase (JNK) 1, and <e2>p38</e2> was unaffected by <e1>sulfasalazine</e1>.","Not"
"Various drugs used in the treatment of IBD, such as glucocorticoids, <e1>5-aminosalicylic acid</e1>, and sulfasalazine, interfere with <e2>NF-kappaB</e2>/Rel signaling.","Regulator"
"Various drugs used in the treatment of IBD, such as glucocorticoids, <e1>5-aminosalicylic acid</e1>, and sulfasalazine, interfere with NF-kappaB/<e2>Rel</e2> signaling.","Regulator"
"Suppression of <e2>NF-kappaB</e2> activity by <e1>sulfasalazine</e1> is mediated by direct inhibition of IkappaB kinases alpha and beta.","Regulator"
"Various drugs used in the treatment of IBD, such as glucocorticoids, 5-aminosalicylic acid, and <e1>sulfasalazine</e1>, interfere with NF-kappaB/<e2>Rel</e2> signaling.","Regulator"
"RESULTS: <e2>NF-kappaB</e2>/Rel activity induced by tumor necrosis factor alpha, <e1>12-O-tetradecanoylphorbol-13-acetate</e1>, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.","Upregulator"
"RESULTS: NF-kappaB/<e2>Rel</e2> activity induced by tumor necrosis factor alpha, <e1>12-O-tetradecanoylphorbol-13-acetate</e1>, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.","Upregulator"
"Suppression of <e2>NF-kappaB</e2> activity by <e1>sulfasalazine</e1> is mediated by direct inhibition of IkappaB kinases alpha and beta.","Downregulator"
"The suppression of NF-kappaB activation by inhibition of the <e2>IKKs</e2> contributes to the well-known anti-inflammatory and immunosuppressive effects of <e1>sulfasalazine</e1>.","Downregulator"
"Suppression of <e2>NF-kappaB</e2> activity by <e1>sulfasalazine</e1> is mediated by direct inhibition of IkappaB kinases alpha and beta.","Downregulator"
"Suppression of <e2>NF-kappaB</e2> activity by <e1>sulfasalazine</e1> is mediated by direct inhibition of IkappaB kinases alpha and beta.","Downregulator"
"Various drugs used in the treatment of IBD, such as glucocorticoids, 5-aminosalicylic acid, and <e1>sulfasalazine</e1>, interfere with NF-kappaB/<e2>Rel</e2> signaling.","Downregulator"
"RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of <e2>NF-kappaB-inducing kinase</e2>, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine</e1>.","Downregulator"
"The direct effect of <e1>sulfasalazine</e1> on IkappaB kinase (IKK) activity was investigated using purified recombinant <e2>IKK-alpha</e2> and -beta proteins.","Downregulator"
"RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, <e2>IKK-beta</e2>, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine</e1>.","Downregulator"
"The direct effect of <e1>sulfasalazine</e1> on IkappaB kinase (IKK) activity was investigated using purified recombinant <e2>IKK-alpha</e2> and -beta proteins.","Downregulator"
"RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, <e2>IKK-beta</e2>, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine</e1>.","Downregulator"
"<e1>Sulfasalazine</e1> inhibited <e2>tumor necrosis factor alpha</e2>-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.","Downregulator"
"<e1>Sulfasalazine</e1> inhibited tumor necrosis factor alpha-induced activation of endogenous <e2>IKK</e2> in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.","Downregulator"
"<e1>Sulfasalazine</e1> inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified <e2>IKK-alpha</e2> and IKK-beta in vitro.","Downregulator"
"<e1>Sulfasalazine</e1> inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and <e2>IKK-beta</e2> in vitro.","Downregulator"
"Suppression of <e2>NF-kappaB</e2> activity by <e1>sulfasalazine</e1> is mediated by direct inhibition of IkappaB kinases alpha and beta.","Downregulator"
"The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of <e2>IKKs</e2> and can be antagonized by excess <e1>adenosine triphosphate</e1>.","Downregulator"
"Selective COX-2 inhibitors, such as <e1>meloxicam</e1>, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not <e2>COX-1</e2>.","Not"
"Selective COX-2 inhibitors, such as meloxicam, <e1>celecoxib</e1> (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not <e2>COX-1</e2>.","Not"
"Selective COX-2 inhibitors, such as meloxicam, celecoxib (<e1>SC-58635</e1>), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not <e2>COX-1</e2>.","Not"
"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and <e1>rofecoxib</e1> (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not <e2>COX-1</e2>.","Not"
"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (<e1>MK-0966</e1>), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not <e2>COX-1</e2>.","Not"
"Selective <e2>COX-2</e2> inhibitors, such as <e1>meloxicam</e1>, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Not"
"This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of <e2>Bcl-2</e2>, as has been demonstrated for some nonselective NSAIDs, for instance, <e1>flurbiprofen</e1>.","Downregulator"
"In contrast, aspirin-like nonselective NSAIDs such as sulindac and <e1>indomethacin</e1> inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>COX-2</e2> but the constitutively expressed, cytoprotective COX-1 as well.","Downregulator"
"In contrast, aspirin-like nonselective NSAIDs such as sulindac and <e1>indomethacin</e1> inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>COX-1</e2> as well.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as <e1>meloxicam</e1>, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as <e1>meloxicam</e1>, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as meloxicam, <e1>celecoxib</e1> (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as meloxicam, <e1>celecoxib</e1> (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as meloxicam, celecoxib (<e1>SC-58635</e1>), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as meloxicam, celecoxib (<e1>SC-58635</e1>), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as meloxicam, celecoxib (SC-58635), and <e1>rofecoxib</e1> (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as meloxicam, celecoxib (SC-58635), and <e1>rofecoxib</e1> (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (<e1>MK-0966</e1>), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (<e1>MK-0966</e1>), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"Selective <e2>COX-2</e2> inhibitors, such as <e1>meloxicam</e1>, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.","Downregulator"
"In contrast, <e1>aspirin</e1>-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>COX-2</e2> but the constitutively expressed, cytoprotective COX-1 as well.","Downregulator"
"In contrast, <e1>aspirin</e1>-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>COX-1</e2> as well.","Downregulator"
"In contrast, aspirin-like nonselective NSAIDs such as <e1>sulindac</e1> and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>COX-2</e2> but the constitutively expressed, cytoprotective COX-1 as well.","Downregulator"
"In contrast, aspirin-like nonselective NSAIDs such as <e1>sulindac</e1> and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>COX-1</e2> as well.","Downregulator"
"<e2>COX-2</e2> produces <e1>prostaglandins</e1> that inhibit apoptosis and stimulate angiogenesis and invasiveness.","Substrate"
"To assess the feasibility of targeting these high <e2>AAAD</e2> levels for chemotherapy, AAAD inhibitors <e1>carbidopa</e1> (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.","Regulator"
"To assess the feasibility of targeting these high <e2>AAAD</e2> levels for chemotherapy, AAAD inhibitors <e1>carbidopa</e1> (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.","Downregulator"
"To assess the feasibility of targeting these high <e2>AAAD</e2> levels for chemotherapy, AAAD inhibitors carbidopa (<e1>alpha-methyl-dopahydrazine</e1>), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.","Downregulator"
"To assess the feasibility of targeting these high <e2>AAAD</e2> levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), <e1>alpha-monofluoromethyldopa</e1> (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.","Downregulator"
"To assess the feasibility of targeting these high <e2>AAAD</e2> levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (<e1>MFMD</e1>), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.","Downregulator"
"To assess the feasibility of targeting these high <e2>AAAD</e2> levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and <e1>3-hydroxybenzylhydrazine</e1> (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.","Downregulator"
"To assess the feasibility of targeting these high <e2>AAAD</e2> levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (<e1>NSD-1015</e1>) were incubated (72 h) with NCI-H727 human lung carcinoid cells.","Downregulator"
"In a search for less flexible analogues of caproctamine (1), a diamine <e1>diamide</e1> endowed with an interesting <e2>AChE</e2> affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.","Regulator"
"In a search for less flexible analogues of <e1>caproctamine</e1> (1), a diamine diamide endowed with an interesting <e2>AChE</e2> affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.","Regulator"
"In a search for less flexible analogues of caproctamine (1), a <e1>diamine</e1> diamide endowed with an interesting <e2>AChE</e2> affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.","Regulator"
"<e1>Hexahydrochromeno[4,3-b]pyrrole</e1> derivatives as <e2>acetylcholinesterase</e2> inhibitors.","Downregulator"
"Since this compound retains good <e2>AChE</e2> inhibitory activity and its <e1>hexahydrochromeno[4,3-b]pyrrole</e1> moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.","Downregulator"
"Since this compound retains good <e2>AChE</e2> inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the <e1>hexahydropyrrolo[2,3-b]indole of physostigmine</e1> (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.","Downregulator"
"In addition, <e1>corticosterone</e1> levels in splenic tissue or serum and <e2>CYP11A1</e2> mRNA expression (mRNA encoding cholesterol side-chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice.","Regulator"
"When the anti-corticosterone drug <e1>aminoglutethimide</e1> (<e2>CYP11A1</e2> inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation.","Downregulator"
"When the anti-corticosterone drug <e1>aminoglutethimide</e1> (<e2>CYP11A1</e2> inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation.","Downregulator"
"Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive <e2>NADH-->UQ oxidoreductase</e2> activity of complex I, which was insensitive to <e1>cAMP</e1> stimulation.","Not"
"Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive NADH-->UQ oxidoreductase activity of <e2>complex I</e2>, which was insensitive to <e1>cAMP</e1> stimulation.","Not"
"Furthermore, h[<e1>Gly2</e1>]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the <e2>GLP-2 receptor</e2>.","Regulator"
"We report here that a human degradation-resistant <e2>GLP-2</e2> analogue, h[<e1>Gly2</e1>]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil.","Regulator"
"Furthermore, h[<e1>Gly2</e1>]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited <e2>poly(ADP-ribose) polymerase</e2> cleavage in heterologous cells transfected with the GLP-2 receptor.","Downregulator"
"We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of <e2>topoisomerase I</e2> inhibitor <e1>irinotecan hydrochloride</e1> or the antimetabolite 5-fluorouracil.","Downregulator"
"OBJECTIVES: The hypothesis of the present study was that differences among <e2>dopamine transporter</e2> (<e1>DA</e1>T) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors.","Substrate"
"OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (<e1>DA</e1>T) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors.","Substrate"
"OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (<e1>DA</e1>T) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors.","Substrate"
"In conclusion, OMCD tubules from <e1>deoxycorticosterone pivalate</e1>-treated rats secrete Cl- into the luminal fluid through <e2>NKCC1</e2>-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.","Regulator"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter <e2>NKCC1</e2> to Cl- secretion in rat OMCD.","Substrate"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter NKCC1 to Cl- secretion in rat OMCD.","Substrate"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter <e2>NKCC1</e2> to Cl- secretion in rat OMCD.","Substrate"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter <e2>NKCC1</e2> to Cl- secretion in rat OMCD.","Substrate"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter <e2>NKCC1</e2> to Cl- secretion in rat OMCD.","Substrate"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter <e2>NKCC1</e2> to Cl- secretion in rat OMCD.","Substrate"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter <e2>NKCC1</e2> to Cl- secretion in rat OMCD.","Substrate"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter <e2>NKCC1</e2> to Cl- secretion in rat OMCD.","Substrate"
"Contribution of the Na+-K+-2<e1>Cl-</e1> cotransporter <e2>NKCC1</e2> to Cl- secretion in rat OMCD.","Substrate"
"This mutation is the first described in exon 9 and impairs the last 27 <e1>amino acids</e1> of the <e2>hormone-binding domain</e2>.","Part_of"
"The anti-emetic and pharmacological profile of <e1>AS-8112</e1> ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and <e2>5-hydroxytryptamine-3 (5-HT3) receptors</e2> ligand, was investigated in the present study.","Regulator"
"The anti-emetic and pharmacological profile of AS-8112 (<e1>(R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate</e1>), a novel and potent dopamine D2, D3 and <e2>5-hydroxytryptamine-3 (5-HT3) receptors</e2> ligand, was investigated in the present study.","Regulator"
"<e1>Domperidone</e1> and haloperidol, which have affinity for <e2>dopamine D3 receptor</e2>, also inhibited R(+)-7-OH-DPAT-induced hypothermia.","Regulator"
"Domperidone and <e1>haloperidol</e1>, which have affinity for <e2>dopamine D3 receptor</e2>, also inhibited R(+)-7-OH-DPAT-induced hypothermia.","Regulator"
"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>dopamine D3 receptor</e2> agonist; <e1>R(+)-7-OH-DPAT</e1> (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).","Regulator"
"In mice, <e1>AS-8112</e1> (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>dopamine D3 receptor</e2> agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).","Downregulator"
"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of <e1>2-methyl-5HT</e1>, a <e2>5-HT3 receptor</e2> agonist (pA2 value of 7.04).","Agonist"
"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>dopamine D3 receptor</e2> agonist; <e1>R(+)-7-OH-DPAT</e1> (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).","Agonist"
"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>dopamine D3 receptor</e2> agonist; R(+)-7-OH-DPAT (<e1>R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline</e1>) (0.3 mg kg(-1) s.c.).","Agonist"
"The broad-spectrum anti-emetic activity of <e1>AS-8112</e1>, a novel dopamine D2, D3 and <e2>5-HT3 receptor</e2>s antagonist.","Antagonist"
"Other <e2>5-HT3 receptor</e2> antagonists also produced such a shift in the following antagonistic-potency order: <e1>granisetron</e1>> ondansetron=AS-8112>>metoclopramide.","Antagonist"
"Other <e2>5-HT3 receptor</e2> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> <e1>ondansetron</e1>=AS-8112>>metoclopramide.","Antagonist"
"The broad-spectrum anti-emetic activity of <e1>AS-8112</e1>, a novel dopamine D2, D3 and <e2>5-HT3 receptor</e2>s antagonist.","Antagonist"
"Other <e2>5-HT3 receptor</e2> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>><e1>metoclopramide</e1>.","Antagonist"
"The broad-spectrum anti-emetic activity of <e1>AS-8112</e1>, a novel dopamine D2, D3 and <e2>5-HT3 receptors</e2> antagonist.","Antagonist"
"The broad-spectrum anti-emetic activity of <e1>AS-8112</e1>, a novel dopamine D2, D3 and <e2>5-HT3 receptors</e2> antagonist.","Antagonist"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (<e2>chymotrypsin</e2> numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (<e2>chymotrypsin</e2> numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues Arg(93), <e1>Lys</e1>(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (<e2>chymotrypsin</e2> numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues Arg(93), <e1>Lys</e1>(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues Arg(93), <e1>Lys</e1>(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (<e2>chymotrypsin</e2> numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues Arg(93), <e1>Lys</e1>(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (<e2>chymotrypsin</e2> numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (<e2>chymotrypsin</e2> numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues Arg(93), <e1>Lys</e1>(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (<e2>chymotrypsin</e2> numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues Arg(93), <e1>Lys</e1>(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues <e1>Arg</e1>(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"Recent studies have indicated that the basic residues Arg(93), <e1>Lys</e1>(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of <e2>factor Xa</e2> that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.","Part_of"
"<e1>Rofecoxib</e1> is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the <e2>COX-1</e2> isoenzyme at doses up to 1000 mg/day.","Not"
"Rofecoxib has greater selectivity for <e2>COX-2</e2> than <e1>celecoxib</e1>, meloxicam, diclofenac and indomethacin.","Regulator"
"Rofecoxib has greater selectivity for <e2>COX-2</e2> than celecoxib, <e1>meloxicam</e1>, diclofenac and indomethacin.","Regulator"
"Rofecoxib has greater selectivity for <e2>COX-2</e2> than celecoxib, meloxicam, <e1>diclofenac</e1> and indomethacin.","Regulator"
"Rofecoxib has greater selectivity for <e2>COX-2</e2> than celecoxib, meloxicam, diclofenac and <e1>indomethacin</e1>.","Regulator"
"<e1>Rofecoxib</e1> is a selective <e2>cyclo-oxygenase (COX)-2</e2> inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day.","Downregulator"
"<e1>Rofecoxib</e1> has greater selectivity for <e2>COX-2</e2> than celecoxib, meloxicam, diclofenac and indomethacin.","Downregulator"
"Different forms of therapy, <e1>potassium</e1> and magnesium substitution, spironolactone and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized <e2>IGF-I</e2> levels in the three patients with short stature.","Regulator"
"Different forms of therapy, potassium and <e1>magnesium</e1> substitution, spironolactone and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized <e2>IGF-I</e2> levels in the three patients with short stature.","Regulator"
"Different forms of therapy, potassium and magnesium substitution, <e1>spironolactone</e1> and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized <e2>IGF-I</e2> levels in the three patients with short stature.","Regulator"
"Different forms of therapy, potassium and magnesium substitution, spironolactone and <e1>indomethacin</e1> failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized <e2>IGF-I</e2> levels in the three patients with short stature.","Regulator"
"To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a <e2>PPAR-gamma</e2>-specific ligand, <e1>rosiglitazone</e1>, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.","Regulator"
"<e1>Fibrates</e1> bind to the <e2>peroxisome proliferator-activated receptor (PPAR)-alpha</e2>, and thiazolidinediones are ligands of PPAR-gamma.","Regulator"
"Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and <e1>thiazolidinediones</e1> are ligands of <e2>PPAR-gamma</e2>.","Regulator"
"To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a <e2>PPAR-alpha</e2>-specific compound, <e1>fenofibrate</e1>, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.","Regulator"
"<e1>Fenofibrate</e1> and GW2331 induced expression of <e2>acyl-coenzyme A (CoA) oxidase</e2> and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.","Upregulator"
"<e1>Fenofibrate</e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and <e2>enoyl-CoA hydratase</e2> and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.","Upregulator"
"Fenofibrate and <e1>GW2331</e1> induced expression of <e2>acyl-coenzyme A (CoA) oxidase</e2> and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.","Upregulator"
"Fenofibrate and <e1>GW2331</e1> induced expression of acyl-coenzyme A (CoA) oxidase and <e2>enoyl-CoA hydratase</e2> and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.","Upregulator"
"<e1>Rosiglitazone</e1> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of <e2>glucose transporter 4</e2> and phosphoenolpyruvate carboxykinase in adipose tissue.","Upregulator"
"<e1>Rosiglitazone</e1> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and <e2>phosphoenolpyruvate carboxykinase</e2> in adipose tissue.","Upregulator"
"<e1>Rosiglitazone</e1> modestly increased <e2>apolipoprotein C-III</e2> mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.","Upregulator"
"<e1>Fenofibrate</e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced <e2>apolipoprotein C-III</e2> and phosphoenolpyruvate carboxykinase mRNAs.","Downregulator"
"<e1>Fenofibrate</e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and <e2>phosphoenolpyruvate carboxykinase</e2> mRNAs.","Downregulator"
"Fenofibrate and <e1>GW2331</e1> induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced <e2>apolipoprotein C-III</e2> and phosphoenolpyruvate carboxykinase mRNAs.","Downregulator"
"Fenofibrate and <e1>GW2331</e1> induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and <e2>phosphoenolpyruvate carboxykinase</e2> mRNAs.","Downregulator"
"We have previously isolated from human hemofiltrate an <e1>N</e1>-terminally truncated form of the <e2>hemofiltrate CC chemokine 1</e2> (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3.","Part_of"
"We have previously isolated from human hemofiltrate an <e1>N</e1>-terminally truncated form of the hemofiltrate CC chemokine 1 (<e2>HCC-1</e2>), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3.","Part_of"
"<e1>Long-chain alkanols</e1> are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (<e2>AChR</e2>) by binding to one or more specific sites on the AChR.","Regulator"
"<e1>Cembranoid</e1> and long-chain alkanol sites on the <e2>nicotinic acetylcholine receptor</e2> and their allosteric interaction.","Regulator"
"Cembranoid and <e1>long-chain alkanol</e1> sites on the <e2>nicotinic acetylcholine receptor</e2> and their allosteric interaction.","Regulator"
"<e1>Long-chain alkanols</e1> are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral <e2>nicotinic acetylcholine receptor</e2> (AChR) by binding to one or more specific sites on the AChR.","Downregulator"
"<e1>Cembranoids</e1> are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal <e2>AChRs</e2>, which have no demonstrable general anesthetic activity in vivo.","Downregulator"
"The <e2>x(c)- cystine transporter</e2> represents a novel target for <e1>sulfasalazine</e1>-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.","Regulator"
"<e1>Sulfasalazine</e1> was fortuitously found to be a novel, potent inhibitor of the <e2>x(c)- transporter</e2>.","Downregulator"
"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <e2>x(c)</e2>--mediated cystine uptake, in contrast to its colonic metabolites, <e1>sulfapyridine</e1> and 5-aminosalicylic acid.","Downregulator"
"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <e2>x(c)</e2>--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and <e1>5-aminosalicylic acid</e1>.","Downregulator"
"<e1>Sulfasalazine</e1>, a potent suppressor of lymphoma growth by inhibition of the <e2>x(c)- cystine transporter</e2>: a new action for an old drug.","Downregulator"
"Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the <e2>x(c)</e2>- <e1>cystine</e1> transporter: a new action for an old drug.","Substrate"
"The <e2>x(c)- cystine transporter</e2> represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular <e1>cyst(e)ine</e1>.","Substrate"
"Like conventional ACE inhibitors, <e1>omapatrilat</e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of <e2>atrial and brain natriuretic peptides</e2> and bradykinin.","Upregulator"
"Like conventional ACE inhibitors, <e1>omapatrilat</e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and <e2>bradykinin</e2>.","Upregulator"
"Like conventional <e2>ACE</e2> inhibitors, <e1>omapatrilat</e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.","Downregulator"
"Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with <e1>omapatrilat</e1>, a <e2>vasopeptidase</e2> inhibitor.","Downregulator"
"<e1>Omapatrilat</e1>, the prototypical <e2>vasopeptidase</e2> inhibitor, inhibits not only ACE but also neutral endopeptidase.","Downregulator"
"<e1>Omapatrilat</e1>, the prototypical vasopeptidase inhibitor, inhibits not only <e2>ACE</e2> but also neutral endopeptidase.","Downregulator"
"<e1>Omapatrilat</e1>, the prototypical vasopeptidase inhibitor, inhibits not only ACE but also <e2>neutral endopeptidase</e2>.","Downregulator"
"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to <e1>Na+</e1>-H+ exchange (<e2>NHE1</e2> isoform).","Substrate"
"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-<e1>H+</e1> exchange (<e2>NHE1</e2> isoform).","Substrate"
"<e1>Salicylates</e1> inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce <e2>BiP</e2> expression.","Not"
"<e1>Aspirin</e1> and salicylate bind to <e2>immunoglobulin heavy chain binding protein</e2> (BiP) and inhibit its ATPase activity in human fibroblasts.","Regulator"
"Aspirin and <e1>salicylate</e1> bind to <e2>immunoglobulin heavy chain binding protein</e2> (BiP) and inhibit its ATPase activity in human fibroblasts.","Regulator"
"Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its <e1>ATP</e1>ase activity in human fibroblasts.","Regulator"
"These results indicate that <e1>salicylates</e1> bind specifically to the polypeptide binding site of <e2>BiP</e2> in human cells that may interfere with folding and transport of proteins important in inflammation.","Regulator"
"The Kd values of <e1>SA</e1> binding to crude extract and to recombinant <e2>BiP</e2> were 45.2 and 54.6 microM, respectively.","Regulator"
"<e1>Salicylates</e1> inhibited <e2>ATPase</e2> activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression.","Downregulator"
"<e1>Aspirin</e1> and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its <e2>ATPase</e2> activity in human fibroblasts.","Downregulator"
"Aspirin and <e1>salicylate</e1> bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its <e2>ATPase</e2> activity in human fibroblasts.","Downregulator"
"The specific activity of only <e2>ornithine aminotransferase</e2> (OAT), the rate-limiting enzyme in the conversion of ornithine to <e1>proline</e1>, increased in 2 weeks of hypertrophy.","Substrate"
"The specific activity of only ornithine aminotransferase (<e2>OAT</e2>), the rate-limiting enzyme in the conversion of ornithine to <e1>proline</e1>, increased in 2 weeks of hypertrophy.","Substrate"
"The specific activity of only <e1>ornithine</e1> aminotransferase (OAT), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy.","Substrate"
"The specific activity of only <e1>ornithine</e1> aminotransferase (<e2>OAT</e2>), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy.","Substrate"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both <e2>COX-1</e2> and COX-2) and <e1>thromboxane B2</e1> (as a biomarker for COX-1 activity) with parallel assessments of pain.","Regulator"
"Celecoxib selectively suppressed PGE2 but not <e1>TxB2</e1> at time points consistent with <e2>COX-2</e2> activity, while producing analgesia.","Regulator"
"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective <e2>cyclooxygenase (COX)-2</e2> inhibitor (<e1>celecoxib</e1>) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac).","Downregulator"
"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual <e2>COX-1</e2>/COX-2 inhibitor (<e1>ketorolac</e1>).","Downregulator"
"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/<e2>COX-2</e2> inhibitor (<e1>ketorolac</e1>).","Downregulator"
"<e1>Celecoxib</e1> selectively suppressed PGE2 but not TxB2 at time points consistent with <e2>COX-2</e2> activity, while producing analgesia.","Downregulator"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of <e1>prostaglandin E2</e1> (PGE2; a product of both <e2>COX-1</e2> and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.","Substrate"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of <e1>prostaglandin E2</e1> (PGE2; a product of both COX-1 and <e2>COX-2</e2>) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.","Substrate"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>PGE2</e1>; a product of both <e2>COX-1</e2> and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.","Substrate"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>PGE2</e1>; a product of both COX-1 and <e2>COX-2</e2>) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.","Substrate"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>PGE2</e1>; a product of both <e2>COX-1</e2> and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.","Substrate"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>PGE2</e1>; a product of both COX-1 and <e2>COX-2</e2>) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.","Substrate"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>PGE2</e1>; a product of both COX-1 and <e2>COX-2</e2>) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.","Substrate"
"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>PGE2</e1>; a product of both COX-1 and <e2>COX-2</e2>) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.","Substrate"
"<e1>[3H]dofetilide</e1> binding to <e2>HERG</e2> transfected membranes: a potential high throughput preclinical screen.","Regulator"
"<e1>[3H]dofetilide</e1> binding to <e2>HERG</e2> transfected membranes: a potential high throughput preclinical screen.","Regulator"
"Acute and chronic <e1>PLZ</e1> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, <e2>GABA transaminase</e2> (GABA-T).","Downregulator"
"Acute and chronic <e1>PLZ</e1> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (<e2>GABA-T</e2>).","Downregulator"
"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of <e1>PLZ</e1> on <e2>alanine transaminase</e2> (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.","Downregulator"
"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of <e1>PLZ</e1> on alanine transaminase (<e2>ALA-T</e2>), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.","Downregulator"
"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of <e1>PLZ</e1> on <e2>alanine transaminase</e2> (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.","Downregulator"
"As with GABA, the metabolism of <e1>alanine</e1> involves a <e2>pyridoxal phosphate-dependent transaminase</e2>.","Substrate"
"In the study reported here, the effects of acute PLZ treatment on the levels of various <e1>amino acids</e1>, some of which are also metabolized by <e2>pyridoxal phosphate-dependent transaminases</e2> were compared in rat whole brain.","Substrate"
"Effects of the antidepressant/antipanic drug phenelzine on <e1>alanine</e1> and <e2>alanine transaminase</e2> in rat brain.","Substrate"
"Effects of the antidepressant/antipanic drug phenelzine on <e1>alanine</e1> and <e2>alanine transaminase</e2> in rat brain.","Substrate"
"The elevation in brain <e1>alanine</e1> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (<e2>ALA-T</e2>), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.","Substrate"
"Acute and chronic PLZ administration increase brain <e1>GABA</e1> levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, <e2>GABA transaminase</e2> (GABA-T).","Substrate"
"Acute and chronic PLZ administration increase brain <e1>GABA</e1> levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (<e2>GABA-T</e2>).","Substrate"
"<e2>Cyclooxygenase-1</e2> (COX-1) inhibitors (<e1>flurbiprofen</e1>, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.","Downregulator"
"Cyclooxygenase-1 (<e2>COX-1</e2>) inhibitors (<e1>flurbiprofen</e1>, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.","Downregulator"
"<e2>Cyclooxygenase-1</e2> (COX-1) inhibitors (flurbiprofen, <e1>ketoprofen</e1> and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.","Downregulator"
"Cyclooxygenase-1 (<e2>COX-1</e2>) inhibitors (flurbiprofen, <e1>ketoprofen</e1> and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.","Downregulator"
"<e2>Cyclooxygenase-1</e2> (COX-1) inhibitors (flurbiprofen, ketoprofen and <e1>ketrolack</e1>) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.","Downregulator"
"Cyclooxygenase-1 (<e2>COX-1</e2>) inhibitors (flurbiprofen, ketoprofen and <e1>ketrolack</e1>) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.","Downregulator"
"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and <e2>cyclooxygenase-2</e2> (COX-2) inhibitors at high concentrations (<e1>nimesulide</e1> and NS-389) slightly attenuated the contraction.","Downregulator"
"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (<e2>COX-2</e2>) inhibitors at high concentrations (<e1>nimesulide</e1> and NS-389) slightly attenuated the contraction.","Downregulator"
"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and <e2>cyclooxygenase-2</e2> (COX-2) inhibitors at high concentrations (nimesulide and <e1>NS-389</e1>) slightly attenuated the contraction.","Downregulator"
"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (<e2>COX-2</e2>) inhibitors at high concentrations (nimesulide and <e1>NS-389</e1>) slightly attenuated the contraction.","Downregulator"
"A <e2>TXA2 synthetase</e2> inhibitor (<e1>OKY-046</e1>) attenuated the contraction to a small extent only at high concentrations.","Downregulator"
"A <e2>TXA2 receptor</e2> antagonist (<e1>S-1452</e1>) attenuated the contraction in a concentration-dependent manner.","Antagonist"
"A <e2>nicotinic receptor</e2> antagonist (<e1>hexamethonium</e1>) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.","Antagonist"
"A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an <e2>alpha-adrenoceptor</e2> antagonist (<e1>prazosin</e1>) nearly abolished the contraction.","Antagonist"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, <e1>zomepirac</e1>, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Regulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, <e1>indomethacin</e1>, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Regulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, <e1>diclofenac</e1> and meclofenamic acid were undertaken using the AMBER program.","Regulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and <e1>meclofenamic acid</e1> were undertaken using the AMBER program.","Regulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: <e1>rofecoxib</e1>, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Regulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, <e1>ketoprofen</e1>, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Regulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, <e1>suprofen</e1>, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Regulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, <e1>carprofen</e1>, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Regulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, <e1>zomepirac</e1>, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Downregulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, <e1>indomethacin</e1>, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Downregulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, <e1>diclofenac</e1> and meclofenamic acid were undertaken using the AMBER program.","Downregulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and <e1>meclofenamic acid</e1> were undertaken using the AMBER program.","Downregulator"
"Non-<e1>steroidal</e1> anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>cyclooxygenase</e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.","Downregulator"
"Non-<e1>steroidal</e1> anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>COX</e2>), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.","Downregulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: <e1>rofecoxib</e1>, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Downregulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, <e1>ketoprofen</e1>, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Downregulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, <e1>suprofen</e1>, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Downregulator"
"Accordingly, docking of different <e2>COX</e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, <e1>carprofen</e1>, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.","Downregulator"
"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>cyclooxygenase</e2> (COX), the enzyme that mediates biosynthesis of <e1>prostaglandins</e1> and thromboxanes from arachidonic acid.","Substrate"
"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>COX</e2>), the enzyme that mediates biosynthesis of <e1>prostaglandins</e1> and thromboxanes from arachidonic acid.","Substrate"
"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>cyclooxygenase</e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and <e1>thromboxanes</e1> from arachidonic acid.","Substrate"
"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>COX</e2>), the enzyme that mediates biosynthesis of prostaglandins and <e1>thromboxanes</e1> from arachidonic acid.","Substrate"
"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>cyclooxygenase</e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from <e1>arachidonic acid</e1>.","Substrate"
"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>COX</e2>), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from <e1>arachidonic acid</e1>.","Substrate"
"ICI 182,780 (fulvestrant) (Faslodex) and <e1>ICI 164,384</e1> are competitive inhibitors of estrogen by binding to the <e2>estrogen receptor</e2> (ER).","Regulator"
"ICI 182,780 (fulvestrant) (Faslodex) and <e1>ICI 164,384</e1> are competitive inhibitors of estrogen by binding to the estrogen receptor (<e2>ER</e2>).","Regulator"
"ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of <e1>estrogen</e1> by binding to the <e2>estrogen receptor</e2> (ER).","Regulator"
"ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of <e1>estrogen</e1> by binding to the estrogen receptor (<e2>ER</e2>).","Regulator"
"<e1>EM-800</e1> and EM-652 are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to <e2>ER</e2>.","Regulator"
"EM-800 and <e1>EM-652</e1> are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to <e2>ER</e2>.","Regulator"
"EM-800 and <e1>EM-652</e1> are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to <e2>ER</e2>.","Regulator"
"<e1>ICI 182,780</e1> (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the <e2>estrogen receptor</e2> (ER).","Regulator"
"<e1>ICI 182,780</e1> (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor (<e2>ER</e2>).","Regulator"
"ICI 182,780 (<e1>fulvestrant</e1>) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the <e2>estrogen receptor</e2> (ER).","Regulator"
"ICI 182,780 (<e1>fulvestrant</e1>) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor (<e2>ER</e2>).","Regulator"
"ICI 182,780 (fulvestrant) (<e1>Faslodex</e1>) and ICI 164,384 are competitive inhibitors of estrogen by binding to the <e2>estrogen receptor</e2> (ER).","Regulator"
"ICI 182,780 (fulvestrant) (<e1>Faslodex</e1>) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor (<e2>ER</e2>).","Regulator"
"<e1>Olopatadine</e1> exerted no significant effects on action potential duration in isolated guinea pig ventricular myocytes, myocardium and <e2>human ether-a-go-go-related gene channel</e2>.","Not"
"Olopatadine hydrochloride (<e1>olopatadine</e1>, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/<e2>histamine H1-receptor</e2> antagonistic drug that was synthesized and evaluated in our laboratories.","Antagonist"
"Olopatadine hydrochloride (olopatadine, <e1>11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride</e1>) is a novel antiallergic/<e2>histamine H1-receptor</e2> antagonistic drug that was synthesized and evaluated in our laboratories.","Antagonist"
"<e1>Olopatadine</e1> hydrochloride (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/<e2>histamine H1-receptor</e2> antagonistic drug that was synthesized and evaluated in our laboratories.","Antagonist"
"<e1>Olopatadine hydrochloride</e1> (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/<e2>histamine H1-receptor</e2> antagonistic drug that was synthesized and evaluated in our laboratories.","Antagonist"
"Considerable evidence indicates that serotonergic mechanisms, particularly the serotonin transporter (<e2>5HTT</e2>), may mediate central effects of <e1>cocaine</e1> and may also be involved in impulsive and aggressive behavior.","Regulator"
"Considerable evidence indicates that serotonergic mechanisms, particularly the <e2>serotonin transporter</e2> (5HTT), may mediate central effects of <e1>cocaine</e1> and may also be involved in impulsive and aggressive behavior.","Regulator"
"This increased <e2>HDAC</e2> activity is then available for corticosteroid recruitment and predicts a cooperative interaction between <e1>corticosteroids</e1> and theophylline.","Regulator"
"<e1>Corticosteroids</e1> act, at least in part, by recruitment of <e2>histone deacetylases</e2> (HDACs) to the site of active inflammatory gene transcription.","Regulator"
"<e1>Corticosteroids</e1> act, at least in part, by recruitment of histone deacetylases (<e2>HDACs</e2>) to the site of active inflammatory gene transcription.","Regulator"
"This increased <e2>HDAC</e2> activity is then available for <e1>corticosteroid</e1> recruitment and predicts a cooperative interaction between corticosteroids and theophylline.","Regulator"
"A molecular mechanism of action of <e1>theophylline</e1>: Induction of <e2>histone deacetylase</e2> activity to decrease inflammatory gene expression.","Upregulator"
"We show both in vitro and in vivo that low-dose <e1>theophylline</e1> enhances <e2>HDAC</e2> activity in epithelial cells and macrophages.","Upregulator"
"We show both in vitro and in vivo that low-dose <e1>theophylline</e1> enhances <e2>HDAC</e2> activity in epithelial cells and macrophages.","Upregulator"
"Therefore, we investigated the effects of <e1>rifamycin SV</e1> and rifampicin on the <e2>OATP</e2>s of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers.","Regulator"
"Therefore, we investigated the effects of rifamycin SV and <e1>rifampicin</e1> on the <e2>OATP</e2>s of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers.","Regulator"
"Inhibition of <e2>human liver OATPs</e2> can explain the previously observed effects of <e1>rifamycin SV</e1> and rifampicin on hepatic organic anion elimination.","Downregulator"
"Inhibition of <e2>human liver OATPs</e2> can explain the previously observed effects of rifamycin SV and <e1>rifampicin</e1> on hepatic organic anion elimination.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited <e2>human organic anion transporting polypeptide C</e2> (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (<e2>SLC21A6</e2>) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (<e2>OATP-C</e2>), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), <e2>human organic anion transporting polypeptide 8</e2> (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (<e2>SLC21A8</e2>) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (<e2>OATP8</e2>), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), <e2>human organic anion transporting polypeptide B</e2> (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (<e2>SLC21A9</e2>) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (<e2>OATP-B</e2>), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and <e2>human organic anion transporting polypeptide A</e2> (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (<e2>SLC21A3</e2>) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV</e1> (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (<e2>OATP-A</e2>) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Downregulator"
"<e1>Rifampicin</e1> (10 micromol/L) inhibited <e2>OATP8</e2>-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.","Downregulator"
"<e1>Rifampicin</e1> (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of <e2>OATP-C</e2>-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.","Downregulator"
"<e1>Rifampicin</e1> (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, <e2>OATP-B</e2>-, and OATP-A-mediated BSP transport was below 15%.","Downregulator"
"<e1>Rifampicin</e1> (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and <e2>OATP-A</e2>-mediated BSP transport was below 15%.","Downregulator"
"In rats, <e1>rifamycin SV</e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the <e2>organic anion transporting polypeptides</e2> Oatp1 and Oatp2.","Downregulator"
"In rats, <e1>rifamycin SV</e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides <e2>Oatp1</e2> and Oatp2.","Downregulator"
"In rats, <e1>rifamycin SV</e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and <e2>Oatp2</e2>.","Downregulator"
"100 micromol/L <e1>rifampicin</e1> inhibited <e2>OATP-C</e2>- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.","Downregulator"
"100 micromol/L <e1>rifampicin</e1> inhibited OATP-C- and <e2>OATP8</e2>-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.","Downregulator"
"100 micromol/L <e1>rifampicin</e1> inhibited OATP-C- and OATP8-, <e2>OATP-B</e2>- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.","Downregulator"
"100 micromol/L <e1>rifampicin</e1> inhibited OATP-C- and OATP8-, OATP-B- and <e2>OATP-A</e2>-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.","Downregulator"
"In rats, rifamycin SV and <e1>rifampicin</e1> were shown to interfere with hepatic organic anion uptake by inhibition of the <e2>organic anion transporting polypeptides</e2> Oatp1 and Oatp2.","Downregulator"
"In rats, rifamycin SV and <e1>rifampicin</e1> were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides <e2>Oatp1</e2> and Oatp2.","Downregulator"
"In rats, rifamycin SV and <e1>rifampicin</e1> were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and <e2>Oatp2</e2>.","Downregulator"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (<e2>OATP8</e2>), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated <e1>BSP</e1> uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Substrate"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (<e2>OATP-C</e2>), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated <e1>BSP</e1> uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Substrate"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (<e2>OATP-B</e2>), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated <e1>BSP</e1> uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Substrate"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (<e2>OATP-A</e2>) mediated <e1>BSP</e1> uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Substrate"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (<e2>OATP-C</e2>), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated <e1>BSP</e1> uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Substrate"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (<e2>OATP8</e2>), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated <e1>BSP</e1> uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Substrate"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (<e2>OATP-B</e2>), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated <e1>BSP</e1> uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Substrate"
"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (<e2>OATP-A</e2>) mediated <e1>BSP</e1> uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.","Substrate"
"100 micromol/L <e1>rifampicin</e1> inhibited <e2>OATP-C</e2>- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.","Substrate"
"100 micromol/L <e1>rifampicin</e1> inhibited OATP-C- and <e2>OATP8</e2>-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.","Substrate"
"The increase in <e2>AMPK alpha2</e2> activity was likely due to a change in muscle energy status because <e1>ATP</e1> and phosphocreatine concentrations were lower after metformin treatment.","Regulator"
"The increase in <e2>AMPK alpha2</e2> activity was likely due to a change in muscle energy status because ATP and <e1>phosphocreatine</e1> concentrations were lower after metformin treatment.","Regulator"
"We recently reported that <e2>AMPK</e2> is activated by <e1>metformin</e1> in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.","Upregulator"
"We recently reported that <e2>AMPK</e2> is activated by <e1>metformin</e1> in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.","Upregulator"
"<e1>Metformin</e1> treatment for 10 weeks significantly increased <e2>AMPK alpha2</e2> activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.","Upregulator"
"<e1>Metformin</e1> treatment for 10 weeks significantly increased <e2>AMPK</e2> alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.","Upregulator"
"<e1>Metformin</e1> increases <e2>AMP-activated protein kinase</e2> activity in skeletal muscle of subjects with type 2 diabetes.","Upregulator"
"The increase in <e2>AMPK alpha2</e2> activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after <e1>metformin</e1> treatment.","Upregulator"
"<e1>Metformin</e1> treatment for 10 weeks significantly increased <e2>AMPK</e2> alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.","Upregulator"
"<e1>Metformin</e1> treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased <e2>acetyl-CoA carboxylase-2</e2> activity.","Downregulator"
"<e2>AMP-activated protein kinase</e2> (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of <e1>glucose</e1> uptake into skeletal muscle and the inhibition of liver gluconeogenesis.","Substrate"
"AMP-activated protein kinase (<e2>AMPK</e2>) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of <e1>glucose</e1> uptake into skeletal muscle and the inhibition of liver gluconeogenesis.","Substrate"
"BACKGROUND & AIMS: Sensitization of Kupffer cells (KCs) to lipopolysaccharide (LPS) and overproduction of <e2>tumor necrosis factor (TNF) alpha</e2> are critical for progression of <e1>alcoholic</e1> liver injury.","Regulator"
"Moreover, <e1>thalidomide</e1> reduced the LPS-induced <e2>TNF-alpha</e2> production by KCs by decreasing TNF-alpha messenger RNA.","Downregulator"
"<e1>Thalidomide</e1> prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and <e2>TNF-alpha</e2> production.","Downregulator"
"<e1>Thalidomide</e1> prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and <e2>TNF-alpha</e2> production.","Downregulator"
"Furthermore, <e1>thalidomide</e1> abolished the LPS-induced increase in <e2>CD14</e2> expression and [Ca2+]i elevation in KCs.","Downregulator"
"Moreover, <e1>thalidomide</e1> reduced the LPS-induced <e2>TNF-alpha</e2> production by KCs by decreasing TNF-alpha messenger RNA.","Downregulator"
"Moreover, <e1>thalidomide</e1> reduced the LPS-induced <e2>TNF-alpha</e2> production by KCs by decreasing TNF-alpha messenger RNA.","Downregulator"
"Substrate specificity using lysates of <e2>oxidase</e2>-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on <e1>N (1)-acetylspermidine</e1>, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.","Not"
"During polyamine catabolism, spermine and <e1>spermidine</e1> are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine <e2>oxidase</e2> (PAO) to produce spermidine and putrescine, respectively.","Not"
"A BLAST search using <e2>maize PAO</e2> sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 <e1>amino acids</e1>.","Part_of"
"Identification and characterization of a novel <e1>flavin</e1>-containing <e2>spermine oxidase</e2> of mammalian cell origin.","Part_of"
"The <e2>PAO</e2> inhibitor, <e1>MDL-72,527</e1>, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.","Downregulator"
"During polyamine catabolism, spermine and <e1>spermidine</e1> are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by <e2>polyamine oxidase</e2> (PAO) to produce spermidine and putrescine, respectively.","Substrate"
"During polyamine catabolism, spermine and <e1>spermidine</e1> are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (<e2>PAO</e2>) to produce spermidine and putrescine, respectively.","Substrate"
"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by <e2>polyamine oxidase</e2> (PAO) to produce spermidine and <e1>putrescine</e1>, respectively.","Substrate"
"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (<e2>PAO</e2>) to produce spermidine and <e1>putrescine</e1>, respectively.","Substrate"
"During polyamine catabolism, <e1>spermine</e1> and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (<e2>SSAT</e2>) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.","Substrate"
"During polyamine catabolism, <e1>spermine</e1> and spermidine are first acetylated by <e2>spermidine/spermine N(1)-acetyltransferase</e2> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.","Substrate"
"During polyamine catabolism, <e1>spermine</e1> and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (<e2>SSAT</e2>) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.","Substrate"
"During polyamine catabolism, spermine and <e1>spermidine</e1> are first acetylated by spermidine/spermine N(1)-acetyltransferase (<e2>SSAT</e2>) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.","Substrate"
"During polyamine catabolism, spermine and <e1>spermidine</e1> are first acetylated by <e2>spermidine/spermine N(1)-acetyltransferase</e2> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.","Substrate"
"During <e1>polyamine</e1> catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (<e2>SSAT</e2>) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.","Substrate"
"During <e1>polyamine</e1> catabolism, spermine and spermidine are first acetylated by <e2>spermidine/spermine N(1)-acetyltransferase</e2> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.","Substrate"
"Identification and characterization of a novel flavin-containing <e1>spermine</e1> <e2>oxidase</e2> of mammalian cell origin.","Substrate"
"Substrate specificity using lysates of <e2>oxidase</e2>-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over <e1>N (1)-acetylspermine</e1> and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.","Substrate"
"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred <e2>PAO</e2> substrate, <e1>N (1), N (12)-diacetylspermine</e1>.","Substrate"
"The <e2>PAO</e2> inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, <e1>N (1)-( n -octanesulphonyl)spermine</e1>, potently inhibited the reaction.","Substrate"
"The effects of abciximab (1-10 microg/ml), <e1>tirofiban</e1> (3-30 nM), or eptifibatide (0.3-3 microg/ml) on basal and ADP (3 microM)-induced <e2>CD62P</e2> externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.","Not"
"The effects of abciximab (1-10 microg/ml), tirofiban (3-30 nM), or <e1>eptifibatide</e1> (0.3-3 microg/ml) on basal and ADP (3 microM)-induced <e2>CD62P</e2> externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.","Not"
"The effects of abciximab (1-10 microg/ml), tirofiban (3-30 nM), or eptifibatide (0.3-3 microg/ml) on basal and <e1>ADP</e1> (3 microM)-induced <e2>CD62P</e2> externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.","Upregulator"
"The effects of abciximab (1-10 microg/ml), tirofiban (3-30 nM), or eptifibatide (0.3-3 microg/ml) on basal and <e1>ADP</e1> (3 microM)-induced <e2>CD62P</e2> externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.","Upregulator"
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with <e1>epsilon-amino</e1> groups of lysine residues in proteins.","Part_of"
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of <e1>lysine</e1> residues in proteins.","Part_of"
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to <e1>pyruvate</e1>, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.","Substrate"
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to pyruvate, <e1>ammonia</e1>, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.","Substrate"
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to pyruvate, ammonia, and an <e1>alpha-chloroenethiolate</e1> (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.","Substrate"
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with <e1>DCVC</e1>) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.","Substrate"
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an <e1>alpha-difluoroalkylthiolate</e1> (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.","Substrate"
"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with <e1>TFEC</e1>) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.","Substrate"
"Most halogenated <e1>cysteine S-conjugates</e1> are metabolized by cysteine S-conjugate <e2>beta-lyases</e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.","Substrate"
"The juvenile visceral steatosis (jvs) mouse, having a mutation in the <e1>carnitine</e1> transporter gene <e2>Octn2</e2>, is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).","Substrate"
"The outflow of [3H]-<e1>MPP+</e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for <e2>OCT</e2>-related transmembrane transporters.","Not"
"No trans-stimulation of <e1>[3H]-MPP+</e1> outflow was observed by the <e2>OCTN1</e2> and OCTN2 substrate carnitine at 100 microM.","Not"
"No trans-stimulation of <e1>[3H]-MPP+</e1> outflow was observed by the OCTN1 and <e2>OCTN2</e2> substrate carnitine at 100 microM.","Not"
"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the <e2>OCT3</e2> inhibitors cyanine 863, <e1>oestradiol</e1> and corticosterone.","Downregulator"
"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the <e2>OCT3</e2> inhibitors cyanine 863, oestradiol and <e1>corticosterone</e1>.","Downregulator"
"Making use of the <e2>NAT</e2> as a powerful, neurone-specific transporter system, we loaded[3H]-N-methyl-4-phenylpyridinium ([3H]-<e1>MPP+</e1>) into cultured rat SCG neurones.","Substrate"
"The outflow of <e1>[3H]-MPP+</e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for <e2>OCT</e2>-related transmembrane transporters.","Substrate"
"Amongst the three <e2>OCTs</e2> expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of <e1>[3H]-MPP+</e1> release.","Substrate"
"Amongst the three OCTs expressed in the SCG, <e2>OCT3</e2> best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of <e1>[3H]-MPP+</e1> release.","Substrate"
"Reuptake of extracellular <e1>noradrenaline</e1> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the <e2>noradrenaline transporter</e2> (NAT, uptake 1).","Substrate"
"Reuptake of extracellular <e1>noradrenaline</e1> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (<e2>NAT</e2>, uptake 1).","Substrate"
"Reuptake of extracellular noradrenaline (<e1>NA</e1>) into superior cervical ganglion (SCG) neurones is mediated by means of the <e2>noradrenaline transporter</e2> (NAT, uptake 1).","Substrate"
"Reuptake of extracellular noradrenaline (<e1>NA</e1>) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (<e2>NAT</e2>, uptake 1).","Substrate"
"The outflow of <e1>[3H]-MPP+</e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for <e2>OCT</e2>-related transmembrane transporters.","Substrate"
"The outflow of <e1>[3H]-MPP+</e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related <e2>transmembrane transporters</e2>.","Substrate"
"The outflow of [3H]-<e1>MPP+</e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for <e2>OCT</e2>-related transmembrane transporters.","Substrate"
"The outflow of [3H]-<e1>MPP+</e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related <e2>transmembrane transporters</e2>.","Substrate"
"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, <e1>guanidine</e1>, choline and amantadine as potential substrates for <e2>OCT</e2>-related transmembrane transporters.","Substrate"
"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, <e1>guanidine</e1>, choline and amantadine as potential substrates for OCT-related <e2>transmembrane transporters</e2>.","Substrate"
"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, <e1>choline</e1> and amantadine as potential substrates for <e2>OCT</e2>-related transmembrane transporters.","Substrate"
"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, <e1>choline</e1> and amantadine as potential substrates for OCT-related <e2>transmembrane transporters</e2>.","Substrate"
"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and <e1>amantadine</e1> as potential substrates for <e2>OCT</e2>-related transmembrane transporters.","Substrate"
"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and <e1>amantadine</e1> as potential substrates for OCT-related <e2>transmembrane transporters</e2>.","Substrate"
"Long-term administration of <e1>propargylamines</e1> to rats increased the activities of antioxidative enzymes <e2>superoxide dismutase</e2> (SOD) and catalase in the brain regions containing dopamine neurons.","Upregulator"
"Long-term administration of <e1>propargylamines</e1> to rats increased the activities of antioxidative enzymes superoxide dismutase (<e2>SOD</e2>) and catalase in the brain regions containing dopamine neurons.","Upregulator"
"Long-term administration of <e1>propargylamines</e1> to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and <e2>catalase</e2> in the brain regions containing dopamine neurons.","Upregulator"
"<e1>Rasagiline</e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic <e2>Bcl-2</e2> and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).","Upregulator"
"<e1>Rasagiline</e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a <e2>neurotrophic factor</e2>, glial cell line-derived neurotrophic factor (GDNF).","Upregulator"
"<e1>Rasagiline</e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, <e2>glial cell line-derived neurotrophic factor</e2> (GDNF).","Upregulator"
"<e1>Rasagiline</e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (<e2>GDNF</e2>).","Upregulator"
"An inhibitor of <e2>type B monoamine oxidase</e2> (MAO-B), <e1>(-)deprenyl</e1> (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.","Downregulator"
"An inhibitor of type B monoamine oxidase (<e2>MAO-B</e2>), <e1>(-)deprenyl</e1> (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.","Downregulator"
"An inhibitor of <e2>type B monoamine oxidase</e2> (MAO-B), (-)deprenyl (<e1>selegiline</e1>), was reported to have neuroprotective activity, but clinical trials failed to confirm it.","Downregulator"
"An inhibitor of type B monoamine oxidase (<e2>MAO-B</e2>), (-)deprenyl (<e1>selegiline</e1>), was reported to have neuroprotective activity, but clinical trials failed to confirm it.","Downregulator"
"These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active <e1>PBZ</e1> metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the <e2>cyclo-oxygenase</e2> (COX) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.","Regulator"
"These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active <e1>PBZ</e1> metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (<e2>COX</e2>) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.","Regulator"
"These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active <e1>PBZ</e1> metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, <e2>COX-1</e2> and COX-2 or; (d) a combination of these factors.","Regulator"
"These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active <e1>PBZ</e1> metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, COX-1 and <e2>COX-2</e2> or; (d) a combination of these factors.","Regulator"
"A streamlined and high-yielding synthesis of <e1>aprepitant</e1> (1), a potent <e2>substance P (SP) receptor</e2> antagonist, is described.","Antagonist"
"Practical asymmetric synthesis of <e1>aprepitant</e1>, a potent human <e2>NK-1 receptor</e2> antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.","Antagonist"
"Pentosan polysulfate <e1>sodium</e1> (PPS) has been shown to exert antitumor activity by antagonizing the binding of <e2>bFGF</e2> to cell surface receptors.","Regulator"
"Pentosan polysulfate <e1>sodium</e1> (PPS) has been shown to exert antitumor activity by antagonizing the binding of <e2>bFGF</e2> to cell surface receptors.","Antagonist"
"Colocalization of <e2>RhBG</e2> with carbonic anhydrase II, the <e1>thiazide</e1>-sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells.","Regulator"
"Localization of the <e1>ammonium</e1> transporter proteins <e2>RhBG</e2> and RhCG in mouse kidney.","Substrate"
"Localization of the <e1>ammonium</e1> transporter proteins RhBG and <e2>RhCG</e2> in mouse kidney.","Substrate"
"Published literature on the nitric oxide-cyclic guanosine monophosphate (cGMP) pathway for penile erection and on <e2>PDE5</e2> inhibition using <e1>sildenafil</e1> as the model for pharmacologic PDE5 inhibition are assessed.","Downregulator"
"<e1>Sildenafil</e1> exhibits inhibitory potency against <e2>PDE</e2>5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods.","Downregulator"
"<e1>Sildenafil</e1> exhibits inhibitory potency against <e2>PDE5</e2> and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods.","Downregulator"
"<e1>Sildenafil</e1> exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment <e2>PDE6</e2>, the predominant PDE in the phototransduction cascade in rods.","Downregulator"
"As free <e1>sildenafil</e1> plasma concentrations approach concentrations sufficient to inhibit retinal <e2>PDE6</e2>, usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.","Downregulator"
"Published literature on the nitric oxide-cyclic guanosine monophosphate (cGMP) pathway for penile erection and on <e2>PDE5</e2> inhibition using <e1>sildenafil</e1> as the model for pharmacologic PDE5 inhibition are assessed.","Downregulator"
"Published literature on the nitric oxide-cyclic guanosine monophosphate (<e1>cGMP</e1>) pathway for penile erection and on <e2>PDE5</e2> inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed.","Downregulator"
"Published literature on the nitric oxide-cyclic guanosine monophosphate (<e1>cGMP</e1>) pathway for penile erection and on <e2>PDE5</e2> inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed.","Substrate"
"Published literature on the nitric oxide-cyclic guanosine monophosphate (<e1>cGMP</e1>) pathway for penile erection and on <e2>PDE</e2>5 inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed.","Substrate"
"These two alleles were shown previously to be associated with <e1>ivermectin</e1> susceptibility (HG1A) and resistance (<e2>HG1E</e2>), respectively.","Not"
"These two alleles were shown previously to be associated with <e1>ivermectin</e1> susceptibility (<e2>HG1A</e2>) and resistance (HG1E), respectively.","Regulator"
"Study of the nematode putative <e2>GABA type-A receptor</e2> subunits: evidence for modulation by <e1>ivermectin</e1>.","Regulator"
"However, when coapplied with 10 micro m <e1>GABA</e1>, ivermectin potentiated the GABA-evoked current of the <e2>GAB-1</e2>/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.","Regulator"
"When gab-1 was coexpressed with either the <e2>HG1A</e2> allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid (<e1>GABA</e1>)-responsive channels with different sensitivity to the agonist were formed.","Regulator"
"However, when coapplied with 10 micro m <e1>GABA</e1>, ivermectin potentiated the GABA-evoked current of the <e2>GAB-1</e2>/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.","Regulator"
"When gab-1 was coexpressed with either the HG1A allele or the <e2>HG1E</e2> allele in Xenopus oocytes, gamma-aminobutyric acid (<e1>GABA</e1>)-responsive channels with different sensitivity to the agonist were formed.","Regulator"
"Two alleles of the <e2>HG1</e2> gene, which encodes a putative <e1>GABA</e1> receptor alpha/gamma subunit, were isolated from Haemonchus contortus.","Regulator"
"However, when coapplied with 10 micro m <e1>GABA</e1>, ivermectin potentiated the GABA-evoked current of the <e2>GAB-1</e2>/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.","Regulator"
"We demonstrated that the coexpressed HG1 and GAB-1 receptors are GABA-responsive, and provide evidence for the possible involvement of <e2>GABA receptors</e2> in the mechanism of <e1>ivermectin</e1> resistance.","Regulator"
"However, when coapplied with 10 micro m GABA, <e1>ivermectin</e1> potentiated the GABA-evoked current of the <e2>GAB-1</e2>/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.","Upregulator"
"These two alleles were shown previously to be associated with <e1>ivermectin</e1> susceptibility (<e2>HG1A</e2>) and resistance (HG1E), respectively.","Upregulator"
"However, when coapplied with 10 micro m GABA, <e1>ivermectin</e1> potentiated the GABA-evoked current of the <e2>GAB-1</e2>/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.","Downregulator"
"These two alleles were shown previously to be associated with <e1>ivermectin</e1> susceptibility (HG1A) and resistance (<e2>HG1E</e2>), respectively.","Downregulator"
"Initial studies showed that <e1>yohimbine</e1> was about 4- and 15-fold more selective for the human <e2>alpha2C-adrenoceptor</e2> in comparison with the alpha2A- and alpha2B-adrenoceptors, respectively.","Regulator"
"Initial studies showed that <e1>yohimbine</e1> was about 4- and 15-fold more selective for the human <e2>alpha2C-adrenoceptor</e2> in comparison with the alpha2A- and alpha2B-adrenoceptors, respectively.","Regulator"
"Initial studies showed that <e1>yohimbine</e1> was about 4- and 15-fold more selective for the human <e2>alpha2C-adrenoceptor</e2> in comparison with the alpha2A- and alpha2B-adrenoceptors, respectively.","Regulator"
"Initial studies showed that <e1>yohimbine</e1> was about 4- and 15-fold more selective for the <e2>human alpha2C-adrenoceptor</e2> in comparison with the alpha2A- and alpha2B-adrenoceptors, respectively.","Regulator"
"<e1>Yohimbine</e1> dimers exhibiting selectivity for the <e2>human alpha 2C-adrenoceptor</e2> subtype.","Regulator"
"<e1>Yohimbine</e1> is a potent and selective <e2>alpha2- versus alpha1-adrenoceptor</e2> antagonist.","Antagonist"
"These results demonstrate that <e1>imidazoquinoline</e1> molecules directly induce pDC maturation as determined by cytokine induction, <e2>CCR7</e2> and co-stimulatory marker expression and prolonging viability.","Regulator"
"Plasmacytoid dendritic cells produce <e2>cytokines</e2> and mature in response to the TLR7 agonists, imiquimod and <e1>resiquimod</e1>.","Regulator"
"Plasmacytoid dendritic cells produce <e2>cytokines</e2> and mature in response to the TLR7 agonists, <e1>imiquimod</e1> and resiquimod.","Regulator"
"Results indicate that <e1>imiquimod</e1> and resiquimod induce <e2>IFN</e2>-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.","Regulator"
"Results indicate that imiquimod and <e1>resiquimod</e1> induce <e2>IFN-alpha</e2> and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.","Regulator"
"Results indicate that imiquimod and <e1>resiquimod</e1> induce <e2>IFN</e2>-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.","Regulator"
"These results demonstrate that <e1>imidazoquinoline</e1> molecules directly induce pDC maturation as determined by <e2>cytokine</e2> induction, CCR7 and co-stimulatory marker expression and prolonging viability.","Upregulator"
"The immune response modifiers, <e1>imiquimod</e1> and resiquimod, are TLR7 agonists that induce <e2>type I interferon</e2> in numerous species, including humans.","Upregulator"
"Results indicate that <e1>imiquimod</e1> and resiquimod induce <e2>IFN-alpha</e2> and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.","Upregulator"
"Results indicate that <e1>imiquimod</e1> and resiquimod induce IFN-alpha and <e2>IFN-omega</e2> from purified pDC, and pDC are the principle IFN-producing cells in the blood.","Upregulator"
"The immune response modifiers, imiquimod and <e1>resiquimod</e1>, are TLR7 agonists that induce <e2>type I interferon</e2> in numerous species, including humans.","Upregulator"
"<e1>Resiquimod</e1>-stimulated pDC also produce a number of other <e2>cytokines</e2> including TNF-alpha and IP-10.","Upregulator"
"<e1>Resiquimod</e1>-stimulated pDC also produce a number of other cytokines including <e2>TNF-alpha</e2> and IP-10.","Upregulator"
"<e1>Resiquimod</e1>-stimulated pDC also produce a number of other cytokines including TNF-alpha and <e2>IP-10</e2>.","Upregulator"
"<e1>Resiquimod</e1> enhances co-stimulatory marker expression, <e2>CCR7</e2> expression, and pDC viability.","Upregulator"
"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>TLR7</e2> agonists, imiquimod and <e1>resiquimod</e1>.","Agonist"
"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>TLR7</e2> agonists, <e1>imiquimod</e1> and resiquimod.","Agonist"
"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>TLR7</e2> agonists, <e1>imiquimod</e1> and resiquimod.","Agonist"
"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>TLR7</e2> agonists, <e1>imiquimod</e1> and resiquimod.","Agonist"
"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>TLR7</e2> agonists, imiquimod and <e1>resiquimod</e1>.","Agonist"
"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>TLR7</e2> agonists, imiquimod and <e1>resiquimod</e1>.","Agonist"
"Pre-treatment with arsenite increased protein kinase B (<e2>Akt</e2>) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after <e1>H2O2</e1>.","Regulator"
"Pre-treatment with arsenite increased <e2>protein kinase B</e2> (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after <e1>H2O2</e1>.","Upregulator"
"Pre-treatment with arsenite increased protein kinase B (<e2>Akt</e2>) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after <e1>H2O2</e1>.","Upregulator"
"Pre-treatment with <e1>arsenite</e1> increased protein kinase B (<e2>Akt</e2>) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after H2O2.","Upregulator"
"Pre-treatment with arsenite increased protein kinase B (<e2>Akt</e2>) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after <e1>H2O2</e1>.","Upregulator"
"Induction of <e2>heat shock proteins</e2> (HSPs) by <e1>sodium arsenite</e1> in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.","Upregulator"
"Induction of heat shock proteins (<e2>HSPs</e2>) by <e1>sodium arsenite</e1> in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.","Upregulator"
"The results show that transient <e1>arsenite</e1> pre-treatment induces <e2>Hsp72</e2>, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.","Upregulator"
"The results show that transient <e1>arsenite</e1> pre-treatment induces Hsp72, <e2>HO-1</e2> and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.","Upregulator"
"The results show that transient <e1>arsenite</e1> pre-treatment induces Hsp72, HO-1 and, to a lesser extent, <e2>Hsp27</e2>; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.","Upregulator"
"<e1>Arsenite</e1> triggered strong induction of <e2>HSPs</e2>, which was prevented by 1 micro g/mL cycloheximide (CXH).","Upregulator"
"Arsenite triggered strong induction of <e2>HSPs</e2>, which was prevented by 1 micro g/mL <e1>cycloheximide</e1> (CXH).","Downregulator"
"Arsenite triggered strong induction of <e2>HSPs</e2>, which was prevented by 1 micro g/mL cycloheximide (<e1>CXH</e1>).","Downregulator"
"However, while <e2>Akt</e2> phosphorylation was prevented by <e1>CHX</e1>, Erk1/2 phosphorylation was further enhanced by CHX.","Downregulator"
"In rat plasma the BrBK half-life values in the absence or in the presence of <e1>GW660511X</e1> (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, <e2>BrBK4-8</e2> and BrBK2-8 metabolites not found in human plasma.","Not"
"In rat plasma the BrBK half-life values in the absence or in the presence of <e1>GW660511X</e1> (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and <e2>BrBK2-8</e2> metabolites not found in human plasma.","Not"
"In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or <e1>omapatrilat</e1> (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, <e2>BrBK4-8</e2> and BrBK2-8 metabolites not found in human plasma.","Not"
"In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or <e1>omapatrilat</e1> (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and <e2>BrBK2-8</e2> metabolites not found in human plasma.","Not"
"In human plasma the BrBK half-life values in the absence or in the presence of <e1>GW660511X</e1> (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, <e2>BrBK1-5</e2> and Br-Phe.","Not"
"In human plasma the BrBK half-life values in the absence or in the presence of <e1>GW660511X</e1> (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, <e2>BrBK1-7</e2>, BrBK1-5 and Br-Phe.","Not"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<e2>NEP</e2> inhibitors <e1>GW660511X</e1> and omapatrilat.","Not"
"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 <e2>Br-Phe5</e2>) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and <e1>omapatrilat</e1>) currently under clinical trial.","Not"
"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) <e2>BrBK</e2> in the presence of two new dual ACE/NEP inhibitors (<e1>GW660511X</e1> and omapatrilat) currently under clinical trial.","Regulator"
"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) <e2>BrBK</e2> in the presence of two new dual ACE/NEP inhibitors (GW660511X and <e1>omapatrilat</e1>) currently under clinical trial.","Regulator"
"Investigation of <e2>bradykinin</e2> metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors <e1>GW660511X</e1> and omapatrilat.","Regulator"
"Investigation of <e2>bradykinin</e2> metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and <e1>omapatrilat</e1>.","Regulator"
"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) <e2>BrBK</e2> in the presence of two new dual ACE/NEP inhibitors (<e1>GW660511X</e1> and omapatrilat) currently under clinical trial.","Regulator"
"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) <e2>BrBK</e2> in the presence of two new dual ACE/NEP inhibitors (GW660511X and <e1>omapatrilat</e1>) currently under clinical trial.","Regulator"
"In human plasma the BrBK half-life values in the absence or in the presence of <e1>GW660511X</e1> (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into <e2>BrBK1-8</e2>, BrBK1-7, BrBK1-5 and Br-Phe.","Upregulator"
"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 <e2>Br-Phe5</e2>) BrBK in the presence of two new dual ACE/NEP inhibitors (<e1>GW660511X</e1> and omapatrilat) currently under clinical trial.","Upregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or <e1>omapatrilat</e1> (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into <e2>BrBK1-8</e2>, BrBK1-7, BrBK1-5 and Br-Phe.","Upregulator"
"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 <e2>Br-Phe5</e2>) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and <e1>omapatrilat</e1>) currently under clinical trial.","Upregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or <e1>omapatrilat</e1> (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into <e2>BrBK1-8</e2>, BrBK1-7, BrBK1-5 and Br-Phe.","Upregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of <e1>GW660511X</e1> (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, <e2>BrBK1-5</e2> and Br-Phe.","Downregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of <e1>GW660511X</e1> (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, <e2>BrBK1-7</e2>, BrBK1-5 and Br-Phe.","Downregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or <e1>omapatrilat</e1> (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, <e2>BrBK1-5</e2> and Br-Phe.","Downregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or <e1>omapatrilat</e1> (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, <e2>BrBK1-7</e2>, BrBK1-5 and Br-Phe.","Downregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or <e1>omapatrilat</e1> (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, <e2>BrBK1-5</e2> and Br-Phe.","Downregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or <e1>omapatrilat</e1> (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, <e2>BrBK1-7</e2>, BrBK1-5 and Br-Phe.","Downregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or <e1>omapatrilat</e1> (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, <e2>BrBK1-5</e2> and Br-Phe.","Downregulator"
"In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or <e1>omapatrilat</e1> (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, <e2>BrBK1-7</e2>, BrBK1-5 and Br-Phe.","Downregulator"
"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 <e2>Br-Phe5</e2>) BrBK in the presence of two new dual ACE/NEP inhibitors (<e1>GW660511X</e1> and omapatrilat) currently under clinical trial.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE</e2>/NEP inhibitors <e1>GW660511X</e1> and omapatrilat.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<e2>NEP</e2> inhibitors <e1>GW660511X</e1> and omapatrilat.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<e2>NEP</e2> inhibitors GW660511X and <e1>omapatrilat</e1>.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE</e2>/NEP inhibitors <e1>GW660511X</e1> and omapatrilat.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<e2>NEP</e2> inhibitors <e1>GW660511X</e1> and omapatrilat.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE</e2>/NEP inhibitors GW660511X and <e1>omapatrilat</e1>.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<e2>NEP</e2> inhibitors GW660511X and <e1>omapatrilat</e1>.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE</e2>/NEP inhibitors GW660511X and <e1>omapatrilat</e1>.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE</e2>/NEP inhibitors <e1>GW660511X</e1> and omapatrilat.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE</e2>/NEP inhibitors <e1>GW660511X</e1> and omapatrilat.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<e2>NEP</e2> inhibitors <e1>GW660511X</e1> and omapatrilat.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE</e2>/NEP inhibitors GW660511X and <e1>omapatrilat</e1>.","Downregulator"
"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<e2>NEP</e2> inhibitors GW660511X and <e1>omapatrilat</e1>.","Downregulator"
"Experimental evidence from the use of agents with enhanced selectivity for <e2>BuChE</e2> (<e1>cymserine</e1> analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.","Regulator"
"Experimental evidence from the use of agents with enhanced selectivity for <e2>BuChE</e2> (cymserine analogues, <e1>MF-8622</e1>) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.","Regulator"
"Experimental evidence from the use of agents with enhanced selectivity for <e2>BuChE</e2> (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, <e1>rivastigmine</e1>, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.","Downregulator"
"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both <e2>AChE</e2> and BuChE, <e1>rivastigmine</e1>, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.","Downregulator"
"Experimental evidence from the use of agents with enhanced selectivity for <e2>BuChE</e2> (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, <e1>rivastigmine</e1>, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.","Downregulator"
"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both <e2>AChE</e2> and BuChE, <e1>rivastigmine</e1>, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.","Downregulator"
"Experimental evidence from the use of agents with enhanced selectivity for <e2>BuChE</e2> (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, <e1>rivastigmine</e1>, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.","Downregulator"
"Acetylcholinesterase (<e2>AChE</e2>) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain <e1>acetylcholine</e1> (ACh) levels.","Substrate"
"Acetylcholinesterase (AChE) predominates in the healthy brain, with <e2>butyrylcholinesterase</e2> (BuChE) considered to play a minor role in regulating brain <e1>acetylcholine</e1> (ACh) levels.","Substrate"
"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (<e2>BuChE</e2>) considered to play a minor role in regulating brain <e1>acetylcholine</e1> (ACh) levels.","Substrate"
"<e2>Acetylcholinesterase</e2> (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain <e1>acetylcholine</e1> (ACh) levels.","Substrate"
"Acetylcholinesterase (<e1>ACh</e1>E) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels.","Substrate"
"Acetylcholinesterase (<e1>ACh</e1>E) predominates in the healthy brain, with <e2>butyrylcholinesterase</e2> (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels.","Substrate"
"Acetylcholinesterase (<e1>ACh</e1>E) predominates in the healthy brain, with butyrylcholinesterase (<e2>BuChE</e2>) considered to play a minor role in regulating brain acetylcholine (ACh) levels.","Substrate"
"<e2>Acetylcholinesterase</e2> (<e1>ACh</e1>E) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels.","Substrate"
"A low toxicity maintenance regime, using <e1>eicosapentaenoic acid</e1> and readily available drugs, for mantle cell lymphoma and other malignancies with excess <e2>cyclin D1</e2> levels.","Regulator"
"Agents which have recently been shown to block <e2>cyclin D1</e2> translation by regulating calcium levels are the <e1>unsaturated essential fatty acid</e1>, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.","Downregulator"
"A low toxicity maintenance regime, using <e1>eicosapentaenoic acid</e1> and readily available drugs, for mantle cell lymphoma and other malignancies with excess <e2>cyclin D1</e2> levels.","Downregulator"
"Agents which have recently been shown to block <e2>cyclin D1</e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (<e1>EPA</e1>), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.","Downregulator"
"Agents which have recently been shown to block <e2>cyclin D1</e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic <e1>thiazolidinediones</e1>, and the antifungal agent, clotrimazole.","Downregulator"
"Agents which have recently been shown to block <e2>cyclin D1</e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, <e1>clotrimazole</e1>.","Downregulator"
"<e1>Angiotensin II</e1> acting on <e2>angiotensin AT1 receptors</e2> at the central nervous system appears to have an important role in these modulatory processes.","Regulator"
"We investigated the effect of <e2>AT1 receptor</e2> blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent <e1>pancuronium bromide</e1>.","Downregulator"
"<e2>Angiotensin AT1 receptor</e2> antagonist <e1>losartan</e1> and the defence reaction in the anaesthetised rat.","Antagonist"
"Defective processing of the <e2>transforming growth factor-beta1</e2> in <e1>azoxymethane</e1>-induced mouse colon tumors.","Regulator"
"Unlike OFQ II(1-17), high concentrations of its C-terminal extension, <e2>OFQ II(1-28)</e2>, stimulated <e1>[35S]-GTPgammaS</e1> binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.","Not"
"Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate <e1>[35S]-GTPgammaS</e1> binding in cells expressing the <e2>mu opioid receptor</e2>.","Not"
"Unlike OFQ II(1-17), high concentrations of its <e1>C</e1>-terminal extension, <e2>OFQ II(1-28)</e2>, stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.","Part_of"
"Utilizing agonist-stimulated GTPgammaS autoradiography, we analyzed the ability of preproorphanin FQ (pp<e2>OFQ</e2>) peptides to stimulate <e1>[35S]-GTPgammaS</e1> binding in adult rat brain.","Regulator"
"Utilizing agonist-stimulated GTPgammaS autoradiography, we analyzed the ability of preproorphanin FQ (<e2>ppOFQ</e2>) peptides to stimulate <e1>[35S]-GTPgammaS</e1> binding in adult rat brain.","Regulator"
"Orphanin FQ (OFQ) stimulated <e1>[35S]-GTPgammaS</e1> binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (<e2>ORL1</e2>) receptor.","Regulator"
"<e2>Orphanin FQ</e2> (OFQ) stimulated <e1>[35S]-GTPgammaS</e1> binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.","Regulator"
"Utilizing agonist-stimulated GTPgammaS autoradiography, we analyzed the ability of preproorphanin FQ (pp<e2>OFQ</e2>) peptides to stimulate <e1>[35S]-GTPgammaS</e1> binding in adult rat brain.","Regulator"
"Orphanin FQ (<e2>OFQ</e2>) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [<e1>125I</e1>]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.","Regulator"
"Unlike <e2>OFQ II(1-17)</e2>, high concentrations of its C-terminal extension, OFQ II(1-28), stimulated <e1>[35S]-GTPgammaS</e1> binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.","Regulator"
"Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated <e1>[35S]-GTPgammaS</e1> binding in a <e2>mu (mu) opioid receptor</e2>-like distribution and the effect was blocked by naloxone.","Regulator"
"Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a <e2>mu (mu) opioid receptor</e2>-like distribution and the effect was blocked by <e1>naloxone</e1>.","Regulator"
"Binding and <e1>GTPgammaS</e1> autoradiographic analysis of preproorphanin precursor peptide products at the <e2>ORL1</e2> and opioid receptors.","Regulator"
"Binding and <e1>GTPgammaS</e1> autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and <e2>opioid receptors</e2>.","Regulator"
"Binding and <e1>GTPgammaS</e1> autoradiographic analysis of <e2>preproorphanin precursor peptide</e2> products at the ORL1 and opioid receptors.","Regulator"
"Unlike OFQ II(1-17), high concentrations of its C-terminal extension, <e2>OFQ II(1-28)</e2>, stimulated <e1>[35S]-GTPgammaS</e1> binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.","Regulator"
"RESULTS: <e1>Rolipram</e1> unmasked the inhibitory effect of <e2>beta(2)-adrenoceptor</e2> stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4).","Regulator"
"CONCLUSIONS: Inhibition of PDE4 by <e1>rolipram</e1> unmasks <e2>beta(2)-adrenergic</e2> blockade of LTC(4) synthesis caused by FMLP/B.","Regulator"
"RESULTS: Rolipram unmasked the inhibitory effect of <e2>beta(2)-adrenoceptor</e2> stimulation with <e1>salmeterol</e1> and significantly attenuated the stimulated release of AA and subsequent LTC(4).","Upregulator"
"Inhibition corresponded to increased cAMP production caused by <e1>rolipram</e1> alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of <e2>gIV-PLA(2)</e2> in FMLP/B-activated eosinophils.","Downregulator"
"Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus <e1>salmeterol</e1> and blocked proportionately the phosphorylation and activation of <e2>gIV-PLA(2)</e2> in FMLP/B-activated eosinophils.","Downregulator"
"OBJECTIVE: To determine (a) whether <e2>PDE4</e2> inhibition alone with <e1>rolipram</e1> blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.","Downregulator"
"OBJECTIVE: To determine (a) whether <e2>PDE4</e2> inhibition alone with <e1>rolipram</e1> blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.","Downregulator"
"Blockade of <e1>LTC4</e1> synthesis caused by additive inhibition of <e2>gIV-PLA2</e2> phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.","Substrate"
"Tazarotene is an acetylenic retinoid which is metabolised to <e1>tazarotenic acid</e1> and which binds selectively to the <e2>retinoid receptors</e2> RARbeta and RARgamma.","Regulator"
"Tazarotene is an acetylenic retinoid which is metabolised to <e1>tazarotenic acid</e1> and which binds selectively to the retinoid receptors <e2>RARbeta</e2> and RARgamma.","Regulator"
"Tazarotene is an acetylenic retinoid which is metabolised to <e1>tazarotenic acid</e1> and which binds selectively to the retinoid receptors RARbeta and <e2>RARgamma</e2>.","Regulator"
"<e1>Tazarotene</e1> is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the <e2>retinoid receptors</e2> RARbeta and RARgamma.","Regulator"
"<e1>Tazarotene</e1> is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors <e2>RARbeta</e2> and RARgamma.","Regulator"
"<e1>Tazarotene</e1> is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and <e2>RARgamma</e2>.","Regulator"
"Tazarotene is an <e1>acetylenic retinoid</e1> which is metabolised to tazarotenic acid and which binds selectively to the <e2>retinoid receptors</e2> RARbeta and RARgamma.","Regulator"
"Tazarotene is an <e1>acetylenic retinoid</e1> which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors <e2>RARbeta</e2> and RARgamma.","Regulator"
"Tazarotene is an <e1>acetylenic retinoid</e1> which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and <e2>RARgamma</e2>.","Regulator"
"These effects were not mimicked by oral administration of the <e2>beta 2-adrenoceptor</e2> agonist salbutamol even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of <e1>DL-propranolol</e1> (200 mg/kg diet).","Not"
"The potent anabolic effects of the beta 2-adrenoceptor agonist <e1>clenbuterol</e1> on skeletal muscle have been reported to be independent of actions on <e2>beta-adrenoceptors</e2>.","Not"
"Anabolic effects of <e1>clenbuterol</e1> on skeletal muscle are mediated by <e2>beta 2-adrenoceptor</e2> activation.","Regulator"
"Anabolic effects of <e1>clenbuterol</e1> on skeletal muscle are mediated by <e2>beta 2-adrenoceptor</e2> activation.","Upregulator"
"These effects were not mimicked by oral administration of the <e2>beta 2-adrenoceptor</e2> agonist <e1>salbutamol</e1> even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).","Agonist"
"Anabolic effects of <e1>clenbuterol</e1> on skeletal muscle are mediated by <e2>beta 2-adrenoceptor</e2> activation.","Agonist"
"Anabolic effects of <e1>clenbuterol</e1> on skeletal muscle are mediated by <e2>beta 2-adrenoceptor</e2> activation.","Agonist"
"In the hot-plate test in mice, the antinociceptive action of the <e2>alpha 2-adrenoceptor</e2> agonist, <e1>UK 14,304</e1>, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.","Agonist"
"The preferential <e2>alpha 2A-adrenoceptor</e2> partial agonist, <e1>guanfacine</e1>, partially inhibited UK 14,304-induced antinociception.","Agonist"
"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, <e1>UK 14,304</e1>, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent <e2>alpha 2A-adrenoceptor</e2> antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.","Agonist"
"In the hot-plate test in mice, the antinociceptive action of the <e2>alpha 2-adrenoceptor</e2> agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, <e1>idazoxan</e1>, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.","Antagonist"
"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent <e2>alpha 2A-adrenoceptor</e2> antagonist, <e1>RX 821002</e1> and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.","Antagonist"
"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent <e2>alpha 2A-adrenoceptor</e2> antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, <e1>BRL 44408</e1>.","Antagonist"
"These characteristics of the bound PLP suggest that <e2>SDH</e2> catalysis is not facilitated by forming the resonance-stabilized structure of the <e1>PLP-Ser aldimine</e1> as seen in aminotransferases.","Not"
"Formation of pyruvate by <e2>SDH</e2> is a two-step reaction in which the <e1>hydroxyl</e1> group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.","Part_of"
"<e2>SDH</e2> (L-<e1>serine</e1> dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Part_of"
"The phosphate group of <e1>PLP</e1> is surrounded by a characteristic <e2>G-rich sequence</e2> ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.","Part_of"
"The phosphate group of PLP is surrounded by a characteristic <e2>G-rich sequence</e2> ((168)<e1>GGGGL</e1>(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.","Part_of"
"<e2>SDH</e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (<e1>PLP</e1>)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Regulator"
"The <e2>holo-SDH</e2> crystallized with <e1>O-methylserine</e1> (OMS) was also determined at 2.6 A resolution by molecular replacement.","Regulator"
"The <e2>holo-SDH</e2> crystallized with O-methylserine (<e1>OMS</e1>) was also determined at 2.6 A resolution by molecular replacement.","Regulator"
"The <e2>holo-SDH</e2> contained PLP-OMS <e1>aldimine</e1> in the active site, indicating that OMS can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur.","Regulator"
"The <e2>holo-SDH</e2> crystallized with O-methylserine (<e1>OMS</e1>) was also determined at 2.6 A resolution by molecular replacement.","Regulator"
"These characteristics of the bound PLP suggest that SDH catalysis is not facilitated by forming the resonance-stabilized structure of the <e1>PLP-Ser aldimine</e1> as seen in <e2>aminotransferases</e2>.","Regulator"
"<e2>SDH</e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the <e1>pyridoxal 5'-phosphate</e1> (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Cofactor"
"SDH (L-serine dehydratase, <e2>EC 4.3.1.17</e2>) catalyzes the <e1>pyridoxal 5'-phosphate</e1> (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Cofactor"
"SDH <e2>(L-serine dehydratase</e2>, EC 4.3.1.17) catalyzes the <e1>pyridoxal 5'-phosphate</e1> (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Cofactor"
"<e2>SDH</e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (<e1>PLP</e1>)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Cofactor"
"SDH (L-serine dehydratase, <e2>EC 4.3.1.17</e2>) catalyzes the pyridoxal 5'-phosphate (<e1>PLP</e1>)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Cofactor"
"SDH <e2>(L-serine dehydratase</e2>, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (<e1>PLP</e1>)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Cofactor"
"The <e2>holo-SDH</e2> contained <e1>PLP</e1>-OMS aldimine in the active site, indicating that OMS can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur.","Cofactor"
"<e2>SDH</e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>pyruvate</e1> and ammonia.","Substrate"
"<e2>SDH</e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>pyruvate</e1> and ammonia.","Substrate"
"<e2>SDH</e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>pyruvate</e1> and ammonia.","Substrate"
"SDH (L-serine dehydratase, <e2>EC 4.3.1.17</e2>) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>pyruvate</e1> and ammonia.","Substrate"
"SDH <e2>(L-serine dehydratase</e2>, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>pyruvate</e1> and ammonia.","Substrate"
"<e2>SDH</e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>ammonia</e1>.","Substrate"
"SDH (L-serine dehydratase, <e2>EC 4.3.1.17</e2>) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>ammonia</e1>.","Substrate"
"SDH <e2>(L-serine dehydratase</e2>, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>ammonia</e1>.","Substrate"
"<e2>SDH</e2> (<e1>L-serine</e1> dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Substrate"
"SDH (<e1>L-serine</e1> dehydratase, <e2>EC 4.3.1.17</e2>) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Substrate"
"SDH (<e1>L-serine</e1> dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.","Substrate"
"Formation of pyruvate by <e2>SDH</e2> is a two-step reaction in which the hydroxyl group of serine is cleaved to produce <e1>aminoacrylate</e1>, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.","Substrate"
"Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated <e2>Ras</e2>-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"Blocking <e2>EGFR</e2> signaling with the EGFR/HER-2 kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated <e2>Ras</e2>-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated <e2>Ras</e2>-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"Blocking <e2>EGFR</e2> signaling with the EGFR/HER-2 kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"Blocking EGFR signaling with the EGFR/<e2>HER-2</e2> kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"Ras-CM and TGF-alpha also increase <e2>PI3-K</e2> activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by <e1>GW572016</e1>.","Downregulator"
"Blocking <e2>EGFR</e2> signaling with the EGFR/HER-2 kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"Blocking <e2>EGFR</e2> signaling with the EGFR/HER-2 kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"Blocking <e2>EGFR</e2> signaling with the EGFR/HER-2 kinase inhibitor (KI) <e1>GW572016</e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.","Downregulator"
"(-)-Isoprenaline and a nonconventional <e2>beta(3)-adrenoceptor</e2> agonist, <e1>(+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride</e1> ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.","Agonist"
"(-)-Isoprenaline and a nonconventional <e2>beta(3)-adrenoceptor</e2> agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride (<e1>(+/-)-CGP12177A</e1>), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.","Agonist"
"Pretreatment with a combination of <e1>(+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate</e1> (CGP20712A, a selective <e2>beta(1)-adrenoceptor</e2> antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.","Antagonist"
"Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (<e1>CGP20712A</e1>, a selective <e2>beta(1)-adrenoceptor</e2> antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.","Antagonist"
"Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and <e1>(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride</e1> (ICI-118,5511, a selective <e2>beta(2)-adrenoceptor</e2> antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.","Antagonist"
"Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (<e1>ICI-118,5511</e1>, a selective <e2>beta(2)-adrenoceptor</e2> antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.","Antagonist"
"BACKGROUND: The <e2>norepinephrine transporter</e2> (NET) is a high-affinity transporter for <e1>catecholamines</e1>.","Regulator"
"BACKGROUND: The norepinephrine transporter (<e2>NET</e2>) is a high-affinity transporter for <e1>catecholamines</e1>.","Regulator"
"The specificity of tracer uptake was determined by adding the <e2>NET</e2> inhibitor <e1>imipramine</e1>.","Downregulator"
"<e1>[(131)I]MIBG</e1> uptake in PC12 cells, which express the <e2>NET</e2> endogenously, was 20- to 28-fold lower than in transduced cells.","Substrate"
"Parental and A431<e2>NET</e2> cells were xenotransplanted into nude mice and tumor uptake of <e1>[(123)I]MIBG</e1> in vivo was determined after tracer administration.","Substrate"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, <e1>formoterol</e1>, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, <e1>broxaterol</e1>) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (<e1>epinephrine</e1>, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, <e1>norepinephrine</e1>, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, <e1>isoproterenol</e1>, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, <e1>fenoterol</e1>, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, <e1>salbutamol</e1>, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, <e1>salmeterol</e1>, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, <e1>terbutalin</e1>, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Agonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (<e1>propranolol</e1>, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, <e1>alprenolol</e1>, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, <e1>atenolol</e1>, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, <e1>metoprolol</e1>, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, <e1>bisoprolol</e1>, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, <e1>carvedilol</e1>, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, <e1>pindolol</e1>, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, <e1>BRL 37344</e1>, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, <e1>CGP 20712</e1>, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, <e1>SR 59230A</e1>, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, <e1>CGP 12177</e1>, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, <e1>ICI 118551</e1>) at all three subtypes of <e2>human beta-adrenergic receptors</e2> in an identical cellular background.","Antagonist"
"Responses to <e1>isoproterenol</e1> were largely mediated through the <e2>beta1AR</e2> in control myocytes.","Regulator"
"Responses to <e1>isoproterenol</e1> were largely mediated through the <e2>beta1AR</e2> in control myocytes.","Regulator"
"To determine the possible interaction between these changes, we investigated the effect of <e2>NCX</e2> overexpression on responses to <e1>isoproterenol</e1> in adult rat ventricular myocytes.","Regulator"
"Responses to <e1>isoproterenol</e1> could be restored to normal by <e2>beta2AR</e2> blockade, suggesting a beta2AR-mediated inhibition of beta1AR signalling.","Regulator"
"Responses to <e1>isoproterenol</e1> could be restored to normal by <e2>beta2AR</e2> blockade, suggesting a beta2AR-mediated inhibition of beta1AR signalling.","Regulator"
"Responses to <e1>isoproterenol</e1> could be restored to normal by <e2>beta2AR</e2> blockade, suggesting a beta2AR-mediated inhibition of beta1AR signalling.","Regulator"
"The nonsteroidal anti-inflammatory drugs <e1>flurbiprofen</e1> and ibuprofen were modified in an attempt to alter the kinetics of inhibitor binding by <e2>COX-1</e2>.","Regulator"
"The nonsteroidal anti-inflammatory drugs flurbiprofen and <e1>ibuprofen</e1> were modified in an attempt to alter the kinetics of inhibitor binding by <e2>COX-1</e2>.","Regulator"
"Manipulation of kinetic profiles in <e1>2-aryl propionic acid</e1> <e2>cyclooxygenase</e2> inhibitors.","Downregulator"
"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of <e1>GW572016</e1> to inhibit downstream <e2>ERK</e2> and Akt activation, despite inhibition of HER2 phosphorylation.","Not"
"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of <e1>GW572016</e1> to inhibit downstream ERK and <e2>Akt</e2> activation, despite inhibition of HER2 phosphorylation.","Not"
"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of <e1>GW572016</e1> to inhibit downstream <e2>ERK</e2> and Akt activation, despite inhibition of HER2 phosphorylation.","Not"
"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of <e1>GW572016</e1> to inhibit downstream ERK and <e2>Akt</e2> activation, despite inhibition of HER2 phosphorylation.","Not"
"RESULTS: GW572016 inhibited constitutive and/or ligand-induced <e2>EGFR</e2> or HER2 <e1>tyrosine</e1> phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.","Part_of"
"RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or <e2>HER2</e2> <e1>tyrosine</e1> phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.","Part_of"
"Effects of the <e2>EGFR</e2>/HER2 kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Regulator"
"Effects of the EGFR/<e2>HER2</e2> kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Regulator"
"Effects of the <e2>EGFR</e2>/HER2 kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the EGFR/<e2>HER2</e2> kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the EGFR/HER2 <e2>kinase</e2> inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the EGFR/<e2>HER2</e2> kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the <e2>EGFR</e2>/HER2 kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the EGFR/<e2>HER2</e2> kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the <e2>EGFR</e2>/HER2 kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the EGFR/<e2>HER2</e2> kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the <e2>EGFR</e2>/HER2 kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"Effects of the EGFR/<e2>HER2</e2> kinase inhibitor <e1>GW572016</e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.","Downregulator"
"<e1>Metformin</e1>, but not leptin, regulates <e2>AMP-activated protein kinase</e2> in pancreatic islets: impact on glucose-stimulated insulin secretion.","Regulator"
"Here, we explore whether 1) <e1>glucose</e1>, metformin, or leptin regulates <e2>AMPK</e2> activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate insulin secretion from human islets.","Regulator"
"Whether <e1>metformin</e1> or the satiety factor leptin, which also stimulates <e2>AMPK</e2> in muscle, regulates this enzyme in pancreatic islets is unknown.","Regulator"
"Whether <e1>metformin</e1> or the satiety factor leptin, which also stimulates <e2>AMPK</e2> in muscle, regulates this enzyme in pancreatic islets is unknown.","Upregulator"
"<e1>Metformin</e1>, but not leptin, regulates <e2>AMP-activated protein kinase</e2> in pancreatic islets: impact on glucose-stimulated insulin secretion.","Upregulator"
"<e1>Metformin</e1>, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (<e2>AMPK</e2>).","Upregulator"
"Whether <e1>metformin</e1> or the satiety factor leptin, which also stimulates <e2>AMPK</e2> in muscle, regulates this enzyme in pancreatic islets is unknown.","Upregulator"
"Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on <e1>glucose</e1>-stimulated <e2>insulin</e2> secretion.","Upregulator"
"Here, we explore whether 1) glucose, <e1>metformin</e1>, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate <e2>insulin</e2> secretion from human islets.","Downregulator"
"Here, we explore whether 1) glucose, <e1>metformin</e1>, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate <e2>insulin</e2> secretion from human islets.","Downregulator"
"Here, we explore whether 1) <e1>glucose</e1>, metformin, or leptin regulates <e2>AMPK</e2> activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate insulin secretion from human islets.","Downregulator"
"The ability of this cis-acting <e1>RA</e1>R-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.","Regulator"
"The ability of this cis-acting <e1>RA</e1>R-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an <e2>octamer transcription factor 1</e2> (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.","Regulator"
"The ability of this cis-acting <e1>RA</e1>R-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a <e2>nuclear factor of activated T cells</e2> (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.","Regulator"
"The ability of this cis-acting <e1>RA</e1>R-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (<e2>NFATc</e2>) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.","Regulator"
"The ability of this cis-acting <e1>RA</e1>R-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a <e2>cyclic AMP response element binding factor</e2> (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.","Regulator"
"The ability of this cis-acting <e1>RA</e1>R-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (<e2>CREB</e2>) site between the transcriptional start and first exon of the blr1 gene, were necessary.","Regulator"
"<e1>RA</e1> is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of <e2>blr1</e2> expression by RA.","Regulator"
"The ability of this cis-acting <e1>RA</e1>R-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (<e2>Oct1</e2>) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.","Regulator"
"A transcription factor-transcription factor binding array analysis of nuclear lysate from <e1>RA</e1>-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, <e2>NFATc3</e2>, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.","Regulator"
"A transcription factor-transcription factor binding array analysis of nuclear lysate from <e1>RA</e1>-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, NFATc3, and <e2>CREB2</e2> were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.","Regulator"
"In sum the results of the present study indicate that <e1>RA</e1>-induced expression of blr1 expression depends on a novel <e2>RA response element</e2>.","Regulator"
"Within this sequence DNase I footprinting revealed that <e1>RA</e1> induced binding of a nuclear protein complex to an element containing two <e2>GT boxes</e2>.","Regulator"
"Within this sequence DNase I footprinting revealed that <e1>RA</e1> induced binding of a <e2>nuclear protein complex</e2> to an element containing two GT boxes.","Regulator"
"Within this sequence DNase I footprinting revealed that <e1>RA</e1> induced binding of a nuclear protein complex to an element containing two <e2>GT boxes</e2>.","Regulator"
"Treatment with <e1>RA</e1>R- and RXR-selective ligands showed that <e2>RARalpha</e2> synergized with RXRalpha to transcriptionally activate blr1 expression.","Regulator"
"<e1>RA</e1> is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of <e2>blr1</e2> expression by RA.","Upregulator"
"<e1>RA</e1> is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of <e2>blr1</e2> expression by RA.","Upregulator"
"A novel <e1>retinoic acid</e1>-responsive element regulates retinoic acid-induced <e2>BLR1</e2> expression.","Upregulator"
"<e1>RA</e1> is known to induce expression of the <e2>Burkitt's lymphoma receptor 1</e2> (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.","Upregulator"
"<e1>RA</e1> is known to induce expression of the Burkitt's lymphoma receptor 1 (<e2>BLR1</e2>) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.","Upregulator"
"<e1>RA</e1> is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of <e2>blr1</e2> expression by RA.","Upregulator"
"The ability of this cis-acting <e1>RA</e1>R-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a <e2>nuclear factor of activated T cells</e2> (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.","Downregulator"
"<e1>[3H]DMI</e1> trapped in membranes was displaceable by the structurally unrelated <e2>NET</e2> inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.","Regulator"
"The present study examined the potential membrane retention of desipramine (<e1>DMI</e1>) following exposures of 293-h<e2>NET</e2> cells to DMI, and its effect on [3H]NE uptake.","Regulator"
"[3H]DMI trapped in membranes was displaceable by the structurally unrelated <e2>NET</e2> inhibitor, <e1>nisoxetine</e1>, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.","Regulator"
"The present study examined the potential membrane retention of desipramine (<e1>DMI</e1>) following exposures of 293-h<e2>NET</e2> cells to DMI, and its effect on [3H]NE uptake.","Regulator"
"[3H]DMI trapped in membranes was displaceable by the structurally unrelated <e2>NET</e2> inhibitor, <e1>nisoxetine</e1>, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.","Regulator"
"<e1>[3H]DMI</e1> trapped in membranes was displaceable by the structurally unrelated <e2>NET</e2> inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.","Regulator"
"The persistent membrane retention of <e1>desipramine</e1> causes lasting inhibition of <e2>norepinephrine transporter</e2> function.","Downregulator"
"[3H]DMI trapped in membranes was displaceable by the structurally unrelated <e2>NET</e2> inhibitor, <e1>nisoxetine</e1>, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.","Downregulator"
"<e1>Irbesartan</e1> is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (<e2>AT1</e2>-receptor).","Regulator"
"<e1>Irbesartan</e1> is a long-acting <e2>angiotensin II</e2> antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).","Downregulator"
"<e1>Irbesartan</e1> is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (<e2>AT1</e2>-receptor).","Downregulator"
"<e1>Irbesartan</e1> is a long-acting <e2>angiotensin II</e2> antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).","Antagonist"
"To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, human <e2>beta(1)-adrenoceptors</e2>, expressed in CHO cells, were labelled with <e1>(-)-[(3)H]-CGP12177</e1>.","Not"
"To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two <e2>beta(1)-adrenoceptor</e2> sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with <e1>(-)-[(3)H]-CGP12177</e1>.","Regulator"
"To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, <e2>human beta(1)-adrenoceptors</e2>, expressed in CHO cells, were labelled with <e1>(-)-[(3)H]-CGP12177</e1>.","Regulator"
"To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two <e2>beta(1)-adrenoceptor</e2> sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with <e1>(-)-[(3)H]-CGP12177</e1>.","Regulator"
"To verify the hypothesis that the non-conventional partial agonist <e1>(-)-CGP12177</e1> binds at two beta(1)-adrenoceptor sites, <e2>human beta(1)-adrenoceptors</e2>, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.","Regulator"
"To verify the hypothesis that the non-conventional partial agonist <e1>(-)-CGP12177</e1> binds at two <e2>beta(1)-adrenoceptor</e2> sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.","Regulator"
"Binding of <e1>(-)-[3H]-CGP12177</e1> at two sites in recombinant <e2>human beta 1-adrenoceptors</e2> and interaction with beta-blockers.","Regulator"
"To verify the hypothesis that the non-conventional partial agonist <e1>(-)-CGP12177</e1> binds at two beta(1)-adrenoceptor sites, <e2>human beta(1)-adrenoceptors</e2>, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.","Agonist"
"To verify the hypothesis that the non-conventional partial agonist <e1>(-)-CGP12177</e1> binds at two <e2>beta(1)-adrenoceptor</e2> sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.","Agonist"
"<e2>Perforin</e2> release from peripheral blood CTLs after PMA/ionomycin-stimulation was not influenced significantly by <e1>IMQ</e1>.","Not"
"<e1>Imiquimod</e1>, a <e2>Toll-like receptor-7</e2> agonist, induces perforin in cytotoxic T lymphocytes in vitro.","Upregulator"
"<e1>Imiquimod</e1> (IMQ), an activator of Toll-like receptor-7 (<e2>TLR-7</e2>), induces by several routes a profound anti-viral and anti-tumor effect in vivo.","Upregulator"
"Imiquimod (<e1>IMQ</e1>), an activator of <e2>Toll-like receptor-7</e2> (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.","Upregulator"
"Imiquimod (<e1>IMQ</e1>), an activator of Toll-like receptor-7 (<e2>TLR-7</e2>), induces by several routes a profound anti-viral and anti-tumor effect in vivo.","Upregulator"
"This functional synergism prompted our current experiments addressing the question whether <e1>IMQ</e1> may influence <e2>perforin</e2>-release and/or induce perforin in CTLs in vitro.","Upregulator"
"This functional synergism prompted our current experiments addressing the question whether <e1>IMQ</e1> may influence <e2>perforin</e2>-release and/or induce perforin in CTLs in vitro.","Upregulator"
"This functional synergism prompted our current experiments addressing the question whether <e1>IMQ</e1> may influence <e2>perforin</e2>-release and/or induce perforin in CTLs in vitro.","Upregulator"
"<e1>Imiquimod</e1>, a Toll-like receptor-7 agonist, induces <e2>perforin</e2> in cytotoxic T lymphocytes in vitro.","Upregulator"
"<e1>Imiquimod</e1>, a <e2>Toll-like receptor-7</e2> agonist, induces perforin in cytotoxic T lymphocytes in vitro.","Agonist"
"<e2>Ang II</e2> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in <e1>irbesartan</e1> group and lower in imidapril group.","Upregulator"
"AIM: To investigate the remodeling of mesenteric artery and the expression of TGF-beta1, <e2>c-Jun</e2> in mesenteric artery and effects of <e1>imidapril</e1> and irbesartan on the remodeling in spontaneously hypertensive rats (SHR).","Upregulator"
"The ratio of TGF-beta1 absorbed light value to <e2>GAPDH</e2> absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, <e1>imidapril</e1> group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).","Upregulator"
"AIM: To investigate the remodeling of mesenteric artery and the expression of TGF-beta1, <e2>c-Jun</e2> in mesenteric artery and effects of imidapril and <e1>irbesartan</e1> on the remodeling in spontaneously hypertensive rats (SHR).","Upregulator"
"The ratio of TGF-beta1 absorbed light value to <e2>GAPDH</e2> absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and <e1>irbesartan</e1> group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).","Upregulator"
"<e2>Ang II</e2> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in <e1>irbesartan</e1> group and lower in imidapril group.","Upregulator"
"AIM: To investigate the remodeling of mesenteric artery and the expression of <e2>TGF-beta1</e2>, c-Jun in mesenteric artery and effects of <e1>imidapril</e1> and irbesartan on the remodeling in spontaneously hypertensive rats (SHR).","Upregulator"
"The ratio of TGF-beta1 absorbed light value to <e2>GAPDH</e2> absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, <e1>imidapril</e1> group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).","Upregulator"
"AIM: To investigate the remodeling of mesenteric artery and the expression of <e2>TGF-beta1</e2>, c-Jun in mesenteric artery and effects of imidapril and <e1>irbesartan</e1> on the remodeling in spontaneously hypertensive rats (SHR).","Upregulator"
"The ratio of TGF-beta1 absorbed light value to <e2>GAPDH</e2> absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and <e1>irbesartan</e1> group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).","Upregulator"
"<e2>Ang II</e2> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in <e1>imidapril</e1> group.","Downregulator"
"CONCLUSION: <e1>Imidapril</e1> and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of <e2>TGF-beta1</e2>, c-Jun in SHR.","Downregulator"
"CONCLUSION: <e1>Imidapril</e1> and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, <e2>c-Jun</e2> in SHR.","Downregulator"
"AIM: To investigate the remodeling of mesenteric artery and the expression of <e2>TGF-beta1</e2>, c-Jun in mesenteric artery and effects of imidapril and <e1>irbesartan</e1> on the remodeling in spontaneously hypertensive rats (SHR).","Downregulator"
"AIM: To investigate the remodeling of mesenteric artery and the expression of TGF-beta1, <e2>c-Jun</e2> in mesenteric artery and effects of imidapril and <e1>irbesartan</e1> on the remodeling in spontaneously hypertensive rats (SHR).","Downregulator"
"<e2>Ang II</e2> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in <e1>imidapril</e1> group.","Downregulator"
"Plasma from <e1>duloxetine</e1>-treated subjects (ex vivo effect) dose-dependently decreased radioligand binding to <e2>human NET</e2> (maximum inhibition was 60%) (P=0.02).","Regulator"
"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (<e2>NET</e2>) function, we chronically antagonized NET by a range of doses of <e1>duloxetine</e1> [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.","Antagonist"
"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (<e2>NET</e2>) function, we chronically antagonized NET by a range of doses of duloxetine [<e1>(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine</e1>], which blocks the NE reuptake process.","Antagonist"
"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (<e1>NE</e1>) transporter (<e2>NET</e2>) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.","Substrate"
"<e1>Auranofin</e1>, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and <e2>glutathione peroxidase</e2>.","Downregulator"
"<e1>Auranofin</e1>, an antirheumatic gold compound, is an inhibitor of <e2>selenocysteine enzymes</e2>, such as thioredoxin reductase and glutathione peroxidase.","Downregulator"
"<e1>Auranofin</e1>, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as <e2>thioredoxin reductase</e2> and glutathione peroxidase.","Downregulator"
"There was significantly less <e2>thioredoxin reductase</e2> activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of <e1>auranofin</e1> used was able to selectively inhibit one of these enzyme systems.","Downregulator"
"Even though its inability to shift between the trivalent and a divalent oxidation state precludes that <e1>gallium</e1> behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with <e2>transferrin</e2> and transferrin receptor-mediated endocytosis.","Regulator"
"Even though its inability to shift between the trivalent and a divalent oxidation state precludes that <e1>gallium</e1> behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and <e2>transferrin receptor</e2>-mediated endocytosis.","Regulator"
"Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an <e1>iron</e1> analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with <e2>transferrin</e2> and transferrin receptor-mediated endocytosis.","Regulator"
"Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an <e1>iron</e1> analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and <e2>transferrin receptor</e2>-mediated endocytosis.","Regulator"
"Apart from the consequences of iron deprivation, <e1>gallium</e1> exerts cytotoxic effects by direct interaction with the iron-dependent enzyme <e2>ribonucleotide reductase</e2>, resulting in reduced dNTP pools and inhibition of DNA synthesis.","Regulator"
"Apart from the consequences of <e1>iron</e1> deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme <e2>ribonucleotide reductase</e2>, resulting in reduced dNTP pools and inhibition of DNA synthesis.","Regulator"
"Both the abundance of <e2>transferrin receptors</e2> and upregulation of ribonucleotide reductase render tumors susceptible to <e1>gallium</e1>-induced cytotoxicity.","Regulator"
"Apart from the consequences of iron deprivation, <e1>gallium</e1> exerts cytotoxic effects by direct interaction with the iron-dependent enzyme <e2>ribonucleotide reductase</e2>, resulting in reduced dNTP pools and inhibition of DNA synthesis.","Regulator"
"Furthermore, <e1>gallium</e1> also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on <e2>vacuolar-type H(+)-ATPases</e2>.","Downregulator"
"However, some experimental findings raise the question whether these effects resulting from the <e1>iron</e1>-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting <e2>tubulin</e2> polymerization.","Downregulator"
"However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of <e1>gallium</e1> are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting <e2>tubulin</e2> polymerization.","Downregulator"
"The <e2>synaptic vesicle protein SV2A</e2> is the binding site for the antiepileptic drug <e1>levetiracetam</e1>.","Regulator"
"Here, we show that the <e2>synaptic vesicle protein SV2A</e2> is the brain binding site of levetiracetam (<e1>LEV</e1>), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.","Regulator"
"The <e2>synaptic vesicle protein SV2A</e2> is the binding site for the antiepileptic drug <e1>levetiracetam</e1>.","Regulator"
"Here, we show that the synaptic vesicle protein <e2>SV2A</e2> is the brain binding site of levetiracetam (<e1>LEV</e1>), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.","Regulator"
"Here, we show that the synaptic vesicle protein <e2>SV2A</e2> is the brain binding site of levetiracetam (<e1>LEV</e1>), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.","Regulator"
"Here, we show that the synaptic vesicle protein <e2>SV2A</e2> is the brain binding site of levetiracetam (<e1>LEV</e1>), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.","Regulator"
"Here, we show that the synaptic vesicle protein <e2>SV2A</e2> is the brain binding site of levetiracetam (<e1>LEV</e1>), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.","Regulator"
"Here, we show that the synaptic vesicle protein <e2>SV2A</e2> is the brain binding site of levetiracetam (<e1>LEV</e1>), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.","Regulator"
"Here, we show that the synaptic vesicle protein <e2>SV2A</e2> is the brain binding site of levetiracetam (<e1>LEV</e1>), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.","Regulator"
"Their affinity for <e1>GABA</e1> was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two <e2>GABA binding sites</e2>.","Regulator"
"Electrophysiological properties of mouse horizontal cell <e1>GABA</e1>A receptors.","Regulator"
"Furthermore, <e2>GABA receptors</e2> of horizontal cells were modulated by extracellular application of <e1>diazepam</e1>, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.","Regulator"
"Furthermore, <e2>GABA receptors</e2> of horizontal cells were modulated by extracellular application of diazepam, <e1>zolpidem</e1>, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.","Regulator"
"Furthermore, <e2>GABA receptors</e2> of horizontal cells were modulated by extracellular application of diazepam, zolpidem, <e1>methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate</e1>, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.","Regulator"
"Furthermore, <e2>GABA receptors</e2> of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, <e1>pentobarbital</e1>, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.","Regulator"
"Furthermore, <e2>GABA receptors</e2> of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and <e1>alphaxalone</e1>, thus showing typical pharmacological properties of CNS GABAA receptors.","Regulator"
"GABA-evoked currents were completely and reversibly blocked by the competitive <e2>GABAA receptor</e2> antagonist <e1>bicuculline</e1> (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.","Antagonist"
"Cerebral <e2>histamine H1 receptor</e2> (H(1)R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and <e1>[(11)C]-doxepin</e1>.","Regulator"
"Cerebral histamine H1 receptor (<e2>H(1)R</e2>) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and <e1>[(11)C]-doxepin</e1>.","Regulator"
"Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain <e2>histamine H1-receptor</e2> occupancy using <e1>11C-doxepin</e1> positron emission tomography.","Regulator"
"This study compared the sedative profiles of the second-generation <e1>antihistamines</e1>, fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of <e2>histamine H1-receptor</e2> occupancy (H1RO) in the brain.","Regulator"
"Central effects of <e1>fexofenadine</e1> and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain <e2>histamine H1-receptor</e2> occupancy using 11C-doxepin positron emission tomography.","Regulator"
"Central effects of fexofenadine and <e1>cetirizine</e1>: measurement of psychomotor performance, subjective sleepiness, and brain <e2>histamine H1-receptor</e2> occupancy using 11C-doxepin positron emission tomography.","Regulator"
"Central effects of <e1>fexofenadine</e1> and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain <e2>histamine H1-receptor</e2> occupancy using 11C-doxepin positron emission tomography.","Regulator"
"Central effects of fexofenadine and <e1>cetirizine</e1>: measurement of psychomotor performance, subjective sleepiness, and brain <e2>histamine H1-receptor</e2> occupancy using 11C-doxepin positron emission tomography.","Regulator"
"<e2>Histamine H1-receptor</e2> (H1R) antagonists, or <e1>antihistamines</e1>, often induce sedative side effects when used for the treatment of allergic disorders.","Antagonist"
"Histamine H1-receptor (<e2>H1R</e2>) antagonists, or <e1>antihistamines</e1>, often induce sedative side effects when used for the treatment of allergic disorders.","Antagonist"
"A novel membrane sensor for <e2>histamine H1-receptor</e2> antagonist ""<e1>fexofenadine</e1>"".","Antagonist"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for <e1>5-fluorouracil</e1> (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for <e1>5-fluorouracil</e1> (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for 5-fluorouracil (<e1>5-FU</e1>) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for 5-fluorouracil (<e1>5-FU</e1>) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, <e1>UFT</e1>/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, <e1>UFT</e1>/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/<e1>LV</e1> (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/<e1>LV</e1> (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (<e1>Orzel</e1>), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (<e1>Orzel</e1>), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), <e1>capecitabine</e1> (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), <e1>capecitabine</e1> (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (<e1>Xeloda</e1>), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (<e1>Xeloda</e1>), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and <e1>S-1</e1>, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and <e1>S-1</e1>, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.","Regulator"
"While fluoropyrimidine antimetabolites have other sites of action, antifolates <e1>ZD1694</e1> (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent <e2>TS</e2> inhibitors.","Downregulator"
"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (<e1>raltitrexed</e1>, Tomudex) and AG337 (Thymitag) are more specific and potent <e2>TS</e2> inhibitors.","Downregulator"
"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, <e1>Tomudex</e1>) and AG337 (Thymitag) are more specific and potent <e2>TS</e2> inhibitors.","Downregulator"
"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and <e1>AG337</e1> (Thymitag) are more specific and potent <e2>TS</e2> inhibitors.","Downregulator"
"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (<e1>Thymitag</e1>) are more specific and potent <e2>TS</e2> inhibitors.","Downregulator"
"<e2>Thymidylate synthase</e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of <e1>2-deoxythymidine-5-monophosphate</e1>, a precursor for DNA synthesis.","Substrate"
"Thymidylate synthase (<e2>TS</e2>) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of <e1>2-deoxythymidine-5-monophosphate</e1>, a precursor for DNA synthesis.","Substrate"
"The availability of the <e1>5-FU</e1> prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that <e2>thymidine phosphorylase</e2>, the activating enzyme for 5-FU, is expressed at a higher level in tumor tissue compared with normal tissue counterparts.","Substrate"
"<e1>Orlistat</e1> is an inhibitor of <e2>pancreatic lipase</e2> which is able to block the absorption of 30% of ingested fat.","Downregulator"
"<e1>Bosentan</e1> also decreased viability as measured by the <e2>LDH</e2>, MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay.","Regulator"
"<e1>Troglitazone</e1>, bosentan and glibenclamide inhibit the <e2>bile salt export pump</e2> (Bsep) which transports taurocholate into bile.","Downregulator"
"<e1>Troglitazone</e1>, bosentan and glibenclamide inhibit the bile salt export pump (<e2>Bsep</e2>) which transports taurocholate into bile.","Downregulator"
"Troglitazone, <e1>bosentan</e1> and glibenclamide inhibit the <e2>bile salt export pump</e2> (Bsep) which transports taurocholate into bile.","Downregulator"
"Troglitazone, <e1>bosentan</e1> and glibenclamide inhibit the bile salt export pump (<e2>Bsep</e2>) which transports taurocholate into bile.","Downregulator"
"Troglitazone, bosentan and <e1>glibenclamide</e1> inhibit the <e2>bile salt export pump</e2> (Bsep) which transports taurocholate into bile.","Downregulator"
"Troglitazone, bosentan and <e1>glibenclamide</e1> inhibit the bile salt export pump (<e2>Bsep</e2>) which transports taurocholate into bile.","Downregulator"
"Troglitazone, bosentan and glibenclamide inhibit the <e2>bile salt export pump</e2> (Bsep) which transports <e1>taurocholate</e1> into bile.","Substrate"
"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (<e2>Bsep</e2>) which transports <e1>taurocholate</e1> into bile.","Substrate"
"We report here the pharmacological properties of a third selective <e2>COX-2</e2> inhibitor, <e1>valdecoxib</e1>, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.","Regulator"
"We report here the pharmacological properties of a third selective <e2>COX-2</e2> inhibitor, <e1>valdecoxib</e1>, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.","Regulator"
"Valdecoxib potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for <e1>celecoxib</e1>, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.","Regulator"
"Valdecoxib potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for <e1>rofecoxib</e1>, and 5 microM for etoricoxib.","Regulator"
"Valdecoxib potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for <e1>etoricoxib</e1>.","Regulator"
"Valdecoxib potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for <e1>rofecoxib</e1>, and 5 microM for etoricoxib.","Regulator"
"<e1>Valdecoxib</e1>: assessment of <e2>cyclooxygenase-2</e2> potency and selectivity.","Regulator"
"Valdecoxib potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for <e1>etoricoxib</e1>.","Regulator"
"We report here the pharmacological properties of a third selective <e2>COX-2</e2> inhibitor, <e1>valdecoxib</e1>, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.","Regulator"
"We report here the pharmacological properties of a third selective <e2>COX-2</e2> inhibitor, <e1>valdecoxib</e1>, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.","Downregulator"
"We report here the pharmacological properties of a third selective <e2>COX-2</e2> inhibitor, <e1>valdecoxib</e1>, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.","Downregulator"
"We report here the pharmacological properties of a third selective <e2>COX-2</e2> inhibitor, <e1>valdecoxib</e1>, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.","Downregulator"
"<e1>Valdecoxib</e1> potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.","Downregulator"
"Valdecoxib potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for <e1>celecoxib</e1>, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.","Downregulator"
"Valdecoxib potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for <e1>rofecoxib</e1>, and 5 microM for etoricoxib.","Downregulator"
"Valdecoxib potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for <e1>etoricoxib</e1>.","Downregulator"
"<e1>Valdecoxib</e1> inhibits <e2>COX-1</e2> in a competitive fashion only at very high concentrations (IC(50) = 150 microM).","Downregulator"
"<e1>Valdecoxib</e1> showed similar activity in the <e2>human whole-blood COX</e2> assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM).","Downregulator"
"<e1>Valdecoxib</e1> potently inhibits recombinant <e2>COX-2</e2>, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.","Downregulator"
"<e1>Valdecoxib</e1> inhibits <e2>COX-1</e2> in a competitive fashion only at very high concentrations (IC(50) = 150 microM).","Downregulator"
"The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing <e1>prostaglandin</e1> formation from <e2>COX-1</e2>.","Substrate"
"An angiotensin II AT1 receptor antagonist, <e1>telmisartan</e1> augments glucose uptake and <e2>GLUT4</e2> protein expression in 3T3-L1 adipocytes.","Upregulator"
"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>telmisartan</e1> caused a dose-dependent increase in mRNA levels for <e2>PPARgamma</e2> target genes such as aP2 and adiponectin.","Upregulator"
"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>telmisartan</e1> caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as <e2>aP2</e2> and adiponectin.","Upregulator"
"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>telmisartan</e1> caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and <e2>adiponectin</e2>.","Upregulator"
"By contrast, <e1>telmisartan</e1> attenuated <e2>11beta-hydroxysteroid dehydrogenase type 1</e2> mRNA level in differentiated adipocytes.","Upregulator"
"An angiotensin II AT1 receptor antagonist, <e1>telmisartan</e1> augments glucose uptake and <e2>GLUT4</e2> protein expression in 3T3-L1 adipocytes.","Upregulator"
"An <e2>angiotensin II AT1 receptor</e2> antagonist, <e1>telmisartan</e1> augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.","Antagonist"
"An angiotensin II AT1 receptor antagonist, telmisartan augments <e1>glucose</e1> uptake and <e2>GLUT4</e2> protein expression in 3T3-L1 adipocytes.","Substrate"
"Of note, we demonstrated for the first time that telmisartan augmented <e2>GLUT4</e2> protein expression and <e1>2-deoxy glucose</e1> uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.","Substrate"
"We found a strong interaction of baseline FEV(1) with the Arg16<e1>Gly</e1>cine (Gly) polymorphism in predicting bronchodilator response.","Part_of"
"Genetic variants at the <e2>beta(2)-adrenergic receptor</e2> (beta(2)AR) may modify asthma severity and <e1>albuterol</e1> responsiveness.","Regulator"
"Genetic variants at the beta(2)-adrenergic receptor (<e2>beta(2)AR</e2>) may modify asthma severity and <e1>albuterol</e1> responsiveness.","Regulator"
"Genetic variants at the beta(2)-adrenergic receptor (<e2>beta(2)AR</e2>) may modify asthma severity and <e1>albuterol</e1> responsiveness.","Regulator"
"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme <e2>tyrosinase</e2>, as compared to the standard tyrosinase inhibitors <e1>kojic acid</e1> (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.","Downregulator"
"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme <e2>tyrosinase</e2>, as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and <e1>L-mimosine</e1> (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.","Downregulator"
"<e1>Antag I</e1> and Antag II did not alter <e2>oxytocin receptor</e2> number or binding affinity significantly at each time point studied compared with controls.","Not"
"Antag I and <e1>Antag II</e1> did not alter <e2>oxytocin receptor</e2> number or binding affinity significantly at each time point studied compared with controls.","Not"
"In Experiment 2, <e1>TT-235</e1> induced a significant decrease (p<0.05) in <e2>oxytocin receptor</e2> number and binding affinity at both 0.5 and 4 hours compared with controls.","Regulator"
"Oxytocin antagonist (OTA), <e1>TT-235</e1>, was developed by our group and shown to inhibit either spontaneous or <e2>oxytocin</e2>-induced uterine contractions in primates.","Regulator"
"In Experiment 2, <e1>TT-235</e1> induced a significant decrease (p<0.05) in <e2>oxytocin receptor</e2> number and binding affinity at both 0.5 and 4 hours compared with controls.","Downregulator"
"In Experiment 2, <e1>TT-235</e1> induced a significant decrease (p<0.05) in <e2>oxytocin receptor</e2> number and binding affinity at both 0.5 and 4 hours compared with controls.","Downregulator"
"Oxytocin antagonist (OTA), <e1>TT-235</e1>, was developed by our group and shown to inhibit either spontaneous or <e2>oxytocin</e2>-induced uterine contractions in primates.","Downregulator"
"Oxytocin antagonist (OTA), <e1>TT-235</e1>, was developed by our group and shown to inhibit either spontaneous or <e2>oxytocin</e2>-induced uterine contractions in primates.","Downregulator"
"Oxytocin antagonist (OTA), <e1>TT-235</e1>, was developed by our group and shown to inhibit either spontaneous or <e2>oxytocin</e2>-induced uterine contractions in primates.","Downregulator"
"In Experiment 1, <e1>Antag I</e1>, Antag II and TT-235 inhibited the integrated uterine response to <e2>oxytocin</e2> at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).","Downregulator"
"In Experiment 1, Antag I, <e1>Antag II</e1> and TT-235 inhibited the integrated uterine response to <e2>oxytocin</e2> at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).","Downregulator"
"Oxytocin antagonist (OTA), <e1>TT-235</e1>, was developed by our group and shown to inhibit either spontaneous or <e2>oxytocin</e2>-induced uterine contractions in primates.","Downregulator"
"Oxytocin antagonist (OTA), <e1>TT-235</e1>, was developed by our group and shown to inhibit either spontaneous or <e2>oxytocin</e2>-induced uterine contractions in primates.","Antagonist"
"<e2>Oxytocin</e2> antagonist (OTA), <e1>TT-235</e1>, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.","Antagonist"
"In cellular assays, <e1>lumiracoxib</e1> had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of <e2>COX-1</e2> at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).","Not"
"Preclinical pharmacology of <e1>lumiracoxib</e1>: a novel selective inhibitor of <e2>cyclooxygenase-2</e2>.","Downregulator"
"This manuscript presents the preclinical profile of <e1>lumiracoxib</e1>, a novel cyclooxygenase-2 (<e2>COX-2</e2>) selective inhibitor.","Downregulator"
"In cellular assays, <e1>lumiracoxib</e1> had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of <e2>COX-1</e2> at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).","Downregulator"
"Preclinical pharmacology of <e1>lumiracoxib</e1>: a novel selective inhibitor of <e2>cyclooxygenase-2</e2>.","Downregulator"
"In cellular assays, <e1>lumiracoxib</e1> had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of <e2>COX-1</e2> at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).","Downregulator"
"<e1>Lumiracoxib</e1> inhibited purified <e2>COX-1</e2> and COX-2 with K(i) values of 3 and 0.06 microM, respectively.","Downregulator"
"<e1>Lumiracoxib</e1> inhibited purified COX-1 and <e2>COX-2</e2> with K(i) values of 3 and 0.06 microM, respectively.","Downregulator"
"However, consistent with its low <e2>COX-1</e2> inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than <e1>diclofenac</e1> (P<0.05).","Downregulator"
"<e1>Lumiracoxib</e1> inhibited purified COX-1 and <e2>COX-2</e2> with K(i) values of 3 and 0.06 microM, respectively.","Downregulator"
"Lumiracoxib is a highly selective <e2>COX-2</e2> inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with <e1>diclofenac</e1>, the reference NSAID, but with much improved gastrointestinal safety.","Downregulator"
"This manuscript presents the preclinical profile of <e1>lumiracoxib</e1>, a novel cyclooxygenase-2 (<e2>COX-2</e2>) selective inhibitor.","Downregulator"
"This manuscript presents the preclinical profile of <e1>lumiracoxib</e1>, a novel cyclooxygenase-2 (<e2>COX-2</e2>) selective inhibitor.","Downregulator"
"In cellular assays, <e1>lumiracoxib</e1> had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of <e2>COX-1</e2> at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).","Downregulator"
"In cellular assays, <e1>lumiracoxib</e1> had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of <e2>COX-1</e2> at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).","Downregulator"
"This manuscript presents the preclinical profile of <e1>lumiracoxib</e1>, a novel cyclooxygenase-2 (<e2>COX-2</e2>) selective inhibitor.","Downregulator"
"Ex vivo, lumiracoxib inhibited <e2>COX-1</e2>-derived <e1>thromboxane B(2)</e1> (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).","Substrate"
"Ex vivo, lumiracoxib inhibited <e2>COX-1</e2>-derived thromboxane B(2) (<e1>TxB(2)</e1>) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).","Substrate"
"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas <e2>COX-2</e2>-derived production of <e1>prostaglandin E(2)</e1> (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).","Substrate"
"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas <e2>COX-2</e2>-derived production of prostaglandin E(2) (<e1>PGE(2)</e1>) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).","Substrate"
"As <e1>thiamine</e1> metabolism deficiencies have been seen in placental infarcts previously, these indicate that <e2>PP20</e2>/hTPK may have a role in placental diseases.","Substrate"
"As <e1>thiamine</e1> metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/<e2>hTPK</e2> may have a role in placental diseases.","Substrate"
"<e1>Denufosol</e1> tetrasodium (INS37217) is a selective <e2>P2Y(2)</e2> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.","Agonist"
"Safety and tolerability of <e1>denufosol tetrasodium</e1> inhalation solution, a novel <e2>P2Y2 receptor</e2> agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.","Agonist"
"<e1>Denufosol tetrasodium</e1> (INS37217) is a selective <e2>P2Y(2)</e2> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.","Agonist"
"Denufosol tetrasodium (<e1>INS37217</e1>) is a selective <e2>P2Y(2)</e2> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.","Agonist"
"The <e1>Cl(-)</e1> secretory response is mediated via a non-<e2>CFTR</e2> pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.","Substrate"
"<e1>Dextromethorphan</e1> and dimemorfan are high-affinity ligands at <e2>sigma1 receptors</e2>.","Regulator"
"Dextromethorphan and <e1>dimemorfan</e1> are high-affinity ligands at <e2>sigma1 receptors</e2>.","Regulator"
"The <e1>dextromethorphan</e1> analog dimemorfan attenuates kainate-induced seizures via <e2>sigma1 receptor</e2> activation: comparison with the effects of dextromethorphan.","Regulator"
"The anticonvulsant action of <e1>dextromethorphan</e1> or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of <e2>AP-1</e2> transcription factors.","Regulator"
"The <e1>dextromethorphan</e1> analog dimemorfan attenuates kainate-induced seizures via <e2>sigma1 receptor</e2> activation: comparison with the effects of dextromethorphan.","Regulator"
"The dextromethorphan analog <e1>dimemorfan</e1> attenuates kainate-induced seizures via <e2>sigma1 receptor</e2> activation: comparison with the effects of dextromethorphan.","Regulator"
"The anticonvulsant action of dextromethorphan or <e1>dimemorfan</e1> was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of <e2>AP-1</e2> transcription factors.","Regulator"
"Dimemorfan pre-treatment also attenuated the <e1>KA</e1>-induced increases in c-fos/c-jun expression, <e2>activator protein (AP)-1</e2> DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","Upregulator"
"The dextromethorphan analog <e1>dimemorfan</e1> attenuates kainate-induced seizures via <e2>sigma1 receptor</e2> activation: comparison with the effects of dextromethorphan.","Upregulator"
"The <e1>dextromethorphan</e1> analog dimemorfan attenuates kainate-induced seizures via <e2>sigma1 receptor</e2> activation: comparison with the effects of dextromethorphan.","Upregulator"
"Dimemorfan pre-treatment also attenuated the <e1>KA</e1>-induced increases in <e2>c-fos</e2>/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","Upregulator"
"Dimemorfan pre-treatment also attenuated the <e1>KA</e1>-induced increases in c-fos/<e2>c-jun</e2> expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","Upregulator"
"<e1>Dimemorfan</e1> pre-treatment also attenuated the KA-induced increases in <e2>c-fos</e2>/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","Downregulator"
"<e1>Dimemorfan</e1> pre-treatment also attenuated the KA-induced increases in c-fos/<e2>c-jun</e2> expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","Downregulator"
"<e1>Dimemorfan</e1> pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, <e2>activator protein (AP)-1</e2> DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.","Downregulator"
"The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective <e2>sigma1 receptor</e2> antagonist <e1>BD 1047</e1>, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.","Antagonist"
"For both agonists, important binding domains were the extracellular <e1>N</e1>-terminus (=E1) and the extracellular loops E2 and E3 from the <e2>oxytocin receptor</e2>.","Part_of"
"In contrast, the binding of <e1>barusiban</e1> was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the <e2>vasopressin V2 receptor</e2>.","Regulator"
"Binding domains of the <e2>oxytocin receptor</e2> for the selective oxytocin receptor antagonist <e1>barusiban</e1> in comparison to the agonists oxytocin and carbetocin.","Regulator"
"Binding domains of the <e2>oxytocin receptor</e2> for the selective oxytocin receptor antagonist <e1>barusiban</e1> in comparison to the agonists oxytocin and carbetocin.","Regulator"
"Binding domains of the <e2>oxytocin receptor</e2> for the selective oxytocin receptor antagonist <e1>barusiban</e1> in comparison to the agonists oxytocin and carbetocin.","Regulator"
"For the vasopressin V1A/oxytocin receptor antagonist <e1>atosiban</e1>, none of the receptor constructs were able to provide a binding with higher affinity than the starting <e2>vasopressin V2 receptor</e2>.","Regulator"
"We have analyzed binding domains of the <e1>oxytocin</e1> receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>vasopressin V1A/oxytocin receptor</e2> antagonist atosiban and the agonists oxytocin and carbetocin.","Agonist"
"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>vasopressin V1A/oxytocin receptor</e2> antagonist atosiban and the agonists oxytocin and <e1>carbetocin</e1>.","Agonist"
"Binding domains of the <e1>oxytocin</e1> receptor for the selective <e2>oxytocin receptor</e2> antagonist barusiban in comparison to the agonists oxytocin and carbetocin.","Agonist"
"Binding domains of the <e2>oxytocin receptor</e2> for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and <e1>carbetocin</e1>.","Agonist"
"The binding domain of barusiban differs from the binding domain of the agonists and the nonselective <e2>oxytocin receptor</e2> antagonist <e1>d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin</e1> that has been used in previous studies.","Antagonist"
"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>vasopressin V1A/oxytocin receptor</e2> antagonist <e1>atosiban</e1> and the agonists oxytocin and carbetocin.","Antagonist"
"Binding domains of the <e2>oxytocin receptor</e2> for the selective oxytocin receptor antagonist <e1>barusiban</e1> in comparison to the agonists oxytocin and carbetocin.","Antagonist"
"Binding domains of the <e2>oxytocin receptor</e2> for the selective oxytocin receptor antagonist <e1>barusiban</e1> in comparison to the agonists oxytocin and carbetocin.","Antagonist"
"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>vasopressin V1A/oxytocin receptor</e2> antagonist <e1>atosiban</e1> and the agonists oxytocin and carbetocin.","Antagonist"
"Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that <e1>AZC</e1> and PCA did not profoundly affect on <e2>CD3-zeta chain</e2> transcription in Jurkat T leukemia cells clone E6-1.","Not"
"Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that AZC and <e1>PCA</e1> did not profoundly affect on <e2>CD3-zeta chain</e2> transcription in Jurkat T leukemia cells clone E6-1.","Not"
"Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that <e1>AZC</e1> and PCA did not profoundly affect on <e2>CD3-zeta chain</e2> transcription in Jurkat T leukemia cells clone E6-1.","Downregulator"
"Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that AZC and <e1>PCA</e1> did not profoundly affect on <e2>CD3-zeta chain</e2> transcription in Jurkat T leukemia cells clone E6-1.","Downregulator"
"The compounds <e1>5'-azacytidine</e1> (AZC) and procainamide (PCA) belong to inhibitors of <e2>DNMT1</e2>, whose low activity correlates with increase in transcription of various genes.","Downregulator"
"The compounds 5'-azacytidine (<e1>AZC</e1>) and procainamide (PCA) belong to inhibitors of <e2>DNMT1</e2>, whose low activity correlates with increase in transcription of various genes.","Downregulator"
"The compounds 5'-azacytidine (AZC) and <e1>procainamide</e1> (PCA) belong to inhibitors of <e2>DNMT1</e2>, whose low activity correlates with increase in transcription of various genes.","Downregulator"
"The compounds 5'-azacytidine (AZC) and procainamide (<e1>PCA</e1>) belong to inhibitors of <e2>DNMT1</e2>, whose low activity correlates with increase in transcription of various genes.","Downregulator"
"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to <e2>TS</e2> inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (<e1>FdUMP</e1>).","Downregulator"
"Clinical studies in cancer patients treated with the new <e1>fluoropyrimidine</e1> analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"Clinical studies in cancer patients treated with the new <e1>fluoropyrimidine</e1> analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue <e1>capecitabine</e1> (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue <e1>capecitabine</e1> (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (<e1>N4-pentoxycarbonyl-5'-5-fluorocytidine</e1>) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (<e1>N4-pentoxycarbonyl-5'-5-fluorocytidine</e1>) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma <e1>2'-deoxyuridine</e1> was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>thymidylate synthase</e2> (TS).","Downregulator"
"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma <e1>2'-deoxyuridine</e1> was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue <e1>capecitabine</e1> (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS</e2>).","Downregulator"
"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to <e2>TS</e2> inhibitory activity of its active metabolite <e1>5-fluoro-2'-deoxyuridine monophosphate</e1> (FdUMP).","Downregulator"
"Western blot analysis of cells incubated with <e1>imatinib</e1> demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated <e2>kinase</e2> kinase 1 (MEK1) and EGFR, but not Her2/ErbB2.","Regulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Regulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Regulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Regulator"
"Induction of <e2>heparin-binding EGF-like growth factor</e2> and activation of EGF receptor in <e1>imatinib mesylate</e1>-treated squamous carcinoma cells.","Regulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Regulator"
"<e1>Imatinib</e1>-induced changes were blocked with the <e2>EGFR</e2> antagonist cetuximab, which suggested direct involvement of EGFR in this process.","Upregulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Upregulator"
"Induction of heparin-binding EGF-like growth factor and activation of <e2>EGF receptor</e2> in <e1>imatinib mesylate</e1>-treated squamous carcinoma cells.","Upregulator"
"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced <e1>imatinib</e1>-mediated <e2>mitogen activated protein kinase</e2> (MAPK) activation.","Upregulator"
"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced <e1>imatinib</e1>-mediated mitogen activated protein kinase (<e2>MAPK</e2>) activation.","Upregulator"
"<e1>Imatinib</e1> stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic <e2>MAPK</e2> activation.","Upregulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Upregulator"
"Although, <e1>imatinib</e1> primarily inhibits <e2>tyrosine kinase</e2>s, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors.","Upregulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with <e2>epidermal growth factor receptor</e2> (EGFR) activation.","Upregulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Upregulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Upregulator"
"<e1>Imatinib</e1> stimulated the rapid release of soluble <e2>HB-EGF</e2> and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation.","Upregulator"
"<e1>Imatinib</e1> stimulated the rapid release of soluble <e2>HB-EGF</e2> and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation.","Upregulator"
"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib</e1>-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR</e2>) activation.","Upregulator"
"<e1>Imatinib mesylate</e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (<e2>PDGFR</e2>), and c-kit kinases.","Downregulator"
"<e1>Imatinib mesylate</e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and <e2>c-kit</e2> kinases.","Downregulator"
"<e1>Imatinib mesylate</e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit <e2>kinases</e2>.","Downregulator"
"<e1>Imatinib mesylate</e1> is a <e2>tyrosine kinase</e2> inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases.","Downregulator"
"<e1>Imatinib mesylate</e1> is a tyrosine kinase inhibitor of the <e2>ABL</e2>, platelet-derived growth factor receptor (PDGFR), and c-kit kinases.","Downregulator"
"<e1>Imatinib mesylate</e1> is a tyrosine kinase inhibitor of the ABL, <e2>platelet-derived growth factor receptor</e2> (PDGFR), and c-kit kinases.","Downregulator"
"Although, <e1>imatinib</e1> primarily inhibits <e2>tyrosine kinases</e2>, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors.","Downregulator"
"<e1>STI 571</e1> (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since Gleevec targets both <e2>PDGFRA</e2> and c-kit oncoproteins.","Regulator"
"<e1>STI 571</e1> (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and <e2>c-kit</e2> oncoproteins.","Regulator"
"STI 571 (<e1>imatinib mesylate</e1> [Gleevec]) might be an effective therapy in this case, since Gleevec targets both <e2>PDGFRA</e2> and c-kit oncoproteins.","Regulator"
"STI 571 (<e1>imatinib mesylate</e1> [Gleevec]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and <e2>c-kit</e2> oncoproteins.","Regulator"
"STI 571 (imatinib mesylate [<e1>Gleevec</e1>]) might be an effective therapy in this case, since Gleevec targets both <e2>PDGFRA</e2> and c-kit oncoproteins.","Regulator"
"STI 571 (imatinib mesylate [<e1>Gleevec</e1>]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and <e2>c-kit</e2> oncoproteins.","Regulator"
"STI 571 (imatinib mesylate [<e1>Gleevec</e1>]) might be an effective therapy in this case, since Gleevec targets both <e2>PDGFRA</e2> and c-kit oncoproteins.","Regulator"
"STI 571 (imatinib mesylate [<e1>Gleevec</e1>]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and <e2>c-kit</e2> oncoproteins.","Regulator"
"The identity of the lung <e2>beta-ADHs</e2> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by <e1>4-methylpyrazole</e1> or 1,10-phenanthroline.","Downregulator"
"The identity of the lung <e2>beta-ADHs</e2> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or <e1>1,10-phenanthroline</e1>.","Downregulator"
"The results suggest that individuals with high Vmax <e2>beta 2-ADH</e2> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with <e1>acetaldehyde</e1> accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","Substrate"
"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial <e2>ALDH2</e2>, accounting for approximately 45% of the Chinese population, may end up with <e1>acetaldehyde</e1> accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","Substrate"
"These findings indicate that human pulmonary <e1>ethanol</e1>-metabolizing activities differ significantly with respect to genetic polymorphism at both the <e2>ADH2</e2> and the ALDH2 loci.","Substrate"
"These findings indicate that human pulmonary <e1>ethanol</e1>-metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the <e2>ALDH2</e2> loci.","Substrate"
"The results suggest that individuals with high Vmax <e2>beta 2-ADH</e2> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during <e1>alcohol</e1> consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","Substrate"
"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial <e2>ALDH2</e2>, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during <e1>alcohol</e1> consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","Substrate"
"The identity of the lung <e2>beta-ADHs</e2> was further demonstrated by their characteristic pH-activity profiles for <e1>ethanol</e1> oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.","Substrate"
"The identity of the lung <e2>beta-ADHs</e2> was further demonstrated by their characteristic pH-activity profiles for <e1>ethanol</e1> oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.","Substrate"
"The <e2>IL-18</e2> production is located upstream of the cytokine cascade activated by <e1>simvastatin</e1>.","Regulator"
"The effects of <e1>simvastatin</e1> were abolished by the addition of the product of the <e2>HMG-CoA reductase</e2>, mevalonate, indicating the involvement of HMG-CoA reductase in the action of simvastatin.","Regulator"
"The IL-18 production is located upstream of the <e2>cytokine</e2> cascade activated by <e1>simvastatin</e1>.","Upregulator"
"In the presence of IL-18, <e1>simvastatin</e1> suppressed the expression of ICAM-1 and CD40 as well as the production of <e2>IL-12</e2>, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.","Upregulator"
"In the presence of IL-18, <e1>simvastatin</e1> suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, <e2>TNF-alpha</e2> and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.","Upregulator"
"In the presence of IL-18, <e1>simvastatin</e1> suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and <e2>IFN-gamma</e2> in PBMC, contributing to the anti-inflammatory effect of simvastatin.","Upregulator"
"<e1>Simvastatin</e1> induces <e2>interleukin-18</e2> production in human peripheral blood mononuclear cells.","Upregulator"
"<e1>Simvastatin</e1>, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of <e2>interleukin (IL)-18</e2>, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).","Upregulator"
"<e1>Simvastatin</e1>, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, <e2>tumor necrosis factor (TNF)-alpha</e2> and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).","Upregulator"
"<e1>Simvastatin</e1>, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and <e2>interferon (IFN)-gamma</e2> in human peripheral blood mononuclear cells (PBMC).","Upregulator"
"The <e2>IL-18</e2> production is located upstream of the cytokine cascade activated by <e1>simvastatin</e1>.","Upregulator"
"Moreover, <e1>simvastatin</e1> concentration-dependently inhibited the expression of ICAM-1 and induced the expression of <e2>CD40</e2> on monocytes.","Upregulator"
"Moreover, <e1>simvastatin</e1> concentration-dependently inhibited the expression of <e2>ICAM-1</e2> and induced the expression of CD40 on monocytes.","Downregulator"
"Moreover, <e1>simvastatin</e1> concentration-dependently inhibited the expression of ICAM-1 and induced the expression of <e2>CD40</e2> on monocytes.","Downregulator"
"Moreover, <e1>simvastatin</e1> concentration-dependently inhibited the expression of <e2>ICAM-1</e2> and induced the expression of CD40 on monocytes.","Downregulator"
"<e1>Simvastatin</e1>, an <e2>HMG-CoA reductase</e2> inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).","Downregulator"
"<e1>Simvastatin</e1>, an HMG-CoA reductase inhibitor with mild inhibition of <e2>LFA-1</e2>, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).","Downregulator"
"The effects of simvastatin were abolished by the addition of the product of the <e2>HMG-CoA reductase</e2>, <e1>mevalonate</e1>, indicating the involvement of HMG-CoA reductase in the action of simvastatin.","Substrate"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, flunixin, <e1>carprofen</e1> and meloxicam: an in vitro analysis.","Downregulator"
"We report on the inhibitory activity of the NSAIDs meloxicam, <e1>carprofen</e1>, phenylbutazone and flunixin, on blood <e2>cyclooxygenases</e2> in the horse using in vitro enzyme-linked assays.","Downregulator"
"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, <e1>phenylbutazone</e1> and flunixin, on blood <e2>cyclooxygenases</e2> in the horse using in vitro enzyme-linked assays.","Downregulator"
"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and <e1>flunixin</e1>, on blood <e2>cyclooxygenases</e2> in the horse using in vitro enzyme-linked assays.","Downregulator"
"<e2>COX-1</e2> and COX-2 inhibition in horse blood by <e1>phenylbutazone</e1>, flunixin, carprofen and meloxicam: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by <e1>phenylbutazone</e1>, flunixin, carprofen and meloxicam: an in vitro analysis.","Downregulator"
"<e2>COX-1</e2> and COX-2 inhibition in horse blood by phenylbutazone, <e1>flunixin</e1>, carprofen and meloxicam: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, <e1>flunixin</e1>, carprofen and meloxicam: an in vitro analysis.","Downregulator"
"<e2>COX-1</e2> and COX-2 inhibition in horse blood by phenylbutazone, flunixin, <e1>carprofen</e1> and meloxicam: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, flunixin, <e1>carprofen</e1> and meloxicam: an in vitro analysis.","Downregulator"
"<e2>COX-1</e2> and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and <e1>meloxicam</e1>: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, flunixin, carprofen and <e1>meloxicam</e1>: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, flunixin, carprofen and <e1>meloxicam</e1>: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, flunixin, <e1>carprofen</e1> and meloxicam: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by <e1>phenylbutazone</e1>, flunixin, carprofen and meloxicam: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, <e1>flunixin</e1>, carprofen and meloxicam: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by <e1>phenylbutazone</e1>, flunixin, carprofen and meloxicam: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, <e1>flunixin</e1>, carprofen and meloxicam: an in vitro analysis.","Downregulator"
"COX-1 and <e2>COX-2</e2> inhibition in horse blood by phenylbutazone, flunixin, carprofen and <e1>meloxicam</e1>: an in vitro analysis.","Downregulator"
"We report on the inhibitory activity of the NSAIDs <e1>meloxicam</e1>, carprofen, phenylbutazone and flunixin, on blood <e2>cyclooxygenases</e2> in the horse using in vitro enzyme-linked assays.","Downregulator"
"Treatment with <e1>valsartan</e1>, doxazosin, or N-acetylcysteine did not significantly affect <e2>HIF-1alpha</e2> and VEGF proteins expression in the banding groups.","Not"
"Treatment with <e1>valsartan</e1>, doxazosin, or N-acetylcysteine did not significantly affect HIF-1alpha and <e2>VEGF</e2> proteins expression in the banding groups.","Not"
"Treatment with valsartan, <e1>doxazosin</e1>, or N-acetylcysteine did not significantly affect <e2>HIF-1alpha</e2> and VEGF proteins expression in the banding groups.","Not"
"Treatment with valsartan, <e1>doxazosin</e1>, or N-acetylcysteine did not significantly affect HIF-1alpha and <e2>VEGF</e2> proteins expression in the banding groups.","Not"
"Treatment with valsartan, doxazosin, or <e1>N-acetylcysteine</e1> did not significantly affect <e2>HIF-1alpha</e2> and VEGF proteins expression in the banding groups.","Not"
"Treatment with valsartan, doxazosin, or <e1>N-acetylcysteine</e1> did not significantly affect HIF-1alpha and <e2>VEGF</e2> proteins expression in the banding groups.","Not"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and <e2>NGF-beta</e2> to the baseline values.","Regulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and <e2>NGF-beta</e2> to the baseline values.","Upregulator"
"<e1>Carvedilol</e1> prevents cardiac hypertrophy and overexpression of <e2>hypoxia-inducible factor-1alpha</e2> and vascular endothelial growth factor in pressure-overloaded rat heart.","Downregulator"
"<e1>Carvedilol</e1> prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and <e2>vascular endothelial growth factor</e2> in pressure-overloaded rat heart.","Downregulator"
"To evaluate the effect of <e1>carvedilol</e1> on both myocardial <e2>HIF-1alpha</e2> expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, <e2>VEGF</e2>, BNP, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>BNP</e2>, and NGF-beta to the baseline values.","Downregulator"
"To evaluate the effect of <e1>carvedilol</e1> on both myocardial <e2>HIF-1alpha</e2> expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, <e2>VEGF</e2>, BNP, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>BNP</e2>, and NGF-beta to the baseline values.","Downregulator"
"To evaluate the effect of <e1>carvedilol</e1> on both myocardial <e2>HIF-1alpha</e2> expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, <e2>VEGF</e2>, BNP, and NGF-beta to the baseline values.","Downregulator"
"Treatment with <e1>carvedilol</e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>BNP</e2>, and NGF-beta to the baseline values.","Downregulator"
"The reported mechanism of <e1>imatinib</e1> resistance in GISTs involves missense mutation in the <e2>kinase domain</e2> of KIT, including Thr670Ile, Tyr823Asp, and Val654Ala.","Not"
"The reported mechanism of <e1>imatinib</e1> resistance in GISTs involves missense mutation in the kinase domain of <e2>KIT,</e2> including Thr670Ile, Tyr823Asp, and Val654Ala.","Not"
"The reported mechanism of <e1>imatinib</e1> resistance in GISTs involves missense mutation in the kinase domain of KIT, including <e2>Thr670Ile</e2>, Tyr823Asp, and Val654Ala.","Not"
"The reported mechanism of <e1>imatinib</e1> resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, <e2>Tyr823Asp</e2>, and Val654Ala.","Not"
"The reported mechanism of <e1>imatinib</e1> resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, Tyr823Asp, and <e2>Val654Ala</e2>.","Not"
"<e1>Imatinib</e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>KIT</e2>, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"<e1>Imatinib</e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL</e2>, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"<e1>Imatinib</e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>BCR</e2>-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"<e1>Imatinib</e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL</e2>, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"<e1>Imatinib</e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>PDGFRA</e2>, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"<e1>Imatinib</e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>PDGFRB,</e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (<e1>STI571</e1>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>KIT</e2>, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (<e1>STI571</e1>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL</e2>, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (<e1>STI571</e1>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>BCR</e2>-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (<e1>STI571</e1>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL</e2>, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (<e1>STI571</e1>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>PDGFRA</e2>, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (<e1>STI571</e1>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>PDGFRB,</e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, <e1>Gleevec</e1>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>KIT</e2>, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, <e1>Gleevec</e1>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL</e2>, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, <e1>Gleevec</e1>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>BCR</e2>-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, <e1>Gleevec</e1>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL</e2>, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, <e1>Gleevec</e1>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>PDGFRA</e2>, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, <e1>Gleevec</e1>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>PDGFRB,</e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, Gleevec, <e1>Glivec</e1>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>KIT</e2>, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, Gleevec, <e1>Glivec</e1>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL</e2>, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, Gleevec, <e1>Glivec</e1>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>BCR</e2>-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, Gleevec, <e1>Glivec</e1>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL</e2>, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, Gleevec, <e1>Glivec</e1>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>PDGFRA</e2>, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Imatinib (STI571, Gleevec, <e1>Glivec</e1>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>PDGFRB,</e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.","Downregulator"
"Almost all of the tested H(1)R and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific <e1>[(3)H]histamine</e1> binding to the <e2>hH(4)R</e2> at concentrations up to 10 microM.","Regulator"
"Most of the tested H(2)R agonists and <e1>imidazole</e1>-based <e2>H(3)R</e2> ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.","Regulator"
"Most of the tested H(2)R agonists and <e1>imidazole</e1>-based H(3)R ligands show micromolar-to-nanomolar range <e2>hH(4)R</e2> affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.","Regulator"
"Interestingly, we identified <e1>4-methylhistamine</e1> as a high-affinity <e2>H(4)R</e2> ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes.","Regulator"
"Interestingly, we identified <e1>4-methylhistamine</e1> as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the <e2>hH(4)R</e2> over the other histamine receptor subtypes.","Regulator"
"Interestingly, we identified <e1>4-methylhistamine</e1> as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other <e2>histamine receptor</e2> subtypes.","Regulator"
"Interestingly, we identified <e1>4-methylhistamine</e1> as a high-affinity <e2>H(4)R</e2> ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes.","Regulator"
"Interestingly, we identified <e1>4-methylhistamine</e1> as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the <e2>hH(4)R</e2> over the other histamine receptor subtypes.","Upregulator"
"Most of the tested H(2)R agonists and <e1>imidazole</e1>-based H(3)R ligands show micromolar-to-nanomolar range <e2>hH(4)R</e2> affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.","Agonist"
"Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine <e2>H4 receptor</e2>: identification of <e1>4-methylhistamine</e1> as the first potent and selective H4 receptor agonist.","Agonist"
"Interestingly, we identified <e1>4-methylhistamine</e1> as a high-affinity <e2>H(4)R</e2> ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes.","Agonist"
"Most of the tested H(2)R agonists and <e1>imidazole</e1>-based H(3)R ligands show micromolar-to-nanomolar range <e2>hH(4)R</e2> affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.","Agonist"
"Moreover, 4-methylhistamine potently activated the h<e2>H(4)R</e2> (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist <e1>JNJ 7777120</e1> [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).","Antagonist"
"Moreover, 4-methylhistamine potently activated the h<e2>H(4)R</e2> (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [<e1>1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine</e1>] (pA(2) = 7.8).","Antagonist"
"Late-onset diarrhea appears to be associated with intestinal exposure to <e1>SN-38</e1> (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to <e2>Topo I</e2> and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.","Regulator"
"Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (<e1>7-ethyl-10-hydroxycamptothecin</e1>), the major active metabolite of CPT-11, which may bind to <e2>Topo I</e2> and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.","Regulator"
"Irinotecan (<e1>CPT-11</e1>, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>Topo I</e2>).","Regulator"
"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of <e2>acetylcholinesterase</e2> activity, which can be eliminated by administration of <e1>atropine</e1>.","Upregulator"
"<e1>CPT-11</e1> and SN-38 may also stimulate the production of pro-inflammatory <e2>cytokines</e2> and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).","Upregulator"
"CPT-11 and <e1>SN-38</e1> may also stimulate the production of pro-inflammatory <e2>cytokines</e2> and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).","Upregulator"
"Irinotecan (CPT-11, <e1>7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin</e1>) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>DNA topoisomerase I</e2> (Topo I).","Downregulator"
"Irinotecan (CPT-11, <e1>7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin</e1>) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>Topo I</e2>).","Downregulator"
"Early-onset diarrhea is observed immediately after <e1>CPT-11</e1> infusion and probably due to the inhibition of <e2>acetylcholinesterase</e2> activity, which can be eliminated by administration of atropine.","Downregulator"
"<e1>Irinotecan</e1> (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>DNA topoisomerase I</e2> (Topo I).","Downregulator"
"<e1>Irinotecan</e1> (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>Topo I</e2>).","Downregulator"
"Irinotecan (<e1>CPT-11</e1>, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>DNA topoisomerase I</e2> (Topo I).","Downregulator"
"Irinotecan (<e1>CPT-11</e1>, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>Topo I</e2>).","Downregulator"
"To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, <e1>N6-methyl-(R)-roscovitine</e1>, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to <e2>CDKs</e2>.","Not"
"To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and <e1>O6-(R)-roscovitine</e1>, the two latter derivatives being designed to bind to PDXK but not to <e2>CDKs</e2>.","Not"
"Affinity chromatography investigations have shown that <e1>(R)-roscovitine</e1> also interacts with <e2>PDXK</e2>.","Regulator"
"Affinity chromatography investigations have shown that <e1>(R)-roscovitine</e1> also interacts with <e2>PDXK</e2>.","Regulator"
"To understand this interaction, we determined the crystal structure of <e2>PDXK</e2> in complex with (R)-roscovitine, <e1>N6-methyl-(R)-roscovitine</e1>, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs.","Regulator"
"To understand this interaction, we determined the crystal structure of <e2>PDXK</e2> in complex with (R)-roscovitine, <e1>N6-methyl-(R)-roscovitine</e1>, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs.","Regulator"
"To understand this interaction, we determined the crystal structure of <e2>PDXK</e2> in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and <e1>O6-(R)-roscovitine</e1>, the two latter derivatives being designed to bind to PDXK but not to CDKs.","Regulator"
"To understand this interaction, we determined the crystal structure of <e2>PDXK</e2> in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and <e1>O6-(R)-roscovitine</e1>, the two latter derivatives being designed to bind to PDXK but not to CDKs.","Regulator"
"Structural analysis revealed that these three <e1>roscovitines</e1> bind similarly in the pyridoxal-binding site of <e2>PDXK</e2> rather than in the anticipated ATP-binding site.","Regulator"
"Pyridoxal kinase (<e2>PDXK</e2>) catalyzes the phosphorylation of <e1>pyridoxal</e1>, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.","Regulator"
"Pyridoxal kinase (<e2>PDXK</e2>) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of <e1>ATP</e1> and Zn2+.","Regulator"
"Crystal structure of <e2>pyridoxal kinase</e2> in complex with <e1>roscovitine</e1> and derivatives.","Regulator"
"Affinity chromatography investigations have shown that (R)-<e1>roscovitine</e1> also interacts with <e2>PDXK</e2>.","Regulator"
"<e2>Pyridoxal kinase</e2> (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of <e1>ATP</e1> and Zn2+.","Regulator"
"Pyridoxal kinase (<e2>PDXK</e2>) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of <e1>ATP</e1> and Zn2+.","Regulator"
"<e2>Pyridoxal kinase</e2> (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and <e1>Zn2+</e1>.","Regulator"
"Pyridoxal kinase (<e2>PDXK</e2>) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and <e1>Zn2+</e1>.","Regulator"
"Affinity chromatography investigations have shown that (R)-<e1>roscovitine</e1> also interacts with <e2>PDXK</e2>.","Regulator"
"To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-<e1>roscovitine</e1>, N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to <e2>CDKs</e2>.","Regulator"
"<e1>(R)-Roscovitine</e1> (CYC202, Seliciclib) is a relatively selective inhibitor of <e2>cyclin-dependent kinases</e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.","Downregulator"
"<e1>(R)-Roscovitine</e1> (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (<e2>CDKs</e2>), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.","Downregulator"
"(R)-Roscovitine (<e1>CYC202</e1>, Seliciclib) is a relatively selective inhibitor of <e2>cyclin-dependent kinases</e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.","Downregulator"
"(R)-Roscovitine (<e1>CYC202</e1>, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (<e2>CDKs</e2>), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.","Downregulator"
"(R)-Roscovitine (CYC202, <e1>Seliciclib</e1>) is a relatively selective inhibitor of <e2>cyclin-dependent kinases</e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.","Downregulator"
"(R)-Roscovitine (CYC202, <e1>Seliciclib</e1>) is a relatively selective inhibitor of cyclin-dependent kinases (<e2>CDKs</e2>), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.","Downregulator"
"<e2>Pyridoxal kinase</e2> (PDXK) catalyzes the phosphorylation of <e1>pyridoxal</e1>, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.","Substrate"
"Pyridoxal kinase (<e2>PDXK</e2>) catalyzes the phosphorylation of <e1>pyridoxal</e1>, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.","Substrate"
"<e2>Pyridoxal kinase</e2> (PDXK) catalyzes the phosphorylation of pyridoxal, <e1>pyridoxamine</e1>, and pyridoxine in the presence of ATP and Zn2+.","Substrate"
"Pyridoxal kinase (<e2>PDXK</e2>) catalyzes the phosphorylation of pyridoxal, <e1>pyridoxamine</e1>, and pyridoxine in the presence of ATP and Zn2+.","Substrate"
"<e2>Pyridoxal kinase</e2> (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and <e1>pyridoxine</e1> in the presence of ATP and Zn2+.","Substrate"
"Pyridoxal kinase (<e2>PDXK</e2>) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and <e1>pyridoxine</e1> in the presence of ATP and Zn2+.","Substrate"
"The <e2>gastric mucin</e2> secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, <e1>PD98059</e1>.","Not"
"Both inhibitors, moreover, blunted the <e2>mucin</e2> secretory responses to beta-adrenergic agonist-generated second messenger, <e1>cAMP</e1> as well as adenylate cyclase activator, forskolin.","Not"
"Both inhibitors, moreover, blunted the <e2>mucin</e2> secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, <e1>forskolin</e1>.","Not"
"The <e2>gastric mucin</e2> secretory responses to <e1>isoproterenol</e1>, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.","Regulator"
"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as <e2>adenylate cyclase</e2> activator, <e1>forskolin</e1>.","Upregulator"
"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>PP2</e1>, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent <e2>EGFR</e2> autophosphorylation, but not by ERK inhibitor, PD98059.","Upregulator"
"Both inhibitors, moreover, blunted the <e2>mucin</e2> secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, <e1>forskolin</e1>.","Downregulator"
"The <e2>gastric mucin</e2> secretory responses to isoproterenol, furthermore, were inhibited by <e1>PP2</e1>, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.","Downregulator"
"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on <e2>mucin</e2> secretion was inhibited by EGFR kinase inhibitor, <e1>PD153035</e1>, as well as wortmannin, a specific inhibitor of PI3K.","Downregulator"
"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on <e2>mucin</e2> secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as <e1>wortmannin</e1>, a specific inhibitor of PI3K.","Downregulator"
"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>PP2</e1>, a selective inhibitor of <e2>tyrosine kinase</e2> Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.","Downregulator"
"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>PP2</e1>, a selective inhibitor of tyrosine kinase <e2>Src</e2> responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.","Downregulator"
"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by <e2>ERK</e2> inhibitor, <e1>PD98059</e1>.","Downregulator"
"The inhibition of <e2>ERK</e2>, moreover, did not cause attenuation in mucin secretion in response to <e1>cAMP</e1> and forskolin.","Downregulator"
"The inhibition of <e2>ERK</e2>, moreover, did not cause attenuation in mucin secretion in response to cAMP and <e1>forskolin</e1>.","Downregulator"
"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by <e2>EGFR</e2> kinase inhibitor, <e1>PD153035</e1>, as well as wortmannin, a specific inhibitor of PI3K.","Downregulator"
"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR <e2>kinase</e2> inhibitor, <e1>PD153035</e1>, as well as wortmannin, a specific inhibitor of PI3K.","Downregulator"
"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as <e1>wortmannin</e1>, a specific inhibitor of <e2>PI3K</e2>.","Downregulator"
"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, <e1>cAMP</e1> as well as <e2>adenylate cyclase</e2> activator, forskolin.","Substrate"
"<e1>Losartan</e1> (parent compound), has moderate affinity for the <e2>AT(1) receptor</e2> (competitive inhibition).","Regulator"
"<e1>Losartan</e1> (parent compound), has moderate affinity for the <e2>AT(1) receptor</e2> (competitive inhibition).","Regulator"
"<e1>Losartan</e1> (parent compound), has moderate affinity for the <e2>AT(1) receptor</e2> (competitive inhibition).","Downregulator"
"Clinical experience in heart failure is growing, and recent data suggest an improved survival with <e1>losartan</e1> versus captopril, a drug from the <e2>angiotensin-converting-enzyme</e2> inhibitor class with proven benefit in this population.","Downregulator"
"Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus <e1>captopril</e1>, a drug from the <e2>angiotensin-converting-enzyme</e2> inhibitor class with proven benefit in this population.","Downregulator"
"The current comprehensive <e1>losartan</e1> clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the <e2>AT(1) receptor</e2> with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.","Downregulator"
"<e1>Losartan</e1>: a selective <e2>angiotensin II type 1 (AT1) receptor</e2> antagonist for the treatment of heart failure.","Antagonist"
"<e1>Losartan</e1> (COZAAR) is the prototype of a new class of potent and selective <e2>angiotensin II (AII) type 1 (AT(1)) receptor</e2> antagonists with the largest published preclinical and clinical data base.","Antagonist"
"Losartan (<e1>COZAAR</e1>) is the prototype of a new class of potent and selective <e2>angiotensin II (AII) type 1 (AT(1)) receptor</e2> antagonists with the largest published preclinical and clinical data base.","Antagonist"
"We now demonstrate that <e1>amrinone</e1>, a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced <e2>TNF</e2> production at concentrations readily achieved in vivo.","Upregulator"
"Abrupt removal of amrinone or <e1>pentoxifylline</e1> from the culture medium prior to LPS stimulation, however, caused significantly augmented <e2>TNF</e2> production.","Upregulator"
"We now demonstrate that <e1>amrinone</e1>, a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced <e2>TNF</e2> production at concentrations readily achieved in vivo.","Downregulator"
"Combined application of <e1>dexamethasone</e1> and amrinone caused additive inhibition of <e2>TNF</e2> biosynthesis in vitro.","Downregulator"
"We now demonstrate that <e1>amrinone</e1>, a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced <e2>TNF</e2> production at concentrations readily achieved in vivo.","Downregulator"
"Therefore, decreases of <e2>PLK</e2> and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with <e1>gamma-aminobutyric acid</e1> (GABA) function.","Downregulator"
"Therefore, decreases of PLK and <e2>PNPO</e2> in the hippocampal CA1 region of aged brains may be involved in aging processes related with <e1>gamma-aminobutyric acid</e1> (GABA) function.","Downregulator"
"Based on double immunofluorescence study, <e2>PLK</e2> and PNPO immunoreactive cells in the strata oriens and radiatum were identified as <e1>GABA</e1>ergic cells.","Downregulator"
"Based on double immunofluorescence study, PLK and <e2>PNPO</e2> immunoreactive cells in the strata oriens and radiatum were identified as <e1>GABA</e1>ergic cells.","Downregulator"
"In the present study, age-related changes of <e1>pyridoxal 5'-phosphate</e1> (PLP) synthesizing enzymes, pyridoxal kinase (<e2>PLK</e2>) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.","Substrate"
"In the present study, age-related changes of <e1>pyridoxal 5'-phosphate</e1> (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and <e2>pyridoxine 5'-phosphate oxidase</e2> (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.","Substrate"
"In the present study, age-related changes of <e1>pyridoxal 5'-phosphate</e1> (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (<e2>PNPO</e2>), their protein contents and activities were examined in the gerbil hippocampus proper.","Substrate"
"In the present study, age-related changes of <e1>pyridoxal 5'-phosphate</e1> (PLP) synthesizing enzymes, <e2>pyridoxal kinase</e2> (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.","Substrate"
"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>PLP</e1>) synthesizing enzymes, pyridoxal kinase (<e2>PLK</e2>) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.","Substrate"
"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>PLP</e1>) synthesizing enzymes, pyridoxal kinase (PLK) and <e2>pyridoxine 5'-phosphate oxidase</e2> (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.","Substrate"
"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>PLP</e1>) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (<e2>PNPO</e2>), their protein contents and activities were examined in the gerbil hippocampus proper.","Substrate"
"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>PLP</e1>) synthesizing enzymes, <e2>pyridoxal kinase</e2> (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.","Substrate"
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by <e1>H(+)</e1>-coupled <e2>monocarboxylate transport system</e2>.","Regulator"
"These results provide biochemical evidence of a <e1>H(+)</e1>-coupled and saturable transport system, presumed to be a <e2>low-affinity monocarboxylate transporter</e2> MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.","Regulator"
"These results provide biochemical evidence of a <e1>H(+)</e1>-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter <e2>MCT4</e2> or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.","Regulator"
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by <e1>H(+)</e1>-coupled monocarboxylate transport system.","Regulator"
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical <e2>monocarboxylate transporter</e2> (MCT) inhibitor, <e1>alpha-cyano-4-hydroxycinnamic acid</e1>, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.","Downregulator"
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (<e2>MCT</e2>) inhibitor, <e1>alpha-cyano-4-hydroxycinnamic acid</e1>, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.","Downregulator"
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that <e1>nicotinate</e1> uptake by rat astrocytes is mediated by H(+)-coupled <e2>monocarboxylate transport system</e2>.","Substrate"
"Because l-lactate reduced to 67% of the <e1>nicotinate</e1> uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by <e2>MCT1</e2> and/or MCT2.","Substrate"
"Because l-lactate reduced to 67% of the <e1>nicotinate</e1> uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or <e2>MCT2</e2>.","Substrate"
"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a <e2>low-affinity monocarboxylate transporter</e2> MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for <e1>nicotinate</e1> in rat cerebrocortical astrocytes.","Substrate"
"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter <e2>MCT4</e2> or other unknown H(+)-coupled monocarboxylate transport system, for <e1>nicotinate</e1> in rat cerebrocortical astrocytes.","Substrate"
"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that <e1>nicotinate</e1> uptake by rat astrocytes is mediated by <e2>H(+)-coupled monocarboxylate transport system</e2>.","Substrate"
"The marked antihypertensive efficacy of <e1>olmesartan medoxomil</e1> may result from a unique pharmacological interaction of the drug with the <e2>AT1</e2> receptor, resulting in a potent, long-lasting, dose-dependent blockade of A-II.","Regulator"
"The angiotensin II (<e1>A-II</e1>) type 1 (AT1) receptor-mediated effects of A-II play a key role in the pathophysiology of hypertension.","Regulator"
"A review of the structural and functional features of <e1>olmesartan medoxomil</e1>, an <e2>angiotensin receptor</e2> blocker.","Downregulator"
"The marked antihypertensive efficacy of <e1>olmesartan medoxomil</e1> may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of <e2>A-II</e2>.","Downregulator"
"Effects of granulocyte colony-stimulating factor (G-CSF) and <e2>neutrophil elastase</e2> inhibitor (<e1>ONO-5046</e1>) on acid-induced lung injury in rats.","Downregulator"
"Effects of <e2>granulocyte colony-stimulating factor</e2> (G-CSF) and neutrophil elastase inhibitor (<e1>ONO-5046</e1>) on acid-induced lung injury in rats.","Downregulator"
"Effects of granulocyte colony-stimulating factor (<e2>G-CSF</e2>) and neutrophil elastase inhibitor (<e1>ONO-5046</e1>) on acid-induced lung injury in rats.","Downregulator"
"Effects of granulocyte colony-stimulating factor (G-CSF) and <e2>neutrophil elastase</e2> inhibitor (<e1>ONO-5046</e1>) on acid-induced lung injury in rats.","Downregulator"
"<e1>Miglustat</e1>, an imino sugar that reversibly inhibits <e2>glucosylceramide synthase</e2> and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.","Downregulator"
"Miglustat, an <e1>imino sugar</e1> that reversibly inhibits <e2>glucosylceramide synthase</e2> and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.","Downregulator"
"Nicotinic-receptor potentiator drugs, huprine X and <e1>galantamine</e1>, increase ACh release by blocking AChE activity but not acting on <e2>nicotinic receptors</e2>.","Not"
"<e2>Nicotinic-receptor</e2> potentiator drugs, huprine X and <e1>galantamine</e1>, increase ACh release by blocking AChE activity but not acting on nicotinic receptors.","Regulator"
"This effect was reverted in the presence of <e1>atropine</e1> (ATR; 0.1 microM), which blocks the pre-synaptic <e2>muscarinic M2 receptor</e2>.","Downregulator"
"This effect was reverted in the presence of atropine (<e1>ATR</e1>; 0.1 microM), which blocks the pre-synaptic <e2>muscarinic M2 receptor</e2>.","Downregulator"
"Nicotinic-receptor potentiator drugs, huprine X and <e1>galantamine</e1>, increase ACh release by blocking <e2>AChE</e2> activity but not acting on nicotinic receptors.","Downregulator"
"To test the role of <e2>nicotinic receptors</e2> in the drugs' effects on [3H]-ACh release, <e1>mecamylamine</e1> (MEC) 100 microM was used to block such receptors.","Downregulator"
"To test the role of <e2>nicotinic receptors</e2> in the drugs' effects on [3H]-ACh release, mecamylamine (<e1>MEC</e1>) 100 microM was used to block such receptors.","Downregulator"
"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of <e1>haloperidol</e1> (HAL; 0.01 microM), a <e2>dopamine D2</e2> antagonist.","Antagonist"
"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (<e1>HAL</e1>; 0.01 microM), a <e2>dopamine D2</e2> antagonist.","Antagonist"
"mRNA levels for <e2>RAR-alpha</e2>, RAR-beta and RAR-gamma, the nuclear receptors for <e1>retinoic acid</e1>, decreased during activation of freshly isolated HSC even with retinoid supplementation.","Regulator"
"mRNA levels for RAR-alpha, <e2>RAR-beta</e2> and RAR-gamma, the nuclear receptors for <e1>retinoic acid</e1>, decreased during activation of freshly isolated HSC even with retinoid supplementation.","Regulator"
"mRNA levels for RAR-alpha, RAR-beta and <e2>RAR-gamma</e2>, the nuclear receptors for <e1>retinoic acid</e1>, decreased during activation of freshly isolated HSC even with retinoid supplementation.","Regulator"
"We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC <e2>nuclear receptors</e2> for <e1>retinoic acid</e1> (RAR) in HSC that are becoming activated or are chronically activated.","Regulator"
"mRNA levels for <e2>RAR-alpha</e2>, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>retinoid</e1> supplementation.","Downregulator"
"mRNA levels for RAR-alpha, <e2>RAR-beta</e2> and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>retinoid</e1> supplementation.","Downregulator"
"mRNA levels for RAR-alpha, RAR-beta and <e2>RAR-gamma</e2>, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>retinoid</e1> supplementation.","Downregulator"
"We also determine if <e1>retinoid</e1>s: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC <e2>nuclear receptors</e2> for retinoic acid (RAR) in HSC that are becoming activated or are chronically activated.","Downregulator"
"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of <e1>methacholine</e1>-contracted preparations in a concentration dependent fashion, indicating desensitization of the <e2>beta(2)-adrenoceptor</e2>.","Regulator"
"Preincubation with 1 microM of the <e2>protein kinase C</e2> (PKC) activator phorbol 12-myristate 13-acetate (<e1>PMA</e1>) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.","Upregulator"
"Preincubation with 1 microM of the protein kinase C (<e2>PKC</e2>) activator phorbol 12-myristate 13-acetate (<e1>PMA</e1>) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.","Upregulator"
"Preincubation with 1 microM of the protein kinase C (<e2>PKC</e2>) activator phorbol 12-myristate 13-acetate (<e1>PMA</e1>) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.","Upregulator"
"Preincubation with 1 microM of the <e2>protein kinase C</e2> (PKC) activator <e1>phorbol 12-myristate 13-acetate</e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.","Upregulator"
"Preincubation with 1 microM of the protein kinase C (<e2>PKC</e2>) activator <e1>phorbol 12-myristate 13-acetate</e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.","Upregulator"
"Preincubation with 1 microM of the protein kinase C (<e2>PKC</e2>) activator <e1>phorbol 12-myristate 13-acetate</e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.","Upregulator"
"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (<e1>PMA</e1>) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous <e2>beta(2)-adrenoceptor</e2> desensitization.","Downregulator"
"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of <e1>fenoterol</e1> decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <e2>beta(2)-adrenoceptor</e2>.","Downregulator"
"Preincubation with 1 microM of the protein kinase C (PKC) activator <e1>phorbol 12-myristate 13-acetate</e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous <e2>beta(2)-adrenoceptor</e2> desensitization.","Downregulator"
"Moreover, the specific <e2>PKC</e2>-inhibitor <e1>2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide</e1> (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.","Downregulator"
"Moreover, the specific <e2>PKC</e2>-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (<e1>GF 109203X</e1>) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.","Downregulator"
"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased <e1>isoprenaline</e1>-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <e2>beta(2)-adrenoceptor</e2>.","Agonist"
"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased <e1>isoprenaline</e1>-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <e2>beta(2)-adrenoceptor</e2>.","Agonist"
"Tyrosine kinase inhibitors are <e1>quinazoline</e1>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including <e2>EGFR</e2>, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.","Downregulator"
"<e2>Tyrosine kinase</e2> inhibitors are <e1>quinazoline</e1>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.","Downregulator"
"Tyrosine kinase inhibitors are <e1>quinazoline</e1>-derived, low molecular weight synthetic molecules that can block the intracellular <e2>tyrosine kinase domain</e2> of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.","Downregulator"
"Tyrosine kinase inhibitors are <e1>quinazoline</e1>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including <e2>EGFR</e2>, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.","Downregulator"
"Tyrosine kinase inhibitors are <e1>quinazoline</e1>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, <e2>Erb2</e2>, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.","Downregulator"
"Tyrosine kinase inhibitors are <e1>quinazoline</e1>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and <e2>vascular endothelial growth factor receptor</e2>, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.","Downregulator"
"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1</e2> mediates pH-dependent, <e1>Na(+)</e1>-independent uptake of proline, glycine, l-alanine and alpha-(methylamino)isobutyric acid.","Not"
"The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475 <e1>amino acids</e1> (92% identity to <e2>human PAT1</e2>).","Part_of"
"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1</e2> mediates pH-dependent, Na(+)-independent uptake of <e1>proline</e1>, glycine, l-alanine and alpha-(methylamino)isobutyric acid.","Substrate"
"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1</e2> mediates pH-dependent, Na(+)-independent uptake of proline, <e1>glycine</e1>, l-alanine and alpha-(methylamino)isobutyric acid.","Substrate"
"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1</e2> mediates pH-dependent, Na(+)-independent uptake of proline, glycine, <e1>l-alanine</e1> and alpha-(methylamino)isobutyric acid.","Substrate"
"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1</e2> mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and <e1>alpha-(methylamino)isobutyric acid</e1>.","Substrate"
"When expressed heterologously in a mammalian cell line, rabbit <e2>PAT1</e2> mediates pH-dependent, Na(+)-independent uptake of <e1>proline</e1>, glycine, l-alanine and alpha-(methylamino)isobutyric acid.","Substrate"
"When expressed heterologously in a mammalian cell line, rabbit <e2>PAT1</e2> mediates pH-dependent, Na(+)-independent uptake of <e1>proline</e1>, glycine, l-alanine and alpha-(methylamino)isobutyric acid.","Substrate"
"When expressed heterologously in a mammalian cell line, rabbit <e2>PAT1</e2> mediates pH-dependent, Na(+)-independent uptake of proline, <e1>glycine</e1>, l-alanine and alpha-(methylamino)isobutyric acid.","Substrate"
"The functional characteristics of rabbit <e2>PAT1</e2> in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of proline, glycine and <e1>hydroxyproline</e1> believed to be defective in patients with iminoglycinuria.","Substrate"
"Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived <e2>IL-10</e2> production, with significant effects elicited by the noradrenaline reuptake inhibitors <e1>reboxetine</e1> and desipramine.","Regulator"
"Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived <e2>IL-10</e2> production, with significant effects elicited by the noradrenaline reuptake inhibitors reboxetine and <e1>desipramine</e1>.","Regulator"
"In this study, antidepressants with selectivity for the <e2>noradrenaline transporter</e2> (<e1>reboxetine</e1> and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.","Regulator"
"In this study, antidepressants with selectivity for the <e2>noradrenaline transporter</e2> (reboxetine and <e1>desipramine</e1>), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.","Regulator"
"In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the <e2>serotonin transporter</e2> (<e1>fluoxetine</e1> and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.","Regulator"
"In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the <e2>serotonin transporter</e2> (fluoxetine and <e1>clomipramine</e1>) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.","Regulator"
"The fact that <e1>trimipramine</e1> also suppressed <e2>IFN-gamma</e2> production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake.","Downregulator"
"<e2>Leptin</e2> is a 167 <e1>amino acid</e1> protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism.","Part_of"
"Effect of <e1>cyproheptadine</e1> on serum <e2>leptin</e2> levels.","Regulator"
"<e1>Cyproheptadine</e1> is a piperidine antihistamine that increases appetite through its antiserotonergic effect on <e2>5-HT2</e2> receptors in the brain.","Regulator"
"Cyproheptadine is a <e1>piperidine</e1> antihistamine that increases appetite through its antiserotonergic effect on <e2>5-HT2</e2> receptors in the brain.","Regulator"
"Cyproheptadine is a piperidine <e1>antihistamine</e1> that increases appetite through its antiserotonergic effect on <e2>5-HT2</e2> receptors in the brain.","Regulator"
"Effect of <e1>cyproheptadine</e1> on serum <e2>leptin</e2> levels.","Upregulator"
"We compared the effects of Captopril (an <e2>ACE</e2> inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), <e1>N-acetylcysteine</e1> (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.","Not"
"It was found that a single intragastric gavage by <e1>L-methionine</e1> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and <e2>angiotensin-converting enzyme</e2> activity compared with the control group.","Not"
"Given the treatment with three doses of <e1>Captopril</e1> (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of <e2>PON1</e2> and SOD in serum by single intragastric gavaged L-methionine.","Regulator"
"We compared the effects of <e1>Captopril</e1> (an <e2>ACE</e2> inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.","Regulator"
"However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), <e1>enalapril</e1> (20 mg/kg), and N-acetylcysteine particular in the activity of <e2>PON1</e2> and ACE.","Regulator"
"Comparison of captopril and <e1>enalapril</e1> to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with <e2>ACE</e2> inhibitors in high dieted methionine mice.","Regulator"
"However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and <e1>N-acetylcysteine</e1> particular in the activity of <e2>PON1</e2> and ACE.","Regulator"
"We compared the effects of Captopril (an <e2>ACE</e2> inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), <e1>N-acetylcysteine</e1> (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.","Regulator"
"Given the treatment with three doses of <e1>Captopril</e1> (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of <e2>PON1</e2> and SOD in serum by single intragastric gavaged L-methionine.","Upregulator"
"Given the treatment with three doses of <e1>Captopril</e1> (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and <e2>SOD</e2> in serum by single intragastric gavaged L-methionine.","Upregulator"
"Given the treatment with three doses of <e1>Captopril</e1> (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of <e2>PON1</e2> and SOD in serum by single intragastric gavaged L-methionine.","Upregulator"
"It was found that a single intragastric gavage by <e1>L-methionine</e1> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of <e2>PON1</e2> and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.","Downregulator"
"We compared the effects of <e1>Captopril</e1> (an <e2>ACE</e2> inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.","Downregulator"
"To examine the role of sulfhydryl (-<e1>SH</e1>) group in improvement of endothelial dysfunction with angiotensin-converting enzyme (<e2>ACE</e2>) inhibitors in experimental high dose of methionine dieted rats.","Downregulator"
"Comparison of captopril and <e1>enalapril</e1> to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with <e2>ACE</e2> inhibitors in high dieted methionine mice.","Downregulator"
"Comparison of <e1>captopril</e1> and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with <e2>ACE</e2> inhibitors in high dieted methionine mice.","Downregulator"
"Comparison of captopril and <e1>enalapril</e1> to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with <e2>ACE</e2> inhibitors in high dieted methionine mice.","Downregulator"
"Comparison of captopril and enalapril to study the role of the <e1>sulfhydryl</e1>-group in improvement of endothelial dysfunction with <e2>ACE</e2> inhibitors in high dieted methionine mice.","Downregulator"
"It was found that a single intragastric gavage by <e1>L-methionine</e1> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of <e2>PON1</e2> and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.","Downregulator"
"It was found that a single intragastric gavage by <e1>L-methionine</e1> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and <e2>SOD</e2>, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.","Downregulator"
"In addition, <e1>sorafenib</e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, <e2>VEGFR-3</e2>, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.","Upregulator"
"In addition, <e1>sorafenib</e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, <e2>platelet-derived growth factor (PDGFR)-beta</e2> Flt-3, and c-KIT.","Upregulator"
"In addition, <e1>sorafenib</e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta <e2>Flt-3</e2>, and c-KIT.","Upregulator"
"In addition, <e1>sorafenib</e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and <e2>c-KIT</e2>.","Upregulator"
"In addition, <e1>sorafenib</e1> demonstrated significant activity against several <e2>receptor tyrosine kinases</e2> involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.","Upregulator"
"In addition, <e1>sorafenib</e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including <e2>vascular-endothelial growth factor (VEGFR)-2</e2>, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.","Upregulator"
"Further characterization showed that <e1>sorafenib</e1> suppresses both wild-type and <e2>V599E</e2> mutant B-Raf activity in vitro.","Downregulator"
"Further characterization showed that <e1>sorafenib</e1> suppresses both wild-type and V599E mutant <e2>B-Raf</e2> activity in vitro.","Downregulator"
"<e1>Sorafenib</e1>, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of <e2>Raf-1</e2> and its favorable kinase selectivity profile.","Downregulator"
"<e1>Sorafenib</e1>, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable <e2>kinase</e2> selectivity profile.","Downregulator"
"Sorafenib, which belongs chemically to a class that can be described as <e1>bis-aryl ureas</e1>, was selected for further pharmacologic characterization based on potent inhibition of <e2>Raf-1</e2> and its favorable kinase selectivity profile.","Downregulator"
"Sorafenib, which belongs chemically to a class that can be described as <e1>bis-aryl ureas</e1>, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable <e2>kinase</e2> selectivity profile.","Downregulator"
"In vivo angiogenesis assay utilising gelfoam sponges, <e1>bexarotene</e1> reduced angiogenesis in sponges containing <e2>vascular endothelial growth factor</e2>, epidermal growth factor and basic fibroblast growth factor to various extent.","Regulator"
"In vivo angiogenesis assay utilising gelfoam sponges, <e1>bexarotene</e1> reduced angiogenesis in sponges containing vascular endothelial growth factor, <e2>epidermal growth factor</e2> and basic fibroblast growth factor to various extent.","Regulator"
"In vivo angiogenesis assay utilising gelfoam sponges, <e1>bexarotene</e1> reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic <e2>fibroblast growth factor</e2> to various extent.","Regulator"
"The ability of <e1>bexarotene</e1> to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner <e2>peroxisome proliferator-activated receptor gamma</e2>.","Upregulator"
"Analysis of tumour-conditioned medium indicated that <e1>bexarotene</e1> decreased the secretion of angiogenic factors and <e2>matrix metalloproteinases</e2> and increased the tissue inhibitor of matrix metalloproteinases.","Upregulator"
"Analysis of tumour-conditioned medium indicated that <e1>bexarotene</e1> decreased the secretion of angiogenic factors and <e2>matrix metalloproteinases</e2> and increased the tissue inhibitor of matrix metalloproteinases.","Downregulator"
"A selective <e2>retinoid X receptor</e2> agonist <e1>bexarotene</e1> (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.","Agonist"
"A selective <e2>retinoid X receptor</e2> agonist bexarotene (<e1>LGD1069</e1>, targretin) inhibits angiogenesis and metastasis in solid tumours.","Agonist"
"A selective <e2>retinoid X receptor</e2> agonist bexarotene (LGD1069, <e1>targretin</e1>) inhibits angiogenesis and metastasis in solid tumours.","Agonist"
"A selective <e2>retinoid X receptor</e2> agonist <e1>bexarotene</e1> (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.","Agonist"
"The dysmenorrhea pain evoked by <e1>vasopressin</e1> correlated poorly with area under the curve, which may suggest that the effect is mediated by more than one <e2>V1a-like receptor</e2>.","Regulator"
"At each menstruation a bolus injection of 10 pmol/kg of <e2>vasopressin</e2> was administered before and during infusion of either 300 microg/min of <e1>atosiban</e1> or placebo.","Downregulator"
"CONCLUSIONS: <e1>Atosiban</e1> reduces <e2>vasopressin</e2>-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.","Downregulator"
"BACKGROUND AND AIMS: <e2>Thymidylate synthase</e2> (TS) is an important enzyme for DNA synthesis and the target for <e1>5-fluorouracil</e1> (5-FU).","Regulator"
"BACKGROUND AND AIMS: Thymidylate synthase (<e2>TS</e2>) is an important enzyme for DNA synthesis and the target for <e1>5-fluorouracil</e1> (5-FU).","Regulator"
"BACKGROUND AND AIMS: <e2>Thymidylate synthase</e2> (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (<e1>5-FU</e1>).","Regulator"
"BACKGROUND AND AIMS: Thymidylate synthase (<e2>TS</e2>) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (<e1>5-FU</e1>).","Regulator"
"Removal of Pro128 from the hepatic <e2>SDH</e2> consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for pyridoxal 5'-phosphate, whereas addition of a <e1>proline</e1> residue to the isoform was without effect.","Part_of"
"Removal of Pro128 from the hepatic <e2>SDH</e2> consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for <e1>pyridoxal 5'-phosphate</e1>, whereas addition of a proline residue to the isoform was without effect.","Cofactor"
"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the <e2>acetylcholinesterase</e2> inhibitor <e1>tacrine</e1>.","Downregulator"
"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the <e1>acetylcholine</e1>sterase inhibitor tacrine.","Substrate"
"Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of <e1>acetylcholine</e1>sterase and of <e2>butyrylcholinesterase</e2> which is another catalytic enzyme hydrolysing acetylcholine.","Substrate"
"Novel highly affine <e1>histamine</e1> H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, <e2>N-methyltransferase</e2>, chemically show structural elements of the acetylcholinesterase inhibitor tacrine.","Substrate"
"For some, pharmacologic inhibitors are available, including <e1>sorafenib</e1> for <e2>BRAF</e2>, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.","Downregulator"
"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, <e1>PD-0325901</e1> for <e2>mitogen-activated protein kinase</e2>/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.","Downregulator"
"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, <e1>PD-0325901</e1> for mitogen-activated protein kinase/<e2>extracellular signal-regulated kinase kinase</e2>, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.","Downregulator"
"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, <e1>rapamycin</e1> analogues for <e2>mammalian target of rapamycin</e2>, and agents that inhibit either vascular endothelial growth factor or its receptors.","Downregulator"
"Similar to the <e2>plasma membrane PS transporter</e2>, Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the <e1>sn-2,3-glycerol</e1> stereoisomer.","Not"
"Similar to the plasma membrane PS transporter, <e2>Atp8a1</e2> is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the <e1>sn-2,3-glycerol</e1> stereoisomer.","Not"
"Activation of <e2>Atp8a1</e2> is also reduced by these modifications; <e1>phosphatidylserine-O-methyl ester</e1>, lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Not"
"Activation of <e2>Atp8a1</e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, <e1>lysophosphatidylserine</e1>, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Not"
"Activation of <e2>Atp8a1</e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, <e1>glycerophosphoserine</e1>, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Not"
"Activation of <e2>Atp8a1</e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycero<e1>phosphoserine</e1>, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Not"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing <e1>phosphatidylcholine</e1>, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.","Not"
"However, <e1>N-methyl-phosphatidylserine</e1>, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating <e2>Atp8a1</e2> activity.","Not"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, <e1>phosphatidic acid</e1>, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.","Not"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or <e1>phosphatidylinositol</e1>, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.","Not"
"This aminophospholipid ""<e2>flippase</e2>"" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to <e1>vanadate</e1>, Ca(2+), and modification by sulfhydryl reagents.","Regulator"
"This aminophospholipid ""<e2>flippase</e2>"" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, <e1>Ca(2+)</e1>, and modification by sulfhydryl reagents.","Regulator"
"This aminophospholipid ""<e2>flippase</e2>"" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by <e1>sulfhydryl</e1> reagents.","Regulator"
"Similar to the <e2>plasma membrane PS transporter</e2>, Atp8a1 is activated only by the naturally occurring <e1>sn-1,2-glycerol</e1> isomer of PS and not the sn-2,3-glycerol stereoisomer.","Upregulator"
"Similar to the plasma membrane PS transporter, <e2>Atp8a1</e2> is activated only by the naturally occurring <e1>sn-1,2-glycerol</e1> isomer of PS and not the sn-2,3-glycerol stereoisomer.","Upregulator"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (<e1>PE</e1>), and is maximally activated by PS.","Upregulator"
"Weakly translocated lipids (PE, <e1>phosphatidylhydroxypropionate</e1>, and phosphatidylhomoserine) are also weak <e2>Atp8a1</e2> activators.","Upregulator"
"Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and <e1>phosphatidylhomoserine</e1>) are also weak <e2>Atp8a1</e2> activators.","Upregulator"
"Although the flippase has not been positively identified, a subfamily of P-type <e2>ATPase</e2>s has been proposed to function as transporters of amphipaths, including <e1>PS</e1> and other phospholipids.","Upregulator"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by <e1>PS</e1>.","Upregulator"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by <e1>phosphatidylglycerol</e1> or phosphatidylethanolamine (PE), and is maximally activated by PS.","Upregulator"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or <e1>phosphatidylethanolamine</e1> (PE), and is maximally activated by PS.","Upregulator"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (<e1>PE</e1>), and is maximally activated by PS.","Upregulator"
"The purified <e2>Atp8a1</e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by <e1>PS</e1>.","Upregulator"
"Activation of <e2>Atp8a1</e2> is also reduced by these modifications; <e1>phosphatidylserine-O-methyl ester</e1>, lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Downregulator"
"Activation of <e2>Atp8a1</e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, <e1>lysophosphatidylserine</e1>, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Downregulator"
"Activation of <e2>Atp8a1</e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, <e1>glycerophosphoserine</e1>, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Downregulator"
"Activation of <e2>Atp8a1</e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycero<e1>phosphoserine</e1>, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.","Downregulator"
"However, <e1>N-methyl-phosphatidylserine</e1>, which is transported by the plasma membrane <e2>flippase</e2> at a rate equivalent to PS, is incapable of activating Atp8a1 activity.","Substrate"
"This aminophospholipid ""<e2>flippase</e2>"" selectively transports <e1>PS</e1> to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.","Substrate"
"This fundamental significance of <e2>NMDA receptor</e2>-related excitotoxicity is discussed in the context of the developing clinical success of <e1>Memantine</e1>, but moreover set into relation to various proteomic and genetic markers of said diseases.","Regulator"
"<e1>Sorafenib</e1> (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of <e2>tyrosine kinases</e2> that are known to be involved in tumor cell proliferation and tumor angiogenesis.","Downregulator"
"Sorafenib (<e1>BAY 43-9006</e1>) is a small-molecule inhibitor that has been shown to target members of multiple classes of <e2>tyrosine kinases</e2> that are known to be involved in tumor cell proliferation and tumor angiogenesis.","Downregulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and inducible NO synthase (iNOS) expression via <e2>heme oxygenase</e2> (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Regulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (<e2>HO-1</e2>) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Regulator"
"<e1>Hydrogen sulfide</e1> inhibits nitric oxide production and nuclear factor-kappaB via <e2>heme oxygenase-1</e2> expression in RAW264.7 macrophages stimulated with lipopolysaccharide.","Regulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (<e2>HO-1</e2>) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Regulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (<e2>HO-1</e2>) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Regulator"
"Both <e1>H(2)S</e1> solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the <e2>extracellular signal-regulated kinase</e2> (ERK).","Upregulator"
"Both <e1>H(2)S</e1> solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (<e2>ERK</e2>).","Upregulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (<e2>HO-1</e2>) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Upregulator"
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on <e2>iNOS</e2> expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (<e1>CO</e1>), an end product of HO-1.","Downregulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and <e2>inducible NO synthase</e2> (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Downregulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and inducible NO synthase (<e2>iNOS</e2>) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Downregulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and inducible NO synthase (<e2>iNOS</e2>) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Downregulator"
"Pretreatment with H(2)S or <e1>NaHS</e1> significantly inhibited LPS-induced <e2>iNOS</e2> expression and NO production.","Downregulator"
"Here, we show that at noncytotoxic concentrations, <e1>H(2)S</e1> was able to inhibit NO production and inducible NO synthase (<e2>iNOS</e2>) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Downregulator"
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on <e2>NF-kappaB</e2> activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (<e1>CO</e1>), an end product of HO-1.","Downregulator"
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of <e1>H(2)S</e1> on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on <e2>NF-kappaB</e2> activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.","Downregulator"
"Moreover, NO production in LPS-stimulated macrophages that are expressing <e2>CSE</e2> mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor <e1>beta-cyano-L-alanine</e1> but not by the CBS inhibitor aminooxyacetic acid.","Downregulator"
"<e1>Hydrogen sulfide</e1> inhibits nitric oxide production and <e2>nuclear factor-kappaB</e2> via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.","Downregulator"
"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the <e2>CBS</e2> inhibitor <e1>aminooxyacetic acid</e1>.","Downregulator"
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of <e1>H(2)S</e1> on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor <e2>(NF)-kappaB</e2> activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.","Downregulator"
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of <e1>H(2)S</e1> on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on <e2>NF-kappaB</e2> activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.","Downregulator"
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of <e2>HO-1</e2> expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with <e1>carbon monoxide</e1> (CO), an end product of HO-1.","Substrate"
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of <e2>HO-1</e2> expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (<e1>CO</e1>), an end product of HO-1.","Substrate"
"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>NO</e1> production and inducible NO synthase (<e2>iNOS</e2>) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Substrate"
"Hydrogen sulfide (<e1>H(2)S</e1>), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE</e2>) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (<e1>H(2)S</e1>), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or <e2>cystathionine beta-synthase</e2> (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (<e1>H(2)S</e1>), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (<e2>CBS</e2>) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (<e1>H(2)S</e1>), a regulatory gaseous molecule that is endogenously synthesized by <e2>cystathionine gamma-lyase</e2> (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of <e2>HO-1</e2> expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (<e1>CO</e1>), an end product of HO-1.","Substrate"
"<e1>Hydrogen sulfide</e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE</e2>) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"<e1>Hydrogen sulfide</e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or <e2>cystathionine beta-synthase</e2> (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"<e1>Hydrogen sulfide</e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (<e2>CBS</e2>) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"<e1>Hydrogen sulfide</e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>cystathionine gamma-lyase</e2> (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>NO</e1> production and <e2>inducible NO synthase</e2> (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Substrate"
"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>NO</e1> production and inducible NO synthase (<e2>iNOS</e2>) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Substrate"
"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>NO</e1> production and inducible NO synthase (<e2>iNOS</e2>) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Substrate"
"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>NO</e1> production and inducible NO synthase (<e2>iNOS</e2>) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE</e2>) and/or cystathionine beta-synthase (CBS) from <e1>L-cysteine</e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or <e2>cystathionine beta-synthase</e2> (CBS) from <e1>L-cysteine</e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (<e2>CBS</e2>) from <e1>L-cysteine</e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>cystathionine gamma-lyase</e2> (CSE) and/or cystathionine beta-synthase (CBS) from <e1>L-cysteine</e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE</e2>) and/or cystathionine beta-synthase (CBS) from L-cysteine (<e1>L-Cys</e1>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or <e2>cystathionine beta-synthase</e2> (CBS) from L-cysteine (<e1>L-Cys</e1>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (<e2>CBS</e2>) from L-cysteine (<e1>L-Cys</e1>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>cystathionine gamma-lyase</e2> (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (<e1>L-Cys</e1>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE</e2>) and/or cystathionine beta-synthase (CBS) from L-cysteine (<e1>L-Cys</e1>) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.","Substrate"
"L-arg is converted to <e1>urea</e1> by <e2>arginase</e2> I in the liver and arginase II in the kidney.","Downregulator"
"L-arg is converted to <e1>urea</e1> by <e2>arginase</e2> I in the liver and arginase II in the kidney.","Downregulator"
"L-arg is converted to <e1>urea</e1> by <e2>arginase I</e2> in the liver and arginase II in the kidney.","Substrate"
"L-arg is converted to <e1>urea</e1> by arginase I in the liver and <e2>arginase II</e2> in the kidney.","Substrate"
"Sources of <e1>L-arg</e1> include dietary proteins and endogenous synthesis by <e2>argininosuccinate synthetase</e2> and argininosuccinate lyase.","Substrate"
"Sources of <e1>L-arg</e1> include dietary proteins and endogenous synthesis by argininosuccinate synthetase and <e2>argininosuccinate lyase</e2>.","Substrate"
"<e1>L-arg</e1> is converted to urea by <e2>arginase I</e2> in the liver and arginase II in the kidney.","Substrate"
"<e1>L-arg</e1> is converted to urea by arginase I in the liver and <e2>arginase II</e2> in the kidney.","Substrate"
"<e1>L-arg</e1> is converted to urea by <e2>arginase</e2> I in the liver and arginase II in the kidney.","Substrate"
"However, several promising nonpeptide, <e2>vasopressin receptor</e2> antagonists have been described; these agents are <e1>VPA-985</e1> (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.","Antagonist"
"However, several promising nonpeptide, <e2>vasopressin receptor</e2> antagonists have been described; these agents are VPA-985 (<e1>lixivaptan</e1>), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.","Antagonist"
"However, several promising nonpeptide, <e2>vasopressin receptor</e2> antagonists have been described; these agents are VPA-985 (lixivaptan), <e1>YM-087</e1> (conivaptan), OPC-41061 (tolvaptan), and SR-121463.","Antagonist"
"However, several promising nonpeptide, <e2>vasopressin receptor</e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (<e1>conivaptan</e1>), OPC-41061 (tolvaptan), and SR-121463.","Antagonist"
"However, several promising nonpeptide, <e2>vasopressin receptor</e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), <e1>OPC-41061</e1> (tolvaptan), and SR-121463.","Antagonist"
"However, several promising nonpeptide, <e2>vasopressin receptor</e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (<e1>tolvaptan</e1>), and SR-121463.","Antagonist"
"However, several promising nonpeptide, <e2>vasopressin receptor</e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and <e1>SR-121463</e1>.","Antagonist"
"Sedation and <e2>histamine H1-receptor</e2> antagonism: studies in man with the enantiomers of chlorpheniramine and <e1>dimethindene</e1>.","Antagonist"
"Sedation and <e2>histamine H1-receptor</e2> antagonism: studies in man with the enantiomers of <e1>chlorpheniramine</e1> and dimethindene.","Antagonist"
"BG also showed a protective effect in the presence of a <e2>DNA polymerase beta</e2> inhibitor (<e1>cytosine arabinoside-3-phosphate</e1>, Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.","Downregulator"
"BG also showed a protective effect in the presence of a <e2>DNA polymerase beta</e2> inhibitor (cytosine arabinoside-3-phosphate, <e1>Ara-C</e1>), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.","Downregulator"
"METHODS: We identified seven SNP(single <e1>nucleotide</e1> polymorphism) (-141Cins>del, TaqIB, TaqID, <e2>Ser311Cys</e2>, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.","Part_of"
"METHODS: We identified seven SNP(single <e1>nucleotide</e1> polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the <e2>DRD2</e2> gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.","Part_of"
"Association of <e2>DRD2</e2> polymorphisms and <e1>chlorpromazine</e1>-induced extrapyramidal syndrome in Chinese schizophrenic patients.","Regulator"
"Calcium-chelating reagents such as <e1>EDTA</e1> and 1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester prevented the cleavage of <e2>GAD65</e2>.","Not"
"Calcium-chelating reagents such as EDTA and <e1>1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester</e1> prevented the cleavage of <e2>GAD65</e2>.","Not"
"Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the <e1>N</e1>-terminus, <e2>GAD65(Delta1-69)</e2>.","Part_of"
"Agents that specifically target <e2>BRAF</e2>, such as <e1>sorafenib</e1>, as well as new molecules that function both upstream and downstream of BRAF, are being actively investigated.","Regulator"
"Our purpose was to test the impact of single and/or combined treatment with the <e2>AT(1)</e2>-receptor blocker <e1>candesartan</e1> and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.","Downregulator"
"Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the <e2>HMG-CoA reductase</e2> inhibitor <e1>rosuvastatin</e1> and their combination.","Downregulator"
"Reduction of cerebral infarct size by the <e2>AT1</e2>-receptor blocker <e1>candesartan</e1>, the HMG-CoA reductase inhibitor rosuvastatin and their combination.","Downregulator"
"Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the <e2>HMG-CoA reductase</e2> inhibitor <e1>rosuvastatin</e1> and their combination.","Downregulator"
"The phosphorylation by gammaPKC resulted in activation of <e2>DGKgamma</e2> because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with <e1>glutamic acid</e1> to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.","Part_of"
"Mass spectrometric analysis and mutation studies revealed that <e2>gammaPKC</e2> <e1>phosphorylated Ser</e1>-776 and Ser-779 in the AD of DGKgamma.","Part_of"
"Mass spectrometric analysis and mutation studies revealed that gammaPKC phosphorylated <e1>Ser</e1>-776 and Ser-779 in the AD of <e2>DGKgamma</e2>.","Part_of"
"Mass spectrometric analysis and mutation studies revealed that gammaPKC phosphorylated <e1>Ser</e1>-776 and Ser-779 in the AD of <e2>DGKgamma</e2>.","Part_of"
"Mass spectrometric analysis and mutation studies revealed that gammaPKC phosphorylated <e1>Ser</e1>-776 and Ser-779 in the AD of <e2>DGKgamma</e2>.","Part_of"
"<e2>gammaPKC</e2> directly associated with DGKgamma through its accessory domain (AD), depending on <e1>Ca2+</e1> as well as phosphatidylserine/diolein in vitro.","Regulator"
"gammaPKC directly associated with <e2>DGKgamma</e2> through its accessory domain (AD), depending on <e1>Ca2+</e1> as well as phosphatidylserine/diolein in vitro.","Regulator"
"<e2>gammaPKC</e2> directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as <e1>phosphatidylserine</e1>/diolein in vitro.","Regulator"
"gammaPKC directly associated with <e2>DGKgamma</e2> through its accessory domain (AD), depending on Ca2+ as well as <e1>phosphatidylserine</e1>/diolein in vitro.","Regulator"
"<e2>gammaPKC</e2> directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/<e1>diolein</e1> in vitro.","Regulator"
"gammaPKC directly associated with <e2>DGKgamma</e2> through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/<e1>diolein</e1> in vitro.","Regulator"
"<e1>Diacylglycerol</e1> (DAG) acts as an allosteric activator of <e2>protein kinase C</e2> (PKC) and is converted to phosphatidic acid by DAG kinase (DGK).","Modulator"
"<e1>Diacylglycerol</e1> (DAG) acts as an allosteric activator of protein kinase C (<e2>PKC</e2>) and is converted to phosphatidic acid by DAG kinase (DGK).","Modulator"
"Diacylglycerol (<e1>DAG</e1>) acts as an allosteric activator of <e2>protein kinase C</e2> (PKC) and is converted to phosphatidic acid by DAG kinase (DGK).","Modulator"
"Diacylglycerol (<e1>DAG</e1>) acts as an allosteric activator of protein kinase C (<e2>PKC</e2>) and is converted to phosphatidic acid by DAG kinase (DGK).","Modulator"
"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to <e1>phosphatidic acid</e1> by <e2>DAG kinase</e2> (DGK).","Substrate"
"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to <e1>phosphatidic acid</e1> by DAG kinase (<e2>DGK</e2>).","Substrate"
"<e1>Diacylglycerol</e1> (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by <e2>DAG kinase</e2> (DGK).","Substrate"
"<e1>Diacylglycerol</e1> (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (<e2>DGK</e2>).","Substrate"
"Diacylglycerol (<e1>DAG</e1>) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by <e2>DAG kinase</e2> (DGK).","Substrate"
"Diacylglycerol (<e1>DAG</e1>) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (<e2>DGK</e2>).","Substrate"
"Among all the organophosphates tested, the combination of a methyl group and a negatively charged <e1>oxygen</e1> attached to the P atom, CH3P(O)(O-)-<e2>AChE</e2>, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.","Regulator"
"Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the <e1>P</e1> atom, CH3P(O)(O-)-<e2>AChE</e2>, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.","Regulator"
"Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, <e1>CH3P(O)(O-)</e1>-<e2>AChE</e2>, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.","Regulator"
"Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-AChE, conferred the greatest protection to the active site of aged or nonaged <e1>organophosphoryl</e1> conjugates of <e2>acetylcholinesterase</e2>.","Regulator"
"Among all the <e1>organophosphates</e1> tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-<e2>AChE</e2>, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.","Regulator"
"Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of <e2>acetylcholinesterase</e2> against denaturation by heat or <e1>guanidine</e1> following phosphorylation by organophosphorus anticholinesterase compounds.","Downregulator"
"Monoclonal antibody 25B1 generated against <e1>diisopropyl phosphorofluoridate</e1> inhibited fetal <e2>bovine serum acetylcholinesterase</e2> has been extensively characterized with respect to its anticholinesterase properties.","Downregulator"
"Effects of <e1>folic acid</e1> deficiency and <e2>MTHFR</e2> C677T polymorphism on spontaneous and radiation-induced micronuclei in human lymphocytes.","Regulator"
"The <e2>C677T</e2> polymorphism of the methylene-tetrahydro<e1>folate</e1> reductase (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status.","Regulator"
"The C677T polymorphism of the methylene-tetrahydro<e1>folate</e1> reductase (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status.","Regulator"
"The C677T polymorphism of the methylene-tetrahydro<e1>folate</e1> reductase (<e2>MTHFR</e2>) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status.","Regulator"
"The main molecular target of <e1>azole</e1> antifungals is the <e2>cytochrome P-450</e2> protein Erg11p/Cyp51p.","Regulator"
"The main molecular target of <e1>azole</e1> antifungals is the cytochrome P-450 protein <e2>Erg11p</e2>/Cyp51p.","Regulator"
"The main molecular target of <e1>azole</e1> antifungals is the cytochrome P-450 protein Erg11p/<e2>Cyp51p</e2>.","Regulator"
"The <e1>phenylmorpholines</e1>, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: <e2>Erg24p</e2> (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase).","Regulator"
"The <e1>phenylmorpholines</e1>, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (<e2>delta 14 reductase</e2>) and Erg2p (delta 8-delta 7 isomerase).","Regulator"
"The <e1>phenylmorpholines</e1>, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and <e2>Erg2p</e2> (delta 8-delta 7 isomerase).","Regulator"
"The <e1>phenylmorpholines</e1>, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p (<e2>delta 8-delta 7 isomerase</e2>).","Regulator"
"The phenylmorpholines, of which <e1>amorolfine</e1> is the sole representative in human therapy, affect two targets in the ergosterol pathway: <e2>Erg24p</e2> (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase).","Regulator"
"The phenylmorpholines, of which <e1>amorolfine</e1> is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (<e2>delta 14 reductase</e2>) and Erg2p (delta 8-delta 7 isomerase).","Regulator"
"The phenylmorpholines, of which <e1>amorolfine</e1> is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and <e2>Erg2p</e2> (delta 8-delta 7 isomerase).","Regulator"
"The phenylmorpholines, of which <e1>amorolfine</e1> is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p (<e2>delta 8-delta 7 isomerase</e2>).","Regulator"
"The <e1>sordarins</e1> group are protein synthesis inhibitors that work by blocking the function of <e2>fungal translation elongation factor 2</e2>.","Downregulator"
"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (<e2>GPCR</e2>) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (<e1>IP3</e1>), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Regulator"
"We show here that <e1>IP1</e1> can be used as a surrogate of IP3 to monitor <e2>GPCR</e2> activation.","Regulator"
"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (<e2>GPCR</e2>) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (<e1>IP3</e1>), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Regulator"
"<e1>D-myo-inositol 1-phosphate</e1> as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor <e2>G protein-coupled receptor</e2> activation.","Regulator"
"D-myo-inositol 1-phosphate as a surrogate of <e1>D-myo-inositol 1,4,5-tris phosphate</e1> to monitor <e2>G protein-coupled receptor</e2> activation.","Regulator"
"<e2>Phospholipase C beta</e2> (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by <e1>D-myo-inositol 1,4,5-trisphosphate</e1> (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Regulator"
"Phospholipase C beta (<e2>PLC-beta</e2>)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by <e1>D-myo-inositol 1,4,5-trisphosphate</e1> (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Regulator"
"Phospholipase C beta (PLC-beta)-coupled <e2>G protein-coupled receptor</e2> (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by <e1>D-myo-inositol 1,4,5-trisphosphate</e1> (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Regulator"
"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (<e2>GPCR</e2>) activities traditionally are assessed by measuring Ca2+ triggered by <e1>D-myo-inositol 1,4,5-trisphosphate</e1> (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Regulator"
"It has been known for decades that <e1>lithium chloride</e1> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on <e2>GPCR</e2> activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.","Upregulator"
"It has been known for decades that lithium chloride (<e1>LiCl</e1>) leads to D-myo-inositol 1-phosphate accumulation on <e2>GPCR</e2> activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.","Upregulator"
"It has been known for decades that <e1>lithium chloride</e1> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>inositol monophosphatase</e2>, the final enzyme of the IP3 metabolic cascade.","Downregulator"
"It has been known for decades that lithium chloride (<e1>LiCl</e1>) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>inositol monophosphatase</e2>, the final enzyme of the IP3 metabolic cascade.","Downregulator"
"Phospholipase C beta (<e2>PLC-beta</e2>)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring <e1>Ca2+</e1> triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Cofactor"
"<e2>Phospholipase C beta</e2> (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring <e1>Ca2+</e1> triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Cofactor"
"Phospholipase C beta (<e2>PLC-beta</e2>)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring <e1>Ca2+</e1> triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Cofactor"
"Phospholipase C beta (<e2>PLC-beta</e2>)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by <e1>D-myo-inositol 1,4,5-trisphosphate</e1> (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Substrate"
"Phospholipase C beta (<e2>PLC-beta</e2>)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (<e1>IP3</e1>), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.","Substrate"
"Phospholipase C beta (<e2>PLC-beta</e2>)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of <e1>inositol phosphate</e1> using cumbersome radioactive assays.","Substrate"
"It has been known for decades that lithium chloride (LiCl) leads to <e1>D-myo-inositol 1-phosphate</e1> accumulation on GPCR activation by inhibiting <e2>inositol monophosphatase</e2>, the final enzyme of the IP3 metabolic cascade.","Substrate"
"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>inositol monophosphatase</e2>, the final enzyme of the <e1>IP3</e1> metabolic cascade.","Substrate"
"Once formed, the molecule can be converted to <e1>glycine</e1> by <e2>alanine-glyoxylate aminotransferase</e2> (AGAT).","Substrate"
"Once formed, the molecule can be converted to <e1>glycine</e1> by alanine-glyoxylate aminotransferase (<e2>AGAT</e2>).","Substrate"
"11Beta-HSD1 activates <e1>cortisone</e1> to cortisol to facilitate <e2>glucocorticoid receptor</e2> (GR)-mediated action.","Regulator"
"11Beta-HSD1 activates <e1>cortisone</e1> to cortisol to facilitate glucocorticoid receptor (<e2>GR</e2>)-mediated action.","Regulator"
"11Beta-HSD1 activates cortisone to <e1>cortisol</e1> to facilitate <e2>glucocorticoid receptor</e2> (GR)-mediated action.","Regulator"
"11Beta-HSD1 activates cortisone to <e1>cortisol</e1> to facilitate glucocorticoid receptor (<e2>GR</e2>)-mediated action.","Regulator"
"By contrast, <e2>11beta-HSD2</e2> plays a pivotal role in <e1>aldosterone</e1> target tissues where it catalyses the opposite reaction (i.e.","Regulator"
"inactivation of <e1>cortisol</e1> to cortisone) to prevent activation of the <e2>mineralocorticoid receptor</e2> (MR) by cortisol.","Upregulator"
"inactivation of <e1>cortisol</e1> to cortisone) to prevent activation of the mineralocorticoid receptor (<e2>MR</e2>) by cortisol.","Upregulator"
"inactivation of <e1>cortisol</e1> to cortisone) to prevent activation of the mineralocorticoid receptor (<e2>MR</e2>) by cortisol.","Upregulator"
"Ingestion of competitive inhibitors of <e2>11beta-HSD2</e2> such as liquorice and <e1>carbenoxolone</e1> result in a similar but milder clinical phenotype.","Downregulator"
"<e2>11Beta-HSD1</e2> activates cortisone to <e1>cortisol</e1> to facilitate glucocorticoid receptor (GR)-mediated action.","Substrate"
"<e2>11Beta-HSD1</e2> activates <e1>cortisone</e1> to cortisol to facilitate glucocorticoid receptor (GR)-mediated action.","Substrate"
"Mutations in the <e2>11beta-HSD2</e2> gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which <e1>cortisol</e1> activates the MR resulting in severe hypertension and hypokalemia.","Substrate"
"<e1>ATRA</e1> regulates gene expression via the activation of the <e2>retinoic acid receptor (RAR)alpha</e2> in human DCs, and RARalpha acutely regulates CD1d expression.","Upregulator"
"<e1>ATRA</e1> regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and <e2>RARalpha</e2> acutely regulates CD1d expression.","Upregulator"
"<e1>ATRA</e1> regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates <e2>CD1d</e2> expression.","Upregulator"
"PPARgamma controls <e2>CD1d</e2> expression by turning on <e1>retinoic acid</e1> synthesis in developing human dendritic cells.","Upregulator"
"Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit <e1>retinoid</e1> signaling leading to <e2>CD1d</e2> up-regulation.","Upregulator"
"Here we demonstrate that PPARgamma, turns on <e1>retinoic acid</e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as <e2>retinol dehydrogenase 10</e2> and retinaldehyde dehydrogenase type 2 (RALDH2).","Substrate"
"Here we demonstrate that PPARgamma, turns on <e1>retinoic acid</e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and <e2>retinaldehyde dehydrogenase type 2</e2> (RALDH2).","Substrate"
"Here we demonstrate that PPARgamma, turns on <e1>retinoic acid</e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<e2>RALDH2</e2>).","Substrate"
"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>retinol</e1> and retinal metabolizing enzymes such as <e2>retinol dehydrogenase 10</e2> and retinaldehyde dehydrogenase type 2 (RALDH2).","Substrate"
"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>retinol</e1> and retinal metabolizing enzymes such as retinol dehydrogenase 10 and <e2>retinaldehyde dehydrogenase type 2</e2> (RALDH2).","Substrate"
"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>retinol</e1> and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<e2>RALDH2</e2>).","Substrate"
"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>retinal</e1> metabolizing enzymes such as <e2>retinol dehydrogenase 10</e2> and retinaldehyde dehydrogenase type 2 (RALDH2).","Substrate"
"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>retinal</e1> metabolizing enzymes such as retinol dehydrogenase 10 and <e2>retinaldehyde dehydrogenase type 2</e2> (RALDH2).","Substrate"
"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>retinal</e1> metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<e2>RALDH2</e2>).","Substrate"
"CONTEXT: <e1>Ramelteon</e1> is a novel <e2>MT1</e2> and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.","Agonist"
"CONTEXT: <e1>Ramelteon</e1> is a novel MT1 and <e2>MT2 melatonin receptor</e2> selective agonist recently approved for insomnia treatment.","Agonist"
"Late INa induced by the <e2>VGSC</e2> long QT mutant R1623Q was reduced by <e1>resveratrol</e1> and quercetin.","Downregulator"
"Late INa induced by the VGSC long QT mutant <e2>R1623Q</e2> was reduced by <e1>resveratrol</e1> and quercetin.","Downregulator"
"Late INa induced by the <e2>VGSC</e2> long QT mutant R1623Q was reduced by resveratrol and <e1>quercetin</e1>.","Downregulator"
"Late INa induced by the VGSC long QT mutant <e2>R1623Q</e2> was reduced by resveratrol and <e1>quercetin</e1>.","Downregulator"
"Enhancement of radiosensitivity by <e2>topoisomerase II</e2> inhibitor, <e1>amrubicin</e1> and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.","Downregulator"
"Enhancement of radiosensitivity by <e2>topoisomerase II</e2> inhibitor, amrubicin and <e1>amrubicinol</e1>, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.","Downregulator"
"Similar to <e1>AMR</e1> and AMROH, adriamycin and etoposide (VP-16) are <e2>DNA topoisomerase II</e2> inhibitors.","Downregulator"
"Similar to AMR and <e1>AMROH</e1>, adriamycin and etoposide (VP-16) are <e2>DNA topoisomerase II</e2> inhibitors.","Downregulator"
"Similar to AMR and AMROH, <e1>adriamycin</e1> and etoposide (VP-16) are <e2>DNA topoisomerase II</e2> inhibitors.","Downregulator"
"Similar to AMR and AMROH, adriamycin and <e1>etoposide</e1> (VP-16) are <e2>DNA topoisomerase II</e2> inhibitors.","Downregulator"
"Similar to AMR and AMROH, adriamycin and etoposide (<e1>VP-16</e1>) are <e2>DNA topoisomerase II</e2> inhibitors.","Downregulator"
"Accumulated evidence in humans and animals shows that both <e1>aspirin</e1> and H. pylori upregulate the expression of cyclooxygenase (COX)-2 both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of <e2>COX-1</e2>.","Not"
"It was, therefore, proposed that H. pylori may in fact, antagonize, <e1>aspirin</e1>-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from <e2>COX-2</e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.","Upregulator"
"Accumulated evidence in humans and animals shows that both <e1>aspirin</e1> and H. pylori upregulate the expression of <e2>cyclooxygenase (COX)-2</e2> both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1.","Upregulator"
"It was, therefore, proposed that H. pylori may in fact, antagonize, <e1>aspirin</e1>-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as <e2>TGF alpha</e2> and VEGF.","Upregulator"
"It was, therefore, proposed that H. pylori may in fact, antagonize, <e1>aspirin</e1>-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and <e2>VEGF</e2>.","Upregulator"
"It was, therefore, proposed that H. pylori may in fact, antagonize, <e1>aspirin</e1>-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from <e2>COX-2</e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.","Upregulator"
"It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in <e1>PGE(2)</e1> possibly derived from <e2>COX-2</e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.","Substrate"
"Based on selective nucleoside protection, <e2>TS</e2> was found to be the primary <e1>pemetrexed</e1> target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations.","Regulator"
"Based on selective nucleoside protection, <e2>TS</e2> was found to be the primary <e1>pemetrexed</e1> target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations.","Regulator"
"Based on selective nucleoside protection, TS was found to be the primary <e1>pemetrexed</e1> target in both cell lines with <e2>GARFT</e2> inhibition requiring 20- to 30-fold higher pemetrexed concentrations.","Regulator"
"Based on selective nucleoside protection, TS was found to be the primary <e1>pemetrexed</e1> target in both cell lines with <e2>GARFT</e2> inhibition requiring 20- to 30-fold higher pemetrexed concentrations.","Downregulator"
"<e2>Methylthioadenosine phosphorylase</e2> (MTAP) salvages purines by releasing <e1>adenine</e1> from methylthioadenosine and is often deleted in mesothelioma.","Substrate"
"Methylthioadenosine phosphorylase (<e2>MTAP</e2>) salvages purines by releasing <e1>adenine</e1> from methylthioadenosine and is often deleted in mesothelioma.","Substrate"
"<e2>Methylthioadenosine phosphorylase</e2> (MTAP) salvages purines by releasing adenine from <e1>methylthioadenosine</e1> and is often deleted in mesothelioma.","Substrate"
"Methylthioadenosine phosphorylase (<e2>MTAP</e2>) salvages purines by releasing adenine from <e1>methylthioadenosine</e1> and is often deleted in mesothelioma.","Substrate"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (<e1>sulfonylureas</e1>, glinides), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, <e1>glinides</e1>), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the <e2>sulfonylurea receptor</e2> stimulating insulin release (<e1>sulfonylureas</e1>, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (<e1>sulfonylureas</e1>, glinides), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the <e2>sulfonylurea receptor</e2> stimulating insulin release (sulfonylureas, <e1>glinides</e1>), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, <e1>glinides</e1>), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Regulator"
"<e1>Sulfonylureas</e1> and glinides exhibit <e2>peroxisome proliferator-activated receptor gamma</e2> activity: a combined virtual screening and biological assay approach.","Regulator"
"Sulfonylureas and <e1>glinides</e1> exhibit <e2>peroxisome proliferator-activated receptor gamma</e2> activity: a combined virtual screening and biological assay approach.","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the <e2>sulfonylurea receptor</e2> stimulating insulin release (<e1>sulfonylureas</e1>, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the <e2>sulfonylurea receptor</e2> stimulating insulin release (sulfonylureas, <e1>glinides</e1>), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the <e2>peroxisome proliferator-activated receptor</e2> (PPARgamma) improving insulin resistance (<e1>thiazolidinediones</e1>).","Regulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (<e1>thiazolidinediones</e1>).","Regulator"
"Among the measured compounds, <e1>gliquidone</e1> and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit <e2>PPARgamma</e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment.","Upregulator"
"The most active of these compounds, gliquidone, is shown to be as potent as <e1>pioglitazone</e1> at inducing <e2>PPARgamma</e2> target gene expression.","Upregulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating <e2>insulin</e2> release (<e1>sulfonylureas</e1>, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).","Upregulator"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating <e2>insulin</e2> release (sulfonylureas, <e1>glinides</e1>), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).","Upregulator"
"Among the measured compounds, <e1>gliquidone</e1> and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit <e2>PPARgamma</e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment.","Agonist"
"Among the measured compounds, gliquidone and <e1>glipizide</e1> (two sulfonylureas), as well as nateglinide (a glinide), exhibit <e2>PPARgamma</e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment.","Agonist"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (<e1>sulfonylureas</e1>, glinides), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Agonist"
"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as <e1>nateglinide</e1> (a glinide), exhibit <e2>PPARgamma</e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment.","Agonist"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, <e1>glinide</e1>s), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Agonist"
"<e1>Glinides</e1>, sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new <e2>PPARgamma</e2> agonists.","Agonist"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (<e1>sulfonylureas</e1>, glinides), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Agonist"
"Glinides, sulfonylureas, and other <e1>acidified sulfonamides</e1> may be promising leads in the development of new <e2>PPARgamma</e2> agonists.","Agonist"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (<e1>sulfonylureas</e1>, glinides), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Agonist"
"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, <e1>glinides</e1>), or target the peroxisome proliferator-activated receptor (<e2>PPARgamma</e2>) improving insulin resistance (thiazolidinediones).","Agonist"
"There is a growing appreciation that the <e1>cyclic adenosine monophosphate</e1> (cAMP)-<e2>protein kinase A</e2> (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages.","Regulator"
"There is a growing appreciation that the <e1>cyclic adenosine monophosphate</e1> (cAMP)-protein kinase A (<e2>PKA</e2>) signaling pathway is organized to form transduction units that function to deliver specific messages.","Regulator"
"There is a growing appreciation that the cyclic adenosine monophosphate (<e1>cAMP</e1>)-<e2>protein kinase A</e2> (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages.","Regulator"
"There is a growing appreciation that the cyclic adenosine monophosphate (<e1>cAMP</e1>)-protein kinase A (<e2>PKA</e2>) signaling pathway is organized to form transduction units that function to deliver specific messages.","Regulator"
"There is a growing appreciation that the cyclic adenosine monophosphate (<e1>cAMP</e1>)-protein kinase A (<e2>PKA</e2>) signaling pathway is organized to form transduction units that function to deliver specific messages.","Upregulator"
"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized <e2>PDE4B</e2> and PDE4D are responsible for selectively modulating the concentration of <e1>cAMP</e1> in individual subcellular compartments.","Substrate"
"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and <e2>PDE4D</e2> are responsible for selectively modulating the concentration of <e1>cAMP</e1> in individual subcellular compartments.","Substrate"
"By using pharmacological and genetic manipulation of phosphodiesterases (<e2>PDEs</e2>), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of <e1>cAMP</e1> in individual subcellular compartments.","Substrate"
"By using pharmacological and genetic manipulation of phosphodiesterases (<e2>PDEs</e2>), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of <e1>cAMP</e1> in individual subcellular compartments.","Substrate"
"We failed to observe any significant activation of <e2>FAS promoter</e2> following exposure to the anti-metabolite <e1>5-fluorouracil</e1>, the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and vincristine.","Not"
"We failed to observe any significant activation of <e2>FAS promoter</e2> following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug <e1>cisplatin</e1>, or the microtubule interfering-agents paclitaxel and vincristine.","Not"
"We failed to observe any significant activation of <e2>FAS promoter</e2> following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents <e1>paclitaxel</e1> and vincristine.","Not"
"We failed to observe any significant activation of <e2>FAS promoter</e2> following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and <e1>vincristine</e1>.","Not"
"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors <e1>doxorubicin</e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in <e2>FAS promoter</e2> activity when compared with control cells growing in drug-free culture conditions.","Upregulator"
"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and <e1>etopoxide</e1> (VP-16) demonstrated a 2- to 3-fold increase in <e2>FAS promoter</e2> activity when compared with control cells growing in drug-free culture conditions.","Upregulator"
"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (<e1>VP-16</e1>) demonstrated a 2- to 3-fold increase in <e2>FAS promoter</e2> activity when compared with control cells growing in drug-free culture conditions.","Upregulator"
"SK-Br3 cells cultured in the presence of <e2>topoisomerase IIalpha</e2> (TOP2A) inhibitors <e1>doxorubicin</e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.","Downregulator"
"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>TOP2A</e2>) inhibitors <e1>doxorubicin</e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.","Downregulator"
"SK-Br3 cells cultured in the presence of <e2>topoisomerase IIalpha</e2> (TOP2A) inhibitors doxorubicin and <e1>etopoxide</e1> (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.","Downregulator"
"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>TOP2A</e2>) inhibitors doxorubicin and <e1>etopoxide</e1> (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.","Downregulator"
"SK-Br3 cells cultured in the presence of <e2>topoisomerase IIalpha</e2> (TOP2A) inhibitors doxorubicin and etopoxide (<e1>VP-16</e1>) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.","Downregulator"
"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>TOP2A</e2>) inhibitors doxorubicin and etopoxide (<e1>VP-16</e1>) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.","Downregulator"
"<e1>Mifepristone</e1> alters expression of endometrial <e2>steroid receptors</e2> and their cofactors in new users of medroxyprogesterone acetate.","Regulator"
"RESULT(S): The expression of endometrial <e2>ERalpha</e2>, PRAB, PRB, and SRC-1 was increased significantly after 1 week of <e1>mifepristone</e1>, but the increase was no longer seen after 10 weeks.","Upregulator"
"RESULT(S): The expression of endometrial ERalpha, <e2>PRAB</e2>, PRB, and SRC-1 was increased significantly after 1 week of <e1>mifepristone</e1>, but the increase was no longer seen after 10 weeks.","Upregulator"
"RESULT(S): The expression of endometrial ERalpha, PRAB, <e2>PRB</e2>, and SRC-1 was increased significantly after 1 week of <e1>mifepristone</e1>, but the increase was no longer seen after 10 weeks.","Upregulator"
"RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and <e2>SRC-1</e2> was increased significantly after 1 week of <e1>mifepristone</e1>, but the increase was no longer seen after 10 weeks.","Upregulator"
"RESULT(S): The expression of endometrial <e2>ERalpha</e2>, PRAB, PRB, and SRC-1 was increased significantly after 1 week of <e1>mifepristone</e1>, but the increase was no longer seen after 10 weeks.","Upregulator"
"RESULT(S): The expression of endometrial ERalpha, <e2>PRAB</e2>, PRB, and SRC-1 was increased significantly after 1 week of <e1>mifepristone</e1>, but the increase was no longer seen after 10 weeks.","Upregulator"
"RESULT(S): The expression of endometrial ERalpha, PRAB, <e2>PRB</e2>, and SRC-1 was increased significantly after 1 week of <e1>mifepristone</e1>, but the increase was no longer seen after 10 weeks.","Upregulator"
"RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and <e2>SRC-1</e2> was increased significantly after 1 week of <e1>mifepristone</e1>, but the increase was no longer seen after 10 weeks.","Upregulator"
"To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of d-galactosamine (<e1>GalN</e1>), we focused on the role of polyprimidine tract-binding protein (<e2>PTB</e2>) in islet insulin synthesis.","Upregulator"
"In the present study, <e1>glucose</e1>-stimulated <e2>insulin</e2> secretion was significantly increased in GalN-treated rats compared to controls.","Upregulator"
"To investigate the mechanism of hyper<e2>insulin</e2>aemia in rats with acute liver failure induced by the administration of d-galactosamine (<e1>GalN</e1>), we focused on the role of polyprimidine tract-binding protein (PTB) in islet insulin synthesis.","Upregulator"
"Levels of mRNA encoding <e2>insulin 1</e2>, ICA512, and PC1/3 were increased in the pancreatic islets of <e1>GalN</e1>-treated rats.","Upregulator"
"Levels of mRNA encoding insulin 1, <e2>ICA512</e2>, and PC1/3 were increased in the pancreatic islets of <e1>GalN</e1>-treated rats.","Upregulator"
"This mRNA level elevation was not prevented by pretreatment with actinomycin D. When the <e2>PTB-binding site</e2> in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from <e1>GalN</e1>-treated rats compared to the level in control rats.","Upregulator"
"Levels of mRNA encoding <e2>insulin 1</e2>, ICA512, and PC1/3 were increased in the pancreatic islets of <e1>GalN</e1>-treated rats.","Upregulator"
"AIM: To determine whether cysteinyl leukotriene receptor 1 (<e2>CysLT1 receptor</e2>) is involved in N-methyl-D-aspartate (<e1>NMDA</e1>)-induced excitotoxic injury in the mouse brain.","Regulator"
"<e2>Cysteinyl leukotriene receptor 1</e2> is involved in <e1>N-methyl-D-aspartate</e1>-mediated neuronal injury in mice.","Regulator"
"AIM: To determine whether cysteinyl leukotriene receptor 1 (<e2>CysLT1 receptor</e2>) is involved in N-methyl-D-aspartate (<e1>NMDA</e1>)-induced excitotoxic injury in the mouse brain.","Upregulator"
"AIM: To determine whether cysteinyl leukotriene receptor 1 (<e2>CysLT1 receptor</e2>) is involved in N-methyl-D-aspartate (<e1>NMDA</e1>)-induced excitotoxic injury in the mouse brain.","Upregulator"
"AIM: To determine whether cysteinyl leukotriene receptor 1 (<e2>CysLT1 receptor</e2>) is involved in N-methyl-D-aspartate (<e1>NMDA</e1>)-induced excitotoxic injury in the mouse brain.","Upregulator"
"The changes in <e2>CysLT1 receptor</e2> expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, <e1>pranlukast</e1> (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.","Downregulator"
"The changes in <e2>CysLT1 receptor</e2> expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, <e1>ketamine</e1> (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.","Downregulator"
"The changes in <e2>CysLT1 receptor</e2> expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, <e1>pranlukast</e1> (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.","Antagonist"
"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an <e2>NMDA receptor</e2> antagonist, <e1>ketamine</e1> (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.","Antagonist"
"We have previously demonstrated that phosphorylation of <e2>Fas-associated death domain-containing protein</e2> (FADD) at 194 <e1>serine</e1> through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.","Part_of"
"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (<e2>FADD</e2>) at 194 <e1>serine</e1> through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.","Part_of"
"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that <e2>Bcl-2</e2> phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by <e1>paclitaxel</e1>.","Regulator"
"We have previously demonstrated that phosphorylation of <e2>Fas-associated death domain-containing protein</e2> (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by <e1>paclitaxel</e1>.","Upregulator"
"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (<e2>FADD</e2>) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by <e1>paclitaxel</e1>.","Upregulator"
"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through <e2>c-jun NH2-terminal kinase</e2> (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by <e1>paclitaxel</e1>.","Upregulator"
"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (<e2>JNK</e2>) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by <e1>paclitaxel</e1>.","Upregulator"
"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (<e2>JNK</e2>) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by <e1>paclitaxel</e1>.","Upregulator"
"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (<e2>FADD</e2>) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by <e1>paclitaxel</e1>.","Upregulator"
"<e1>Carvedilol</e1> produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the <e2>alpha 2 adrenoceptor</e2> mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.","Not"
"<e1>Carvedilol</e1> had no effect on the pressor response elicited by <e2>angiotensin II</e2>, indicating a lack of nonspecific vasodilator activity.","Not"
"This same dose of carvedilol also inhibited, but to a lesser degree, the <e2>beta 2 adrenoceptor</e2> mediated vasodepressor response to <e1>salbutamol</e1> in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.","Regulator"
"Carvedilol produced significant inhibition of the <e2>alpha 1 adrenoceptor</e2> mediated pressor response to <e1>cirazoline</e1> in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.","Regulator"
"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the <e2>alpha 2 adrenoceptor</e2> mediated pressor response to <e1>B-HT 933</e1>, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.","Regulator"
"Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the <e2>beta 1 adrenoceptor</e2> mediated positive chronotropic response to <e1>isoproterenol</e1>.","Upregulator"
"The vasopressor response to the <e2>calcium channel</e2> activator, <e1>BAY-K-8644</e1>, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","Upregulator"
"The vasopressor response to the calcium channel activator, <e1>BAY-K-8644</e1>, which is mediated through the opening of <e2>voltage dependent calcium channels</e2> and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","Upregulator"
"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of <e2>voltage dependent calcium channels</e2> and the subsequent translocation of extracellular calcium, was significantly inhibited by <e1>carvedilol</e1> (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","Downregulator"
"Thus, <e1>carvedilol</e1> blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the <e2>beta 1 adrenoceptor</e2> subtype.","Downregulator"
"<e1>Carvedilol</e1> (0.3 mg/kg, iv) produced a significant inhibition of the <e2>beta 1 adrenoceptor</e2> mediated positive chronotropic response to isoproterenol.","Downregulator"
"This same dose of <e1>carvedilol</e1> also inhibited, but to a lesser degree, the <e2>beta 2 adrenoceptor</e2> mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.","Downregulator"
"<e1>Carvedilol</e1> produced significant inhibition of the <e2>alpha 1 adrenoceptor</e2> mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.","Downregulator"
"The vasopressor response to the <e2>calcium channel</e2> activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by <e1>carvedilol</e1> (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","Antagonist"
"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the <e2>alpha 1 adrenoceptor</e2> antagonist, <e1>prazosin</e1> (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.","Antagonist"
"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective <e2>beta adrenoceptor</e2> antagonist, <e1>propranolol</e1> (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.","Antagonist"
"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent <e2>calcium channels</e2> and the subsequent translocation of extracellular calcium, was significantly inhibited by <e1>carvedilol</e1> (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","Antagonist"
"The mechanism(s) responsible for arterial vasodilation observed following acute administration of <e1>racemic carvedilol</e1>, a novel vasodilator/<e2>beta adrenoceptor</e2> antagonist, has been investigated in rats.","Antagonist"
"Carvedilol produced significant inhibition of the <e2>alpha 1 adrenoceptor</e2> mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that <e1>carvedilol</e1> is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.","Antagonist"
"The vasopressor response to the <e1>calcium</e1> channel activator, BAY-K-8644, which is mediated through the opening of <e2>voltage dependent calcium channels</e2> and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.","Substrate"
"<e1>5-HT</e1>3 receptor antagonism with alosetron reduced responses to 5-HT in controls but not during inflammation.","Regulator"
"<e2>5-HT3 receptor</e2> antagonism with <e1>alosetron</e1> reduced responses to 5-HT in controls but not during inflammation.","Antagonist"
"Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of <e1>progestin</e1> on <e2>cyclin D1</e2> expression and cell cycle was observed in the presence of PR-A.","Not"
"<e1>Progestin</e1> activation of Src/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with <e2>PR-A</e2> that was predominantly nuclear.","Not"
"<e1>Progestin</e1> induction of the <e2>cyclin D1</e2> gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.","Regulator"
"<e1>Progestin</e1> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the <e2>Sgk</e2> (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.","Regulator"
"<e1>Progestin</e1> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (<e2>serum and glucocorticoid regulated kinase</e2>) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.","Regulator"
"The role of extranuclear signaling actions of <e1>progesterone</e1> receptor in mediating progesterone regulation of gene expression and the cell cycle.","Regulator"
"Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of <e1>progestin</e1> on cyclin D1 expression and cell cycle was observed in the presence of <e2>PR-A</e2>.","Regulator"
"<e1>Progestin</e1> activation of Src/MAPK occurred outside the nucleus with the <e2>B isoform of PR</e2> that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.","Regulator"
"Human <e1>progesterone</e1> receptor (<e2>PR</e2>) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor.","Upregulator"
"Human <e1>progesterone</e1> receptor (PR) contains a motif that interacts with the SH3 domain of <e2>Src</e2> and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor.","Upregulator"
"Human <e1>progesterone</e1> receptor (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream <e2>MAPK</e2> (Erk-1/-2) without relying on the transcriptional activity of the receptor.","Upregulator"
"<e1>Progestin</e1> activation of <e2>Src</e2>/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.","Upregulator"
"<e1>Progestin</e1> activation of Src/<e2>MAPK</e2> occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.","Upregulator"
"<e1>Progestin</e1> activation of Src/MAPK occurred outside the nucleus with the B isoform of <e2>PR</e2> that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.","Upregulator"
"<e1>Progestin</e1> activation of <e2>Src</e2>/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.","Upregulator"
"<e1>Progestin</e1> activation of Src/<e2>MAPK</e2> occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.","Upregulator"
"injection of a subthreshold dose of <e1>picrotoxin</e1>, a use-dependent <e2>gamma-aminobutyric acid receptor</e2> antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.","Antagonist"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and <e1>2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane</e1> (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (<e2>SERT</e2>, DAT, and NET, respectively) using transfected cells.","Regulator"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and <e1>2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane</e1> (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, <e2>DAT</e2>, and NET, respectively) using transfected cells.","Regulator"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and <e1>2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane</e1> (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and <e2>NET</e2>, respectively) using transfected cells.","Regulator"
"Chase studies with <e1>citalopram</e1> and methylphenidate demonstrated that this uptake is the result of preferential binding to the <e2>SERT</e2>.","Regulator"
"Chase studies with citalopram and <e1>methylphenidate</e1> demonstrated that this uptake is the result of preferential binding to the <e2>SERT</e2>.","Regulator"
"Synthesis, radiosynthesis, and biological evaluation of <e1>carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes</e1>: candidate radioligands for in vivo imaging of the <e2>serotonin transporter</e2> with positron emission tomography.","Regulator"
"<e1>2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane</e1> (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (<e2>SERT</e2>, DAT, and NET, respectively) using transfected cells.","Regulator"
"<e1>2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane</e1> (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, <e2>DAT</e2>, and NET, respectively) using transfected cells.","Regulator"
"<e1>2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane</e1> (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and <e2>NET</e2>, respectively) using transfected cells.","Regulator"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (<e1>mZBrENT</e1>, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (<e2>SERT</e2>, DAT, and NET, respectively) using transfected cells.","Regulator"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (<e1>mZBrENT</e1>, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, <e2>DAT</e2>, and NET, respectively) using transfected cells.","Regulator"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (<e1>mZBrENT</e1>, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and <e2>NET</e2>, respectively) using transfected cells.","Regulator"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (<e1>mZIENT</e1>, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (<e2>SERT</e2>, DAT, and NET, respectively) using transfected cells.","Regulator"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (<e1>mZIENT</e1>, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, <e2>DAT</e2>, and NET, respectively) using transfected cells.","Regulator"
"2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (<e1>mZIENT</e1>, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and <e2>NET</e2>, respectively) using transfected cells.","Regulator"
"MicroPET imaging in nonhuman primates with [<e1>11C</e1>]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the <e2>SERT</e2>-rich brain regions and peak uptake being achieved in about 55 min postinjection.","Substrate"
"MicroPET imaging in nonhuman primates with [<e1>11C</e1>]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the <e2>SERT</e2>-rich brain regions and peak uptake being achieved in about 55 min postinjection.","Substrate"
"This trial investigated the possibility of pharmacokinetic interactions between the <e2>AT1 receptor</e2> antagonist <e1>olmesartan medoxomil</e1> and the thiazide diuretic hydrochlorothiazide in healthy subjects.","Antagonist"
"In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous <e2>S100P</e2> (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of <e1>gemcitabine</e1> (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001).","Regulator"
"In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous <e2>S100P</e2> (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of <e1>gemcitabine</e1> (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001).","Regulator"
"In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous <e2>S100P</e2> (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of <e1>gemcitabine</e1> (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001).","Regulator"
"In addition, we found that selenophosphate synthetase 2 could synthesize <e1>monoselenophosphate</e1> in vitro but <e2>selenophosphate synthetase 1</e2> could not.","Not"
"Herein, comparative genomics and experimental analyses revealed that the <e2>mammalian Sec synthase</e2> (SecS) is the previously identified <e1>pyridoxal phosphate</e1>-containing protein known as the soluble liver antigen.","Cofactor"
"Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase (<e2>SecS</e2>) is the previously identified <e1>pyridoxal phosphate</e1>-containing protein known as the soluble liver antigen.","Cofactor"
"Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase (SecS) is the previously identified <e1>pyridoxal phosphate</e1>-containing protein known as the <e2>soluble liver antigen</e2>.","Cofactor"
"<e2>SecS</e2> required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate <e1>selenocysteyl</e1>-tRNA([Ser]Sec).","Substrate"
"In addition, we found that <e2>selenophosphate synthetase 2</e2> could synthesize <e1>monoselenophosphate</e1> in vitro but selenophosphate synthetase 1 could not.","Substrate"
"<e2>SecS</e2> required selenophosphate and <e1>O-phosphoseryl</e1>-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).","Substrate"
"<e2>SecS</e2> required <e1>selenophosphate</e1> and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).","Substrate"
"<e1>Triflusal</e1> (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of <e2>GFAP</e2> or Hsp27 immunostaining.","Not"
"<e1>Triflusal</e1> (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of GFAP or <e2>Hsp27</e2> immunostaining.","Not"
"Triflusal (30 mg/kg) or <e1>aspirin</e1> treatment (30 mg/kg) did not reduce the levels of <e2>GFAP</e2> or Hsp27 immunostaining.","Not"
"Triflusal (30 mg/kg) or <e1>aspirin</e1> treatment (30 mg/kg) did not reduce the levels of GFAP or <e2>Hsp27</e2> immunostaining.","Not"
"<e1>Triflusal</e1> (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not <e2>nuclear factor kappa B</e2> or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.","Not"
"<e1>Triflusal</e1> (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or <e2>tumor necrosis factor-alpha</e2> in the cortex ipsilateral to the middle cerebral artery occlusion.","Not"
"<e1>Triflusal</e1>, a selective <e2>cyclooxygenase-2</e2>, and its active metabolite 3-hydroxy-4-trifluoromethylbenzoic acid may inhibit apoptosis and inflammation after cerebral ischemia.","Regulator"
"Triflusal, a selective <e2>cyclooxygenase-2</e2>, and its active metabolite <e1>3-hydroxy-4-trifluoromethylbenzoic acid</e1> may inhibit apoptosis and inflammation after cerebral ischemia.","Regulator"
"<e1>Triflusal</e1> (30 mg/kg) also significantly decreased the protein levels of <e2>IL-Ibeta</e2> but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.","Downregulator"
"The <e2>GRIP1</e2> reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by <e1>6-cyano-7-nitroquinoxaline-2,3-dione</e1> (CNQX), an AMPA receptor antagonist.","Not"
"The <e2>GRIP1</e2> reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (<e1>CNQX</e1>), an AMPA receptor antagonist.","Not"
"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not <e1>nifedipine</e1>, an L-type Ca2+ channel blocker, prevented <e2>GRIP1</e2> degradation.","Not"
"Here we report that <e1>glutamate</e1> stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor <e2>(GluR) 1</e2>, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.","Not"
"Glutamate stimulates <e1>glutamate</e1> receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of <e2>GluR2</e2>.","Not"
"Here we report that <e1>glutamate</e1> stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and <e2>protein interacting with C kinase 1</e2> (PICK1) in rat primary cortical neuron cultures.","Not"
"Here we report that <e1>glutamate</e1> stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (<e2>PICK1</e2>) in rat primary cortical neuron cultures.","Not"
"Glutamate stimulates <e1>glutamate</e1> receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of <e2>GluR2</e2>.","Regulator"
"Furthermore, <e1>MG132</e1> prevented glutamate-stimulated reduction in surface amount of <e2>GluR2</e2>, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.","Regulator"
"<e1>Glutamate</e1> stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of <e2>GluR2</e2>.","Regulator"
"Down-regulation of <e2>GRIP1</e2> by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (<e1>MG132</e1>), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.","Regulator"
"Glutamate stimulates <e1>glutamate</e1> receptor interacting protein 1 degradation by ubiquitin-<e2>proteasome</e2> system to regulate surface expression of GluR2.","Regulator"
"Our results suggest that <e1>glutamate</e1> induces GRIP1 degradation by proteasome through an <e2>NMDA receptor</e2>-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.","Regulator"
"<e1>Glutamate</e1> stimulates glutamate receptor interacting protein 1 degradation by <e2>ubiquitin</e2>-proteasome system to regulate surface expression of GluR2.","Regulator"
"<e1>Glutamate</e1> stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-<e2>proteasome</e2> system to regulate surface expression of GluR2.","Regulator"
"Down-regulation of <e2>GRIP1</e2> by glutamate was blocked by <e1>carbobenzoxyl-leucinyl-leucinyl-leucinal</e1> (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.","Regulator"
"The <e2>GRIP1</e2> reduction was inhibited by <e1>MK-801</e1>, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.","Upregulator"
"<e1>EGTA</e1> and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GRIP1</e2> degradation.","Upregulator"
"EGTA and <e1>1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis</e1> (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GRIP1</e2> degradation.","Upregulator"
"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (<e1>BAPTA</e1>), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GRIP1</e2> degradation.","Upregulator"
"The <e1>glutamate</e1> receptor interacting protein 1 (<e2>GRIP1</e2>) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins.","Downregulator"
"The <e1>glutamate</e1> receptor interacting protein 1 (<e2>GRIP1</e2>) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins.","Downregulator"
"<e1>Glutamate</e1> stimulates <e2>glutamate receptor interacting protein 1</e2> degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.","Downregulator"
"The <e1>glutamate</e1> receptor interacting protein 1 (<e2>GRIP1</e2>) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins.","Downregulator"
"Glutamate stimulates <e1>glutamate</e1> receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of <e2>GluR2</e2>.","Downregulator"
"The <e1>glutamate</e1> receptor interacting protein 1 (<e2>GRIP1</e2>) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins.","Downregulator"
"Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (<e1>MG132</e1>), a <e2>proteasome</e2> inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.","Downregulator"
"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not <e1>nifedipine</e1>, an <e2>L-type Ca2+ channel</e2> blocker, prevented GRIP1 degradation.","Downregulator"
"Down-regulation of GRIP1 by glutamate was blocked by <e1>carbobenzoxyl-leucinyl-leucinyl-leucinal</e1> (MG132), a <e2>proteasome</e2> inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.","Downregulator"
"The GRIP1 reduction was inhibited by <e1>MK-801</e1>, an <e2>N-methyl-d-aspartate (NMDA) receptor</e2> antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.","Antagonist"
"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by <e1>6-cyano-7-nitroquinoxaline-2,3-dione</e1> (CNQX), an <e2>AMPA receptor</e2> antagonist.","Antagonist"
"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (<e1>CNQX</e1>), an <e2>AMPA receptor</e2> antagonist.","Antagonist"
"Cytokines, lipopolysaccharides and other inflammatory mediators such as <e1>prostaglandin</e1> and leukotriene are related to the secretion and production of <e2>mucin</e2>.","Regulator"
"The inhibitory effect of the <e1>leukotriene</e1> receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and <e2>mucin</e2> secretion in human airway epithelial cells.","Regulator"
"However, the relationship of <e1>leukotrienes</e1> with <e2>mucin</e2> genes expression is not clear.","Regulator"
"RESULTS: <e1>Leukotriene D(4)</e1> upregulated <e2>MUC2/5AC</e2> gene expression and mucin secretion in a dose dependent pattern.","Upregulator"
"RESULTS: <e1>Leukotriene D(4)</e1> upregulated MUC2/5AC gene expression and <e2>mucin</e2> secretion in a dose dependent pattern.","Upregulator"
"The inhibitory effect of the leukotriene receptor antagonist on <e1>leukotriene D4</e1>-induced MUC2/5AC gene expression and <e2>mucin</e2> secretion in human airway epithelial cells.","Upregulator"
"The inhibitory effect of the leukotriene receptor antagonist on <e1>leukotriene D4</e1>-induced <e2>MUC2/5AC</e2> gene expression and mucin secretion in human airway epithelial cells.","Upregulator"
"METHODS: The effect of <e1>leukotriene D(4)</e1> and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of <e2>MUC2/5AC</e2> gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.","Upregulator"
"METHODS: The effect of <e1>leukotriene D(4)</e1> and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and <e2>mucin</e2> secretion were observed in human airway NCI-H292 epithelial cells.","Upregulator"
"<e1>Pranlukast hydrate</e1> (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced <e2>MUC2/5AC</e2> gene expression and mucin secretion.","Downregulator"
"<e1>Pranlukast hydrate</e1> (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and <e2>mucin</e2> secretion.","Downregulator"
"METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (<e1>ONO-1078</e1>) on the regulation of <e2>MUC2/5AC</e2> gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.","Downregulator"
"METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (<e1>ONO-1078</e1>) on the regulation of MUC2/5AC gene expression and <e2>mucin</e2> secretion were observed in human airway NCI-H292 epithelial cells.","Downregulator"
"METHODS: The effect of leukotriene D(4) and the <e2>leukotriene receptor</e2> antagonist, <e1>pranlukast hydrate</e1> (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.","Antagonist"
"METHODS: The effect of leukotriene D(4) and the <e2>leukotriene receptor</e2> antagonist, pranlukast hydrate (<e1>ONO-1078</e1>) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.","Antagonist"
"Effect of isolated <e1>isoflavone</e1> supplementation on <e2>ABCA1</e2>-dependent cholesterol efflux potential in postmenopausal women.","Not"
"Effect of isolated <e1>isoflavone</e1> supplementation on <e2>ABCA1</e2>-dependent cholesterol efflux potential in postmenopausal women.","Not"
"We studied in a clinical trial whether isolated <e1>isoflavone</e1> treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by <e2>adenosine triphosphate-binding cassette A1</e2>- (ABCA1), dependent cholesterol efflux from macrophages.","Regulator"
"Effect of isolated <e1>isoflavone</e1> supplementation on <e2>ABCA1</e2>-dependent cholesterol efflux potential in postmenopausal women.","Regulator"
"However, as a novel finding, <e1>isoflavone</e1> treatment increased a subclass of high-density lipoprotein, the <e2>pre-beta high-density lipoprotein</e2> levels by 18% without affecting any other serum lipid concentrations.","Upregulator"
"However, as a novel finding, <e1>isoflavone</e1> treatment increased a subclass of <e2>high-density lipoprotein</e2>, the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations.","Upregulator"
"However, as a novel finding, <e1>isoflavone</e1> treatment increased a subclass of high-density lipoprotein, the <e2>pre-beta high-density lipoprotein</e2> levels by 18% without affecting any other serum lipid concentrations.","Upregulator"
"Effect of isolated isoflavone supplementation on <e2>ABCA1</e2>-dependent <e1>cholesterol</e1> efflux potential in postmenopausal women.","Substrate"
"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse <e1>cholesterol</e1> transport as evaluated by <e2>adenosine triphosphate-binding cassette A1</e2>- (ABCA1), dependent cholesterol efflux from macrophages.","Substrate"
"Effect of isolated isoflavone supplementation on <e2>ABCA1</e2>-dependent <e1>cholesterol</e1> efflux potential in postmenopausal women.","Substrate"
"Effect of isolated isoflavone supplementation on <e2>ABCA1</e2>-dependent <e1>cholesterol</e1> efflux potential in postmenopausal women.","Substrate"
"Effect of isolated isoflavone supplementation on <e2>ABCA1</e2>-dependent <e1>cholesterol</e1> efflux potential in postmenopausal women.","Substrate"
"Effect of isolated isoflavone supplementation on <e2>ABCA1</e2>-dependent <e1>cholesterol</e1> efflux potential in postmenopausal women.","Substrate"
"The <e1>imatinib</e1>-resistant <e2>KIT</e2>(D816V) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib.","Not"
"The <e1>imatinib</e1>-resistant KIT(<e2>D816V</e2>) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib.","Not"
"We investigated the efficacy of <e1>sorafenib</e1> at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, <e2>KIT</e2>, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.","Not"
"DESIGN AND METHODS: We tested the effect of <e1>sorafenib</e1> on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(<e2>D816V</e2>) mutant.","Not"
"We investigated the efficacy of <e1>sorafenib</e1> at inhibiting mutants of the receptor tyrosine <e2>kinases</e2> PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.","Regulator"
"<e1>Sorafenib</e1> (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against <e2>receptor tyrosine kinases</e2> from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"<e1>Sorafenib</e1> (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the <e2>platelet-derived growth factor receptor</e2> (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"<e1>Sorafenib</e1> (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (<e2>PDGFR</e2>) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"<e1>Sorafenib</e1> (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and <e2>vascular endothelial growth factor receptor</e2> (VEGFR) families.","Regulator"
"<e1>Sorafenib</e1> (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (<e2>VEGFR</e2>) families.","Regulator"
"Sorafenib (<e1>BAY43-9006</e1>, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against <e2>receptor tyrosine kinases</e2> from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"Sorafenib (<e1>BAY43-9006</e1>, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the <e2>platelet-derived growth factor receptor</e2> (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"Sorafenib (<e1>BAY43-9006</e1>, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (<e2>PDGFR</e2>) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"Sorafenib (<e1>BAY43-9006</e1>, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and <e2>vascular endothelial growth factor receptor</e2> (VEGFR) families.","Regulator"
"Sorafenib (<e1>BAY43-9006</e1>, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (<e2>VEGFR</e2>) families.","Regulator"
"Sorafenib (BAY43-9006, <e1>Nexavar</e1>) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against <e2>receptor tyrosine kinases</e2> from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"Sorafenib (BAY43-9006, <e1>Nexavar</e1>) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the <e2>platelet-derived growth factor receptor</e2> (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"Sorafenib (BAY43-9006, <e1>Nexavar</e1>) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (<e2>PDGFR</e2>) and vascular endothelial growth factor receptor (VEGFR) families.","Regulator"
"Sorafenib (BAY43-9006, <e1>Nexavar</e1>) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and <e2>vascular endothelial growth factor receptor</e2> (VEGFR) families.","Regulator"
"Sorafenib (BAY43-9006, <e1>Nexavar</e1>) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (<e2>VEGFR</e2>) families.","Regulator"
"We investigated the efficacy of <e1>sorafenib</e1> at inhibiting mutants of the <e2>receptor tyrosine kinases</e2> PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic <e2>PDGFRbeta</e2> and FLT3 mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"We investigated the efficacy of <e1>sorafenib</e1> at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, <e2>KIT</e2>, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic PDGFRbeta and <e2>FLT3</e2> mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic <e2>PDGFRbeta</e2> and FLT3 mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic PDGFRbeta and <e2>FLT3</e2> mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"DESIGN AND METHODS: We tested the effect of <e1>sorafenib</e1> on the proliferation of hematopoietic cells transformed by <e2>ETV6</e2>-PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic <e2>PDGFRbeta</e2> and FLT3 mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic PDGFRbeta and <e2>FLT3</e2> mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic PDGFRbeta and <e2>FLT3</e2> mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"<e1>Sorafenib</e1> induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing <e2>FLT3</e2> with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines.","Downregulator"
"<e1>Sorafenib</e1> (BAY43-9006, Nexavar) is a small molecule <e2>B-RAF</e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic <e2>PDGFRbeta</e2> and FLT3 mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"The ability of <e1>sorafenib</e1> to inhibit oncogenic PDGFRbeta and <e2>FLT3</e2> mutants and overcome resistance to other small molecule inhibitors.","Downregulator"
"Sorafenib (<e1>BAY43-9006</e1>, Nexavar) is a small molecule <e2>B-RAF</e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Downregulator"
"Sorafenib (BAY43-9006, <e1>Nexavar</e1>) is a small molecule <e2>B-RAF</e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.","Downregulator"
"We hypothesized that corticosteroid exposure modulates epithelial <e1>Na(+)</e1> channel (<e2>ENaC</e2>) expression and/or activity in bovine mammary epithelial cells.","Regulator"
"We conclude that <e1>Na(+)</e1> movement across mammary epithelia is modulated by corticosteroids via a <e2>glucocorticoid receptor</e2>-mediated mechanism that regulates the expression of the beta- and gamma-subunits of ENaC.","Regulator"
"We hypothesized that corticosteroid exposure modulates epithelial <e1>Na(+)</e1> channel (<e2>ENaC</e2>) expression and/or activity in bovine mammary epithelial cells.","Regulator"
"Exposure to <e1>mifepristone</e1> (a <e2>glucocorticoid receptor</e2> antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.","Antagonist"
"Exposure to mifepristone (a glucocorticoid receptor antagonist), but not <e1>spironolactone</e1> (a <e2>mineralocorticoid receptor</e2> antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.","Antagonist"
"All three <e1>salicylates</e1> inhibited the diabetes-induced translocation of <e2>p50</e2> (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.","Downregulator"
"All three <e1>salicylates</e1> inhibited the diabetes-induced translocation of <e2>p50</e2> (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.","Downregulator"
"All three <e1>salicylates</e1> inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and <e2>p65</e2> into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.","Downregulator"
"Oral <e1>aspirin</e1> (as a representative of the salicylate family) inhibited diabetes-induced increase in <e2>NF-kappaB</e2> DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.","Downregulator"
"Oral aspirin (as a representative of the <e1>salicylate</e1> family) inhibited diabetes-induced increase in <e2>NF-kappaB</e2> DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.","Downregulator"
"All three <e1>salicylates</e1> inhibited the diabetes-induced translocation of p50 (a subunit of <e2>NF-kappaB</e2>) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.","Downregulator"
"<e1>Sulfasalazine</e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by <e2>NF-kappaB</e2>, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.","Downregulator"
"<e1>Sulfasalazine</e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, <e2>intracellular adhesion molecule-1</e2>, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.","Downregulator"
"<e1>Sulfasalazine</e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, <e2>inducible nitric oxide synthase</e2>, and cyclooxygenase-2 in whole-retinal lysate.","Downregulator"
"<e1>Sulfasalazine</e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and <e2>cyclooxygenase-2</e2> in whole-retinal lysate.","Downregulator"
"All three <e1>salicylates</e1> inhibited the diabetes-induced translocation of p50 (a subunit of <e2>NF-kappaB</e2>) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.","Downregulator"
"<e1>Salicylates</e1>, in doses administrated in our experiments, inhibited <e2>NF-kappa</e2>B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.","Downregulator"
"We have named this activity <e2>11 beta HSD</e2>2 to distinguish it from the <e1>NADP</e1>-dependent 11 beta HSD.","Regulator"
"These results demonstrate the presence of a dehydrogenase activity separate from the <e1>nicotinamide-adenine dinucleotide phosphate</e1> (NADP)-dependent <e2>11 beta hydroxysteroid dehydrogenase</e2> recently purified and cloned from rat liver.","Regulator"
"These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate (<e1>NADP</e1>)-dependent <e2>11 beta hydroxysteroid dehydrogenase</e2> recently purified and cloned from rat liver.","Regulator"
"<e1>Fluoxetine</e1> affected mainly the <e2>hSERT</e2> transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level.","Not"
"<e1>Fluoxetine</e1> affected mainly the <e2>hSERT</e2> transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level.","Not"
"These results suggest that the effect of <e1>fluoxetine</e1> on the expression of hSERT is post-translational and has shown itself to be independent of <e2>PKC</e2> and PKA activity.","Not"
"These results suggest that the effect of <e1>fluoxetine</e1> on the expression of hSERT is post-translational and has shown itself to be independent of PKC and <e2>PKA</e2> activity.","Not"
"The aim of this study was to determine the specific effect of long-term <e1>fluoxetine</e1> treatment on human serotonin transporter (<e2>hSERT</e2>) in vitro, by using the human enterocyte-like cell line Caco-2.","Regulator"
"<e1>Fluoxetine</e1> affected mainly the <e2>hSERT</e2> transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level.","Regulator"
"The cholesterol-lowering drug <e1>simvastatin</e1> inhibits <e2>LFA-1</e2> signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.","Regulator"
"The cholesterol-lowering drug <e1>simvastatin</e1> inhibits LFA-1 signaling by binding to an allosteric site on <e2>CD11a</e2> (LFA-1 alpha chain), which leads to immunomodulation.","Regulator"
"In addition, activation of protein kinase C and increases in intracellular <e1>cAMP</e1> also enhance cholinergic activity in T cells, and <e2>lymphocyte function associated antigen-1</e2> (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.","Upregulator"
"In addition, activation of protein kinase C and increases in intracellular <e1>cAMP</e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (<e2>LFA-1</e2>; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.","Upregulator"
"In addition, activation of protein kinase C and increases in intracellular <e1>cAMP</e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; <e2>CD11a</e2>/CD18) is an important mediator of leukocyte migration and T cell activation.","Upregulator"
"In addition, activation of protein kinase C and increases in intracellular <e1>cAMP</e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/<e2>CD18</e2>) is an important mediator of leukocyte migration and T cell activation.","Upregulator"
"The cholesterol-lowering drug <e1>simvastatin</e1> inhibits LFA-1 signaling by binding to an allosteric site on <e2>CD11a</e2> (LFA-1 alpha chain), which leads to immunomodulation.","Downregulator"
"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (<e1>ACh</e1>); <e2>choline acetyltransferase</e2> (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).","Substrate"
"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (<e1>ACh</e1>); choline acetyltransferase (<e2>ChAT</e2>), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).","Substrate"
"Lymphocytes possess the essential components of a cholinergic system, including <e1>acetylcholine</e1> (ACh); <e2>choline acetyltransferase</e2> (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).","Substrate"
"Lymphocytes possess the essential components of a cholinergic system, including <e1>acetylcholine</e1> (ACh); choline acetyltransferase (<e2>ChAT</e2>), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).","Substrate"
"INTRODUCTION: Medroxy<e1>progesterone</e1> acetate (MPA) induces estrogen receptor (<e2>ER</e2>)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.","Regulator"
"INTRODUCTION: Medroxy<e1>progesterone</e1> acetate (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (<e2>PR</e2>)-positive ductal invasive mammary carcinomas in BALB/c mice.","Regulator"
"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA</e1>) induces estrogen receptor (<e2>ER</e2>)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.","Regulator"
"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA</e1>) induces estrogen receptor (ER)-positive and progesterone receptor (<e2>PR</e2>)-positive ductal invasive mammary carcinomas in BALB/c mice.","Regulator"
"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA</e1>) induces estrogen receptor (ER)-positive and <e2>progesterone receptor</e2> (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.","Regulator"
"<e2>PR isoform B</e2> levels were low in virgin control mice and increased after <e1>progestin</e1> treatment in both strains.","Upregulator"
"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA</e1>) induces estrogen receptor (ER)-positive and progesterone receptor (<e2>PR</e2>)-positive ductal invasive mammary carcinomas in BALB/c mice.","Upregulator"
"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA</e1>) induces <e2>estrogen receptor</e2> (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.","Upregulator"
"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA</e1>) induces estrogen receptor (<e2>ER</e2>)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.","Upregulator"
"INTRODUCTION: <e1>Medroxyprogesterone acetate</e1> (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (<e2>PR</e2>)-positive ductal invasive mammary carcinomas in BALB/c mice.","Upregulator"
"INTRODUCTION: <e1>Medroxyprogesterone acetate</e1> (MPA) induces <e2>estrogen receptor</e2> (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.","Upregulator"
"INTRODUCTION: <e1>Medroxyprogesterone acetate</e1> (MPA) induces estrogen receptor (<e2>ER</e2>)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.","Upregulator"
"INTRODUCTION: <e1>Medroxyprogesterone acetate</e1> (MPA) induces estrogen receptor (ER)-positive and <e2>progesterone receptor</e2> (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.","Upregulator"
"The expression of <e2>ER-alpha</e2> and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in <e1>progestin</e1>-treated BALB/c mice (P < 0.05).","Downregulator"
"The expression of ER-alpha and <e2>PR isoform A</e2> in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in <e1>progestin</e1>-treated BALB/c mice (P < 0.05).","Downregulator"
"Several genes involved with <e1>steroid</e1> metabolism also showed remarkable expression changes, including increased expression of <e2>17beta-hydroxysteroid dehydrogenase-7</e2> (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production).","Regulator"
"Several genes involved with <e1>steroid</e1> metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of <e2>HSD17beta5</e2> (involved in testosterone production).","Regulator"
"Various genes controlled by <e1>estrogen</e1>, including <e2>X-inactive-specific transcript</e2>, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.","Upregulator"
"Various genes controlled by <e1>estrogen</e1>, including X-inactive-specific transcript, <e2>anterior gradient-2</e2>, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.","Upregulator"
"Various genes controlled by <e1>estrogen</e1>, including X-inactive-specific transcript, anterior gradient-2, <e2>trefoil factor-1</e2>, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.","Upregulator"
"Various genes controlled by <e1>estrogen</e1>, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, <e2>CRP-ductin</e2>, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.","Upregulator"
"Various genes controlled by <e1>estrogen</e1>, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, <e2>ghrelin</e2>, and small proline-rich protein-2A, were dramatically over-expressed.","Upregulator"
"Various genes controlled by <e1>estrogen</e1>, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and <e2>small proline-rich protein-2A</e2>, were dramatically over-expressed.","Upregulator"
"<e1>Estrogen</e1>-regulated genes including cytokeratin 1-19 and <e2>Cyp2a4</e2> were over-expressed, although Cyp3a25 was suppressed.","Upregulator"
"<e1>Estrogen</e1>-regulated genes including <e2>cytokeratin 1-19</e2> and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed.","Upregulator"
"<e1>Estrogen</e1>-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although <e2>Cyp3a25</e2> was suppressed.","Downregulator"
"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of <e2>17beta-hydroxysteroid dehydrogenase-7</e2> (HSD17beta7; involved in <e1>estradiol</e1> production) and decreased expression of HSD17beta5 (involved in testosterone production).","Substrate"
"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (<e2>HSD17beta7</e2>; involved in <e1>estradiol</e1> production) and decreased expression of HSD17beta5 (involved in testosterone production).","Substrate"
"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of <e2>HSD17beta5</e2> (involved in <e1>testosterone</e1> production).","Substrate"
"The expression of key genes important in <e1>methionine</e1> metabolism, such as <e2>methionine adenosyltransferase-1a</e2>, betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.","Substrate"
"The expression of key genes important in <e1>methionine</e1> metabolism, such as methionine adenosyltransferase-1a, <e2>betaine-homocysteine methyltransferase</e2> and thioether S-methyltransferase, were suppressed.","Substrate"
"The expression of key genes important in <e1>methionine</e1> metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and <e2>thioether S-methyltransferase</e2>, were suppressed.","Substrate"
"<e1>Monosodium urate</e1> crystals stimulate monocytes and macrophages to release IL-1beta through the <e2>NALP3</e2> component of the inflammasome.","Regulator"
"<e1>Monosodium urate</e1> crystals stimulate monocytes and macrophages to release <e2>IL-1beta</e2> through the NALP3 component of the inflammasome.","Upregulator"
"Our structural studies provide a view of a synthetic inhibitory compound in a <e2>sirtuin</e2> active site revealing that suramin binds into the <e1>NAD(+)</e1>, the product, and the substrate-binding site.","Part_of"
"We identified <e1>suramin</e1> as a compound that binds to <e2>human SIRT5</e2> and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM.","Regulator"
"To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of <e2>SIRT5</e2>, one in complex with <e1>ADP</e1>-ribose, the other bound to suramin.","Regulator"
"Structural basis of inhibition of the human NAD+-dependent deacetylase <e2>SIRT5</e2> by <e1>suramin</e1>.","Regulator"
"To provide insights into how <e2>sirtuin</e2> function is altered by inhibitors, we determined two crystal structures of SIRT5, one in complex with ADP-ribose, the other bound to <e1>suramin</e1>.","Regulator"
"We identified <e1>suramin</e1> as a compound that binds to human SIRT5 and showed that it inhibits <e2>SIRT5 NAD(+)-dependent deacetylase</e2> activity with an IC(50) value of 22 microM.","Downregulator"
"Structural basis of inhibition of the <e2>human NAD+-dependent deacetylase SIRT5</e2> by <e1>suramin</e1>.","Downregulator"
"In humans, <e2>methionine synthase</e2> deficiency results in the accumulation of <e1>methyltetrahydrofolate</e1> at the expense of folate derivatives required for purine and thymidylate biosynthesis.","Substrate"
"Metformin and <e1>phenformin</e1>, which are biguanides, have been reported to increase <e2>AMPK</e2> activity without increasing AMP/ATP.","Upregulator"
"In hearts treated with <e1>metformin</e1>, [AMP] was increased at 50 min and <e2>AMPK</e2> activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.","Upregulator"
"<e1>AMP</e1>-activated protein kinase (<e2>AMPK</e2>) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP).","Upregulator"
"<e1>Metformin</e1> and phenformin, which are biguanides, have been reported to increase <e2>AMPK</e2> activity without increasing AMP/ATP.","Upregulator"
"Metformin and <e1>phenformin</e1>, which are biguanides, have been reported to increase <e2>AMPK</e2> activity without increasing AMP/ATP.","Upregulator"
"Metformin and phenformin, which are <e1>biguanides</e1>, have been reported to increase <e2>AMPK</e2> activity without increasing AMP/ATP.","Upregulator"
"Metformin and <e1>phenformin</e1>, which are biguanides, have been reported to increase <e2>AMPK</e2> activity without increasing AMP/ATP.","Upregulator"
"In hearts treated with <e1>metformin</e1>, [AMP] was increased at 50 min and <e2>AMPK</e2> activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.","Upregulator"
"In hearts treated with <e1>metformin</e1>, [AMP] was increased at 50 min and <e2>AMPK</e2> activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.","Upregulator"
"In hearts treated with <e1>metformin</e1>, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and <e2>phosphorylated acetyl-CoA carboxylase</e2> were elevated at 61 min.","Upregulator"
"<e1>Metformin</e1> and phenformin activate <e2>AMP-activated protein kinase</e2> in the heart by increasing cytosolic AMP concentration.","Upregulator"
"Metformin and <e1>phenformin</e1> activate <e2>AMP-activated protein kinase</e2> in the heart by increasing cytosolic AMP concentration.","Upregulator"
"Characterization of <e2>5-hydroxytryptamine1B</e2> receptors in rat spinal cord via <e1>[125I]iodocyanopindolol</e1> binding and inhibition of [3H]-5-hydroxytryptamine release.","Regulator"
"Histamine <e2>H(1)</e2> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic <e1>clozapine</e1>.","Regulator"
"<e2>Histamine H1 receptor</e2> involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of <e1>clozapine</e1>.","Regulator"
"In the current project, we found that the selective <e2>H(1)</e2> antagonist pyrilamine also reversed the <e1>dizocilpine</e1>-induced impairment in PPI of tactile startle with an auditory prepulse.","Upregulator"
"Histamine <e2>H(1)</e2> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic <e1>clozapine</e1>.","Downregulator"
"<e2>Histamine H(1)</e2> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic <e1>clozapine</e1>.","Downregulator"
"Histamine <e2>H(1)</e2> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic <e1>clozapine</e1>.","Antagonist"
"Histamine <e2>H(1)</e2> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic <e1>clozapine</e1>.","Antagonist"
"In the current project, we found that the selective <e2>H(1)</e2> antagonist <e1>pyrilamine</e1> also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.","Antagonist"
"In the current project, we found that the selective <e2>H(1)</e2> antagonist <e1>pyrilamine</e1> also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.","Antagonist"
"In the current project, we found that the selective <e2>H(1)</e2> antagonist <e1>pyrilamine</e1> also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.","Antagonist"
"The mRNA expression of <e2>PtdSer synthase 1</e2> (PSS1) and PtdSer synthase 2 (PSS2) was not reduced by <e1>ethanol</e1>.","Not"
"The mRNA expression of PtdSer synthase 1 (<e2>PSS1</e2>) and PtdSer synthase 2 (PSS2) was not reduced by <e1>ethanol</e1>.","Not"
"The mRNA expression of PtdSer synthase 1 (PSS1) and <e2>PtdSer synthase 2</e2> (PSS2) was not reduced by <e1>ethanol</e1>.","Not"
"The mRNA expression of PtdSer synthase 1 (PSS1) and PtdSer synthase 2 (<e2>PSS2</e2>) was not reduced by <e1>ethanol</e1>.","Not"
"The mRNA expression of PtdSer synthase 1 (<e2>PSS1</e2>) and PtdSer synthase 2 (PSS2) was not reduced by <e1>ethanol</e1>.","Not"
"Furthermore, the enzymatic activity of <e2>alanine aminotransferase</e2> (ALT), which converts the critical gluconeogenic amino acid alanine into <e1>pyruvate</e1>, is decreased (approximately 50%) in KLF15-/- hepatocytes.","Substrate"
"Furthermore, the enzymatic activity of alanine aminotransferase (<e2>ALT</e2>), which converts the critical gluconeogenic amino acid alanine into <e1>pyruvate</e1>, is decreased (approximately 50%) in KLF15-/- hepatocytes.","Substrate"
"Furthermore, the enzymatic activity of <e2>alanine aminotransferase</e2> (ALT), which converts the critical gluconeogenic <e1>amino acid</e1> alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.","Substrate"
"Furthermore, the enzymatic activity of alanine aminotransferase (<e2>ALT</e2>), which converts the critical gluconeogenic <e1>amino acid</e1> alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.","Substrate"
"Furthermore, the enzymatic activity of <e1>alanine</e1> aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.","Substrate"
"Furthermore, the enzymatic activity of <e1>alanine</e1> aminotransferase (<e2>ALT</e2>), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.","Substrate"
"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), <e1>L-[(3)H]citrulline</e1> formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (<e2>eNOS</e2>) protein abundance, but did not alter eNOS phosphorylation.","Not"
"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from <e1>L-[(3)H]arginine</e1> (index of NO synthesis) and endothelial NO synthase (<e2>eNOS</e2>) protein abundance, but did not alter eNOS phosphorylation.","Not"
"<e1>D-glucose</e1> stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional <e2>type II TGF-beta receptors</e2> in human umbilical vein endothelium.","Regulator"
"Elevated extracellular <e1>D-glucose</e1> increases transforming growth factor beta1 (<e2>TGF-beta1</e2>) release from human umbilical vein endothelium (HUVEC).","Regulator"
"Elevated extracellular <e1>D-glucose</e1> increases transforming growth factor beta1 (<e2>TGF-beta1</e2>) release from human umbilical vein endothelium (HUVEC).","Regulator"
"<e1>D-glucose</e1> stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and <e2>Smad2</e2> requiring functional type II TGF-beta receptors in human umbilical vein endothelium.","Upregulator"
"<e1>D-glucose</e1> stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and <e2>Smad2</e2> requiring functional type II TGF-beta receptors in human umbilical vein endothelium.","Upregulator"
"However, TGF-beta1 and high <e1>D-glucose</e1> were ineffective in cells expressing a truncated, negative dominant <e2>TbetaRII</e2>.","Upregulator"
"<e1>D-glucose</e1> stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and <e2>Smad2</e2> requiring functional type II TGF-beta receptors in human umbilical vein endothelium.","Upregulator"
"Elevated extracellular <e1>D-glucose</e1> increases transforming growth factor beta1 (<e2>TGF-beta1</e2>) release from human umbilical vein endothelium (HUVEC).","Upregulator"
"TGF-beta1 and high <e1>D-glucose</e1> increased <e2>hCAT-1</e2> mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.","Upregulator"
"TGF-beta1 and high <e1>D-glucose</e1> increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (<e2>eNOS</e2>) protein abundance, but did not alter eNOS phosphorylation.","Upregulator"
"Elevated extracellular <e1>D-glucose</e1> increases <e2>transforming growth factor beta1</e2> (TGF-beta1) release from human umbilical vein endothelium (HUVEC).","Upregulator"
"Elevated extracellular <e1>D-glucose</e1> increases transforming growth factor beta1 (<e2>TGF-beta1</e2>) release from human umbilical vein endothelium (HUVEC).","Upregulator"
"TGF-beta1 and high D-glucose increased p42/44(mapk) and <e2>Smad2</e2> phosphorylation, an effect blocked by <e1>PD-98059</e1> (MEK1/2 inhibitor).","Downregulator"
"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of <e1>NO</e1> synthesis) and <e2>endothelial NO synthase</e2> (eNOS) protein abundance, but did not alter eNOS phosphorylation.","Substrate"
"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of <e1>NO</e1> synthesis) and endothelial NO synthase (<e2>eNOS</e2>) protein abundance, but did not alter eNOS phosphorylation.","Substrate"
"We demonstrate that only treatment of HaCaT with GLA and EPA or a <e2>PPARgamma</e2> ligand (<e1>roziglitazone</e1>), induced COX-2 expression (protein and mRNA).","Regulator"
"The inhibitory effects of <e1>GW9662</e1> and T0070907 (PPARgamma antagonists), on <e2>COX-2</e2> expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.","Regulator"
"The inhibitory effects of <e1>GW9662</e1> and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of <e2>COX-2 promoter</e2> activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.","Regulator"
"The inhibitory effects of GW9662 and <e1>T0070907</e1> (PPARgamma antagonists), on <e2>COX-2</e2> expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.","Regulator"
"The inhibitory effects of GW9662 and <e1>T0070907</e1> (PPARgamma antagonists), on COX-2 expression and on stimulation of <e2>COX-2 promoter</e2> activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.","Regulator"
"The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of <e2>COX-2 promoter</e2> activity by <e1>EPA</e1> and GLA suggest that PPARgamma is implicated in COX-2 induction.","Regulator"
"The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of <e2>COX-2 promoter</e2> activity by EPA and <e1>GLA</e1> suggest that PPARgamma is implicated in COX-2 induction.","Regulator"
"We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 <e1>PUFA</e1>, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (<e2>COX-2</e2>), an enzyme pivotal to skin inflammation and reparation.","Regulator"
"Moreover stimulation of <e2>COX-2 promoter</e2> activity was increased by those <e1>PUFAs</e1> or rosiglitazone.","Upregulator"
"Moreover stimulation of <e2>COX-2 promoter</e2> activity was increased by those PUFAs or <e1>rosiglitazone</e1>.","Upregulator"
"<e1>n-3 and n-6 polyunsaturated fatty acids</e1> induce the expression of COX-2 via <e2>PPARgamma</e2> activation in human keratinocyte HaCaT cells.","Upregulator"
"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of <e1>AA</e1> metabolites in <e2>PPAR</e2> activation.","Upregulator"
"These findings demonstrate that <e1>n-3 and n-6 PUFA</e1> increased <e2>PPARgamma</e2> activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells.","Upregulator"
"These findings demonstrate that <e1>n-3 and n-6 PUFA</e1> increased PPARgamma activity is necessary for the <e2>COX-2</e2> induction in HaCaT human keratinocyte cells.","Upregulator"
"Given the anti-inflammatory properties of EPA, we suggest that induction of <e2>COX-2</e2> in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of <e1>PUFAs n-3</e1> or n-6.","Upregulator"
"We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (<e1>GLA</e1>) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (<e2>COX-2</e2>), an enzyme pivotal to skin inflammation and reparation.","Upregulator"
"We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (<e1>EPA</e1>) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (<e2>COX-2</e2>), an enzyme pivotal to skin inflammation and reparation.","Upregulator"
"We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (<e1>roziglitazone</e1>), induced <e2>COX-2</e2> expression (protein and mRNA).","Upregulator"
"<e1>n-3 and n-6 polyunsaturated fatty acids</e1> induce the expression of <e2>COX-2</e2> via PPARgamma activation in human keratinocyte HaCaT cells.","Upregulator"
"Finally, <e2>PLA2</e2> inhibitor methyl <e1>arachidonyl fluorophosphonate</e1> blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.","Downregulator"
"Finally, PLA2 inhibitor methyl <e1>arachidonyl fluorophosphonate</e1> blocked the PUFA effects on <e2>COX-2</e2> induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.","Downregulator"
"The inhibitory effects of <e1>GW9662</e1> and T0070907 (<e2>PPARgamma</e2> antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.","Antagonist"
"The inhibitory effects of GW9662 and <e1>T0070907</e1> (<e2>PPARgamma</e2> antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.","Antagonist"
"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting <e2>beta(2)-adrenergic</e2> agonist that is the [R,R] isomer of formoterol) and <e1>salmeterol xinafoate</e1> versus placebo in patients with chronic obstructive pulmonary disease (COPD).","Regulator"
"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting <e2>beta(2)-adrenergic</e2> agonist that is the <e1>[R,R] isomer of formoterol</e1>) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).","Agonist"
"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized <e1>arformoterol tartrate</e1> (a selective, long-acting <e2>beta(2)-adrenergic</e2> agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).","Agonist"
"The cytosolic <e2>ACC1</e2> is expressed primarily in liver and adipose tissue, and uses <e1>malonyl-coenzyme A</e1> as a key building block in fatty acid biosynthesis.","Regulator"
"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, <e2>ACC1</e2> and ACC2, which play critical roles in <e1>fatty acid</e1> biosynthesis and oxidation.","Substrate"
"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and <e2>ACC2</e2>, which play critical roles in <e1>fatty acid</e1> biosynthesis and oxidation.","Substrate"
"<e2>Acetyl-coenzyme A carboxylase</e2> (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in <e1>fatty acid</e1> biosynthesis and oxidation.","Substrate"
"Acetyl-coenzyme A carboxylase (<e2>ACC</e2>) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in <e1>fatty acid</e1> biosynthesis and oxidation.","Substrate"
"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, <e2>ACC1</e2> and ACC2, which play critical roles in <e1>fatty acid</e1> biosynthesis and oxidation.","Substrate"
"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and <e2>ACC2</e2>, which play critical roles in <e1>fatty acid</e1> biosynthesis and oxidation.","Substrate"
"In contrast, the <e1>RA</e1> catabolising enzymes <e2>Cyp26A1</e2> and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.","Substrate"
"In contrast, the <e1>RA</e1> catabolising enzymes Cyp26A1 and <e2>Cyp26B1</e2> which are known to be RA-responsive were not expressed at all in the developing eye.","Substrate"
"This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides <e1>glucose</e1>-dependent insulinotropic polypeptide (GIP) and <e2>glucagon</e2>-like peptide-1 (GLP-1).","Regulator"
"This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides <e1>glucose</e1>-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (<e2>GLP-1</e2>).","Regulator"
"This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides <e1>glucose</e1>-dependent <e2>insulin</e2>otropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).","Upregulator"
"This report reviews published and unpublished data that suggest that <e1>aripiprazole</e1> acts as a selective partial agonist at the dopamine D(2) receptor and does not affect <e2>5-HT receptors</e2> at therapeutic doses.","Not"
"It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the <e2>5-HT(2)</e2> receptor contribute to the clinical profile of <e1>aripiprazole</e1>, a so-called dopamine- and 5-HT stabiliser.","Regulator"
"This report reviews published and unpublished data that suggest that <e1>aripiprazole</e1> acts as a selective partial agonist at the <e2>dopamine D(2) receptor</e2> and does not affect 5-HT receptors at therapeutic doses.","Agonist"
"<e1>Mifepriston'e</e1> blocks <e2>glucocorticoid receptor</e2> activation without modifying cortisol synthesis.","Downregulator"
"The present findings confirm that PVN <e2>CB1 receptors</e2>, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of CB1 receptors by <e1>SR 141716A</e1> increases the density of these receptors in the PVN.","Regulator"
"The present findings confirm that PVN <e2>CB1 receptors</e2>, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of CB1 receptors by <e1>SR 141716A</e1> increases the density of these receptors in the PVN.","Downregulator"
"[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (<e1>SR 141716A</e1>), a selective <e2>cannabinoid CB1 receptor</e2> antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.","Antagonist"
"[<e1>N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide</e1>] (SR 141716A), a selective <e2>cannabinoid CB1 receptor</e2> antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.","Antagonist"
"<e2>Amyloid</e2>-induced platelet aggregation was independent of <e1>thromboxane A2</e1> formation and ADP secretion but enhanced by feedback stimulation through these pathways.","Regulator"
"Modulation of the function of CD36 (CD36-/- mice), <e2>p38</e2>(MAPK) (<e1>SB203580</e1>), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.","Downregulator"
"Modulation of the function of CD36 (CD36-/- mice), p38(<e2>MAPK</e2>) (<e1>SB203580</e1>), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.","Downregulator"
"Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), <e2>COX-1</e2> (<e1>indomethacin</e1>), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.","Downregulator"
"We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that <e2>human type 12 RDH</e2> reduces dihydrotestosterone to <e1>androstanediol</e1>, and is thus also involved in steroid metabolism.","Substrate"
"The LS/SS genotype of the promoter for <e2>SLC6A4</e2> was associated with enhanced weight loss with <e1>sibutramine</e1>.","Regulator"
"The LS/SS genotype of the promoter for <e2>SLC6A4</e2> was associated with enhanced weight loss with <e1>sibutramine</e1>.","Regulator"
"The LS/SS genotype of the promoter for <e2>SLC6A4</e2> was associated with enhanced weight loss with <e1>sibutramine</e1>.","Regulator"
"The <e1>sibutramine</e1> group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial <e2>peptide YY</e2> compared with the placebo group.","Upregulator"
"The <e1>sibutramine</e1> group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial <e2>peptide YY</e2> compared with the placebo group.","Upregulator"
"Multiple <e2>rat brain calpastatin</e2> forms are produced by distinct starting points and alternative splicing of the <e1>N</e1>-terminal exons.","Part_of"
"An investigation of the absolute configuration of the potent <e2>histamine H3 receptor</e2> antagonist <e1>GT-2331</e1> using vibrational circular dichroism.","Regulator"
"An investigation of the absolute configuration of the potent <e2>histamine H3 receptor</e2> antagonist <e1>GT-2331</e1> using vibrational circular dichroism.","Antagonist"
"In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of <e1>atropine</e1> induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <e2>human muscarinic M2 receptors</e2> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).","Regulator"
"In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced <e1>[(3)H]N-methylscopolamine</e1> dissociation from Chinese hamster ovary cells expressing recombinant <e2>human muscarinic M2 receptors</e2> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).","Regulator"
"Allosteric interaction of the neuromuscular blockers <e1>vecuronium</e1> and pancuronium with recombinant <e2>human muscarinic M2 receptors</e2>.","Downregulator"
"In this study the neuromuscular blocking drug vecuronium and the controls <e1>gallamine</e1> and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <e2>human muscarinic M2 receptors</e2> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).","Downregulator"
"Allosteric interaction of the neuromuscular blockers vecuronium and <e1>pancuronium</e1> with recombinant <e2>human muscarinic M2 receptors</e2>.","Downregulator"
"Allosteric interaction of the neuromuscular blockers <e1>vecuronium</e1> and pancuronium with recombinant human <e2>muscarinic M2 receptor</e2>s.","Modulator"
"In this study the neuromuscular blocking drug vecuronium and the controls <e1>gallamine</e1> and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant human <e2>muscarinic M2 receptor</e2>s K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).","Modulator"
"Allosteric interaction of the neuromuscular blockers vecuronium and <e1>pancuronium</e1> with recombinant human <e2>muscarinic M2 receptor</e2>s.","Modulator"
"Allosteric interaction of the neuromuscular blockers <e1>vecuronium</e1> and pancuronium with recombinant <e2>human muscarinic M2 receptors</e2>.","Modulator"
"Allosteric interaction of the neuromuscular blockers vecuronium and <e1>pancuronium</e1> with recombinant <e2>human muscarinic M2 receptors</e2>.","Modulator"
"Hydrogen peroxide-mediated oxidative stress disrupts <e1>calcium</e1> binding on <e2>calmodulin</e2>: more evidence for oxidative stress in vitiligo.","Regulator"
"Hydrogen peroxide-mediated oxidative stress disrupts <e1>calcium</e1> binding on <e2>calmodulin</e2>: more evidence for oxidative stress in vitiligo.","Regulator"
"Hydrogen peroxide-mediated oxidative stress disrupts <e1>calcium</e1> binding on <e2>calmodulin</e2>: more evidence for oxidative stress in vitiligo.","Regulator"
"Hydrogen peroxide-mediated oxidative stress disrupts <e1>calcium</e1> binding on <e2>calmodulin</e2>: more evidence for oxidative stress in vitiligo.","Regulator"
"Since 10(-3)M <e1>H(2)O(2)</e1> oxidises methionine and tryptophan residues in proteins, we examined calcium binding to <e2>calmodulin</e2> in the presence and absence of H(2)O(2) utilising (45)calcium.","Regulator"
"<e1>Hydrogen peroxide</e1>-mediated oxidative stress disrupts calcium binding on <e2>calmodulin</e2>: more evidence for oxidative stress in vitiligo.","Regulator"
"Since 10(-3)M <e1>H(2)O(2)</e1> oxidises methionine and tryptophan residues in proteins, we examined calcium binding to <e2>calmodulin</e2> in the presence and absence of H(2)O(2) utilising (45)calcium.","Regulator"
"Patients with acute vitiligo have low epidermal <e2>catalase</e2> expression/activities and accumulate 10(-3) M <e1>H(2)O(2)</e1>.","Substrate"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of l-cysteine prior to <e1>NO</e1> (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.","Not"
"The active site coordination of <e2>CDO</e2> comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived <e1>histidines</e1>, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif.","Part_of"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of l-cysteine prior to <e1>NO</e1> (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.","Regulator"
"Mammalian cysteine dioxygenase (<e2>CDO</e2>) is a non-heme <e1>iron</e1> metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.","Regulator"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of <e1>l-cysteine</e1> prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.","Regulator"
"In these experiments, CDO exhibits an ordered binding of <e1>l-cysteine</e1> prior to NO (and presumably O2) similar to that observed for the <e2>2H1C class of non-heme iron enzymes</e2>.","Regulator"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of l-cysteine prior to <e1>NO</e1> (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.","Regulator"
"In these experiments, CDO exhibits an ordered binding of l-cysteine prior to <e1>NO</e1> (and presumably O2) similar to that observed for the <e2>2H1C class of non-heme iron enzymes</e2>.","Regulator"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of l-cysteine prior to NO (and presumably <e1>O2</e1>) similar to that observed for the 2H1C class of non-heme iron enzymes.","Regulator"
"In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably <e1>O2</e1>) similar to that observed for the <e2>2H1C class of non-heme iron enzymes</e2>.","Regulator"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of <e1>l-cysteine</e1> prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.","Regulator"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of l-cysteine prior to <e1>NO</e1> (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.","Regulator"
"Characterization of the <e1>nitrosyl</e1> adduct of substrate-bound <e2>mouse cysteine dioxygenase</e2> by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications.","Regulator"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of l-cysteine prior to <e1>NO</e1> (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.","Regulator"
"<e2>Mammalian cysteine dioxygenase</e2> (CDO) is a non-heme <e1>iron</e1> metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.","Cofactor"
"Mammalian cysteine dioxygenase (<e2>CDO</e2>) is a non-heme <e1>iron</e1> metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.","Cofactor"
"In these experiments, <e2>CDO</e2> exhibits an ordered binding of <e1>l-cysteine</e1> prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.","Substrate"
"Mammalian <e1>cysteine</e1> dioxygenase (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.","Substrate"
"Mammalian <e1>cysteine</e1> dioxygenase (<e2>CDO</e2>) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.","Substrate"
"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by <e1>Wy-14643</e1> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of <e2>PPARalpha2</e2>, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Regulator"
"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and <e1>5,8,11,14-eicosatetraynoic acid</e1> (ETYA) each at 10 microM, respectively, whereas that of <e2>PPARalpha2</e2>, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Regulator"
"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<e1>ETYA</e1>) each at 10 microM, respectively, whereas that of <e2>PPARalpha2</e2>, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Regulator"
"The transcriptional activity of torafugu <e2>PPARalpha1</e2> was enhanced 4.5- and 11.5-fold by <e1>Wy-14643</e1> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Upregulator"
"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by <e1>Wy-14643</e1> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of <e2>PPARalpha2</e2>, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Upregulator"
"The transcriptional activity of torafugu <e2>PPARalpha1</e2> was enhanced 4.5- and 11.5-fold by Wy-14643 and <e1>5,8,11,14-eicosatetraynoic acid</e1> (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Upregulator"
"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and <e1>5,8,11,14-eicosatetraynoic acid</e1> (ETYA) each at 10 microM, respectively, whereas that of <e2>PPARalpha2</e2>, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Upregulator"
"The transcriptional activity of torafugu <e2>PPARalpha1</e2> was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<e1>ETYA</e1>) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Upregulator"
"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<e1>ETYA</e1>) each at 10 microM, respectively, whereas that of <e2>PPARalpha2</e2>, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.","Upregulator"
"Furthermore, the activities of the two <e2>torafugu PPARalphas</e2> were enhanced 4.3- and 7.6-fold by <e1>arachidonic acid</e1>, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.","Upregulator"
"Furthermore, the activities of the two <e2>torafugu PPARalphas</e2> were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by <e1>docosahexaenoic acid</e1>, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.","Upregulator"
"Furthermore, the activities of the two <e2>torafugu PPARalphas</e2> were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by <e1>eicosapentaenoic acid</e1> each at 50 microM, respectively.","Upregulator"
"Combination chemotherapy with a <e2>substance P receptor</e2> antagonist (<e1>aprepitant</e1>) and melarsoprol in a mouse model of human African trypanosomiasis.","Antagonist"
"Combination chemotherapy with a <e2>substance P receptor</e2> antagonist (aprepitant) and <e1>melarsoprol</e1> in a mouse model of human African trypanosomiasis.","Antagonist"
"In this study we investigated the effects of combination chemotherapy with melarsoprol and a <e2>humanised SP receptor</e2> antagonist <e1>aprepitant</e1> (EMEND) in this mouse model.","Antagonist"
"In this study we investigated the effects of combination chemotherapy with melarsoprol and a <e2>humanised SP receptor</e2> antagonist aprepitant (<e1>EMEND</e1>) in this mouse model.","Antagonist"
"PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a <e2>36-kDa water-soluble protein</e2> with 316 <e1>amino acids</e1> found in the retinal pigment epithelium (RPE) and in retinal Muller cells.","Part_of"
"It is thought to play a critical role in the visual cycle by functioning as an acceptor of <e1>11-cis-retinol</e1> from the <e2>isomerohydrolase</e2> reaction.","Substrate"
"<e2>Arginase</e2> or nitric oxide synthase isoenzymes were not found to influence <e1>L-citrulline</e1> production.","Not"
"Arginase or <e2>nitric oxide synthase</e2> isoenzymes were not found to influence <e1>L-citrulline</e1> production.","Not"
"Using this assay, we found that both <e1>superoxide</e1> and nitric oxide inhibit renal cortical <e2>DDAH</e2> activity in vitro.","Downregulator"
"Using this assay, we found that both superoxide and <e1>nitric oxide</e1> inhibit renal cortical <e2>DDAH</e2> activity in vitro.","Downregulator"
"Dimethylarginine dimethylaminohydrolase (<e2>DDAH</e2>) metabolizes asymmetric dimethylarginine to generate <e1>L-citrulline</e1> and is present in large quantities in the kidney.","Substrate"
"<e2>Dimethylarginine dimethylaminohydrolase</e2> (DDAH) metabolizes asymmetric dimethylarginine to generate <e1>L-citrulline</e1> and is present in large quantities in the kidney.","Substrate"
"Dimethylarginine dimethylaminohydrolase (<e2>DDAH</e2>) metabolizes asymmetric dimethylarginine to generate <e1>L-citrulline</e1> and is present in large quantities in the kidney.","Substrate"
"Dimethylarginine dimethylaminohydrolase (<e2>DDAH</e2>) metabolizes asymmetric dimethylarginine to generate <e1>L-citrulline</e1> and is present in large quantities in the kidney.","Substrate"
"Dimethylarginine dimethylaminohydrolase (<e2>DDAH</e2>) metabolizes asymmetric <e1>dimethylarginine</e1> to generate L-citrulline and is present in large quantities in the kidney.","Substrate"
"We found that the removal of <e1>urea</e1> with <e2>urease</e2> is necessary since urea also produces a positive reaction.","Substrate"
"<e2>Dimethylarginine dimethylaminohydrolase</e2> (DDAH) metabolizes asymmetric <e1>dimethylarginine</e1> to generate L-citrulline and is present in large quantities in the kidney.","Substrate"
"Dimethylarginine dimethylaminohydrolase (<e2>DDAH</e2>) metabolizes asymmetric <e1>dimethylarginine</e1> to generate L-citrulline and is present in large quantities in the kidney.","Substrate"
"A humanized antibody to <e2>HER2</e2>/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including <e1>doxorubicin</e1>, cyclophosphamide, and paclitaxel.","Regulator"
"A humanized antibody to HER2/<e2>neu</e2>, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including <e1>doxorubicin</e1>, cyclophosphamide, and paclitaxel.","Regulator"
"A humanized antibody to <e2>HER2</e2>/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, <e1>cyclophosphamide</e1>, and paclitaxel.","Regulator"
"A humanized antibody to HER2/<e2>neu</e2>, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, <e1>cyclophosphamide</e1>, and paclitaxel.","Regulator"
"A humanized antibody to <e2>HER2</e2>/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and <e1>paclitaxel</e1>.","Regulator"
"A humanized antibody to HER2/<e2>neu</e2>, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and <e1>paclitaxel</e1>.","Regulator"
"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting <e2>HER2</e2>/neu as well as the epidermal growth factor receptor (EGFR), <e1>lapatinib</e1>.","Downregulator"
"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/<e2>neu</e2> as well as the epidermal growth factor receptor (EGFR), <e1>lapatinib</e1>.","Downregulator"
"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the <e2>epidermal growth factor receptor</e2> (EGFR), <e1>lapatinib</e1>.","Downregulator"
"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor (<e2>EGFR</e2>), <e1>lapatinib</e1>.","Downregulator"
"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas <e1>l-glutamate</e1> (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to <e2>fibronectin</e2>.","Regulator"
"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <e1>NMDA</e1> receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to <e2>fibronectin</e2>.","Regulator"
"Exposure of Jurkat cells to either <e1>(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine</e1> [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <e2>NMDA receptor</e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.","Antagonist"
"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [<e1>(+)-MK 801</e1>] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <e2>NMDA receptor</e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.","Antagonist"
"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or <e1>D-(-)-2-amino-5-phosphonopentanoic acid</e1> (D-AP5), two selective <e2>NMDA receptor</e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.","Antagonist"
"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (<e1>D-AP5</e1>), two selective <e2>NMDA receptor</e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.","Antagonist"
"In an initial search for molecular features that differentially define antagonist binding determinants, we document that Val148 in <e2>hNET transmembrane domain 3</e2> selectively disrupts <e1>NIS</e1> binding but not that of DVS.","Not"
"Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the <e2>hNET</e2> expressed in membranes compared with whole cells when competing for <e1>[(3)H]nisoxetine</e1> (NIS) binding.","Regulator"
"Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the <e2>hNET</e2> expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine (<e1>NIS</e1>) binding.","Regulator"
"Desvenlafaxine succinate (<e1>DVS</e1>) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>hNET</e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.","Regulator"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by <e1>[(3)H]NIS</e1> was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Regulator"
"Desvenlafaxine succinate (<e1>DVS</e1>) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>hNET</e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog <e1>rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol</e1> (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (<e1>WY-46824</e1>), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), <e1>methylphenidate</e1>, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the <e1>cocaine</e1> analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog <e1>3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester</e1> (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (<e1>RTI-55</e1>) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Antagonist"
"Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the <e2>hNET</e2> expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine (<e1>NIS</e1>) binding.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, <e1>mazindol</e1>, tricyclic antidepressants, and cocaine.","Antagonist"
"<e1>Desvenlafaxine succinate</e1> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>hNET</e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.","Antagonist"
"<e1>Desvenlafaxine succinate</e1> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and <e2>hSERT</e2>, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, <e1>tricyclic</e1> antidepressants, and cocaine.","Antagonist"
"Using <e2>hNET</e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the <e1>cocaine</e1> analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.","Antagonist"
"<e1>Desvenlafaxine succinate</e1> identifies novel antagonist binding determinants in the <e2>human norepinephrine transporter</e2>.","Antagonist"
"Desvenlafaxine succinate (<e1>DVS</e1>) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>hNET</e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.","Antagonist"
"Desvenlafaxine succinate (<e1>DVS</e1>) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and <e2>hSERT</e2>, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.","Antagonist"
"Desvenlafaxine succinate (<e1>DVS</e1>) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>hNET</e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.","Antagonist"
"The key difference in structure of <e2>Lp(a)</e2> and plasminogen is replacement of <e1>Arg</e1> with Ser at position 560.","Part_of"
"The key difference in structure of Lp(a) and <e2>plasminogen</e2> is replacement of <e1>Arg</e1> with Ser at position 560.","Part_of"
"The key difference in structure of <e2>Lp(a)</e2> and plasminogen is replacement of Arg with <e1>Ser</e1> at position 560.","Part_of"
"The key difference in structure of Lp(a) and <e2>plasminogen</e2> is replacement of Arg with <e1>Ser</e1> at position 560.","Part_of"
"<e1>Sorafenib</e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (<e2>VEGFR-2</e2>, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.","Downregulator"
"<e1>Sorafenib</e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, <e2>VEGFR-3</e2>) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.","Downregulator"
"<e1>Sorafenib</e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and <e2>platelet-derived growth factor receptor beta</e2> (PDGFR-beta), while temsirolimus is an mTOR inhibitor.","Downregulator"
"<e1>Sorafenib</e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (<e2>PDGFR-beta</e2>), while temsirolimus is an mTOR inhibitor.","Downregulator"
"Sorafenib and <e1>sunitinib</e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (<e2>VEGFR-2</e2>, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.","Downregulator"
"Sorafenib and <e1>sunitinib</e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, <e2>VEGFR-3</e2>) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.","Downregulator"
"Sorafenib and <e1>sunitinib</e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and <e2>platelet-derived growth factor receptor beta</e2> (PDGFR-beta), while temsirolimus is an mTOR inhibitor.","Downregulator"
"Sorafenib and <e1>sunitinib</e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (<e2>PDGFR-beta</e2>), while temsirolimus is an mTOR inhibitor.","Downregulator"
"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while <e1>temsirolimus</e1> is an <e2>mTOR</e2> inhibitor.","Downregulator"
"One is that the binding of <e1>retinoids</e1> to nuclear <e2>retinoic acid receptors</e2> (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.","Regulator"
"One is that the binding of <e1>retinoids</e1> to nuclear retinoic acid receptors (<e2>RARs</e2>) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.","Regulator"
"One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, <e2>RAR-alpha</e2>, -beta and -gamma, without measurable receptor binding, whereas <e1>tazarotene</e1> preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.","Regulator"
"One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, <e2>RAR-alpha</e2>, -beta and -gamma, without measurable receptor binding, whereas <e1>tazarotene</e1> preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.","Upregulator"
"Based on the results from those studies, we concluded that <e1>rasagiline</e1> PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited <e2>MAO-B</e2>.","Not"
"Rasagiline [<e1>N-propargyl-l(R)-aminoindan</e1>] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain <e2>MAO-B</e2> and is specifically designed for the treatment of Parkinson's disease (PD).","Downregulator"
"Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation <e1>propargylamine</e1> pharmacophore that selectively and irreversibly inhibits brain <e2>MAO-B</e2> and is specifically designed for the treatment of Parkinson's disease (PD).","Downregulator"
"Comprehensive review of <e1>rasagiline</e1>, a second-generation <e2>monoamine oxidase</e2> inhibitor, for the treatment of Parkinson's disease.","Downregulator"
"Based on the results from those studies, we concluded that <e1>rasagiline</e1> PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited <e2>MAO-B</e2>.","Downregulator"
"<e1>Rasagiline</e1> [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain <e2>MAO-B</e2> and is specifically designed for the treatment of Parkinson's disease (PD).","Downregulator"
"We report that mutation of this conserved <e1>Gly</e1> in yeast <e2>Top1p</e2> alters enzyme sensitivity to CPT.","Part_of"
"<e2>Top1p</e2> is the cellular target of the anti-cancer drug camptothecin (<e1>C</e1>PT), which reversibly stabilizes a covalent enzyme-DNA intermediate.","Part_of"
"Top1p clamps around duplex DNA, wherein the core and <e1>C</e1>-terminal domains are connected by extended <e2>alpha-helices</e2> (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket.","Part_of"
"Top1p clamps around duplex DNA, wherein the core and <e1>C</e1>-terminal domains are connected by extended alpha-helices (<e2>linker domain</e2>), which position the active site Tyr of the C-terminal domain within the catalytic pocket.","Part_of"
"We report that mutation of this conserved <e1>Gly</e1> in <e2>yeast Top1p</e2> alters enzyme sensitivity to CPT.","Part_of"
"<e2>Top1p</e2> clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site <e1>Tyr</e1> of the C-terminal domain within the catalytic pocket.","Part_of"
"Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended <e2>alpha-helices</e2> (linker domain), which position the active site <e1>Tyr</e1> of the C-terminal domain within the catalytic pocket.","Part_of"
"<e2>Top1p</e2> is the cellular target of the anti-cancer drug camptothecin (<e1>C</e1>PT), which reversibly stabilizes a covalent enzyme-DNA intermediate.","Part_of"
"Top1p clamps around duplex DNA, wherein the core and <e1>C</e1>-terminal domains are connected by extended alpha-helices (<e2>linker domain</e2>), which position the active site Tyr of the C-terminal domain within the catalytic pocket.","Part_of"
"Crystallographic data reveal that a conserved <e1>Gly</e1> residue (located at the juncture between the linker and C-terminal domains) is at one end of a short <e2>alpha-helix</e2>, which extends to the active site Tyr covalently linked to the DNA.","Part_of"
"<e1>C</e1>rystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and C-terminal domains) is at one end of a short <e2>alpha-helix</e2>, which extends to the active site Tyr covalently linked to the DNA.","Part_of"
"Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and C-terminal domains) is at one end of a short <e2>alpha-helix</e2>, which extends to the active site <e1>Tyr</e1> covalently linked to the DNA.","Part_of"
"Crystallographic data reveal that a conserved <e1>Gly</e1> residue (located at the juncture between the linker and C-terminal domains) is at one end of a short <e2>alpha-helix</e2>, which extends to the active site Tyr covalently linked to the DNA.","Part_of"
"In the presence of drug, the linker is rigid and this <e2>alpha-helix</e2> extends to include Gly and the preceding <e1>Leu</e1>.","Part_of"
"<e2>Top1p</e2> is the cellular target of the anti-cancer drug <e1>camptothecin</e1> (CPT), which reversibly stabilizes a covalent enzyme-DNA intermediate.","Regulator"
"<e2>Top1p</e2> is the cellular target of the anti-cancer drug camptothecin (<e1>CPT</e1>), which reversibly stabilizes a covalent enzyme-DNA intermediate.","Regulator"
"<e2>Top1p</e2> is the cellular target of the anti-cancer drug camptothecin (<e1>CPT</e1>), which reversibly stabilizes a covalent enzyme-DNA intermediate.","Regulator"
"Mutation of Gly721 alters <e2>DNA topoisomerase I</e2> active site architecture and sensitivity to <e1>camptothecin</e1>.","Regulator"
"We report that mutation of this conserved Gly in <e2>yeast Top1p</e2> alters enzyme sensitivity to <e1>CPT</e1>.","Regulator"
"The binding of U46619 to the <e2>PGIS</e2> protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at <e1>C-11</e1>, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.","Part_of"
"The binding of U46619 to the <e2>PGIS</e2> protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, <e1>H2C</e1>, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.","Part_of"
"The binding of U46619 to the <e2>PGIS</e2> protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and <e1>H20</e1> of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.","Part_of"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Part_of"
"The binding of U46619 to the <e2>PGIS</e2> protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and <e1>H20</e1> of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.","Part_of"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin <e1>H2</e1>) mimic (U46619) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Part_of"
"The distances between the protons H20 and H2, <e1>H18</e1> and H2, and H18 and H4 are shorter following their binding to the <e2>PGIS</e2> in solution-down to within 5 A.","Part_of"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin <e1>H2</e1>) mimic (U46619) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Part_of"
"The distances between the protons H20 and H2, <e1>H18</e1> and H2, and H18 and H4 are shorter following their binding to the <e2>PGIS</e2> in solution-down to within 5 A.","Part_of"
"The distances between the protons H20 and H2, H18 and H2, and H18 and <e1>H4</e1> are shorter following their binding to the <e2>PGIS</e2> in solution-down to within 5 A.","Part_of"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered <e2>prostacyclin (PGI2) synthase</e2> (PGIS) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (<e1>prostaglandin H2</e1>) mimic (U46619) to the engineered <e2>prostacyclin (PGI2) synthase</e2> (PGIS) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (<e1>prostaglandin H2</e1>) mimic (U46619) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<e1>U46619</e1>) to the engineered prostacyclin (PGI2) synthase (<e2>PGIS</e2>) in solution.","Regulator"
"This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to <e2>factor Xa</e2> (<e1>rivaroxaban</e1> and apixaban) and IIa (dabigatran).","Downregulator"
"This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to <e2>factor Xa</e2> (rivaroxaban and <e1>apixaban</e1>) and IIa (dabigatran).","Downregulator"
"INTERVENTIONS: In the 8-week run-in period, all participants received the <e2>ACE</e2> inhibitor <e1>cilazapril</e1> (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.","Downregulator"
"Two <e1>imidazoquinoline</e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and <e2>TLR8</e2> whereas only human TLR7, but not TLR8, was activated by the ligands.","Not"
"Porcine <e2>TLR8</e2> and TLR7 are both activated by a selective TLR7 ligand, <e1>imiquimod</e1>.","Not"
"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod</e1>, markedly activated both porcine TLR7 and <e2>TLR8</e2> whereas only human TLR7, but not TLR8, was activated by the ligands.","Not"
"Both <e2>porcine TLR7</e2> and TLR8 proteins were expressed in cell lines and were <e1>N</e1>-glycosylated.","Part_of"
"Both porcine TLR7 and <e2>TLR8</e2> proteins were expressed in cell lines and were <e1>N</e1>-glycosylated.","Part_of"
"Two <e1>imidazoquinoline</e1> molecules, imiquimod and gardiquimod, markedly activated both <e2>porcine TLR7</e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.","Regulator"
"Two <e1>imidazoquinoline</e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and <e2>TLR8</e2> whereas only human TLR7, but not TLR8, was activated by the ligands.","Regulator"
"Two <e1>imidazoquinoline</e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7</e2>, but not TLR8, was activated by the ligands.","Regulator"
"Two <e1>imidazoquinoline</e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and <e2>TLR8</e2> whereas only human TLR7, but not TLR8, was activated by the ligands.","Regulator"
"Two imidazoquinoline molecules, <e1>imiquimod</e1> and gardiquimod, markedly activated both <e2>porcine TLR7</e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.","Regulator"
"Porcine <e2>TLR8</e2> and TLR7 are both activated by a selective TLR7 ligand, <e1>imiquimod</e1>.","Regulator"
"Two imidazoquinoline molecules, <e1>imiquimod</e1> and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7</e2>, but not TLR8, was activated by the ligands.","Regulator"
"Porcine <e2>TLR8</e2> and TLR7 are both activated by a selective TLR7 ligand, <e1>imiquimod</e1>.","Regulator"
"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod</e1>, markedly activated both <e2>porcine TLR7</e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.","Regulator"
"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod</e1>, markedly activated both porcine TLR7 and <e2>TLR8</e2> whereas only human TLR7, but not TLR8, was activated by the ligands.","Regulator"
"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod</e1>, markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7</e2>, but not TLR8, was activated by the ligands.","Regulator"
"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod</e1>, markedly activated both porcine TLR7 and <e2>TLR8</e2> whereas only human TLR7, but not TLR8, was activated by the ligands.","Regulator"
"Porcine TLR8 and <e2>TLR7</e2> are both activated by a selective TLR7 ligand, <e1>imiquimod</e1>.","Regulator"
"Two <e1>imidazoquinoline</e1> molecules, imiquimod and gardiquimod, markedly activated both <e2>porcine TLR7</e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.","Upregulator"
"Two <e1>imidazoquinoline</e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and <e2>TLR8</e2> whereas only human TLR7, but not TLR8, was activated by the ligands.","Upregulator"
"Two <e1>imidazoquinoline</e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7</e2>, but not TLR8, was activated by the ligands.","Upregulator"
"Two imidazoquinoline molecules, <e1>imiquimod</e1> and gardiquimod, markedly activated both <e2>porcine TLR7</e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.","Upregulator"
"Porcine <e2>TLR8</e2> and TLR7 are both activated by a selective TLR7 ligand, <e1>imiquimod</e1>.","Upregulator"
"Two imidazoquinoline molecules, <e1>imiquimod</e1> and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7</e2>, but not TLR8, was activated by the ligands.","Upregulator"
"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod</e1>, markedly activated both <e2>porcine TLR7</e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.","Upregulator"
"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod</e1>, markedly activated both porcine TLR7 and <e2>TLR8</e2> whereas only human TLR7, but not TLR8, was activated by the ligands.","Upregulator"
"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod</e1>, markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7</e2>, but not TLR8, was activated by the ligands.","Upregulator"
"Porcine TLR8 and <e2>TLR7</e2> are both activated by a selective TLR7 ligand, <e1>imiquimod</e1>.","Upregulator"
"Porcine <e2>TLR8</e2> and TLR7 are both activated by a selective TLR7 ligand, <e1>imiquimod</e1>.","Upregulator"
"Moreover, activation of transfected cells and porcine PBMC by <e2>TLR7</e2> ligands was inhibited by <e1>bafilomycin A(1)</e1> indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.","Downregulator"
"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for <e1>4-iodopropofol</e1>, 4-bromopropofol and 4-chloropropofol in <e2>Na(V)1.4</e2>, and 450 nM for 4-chloropropofol in Na(V)1.2.","Regulator"
"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, <e1>4-bromopropofol</e1> and 4-chloropropofol in <e2>Na(V)1.4</e2>, and 450 nM for 4-chloropropofol in Na(V)1.2.","Regulator"
"EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (<e2>Na(V)1.4</e2>) and the effect of one compound (<e1>4-chloropropofol</e1>) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.","Regulator"
"EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (<e1>4-chloropropofol</e1>) on neuronal sodium channels (<e2>Na(V)1.2</e2>) heterologously expressed in human embryonic kidney cell line 293.","Regulator"
"CONCLUSIONS AND IMPLICATIONS: Halogenated propofol analogues constitute a novel class of <e2>sodium channel</e2>-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug <e1>lidocaine</e1>.","Regulator"
"EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (<e1>4-chloropropofol</e1>) on neuronal sodium channels (<e2>Na(V)1.2</e2>) heterologously expressed in human embryonic kidney cell line 293.","Downregulator"
"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for <e1>4-iodopropofol</e1>, 4-bromopropofol and 4-chloropropofol in <e2>Na(V)1.4</e2>, and 450 nM for 4-chloropropofol in Na(V)1.2.","Downregulator"
"High-affinity blockade of <e2>voltage-operated skeletal muscle and neuronal sodium channels</e2> by <e1>halogenated propofol</e1> analogues.","Downregulator"
"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, <e1>4-bromopropofol</e1> and 4-chloropropofol in <e2>Na(V)1.4</e2>, and 450 nM for 4-chloropropofol in Na(V)1.2.","Downregulator"
"EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (<e2>Na(V)1.4</e2>) and the effect of one compound (<e1>4-chloropropofol</e1>) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.","Downregulator"
"EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (<e1>4-chloropropofol</e1>) on neuronal sodium channels (<e2>Na(V)1.2</e2>) heterologously expressed in human embryonic kidney cell line 293.","Downregulator"
"CONCLUSIONS AND IMPLICATIONS: <e1>Halogenated propofol</e1> analogues constitute a novel class of <e2>sodium channel</e2>-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine.","Downregulator"
"<e1>Irbesartan</e1> (Aprovel, Avapro, Irbetan, Karvea), an <e2>angiotensin II receptor type 1</e2> antagonist, is approved in many countries worldwide for the treatment of hypertension.","Antagonist"
"Irbesartan (<e1>Aprovel</e1>, Avapro, Irbetan, Karvea), an <e2>angiotensin II receptor type 1</e2> antagonist, is approved in many countries worldwide for the treatment of hypertension.","Antagonist"
"Irbesartan (Aprovel, <e1>Avapro</e1>, Irbetan, Karvea), an <e2>angiotensin II receptor type 1</e2> antagonist, is approved in many countries worldwide for the treatment of hypertension.","Antagonist"
"Irbesartan (Aprovel, Avapro, <e1>Irbetan</e1>, Karvea), an <e2>angiotensin II receptor type 1</e2> antagonist, is approved in many countries worldwide for the treatment of hypertension.","Antagonist"
"Irbesartan (Aprovel, Avapro, Irbetan, <e1>Karvea</e1>), an <e2>angiotensin II receptor type 1</e2> antagonist, is approved in many countries worldwide for the treatment of hypertension.","Antagonist"
"When <e2>RAD51</e2>, which is a central component of HR, was depleted by siRNA cells were sensitized to <e1>raltitrexed</e1> (RTX), which specifically inhibits TS.","Regulator"
"When <e2>RAD51</e2>, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (<e1>RTX</e1>), which specifically inhibits TS.","Regulator"
"Phosphorylation of replication protein A (<e2>RPA2</e2> subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of <e1>RTX</e1>.","Regulator"
"Phosphorylation of <e2>replication protein A</e2> (RPA2 subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of <e1>RTX</e1>.","Regulator"
"Phosphorylation of replication protein A (<e2>RPA2</e2> subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of <e1>RTX</e1>.","Regulator"
"When <e2>RAD51</e2>, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (<e1>RTX</e1>), which specifically inhibits TS.","Upregulator"
"<e1>RTX</e1> treatment also induced foci of RAD51, <e2>gamma-H2AX</e2>, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.","Upregulator"
"<e1>RTX</e1> treatment also induced foci of RAD51, gamma-H2AX, <e2>phospho-Chk1</e2>, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.","Upregulator"
"<e1>RTX</e1> treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and <e2>phospho-NBS1</e2>, although the extent of co-localization with RPA2 foci varied.","Upregulator"
"When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (<e1>RTX</e1>), which specifically inhibits <e2>TS</e2>.","Downregulator"
"DNA damage is accepted as a consequence of <e1>thymidylate</e1> deprivation induced by chemotherapeutic inhibitors of <e2>thymidylate synthase</e2> (TS), but the types of damage and signaling responses remain incompletely understood.","Substrate"
"DNA damage is accepted as a consequence of <e1>thymidylate</e1> deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (<e2>TS</e2>), but the types of damage and signaling responses remain incompletely understood.","Substrate"
"<e2>NNMT</e2> mR<e1>NA</e1> levels and enzyme activity increased in 3T3-L1 cells in a differentiation-dependent manner.","Regulator"
"<e2>NNMT</e2> mR<e1>NA</e1> levels and enzyme activity increased in 3T3-L1 cells in a differentiation-dependent manner.","Upregulator"
"<e1>Nicotinic acid</e1> (NA), a widely used drug to lower elevated plasma lipid levels, induced <e2>NNMT</e2> enzyme activity in white adipose tissue of mice.","Upregulator"
"Nicotinamide N-methyltransferase (<e2>NNMT</e2>) catalyses the conversion of nicotinamide to <e1>1-methylnicotinamide</e1> and plays an important role in hepatic detoxification reactions.","Downregulator"
"<e2>Nicotinamide N-methyltransferase</e2> (NNMT) catalyses the conversion of nicotinamide to <e1>1-methylnicotinamide</e1> and plays an important role in hepatic detoxification reactions.","Substrate"
"Nicotinamide N-methyltransferase (<e2>NNMT</e2>) catalyses the conversion of nicotinamide to <e1>1-methylnicotinamide</e1> and plays an important role in hepatic detoxification reactions.","Substrate"
"These data support the concept that adipose tissue <e2>NNMT</e2> contributes to the increased plasma <e1>homocysteine</e1> levels in patients treated with NA.","Substrate"
"<e1>Homocysteine</e1>, the atherogenic product of the <e2>NNMT</e2>-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.","Substrate"
"<e2>Nicotinamide N-methyltransferase</e2> (NNMT) catalyses the conversion of <e1>nicotinamide</e1> to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.","Substrate"
"Nicotinamide N-methyltransferase (<e2>NNMT</e2>) catalyses the conversion of <e1>nicotinamide</e1> to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.","Substrate"
"The L-type calcium channel (<e2>LTCC</e2>) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (<e1>DHP</e1>) binding properties and are both expressed in mammalian brain.","Regulator"
"The <e2>L-type calcium channel</e2> (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (<e1>DHP</e1>) binding properties and are both expressed in mammalian brain.","Regulator"
"The L-type calcium channel (LTCC) isoforms <e2>Ca(v)1.2</e2> and Ca(v)1.3 display similar 1,4-dihydropyridine (<e1>DHP</e1>) binding properties and are both expressed in mammalian brain.","Regulator"
"The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and <e2>Ca(v)1.3</e2> display similar 1,4-dihydropyridine (<e1>DHP</e1>) binding properties and are both expressed in mammalian brain.","Regulator"
"<e1>(+)-[(3)H]isradipine</e1> binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that <e2>Ca(v)1.3</e2> accounts for 10.7% of brain LTCCs.","Regulator"
"<e1>(+)-[(3)H]isradipine</e1> binding to <e2>Ca(v)1.2</e2>DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs.","Regulator"
"Inhibition of (+)-[(3)H]isradipine binding to <e2>Ca(v)1.2</e2>DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of <e1>nitrendipine</e1> and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.","Regulator"
"Inhibition of (+)-[(3)H]isradipine binding to <e2>Ca(v)1.2</e2>DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and <e1>nifedipine</e1> for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.","Regulator"
"<e1>(+)-[(3)H]isradipine</e1> binding to <e2>Ca(v)</e2>1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs.","Regulator"
"<e1>(+)-[(3)H]isradipine</e1> binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that <e2>Ca(v)1.3</e2> accounts for 10.7% of brain LTCCs.","Regulator"
"<e1>(+)-[(3)H]isradipine</e1> binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain <e2>LTCCs</e2>.","Regulator"
"The L-type calcium channel (<e2>LTCC</e2>) isoforms Ca(v)1.2 and Ca(v)1.3 display similar <e1>1,4-dihydropyridine</e1> (DHP) binding properties and are both expressed in mammalian brain.","Regulator"
"Expression and <e1>1,4-dihydropyridine</e1>-binding properties of brain <e2>L-type calcium channel</e2> isoforms.","Regulator"
"The L-type calcium channel (LTCC) isoforms <e2>Ca(v)1.2</e2> and Ca(v)1.3 display similar <e1>1,4-dihydropyridine</e1> (DHP) binding properties and are both expressed in mammalian brain.","Regulator"
"The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and <e2>Ca(v)1.3</e2> display similar <e1>1,4-dihydropyridine</e1> (DHP) binding properties and are both expressed in mammalian brain.","Regulator"
"Expression and <e1>1,4-dihydropyridine</e1>-binding properties of brain <e2>L-type calcium channel</e2> isoforms.","Regulator"
"<e1>Bosutinib</e1> did not inhibit <e2>KIT</e2> or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.","Not"
"<e1>Bosutinib</e1> did not inhibit KIT or <e2>platelet-derived growth factor receptor</e2>, but prominently targeted the apoptosis-linked STE20 kinases.","Not"
"Here, we characterized the target profile of the dual SRC/<e2>ABL</e2> inhibitor <e1>bosutinib</e1> employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.","Not"
"Although in vivo <e1>bosutinib</e1> is inactive against ABL <e2>T315I</e2>, we found this clinically important mutant to be enzymatically inhibited in the mid-nanomolar range.","Not"
"<e1>Bosutinib</e1> did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked <e2>STE20 kinases</e2>.","Regulator"
"A comparison of bosutinib with <e1>dasatinib</e1> across the whole <e2>kinase</e2> panel revealed overlapping, but distinct, inhibition profiles.","Downregulator"
"Global target profile of the <e2>kinase</e2> inhibitor <e1>bosutinib</e1> in primary chronic myeloid leukemia cells.","Downregulator"
"Global target profile of the <e2>kinase</e2> inhibitor <e1>bosutinib</e1> in primary chronic myeloid leukemia cells.","Downregulator"
"Finally, <e1>bosutinib</e1> is the first kinase inhibitor shown to target <e2>CAMK2G</e2>, recently implicated in myeloid leukemia cell proliferation.","Downregulator"
"Here, we characterized the target profile of the dual <e2>SRC</e2>/ABL inhibitor <e1>bosutinib</e1> employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.","Downregulator"
"Here, we characterized the target profile of the dual SRC/<e2>ABL</e2> inhibitor <e1>bosutinib</e1> employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.","Downregulator"
"Global target profile of the <e2>kinase</e2> inhibitor <e1>bosutinib</e1> in primary chronic myeloid leukemia cells.","Downregulator"
"A positively charged derivative, <e1>estramustine sarcosinate</e1>, did not inhibit microtubule assembly or alter the composition of the coassembled <e2>MAPs</e2>.","Not"
"Both these <e2>MAPs</e2> were found to have two to three binding sites for <e1>estramustine</e1> phosphate which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains.","Not"
"Both these <e2>MAPs</e2> were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic <e1>amino acid</e1> repeats of these MAPs, considered to be the ultimate tubulin binding domains.","Part_of"
"Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic <e1>amino acid</e1> repeats of these MAPs, considered to be the ultimate <e2>tubulin</e2> binding domains.","Part_of"
"Both these <e2>MAPs</e2> were found to have two to three binding sites for <e1>estramustine phosphate</e1> which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains.","Regulator"
"In the present study the binding of <e1>estramustine phosphate</e1> to <e2>MAP2</e2> and tau was investigated.","Regulator"
"Both these MAPs were found to have two to three binding sites for <e1>estramustine</e1> phosphate which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate <e2>tubulin</e2> binding domains.","Regulator"
"Both these <e2>MAPs</e2> were found to have two to three binding sites for <e1>estramustine</e1> phosphate which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains.","Regulator"
"The negatively charged <e1>estramustine</e1> phosphate has been found previously to be a microtubule-associated protein (<e2>MAP</e2>)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].","Regulator"
"The negatively charged <e1>estramustine phosphate</e1> has been found previously to be a <e2>microtubule-associated protein</e2> (MAP)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].","Regulator"
"The negatively charged <e1>estramustine phosphate</e1> has been found previously to be a microtubule-associated protein (<e2>MAP</e2>)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].","Regulator"
"The negatively charged <e1>estramustine</e1> phosphate has been found previously to be a microtubule-associated protein (<e2>MAP</e2>)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].","Regulator"
"Two new negatively charged estramustine derivatives, <e1>estramustine sulphate</e1> and estramustine glucuronide, were found to be similar <e2>MAP</e2>-dependent microtubule inhibitors.","Regulator"
"Two new negatively charged estramustine derivatives, estramustine sulphate and <e1>estramustine glucuronide</e1>, were found to be similar <e2>MAP</e2>-dependent microtubule inhibitors.","Regulator"
"Unlike bacterial <e2>3-keto-5-ene-steroid isomerase</e2>, the human isomerase reaction is stimulated by <e1>diphosphopyridine nucleotides</e1> (NADH, NAD+).","Not"
"Unlike bacterial <e2>3-keto-5-ene-steroid isomerase</e2>, the human isomerase reaction is stimulated by diphosphopyridine nucleotides (<e1>NADH</e1>, NAD+).","Not"
"Unlike bacterial <e2>3-keto-5-ene-steroid isomerase</e2>, the human isomerase reaction is stimulated by diphosphopyridine nucleotides (NADH, <e1>NAD+</e1>).","Not"
"The <e1>3 beta-hydroxysteroid</e1> substrate, pregnenolone, protects isomerase as well as <e2>dehydrogenase</e2> from inactivation by FSA.","Not"
"The 3 beta-hydroxysteroid substrate, <e1>pregnenolone</e1>, protects isomerase as well as <e2>dehydrogenase</e2> from inactivation by FSA.","Not"
"Analysis of coenzyme binding by <e2>human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase</e2> and steroid 5----4-ene-isomerase using <e1>5'-[p-(fluorosulfonyl)benzoyl]adenosine</e1>, an affinity labeling cofactor analog.","Regulator"
"Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and <e2>steroid 5----4-ene-isomerase</e2> using <e1>5'-[p-(fluorosulfonyl)benzoyl]adenosine</e1>, an affinity labeling cofactor analog.","Regulator"
"The affinity labeling <e1>nucleotide</e1> analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the <e2>dehydrogenase</e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).","Downregulator"
"Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid <e2>dehydrogenase</e2> and steroid 5----4-ene-isomerase using <e1>5'-[p-(fluorosulfonyl)benzoyl]adenosine</e1>, an affinity labeling cofactor analog.","Downregulator"
"The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (<e1>FSA</e1>), inactivates the <e2>dehydrogenase</e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).","Downregulator"
"The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (<e1>FSA</e1>), inactivates the <e2>dehydrogenase</e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).","Downregulator"
"Analysis of coenzyme binding by <e2>human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase</e2> and steroid 5----4-ene-isomerase using <e1>5'-[p-(fluorosulfonyl)benzoyl]adenosine</e1>, an affinity labeling cofactor analog.","Cofactor"
"Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and <e2>steroid 5----4-ene-isomerase</e2> using <e1>5'-[p-(fluorosulfonyl)benzoyl]adenosine</e1>, an affinity labeling cofactor analog.","Cofactor"
"FSA is a cofactor site-directed reagent that binds with similar affinity as a competitive inhibitor of <e1>NAD+</e1> reduction by <e2>dehydrogenase</e2> (Ki = 162 microM) or as a stimulator of isomerase (Km = 153 microM).","Cofactor"
"Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the <e2>dehydrogenase</e2> and isomerase substrate <e1>steroids</e1> bind at different sites on the same protein.","Substrate"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<e1>SU 11248</e1>, Sutent) specific for <e2>VEGF receptor</e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others <e2>kinase</e2> inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<e1>SU 11248</e1>, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, <e1>Sutent</e1>) specific for <e2>VEGF receptor</e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others <e2>kinase</e2> inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, <e1>Sutent</e1>) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, <e1>AMN107</e1> (Nilotinib) and INNO-406 (NS-187) specific for <e2>c-KIT</e2> kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (<e1>Nilotinib</e1>) and INNO-406 (NS-187) specific for <e2>c-KIT</e2> kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and <e1>INNO-406</e1> (NS-187) specific for <e2>c-KIT</e2> kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (<e1>NS-187</e1>) specific for <e2>c-KIT</e2> kinase.","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: <e1>Lapatinib</e1> (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (<e1>Lapatinib ditosylate</e1>, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, <e1>Tykerb</e1>, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, <e1>GW-572016</e1>), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), <e1>Canertinib</e1> (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (<e1>CI-1033</e1>), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), <e1>Zactima</e1> (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (<e1>ZD6474</e1>), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), <e1>Vatalanib</e1> (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (<e1>PTK787</e1>/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/<e1>ZK 222584</e1>), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), <e1>Sorafenib</e1> (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (<e1>Bay 43-9006</e1>, Nexavar), and Leflunomide (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, <e1>Nexavar</e1>), and Leflunomide (SU101, Arava).","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include <e1>Dasatinib</e1> (BMS-354825) specific for <e2>ABL</e2> non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include <e1>Dasatinib</e1> (BMS-354825) specific for ABL <e2>non-receptor cytoplasmic kinase</e2>, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and <e1>Leflunomide</e1> (SU101, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (<e1>SU101</e1>, Arava).","Downregulator"
"The following <e2>TK</e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, <e1>Arava</e1>).","Downregulator"
"The most successful example of <e2>kinase</e2> blockers is <e1>Imatinib</e1> (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of kinase blockers is <e1>Imatinib</e1> (Imatinib mesylate, Gleevec, STI571), the inhibitor of <e2>Bcr</e2>/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of kinase blockers is <e1>Imatinib</e1> (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/<e2>Abl</e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of <e2>kinase</e2> blockers is Imatinib (<e1>Imatinib mesylate</e1>, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of kinase blockers is Imatinib (<e1>Imatinib mesylate</e1>, Gleevec, STI571), the inhibitor of <e2>Bcr</e2>/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of kinase blockers is Imatinib (<e1>Imatinib mesylate</e1>, Gleevec, STI571), the inhibitor of Bcr/<e2>Abl</e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of <e2>kinase</e2> blockers is Imatinib (Imatinib mesylate, <e1>Gleevec</e1>, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, <e1>Gleevec</e1>, STI571), the inhibitor of <e2>Bcr</e2>/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, <e1>Gleevec</e1>, STI571), the inhibitor of Bcr/<e2>Abl</e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of <e2>kinase</e2> blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>STI571</e1>), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>STI571</e1>), the inhibitor of <e2>Bcr</e2>/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>STI571</e1>), the inhibitor of Bcr/<e2>Abl</e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (<e1>BMS-354825</e1>) specific for <e2>ABL</e2> non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, <e1>Gefitinib</e1> (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor</e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others <e2>kinase</e2> inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, <e1>Gefitinib</e1> (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (<e1>Iressa</e1>), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor</e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others <e2>kinase</e2> inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (<e1>Iressa</e1>), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), <e1>Erlotinib</e1> (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor</e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others <e2>kinase</e2> inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), <e1>Erlotinib</e1> (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (<e1>OSI-774</e1>, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor</e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others <e2>kinase</e2> inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (<e1>OSI-774</e1>, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, <e1>Tarceva</e1>) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor</e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others <e2>kinase</e2> inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, <e1>Tarceva</e1>) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and <e1>Sunitinib</e1> (SU 11248, Sutent) specific for <e2>VEGF receptor</e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Others <e2>kinase</e2> inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and <e1>Sunitinib</e1> (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.","Downregulator"
"Currently, the use of orally administered <e2>MAO</e2> inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of <e1>tyramine</e1>-provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary tyramine.","Regulator"
"Currently, the use of orally administered <e2>MAO</e2> inhibitor antidepressants (eg, <e1>phenelzine</e1>, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary tyramine.","Downregulator"
"Currently, the use of orally administered <e2>MAO</e2> inhibitor antidepressants (eg, phenelzine, <e1>tranylcypromine</e1>) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the ""cheese reaction"") when combined with dietary tyramine.","Downregulator"
"<e1>Atomoxetine</e1> has a high affinity and selectivity for norepinephrine transporters, but little or no affinity for various <e2>neurotransmitter receptors</e2>.","Not"
"<e1>Atomoxetine</e1> has a high affinity and selectivity for <e2>norepinephrine transporters</e2>, but little or no affinity for various neurotransmitter receptors.","Regulator"
"<e2>CYP2D6</e2> inhibitors, such as <e1>paroxetine</e1>, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.","Downregulator"
"It undergoes extensive biotransformation, which is affected by poor metabolism by <e2>cytochrome P450 (CYP) 2D6</e2> in a small percentage of the population; these patients have greater exposure to and slower elimination of <e1>atomoxetine</e1> than extensive metabolizers.","Substrate"
"<e2>CYP2D6</e2> inhibitors, such as paroxetine, are associated with changes in <e1>atomoxetine</e1> pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.","Substrate"
"<e1>Atomoxetine</e1> appeared better tolerated among extensive <e2>CYP2D6</e2> metabolizers than among poor metabolizers.","Substrate"
"<e1>Hexachlorophene</e1> forms a ring around the internal cavity in <e2>GDH</e2> through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves.","Regulator"
"<e1>Hexachlorophene</e1> forms a ring around the internal cavity in <e2>GDH</e2> through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves.","Regulator"
"<e2>Mammalian glutamate dehydrogenase</e2> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using <e1>NAD(P)(+)</e1> as coenzyme.","Regulator"
"Mammalian glutamate dehydrogenase (<e2>GDH</e2>) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using <e1>NAD(P)(+)</e1> as coenzyme.","Regulator"
"The recently discovered hyper<e2>insulin</e2>ism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by <e1>GTP</e1> causes excessive secretion of insulin.","Upregulator"
"Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of <e2>GDH</e2> are inhibited by the green tea polyphenols, <e1>epigallocatechin gallate</e1> and epicatechin gallate.","Downregulator"
"Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of <e2>GDH</e2> are inhibited by the green tea polyphenols, epigallocatechin gallate and <e1>epicatechin gallate</e1>.","Downregulator"
"The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of <e2>GDH</e2> by <e1>GTP</e1> causes excessive secretion of insulin.","Modulator"
"<e2>Mammalian glutamate dehydrogenase</e2> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to <e1>2-oxoglutarate</e1> using NAD(P)(+) as coenzyme.","Substrate"
"Mammalian glutamate dehydrogenase (<e2>GDH</e2>) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to <e1>2-oxoglutarate</e1> using NAD(P)(+) as coenzyme.","Substrate"
"<e2>Mammalian glutamate dehydrogenase</e2> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of <e1>l-glutamate</e1> to 2-oxoglutarate using NAD(P)(+) as coenzyme.","Substrate"
"Mammalian glutamate dehydrogenase (<e2>GDH</e2>) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of <e1>l-glutamate</e1> to 2-oxoglutarate using NAD(P)(+) as coenzyme.","Substrate"
"In this study, we evaluated the effect of <e1>bupivacaine</e1> administered via a nerve block or via a systemic route on the spinal expression of PGE2 and <e2>COX</e2> in a model of peripheral inflammation in rats.","Not"
"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord <e2>COX-2</e2> (cyclooxygenase-2), with a subsequent increase in central <e1>prostaglandin E2</e1> (PGE2) levels associated with the development of hyperalgesia.","Substrate"
"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (<e2>cyclooxygenase-2</e2>), with a subsequent increase in central <e1>prostaglandin E2</e1> (PGE2) levels associated with the development of hyperalgesia.","Substrate"
"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord <e2>COX-2</e2> (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 (<e1>PGE2</e1>) levels associated with the development of hyperalgesia.","Substrate"
"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (<e2>cyclooxygenase-2</e2>), with a subsequent increase in central prostaglandin E2 (<e1>PGE2</e1>) levels associated with the development of hyperalgesia.","Substrate"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (CEC), <e1>WB4101</e1>, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Regulator"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and <e1>5-methyl-urapidil</e1>, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Regulator"
"Radioligand binding studies with the nonselective <e2>alpha 1-adrenoceptor</e2> antagonist radioligand <e1>125I-BE2254</e1> showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).","Regulator"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (<e1>CEC</e1>), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Regulator"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (CEC), <e1>WB4101</e1>, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Regulator"
"Radioligand binding studies with the nonselective <e2>alpha 1-adrenoceptor</e2> antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for <e1>5-methylurapidil</e1> (pKd = 7.1).","Regulator"
"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against <e2>alpha 1a-adrenoceptor</e2>-selective agonist <e1>methoxamine</e1>-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","Agonist"
"The Schild plots for the competitive antagonists <e1>WB4101</e1> and 5-methyl-urapidil against <e2>alpha 1a-adrenoceptor</e2>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","Antagonist"
"The Schild plots for the competitive antagonists WB4101 and <e1>5-methyl-urapidil</e1> against <e2>alpha 1a-adrenoceptor</e2>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","Antagonist"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (CEC), <e1>WB4101</e1>, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Antagonist"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and <e1>5-methyl-urapidil</e1>, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Antagonist"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and <e1>5-methyl-urapidil</e1>, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Antagonist"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists <e1>chlorethylclonidine</e1> (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Antagonist"
"Radioligand binding studies with the nonselective <e2>alpha 1-adrenoceptor</e2> antagonist radioligand <e1>125I-BE2254</e1> showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).","Antagonist"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (<e1>CEC</e1>), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Antagonist"
"Using the <e2>alpha 1-adrenoceptor</e2> subtype-selective antagonists chlorethylclonidine (CEC), <e1>WB4101</e1>, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.","Antagonist"
"The Schild plots for the competitive antagonists <e1>WB4101</e1> and 5-methyl-urapidil against <e2>alpha 1a-adrenoceptor</e2>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","Antagonist"
"The Schild plots for the competitive antagonists WB4101 and <e1>5-methyl-urapidil</e1> against <e2>alpha 1a-adrenoceptor</e2>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.","Antagonist"
"<e1>Ambrisentan</e1> is an <e2>endothelin receptor</e2> antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).","Antagonist"
"<e1>Ambrisentan</e1> is the first <e2>ET(A)</e2> selective ERA approved for use in the US.","Antagonist"
"A series of 4,5-diaryloxazole analogs were designed and the interaction between <e1>oxaprozin</e1> and <e2>cyclooxygenase-2</e2> studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of oxaprozin.","Regulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, <e1>promegestone</e1>, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase</e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","Downregulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, <e1>promegestone</e1>, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1</e2> activities.","Downregulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, <e1>nomegestrol acetate</e1> and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase</e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","Downregulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, <e1>nomegestrol acetate</e1> and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1</e2> activities.","Downregulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and <e1>norelgestromin</e1> can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase</e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","Downregulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and <e1>norelgestromin</e1> can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1</e2> activities.","Downregulator"
"As discussed in this review, various <e1>progestogens</e1> including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase</e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","Downregulator"
"As discussed in this review, various <e1>progestogens</e1> including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1</e2> activities.","Downregulator"
"As discussed in this review, various progestogens including <e1>dydrogesterone</e1> and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase</e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","Downregulator"
"As discussed in this review, various progestogens including <e1>dydrogesterone</e1> and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1</e2> activities.","Downregulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, <e1>medrogestone</e1>, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase</e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","Downregulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, <e1>medrogestone</e1>, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1</e2> activities.","Downregulator"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of <e1>estradiol</e1> in breast cancer by blocking <e2>sulfatase</e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities.","Substrate"
"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of <e1>estradiol</e1> in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1</e2> activities.","Substrate"
"OBJECTIVE: <e1>Mitiglinide</e1>, a rapid- and short-acting insulinotropic <e2>sulfonylurea receptor</e2> ligand, exhibits hypoglycemic action unlike other sulfonylureas.","Regulator"
"OBJECTIVE: Mitiglinide, a rapid- and short-acting insulinotropic <e2>sulfonylurea receptor</e2> ligand, exhibits hypoglycemic action unlike other <e1>sulfonylureas</e1>.","Regulator"
"<e1>Mitiglinide</e1> reduced fasting plasma glucose and <e2>GA</e2> levels after 4 weeks and Hb(A1c) levels after 8 weeks.","Downregulator"
"<e1>Mitiglinide</e1> reduced fasting plasma glucose and GA levels after 4 weeks and <e2>Hb(A1c)</e2> levels after 8 weeks.","Downregulator"
"<e1>C</e1>yan fluorescent protein was fused to the C terminus of the <e2>M(2) muscarinic receptor</e2>, and a specific binding sequence for the small fluorescent compound fluorescein arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.","Part_of"
"Cyan fluorescent protein was fused to the C terminus of the <e2>M(2) muscarinic receptor</e2>, and a specific binding sequence for the small fluorescent compound <e1>fluorescein</e1> arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.","Regulator"
"Because these speeds are significantly faster than the responses to antagonists, these data indicate that <e1>gallamine</e1> and dimethyl-W84 are allosteric ligands and actively induce a conformation of the <e2>M(2) receptor</e2> with a reduced affinity for its agonists.","Modulator"
"Because these speeds are significantly faster than the responses to antagonists, these data indicate that gallamine and <e1>dimethyl-W84</e1> are allosteric ligands and actively induce a conformation of the <e2>M(2) receptor</e2> with a reduced affinity for its agonists.","Modulator"
"Here, we report that the transcription factor <e2>peroxisome proliferator-activated receptor gamma</e2> (PPARgamma) is essential for coupling <e1>ibuprofen</e1> to RhoA inhibition and subsequent neurite growth promotion in neurons.","Regulator"
"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (<e2>PPARgamma</e2>) is essential for coupling <e1>ibuprofen</e1> to RhoA inhibition and subsequent neurite growth promotion in neurons.","Regulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Regulator"
"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (<e2>PPARgamma</e2>) is essential for coupling <e1>ibuprofen</e1> to RhoA inhibition and subsequent neurite growth promotion in neurons.","Regulator"
"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (<e2>PPARgamma</e2>) is essential for coupling <e1>ibuprofen</e1> to RhoA inhibition and subsequent neurite growth promotion in neurons.","Regulator"
"<e1>Ibuprofen</e1> activates <e2>PPARgamma</e2> in neuron-like PC12 and B104 cells.","Upregulator"
"In addition, another study suggests that <e1>ibuprofen</e1> reduces generation of <e2>amyloid-beta42</e2> peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.","Upregulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Downregulator"
"In addition, another study suggests that <e1>ibuprofen</e1> reduces generation of <e2>amyloid-beta42</e2> peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.","Downregulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Downregulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Downregulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Downregulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Downregulator"
"<e1>Ibuprofen</e1> is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of <e2>cyclooxygenases</e2>.","Downregulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Downregulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Downregulator"
"A molecular mechanism for <e1>ibuprofen</e1>-mediated <e2>RhoA</e2> inhibition in neurons.","Downregulator"
"In addition, another study suggests that <e1>ibuprofen</e1> reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the <e2>gamma-secretase complex</e2>.","Downregulator"
"Of these, the <e2>thrombin</e2> inhibitor <e1>dabigatran</e1> and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.","Downregulator"
"Of these, the thrombin inhibitor dabigatran and <e2>factor Xa</e2> inhibitor <e1>rivaroxaban</e1> have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.","Downregulator"
"In addition, the <e2>factor Xa</e2> inhibitor <e1>apixaban</e1> is in late-stage clinical development.","Downregulator"
"We determined whether an angiotensin-converting enzyme (ACE) inhibitor, <e1>captopril</e1>, inhibits <e2>MMP-2</e2> activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","Regulator"
"We determined whether an angiotensin-converting enzyme (ACE) inhibitor, <e1>captopril</e1>, inhibits <e2>MMP-2</e2> activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","Regulator"
"We determined whether an angiotensin-converting enzyme (ACE) inhibitor, <e1>captopril</e1>, inhibits <e2>MMP-2</e2> activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","Regulator"
"We determined whether an <e2>angiotensin-converting enzyme</e2> (ACE) inhibitor, <e1>captopril</e1>, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","Downregulator"
"We determined whether an angiotensin-converting enzyme (<e2>ACE</e2>) inhibitor, <e1>captopril</e1>, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","Downregulator"
"We determined whether an angiotensin-converting enzyme (ACE) inhibitor, <e1>captopril</e1>, inhibits <e2>MMP-2</e2> activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","Downregulator"
"RESULTS: <e1>Captopril</e1> directly inhibited <e2>MMP-2</e2> activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion.","Downregulator"
"We determined whether an angiotensin-converting enzyme (ACE) inhibitor, <e1>captopril</e1>, inhibits <e2>MMP-2</e2> activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","Downregulator"
"We determined whether an angiotensin-converting enzyme (<e2>ACE</e2>) inhibitor, <e1>captopril</e1>, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.","Downregulator"
"<e1>Captopril</e1> directly inhibits <e2>matrix metalloproteinase-2</e2> activity in continuous ambulatory peritoneal dialysis therapy.","Downregulator"
"Phenformin but not <e1>metformin</e1> inhibits a number of variants of <e2>K(ATP)</e2> including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Not"
"Phenformin but not <e1>metformin</e1> inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (<e2>Kir6.1</e2>/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Not"
"Phenformin but not <e1>metformin</e1> inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/<e2>SUR2B</e2> and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Not"
"Phenformin but not <e1>metformin</e1> inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and <e2>Kir6.2</e2>/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Not"
"Phenformin but not <e1>metformin</e1> inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/<e2>SUR2B</e2> and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Not"
"Phenformin but not <e1>metformin</e1> inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and <e2>Kir6.2</e2>/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Not"
"Phenformin but not <e1>metformin</e1> inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/<e2>SUR1</e2>).","Not"
"These findings suggest that <e1>phenformin</e1> interacts directly with the pore-forming <e2>Kir6.0</e2> subunit however the sulphonylurea receptor is able to significantly modulate the affinity.","Regulator"
"Additionally, <e1>phenformin</e1> inhibited the current elicited through the Kir6.2DeltaC26 (functional without <e2>SUR</e2>) channel with an IC50 of 1.78 mM.","Regulator"
"These findings suggest that <e1>phenformin</e1> interacts directly with the pore-forming Kir6.0 subunit however the <e2>sulphonylurea receptor</e2> is able to significantly modulate the affinity.","Regulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (<e2>Kir6.1</e2>/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Downregulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/<e2>SUR2B</e2> and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Downregulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of <e2>K(ATP)</e2> including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Downregulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (<e2>Kir6.1</e2>/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Downregulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/<e2>SUR2B</e2> and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Downregulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and <e2>Kir6.2</e2>/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Downregulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/<e2>SUR2B</e2> and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Downregulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and <e2>Kir6.2</e2>/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).","Downregulator"
"<e1>Phenformin</e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/<e2>SUR1</e2>).","Downregulator"
"<e1>Phenformin</e1> has a direct inhibitory effect on the <e2>ATP-sensitive potassium channel</e2>.","Downregulator"
"The extent and rate of inhibition are similar to that seen with the known <e2>K(ATP)</e2> blocker <e1>PNU 37883A</e1>.","Downregulator"
"Additionally, <e1>phenformin</e1> inhibited the current elicited through the <e2>Kir6.2DeltaC26</e2> (functional without SUR) channel with an IC50 of 1.78 mM.","Downregulator"
"In this study, we compared the effects of <e1>paricalcitol</e1> and doxercalciferol on regulating serum Ca and PTH, and also the expression of PTH, <e2>VDR</e2>, and CaSR mRNA.","Regulator"
"In this study, we compared the effects of paricalcitol and <e1>doxercalciferol</e1> on regulating serum Ca and PTH, and also the expression of PTH, <e2>VDR</e2>, and CaSR mRNA.","Regulator"
"Different VDRAs are known to have differential effects on serum calcium (<e1>Ca</e1>), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the <e2>Ca-sensing receptor</e2> (CaSR).","Regulator"
"Different VDRAs are known to have differential effects on serum calcium (<e1>Ca</e1>), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (<e2>CaSR</e2>).","Regulator"
"In this study, we compared the effects of <e1>paricalcitol</e1> and doxercalciferol on regulating serum Ca and PTH, and also the expression of PTH, VDR, and <e2>CaSR</e2> mRNA.","Upregulator"
"Different VDRAs are known to have differential effects on serum calcium (<e1>Ca</e1>), which may also affect serum <e2>PTH</e2> levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR).","Upregulator"
"In this study, we compared the effects of <e1>paricalcitol</e1> and doxercalciferol on regulating serum Ca and <e2>PTH</e2>, and also the expression of PTH, VDR, and CaSR mRNA.","Downregulator"
"In this study, we compared the effects of paricalcitol and <e1>doxercalciferol</e1> on regulating serum Ca and <e2>PTH</e2>, and also the expression of PTH, VDR, and CaSR mRNA.","Downregulator"
"In this study, we compared the effects of <e1>paricalcitol</e1> and doxercalciferol on regulating serum Ca and <e2>PTH</e2>, and also the expression of PTH, VDR, and CaSR mRNA.","Downregulator"
"In this study, we compared the effects of paricalcitol and <e1>doxercalciferol</e1> on regulating serum Ca and <e2>PTH</e2>, and also the expression of PTH, VDR, and CaSR mRNA.","Downregulator"
"In this study, we compared the effects of <e1>paricalcitol</e1> and doxercalciferol on regulating serum Ca and <e2>PTH</e2>, and also the expression of PTH, VDR, and CaSR mRNA.","Downregulator"
"In this study, we compared the effects of paricalcitol and <e1>doxercalciferol</e1> on regulating serum Ca and <e2>PTH</e2>, and also the expression of PTH, VDR, and CaSR mRNA.","Downregulator"
"<e1>Thalidomide</e1> initiates its teratogenic effects by binding to <e2>CRBN</e2> and inhibiting the associated ubiquitin ligase activity.","Regulator"
"<e1>Thalidomide</e1> initiates its teratogenic effects by binding to CRBN and inhibiting the associated <e2>ubiquitin ligase</e2> activity.","Downregulator"
"<e1>Telmisartan</e1> is an <e2>angiotensin II receptor</e2> blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.","Downregulator"
"With the pentapeptide linked through the C7alpha position of <e1>estradiol</e1>, the resulting PROTAC shows the most effective ER degradation and highest affinity for the <e2>estrogen receptor</e2>.","Regulator"
"The <e2>ER</e2>-targeting PROTACs are composed of an <e1>estradiol</e1> on one end and a hypoxia-inducing factor 1alpha (HIF-1alpha)-derived synthetic pentapeptide on the other.","Regulator"
"The <e2>ER</e2>-targeting PROTACs are composed of an <e1>estradiol</e1> on one end and a hypoxia-inducing factor 1alpha (HIF-1alpha)-derived synthetic pentapeptide on the other.","Downregulator"
"Recent studies indicate that <e1>tamoxifen</e1> initially acts as an antagonist, but later functions as an <e2>ER</e2> agonist, promoting tumor growth.","Agonist"
"Recent studies indicate that <e1>tamoxifen</e1> initially acts as an antagonist, but later functions as an <e2>ER</e2> agonist, promoting tumor growth.","Antagonist"
"denopamine for beta(1); clenbuterol, AZ 40140d, <e1>salbutamol</e1> for <e2>beta(2)</e2>) were found to have subtype-selective intrinsic efficacy.","Regulator"
"<e1>denopamine</e1> for <e2>beta(1)</e2>; clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy.","Regulator"
"denopamine for beta(1); <e1>clenbuterol</e1>, AZ 40140d, salbutamol for <e2>beta(2)</e2>) were found to have subtype-selective intrinsic efficacy.","Regulator"
"denopamine for beta(1); clenbuterol, <e1>AZ 40140d</e1>, salbutamol for <e2>beta(2)</e2>) were found to have subtype-selective intrinsic efficacy.","Regulator"
"<e1>salmeterol</e1> and formoterol, for the <e2>beta(2)-adrenoceptor</e2> over the beta(1) or beta(3)), while others (e.g.","Agonist"
"<e1>salmeterol</e1> and formoterol, for the beta(2)-adrenoceptor over the <e2>beta(1)</e2> or beta(3)), while others (e.g.","Agonist"
"salmeterol and <e1>formoterol</e1>, for the <e2>beta(2)-adrenoceptor</e2> over the beta(1) or beta(3)), while others (e.g.","Agonist"
"salmeterol and <e1>formoterol</e1>, for the beta(2)-adrenoceptor over the beta(1) or <e2>beta(3)</e2>), while others (e.g.","Agonist"
"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the <e1>N-propargyl</e1> moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating <e2>Bcl-2</e2> family proteins.","Upregulator"
"<e1>Rasagiline</e1>: a novel anti-Parkinsonian <e2>monoamine oxidase-B</e2> inhibitor with neuroprotective activity.","Downregulator"
"<e1>Rasagiline</e1> (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible <e2>monoamine oxidase (MAO)-B</e2> inhibitor, anti-Parkinsonian drug.","Downregulator"
"Rasagiline (<e1>N-propargyl-1-(R)-aminoindan</e1>) is a novel, highly potent irreversible <e2>monoamine oxidase (MAO)-B</e2> inhibitor, anti-Parkinsonian drug.","Downregulator"
"Its S-isomer, <e1>TVP1022</e1> is thousand times less potent as an <e2>MAO-B</e2> inhibitor.","Downregulator"
"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of <e1>rasagiline</e1> does not depend on inhibition of <e2>MAO-B</e2>, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.","Downregulator"
"Supplementation with <e1>levothyroxine</e1> at a dose of >350 microg/day did not normalize the serum <e2>TSH</e2> level; however, the patient showed normal growth and intelligence at 14 years of age.","Not"
"Consistent with the results of a computer analysis, the binding of <e2>R316C</e2> to triiodothyronine (<e1>T3</e1>) was significantly decreased to 38% that of the wild type.","Regulator"
"Consistent with the results of a computer analysis, the binding of <e2>R316C</e2> to <e1>triiodothyronine</e1> (T3) was significantly decreased to 38% that of the wild type.","Regulator"
"Consistent with the results of a computer analysis, the binding of <e2>R316C</e2> to triiodothyronine (<e1>T3</e1>) was significantly decreased to 38% that of the wild type.","Regulator"
"However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with <e2>NCoR</e2> in the absence of <e1>T3</e1> and impaired release in the presence of T3.","Regulator"
"Supplementation with <e1>levothyroxine</e1> at a dose of >350 microg/day did not normalize the serum <e2>TSH</e2> level; however, the patient showed normal growth and intelligence at 14 years of age.","Upregulator"
"With exposure to <e1>rofecoxib</e1>, a selective <e2>COX-2</e2> inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.","Downregulator"
"With exposure to <e1>rofecoxib</e1>, a selective <e2>COX-2</e2> inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.","Downregulator"
"METHODS: We conducted a case-control study to measure the association between selective <e2>cox-2</e2> inhibitors, particularly <e1>celecoxib</e1>, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.","Downregulator"
"METHODS: We conducted a case-control study to measure the association between selective <e2>cox-2</e2> inhibitors, particularly celecoxib, <e1>rofecoxib</e1>, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.","Downregulator"
"METHODS: We conducted a case-control study to measure the association between selective <e2>cox-2</e2> inhibitors, particularly celecoxib, rofecoxib, <e1>valdecoxib</e1> and non-specific NSAID subgroups, and breast cancer risk.","Downregulator"
"BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<e1>steroidal</e1> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of <e2>cyclooxygenase-2</e2> (COX-2).","Downregulator"
"BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<e1>steroidal</e1> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (<e2>COX-2</e2>).","Downregulator"
"These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by <e1>SMS 201-995</e1> in a long-lasting manner possibly acting through <e2>CCK-A receptor</e2>.","Regulator"
"Intracerebroventricular administration of <e1>SMS 201-995</e1> (5 micrograms/rat), a <e2>somatostatin</e2> analogue, induced barrel rotation in rats.","Regulator"
"The suppressive effect of <e1>ceruletide</e1> on barrel rotation could be partially countered by MK-329, a selective peripheral <e2>CCK</e2> (CCK-A) receptor antagonist.","Downregulator"
"The suppressive effect of <e1>ceruletide</e1> on barrel rotation could be partially countered by MK-329, a selective peripheral CCK <e2>(CCK-A) receptor</e2> antagonist.","Downregulator"
"These findings suggest that <e1>ceruletide</e1> specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through <e2>CCK-A receptor</e2>.","Downregulator"
"The suppressive effect of ceruletide on barrel rotation could be partially countered by <e1>MK-329</e1>, a selective peripheral <e2>CCK</e2> (CCK-A) receptor antagonist.","Antagonist"
"The suppressive effect of ceruletide on barrel rotation could be partially countered by <e1>MK-329</e1>, a selective peripheral CCK <e2>(CCK-A) receptor</e2> antagonist.","Antagonist"
"The altered genes associated with <e1>chlorcyclizine</e1>-induced cleft palate included Wnt5a, <e2>Bmp2</e2>, Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).","Regulator"
"The altered genes associated with <e1>chlorcyclizine</e1>-induced cleft palate included Wnt5a, Bmp2, <e2>Bmp4</e2>, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).","Regulator"
"The altered genes associated with <e1>chlorcyclizine</e1>-induced cleft palate included Wnt5a, Bmp2, Bmp4, <e2>Fgf10</e2>, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).","Regulator"
"The altered genes associated with <e1>chlorcyclizine</e1>-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, <e2>Fgfr2</e2>, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).","Regulator"
"The altered genes associated with <e1>chlorcyclizine</e1>-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2, <e2>Msx1</e2>, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).","Regulator"
"The altered genes associated with <e1>chlorcyclizine</e1>-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and <e2>Insig1</e2> but the magnitude of the change was relatively small (1.5- to 2-fold).","Regulator"
"The altered genes associated with <e1>chlorcyclizine</e1>-induced cleft palate included <e2>Wnt5a</e2>, Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).","Regulator"
"Effects of the <e2>histamine H1</e2> antagonist <e1>chlorcyclizine</e1> on rat fetal palate development.","Antagonist"
"Effects of the <e2>histamine H1</e2> antagonist <e1>chlorcyclizine</e1> on rat fetal palate development.","Antagonist"
"Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane <e1>amino acids</e1> that were affinity labelled in purified <e2>bovine brain GABA(A)-R</e2>. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the beta/alpha interface.","Part_of"
"PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate <e2>GABA(A)-R</e2>-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of GABA(A)-R subunits of varying sensitivity led to identification of <e1>amino acid</e1> residues in the transmembrane domain that are critical for the drug actions in vitro.","Part_of"
"PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate <e2>GABA(A)-R</e2>-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of GABA(A)-R subunits of varying sensitivity led to identification of <e1>amino acid</e1> residues in the transmembrane domain that are critical for the drug actions in vitro.","Part_of"
"Using a photo incorporable analogue of the general anesthetic, <e1>R(+)etomidate</e1>, we identified two transmembrane amino acids that were affinity labelled in purified <e2>bovine brain GABA(A)-R</e2>. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the beta/alpha interface.","Regulator"
"The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the <e1>Ca2(+)</e1>-<e2>calmodulin</e2> interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01).","Regulator"
"The smooth muscle relaxant, <e1>W-7</e1>, which is believed relatively specific in inhibiting the Ca2(+)-<e2>calmodulin</e2> interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01).","Regulator"
"Role of extracellular <e1>calcium</e1> and calmodulin in <e2>prolactin</e2> secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells.","Regulator"
"The smooth muscle relaxant, <e1>W-7</e1>, which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced <e2>PRL</e2> secretion in a dose-dependent manner (r = -0.991, p less than 0.01).","Downregulator"
"Removing medium Ca2+, blocking <e2>Ca2+ channels</e2> with 50 mumol/l <e1>verapamil</e1>, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.","Downregulator"
"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting <e2>calmodulin</e2> activation with 20 mumol/l <e1>trifluoperazine</e1>, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.","Downregulator"
"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting <e2>calmodulin</e2> activation with 20 mumol/l trifluoperazine, 10 mumol/l <e1>chlorpromazine</e1> or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.","Downregulator"
"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting <e2>calmodulin</e2> activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l <e1>pimozide</e1> almost completely blocked hyposmolarity-induced secretion.","Downregulator"
"An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement <e1>spermine</e1> and this can be accomplished by breeding with CAG-<e2>SMS</e2> mice that express SpmS from a ubiquitous promoter.","Substrate"
"Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of <e1>spermine</e1>) is lethal, but male mice lacking spermine synthase (<e2>SpmS</e2>) due to a deletion of part of the X chromosome are viable on the B6C3H background.","Substrate"
"Treatment with <e1>cabozantinib</e1> inhibited <e2>MET</e2> and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.","Not"
"Treatment with <e1>cabozantinib</e1> inhibited MET and <e2>VEGF</e2>R2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.","Downregulator"
"Treatment with <e1>cabozantinib</e1> inhibited <e2>MET</e2> and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.","Downregulator"
"Treatment with <e1>cabozantinib</e1> inhibited MET and <e2>VEGFR</e2>2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.","Downregulator"
"<e1>Cabozantinib</e1> (XL184) is a small-molecule <e2>kinase</e2> inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.","Downregulator"
"<e1>Cabozantinib</e1> (XL184), a novel <e2>MET</e2> and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","Downregulator"
"<e1>Cabozantinib</e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and <e2>VEGF receptor 2</e2> (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.","Downregulator"
"<e1>Cabozantinib</e1> (XL184), a novel MET and <e2>VEGFR2</e2> inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","Downregulator"
"<e1>Cabozantinib</e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other <e2>receptor tyrosine kinases</e2> that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.","Downregulator"
"<e1>Cabozantinib</e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including <e2>RET</e2>, KIT, AXL, and FLT3.","Downregulator"
"<e1>Cabozantinib</e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, <e2>KIT</e2>, AXL, and FLT3.","Downregulator"
"<e1>Cabozantinib</e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, <e2>AXL</e2>, and FLT3.","Downregulator"
"<e1>Cabozantinib</e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and <e2>FLT3</e2>.","Downregulator"
"Cabozantinib (<e1>XL184</e1>) is a small-molecule <e2>kinase</e2> inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.","Downregulator"
"Cabozantinib (<e1>XL184</e1>), a novel <e2>MET</e2> and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","Downregulator"
"Cabozantinib (<e1>XL184</e1>) is a small-molecule kinase inhibitor with potent activity toward MET and <e2>VEGF receptor 2</e2> (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.","Downregulator"
"Cabozantinib (<e1>XL184</e1>), a novel MET and <e2>VEGFR2</e2> inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","Downregulator"
"Cabozantinib (<e1>XL184</e1>) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other <e2>receptor tyrosine kinases</e2> that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.","Downregulator"
"Cabozantinib (<e1>XL184</e1>) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including <e2>RET</e2>, KIT, AXL, and FLT3.","Downregulator"
"Cabozantinib (<e1>XL184</e1>) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, <e2>KIT</e2>, AXL, and FLT3.","Downregulator"
"Cabozantinib (<e1>XL184</e1>) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, <e2>AXL</e2>, and FLT3.","Downregulator"
"Cabozantinib (<e1>XL184</e1>) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and <e2>FLT3</e2>.","Downregulator"
"Treatment with <e1>cabozantinib</e1> inhibited <e2>MET</e2> and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.","Downregulator"
"Treatment with <e1>cabozantinib</e1> inhibited MET and <e2>VEGFR2</e2> phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.","Downregulator"
"<e1>Cabozantinib</e1> (XL184), a novel <e2>MET</e2> and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","Downregulator"
"<e1>Cabozantinib</e1> (XL184), a novel MET and <e2>VEGFR2</e2> inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","Downregulator"
"Cabozantinib (<e1>XL184</e1>), a novel <e2>MET</e2> and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","Downregulator"
"Cabozantinib (<e1>XL184</e1>), a novel MET and <e2>VEGFR2</e2> inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","Downregulator"
"<e1>Thiocolchicoside</e1> suppresses osteoclastogenesis induced by <e2>RANKL</e2> and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.","Regulator"
"<e1>Thiocolchicoside</e1> suppresses osteoclastogenesis induced by <e2>RANKL</e2> and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.","Regulator"
"To search for an inhibitor of cancer-induced bone loss, we investigated the effect of thio<e1>colchicoside</e1>, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of <e2>NF-kappaB</e2> ligand (RANKL) and tumour cells.","Downregulator"
"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside</e1> inhibited RANKL-induced NF-kappaB activation, activation of <e2>IkappaB kinase</e2> (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.","Downregulator"
"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside</e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (<e2>IKK</e2>) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.","Downregulator"
"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside</e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of <e2>NF-kappaBalpha</e2> (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.","Downregulator"
"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside</e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (<e2>IkappaBalpha</e2>) phosphorylation and degradation, an inhibitor of NF-kappaB.","Downregulator"
"To search for an inhibitor of cancer-induced bone loss, we investigated the effect of thio<e1>colchicoside</e1>, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of <e2>NF-kappaB</e2> ligand (RANKL) and tumour cells.","Downregulator"
"Thio<e1>colchicoside</e1> suppresses osteoclastogenesis induced by <e2>RANKL</e2> and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.","Downregulator"
"To search for an inhibitor of cancer-induced bone loss, we investigated the effect of <e1>thiocolchicoside</e1>, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (<e2>RANKL</e2>) and tumour cells.","Downregulator"
"To search for an inhibitor of cancer-induced bone loss, we investigated the effect of <e1>thiocolchicoside</e1>, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of <e2>NF-kappaB</e2> ligand (RANKL) and tumour cells.","Downregulator"
"Although genetic polymorphisms in the endothelial nitric oxide synthase (<e2>eNOS</e2>) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to <e1>sildenafil</e1>.","Regulator"
"Although genetic polymorphisms in the endothelial nitric oxide synthase (<e2>eNOS</e2>) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to <e1>sildenafil</e1>.","Regulator"
"<e2>Endothelial nitric oxide synthase</e2> genotypes and haplotypes modify the responses to <e1>sildenafil</e1> in patients with erectile dysfunction.","Regulator"
"Although genetic polymorphisms in the endothelial nitric oxide synthase (e<e1>NO</e1>S) gene may impair endogenous NO formation, there is little information about how <e2>eNOS</e2> polymorphisms and haplotypes affect the responses to sildenafil.","Substrate"
"Although genetic polymorphisms in the <e2>endothelial nitric oxide synthase</e2> (e<e1>NO</e1>S) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.","Substrate"
"Here, we report biochemical evidence that <e1>mercury</e1> alone induces <e2>NF-κB</e2> activation, resulting in the induced expression of COX-2 and iNOS.","Upregulator"
"Here, we report biochemical evidence that <e1>mercury</e1> alone induces NF-κB activation, resulting in the induced expression of <e2>COX-2</e2> and iNOS.","Upregulator"
"Here, we report biochemical evidence that <e1>mercury</e1> alone induces NF-κB activation, resulting in the induced expression of COX-2 and <e2>iNOS</e2>.","Upregulator"
"<e1>Mercury</e1> induces the expression of <e2>cyclooxygenase-2</e2> and inducible nitric oxide synthase.","Upregulator"
"<e1>Mercury</e1> induces the expression of cyclooxygenase-2 and <e2>inducible nitric oxide synthase</e2>.","Upregulator"
"Unexpectedly, both the <e2>mGluR(5)</e2>specific agonist, <e1>CHPG</e1>, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.","Agonist"
"Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the <e2>group II mGluR</e2> (mGlu(2/3)) agonist, <e1>LY379268</e1> (LY), induced a TTX-insensitive outward current/hyperpolarization.","Agonist"
"Both outward currents were significantly reduced by the <e2>mGluR</e2> antagonist <e1>MCPG</e1> and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.","Antagonist"
"Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific <e2>mGluR(5)</e2> antagonist <e1>MTEP</e1>.","Antagonist"
"We have examined the effectiveness of two novel <e2>Chk1</e2> selective inhibitors, <e1>AR323</e1> and AR678, in a panel of melanoma cell lines and normal cell types.","Downregulator"
"We have examined the effectiveness of two novel <e2>Chk1</e2> selective inhibitors, AR323 and <e1>AR678</e1>, in a panel of melanoma cell lines and normal cell types.","Downregulator"
"We investigated whether <e1>aspirin</e1> affects adenosine monophosphate-activated protein kinase (<e2>AMPK</e2>) and mTOR signaling in CRC cells.","Not"
"We investigated whether <e1>aspirin</e1> affects adenosine monophosphate-activated protein kinase (<e2>AMPK</e2>) and mTOR signaling in CRC cells.","Regulator"
"Aspirin and <e1>metformin</e1> (an activator of <e2>AMPK</e2>) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.","Upregulator"
"<e1>Aspirin</e1> changed nucleotide ratios and activated <e2>AMPK</e2> in CRC cells.","Upregulator"
"<e1>Aspirin</e1> inhibits mTOR signaling, activates <e2>AMP-activated protein kinase</e2>, and induces autophagy in colorectal cancer cells.","Upregulator"
"<e1>Aspirin</e1> changed nucleotide ratios and activated <e2>AMPK</e2> in CRC cells.","Upregulator"
"<e1>Aspirin</e1> changed nucleotide ratios and activated <e2>AMPK</e2> in CRC cells.","Upregulator"
"<e1>Aspirin</e1> inhibits <e2>mTOR</e2> signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.","Downregulator"
"<e1>Aspirin</e1> inhibits <e2>mTOR</e2> signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.","Downregulator"
"Aspirin and <e1>metformin</e1> (an activator of AMPK) increased inhibition of <e2>mTOR</e2> and Akt, as well as autophagy in CRC cells.","Downregulator"
"Aspirin and <e1>metformin</e1> (an activator of AMPK) increased inhibition of mTOR and <e2>Akt</e2>, as well as autophagy in CRC cells.","Downregulator"
"METHODS: The effects of <e1>aspirin</e1> on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (<e2>S6K1</e2>), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.","Downregulator"
"METHODS: The effects of <e1>aspirin</e1> on mTOR signaling, the ribosomal protein <e2>S6</e2>, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.","Downregulator"
"<e1>Aspirin</e1> inhibits <e2>mTOR</e2> signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.","Downregulator"
"<e1>Aspirin</e1> inhibits <e2>mTOR</e2> signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.","Downregulator"
"RESULTS: <e1>Aspirin</e1> reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors <e2>S6K1</e2> and 4E-BP1.","Downregulator"
"RESULTS: <e1>Aspirin</e1> reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and <e2>4E-BP1</e2>.","Downregulator"
"We investigated whether <e1>aspirin</e1> affects adenosine monophosphate-activated protein kinase (AMPK) and <e2>mTOR</e2> signaling in CRC cells.","Downregulator"
"We investigated whether <e1>aspirin</e1> affects adenosine monophosphate-activated protein kinase (AMPK) and <e2>mTOR</e2> signaling in CRC cells.","Downregulator"
"<e1>Aspirin</e1> inhibits <e2>mTOR</e2> signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.","Downregulator"
"<e1>Aspirin</e1> inhibits <e2>mTOR</e2> signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.","Downregulator"
"<e1>Aspirin</e1> and metformin (an activator of AMPK) increased inhibition of mTOR and <e2>Akt</e2>, as well as autophagy in CRC cells.","Downregulator"
"Oncogenic <e2>K-ras</e2> expression is associated with derangement of the cAMP/PKA pathway and <e1>forskolin</e1>-reversible alterations of mitochondrial dynamics and respiration.","Regulator"
"In previous papers, it has been shown that <e2>K-ras</e2> transformed mouse cells are much more sensitive as compared with normal cells to <e1>glucose</e1> withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of mitochondrial complex I.","Regulator"
"Oncogenic <e2>K-ras</e2> expression is associated with derangement of the cAMP/PKA pathway and <e1>forskolin</e1>-reversible alterations of mitochondrial dynamics and respiration.","Regulator"
"Oncogenic K-ras expression is associated with derangement of the cAMP/<e2>PKA</e2> pathway and <e1>forskolin</e1>-reversible alterations of mitochondrial dynamics and respiration.","Regulator"
"Oncogenic K-ras expression is associated with derangement of the cAMP/<e2>PKA</e2> pathway and <e1>forskolin</e1>-reversible alterations of mitochondrial dynamics and respiration.","Upregulator"
"Exogenous stimulation of PKA activity, achieved by <e1>forskolin</e1> treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced <e2>complex I</e2> activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.","Upregulator"
"In previous papers, it has been shown that <e2>K-ras</e2> transformed mouse cells are much more sensitive as compared with normal cells to <e1>glucose</e1> withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of mitochondrial complex I.","Downregulator"
"<e1>Berberine</e1> inhibits myofibroblast differentiation in nasal polyp-derived fibroblasts via the <e2>p38</e2> pathway.","Regulator"
"<e1>Berberine</e1> inhibits myofibroblast differentiation in nasal polyp-derived fibroblasts via the <e2>p38</e2> pathway.","Regulator"
"<e1>SB203580</e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of <e2>collagen type I</e2> and α-SMA in TGF-β1-induced NPDFs.","Downregulator"
"<e1>SB203580</e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and <e2>α-SMA</e2> in TGF-β1-induced NPDFs.","Downregulator"
"<e1>SB203580</e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and α-SMA in <e2>TGF-β1</e2>-induced NPDFs.","Downregulator"
"In <e2>TGF-β1</e2>-induced NPDFs, <e1>berberine</e1> significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and collagen protein levels.","Downregulator"
"In TGF-β1-induced NPDFs, <e1>berberine</e1> significantly inhibited the expression of <e2>α-SMA</e2> and collagen type I mRNA and reduced α-SMA and collagen protein levels.","Downregulator"
"In TGF-β1-induced NPDFs, <e1>berberine</e1> significantly inhibited the expression of α-SMA and <e2>collagen type I</e2> mRNA and reduced α-SMA and collagen protein levels.","Downregulator"
"In TGF-β1-induced NPDFs, <e1>berberine</e1> significantly inhibited the expression of <e2>α-SMA</e2> and collagen type I mRNA and reduced α-SMA and collagen protein levels.","Downregulator"
"In TGF-β1-induced NPDFs, <e1>berberine</e1> significantly inhibited the expression of α-SMA and <e2>collagen</e2> type I mRNA and reduced α-SMA and collagen protein levels.","Downregulator"
"<e1>Berberine</e1> only suppressed the expression of <e2>pp38</e2> among the evaluated signaling molecules.","Downregulator"
"<e1>SB203580</e1> (a specific inhibitor of <e2>p38</e2> kinase) markedly suppressed the increased expression of collagen type I and α-SMA in TGF-β1-induced NPDFs.","Downregulator"
"<e1>SB203580</e1> (a specific inhibitor of p38 <e2>kinase</e2>) markedly suppressed the increased expression of collagen type I and α-SMA in TGF-β1-induced NPDFs.","Downregulator"
"<e1>Lenalidomide</e1> and pomalidomide inhibited autoubiquitination of <e2>CRBN</e2> in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).","Not"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Not"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Regulator"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Regulator"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous CRBN and recombinant CRBN-<e2>DNA damage binding protein-1</e2> (DDB1) complexes.","Regulator"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (<e2>DDB1</e2>) complexes.","Regulator"
"The ubiquitously expressed E3 ligase protein cereblon (<e2>CRBN</e2>) has been identified as the primary teratogenic target of <e1>thalidomide</e1>.","Regulator"
"The ubiquitously expressed E3 ligase protein cereblon (<e2>CRBN</e2>) has been identified as the primary teratogenic target of <e1>thalidomide</e1>.","Regulator"
"The ubiquitously expressed E3 ligase protein cereblon (<e2>CRBN</e2>) has been identified as the primary teratogenic target of <e1>thalidomide</e1>.","Regulator"
"The ubiquitously expressed E3 ligase protein cereblon (<e2>CRBN</e2>) has been identified as the primary teratogenic target of <e1>thalidomide</e1>.","Regulator"
"Our studies demonstrate that <e1>thalidomide</e1>, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-<e2>DNA damage binding protein-1</e2> (DDB1) complexes.","Regulator"
"Our studies demonstrate that <e1>thalidomide</e1>, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (<e2>DDB1</e2>) complexes.","Regulator"
"Our studies demonstrate that thalidomide, <e1>lenalidomide</e1> and another immunomodulatory drug, pomalidomide, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Regulator"
"Our studies demonstrate that thalidomide, <e1>lenalidomide</e1> and another immunomodulatory drug, pomalidomide, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Regulator"
"Our studies demonstrate that thalidomide, <e1>lenalidomide</e1> and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-<e2>DNA damage binding protein-1</e2> (DDB1) complexes.","Regulator"
"Our studies demonstrate that thalidomide, <e1>lenalidomide</e1> and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (<e2>DDB1</e2>) complexes.","Regulator"
"Our studies demonstrate that thalidomide, <e1>lenalidomide</e1> and another immunomodulatory drug, pomalidomide, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Regulator"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Regulator"
"<e2>Cereblon</e2> is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and <e1>pomalidomide</e1>.","Regulator"
"<e2>Cereblon</e2> is a direct protein target for immunomodulatory and antiproliferative activities of <e1>lenalidomide</e1> and pomalidomide.","Regulator"
"Our studies demonstrate that thalidomide, <e1>lenalidomide</e1> and another immunomodulatory drug, pomalidomide, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Regulator"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Regulator"
"The ubiquitously expressed E3 ligase protein <e2>cereblon</e2> (CRBN) has been identified as the primary teratogenic target of <e1>thalidomide</e1>.","Regulator"
"The ubiquitously expressed E3 ligase protein cereblon (<e2>CRBN</e2>) has been identified as the primary teratogenic target of <e1>thalidomide</e1>.","Regulator"
"CRBN mediated antiproliferative activities of <e1>lenalidomide</e1> and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced <e2>cytokine</e2> production in T cells.","Upregulator"
"CRBN mediated antiproliferative activities of lenalidomide and <e1>pomalidomide</e1> in myeloma cells, as well as lenalidomide- and pomalidomide-induced <e2>cytokine</e2> production in T cells.","Upregulator"
"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>pomalidomide</e1>-mediated reductions in c-myc and IRF4 expression and increases in p21(<e2>WAF-1</e2>) expression.","Upregulator"
"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>pomalidomide</e1>-mediated reductions in c-myc and IRF4 expression and increases in <e2>p21</e2>(WAF-1) expression.","Upregulator"
"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>pomalidomide</e1>-mediated reductions in <e2>c-myc</e2> and IRF4 expression and increases in p21(WAF-1) expression.","Downregulator"
"Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>pomalidomide</e1>-mediated reductions in c-myc and <e2>IRF4</e2> expression and increases in p21(WAF-1) expression.","Downregulator"
"Our studies demonstrate that thalidomide, <e1>lenalidomide</e1> and another immunomodulatory drug, pomalidomide, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Downregulator"
"<e1>Lenalidomide</e1> and pomalidomide inhibited autoubiquitination of <e2>CRBN</e2> in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).","Downregulator"
"<e1>Lenalidomide</e1> and pomalidomide inhibited autoubiquitination of <e2>CRBN</e2> in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).","Downregulator"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Downregulator"
"Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, <e1>pomalidomide</e1>, bound endogenous <e2>CRBN</e2> and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.","Downregulator"
"These <e1>polyphenols</e1>, but not GvEx, showed a certain level of inhibition of human-cDNA-expressed <e2>CYPs</e2>.","Downregulator"
"Emerging data suggest that <e1>crizotinib</e1> may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the <e2>MET</e2> oncogene, or translocation of the ROS1 oncogene.","Regulator"
"Emerging data suggest that <e1>crizotinib</e1> may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the MET oncogene, or translocation of the <e2>ROS1</e2> oncogene.","Regulator"
"<e1>Crizotinib</e1> is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the <e2>ALK</e2> fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.","Regulator"
"<e1>Crizotinib</e1> is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the <e2>ALK</e2> fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.","Regulator"
"<e1>Crizotinib</e1> is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the <e2>ALK</e2> fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.","Downregulator"
"<e1>Crizotinib</e1> is an oral <e2>tyrosine kinase</e2> inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.","Downregulator"
"Central <e2>adenosine</e2>rgic system involvement in <e1>ethanol</e1>-induced motor incoordination in mice.","Regulator"
"Central <e2>adenosine</e2>rgic system involvement in <e1>ethanol</e1>-induced motor incoordination in mice.","Regulator"
"Central <e2>adenosine</e2>rgic system involvement in <e1>ethanol</e1>-induced motor incoordination in mice.","Regulator"
"Results from R-PIA and <e1>N6-(S-phenylisopropyl)adenosine</e1> experiments showed nearly a 40-fold greater potency of R-vs. S-diastereoisomer, suggesting predominance of <e2>adenosine A1</e2> subtype.","Regulator"
"Central <e2>adenosine</e2>rgic system involvement in <e1>ethanol</e1>-induced motor incoordination in mice.","Regulator"
"Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter <e1>ethanol</e1>'s motor incoordination, further supporting involvement of brain <e2>adenosine receptor</e2> mechanism(s) in ethanol-adenosine interactions.","Regulator"
"However, <e1>5'-(N-cyclopropyl)-carboxamidoadenosine</e1> data indicate complexity of the mechanism(s) and point toward an additional involvement of a yet unknown subtype of <e2>adenosine A2</e2>.","Regulator"
"Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter <e1>ethanol</e1>'s motor incoordination, further supporting involvement of brain <e2>adenosine receptor</e2> mechanism(s) in ethanol-adenosine interactions.","Regulator"
"<e1>Enprofylline</e1>, a weak adenosine antagonist but potent inhibitor of <e2>cyclic AMP phosphodiesterase</e2>, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.","Downregulator"
"<e2>adenosine</e2> agonists, <e1>N6-(R-phenylisopropyl)adenosine</e1> (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.","Agonist"
"<e2>adenosine</e2> agonists, N6-(R-phenylisopropyl)adenosine (<e1>R-PIA</e1>), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.","Agonist"
"<e2>adenosine</e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), <e1>N6-(S-phenylisopropyl)adenosine</e1>, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.","Agonist"
"<e2>adenosine</e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, <e1>5'-(N-cyclopropyl)-carboxamidoadenosine</e1>, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.","Agonist"
"<e2>adenosine</e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, <e1>theophylline</e1> and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.","Antagonist"
"<e2>adenosine</e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and <e1>8-p-(sulfophenyl)theophylline</e1> as well as enprofylline on ethanol-(i.p.","Antagonist"
"<e2>adenosine</e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as <e1>enprofylline</e1> on ethanol-(i.p.","Antagonist"
"<e1>Enprofylline</e1>, a weak <e2>adenosine</e2> antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.","Antagonist"
"<e1>Celastrol</e1>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased <e2>TGF-β</e2>1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.","Regulator"
"<e1>Celastrol</e1>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced <e2>NF-κB</e2> reporter gene activity.","Regulator"
"<e1>Celastrol</e1> also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and <e2>Annexin V</e2> markers of apoptosis.","Upregulator"
"<e1>Celastrol</e1>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased <e2>TGF-β1</e2>-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.","Downregulator"
"<e1>Celastrol</e1>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased <e2>TGF-β1</e2>-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.","Downregulator"
"<e1>Celastrol</e1>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and <e2>tumor necrosis factor-alpha</e2> (TNF-α)-induced NF-κB reporter gene activity.","Downregulator"
"<e1>Celastrol</e1>, a <e2>TAK1</e2> inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.","Downregulator"
"<e1>Celastrol</e1>, a <e2>TAK1</e2> inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.","Downregulator"
"<e1>Celastrol</e1>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and <e2>RELA</e2>, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.","Downregulator"
"<e1>Celastrol</e1>, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced <e2>NF-κB</e2> reporter gene activity.","Downregulator"
"<e1>Celastrol</e1>, a <e2>TAK1</e2> inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.","Downregulator"
"In <e1>[(35)S]GTPgammaS</e1> assays, mianserin selectively activated <e2>kappa-opioid receptor</e2>s.","Regulator"
"In <e1>[(35)S]GTPgammaS</e1> assays, mianserin selectively activated <e2>kappa-opioid receptors</e2>.","Regulator"
"In rat striatum and nucleus accumbens, mianserin stimulated <e1>[35S]GTPgammaS</e1> binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <e2>kappa-opioid</e2> agonists (-)-U50,488 and dynorphin A.","Regulator"
"<e1>Mianserin</e1> and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing <e2>kappa-opioid receptors</e2> and C6 cells, and these effects were antagonized by nor-BNI.","Regulator"
"Mianserin and <e1>mirtazapine</e1> increased ERK1/2 phosphorylation in CHO cells expressing <e2>kappa-opioid receptors</e2> and C6 cells, and these effects were antagonized by nor-BNI.","Regulator"
"Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing <e2>kappa-opioid receptors</e2> and C6 cells, and these effects were antagonized by <e1>nor-BNI</e1>.","Regulator"
"The atypical antidepressant <e1>mianserin</e1> exhibits agonist activity at <e2>kappa-opioid</e2> receptors.","Regulator"
"The agonist activity was antagonized by the selective <e2>kappa-opioid</e2> blocker nor-binaltorphimine (<e1>nor-BNI</e1>).","Regulator"
"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of <e2>p38</e2> MAPK and ERK1/2 phosphorylation by <e1>dynorphin A</e1>.","Upregulator"
"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 <e2>MAPK</e2> and ERK1/2 phosphorylation by <e1>dynorphin A</e1>.","Upregulator"
"The atypical antidepressant <e1>mianserin</e1> exhibits agonist activity at <e2>kappa-opioid receptors</e2>.","Upregulator"
"The atypical antidepressant <e1>mianserin</e1> exhibits agonist activity at <e2>kappa-opioid receptors</e2>.","Upregulator"
"The agonist activity was antagonized by the selective <e2>kappa-opioid</e2> blocker <e1>nor-binaltorphimine</e1> (nor-BNI).","Downregulator"
"The agonist activity was antagonized by the selective <e2>kappa-opioid</e2> blocker nor-binaltorphimine (<e1>nor-BNI</e1>).","Downregulator"
"When combined, <e1>mianserin</e1> antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of <e2>p38</e2> MAPK and ERK1/2 phosphorylation by dynorphin A.","Downregulator"
"EXPERIMENTAL APPROACH: Effects of <e1>mianserin</e1> were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and <e2>MAPK</e2> phosphorylation.","Downregulator"
"We previously reported that <e1>tricyclic</e1> antidepressants act as agonists at distinct <e2>opioid receptors</e2>.","Agonist"
"The atypical antidepressant <e1>mianserin</e1> exhibits agonist activity at <e2>kappa-opioid receptors</e2>.","Agonist"
"The atypical antidepressant <e1>mianserin</e1> exhibits agonist activity at <e2>kappa-opioid</e2> receptors.","Agonist"
"The mianserin analogue <e1>mirtazapine</e1> also displayed <e2>kappa-opioid</e2> agonist activity.","Agonist"
"The atypical antidepressant <e1>mianserin</e1> exhibits agonist activity at <e2>kappa-opioid receptors</e2>.","Agonist"
"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <e2>kappa-opioid</e2> agonists <e1>(-)-U50,488</e1> and dynorphin A.","Agonist"
"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <e2>kappa-opioid</e2> agonists (-)-U50,488 and <e1>dynorphin A</e1>.","Agonist"
"The agonist activity was antagonized by the selective <e2>kappa-opioid</e2> blocker <e1>nor-binaltorphimine</e1> (nor-BNI).","Antagonist"
"The agonist activity was antagonized by the selective <e2>kappa-opioid</e2> blocker nor-binaltorphimine (<e1>nor-BNI</e1>).","Antagonist"
"The atypical antidepressant <e1>mianserin</e1> exhibits agonist activity at <e2>kappa-opioid receptor</e2>s.","Antagonist"
"In the present study we tested whether <e1>propranolol</e1>, a <e2>β-receptor</e2> antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).","Antagonist"
"Effect of <e1>chalcones</e1> on lipid peroxidation, <e2>heme oxygenase 1</e2>(HO-1), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.","Regulator"
"Effect of <e1>chalcones</e1> on lipid peroxidation, heme oxygenase 1(<e2>HO-1</e2>), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.","Regulator"
"Effect of <e1>chalcones</e1> on lipid peroxidation, heme oxygenase 1(HO-1), <e2>cyclooxygenase</e2> (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.","Regulator"
"Effect of <e1>chalcones</e1> on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (<e2>COX</e2>), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.","Regulator"
"Effect of <e1>chalcones</e1> on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), <e2>interleukin 5</e2> (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.","Regulator"
"Effect of <e1>chalcones</e1> on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), interleukin 5 (<e2>IL-5</e2>), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.","Regulator"
"<e2>LXR</e2>s are thought to be activated predominantly by <e1>oxysterol</e1>s generated enzymatically from cholesterol in different cell organelles.","Regulator"
"<e2>LXR</e2>s are thought to be activated predominantly by <e1>oxysterol</e1>s generated enzymatically from cholesterol in different cell organelles.","Upregulator"
"<e2>LXRs</e2> are thought to be activated predominantly by <e1>oxysterols</e1> generated enzymatically from cholesterol in different cell organelles.","Upregulator"
"Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in <e2>sterol-27-hydroxylase</e2> activity lead to specific blocks in <e1>oxysterol</e1> production and impaired LXR-dependent gene activation.","Substrate"
"Mass spectral analysis of CBDP-inhibited <e2>BChE</e2> digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on <e1>lysine</e1> 499, a residue far from the active site, but not on His-438.","Part_of"
"Mass spectral analysis of CBDP-inhibited <e2>BChE</e2> digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on <e1>His</e1>-438.","Part_of"
"Cresyl saligenin phosphate makes multiple adducts on free <e1>histidine</e1>, but does not form an adduct on histidine 438 of <e2>human butyrylcholinesterase</e2>.","Part_of"
"CBDP irreversibly inhibits <e2>butyrylcholinesterase</e2> (BChE) in human plasma by forming adducts on the active site <e1>serine</e1> (Ser-198).","Part_of"
"CBDP irreversibly inhibits butyrylcholinesterase (<e2>BChE</e2>) in human plasma by forming adducts on the active site <e1>serine</e1> (Ser-198).","Part_of"
"CBDP irreversibly inhibits <e2>butyrylcholinesterase</e2> (BChE) in human plasma by forming adducts on the active site serine (<e1>Ser</e1>-198).","Part_of"
"CBDP irreversibly inhibits butyrylcholinesterase (<e2>BChE</e2>) in human plasma by forming adducts on the active site serine (<e1>Ser</e1>-198).","Part_of"
"Mass spectral analysis of CBDP-inhibited <e2>BChE</e2> digested with Glu-C showed an <e1>o-hydroxybenzyl</e1> adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.","Regulator"
"Mass spectral analysis of CBDP-inhibited <e2>BChE</e2> digested with <e1>Glu</e1>-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.","Regulator"
"<e1>Cresyl saligenin phosphate</e1> makes multiple adducts on free histidine, but does not form an adduct on histidine 438 of <e2>human butyrylcholinesterase</e2>.","Regulator"
"<e1>CBDP</e1> irreversibly inhibits butyrylcholinesterase (<e2>BChE</e2>) in human plasma by forming adducts on the active site serine (Ser-198).","Downregulator"
"<e1>CBDP</e1> irreversibly inhibits <e2>butyrylcholinesterase</e2> (BChE) in human plasma by forming adducts on the active site serine (Ser-198).","Downregulator"
"<e1>CBDP</e1> irreversibly inhibits butyrylcholinesterase (<e2>BChE</e2>) in human plasma by forming adducts on the active site serine (Ser-198).","Downregulator"
"We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by <e1>α-tocopherol</e1> in the rat dentate gyrus, increasing <e2>cyclic adenosine monophosphate response element binding protein</e2> phosphorylation.","Upregulator"
"After <e1>SU5416</e1> treatment, cell viability, <e2>PARP-1</e2>, and caspase-3 protein levels were not changed.","Not"
"After <e1>SU5416</e1> treatment, cell viability, PARP-1, and <e2>caspase-3</e2> protein levels were not changed.","Not"
"<e2>CCAAT/Enhancer-binding protein-homologous protein</e2> sensitizes to <e1>SU5416</e1> by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.","Regulator"
"CCAAT/Enhancer-binding protein-homologous protein sensitizes to <e1>SU5416</e1> by modulating <e2>p21</e2> and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.","Regulator"
"CCAAT/Enhancer-binding protein-homologous protein sensitizes to <e1>SU5416</e1> by modulating p21 and <e2>PI3K</e2>/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.","Regulator"
"CCAAT/Enhancer-binding protein-homologous protein sensitizes to <e1>SU5416</e1> by modulating p21 and PI3K/<e2>Akt</e2> signal pathway in FRO anaplastic thyroid carcinoma cells.","Regulator"
"CCAAT/Enhancer-binding protein-homologous protein sensitizes to <e1>SU5416</e1> by modulating <e2>p21</e2> and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.","Regulator"
"CCAAT/Enhancer-binding protein-homologous protein sensitizes to <e1>SU5416</e1> by modulating p21 and <e2>PI3K</e2>/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.","Regulator"
"CCAAT/Enhancer-binding protein-homologous protein sensitizes to <e1>SU5416</e1> by modulating p21 and PI3K/<e2>Akt</e2> signal pathway in FRO anaplastic thyroid carcinoma cells.","Regulator"
"Moreover, we investigated the roles of <e2>CHOP</e2> in cell survival under condition of <e1>SU5416</e1> treatment in FRO ATC cells.","Regulator"
"Moreover, we investigated the roles of <e2>CHOP</e2> in cell survival under condition of <e1>SU5416</e1> treatment in FRO ATC cells.","Regulator"
"<e1>Galantamine</e1> is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of <e2>nicotinic acetylcholine receptors</e2> (nAChR-APL) that shares many common structural elements with morphinan-based opioids.","Regulator"
"<e1>Galantamine</e1> is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (<e2>nAChR</e2>-APL) that shares many common structural elements with morphinan-based opioids.","Regulator"
"The structurally diverse opioids <e1>codeine</e1> and eseroline, like galantamine, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Regulator"
"The structurally diverse opioids <e1>codeine</e1> and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for <e2>AChE</e2>, representing potential lead compounds for selective nAChR-APL development.","Regulator"
"The structurally diverse opioids codeine and <e1>eseroline</e1>, like galantamine, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Regulator"
"The structurally diverse opioids codeine and <e1>eseroline</e1>, like galantamine, are also nAChR-APL that have greatly diminished affinity for <e2>AChE</e2>, representing potential lead compounds for selective nAChR-APL development.","Regulator"
"The structurally diverse opioids codeine and eseroline, like <e1>galantamine</e1>, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Regulator"
"The structurally diverse opioids codeine and eseroline, like <e1>galantamine</e1>, are also nAChR-APL that have greatly diminished affinity for <e2>AChE</e2>, representing potential lead compounds for selective nAChR-APL development.","Regulator"
"<e1>Galantamine</e1> is a reversible, competitive <e2>acetylcholinesterase</e2> (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.","Downregulator"
"<e1>Galantamine</e1> is a reversible, competitive acetylcholinesterase (<e2>AChE</e2>) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.","Downregulator"
"<e1>Galantamine</e1> is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of <e2>nicotinic acetylcholine receptors</e2> (nAChR-APL) that shares many common structural elements with morphinan-based opioids.","Modulator"
"<e1>Galantamine</e1> is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (<e2>nAChR</e2>-APL) that shares many common structural elements with morphinan-based opioids.","Modulator"
"The structurally diverse opioids <e1>codeine</e1> and eseroline, like galantamine, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Modulator"
"The structurally diverse opioids <e1>codeine</e1> and eseroline, like galantamine, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Modulator"
"The structurally diverse opioids codeine and <e1>eseroline</e1>, like galantamine, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Modulator"
"The structurally diverse opioids codeine and <e1>eseroline</e1>, like galantamine, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Modulator"
"The structurally diverse opioids codeine and eseroline, like <e1>galantamine</e1>, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Modulator"
"The structurally diverse opioids codeine and eseroline, like <e1>galantamine</e1>, are also <e2>nAChR</e2>-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.","Modulator"
"Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), <e2>GnRH</e2> analogues, <e1>Danazol</e1> and Levonorgestrel releasing intra uterine system (LNG IUS).","Regulator"
"Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), <e2>GnRH</e2> analogues, Danazol and <e1>Levonorgestrel</e1> releasing intra uterine system (LNG IUS).","Regulator"
"These results suggest that the regulation of nitrergic system by <e2>ERs</e2> may play a role in the control of <e1>oestrogen</e1>-dependent physiological mechanisms regulated by the SON and the PVN.","Regulator"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <e2>ERβ</e2> agonist-<e1>DPN</e1> [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Agonist"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <e2>ERβ</e2> agonist-DPN [<e1>2,3-bis(4-hydroxyphenyl)-propionitrile</e1>], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Agonist"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>ERα</e2> agonist-<e1>PPT</e1> [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Agonist"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>ERα</e2> agonist-PPT [<e1>4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol</e1>], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Agonist"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>ERα</e2> agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-<e1>MPP</e1> [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Antagonist"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>ERα</e2> agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [<e1>1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol</e1>]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Antagonist"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>ERα</e2> agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-<e1>1H-pyrazole dihydrochloride</e1>] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Antagonist"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <e2>ERβ</e2> agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-<e1>PHTPP</e1> (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).","Antagonist"
"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <e2>ERβ</e2> agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (<e1>4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol</e1>).","Antagonist"
"Modulation of the <e1>nitric oxide</e1> producing system (demonstrated via the <e2>NADPH-diaphorase</e2> histochemical reaction) by oestradiol has been established in several structures of the rat brain.","Substrate"
"The residence time of a stoichiometric bioscavenger, human butyrylcholinesterase (<e2>huBuChE</e2>), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs (<e1>oxime</e1>, anti-muscarinic, anticonvulsant).","Regulator"
"The residence time of a stoichiometric bioscavenger, <e2>human butyrylcholinesterase</e2> (huBuChE), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs (<e1>oxime</e1>, anti-muscarinic, anticonvulsant).","Regulator"
"The residence time of a stoichiometric bioscavenger, human butyrylcholinesterase (<e2>huBuChE</e2>), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs (<e1>oxime</e1>, anti-muscarinic, anticonvulsant).","Regulator"
"Therefore, we examined whether <e1>verrucarin A</e1> (VA) sensitize <e2>TRAIL</e2>-induced apoptosis in cancer cells by induction of ER stress.","Regulator"
"<e1>Verrucarin A</e1> sensitizes <e2>TRAIL</e2>-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner.","Regulator"
"Furthermore, <e1>salubrinal</e1>, a specific <e2>eIF2α</e2> phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA.","Upregulator"
"Furthermore, <e1>salubrinal</e1>, a specific eIF2α phosphorylation-inducing agent, increased <e2>CHOP</e2> and DR5 expression in the presence of VA.","Upregulator"
"Furthermore, <e1>salubrinal</e1>, a specific eIF2α phosphorylation-inducing agent, increased CHOP and <e2>DR5</e2> expression in the presence of VA.","Upregulator"
"<e1>Verrucarin A</e1> sensitizes TRAIL-induced apoptosis via the upregulation of <e2>DR5</e2> in an eIF2α/CHOP-dependent manner.","Upregulator"
"<e1>Verrucarin A</e1> sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an <e2>eIF2α</e2>/CHOP-dependent manner.","Upregulator"
"<e1>Verrucarin A</e1> sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/<e2>CHOP</e2>-dependent manner.","Upregulator"
"Though microtubule mediated actin remodeling through PKCζ, reorganization of microtubule depended on <e1>tyrosine</e1> phosphorylation of <e2>insulin receptor</e2>, the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and PKCζ.","Part_of"
"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface <e1>glucose</e1> transporter isoform 4 (GLUT4) and glucose uptake.","Substrate"
"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface <e1>glucose</e1> transporter isoform 4 (<e2>GLUT4</e2>) and glucose uptake.","Substrate"
"Androstanol and <e1>androstenol</e1>, estrone, 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both <e2>CARs</e2>.","Regulator"
"Androstanol and androstenol, <e1>estrone</e1>, 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both <e2>CARs</e2>.","Regulator"
"Androstanol and androstenol, estrone, <e1>17β-estradiol</e1>, TCPOBOP, and CITCO showed compound-specific but similar affinities for both <e2>CARs</e2>.","Regulator"
"Androstanol and androstenol, estrone, 17β-estradiol, <e1>TCPOBOP</e1>, and CITCO showed compound-specific but similar affinities for both <e2>CARs</e2>.","Regulator"
"Androstanol and androstenol, estrone, 17β-estradiol, TCPOBOP, and <e1>CITCO</e1> showed compound-specific but similar affinities for both <e2>CARs</e2>.","Regulator"
"<e1>Androstanol</e1> and androstenol, estrone, 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both <e2>CARs</e2>.","Regulator"
"Other groups received either an infusion of the selective <e2>NMDA receptor</e2> antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to <e1>PILO</e1> preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).","Regulator"
"Other groups received either an infusion of the selective <e2>NMDA receptor</e2> antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to <e1>PILO</e1> preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).","Regulator"
"Other groups received either an infusion of the selective <e2>NMDA receptor</e2> antagonist (<e1>AP7</e1>; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).","Downregulator"
"Other groups received either an infusion of the selective <e2>NMDA receptor</e2> antagonist (<e1>AP7</e1>; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).","Antagonist"
"We recently showed that <e1>TETA</e1> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (<e2>SSAT1</e2>) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).","Substrate"
"However, SSAT1-deficient mice metabolize <e1>TETA</e1> at the same rate as the wild-type mice, indicating the existence of another <e2>N-acetylase</e2> respons 2ible for its metabolism in mice.","Substrate"
"We recently showed that <e1>TETA</e1> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (<e2>SSAT2</e2>) to its monoacetylated derivative (MAT).","Substrate"
"By contrast, <e1>1,12-diamino-3,6,9-triazadodecane</e1>(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>SSAT1</e2> in HEPG2 cells and in wild-type primary hepatocytes.","Substrate"
"By contrast, <e1>1,12-diamino-3,6,9-triazadodecane</e1>(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of <e2>human recombinant SSAT2</e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.","Substrate"
"By contrast, 1,12-diamino-3,6,9-triazadodecane(<e1>SpmTrien</e1>), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>SSAT1</e2> in HEPG2 cells and in wild-type primary hepatocytes.","Substrate"
"By contrast, 1,12-diamino-3,6,9-triazadodecane(<e1>SpmTrien</e1>), a charge-deficient spermine analog, was an extremely poor substrate of <e2>human recombinant SSAT2</e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.","Substrate"
"We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/<e1>spermine</e1>-N(1)-acetyltransferase (<e2>SSAT1</e2>) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).","Substrate"
"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient <e1>spermine</e1> analog, was an extremely poor substrate of <e2>human recombinant SSAT2</e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.","Substrate"
"Metabolism of <e1>triethylenetetramine</e1> and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and <e2>thialysine acetyltransferase</e2>.","Substrate"
"Metabolism of <e1>triethylenetetramine</e1> and 1,12-diamino-3,6,9-triazadodecane by the <e2>spermidine/spermine-N(1)-acetyltransferase</e2> and thialysine acetyltransferase.","Substrate"
"Metabolism of triethylenetetramine and <e1>1,12-diamino-3,6,9-triazadodecane</e1> by the spermidine/spermine-N(1)-acetyltransferase and <e2>thialysine acetyltransferase</e2>.","Substrate"
"Metabolism of triethylenetetramine and <e1>1,12-diamino-3,6,9-triazadodecane</e1> by the <e2>spermidine/spermine-N(1)-acetyltransferase</e2> and thialysine acetyltransferase.","Substrate"
"We recently showed that <e1>TETA</e1> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (<e2>SSAT2</e2>) to its monoacetylated derivative (MAT).","Substrate"
"By contrast, 1,12-diamino-3,6,9-triazadodecane(<e1>SpmTrien</e1>), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>SSAT1</e2> in HEPG2 cells and in wild-type primary hepatocytes.","Substrate"
"We recently showed that <e1>TETA</e1> is metabolized in vitro by polyamine catabolic enzyme <e2>spermidine/spermine-N(1)-acetyltransferase</e2> (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).","Substrate"
"We recently showed that <e1>TETA</e1> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (<e2>SSAT1</e2>) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).","Substrate"
"We recently showed that <e1>TETA</e1> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by <e2>thialysine acetyltransferase</e2> (SSAT2) to its monoacetylated derivative (MAT).","Substrate"
"We recently showed that <e1>TETA</e1> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (<e2>SSAT2</e2>) to its monoacetylated derivative (MAT).","Substrate"
"We recently showed that TETA is metabolized in vitro by <e1>polyamine</e1> catabolic enzyme <e2>spermidine/spermine-N(1)-acetyltransferase</e2> (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).","Substrate"
"We recently showed that TETA is metabolized in vitro by <e1>polyamine</e1> catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (<e2>SSAT1</e2>) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).","Substrate"
"<e2>Cytochrome b5</e2> has shown to be an essential component in P450 3A4 catalyzed <e1>5-hydroxyelzasonan</e1> formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.","Regulator"
"In vitro metabolism of the <e2>5-hydroxytryptamine1B</e2> receptor antagonist <e1>elzasonan</e1>.","Antagonist"
"Cytochrome b5 has shown to be an essential component in <e2>P450 3A4</e2> catalyzed <e1>5-hydroxyelzasonan</e1> formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.","Substrate"
"The metabolism of <e1>elzasonan</e1> has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes (<e2>rCYP</e2>).","Substrate"
"The mutant Fc domain (<e2>AglycoT-Fc1004</e2>) contained a total of 5 <e1>amino acid</e1> substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:FcγRIIb).","Part_of"
"The mutant Fc domain (AglycoT-Fc1004) contained a total of 5 <e1>amino acid</e1> substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; <e2>FcyRIIa</e2>-R131:FcγRIIb).","Part_of"
"The mutant Fc domain (AglycoT-Fc1004) contained a total of 5 <e1>amino acid</e1> substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:<e2>FcγRIIb</e2>).","Part_of"
"The mutant <e2>Fc domain</e2> (AglycoT-Fc1004) contained a total of 5 <e1>amino acid</e1> substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:FcγRIIb).","Part_of"
"Valpromide (<e1>VPD</e1>), the amide derivative of VPA, does not inhibit <e2>HDAC</e2> activity and is a weak teratogen in vivo.","Not"
"Valpromide (<e1>VPD</e1>), the amide derivative of VPA, does not inhibit <e2>HDAC</e2> activity and is a weak teratogen in vivo.","Not"
"<e1>Valpromide</e1> (VPD), the amide derivative of VPA, does not inhibit <e2>HDAC</e2> activity and is a weak teratogen in vivo.","Not"
"Valpromide (<e1>VPD</e1>), the amide derivative of VPA, does not inhibit <e2>HDAC</e2> activity and is a weak teratogen in vivo.","Not"
"Valpromide (VPD), the <e1>amide</e1> derivative of VPA, does not inhibit <e2>HDAC</e2> activity and is a weak teratogen in vivo.","Not"
"In utero exposure to valproic acid (<e1>VPA</e1>), a histone deacetylase (<e2>HDAC</e2>) inhibitor, causes neural tube, heart, and limb defects.","Not"
"The signaling of both <e2>Sox9</e2> and Runx2, key regulators of chondrogenesis, was downregulated by <e1>VPA</e1>.","Downregulator"
"The signaling of both Sox9 and <e2>Runx2</e2>, key regulators of chondrogenesis, was downregulated by <e1>VPA</e1>.","Downregulator"
"In utero exposure to valproic acid (<e1>VPA</e1>), a histone deacetylase (<e2>HDAC</e2>) inhibitor, causes neural tube, heart, and limb defects.","Downregulator"
"In utero exposure to <e1>valproic acid</e1> (VPA), a <e2>histone deacetylase</e2> (HDAC) inhibitor, causes neural tube, heart, and limb defects.","Downregulator"
"In utero exposure to <e1>valproic acid</e1> (VPA), a histone deacetylase (<e2>HDAC</e2>) inhibitor, causes neural tube, heart, and limb defects.","Downregulator"
"In utero exposure to valproic acid (<e1>VPA</e1>), a <e2>histone deacetylase</e2> (HDAC) inhibitor, causes neural tube, heart, and limb defects.","Downregulator"
"In utero exposure to valproic acid (<e1>VPA</e1>), a histone deacetylase (<e2>HDAC</e2>) inhibitor, causes neural tube, heart, and limb defects.","Downregulator"
"Activation of <e2>caspases</e2> 9 and 3/7 was observed in <e1>AMD</e1>/TNF-cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity.","Upregulator"
"<e1>α-TOCO</e1> plus a <e2>pancaspase</e2> inhibitor completely abolished AMD/TNF-induced cytotoxicity.","Downregulator"
"Studies have indicated that the three-dimensional structure and the domains of <e2>HuBChE</e2> (<e1>acyl</e1> pocket, lip of the active center gorge, and the anionic substrate-binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs.","Part_of"
"<e1>Amino acid</e1> residues at the N- and C-termini are essential for the folding of active <e2>human butyrylcholinesterase</e2> polypeptide.","Part_of"
"Human serum butyrylcholinesterase (<e2>HuBChE</e2>) is currently the most suitable bioscavenger for the prophylaxis of highly toxic <e1>organophosphate</e1> (OP) nerve agents.","Substrate"
"<e2>Human serum butyrylcholinesterase</e2> (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic <e1>organophosphate</e1> (OP) nerve agents.","Substrate"
"Claudin-3 and claudin-4 regulate sensitivity to <e1>cisplatin</e1> by controlling expression of the copper and cisplatin influx transporter <e2>CTR1</e2>.","Regulator"
"Claudin-3 and claudin-4 regulate sensitivity to <e1>cisplatin</e1> by controlling expression of the <e2>copper and cisplatin influx transporter</e2> CTR1.","Regulator"
"<e2>Claudin-3</e2> and claudin-4 regulate sensitivity to <e1>cisplatin</e1> by controlling expression of the copper and cisplatin influx transporter CTR1.","Regulator"
"Claudin-3 and <e2>claudin-4</e2> regulate sensitivity to <e1>cisplatin</e1> by controlling expression of the copper and cisplatin influx transporter CTR1.","Regulator"
"<e1>Cu</e1>-dependent <e2>tyrosinase</e2> activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA.","Regulator"
"Cu-dependent <e2>tyrosinase</e2> activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate <e1>l-DOPA</e1>.","Substrate"
"Protein expression of <e2>Ugt1a6</e2> also decreased and corresponded with reduced in vitro glucuronidation of <e1>bisphenol A</e1> in S9 fractions from livers of pregnant mice.","Downregulator"
"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as <e2>NQO1</e2>, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of <e1>DMF</e1> on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","Regulator"
"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, <e2>HO-1</e2> and glutathione S-transferase (GST) did not reverse the inhibitory effect of <e1>DMF</e1> on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","Regulator"
"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and <e2>glutathione S-transferase</e2> (GST) did not reverse the inhibitory effect of <e1>DMF</e1> on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","Regulator"
"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (<e2>GST</e2>) did not reverse the inhibitory effect of <e1>DMF</e1> on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","Regulator"
"However, downregulation of the <e2>antioxidant response element</e2> (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of <e1>DMF</e1> on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","Regulator"
"However, downregulation of the antioxidant response element (<e2>ARE</e2>)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of <e1>DMF</e1> on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","Regulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates <e2>Nrf2</e2>, prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling.","Regulator"
"However, downregulation of the antioxidant response element (<e2>ARE</e2>)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of <e1>DMF</e1> on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","Regulator"
"However, downregulation of the antioxidant response element (<e2>ARE</e2>)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of <e1>DMF</e1> on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.","Regulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of <e2>TGF-beta</e2> signaling.","Regulator"
"<e1>Dimethylfumarate</e1> attenuates renal fibrosis via <e2>NF-E2-related factor 2</e2>-mediated inhibition of transforming growth factor-beta/Smad signaling.","Regulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates <e2>Nrf2</e2>, prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling.","Regulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates <e2>Nrf2</e2>, prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling.","Upregulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates <e2>Nrf2</e2>, prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling.","Upregulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates <e2>Nrf2</e2>, prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling.","Upregulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of <e2>TGF-beta</e2> signaling.","Downregulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of <e2>TGF-beta</e2> signaling.","Downregulator"
"Results showed that <e1>DMF</e1> increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased <e2>PAI-1</e2>, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Downregulator"
"Results showed that <e1>DMF</e1> increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, <e2>alpha-smooth muscle actin</e2> (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Downregulator"
"Results showed that <e1>DMF</e1> increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (<e2>alpha-SMA</e2>), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Downregulator"
"Results showed that <e1>DMF</e1> increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), <e2>fibronectin</e2> and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Downregulator"
"Results showed that <e1>DMF</e1> increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and <e2>type 1 collagen</e2> expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Downregulator"
"<e1>Dimethylfumarate</e1> attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/<e2>Smad</e2> signaling.","Downregulator"
"<e1>Dimethylfumarate</e1> attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of <e2>transforming growth factor-beta</e2>/Smad signaling.","Downregulator"
"Results showed that <e1>DMF</e1> increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (<e2>alpha-SMA</e2>), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Downregulator"
"Results showed that <e1>DMF</e1> increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), <e2>fibronectin</e2> and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Downregulator"
"Results showed that <e1>DMF</e1> increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and <e2>type 1 collagen</e2> expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).","Downregulator"
"Finally, <e1>DMF</e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and <e2>phospho-Smad3</e2>, respectively.","Downregulator"
"This study examines whether dimethylfumarate (<e1>DMF</e1>), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of <e2>TGF-beta</e2> signaling.","Downregulator"
"Additionally, <e1>DMF</e1> and Ad-Nrf2 repressed TGF-beta-stimulated <e2>Smad3</e2> activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.","Downregulator"
"Additionally, <e1>DMF</e1> and Ad-Nrf2 repressed TGF-beta-stimulated <e2>Smad3</e2> activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.","Downregulator"
"Additionally, <e1>DMF</e1> and Ad-Nrf2 repressed TGF-beta-stimulated <e2>Smad3</e2> activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.","Downregulator"
"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while <e2>osteocalcin</e2> (OCN) was augmented in CCL3(-/-) and <e1>Met</e1>-RANTES-treated mice.","Upregulator"
"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (<e2>OCN</e2>) was augmented in CCL3(-/-) and <e1>Met</e1>-RANTES-treated mice.","Upregulator"
"The expression of the osteoblast markers runt-related transcription factor 2 (<e2>RUNX2</e2>) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and <e1>Met</e1>-RANTES-treated mice.","Downregulator"
"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and <e2>periostin</e2> was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and <e1>Met</e1>-RANTES-treated mice.","Downregulator"
"The expression of the osteoblast markers <e2>runt-related transcription factor 2</e2> (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and <e1>Met</e1>-RANTES-treated mice.","Downregulator"
"mRNA levels of <e2>receptor activator of nuclear factor kappa-B</e2> (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with <e1>Met</e1>-RANTES.","Downregulator"
"mRNA levels of receptor activator of nuclear factor kappa-B (<e2>RANK</e2>), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with <e1>Met</e1>-RANTES.","Downregulator"
"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand <e2>RANKL</e2>, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with <e1>Met</e1>-RANTES.","Downregulator"
"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, <e2>tumor necrosis factor alpha</e2> (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with <e1>Met</e1>-RANTES.","Downregulator"
"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (<e2>TNF-α</e2>) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with <e1>Met</e1>-RANTES.","Downregulator"
"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand <e2>RANKL</e2>, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with <e1>Met</e1>-RANTES.","Downregulator"
"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/<e2>osteoprotegerin</e2> (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with <e1>Met</e1>-RANTES.","Downregulator"
"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (<e2>OPG</e2>) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with <e1>Met</e1>-RANTES.","Downregulator"
"<e1>Met</e1>-RANTES treatment also reduced the levels of <e2>cathepsin K</e2> and metalloproteinase 13 (MMP13).","Downregulator"
"<e1>Met</e1>-RANTES treatment also reduced the levels of cathepsin K and <e2>metalloproteinase 13</e2> (MMP13).","Downregulator"
"<e1>Met</e1>-RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (<e2>MMP13</e2>).","Downregulator"
"Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with <e1>Met</e1>-RANTES (an antagonist of <e2>CCR5</e2> and CCR1).","Antagonist"
"Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and <e2>CCR1</e2>(-/-) mice and in animals treated with <e1>Met</e1>-RANTES (an antagonist of CCR5 and CCR1).","Antagonist"
"The quinolizidine alkaloids (natural products) such as oxy<e1>matrine</e1>, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG</e2> blocking activity.","Downregulator"
"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of <e1>O=C=N-C-C-C-N</e1> that possessed positive ionotropic effect and <e2>hERG</e2> blocking activity.","Downregulator"
"The <e1>quinolizidine alkaloids</e1> (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG</e2> blocking activity.","Downregulator"
"The quinolizidine alkaloids (natural products) such as <e1>oxymatrine</e1>, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG</e2> blocking activity.","Downregulator"
"The quinolizidine alkaloids (natural products) such as oxymatrine, <e1>sophoridine</e1>, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG</e2> blocking activity.","Downregulator"
"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, <e1>sophocarpine</e1> and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG</e2> blocking activity.","Downregulator"
"Multifunctional targets of dietary <e1>polyphenols</e1> in disease: a case for the <e2>chemokine</e2> network and energy metabolism.","Regulator"
"Several effects of <e1>polyphenols</e1> are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, <e2>AMPK</e2> activators, calorie-restriction mimetics or epigenetic regulators.","Upregulator"
"Several effects of <e1>polyphenols</e1> are useful in this scenario, including a reduction in the activities of <e2>cytokines</e2> and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.","Downregulator"
"Several effects of <e1>polyphenols</e1> are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through <e2>histone deacetylase</e2> inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.","Downregulator"
"We use <e2>EGF</e2> as a metastatic inducer of MDA-MB-231 cells to investigate the effect of <e1>NFD</e1> on cell migration and invasion.","Downregulator"
"We use <e2>EGF</e2> as a metastatic inducer of MDA-MB-231 cells to investigate the effect of <e1>NFD</e1> on cell migration and invasion.","Downregulator"
"Furthermore, the EGFR inhibitor <e1>AG1478</e1> inhibited EGF-induced <e2>MMP-9</e2> expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Downregulator"
"<e1>NFD</e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (<e2>PI3K</e2>)/Akt.","Downregulator"
"<e1>NFD</e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/<e2>Akt</e2>.","Downregulator"
"<e1>NFD</e1> suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced <e2>MMP-9</e2> expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.","Downregulator"
"<e1>NFD</e1> suppressed EGF-mediated protein levels of <e2>c-Jun</e2> and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.","Downregulator"
"<e1>NFD</e1> suppressed EGF-mediated protein levels of c-Jun and <e2>c-Fos</e2>, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.","Downregulator"
"<e1>NFD</e1> suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced <e2>MMP-9</e2> expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.","Downregulator"
"Furthermore, the EGFR inhibitor <e1>AG1478</e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of <e2>PI3K</e2>/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Downregulator"
"Furthermore, the EGFR inhibitor <e1>AG1478</e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/<e2>Akt</e2>, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Downregulator"
"Furthermore, the <e2>EGFR</e2> inhibitor <e1>AG1478</e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Downregulator"
"Furthermore, the <e2>EGFR</e2> inhibitor <e1>AG1478</e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Downregulator"
"Furthermore, the <e2>EGF</e2>R inhibitor <e1>AG1478</e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Downregulator"
"Furthermore, the EGFR inhibitor <e1>AG1478</e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of <e2>PI3K</e2>/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Downregulator"
"Furthermore, the EGFR inhibitor <e1>AG1478</e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/<e2>Akt</e2>, suggesting that PI3K/Akt activation occur downstream of EGFR activation.","Downregulator"
"Inhibition of <e2>EGF</e2>/EGFR activation with <e1>naphtho[1,2-b]furan-4,5-dione</e1> blocks migration and invasion of MDA-MB-231 cells.","Downregulator"
"Inhibition of EGF/<e2>EGFR</e2> activation with <e1>naphtho[1,2-b]furan-4,5-dione</e1> blocks migration and invasion of MDA-MB-231 cells.","Downregulator"
"We use <e2>EGF</e2> as a metastatic inducer of MDA-MB-231 cells to investigate the effect of <e1>NFD</e1> on cell migration and invasion.","Downregulator"
"<e1>NFD</e1> abrogated EGF-induced phosphorylation of EGF receptor (<e2>EGFR</e2>) and phosphatidylinositol 3-kinase (PI3K)/Akt.","Downregulator"
"<e1>NFD</e1> suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced <e2>MMP-9</e2> expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.","Downregulator"
"<e1>NFD</e1> abrogated EGF-induced phosphorylation of <e2>EGF receptor</e2> (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.","Downregulator"
"<e1>NFD</e1> abrogated EGF-induced phosphorylation of EGF receptor (<e2>EGFR</e2>) and phosphatidylinositol 3-kinase (PI3K)/Akt.","Downregulator"
"<e1>NFD</e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and <e2>phosphatidylinositol 3-kinase</e2> (PI3K)/Akt.","Downregulator"
"<e1>NFD</e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (<e2>PI3K</e2>)/Akt.","Downregulator"
"<e1>NFD</e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/<e2>Akt</e2>.","Downregulator"
"The specific <e2>PI3K</e2> inhibitor, <e1>wortmannin</e1>, blocked significantly EGF-induced cell migration and invasion.","Downregulator"
"The specific PI3K inhibitor, <e1>wortmannin</e1>, blocked significantly <e2>EGF</e2>-induced cell migration and invasion.","Downregulator"
"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile</e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>insulin</e2> secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09</e1>), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>insulin</e2> secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide</e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>insulin</e2> secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile</e1> (ESI-09), a novel noncyclic nucleotide <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile</e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>Rap1</e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile</e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>Akt</e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile</e1> (ESI-09), a novel noncyclic nucleotide <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09</e1>), a novel noncyclic nucleotide <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09</e1>), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>Rap1</e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09</e1>), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>Akt</e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09</e1>), a novel noncyclic nucleotide <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide</e1> <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide</e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>Rap1</e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide</e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>Akt</e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide</e1> <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Downregulator"
"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile</e1> (ESI-09), a novel noncyclic nucleotide <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Antagonist"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09</e1>), a novel noncyclic nucleotide <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Antagonist"
"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide</e1> <e2>EPAC</e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.","Antagonist"
"To test whether <e1>Metformin</e1> directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (<e2>AMPK</e2>) were examined.","Regulator"
"<e1>Metformin</e1> directly inhibits ghrelin secretion through <e2>AMP-activated protein kinase</e2> in rat primary gastric cells.","Regulator"
"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the <e2>AMPK</e2> inhibitor compound C. Furthermore, the AMPK activator <e1>5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide</e1> (AICAR) significantly inhibited ghrelin secretion.","Upregulator"
"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the <e2>AMPK</e2> inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (<e1>AICAR</e1>) significantly inhibited ghrelin secretion.","Upregulator"
"Finally, <e1>Metformin</e1> treatment caused a significant increase in the level of <e2>phosphorylated (active) AMPK</e2>.","Upregulator"
"Metformin significantly reduced <e2>ghrelin</e2> secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor <e1>compound C</e1>. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.","Upregulator"
"Metformin significantly reduced ghrelin secretion and <e2>proghrelin</e2> mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor <e1>compound C</e1>. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.","Upregulator"
"<e1>Metformin</e1> directly inhibits <e2>ghrelin</e2> secretion through AMP-activated protein kinase in rat primary gastric cells.","Downregulator"
"<e1>Metformin</e1> treatment is also associated with lower circulating levels of the <e2>orexigenic hormone</e2> ghrelin.","Downregulator"
"<e1>Metformin</e1> directly inhibits <e2>ghrelin</e2> secretion through AMP-activated protein kinase in rat primary gastric cells.","Downregulator"
"<e1>Metformin</e1> directly inhibits <e2>ghrelin</e2> secretion through AMP-activated protein kinase in rat primary gastric cells.","Downregulator"
"<e1>Metformin</e1> directly inhibits <e2>ghrelin</e2> secretion through AMP-activated protein kinase in rat primary gastric cells.","Downregulator"
"To test whether <e1>Metformin</e1> directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, <e2>proghrelin</e2> gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined.","Downregulator"
"Metformin significantly reduced <e2>ghrelin</e2> secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (<e1>AICAR</e1>) significantly inhibited ghrelin secretion.","Downregulator"
"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the <e2>AMPK</e2> inhibitor <e1>compound C</e1>. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.","Downregulator"
"Fungicide <e1>prochloraz</e1> and environmental pollutant dioxin induce the <e2>ABCG2</e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.","Regulator"
"Fungicide prochloraz and environmental pollutant <e1>dioxin</e1> induce the <e2>ABCG2</e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.","Regulator"
"As these regulatory motifs mediate regulation of target genes by AhR agonists including <e1>TCDD</e1> and prochloraz, we have systematically investigated the effect of both contaminants on functional <e2>ABCG2</e2> transport activity in primary bovine mammary epithelial cells.","Regulator"
"Fungicide <e1>prochloraz</e1> and environmental pollutant dioxin induce the <e2>ABCG2</e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.","Regulator"
"Fungicide <e1>prochloraz</e1> and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the <e2>arylhydrocarbon receptor</e2> signaling pathway.","Regulator"
"Fungicide prochloraz and environmental pollutant <e1>dioxin</e1> induce the ABCG2 transporter in bovine mammary epithelial cells by the <e2>arylhydrocarbon receptor</e2> signaling pathway.","Regulator"
"As these regulatory motifs mediate regulation of target genes by AhR agonists including <e1>TCDD</e1> and prochloraz, we have systematically investigated the effect of both contaminants on functional <e2>ABCG2</e2> transport activity in primary bovine mammary epithelial cells.","Upregulator"
"Fungicide <e1>prochloraz</e1> and environmental pollutant dioxin induce the <e2>ABCG2</e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.","Upregulator"
"Fungicide <e1>prochloraz</e1> and environmental pollutant dioxin induce the <e2>ABCG2</e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.","Upregulator"
"Fungicide prochloraz and environmental pollutant <e1>dioxin</e1> induce the <e2>ABCG2</e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.","Upregulator"
"As these regulatory motifs mediate regulation of target genes by <e2>AhR</e2> agonists including <e1>TCDD</e1> and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.","Upregulator"
"As these regulatory motifs mediate regulation of target genes by <e2>AhR</e2> agonists including TCDD and <e1>prochloraz</e1>, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.","Upregulator"
"This effect was almost completely reversed by specific <e2>ABCG2</e2> inhibitor <e1>Ko143</e1>.","Downregulator"
"As these regulatory motifs mediate regulation of target genes by <e2>AhR</e2> agonists including <e1>TCDD</e1> and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.","Agonist"
"As these regulatory motifs mediate regulation of target genes by <e2>AhR</e2> agonists including TCDD and <e1>prochloraz</e1>, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.","Agonist"
"Receptor binding was significantly reduced by specific <e2>AhR</e2> antagonist <e1>salicyl amide</e1>.","Antagonist"
"TCDD or prochloraz doubled <e2>ABCG2</e2>-mediated <e1>Hoechst H33342</e1> secretion.","Substrate"
"We found that <e1>Ag</e1> NPs were highly cytotoxic to hepatocytes (LC(50) <e2>lactate dehydrogenase</e2>: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing albumin release.","Regulator"
"We observed similar effects of <e1>Ag</e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of <e2>interleukin-8</e2> (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.","Upregulator"
"We observed similar effects of <e1>Ag</e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (<e2>IL-8</e2>)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.","Upregulator"
"We observed similar effects of <e1>Ag</e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/<e2>macrophage inflammatory protein 2</e2>, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.","Upregulator"
"We observed similar effects of <e1>Ag</e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, <e2>IL-1RI</e2>, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.","Upregulator"
"We observed similar effects of <e1>Ag</e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and <e2>tumor necrosis factor-α</e2> expression in both models and increased IL-8 protein release in vitro.","Upregulator"
"We observed similar effects of <e1>Ag</e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (<e2>IL-8</e2>)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.","Upregulator"
"We found that <e1>Ag</e1> NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing <e2>albumin</e2> release.","Downregulator"
"Seven point mutations were introduced into the conserved motif in the second extracellular loop (<e2>ECII</e2>) of EP3, resulting in acquisition of <e1>GTP</e1>-sensitive agonist binding.","Not"
"Seven point mutations were introduced into the conserved motif in the second extracellular loop (<e2>ECII</e2>) of EP3, resulting in acquisition of <e1>GTP</e1>-sensitive agonist binding.","Not"
"Unlike the majority of G protein-coupled receptors, the <e2>prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor</e2> binds agonist with high affinity that is insensitive to the presence of <e1>guanosine 5[prime]-O-(3-thio)triphosphate</e1> (GTPγS).","Not"
"Unlike the majority of G protein-coupled receptors, the <e2>prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor</e2> binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (<e1>GTPγS</e1>).","Not"
"Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the <e2>W203A</e2> receptor, conditions where high GTP levels are present; however, high affinity binding <e1>[(3)H]PGE(2)</e1> was observed in broken cell preparations washed free of GTP.","Regulator"
"Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the <e2>W203A</e2> receptor, conditions where high GTP levels are present; however, high affinity binding <e1>[(3)H]PGE(2)</e1> was observed in broken cell preparations washed free of GTP.","Regulator"
"The [(3)H]PGE(2) binding of <e2>W203A</e2> in broken cell membrane fractions was inhibited by addition of <e1>GTPγS</e1> (IC(50) 21 ± 1.8 nM).","Regulator"
"This suggests that for the mutant receptors, ECII plays a critical role in linking the agonist bound receptor conformation to the <e2>G protein</e2> <e1>nucleotide</e1> bound state.","Regulator"
"<e2>Extracellular loop II</e2> modulates <e1>GTP</e1> sensitivity of the prostaglandin EP3 receptor.","Regulator"
"Extracellular loop II modulates <e1>GTP</e1> sensitivity of the <e2>prostaglandin EP3 receptor</e2>.","Regulator"
"Seven point mutations were introduced into the conserved motif in the <e2>second extracellular loop</e2> (ECII) of EP3, resulting in acquisition of <e1>GTP</e1>-sensitive agonist binding.","Regulator"
"Seven point mutations were introduced into the conserved motif in the second extracellular loop (<e2>ECII</e2>) of EP3, resulting in acquisition of <e1>GTP</e1>-sensitive agonist binding.","Regulator"
"Extracellular loop II modulates <e1>GTP</e1> sensitivity of the prostaglandin <e2>EP3</e2> receptor.","Regulator"
"Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the <e2>W203A</e2> receptor, conditions where high <e1>GTP</e1> levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of GTP.","Regulator"
"Blood pressure was increased in rats exposed to IH, and treatment with the <e2>PDK-1</e2> inhibitor <e1>OSU-03012</e1> [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats.","Downregulator"
"Blood pressure was increased in rats exposed to IH, and treatment with the <e2>PDK-1</e2> inhibitor OSU-03012 [<e1>2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide</e1>] (33 mg/day) lowered blood pressure in IH but not sham group rats.","Downregulator"
"Following <e1>CdCl₂</e1> treatment, <e2>ICAM2</e2> was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.","Regulator"
"Following <e1>CdCl₂</e1> treatment, <e2>ICAM2</e2> was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.","Upregulator"
"Following <e1>CdCl₂</e1> treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to <e2>actin</e2> during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.","Downregulator"
"The reaction was inhibited by the specific <e2>CYP2D</e2> inhibitors <e1>quinine</e1> and fluoxetine.","Downregulator"
"The reaction was inhibited by the specific <e2>CYP2D</e2> inhibitors quinine and <e1>fluoxetine</e1>.","Downregulator"
"Of the rat CYP isoforms studied, <e2>CYP2D</e2> isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>serotonin</e1>, but they were less effective than the human isoform CYP2D6.","Substrate"
"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>serotonin</e1>, but they were less effective than the <e2>human isoform CYP2D6</e2>.","Substrate"
"The catalytic competence of <e2>cytochrome P450</e2> in the synthesis of <e1>serotonin</e1> from 5-methoxytryptamine in the brain: an in vitro study.","Substrate"
"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>serotonin</e1>, but they were less effective than the human isoform <e2>CYP2D6</e2>.","Substrate"
"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>serotonin</e1>, but they were less effective than the human isoform <e2>CYP2D6</e2>.","Substrate"
"The obtained results indicate that <e2>rat brain CYP2D</e2> isoforms catalyze the formation of <e1>serotonin</e1> from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.","Substrate"
"Of the rat CYP isoforms studied, <e2>CYP2D</e2> isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>serotonin</e1>, but they were less effective than the human isoform CYP2D6.","Substrate"
"<e1>O</e1>f the rat CYP isoforms studied, <e2>CYP2D</e2> isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6.","Substrate"
"<e1>O</e1>f the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the <e2>human isoform CYP2D6</e2>.","Substrate"
"Of the rat CYP isoforms studied, <e2>CYP2D</e2> isoforms were the most efficient in catalyzing the O-demethylation of <e1>5-methoxytryptamine</e1> to serotonin, but they were less effective than the human isoform CYP2D6.","Substrate"
"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of <e1>5-methoxytryptamine</e1> to serotonin, but they were less effective than the <e2>human isoform CYP2D6</e2>.","Substrate"
"The catalytic competence of <e2>cytochrome P450</e2> in the synthesis of serotonin from <e1>5-methoxytryptamine</e1> in the brain: an in vitro study.","Substrate"
"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of <e1>5-methoxytryptamine</e1> to serotonin, but they were less effective than the human isoform <e2>CYP2D6</e2>.","Substrate"
"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of <e1>5-methoxytryptamine</e1> to serotonin, but they were less effective than the human isoform <e2>CYP2D6</e2>.","Substrate"
"The obtained results indicate that <e2>rat brain CYP2D</e2> isoforms catalyze the formation of serotonin from <e1>5-methoxytryptamine</e1>, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.","Substrate"
"In breast cancer (BC) epithelial cells, the mitogenic action of <e1>estradiol</e1> is transduced through binding to two receptors, <e2>ERα</e2> and ERβ, which act as transcription factors.","Regulator"
"In breast cancer (BC) epithelial cells, the mitogenic action of <e1>estradiol</e1> is transduced through binding to two receptors, ERα and <e2>ERβ</e2>, which act as transcription factors.","Regulator"
"<e1>Estrogen</e1> effects are mediated not only through nuclear <e2>ERs</e2> but also through cytoplasmic/membrane ERs and G-protein-coupled ERs.","Regulator"
"<e1>Estrogen</e1> effects are mediated not only through nuclear <e2>ERs</e2> but also through cytoplasmic/membrane ERs and G-protein-coupled ERs.","Regulator"
"<e1>Estrogen</e1> effects are mediated not only through nuclear ERs but also through cytoplasmic/membrane ERs and <e2>G-protein</e2>-coupled ERs.","Regulator"
"<e1>Estrogen</e1> effects are mediated not only through nuclear <e2>ERs</e2> but also through cytoplasmic/membrane ERs and G-protein-coupled ERs.","Regulator"
"Western blot analysis indicated that <e1>TSN</e1> inhibits the CDC42/MEKK1/<e2>JNK</e2> pathway.","Regulator"
"<e1>Toosendanin</e1> induces apoptosis through suppression of <e2>JNK</e2> signaling pathway in HL-60 cells.","Downregulator"
"Western blot analysis indicated that <e1>TSN</e1> inhibits the <e2>CDC42</e2>/MEKK1/JNK pathway.","Downregulator"
"Western blot analysis indicated that <e1>TSN</e1> inhibits the CDC42/<e2>MEKK1</e2>/JNK pathway.","Downregulator"
"Western blot analysis indicated that <e1>TSN</e1> inhibits the CDC42/MEKK1/<e2>JNK</e2> pathway.","Downregulator"
"Administration of low, but not high, doses of oral <e1>nicotine</e1> in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of <e2>tumor necrosis factor-α</e2>.","Upregulator"
"Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical <e1>hydrogen</e1> bonds required to stabilise the <e2>KIR</e2>-Keap1 complex.","Part_of"
"<e2>Keap1</e2> is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical <e1>hydrogen</e1> bonds required to stabilise the KIR-Keap1 complex.","Part_of"
"<e2>Orexin-A</e2> suppresses postischemic <e1>glucose</e1> intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.","Regulator"
"Small interfering RNA directed BDNF, <e2>orexin-A</e2>, and <e1>SB334867</e1> [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus.","Downregulator"
"The MCAO-induced decrease in <e2>insulin receptor</e2> levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of <e1>SB334867</e1> as well as by hypothalamic BDNF knockdown.","Downregulator"
"Small interfering RNA directed BDNF, orexin-A, and <e1>SB334867</e1> [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific <e2>orexin-1 receptor</e2> antagonist] were administered directly into the hypothalamus.","Antagonist"
"Small interfering RNA directed BDNF, orexin-A, and SB334867 [<e1>N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea</e1>; a specific <e2>orexin-1 receptor</e2> antagonist] were administered directly into the hypothalamus.","Antagonist"
"Filtering and analysis of data identified three oncogenic pathways interfered by <e1>5-ASA</e1>: MAPK/ERK pathway, cell adhesion and <e2>β-catenin</e2>/Wnt signaling.","Regulator"
"Filtering and analysis of data identified three oncogenic pathways interfered by <e1>5-ASA</e1>: MAPK/ERK pathway, cell adhesion and β-catenin/<e2>Wnt</e2> signaling.","Regulator"
"Filtering and analysis of data identified three oncogenic pathways interfered by <e1>5-ASA</e1>: <e2>MAPK</e2>/ERK pathway, cell adhesion and β-catenin/Wnt signaling.","Regulator"
"Filtering and analysis of data identified three oncogenic pathways interfered by <e1>5-ASA</e1>: MAPK/<e2>ERK</e2> pathway, cell adhesion and β-catenin/Wnt signaling.","Regulator"
"<e2>PAK1</e2> emerged as a consensus target of <e1>5-ASA</e1>, orchestrating these pathways.","Regulator"
"Role of <e2>PAK1</e2> as a mediator of <e1>mesalamine</e1> activity was validated in vitro and in vivo.","Regulator"
"Moreover, <e1>5-ASA</e1> treatment restored membranous expression of adhesion molecules <e2>E-cadherin</e2> and β-catenin.","Upregulator"
"Filtering and analysis of data identified three oncogenic pathways interfered by <e1>5-ASA</e1>: MAPK/ERK pathway, cell adhesion and <e2>β-catenin</e2>/Wnt signaling.","Upregulator"
"<e2>PAK1</e2> emerged as a consensus target of <e1>5-ASA</e1>, orchestrating these pathways.","Downregulator"
"<e2>PAK1</e2> emerged as a consensus target of <e1>5-ASA</e1>, orchestrating these pathways.","Downregulator"
"<e1>Mesalamine</e1> modulates intercellular adhesion through inhibition of <e2>p-21 activated kinase-1</e2>.","Downregulator"
"<e2>PAK1</e2> emerged as a consensus target of <e1>5-ASA</e1>, orchestrating these pathways.","Downregulator"
"While protein levels of the main hepatic bile acid transporters were unchanged, the rate-limiting enzyme in the bile acid synthesis, <e2>Cyp7a1</e2>, was significantly increased by <e1>EGCG</e1>.","Upregulator"
"While protein levels of the main hepatic <e2>bile acid transporters</e2> were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by <e1>EGCG</e1>.","Downregulator"
"In contrast, <e1>EGCG</e1> markedly downregulated major bile acid transporters (<e2>Asbt</e2> and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.","Downregulator"
"In contrast, <e1>EGCG</e1> markedly downregulated major bile acid transporters (Asbt and <e2>Ostα</e2>) and regulatory molecules (Shp and Fgf15) in the ileum.","Downregulator"
"In contrast, <e1>EGCG</e1> markedly downregulated major bile acid transporters (Asbt and Ostα) and regulatory molecules (<e2>Shp</e2> and Fgf15) in the ileum.","Downregulator"
"In contrast, <e1>EGCG</e1> markedly downregulated major bile acid transporters (Asbt and Ostα) and regulatory molecules (Shp and <e2>Fgf15</e2>) in the ileum.","Downregulator"
"The serotonin (5-HT) receptors of type 6 (<e2>5-HT6</e2>) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long <e1>C</e1>-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.","Part_of"
"The <e2>serotonin (5-HT) receptors</e2> of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long <e1>C</e1>-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.","Part_of"
"<e2>ColQ-1a</e2> is expressed at the neuromuscular junction (NMJ) in fast-twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a <e1>cAMP</e1>-dependent pathway in muscle.","Regulator"
"<e2>ColQ-1a</e2> is expressed at the neuromuscular junction (NMJ) in fast-twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a <e1>cAMP</e1>-dependent pathway in muscle.","Regulator"
"Biochemical analyses showed that NO and ROS production and <e2>iNOS</e2> activity were significantly reduced by <e1>catalpol</e1>.","Downregulator"
"Data at transcriptional level also demonstrated that <e1>catalpol</e1> potently attenuated gene expressions involved in inflammation, such as iNOS, <e2>COX-2</e2> and TLR4.","Downregulator"
"Data at transcriptional level also demonstrated that <e1>catalpol</e1> potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and <e2>TLR4</e2>.","Downregulator"
"In addition, our exploration further revealed that the suppressive action of <e1>catalpol</e1> on inflammation was mediated via inhibiting nuclear factor-κB (<e2>NF-κB</e2>) activation.","Downregulator"
"In addition, our exploration further revealed that the suppressive action of <e1>catalpol</e1> on inflammation was mediated via inhibiting <e2>nuclear factor-κB</e2> (NF-κB) activation.","Downregulator"
"<e1>Catalpol</e1> inhibits LPS plus <e2>IFN-γ</e2>-induced inflammatory response in astrocytes primary cultures.","Downregulator"
"In addition, our exploration further revealed that the suppressive action of <e1>catalpol</e1> on inflammation was mediated via inhibiting nuclear factor-κB (<e2>NF-κB</e2>) activation.","Downregulator"
"Biochemical analyses showed that NO and ROS production and <e2>iNOS</e2> activity were significantly reduced by <e1>catalpol</e1>.","Downregulator"
"<e2>Protein tyrosine phosphatase 1B</e2> inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum <e1>saponins</e1>.","Downregulator"
"<e2>Protein tyrosine phosphatase 1B</e2> inhibitory effect by <e1>dammarane</e1>-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.","Downregulator"
"<e2>Protein tyrosine phosphatase 1B</e2> inhibitory effect by dammarane-type <e1>triterpenes</e1> from hydrolyzate of total Gynostemma pentaphyllum saponins.","Downregulator"
"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however <e2>phospho-GSK-3-β</e2> (Ser9) was not altered in <e1>(PhTe)(2)</e1> injected rat.","Not"
"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however <e2>phospho-GSK-3-β</e2> (<e1>Ser</e1>9) was not altered in (PhTe)(2) injected rat.","Part_of"
"Therefore, the present results show that the earlier cerebellar responses to <e1>(PhTe)(2)</e1> include disruption of cytoskeletal homeostasis that could be related with <e2>MAPK</e2> and PKA activation and reactive astrogliosis.","Upregulator"
"Therefore, the present results show that the earlier cerebellar responses to <e1>(PhTe)(2)</e1> include disruption of cytoskeletal homeostasis that could be related with MAPK and <e2>PKA</e2> activation and reactive astrogliosis.","Upregulator"
"Also, reactive astrogliosis takes part of the early responses to the insult with <e1>(PhTe)(2)</e1>, evidenced by upregulated <e2>GFAP</e2> in Western blot, PCR and immunofluorescence analysis.","Upregulator"
"Six days after <e1>(PhTe)(2)</e1> injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in <e2>NeuN</e2> positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death.","Downregulator"
"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased <e2>Akt</e2> immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in <e1>(PhTe)(2)</e1> injected rat.","Downregulator"
"Fluorescence of the reporter dye is turned on by rapid removal of the <e1>quinone</e1> quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated <e2>human NAD(P)H:quinone oxidoreductase isozyme 1</e2> (hNQO1).","Substrate"
"Fluorescence of the reporter dye is turned on by rapid removal of the <e1>quinone</e1> quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (<e2>hNQO1</e2>).","Substrate"
"Synthesis, biological evaluation, and molecular modeling of <e1>glycyrrhizin</e1> derivatives as potent <e2>high-mobility group box-1</e2> inhibitors with anti-heart-failure activity in vivo.","Downregulator"
"Within the <e1>TPBP</e1> scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-<e2>mAChR</e2> antagonism, which was demonstrated to be mediated via the orthosteric site.","Antagonist"
"Within the TPBP scaffold, either electronic or steric perturbations to the central <e1>piperidine</e1> ring led to a loss of selective M(1) allosteric agonism and afforded pan-<e2>mAChR</e2> antagonism, which was demonstrated to be mediated via the orthosteric site.","Antagonist"
"Additional SAR around a related M(1) allosteric agonist family (<e1>VU0357017</e1>) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-<e2>mAChR</e2> orthosteric antagonism.","Antagonist"
"The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a <e2>P-gp</e2> substrate, <e1>risperidone</e1>, and its major metabolite, 9-hydroxyrisperidone, in rats.","Substrate"
"The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a <e2>P-gp</e2> substrate, risperidone, and its major metabolite, <e1>9-hydroxyrisperidone</e1>, in rats.","Substrate"
"In this study, we present the synthesis and pharmacological properties of new analogues of <e2>arginine vasopressin</e2> modified in the <e1>N</e1>-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid.","Part_of"
"In this study, we present the synthesis and pharmacological properties of new analogues of <e2>arginine vasopressin</e2> modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and <e1>(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid</e1>.","Antagonist"
"<e2>Liver X Receptor (LXR) α</e2> and LXR β are nuclear receptors activated by <e1>oxysterols</e1>, oxidized derivatives of cholesterol.","Upregulator"
"Liver X Receptor (LXR) α and <e2>LXR β</e2> are nuclear receptors activated by <e1>oxysterols</e1>, oxidized derivatives of cholesterol.","Upregulator"
"<e2>β-catenin</e2> regulates <e1>GnRH</e1>-induced FSHβ gene expression.","Regulator"
"β-catenin regulates <e1>GnRH</e1>-induced <e2>FSHβ</e2> gene expression.","Upregulator"
"β-catenin regulates <e1>GnRH</e1>-induced <e2>FSHβ</e2> gene expression.","Upregulator"
"β-catenin regulates <e1>GnRH</e1>-induced <e2>FSHβ</e2> gene expression.","Upregulator"
"<e2>β-catenin</e2> regulates <e1>GnRH</e1>-induced FSHβ gene expression.","Upregulator"
"β-catenin regulates <e1>GnRH</e1>-induced <e2>FSHβ</e2> gene expression.","Upregulator"
"In conclusion, in this cellular model, <e1>DOX</e1> effectively protects against PQ toxicity by inducing P-gp and through the interaction with the <e2>choline transporter</e2>, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.","Regulator"
"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (<e1>DOX</e1>), a known <e2>P-gp</e2> inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.","Upregulator"
"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether <e1>doxorubicin</e1> (DOX), a known <e2>P-gp</e2> inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.","Upregulator"
"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (<e1>DOX</e1>), a known <e2>P-gp</e2> inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.","Upregulator"
"The herbicide <e1>paraquat</e1> (PQ) is a <e2>P-gp</e2> substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.","Substrate"
"<e1>P505-15</e1> successfully inhibited SYK-mediated <e2>B-cell receptor</e2> signaling and decreased cell viability in NHL and CLL.","Downregulator"
"The selective <e2>SYK</e2> inhibitor <e1>P505-15</e1> (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"The selective <e2>SYK</e2> inhibitor P505-15 (<e1>PRT062607</e1>) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"The selective <e2>SYK</e2> inhibitor <e1>P505-15</e1> (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"The selective <e2>SYK</e2> inhibitor <e1>P505-15</e1> (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"The selective <e2>SYK</e2> inhibitor <e1>P505-15</e1> (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"The selective <e2>SYK</e2> inhibitor P505-15 (<e1>PRT062607</e1>) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"The selective <e2>SYK</e2> inhibitor P505-15 (<e1>PRT062607</e1>) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"The selective <e2>SYK</e2> inhibitor P505-15 (<e1>PRT062607</e1>) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"The selective <e2>SYK</e2> inhibitor <e1>P505-15</e1> (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.","Downregulator"
"Alleles of <e2>RPB1</e2> (RPO21) with elevated slippage rates were identified among <e1>6-azauracil</e1>-sensitive mutants and were also isolated using a slippage-dependent reporter gene.","Regulator"
"Alleles of RPB1 (<e2>RPO21</e2>) with elevated slippage rates were identified among <e1>6-azauracil</e1>-sensitive mutants and were also isolated using a slippage-dependent reporter gene.","Regulator"
"Here we investigated whether <e2>AhR</e2> plays a role in <e1>17-AAG</e1>-mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy.","Regulator"
"<e2>Aryl hydrocarbon receptor</e2> is a target of <e1>17-Allylamino-17-demethoxygeldanamycin</e1> and enhances its anticancer activity in lung adenocarcinoma cells.","Regulator"
"Here we investigated whether <e2>AhR</e2> plays a role in <e1>17-AAG</e1>-mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy.","Downregulator"
"Here we investigated whether <e2>AhR</e2> plays a role in <e1>17-AAG</e1>-mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy.","Downregulator"
"In addition, <e1>17-AAG</e1> treatment reduced cell viability, <e2>CDK2</e2>, CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.","Downregulator"
"In addition, <e1>17-AAG</e1> treatment reduced cell viability, CDK2, <e2>CDK4</e2>, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.","Downregulator"
"In addition, <e1>17-AAG</e1> treatment reduced cell viability, CDK2, CDK4, <e2>cyclin E</e2>, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.","Downregulator"
"In addition, <e1>17-AAG</e1> treatment reduced cell viability, CDK2, CDK4, cyclin E, <e2>cyclin D1</e2>, and phosphorylated Rb levels in AhR-expressing lung AD cells.","Downregulator"
"In addition, <e1>17-AAG</e1> treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and <e2>phosphorylated Rb</e2> levels in AhR-expressing lung AD cells.","Downregulator"
"<e1>17-Allylamino-17-demethoxygeldanamycin</e1> (17-AAG), an <e2>Hsp90</e2> inhibitor, is currently under evaluation for its anticancer activity in clinical trials.","Downregulator"
"17-Allylamino-17-demethoxygeldanamycin (<e1>17-AAG</e1>), an <e2>Hsp90</e2> inhibitor, is currently under evaluation for its anticancer activity in clinical trials.","Downregulator"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK</e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (<e1>dFdU</e1>) as substrates.","Not"
"In conclusion, the <e2>Lys27Gln</e2> substitution does not significantly modulate CDA activity toward dFdC, and therefore would not contribute to interindividual variability in response to <e1>gemcitabine</e1>.","Not"
"In conclusion, the Lys27Gln substitution does not significantly modulate <e2>CDA</e2> activity toward dFdC, and therefore would not contribute to interindividual variability in response to <e1>gemcitabine</e1>.","Not"
"Wild-type enzymes and variants of <e2>CDA</e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (<e2>Lys27Gln</e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>Ala70Thr</e2>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK</e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>Ile24Val</e2>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>Ala119Gly</e2>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>Pro122Ser</e2>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>CDA</e2>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Wild-type enzymes and variants of CDA (<e2>Lys27Gln</e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC</e1>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>Ala70Thr</e2>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC</e1>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK</e2>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>Ile24Val</e2>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC</e1>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>Ala119Gly</e2>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC</e1>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>Pro122Ser</e2>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC</e1>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of <e2>CDA</e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine</e1> (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (<e2>Lys27Gln</e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine</e1> (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>Ala70Thr</e2>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine</e1> (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK</e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine</e1> (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>Ile24Val</e2>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine</e1> (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>Ala119Gly</e2>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine</e1> (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>Pro122Ser</e2>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine</e1> (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of <e2>CDA</e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (<e1>dFdU</e1>) as substrates.","Substrate"
"Wild-type enzymes and variants of <e2>CDA</e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>CDA</e2>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Wild-type enzymes and variants of <e2>CDA</e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK</e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C</e1>), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK</e2>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"<e1>Gemcitabine</e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK</e2>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"<e1>Gemcitabine</e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by <e2>cytidine deaminase</e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"<e1>Gemcitabine</e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>CDA</e2>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"<e1>Gemcitabine</e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and <e2>deoxycytidine kinase</e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK</e2>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Wild-type enzymes and variants of CDA (<e2>Lys27Gln</e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC</e1>, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>CDA</e2>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK</e2>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by <e2>cytidine deaminase</e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>CDA</e2>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and <e2>deoxycytidine kinase</e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK</e2>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (<e1>dFdC</e1>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK</e2>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (dFdC, <e1>2',2'-difluorodeoxycytidine</e1>) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK</e2>), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (dFdC, <e1>2',2'-difluorodeoxycytidine</e1>) is metabolized by <e2>cytidine deaminase</e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (dFdC, <e1>2',2'-difluorodeoxycytidine</e1>) is metabolized by cytidine deaminase (<e2>CDA</e2>) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Gemcitabine (dFdC, <e1>2',2'-difluorodeoxycytidine</e1>) is metabolized by cytidine deaminase (CDA) and <e2>deoxycytidine kinase</e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.","Substrate"
"Wild-type enzymes and variants of <e2>CDA</e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine</e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (<e2>Lys27Gln</e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine</e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>Ala70Thr</e2>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine</e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK</e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine</e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>Ile24Val</e2>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine</e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>Ala119Gly</e2>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine</e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>Pro122Ser</e2>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine</e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.","Substrate"
"A series of compounds based on a <e1>4-phenyl-2-phenylaminopyridine</e1> scaffold that are potent and selective inhibitors of <e2>Traf2- and Nck-interacting kinase</e2> (TNIK) activity are described.","Downregulator"
"Discovery of <e1>4-phenyl-2-phenylaminopyridine</e1> based <e2>TNIK</e2> inhibitors.","Downregulator"
"Discovery of <e1>4-phenyl-2-phenylaminopyridine</e1> based <e2>TNIK</e2> inhibitors.","Downregulator"
"Here we present <e1>boronic</e1> and borinic acid derivatives as a new class of potent and nontoxic <e2>APT</e2> inhibitors.","Downregulator"
"Here we present boronic and <e1>borinic acid</e1> derivatives as a new class of potent and nontoxic <e2>APT</e2> inhibitors.","Downregulator"
"<e1>Boron</e1>-based inhibitors of <e2>acyl protein thioesterases 1 and 2</e2>.","Downregulator"
"<e1>Genistein</e1> also reduced the formation of stress fibers by <e2>thrombin</e2> and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).","Not"
"Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of <e2>myosin light chain</e2> (MLC) on <e1>Ser</e1>(19)/Thr(18) in endothelial cells (ECs).","Part_of"
"Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (<e2>MLC</e2>) on <e1>Ser</e1>(19)/Thr(18) in endothelial cells (ECs).","Part_of"
"Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of <e2>myosin light chain</e2> (MLC) on Ser(19)/<e1>Thr</e1>(18) in endothelial cells (ECs).","Part_of"
"Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (<e2>MLC</e2>) on Ser(19)/<e1>Thr</e1>(18) in endothelial cells (ECs).","Part_of"
"Phytoestrogen <e1>genistein</e1> protects against endothelial barrier dysfunction in vascular endothelial cells through PKA-mediated suppression of <e2>RhoA</e2> signaling.","Regulator"
"Phytoestrogen <e1>genistein</e1> protects against endothelial barrier dysfunction in vascular endothelial cells through PKA-mediated suppression of <e2>RhoA</e2> signaling.","Regulator"
"Phytoestrogen <e1>genistein</e1> protects against endothelial barrier dysfunction in vascular endothelial cells through <e2>PKA</e2>-mediated suppression of RhoA signaling.","Regulator"
"Here, we report that <e1>genistein</e1> at physiologically relevant concentrations (0.1-10 μM) significantly inhibited <e2>thrombin</e2>-induced increase in endothelial monolayer permeability.","Regulator"
"RhoA inhibitor blocked the protective effect of <e1>genistein</e1> on endothelial permeability and also ablated thrombin-induced <e2>MLC</e2>-phosphorylation in ECs.","Regulator"
"Phytoestrogen <e1>genistein</e1> protects against endothelial barrier dysfunction in vascular endothelial cells through PKA-mediated suppression of <e2>RhoA</e2> signaling.","Regulator"
"Here, we report that <e1>genistein</e1> at physiologically relevant concentrations (0.1-10 μM) significantly inhibited <e2>thrombin</e2>-induced increase in endothelial monolayer permeability.","Regulator"
"Phytoestrogen <e1>genistein</e1> protects against endothelial barrier dysfunction in vascular endothelial cells through <e2>PKA</e2>-mediated suppression of RhoA signaling.","Regulator"
"Here, we report that <e1>genistein</e1> at physiologically relevant concentrations (0.1-10 μM) significantly inhibited <e2>thrombin</e2>-induced increase in endothelial monolayer permeability.","Downregulator"
"Here, we report that <e1>genistein</e1> at physiologically relevant concentrations (0.1-10 μM) significantly inhibited <e2>thrombin</e2>-induced increase in endothelial monolayer permeability.","Downregulator"
"<e1>Genistein</e1> also reduced the formation of stress fibers by <e2>thrombin</e2> and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).","Downregulator"
"<e1>Genistein</e1> also reduced the formation of stress fibers by <e2>thrombin</e2> and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).","Downregulator"
"<e1>Genistein</e1> also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of <e2>myosin light chain</e2> (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).","Downregulator"
"<e1>Genistein</e1> also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (<e2>MLC</e2>) on Ser(19)/Thr(18) in endothelial cells (ECs).","Downregulator"
"However, <e1>GSK1292263</e1> inhibited BCRP and <e2>OATP1B1</e2>, which are transporters involved in statin disposition.","Not"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards <e2>CYPs</e2> (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.","Downregulator"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (<e2>CYP1A2</e2>, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.","Downregulator"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, <e2>2C9</e2>, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.","Downregulator"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, <e2>2C19</e2>, 2D6, 3A4), Pgp, OATP1B3, or OCT2.","Downregulator"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, <e2>2D6</e2>, 3A4), Pgp, OATP1B3, or OCT2.","Downregulator"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, <e2>3A4</e2>), Pgp, OATP1B3, or OCT2.","Downregulator"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), <e2>Pgp</e2>, OATP1B3, or OCT2.","Downregulator"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, <e2>OATP1B3</e2>, or OCT2.","Downregulator"
"In vitro, <e1>GSK1292263</e1> demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or <e2>OCT2</e2>.","Downregulator"
"However, <e1>GSK1292263</e1> inhibited <e2>BCRP</e2> and OATP1B1, which are transporters involved in statin disposition.","Downregulator"
"However, <e1>GSK1292263</e1> inhibited BCRP and <e2>OATP1B1</e2>, which are transporters involved in statin disposition.","Downregulator"
"In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with <e1>GSK1292263</e1>, which is consistent with an inhibitory effect on intestinal BCRP and <e2>CYP3A4</e2>.","Downregulator"
"However, <e1>GSK1292263</e1> inhibited <e2>BCRP</e2> and OATP1B1, which are transporters involved in statin disposition.","Downregulator"
"This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the <e2>HMG-coA reductase</e2> inhibitors <e1>simvastatin</e1> and rosuvastatin.","Downregulator"
"In vitro experiments assessed the inhibition of <e2>transporters</e2> and CYP enzymes by <e1>GSK1292263</e1>, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).","Downregulator"
"This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the <e2>HMG-coA reductase</e2> inhibitors simvastatin and <e1>rosuvastatin</e1>.","Downregulator"
"In vitro experiments assessed the inhibition of <e2>transporters</e2> and CYP enzymes by <e1>GSK1292263</e1>, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).","Downregulator"
"In vitro experiments assessed the inhibition of transporters and <e2>CYP</e2> enzymes by <e1>GSK1292263</e1>, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).","Downregulator"
"Evaluation of drug interactions of <e1>GSK1292263</e1> (a <e2>GPR119</e2> agonist) with statins: from in vitro data to clinical study design.","Agonist"
"Evaluation of drug interactions of <e1>GSK1292263</e1> (a <e2>GPR119</e2> agonist) with statins: from in vitro data to clinical study design.","Agonist"
"Proteins <e2>Aus1</e2> and Dan1 were not found to be involved in <e1>steroid</e1> import.","Not"
"Proteins Aus1 and <e2>Dan1</e2> were not found to be involved in <e1>steroid</e1> import.","Not"
"The presence of <e1>steroid</e1> hormones most probably causes the degradation of the <e2>Tat2</e2> permease and impairment of tryptophan import.","Downregulator"
"Promoter replacements conferring constitutive expression of <e2>MSH2</e2> revealed that the transcriptional induction in response to <e1>MMS</e1> is required to maintain induced levels of Msh2.","Regulator"
"Promoter replacements conferring constitutive expression of MSH2 revealed that the transcriptional induction in response to <e1>MMS</e1> is required to maintain induced levels of <e2>Msh2</e2>.","Regulator"
"Further study showed that <e1>icariin</e1> dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory <e2>cytokine</e2> levels of activated T cells.","Downregulator"
"Inhibition of Th1/Th17 responses via suppression of <e2>STAT1</e2> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside <e1>icariin</e1>.","Downregulator"
"Inhibition of Th1/Th17 responses via suppression of STAT1 and <e2>STAT3</e2> activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside <e1>icariin</e1>.","Downregulator"
"Inhibition of Th1/Th17 responses via suppression of <e2>STAT1</e2> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside <e1>icariin</e1>.","Downregulator"
"Inhibition of Th1/Th17 responses via suppression of STAT1 and <e2>STAT3</e2> activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside <e1>icariin</e1>.","Downregulator"
"Inhibition of Th1/Th17 responses via suppression of <e2>STAT1</e2> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural <e1>flavonoid</e1> glucoside icariin.","Downregulator"
"Inhibition of Th1/Th17 responses via suppression of STAT1 and <e2>STAT3</e2> activation contributes to the amelioration of murine experimental colitis by a natural <e1>flavonoid</e1> glucoside icariin.","Downregulator"
"The present study examined the effect of <e2>insulin</e2>-mediated activation of the mammalian target of <e1>rapamycin</e1> complex 1 (MTORC1) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells.","Downregulator"
"The present study examined the effect of <e2>insulin</e2>-mediated activation of the mammalian target of <e1>rapamycin</e1> complex 1 (MTORC1) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells.","Downregulator"
"Furthermore, insulin-stimulated T-I cell proliferation and the expression of <e2>cell cycle regulatory proteins</e2> CDK4, CCND3 and PCNA were also blocked by <e1>rapamycin</e1>.","Downregulator"
"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins <e2>CDK4</e2>, CCND3 and PCNA were also blocked by <e1>rapamycin</e1>.","Downregulator"
"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, <e2>CCND3</e2> and PCNA were also blocked by <e1>rapamycin</e1>.","Downregulator"
"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and <e2>PCNA</e2> were also blocked by <e1>rapamycin</e1>.","Downregulator"
"The present study examined the effect of insulin-mediated activation of the mammalian target of <e1>rapamycin</e1> complex 1 (<e2>MTORC1</e2>) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells.","Downregulator"
"Pharmacological inhibition of MTORC1 with <e1>rapamycin</e1> abrogated the insulin-induced phosphorylation of <e2>EIF4EBP1</e2>, RPS6KB1 and its downstream effector, RPS6.","Downregulator"
"Pharmacological inhibition of MTORC1 with <e1>rapamycin</e1> abrogated the insulin-induced phosphorylation of EIF4EBP1, <e2>RPS6KB1</e2> and its downstream effector, RPS6.","Downregulator"
"Pharmacological inhibition of MTORC1 with <e1>rapamycin</e1> abrogated the insulin-induced phosphorylation of EIF4EBP1, <e2>RPS6</e2>KB1 and its downstream effector, RPS6.","Downregulator"
"<e2>AF10</e2> has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the <e1>N</e1>-terminal PHD fingers of AF10.","Part_of"
"We demonstrate that the <e2>PHD1-PHD2</e2> region is essential for viability and that the first PHD finger contributes to the preferred binding of PHD1-PHD2 to <e1>lysine</e1> 4-methylated histone H3 tails.","Regulator"
"We report the discovery of novel series of highly potent <e2>TLR7</e2> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various <e1>tertiary amines</e1> onto the N(9)-position of the adenine moiety.","Agonist"
"We report the discovery of novel series of highly potent <e2>TLR7</e2> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the <e1>N</e1>(9)-position of the adenine moiety.","Agonist"
"We report the discovery of novel series of highly potent <e2>TLR7</e2> agonists based on 8-oxo<e1>adenine</e1>s, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety.","Agonist"
"The introduction of the <e1>amino</e1> group resulted in not only improved water solubility but also enhanced <e2>TLR7</e2> agonistic activity.","Agonist"
"We report the discovery of novel series of highly potent <e2>TLR7</e2> agonists based on <e1>8-oxoadenines</e1>, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety.","Agonist"
"Synthesis and evaluation of <e1>8-oxoadenine</e1> derivatives as potent <e2>Toll-like receptor 7</e2> agonists with high water solubility.","Agonist"
"Inhibitors based on a <e1>benzo-fused spirocyclic oxazepine</e1> scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (<e2>SCD1</e2>) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.","Downregulator"
"Inhibitors based on a <e1>benzo-fused spirocyclic oxazepine</e1> scaffold were discovered for <e2>stearoyl-coenzyme A (CoA) desaturase 1</e2> (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.","Downregulator"
"The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited <e2>human Hsp60</e2> chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of <e1>ETB</e1> (IC(50): 10.9 ± 0.63 μM).","Downregulator"
"<e1>Apocynin</e1> and raisanberine alleviate intermittent hypoxia induced abnormal <e2>StAR</e2> and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.","Regulator"
"<e1>Apocynin</e1> and raisanberine alleviate intermittent hypoxia induced abnormal StAR and <e2>3β-HSD</e2> and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.","Regulator"
"Apocynin and <e1>raisanberine</e1> alleviate intermittent hypoxia induced abnormal <e2>StAR</e2> and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.","Regulator"
"<e1>Apocynin</e1> and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated <e2>p66Shc</e2> in rat testes.","Downregulator"
"Apocynin and <e1>raisanberine</e1> alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated <e2>p66Shc</e2> in rat testes.","Downregulator"
"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (<e2>NOX</e2>), therefore, <e1>APO</e1> (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.","Downregulator"
"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (<e2>NOX</e2>), therefore, APO (<e1>apocynin</e1>) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.","Downregulator"
"<e1>APO</e1> and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and <e2>p66Shc</e2> in testes.","Downregulator"
"Apocynin and <e1>raisanberine</e1> alleviate intermittent hypoxia induced abnormal StAR and <e2>3β-HSD</e2> and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.","Substrate"
"Here we found that <e1>arsenic trioxide</e1>, a frontline agent for acute promyelocytic leukemia, inhibits ΔNp63 but not <e2>TAp63</e2> expression in time- and dose-dependent manners.","Not"
"Here we found that <e1>arsenic trioxide</e1>, a frontline agent for acute promyelocytic leukemia, inhibits <e2>ΔNp63</e2> but not TAp63 expression in time- and dose-dependent manners.","Regulator"
"<e1>Arsenic</e1> suppresses cell survival via Pirh2-mediated proteasomal degradation of <e2>ΔNp63</e2> protein.","Regulator"
"Furthermore, we found that <e1>arsenic</e1> trioxide activates the <e2>Pirh2</e2> promoter and consequently induces Pirh2 expression.","Regulator"
"In addition, we found that <e1>arsenic trioxide</e1> decreases the stability of ΔNp63 protein via a <e2>proteasome</e2>-dependent pathway but has little effect on the level of ΔNp63 transcript.","Regulator"
"<e1>Arsenic</e1> suppresses cell survival via <e2>Pirh2</e2>-mediated proteasomal degradation of ΔNp63 protein.","Regulator"
"Furthermore, we found that <e1>arsenic trioxide</e1> activates the <e2>Pirh2 promoter</e2> and consequently induces Pirh2 expression.","Upregulator"
"Furthermore, we found that <e1>arsenic trioxide</e1> activates the <e2>Pirh2</e2> promoter and consequently induces Pirh2 expression.","Upregulator"
"Here we found that <e1>arsenic</e1> trioxide, a frontline agent for acute promyelocytic leukemia, inhibits <e2>ΔNp63</e2> but not TAp63 expression in time- and dose-dependent manners.","Downregulator"
"Here we found that <e1>arsenic</e1> trioxide, a frontline agent for acute promyelocytic leukemia, inhibits <e2>ΔNp63</e2> but not TAp63 expression in time- and dose-dependent manners.","Downregulator"
"Here we found that <e1>arsenic</e1> trioxide, a frontline agent for acute promyelocytic leukemia, inhibits <e2>ΔNp63</e2> but not TAp63 expression in time- and dose-dependent manners.","Downregulator"
"Here we found that <e1>arsenic trioxide</e1>, a frontline agent for acute promyelocytic leukemia, inhibits <e2>ΔNp63</e2> but not TAp63 expression in time- and dose-dependent manners.","Downregulator"
"Here we found that <e1>arsenic trioxide</e1>, a frontline agent for acute promyelocytic leukemia, inhibits <e2>ΔNp63</e2> but not TAp63 expression in time- and dose-dependent manners.","Downregulator"
"<e1>Jaceosidin</e1> induced G2/M phase cell cycle arrest and modulated the levels of <e2>cyclin B</e2> and p-Cdc2 in Hec1A cells.","Regulator"
"<e1>Jaceosidin</e1> induced G2/M phase cell cycle arrest and modulated the levels of cyclin B and <e2>p-Cdc2</e2> in Hec1A cells.","Regulator"
"Moreover, <e1>jaceosidin</e1> treatment resulted in phosphorylation of <e2>ERK</e2>, and pretreatment with the ERK inhibitor, PD98059, attenuated cell growth inhibition by jaceosidin.","Regulator"
"Moreover, <e1>jaceosidin</e1> treatment resulted in phosphorylation of <e2>ERK</e2>, and pretreatment with the ERK inhibitor, PD98059, attenuated cell growth inhibition by jaceosidin.","Regulator"
"Additional mechanistic studies revealed that <e1>jaceosidin</e1> treatment resulted in an increase in phosphorylation of Cdc25C and <e2>ATM</e2>-Chk1/2.","Regulator"
"Additional mechanistic studies revealed that <e1>jaceosidin</e1> treatment resulted in an increase in phosphorylation of <e2>Cdc25C</e2> and ATM-Chk1/2.","Upregulator"
"Additional mechanistic studies revealed that <e1>jaceosidin</e1> treatment resulted in an increase in phosphorylation of Cdc25C and <e2>ATM</e2>-Chk1/2.","Upregulator"
"<e1>Jaceosidin</e1>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via <e2>ATM</e2>-Chk1/2 activation.","Upregulator"
"<e1>Jaceosidin</e1>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating <e2>cdc25C</e2>-cdc2 via ATM-Chk1/2 activation.","Downregulator"
"<e1>Jaceosidin</e1>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating <e2>cdc2</e2>5C-cdc2 via ATM-Chk1/2 activation.","Downregulator"
"Moreover, jaceosidin treatment resulted in phosphorylation of <e2>ERK</e2>, and pretreatment with the ERK inhibitor, <e1>PD98059</e1>, attenuated cell growth inhibition by jaceosidin.","Downregulator"
"Additional mechanistic studies revealed that <e1>jaceosidin</e1> treatment resulted in an increase in phosphorylation of <e2>Cdc2</e2>5C and ATM-Chk1/2.","Downregulator"
"These data suggest that <e1>jaceosidin</e1>, isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-<e2>cyclin B1</e2> complex, followed by G2/M cell cycle arrest in endometrial cancer cells.","Downregulator"
"Electrical Stimuli Release <e1>ATP</e1> to Increase <e2>GLUT4</e2> Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.","Regulator"
"Electrical Stimuli Release <e1>ATP</e1> to Increase GLUT4 Translocation and Glucose Uptake via <e2>PI3Kγ</e2>-Akt-AS160 in Skeletal Muscle Cells.","Regulator"
"Electrical Stimuli Release <e1>ATP</e1> to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-<e2>Akt</e2>-AS160 in Skeletal Muscle Cells.","Regulator"
"Electrical Stimuli Release <e1>ATP</e1> to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-<e2>AS160</e2> in Skeletal Muscle Cells.","Regulator"
"Electrical Stimuli Release <e1>ATP</e1> to Increase <e2>GLUT4</e2> Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.","Regulator"
"<e1>ATP</e1> is released from skeletal muscle by contractile activity and can autocrinely signal through <e2>purinergic receptors</e2>, and we hypothesized it may influence glucose uptake.","Regulator"
"Electrical Stimuli Release <e1>ATP</e1> to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-<e2>Akt</e2>-AS160 in Skeletal Muscle Cells.","Upregulator"
"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by <e2>adenosine-phosphate phosphatase</e2> and by purinergic receptor blockade (<e1>suramin</e1>).","Downregulator"
"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by <e2>purinergic receptor</e2> blockade (<e1>suramin</e1>).","Downregulator"
"Electrical stimulation transiently elevated extracellular ATP and caused <e2>Akt</e2> phosphorylation that was additive to insulin and inhibited by <e1>suramin</e1>.","Downregulator"
"ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the <e2>phosphatidylinositol 3-kinase-γ</e2> (PI3Kγ) inhibitor <e1>AS605240</e1>.","Downregulator"
"ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (<e2>PI3Kγ</e2>) inhibitor <e1>AS605240</e1>.","Downregulator"
"Electrical Stimuli Release ATP to Increase <e2>GLUT4</e2> Translocation and <e1>Glucose</e1> Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.","Substrate"
"The CSN/<e2>IRF5</e2> interaction occurred on the <e1>carboxyl</e1> and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.","Part_of"
"The CSN/<e2>IRF5</e2> interaction occurred on the carboxyl and <e1>amino</e1> termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.","Part_of"
"The CSN/<e2>IRF5</e2> interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from <e1>amino acids</e1> 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.","Part_of"
"A series of <e1>anthra[1,2-d]imidazole-6,11-dione</e1> derivatives were synthesized and evaluated for telomerase inhibition, <e2>hTERT</e2> expression and suppression of cancer cell growth in vitro.","Regulator"
"Structure-based design, synthesis and evaluation of novel <e1>anthra[1,2-d]imidazole-6,11-dione</e1> derivatives as <e2>telomerase</e2> inhibitors and potential for cancer polypharmacology.","Downregulator"
"Structure-based design, synthesis and evaluation of novel <e1>anthra[1,2-d]imidazole-6,11-dione</e1> derivatives as <e2>telomerase</e2> inhibitors and potential for cancer polypharmacology.","Downregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of <e1>TSA</e1>, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (<e2>Nrf2</e2>-ARE) activator sulforaphane, or small interfering RNA.","Regulator"
"The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by <e1>TSA</e1> on <e2>transforming growth factor-β</e2> (TGF-β)-induced myofibroblast differentiation of corneal fibroblasts in vitro.","Regulator"
"Human immortalized corneal fibroblasts were treated with <e2>TGF-β</e2> in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (<e1>DPI</e1>), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.","Regulator"
"Human immortalized corneal fibroblasts were treated with <e2>TGF-β</e2> in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (<e1>NAC</e1>), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.","Regulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the <e2>NF-E2-related factor 2</e2>-antioxidant response element (Nrf2-ARE) activator <e1>sulforaphane</e1>, or small interfering RNA.","Upregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-<e2>antioxidant response element</e2> (Nrf2-ARE) activator <e1>sulforaphane</e1>, or small interfering RNA.","Upregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (<e2>Nrf2</e2>-ARE) activator <e1>sulforaphane</e1>, or small interfering RNA.","Upregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-<e2>ARE</e2>) activator <e1>sulforaphane</e1>, or small interfering RNA.","Upregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of <e1>TSA</e1>, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (<e2>Nrf2</e2>-ARE) activator sulforaphane, or small interfering RNA.","Upregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of <e1>TSA</e1>, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-<e2>ARE</e2>) activator sulforaphane, or small interfering RNA.","Upregulator"
"<e1>Trichostatin A</e1> inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced <e2>NF-E2-related factor 2</e2>-antioxidant response element signaling.","Upregulator"
"<e1>Trichostatin A</e1> inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-<e2>antioxidant response element</e2> signaling.","Upregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of <e1>TSA</e1>, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (<e2>Nrf2</e2>-ARE) activator sulforaphane, or small interfering RNA.","Upregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of <e1>TSA</e1>, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-<e2>ARE</e2>) activator sulforaphane, or small interfering RNA.","Upregulator"
"The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by <e1>TSA</e1> on transforming growth factor-β (<e2>TGF-β</e2>)-induced myofibroblast differentiation of corneal fibroblasts in vitro.","Downregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the <e2>NAD(P)H oxidase</e2> inhibitor <e1>diphenyleneiodonium</e1> (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.","Downregulator"
"Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the <e2>NAD(P)H oxidase</e2> inhibitor diphenyleneiodonium (<e1>DPI</e1>), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.","Downregulator"
"The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by <e1>TSA</e1> on transforming growth factor-β (<e2>TGF-β</e2>)-induced myofibroblast differentiation of corneal fibroblasts in vitro.","Downregulator"
"<e1>Trichostatin A</e1> inhibits <e2>transforming growth factor-β</e2>-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.","Downregulator"
"The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by <e1>TSA</e1> on transforming growth factor-β (<e2>TGF-β</e2>)-induced myofibroblast differentiation of corneal fibroblasts in vitro.","Downregulator"
"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist <e1>AM4113</e1> were compared for their ability to modify <e2>CB(1) receptor</e2>-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.","Regulator"
"In the present studies, the CB(1) inverse agonist <e1>SR141716A</e1> (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify <e2>CB(1) receptor</e2>-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.","Regulator"
"In the present studies, the CB(1) inverse agonist SR141716A (<e1>rimonabant</e1>) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify <e2>CB(1) receptor</e2>-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.","Regulator"
"In the present studies, the <e2>CB(1)</e2> inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist <e1>AM4054</e1>.","Upregulator"
"In the present studies, the <e2>CB(1)</e2> inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist <e1>AM4054</e1>.","Agonist"
"Results indicate that AM4054 serves as an effective <e2>CB(1)</e2> discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist <e1>Δ(9)-tetrahydrocannabinol</e1>, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.","Agonist"
"In the present studies, the <e2>CB(1)</e2> inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist <e1>AM4054</e1>.","Agonist"
"In the present studies, the <e2>CB(1)</e2> inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist <e1>AM4054</e1>.","Agonist"
"Cannabinoid receptor 1 (<e2>CB(1)</e2>) inverse agonists (e.g., <e1>rimonabant</e1>) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.","Agonist"
"In the present studies, the <e2>CB(1)</e2> inverse agonist <e1>SR141716A</e1> (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.","Agonist"
"Cannabinoid receptor 1 (<e2>CB(1)</e2>) inverse agonists (e.g., <e1>rimonabant</e1>) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.","Agonist"
"<e2>Cannabinoid receptor 1</e2> (CB(1)) inverse agonists (e.g., <e1>rimonabant</e1>) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.","Agonist"
"Cannabinoid receptor 1 (<e2>CB(1)</e2>) inverse agonists (e.g., <e1>rimonabant</e1>) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.","Agonist"
"In the present studies, the <e2>CB(1)</e2> inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist <e1>AM4113</e1> were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.","Antagonist"
"In the present studies, the <e2>CB(1)</e2> inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist <e1>AM4113</e1> were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.","Antagonist"
"In early pregnancy, there were no significant differences in <e2>insulin</e2> sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-<e1>glucose</e1>-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups.","Regulator"
"<e1>Dabigatran</e1> has an advantage over the indirect <e2>thrombin</e2> inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin.","Downregulator"
"<e1>Dabigatran</e1> has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and <e2>fibrin</e2>-bound thrombin.","Downregulator"
"<e1>Dabigatran</e1> has an advantage over the indirect <e2>thrombin</e2> inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin.","Downregulator"
"Although parenteral oral direct <e2>thrombin</e2> inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as <e1>dabigatran</e1> are novel synthetic thrombin antagonists.","Downregulator"
"<e1>rivaroxaban</e1> and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free <e2>FXa</e2>.","Downregulator"
"<e1>rivaroxaban</e1> and apixaban, are potent, oral direct inhibitors of <e2>prothrombinase</e2>-bound, clot-associated or free FXa.","Downregulator"
"<e1>rivaroxaban</e1> and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free <e2>FXa</e2>.","Downregulator"
"rivaroxaban and <e1>apixaban</e1>, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free <e2>FXa</e2>.","Downregulator"
"rivaroxaban and <e1>apixaban</e1>, are potent, oral direct inhibitors of <e2>prothrombinase</e2>-bound, clot-associated or free FXa.","Downregulator"
"rivaroxaban and <e1>apixaban</e1>, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free <e2>FXa</e2>.","Downregulator"
"Although parenteral oral direct <e2>thrombin</e2> inhibitors (DTIs), such as <e1>argatroban</e1> and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists.","Downregulator"
"Although parenteral oral direct <e2>thrombin</e2> inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as <e1>dabigatran</e1> are novel synthetic thrombin antagonists.","Antagonist"
"Physiologic levels of Mg(2+) ions decrease <e2>ALDH1</e2> activity in part by increasing <e1>NADH</e1> binding affinity to the enzyme.","Regulator"
"Physiologic levels of Mg(2+) ions decrease <e2>ALDH1</e2> activity in part by increasing <e1>NADH</e1> binding affinity to the enzyme.","Regulator"
"Physiologic levels of Mg(2+) ions decrease <e2>ALDH1</e2> activity in part by increasing <e1>NADH</e1> binding affinity to the enzyme.","Regulator"
"Physiologic levels of Mg(2+) ions decrease <e2>ALDH1</e2> activity in part by increasing <e1>NADH</e1> binding affinity to the enzyme.","Regulator"
"Physiologic levels of Mg(2+) ions decrease <e2>ALDH1</e2> activity in part by increasing <e1>NADH</e1> binding affinity to the enzyme.","Regulator"
"We used this technique to investigate the effects of Mg(2+) ions on the <e2>ALDH1A1</e2>-<e1>NADH</e1> binding characteristics and enzyme catalysis.","Regulator"
"Fluorescence lifetime analysis and effect of magnesium ions on binding of <e1>NADH</e1> to <e2>human aldehyde dehydrogenase 1</e2>.","Regulator"
"We used this technique to investigate the effects of <e1>Mg(2+)</e1> ions on the <e2>ALDH1A1</e2>-NADH binding characteristics and enzyme catalysis.","Regulator"
"Physiologic levels of <e1>Mg(2+)</e1> ions decrease <e2>ALDH1</e2> activity in part by increasing NADH binding affinity to the enzyme.","Downregulator"
"Physiologic levels of <e1>Mg(2+)</e1> ions decrease <e2>ALDH1</e2> activity in part by increasing NADH binding affinity to the enzyme.","Downregulator"
"Physiologic levels of <e1>Mg(2+)</e1> ions decrease <e2>ALDH1</e2> activity in part by increasing NADH binding affinity to the enzyme.","Downregulator"
"<e2>Aldehyde dehydrogenase 1</e2> (ALDH1A1) catalyzes the oxidation of toxic aldehydes to <e1>carboxylic acids</e1>.","Substrate"
"Aldehyde dehydrogenase 1 (<e2>ALDH1A1</e2>) catalyzes the oxidation of toxic aldehydes to <e1>carboxylic acids</e1>.","Substrate"
"<e2>Aldehyde dehydrogenase 1</e2> (ALDH1A1) catalyzes the oxidation of toxic <e1>aldehydes</e1> to carboxylic acids.","Substrate"
"Aldehyde dehydrogenase 1 (<e2>ALDH1A1</e2>) catalyzes the oxidation of toxic <e1>aldehydes</e1> to carboxylic acids.","Substrate"
"Interestingly, <e1>Acrolein</e1> increased proteins' levels of amyloid precursor protein (<e2>APP</e2>), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.","Regulator"
"Interestingly, <e1>Acrolein</e1> increased proteins' levels of amyloid precursor protein (APP), β-secretase (<e2>BACE-1</e2>) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.","Upregulator"
"Interestingly, <e1>Acrolein</e1> increased proteins' levels of <e2>amyloid precursor protein</e2> (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.","Upregulator"
"Interestingly, <e1>Acrolein</e1> increased proteins' levels of amyloid precursor protein (APP), <e2>β-secretase</e2> (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.","Upregulator"
"Interestingly, <e1>Acrolein</e1> increased proteins' levels of amyloid precursor protein (APP), β-secretase (<e2>BACE-1</e2>) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.","Upregulator"
"Interestingly, <e1>Acrolein</e1> increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the <e2>amyloid β-peptide transporter</e2> receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.","Upregulator"
"Interestingly, <e1>Acrolein</e1> increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter <e2>receptor for advanced glycation end products</e2>, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.","Upregulator"
"Moreover, <e1>Acrolein</e1> resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of <e2>ADAM-10</e2> in hippocampus and cortex.","Downregulator"
"Interestingly, <e1>Acrolein</e1> increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased <e2>A-disintegrin and metalloprotease (ADAM) 10</e2> levels.","Downregulator"
"Regulation of sexual reproduction by <e1>estradiol</e1> involves the activation of <e2>estrogen receptors</e2> (ERs) in the hypothalamus.","Upregulator"
"Regulation of sexual reproduction by <e1>estradiol</e1> involves the activation of estrogen receptors (<e2>ERs</e2>) in the hypothalamus.","Upregulator"
"Mechanisms underlying membrane-initiated <e1>estradiol</e1> signaling are emerging, including evidence that activation of plasma membrane <e2>ERα</e2> involves receptor trafficking.","Upregulator"
"Mechanisms underlying membrane-initiated <e1>estradiol</e1> signaling are emerging, including evidence that activation of plasma membrane <e2>ERα</e2> involves receptor trafficking.","Upregulator"
"Mechanisms underlying membrane-initiated <e1>estradiol</e1> signaling are emerging, including evidence that activation of plasma membrane <e2>ERα</e2> involves receptor trafficking.","Upregulator"
"Insertion of <e2>ERα</e2> was blocked by the ER antagonist <e1>ICI 182,780</e1> or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).","Downregulator"
"Insertion of <e2>ERα</e2> was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor <e1>bisindolylmaleimide</e1> (BIS).","Downregulator"
"Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the <e2>protein kinase C</e2> (PKC) pathway inhibitor <e1>bisindolylmaleimide</e1> (BIS).","Downregulator"
"Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (<e2>PKC</e2>) pathway inhibitor <e1>bisindolylmaleimide</e1> (BIS).","Downregulator"
"Insertion of <e2>ERα</e2> was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (<e1>BIS</e1>).","Downregulator"
"Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the <e2>protein kinase C</e2> (PKC) pathway inhibitor bisindolylmaleimide (<e1>BIS</e1>).","Downregulator"
"Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (<e2>PKC</e2>) pathway inhibitor bisindolylmaleimide (<e1>BIS</e1>).","Downregulator"
"Insertion of <e2>ER</e2>α was blocked by the ER antagonist <e1>ICI 182,780</e1> or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).","Antagonist"
"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (<e2>PP2A</e2>), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <e1>EHT</e1>.","Regulator"
"These findings indicate that the neuroprotective effect of EHT against <e1>MPTP</e1> is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of <e2>PP2A</e2>.","Regulator"
"One of these compounds is <e1>eicosanoyl-5-hydroxytryptamide</e1> (EHT), which ameliorates the phenotype of <e2>α-synuclein</e2> transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation.","Regulator"
"One of these compounds is eicosanoyl-5-hydroxytryptamide (<e1>EHT</e1>), which ameliorates the phenotype of <e2>α-synuclein</e2> transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation.","Regulator"
"Reductions in striatal dopamine and <e2>tyrosine hydroxylase</e2> content were also less pronounced with <e1>EHT</e1> treatment.","Upregulator"
"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of <e2>phosphoprotein phosphatase 2A</e2> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <e1>EHT</e1>.","Upregulator"
"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (<e2>PP2A</e2>), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <e1>EHT</e1>.","Upregulator"
"Additionally, in SH-SY5Y cells, <e1>MPP(+)</e1>-induced demethylation of <e2>phosphoprotein phosphatase 2A</e2> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.","Downregulator"
"Additionally, in SH-SY5Y cells, <e1>MPP(+)</e1>-induced demethylation of phosphoprotein phosphatase 2A (<e2>PP2A</e2>), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.","Downregulator"
"The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and <e2>JNK</e2> activation were significantly prevented with <e1>EHT</e1>.","Downregulator"
"In cultured primary microglia and astrocytes, <e1>EHT</e1> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced <e2>NFκB</e2> activation, iNOS induction, and nitric oxide production.","Downregulator"
"In cultured primary microglia and astrocytes, <e1>EHT</e1> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation, <e2>iNOS</e2> induction, and nitric oxide production.","Downregulator"
"Substantial evidence shows that <e1>H(2)S</e1> is involved in aging by inhibiting free-radical reactions, activating SIRT1, and probably interacting with the age-related gene <e2>Klotho</e2>.","Regulator"
"Substantial evidence shows that <e1>H(2)S</e1> is involved in aging by inhibiting free-radical reactions, activating <e2>SIRT1</e2>, and probably interacting with the age-related gene Klotho.","Upregulator"
"The induction of <e2>HO-1</e2> by EIH was inhibited by SB203580 but not by <e1>SP600125</e1>, PD98059, nor LY294002.","Not"
"The induction of <e2>HO-1</e2> by EIH was inhibited by SB203580 but not by SP600125, <e1>PD98059</e1>, nor LY294002.","Not"
"The induction of <e2>HO-1</e2> by EIH was inhibited by SB203580 but not by SP600125, PD98059, nor <e1>LY294002</e1>.","Not"
"Induction of <e2>HO-1</e2> through p38 MAPK/Nrf2 signaling pathway by <e1>ethanol</e1> extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.","Upregulator"
"Induction of HO-1 through <e2>p38</e2> MAPK/Nrf2 signaling pathway by <e1>ethanol</e1> extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.","Upregulator"
"Induction of HO-1 through p38 <e2>MAPK</e2>/Nrf2 signaling pathway by <e1>ethanol</e1> extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.","Upregulator"
"The induction of <e2>HO-1</e2> by EIH was inhibited by <e1>SB203580</e1> but not by SP600125, PD98059, nor LY294002.","Downregulator"
"FMO3 expression is induced by dietary <e1>bile acids</e1> by a mechanism that involves the <e2>farnesoid X receptor</e2> (FXR), a bile acid-activated nuclear receptor.","Regulator"
"FMO3 expression is induced by dietary <e1>bile acids</e1> by a mechanism that involves the farnesoid X receptor (<e2>FXR</e2>), a bile acid-activated nuclear receptor.","Regulator"
"FMO3 expression is induced by dietary <e1>bile acid</e1>s by a mechanism that involves the <e2>farnesoid X receptor</e2> (FXR), a bile acid-activated nuclear receptor.","Upregulator"
"FMO3 expression is induced by dietary <e1>bile acid</e1>s by a mechanism that involves the farnesoid X receptor (<e2>FXR</e2>), a bile acid-activated nuclear receptor.","Upregulator"
"<e2>FMO3</e2> expression is induced by dietary <e1>bile acids</e1> by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor.","Upregulator"
"In mice, this reduction in <e2>FMO3</e2> expression is due primarily to downregulation by <e1>androgens</e1>.","Downregulator"
"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3</e2>, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO</e1>.","Substrate"
"We demonstrate that two <e2>flavin mono-oxygenase</e2> family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO</e1>.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, <e2>FMO1</e2> and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO</e1>.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3</e2>, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO</e1>.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3</e2>, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO</e1>.","Substrate"
"We demonstrate that two <e2>flavin mono-oxygenase</e2> family members, FMO1 and FMO3, oxidize <e1>trimethylamine</e1> (TMA), derived from gut flora metabolism of choline, to TMAO.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, <e2>FMO1</e2> and FMO3, oxidize <e1>trimethylamine</e1> (TMA), derived from gut flora metabolism of choline, to TMAO.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3</e2>, oxidize <e1>trimethylamine</e1> (TMA), derived from gut flora metabolism of choline, to TMAO.","Substrate"
"We demonstrate that two <e2>flavin mono-oxygenase</e2> family members, FMO1 and FMO3, oxidize trimethylamine (<e1>TMA</e1>), derived from gut flora metabolism of choline, to TMAO.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, <e2>FMO1</e2> and FMO3, oxidize trimethylamine (<e1>TMA</e1>), derived from gut flora metabolism of choline, to TMAO.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3</e2>, oxidize trimethylamine (<e1>TMA</e1>), derived from gut flora metabolism of choline, to TMAO.","Substrate"
"We demonstrate that two <e2>flavin mono-oxygenase</e2> family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>choline</e1>, to TMAO.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, <e2>FMO1</e2> and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>choline</e1>, to TMAO.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3</e2>, oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>choline</e1>, to TMAO.","Substrate"
"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3</e2>, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO</e1>.","Substrate"
"However, other <e1>steroids</e1>, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to <e2>estrogen receptor-α</e2> (ERα) and ERβ.","Regulator"
"However, other <e1>steroids</e1>, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (<e2>ERα</e2>) and ERβ.","Regulator"
"However, other <e1>steroids</e1>, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and <e2>ERβ</e2>.","Regulator"
"However, other steroids, including <e1>Δ(5)-androstenediol</e1>, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to <e2>estrogen receptor-α</e2> (ERα) and ERβ.","Regulator"
"However, other steroids, including <e1>Δ(5)-androstenediol</e1>, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (<e2>ERα</e2>) and ERβ.","Regulator"
"However, other steroids, including <e1>Δ(5)-androstenediol</e1>, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and <e2>ERβ</e2>.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, <e1>5α-androstanediol</e1> and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to <e2>estrogen receptor-α</e2> (ERα) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, <e1>5α-androstanediol</e1> and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (<e2>ERα</e2>) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, <e1>5α-androstanediol</e1> and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and <e2>ERβ</e2>.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and <e1>27-hydroxycholesterol</e1>, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to <e2>estrogen receptor-α</e2> (ERα) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and <e1>27-hydroxycholesterol</e1>, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (<e2>ERα</e2>) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and <e1>27-hydroxycholesterol</e1>, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and <e2>ERβ</e2>.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a <e1>3β-hydroxyl</e1> and a C19 methyl group, also mediate physiological responses through binding to <e2>estrogen receptor-α</e2> (ERα) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a <e1>3β-hydroxyl</e1> and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (<e2>ERα</e2>) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a <e1>3β-hydroxyl</e1> and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and <e2>ERβ</e2>.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 <e1>methyl</e1> group, also mediate physiological responses through binding to <e2>estrogen receptor-α</e2> (ERα) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 <e1>methyl</e1> group, also mediate physiological responses through binding to estrogen receptor-α (<e2>ERα</e2>) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 <e1>methyl</e1> group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and <e2>ERβ</e2>.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to <e1>estrogen</e1> receptor-α (<e2>ERα</e2>) and ERβ.","Regulator"
"However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to <e1>estrogen</e1> receptor-α (ERα) and <e2>ERβ</e2>.","Regulator"
"However, other <e1>steroids</e1>, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (<e2>ERα</e2>) and ERβ.","Regulator"
"However, other <e1>steroids</e1>, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and <e2>ERβ</e2>.","Regulator"
"Synthesis of <e1>quinoline</e1> derivatives: discovery of a potent and selective <e2>phosphodiesterase 5</e2> inhibitor for the treatment of Alzheimer's disease.","Downregulator"
"Phosphodiesterase type 5 (<e2>PDE5</e2>) mediates the degradation of <e1>cGMP</e1> in a variety of tissues including brain.","Substrate"
"<e2>Phosphodiesterase type 5</e2> (PDE5) mediates the degradation of <e1>cGMP</e1> in a variety of tissues including brain.","Substrate"
"A novel potent compound, <e1>N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide</e1> (12c), which binds <e2>Mcl-1</e2> with an IC(50) value of 54 nM was obtained.","Regulator"
"A novel potent compound, <e1>N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide</e1> (12c), which binds <e2>Mcl-1</e2> with an IC(50) value of 54 nM was obtained.","Downregulator"
"We have previously reported a nanomolar inhibitor of antiapoptotic <e2>Mcl-1</e2> protein, <e1>3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile</e1> (S1).","Downregulator"
"Fragment-based design, synthesis, and biological evaluation of <e1>N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide</e1> derivatives as novel <e2>Mcl-1</e2> inhibitors.","Downregulator"
"<e1>Peginesatide</e1>, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>erythropoietin receptor</e2> dimer that governs erythropoiesis.","Upregulator"
"Peginesatide, a <e1>polyethylene glycol</e1> (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>erythropoietin receptor</e2> dimer that governs erythropoiesis.","Upregulator"
"Peginesatide, a polyethylene glycol (<e1>PEG</e1>)ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>erythropoietin receptor</e2> dimer that governs erythropoiesis.","Upregulator"
"Electron paramagnetic resonance (EPR) studies using <e1>nucleotide</e1> analog spin label probes showed that dephosphorylated myosin heads are highly ordered in the relaxed fibers and have very low <e2>ATPase</e2> activity.","Regulator"
"Electron paramagnetic resonance (EPR) studies using <e1>nucleotide</e1> analog spin label probes showed that <e2>dephosphorylated myosin</e2> heads are highly ordered in the relaxed fibers and have very low ATPase activity.","Regulator"
"Activation of mesothelial cell <e1>LPA</e1>1 induced CTGF expression by inducing cytoskeleton reorganization in these cells, causing nuclear translocation of myocardin-related transcription factor (<e2>MRTF</e2>)-A and MRTF-B.","Regulator"
"<e1>LPA</e1>1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.","Regulator"
"There has been much recent interest in <e1>lysophosphatidic acid</e1> (LPA) signaling through one of its receptors, <e2>LPA1</e2>, in fibrotic diseases, but the mechanisms by which LPA-LPA1 signaling promotes pathological fibrosis remain to be fully elucidated.","Regulator"
"<e1>LPA</e1>1-induced cytoskeleton reorganization drives fibrosis through <e2>CTGF</e2>-dependent fibroblast proliferation.","Upregulator"
"Styrene oxide and <e1>4-vinylphenol</e1> possessed similar affinity for <e2>CYP2E1</e2>.","Regulator"
"Cooperative effects for <e2>CYP2E1</e2> differ between <e1>styrene</e1> and its metabolites.","Regulator"
"Cooperative effects for <e2>CYP2E1</e2> differ between <e1>styrene</e1> and its metabolites.","Regulator"
"<e1>Styrene oxide</e1> and 4-vinylphenol possessed similar affinity for <e2>CYP2E1</e2>.","Regulator"
"Cooperative effects for <e2>CYP2E1</e2> differ between <e1>styrene</e1> and its metabolites.","Regulator"
"<e1>Bile acids</e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, <e2>constitutive androstane receptor</e2>, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.","Upregulator"
"<e1>Bile acids</e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and <e2>vitamin D receptor</e2>, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.","Upregulator"
"<e1>Bile acids</e1> are signaling molecules that activate <e2>nuclear receptors</e2>, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.","Upregulator"
"<e1>Bile acids</e1> are signaling molecules that activate nuclear receptors, such as <e2>farnesoid X receptor</e2>, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.","Upregulator"
"<e1>Bile acids</e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, <e2>pregnane X receptor</e2>, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.","Upregulator"
"The peptide <e1>YR-11</e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited <e2>RANK</e2>-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Regulator"
"The peptide <e1>YR-11</e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-<e2>RANKL</e2> binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Regulator"
"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of <e1>cysteine</e1> with a serine residue in the template sequence, significantly (p<0.05) inhibited <e2>RANK</e2>-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Regulator"
"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of <e1>cysteine</e1> with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-<e2>RANKL</e2> binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Regulator"
"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a <e1>serine</e1> residue in the template sequence, significantly (p<0.05) inhibited <e2>RANK</e2>-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Regulator"
"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a <e1>serine</e1> residue in the template sequence, significantly (p<0.05) inhibited RANK-<e2>RANKL</e2> binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Regulator"
"Results confirmed that <e1>YR-11</e1> peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of <e2>NF-κB</e2>.","Downregulator"
"The peptide <e1>YR-11</e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-<e2>RANKL</e2> binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Downregulator"
"The peptide <e1>YR-11</e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>TRAP</e2> activity and formation of multinucleated osteoclasts without any cytotoxicity.","Downregulator"
"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of <e1>cysteine</e1> with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-<e2>RANKL</e2> binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Downregulator"
"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of <e1>cysteine</e1> with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>TRAP</e2> activity and formation of multinucleated osteoclasts without any cytotoxicity.","Downregulator"
"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a <e1>serine</e1> residue in the template sequence, significantly (p<0.05) inhibited RANK-<e2>RANKL</e2> binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Downregulator"
"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a <e1>serine</e1> residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>TRAP</e2> activity and formation of multinucleated osteoclasts without any cytotoxicity.","Downregulator"
"Results confirmed that <e1>YR-11</e1> peptide inhibited pro-inflammatory <e2>cytokines</e2> in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-κB.","Downregulator"
"The peptide <e1>YR-11</e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-<e2>RANKL</e2> binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.","Downregulator"
"RESULTS: In contrast to immune stimulatory sequence ISS 1018, BCG DNA spontaneously formed nanoparticulate structures and induced <e2>actin</e2> polymerization as did synthetic <e1>silica</e1> nanoparticles.","Regulator"
"The activation of <e2>Rac1</e2> was induced by <e1>silica</e1> nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.","Upregulator"
"In this small library of novel bioactive macrocyclic <e1>lathyrane diterpene</e1> derivatives, designed to evaluate structure-activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and octanol/water partition coefficient were identified that can contribute to the development of new selective <e2>P-gp</e2> reversal agents.","Regulator"
"Additionally, these effects of <e1>ATO</e1> on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an <e2>ATM</e2> inhibitor.","Upregulator"
"Osteoblasts survive the <e1>arsenic trioxide</e1> treatment by activation of <e2>ATM</e2>-mediated pathway.","Upregulator"
"Additionally, these effects of <e1>ATO</e1> on γ-H2AX, <e2>Chk1</e2>, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor.","Upregulator"
"Additionally, these effects of <e1>ATO</e1> on γ-H2AX, Chk1, <e2>Chk2</e2>, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor.","Upregulator"
"Additionally, these effects of <e1>ATO</e1> on γ-H2AX, Chk1, Chk2, <e2>p53</e2>, and p21(waf1/cip1) were reduced by an ATM inhibitor.","Upregulator"
"Additionally, these effects of <e1>ATO</e1> on γ-H2AX, Chk1, Chk2, p53, and <e2>p21</e2>(waf1/cip1) were reduced by an ATM inhibitor.","Upregulator"
"Additionally, these effects of <e1>ATO</e1> on γ-H2AX, Chk1, Chk2, p53, and p21(<e2>waf1</e2>/cip1) were reduced by an ATM inhibitor.","Upregulator"
"Additionally, these effects of <e1>ATO</e1> on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/<e2>cip1</e2>) were reduced by an ATM inhibitor.","Upregulator"
"Additionally, these effects of <e1>ATO</e1> on γ-<e2>H2AX</e2>, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor.","Upregulator"
"Furthermore, a mixture of <e1>isoflavonoid</e1> parent compounds, and a mixture of isoflavonoid metabolites were found to have <e2>PPARγ</e2> activating abilities.","Upregulator"
"Furthermore, a mixture of <e1>isoflavonoid</e1> parent compounds, and a mixture of isoflavonoid metabolites were found to have <e2>PPARγ</e2> activating abilities.","Upregulator"
"Both <e1>fatty acids</e1>, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker <e2>CD69</e2> was unaltered on activated T cells.","Not"
"Both fatty acids, but <e1>DHA</e1> to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker <e2>CD69</e2> was unaltered on activated T cells.","Not"
"Both fatty acids, but DHA to a lesser extent compared with <e1>EPA</e1>, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker <e2>CD69</e2> was unaltered on activated T cells.","Not"
"In monocytes, both <e1>EPA</e1> and DHA increased interleukin (IL)-10 without affecting <e2>tumor necrosis factor (TNF)-α</e2> and IL-6.","Not"
"In monocytes, both <e1>EPA</e1> and DHA increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-α and <e2>IL-6</e2>.","Not"
"In monocytes, both EPA and <e1>DHA</e1> increased interleukin (IL)-10 without affecting <e2>tumor necrosis factor (TNF)-α</e2> and IL-6.","Not"
"In monocytes, both EPA and <e1>DHA</e1> increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-α and <e2>IL-6</e2>.","Not"
"Both <e1>fatty acids</e1>, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a <e2>peroxisome proliferator-activated receptor (PPAR)γ</e2>-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.","Regulator"
"Both fatty acids, but <e1>DHA</e1> to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a <e2>peroxisome proliferator-activated receptor (PPAR)γ</e2>-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.","Regulator"
"Both fatty acids, but DHA to a lesser extent compared with <e1>EPA</e1>, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a <e2>peroxisome proliferator-activated receptor (PPAR)γ</e2>-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.","Regulator"
"In monocytes, both <e1>EPA</e1> and DHA increased <e2>interleukin (IL)-10</e2> without affecting tumor necrosis factor (TNF)-α and IL-6.","Upregulator"
"In monocytes, both EPA and <e1>DHA</e1> increased <e2>interleukin (IL)-10</e2> without affecting tumor necrosis factor (TNF)-α and IL-6.","Upregulator"
"Both <e1>fatty acids</e1>, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of <e2>cytokine</e2>-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.","Downregulator"
"Both fatty acids, but <e1>DHA</e1> to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of <e2>cytokine</e2>-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.","Downregulator"
"Both fatty acids, but DHA to a lesser extent compared with <e1>EPA</e1>, selectively and dose-dependently reduced the percentage of <e2>cytokine</e2>-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.","Downregulator"
"In the in vitro model we observed high permeability of <e1>imperatorin</e1> and isoimperatorin with the <e2>P-gp</e2>-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.","Substrate"
"In the in vitro model we observed high permeability of imperatorin and <e1>isoimperatorin</e1> with the <e2>P-gp</e2>-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.","Substrate"
"In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the <e2>P-gp</e2>-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of <e1>cnidilin</e1> with 0.82.","Substrate"
"In this study, we examined the effects of transmethylation on tumorigenic responses and its regulatory mechanism using an upregulation strategy of adenosylhomocysteine (<e1>SAH</e1>) <e2>actin</e2>g as a negative feedback inhibitor.","Regulator"
"In this study, we examined the effects of transmethylation on tumorigenic responses and its regulatory mechanism using an upregulation strategy of adenosylhomocysteine (<e1>SAH</e1>) <e2>actin</e2>g as a negative feedback inhibitor.","Regulator"
"In agreement with these data, the exogenous treatment of <e1>SAH</e1> or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on <e2>Src</e2>, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.","Regulator"
"Involvement of <e2>Src</e2> and the actin cytoskeleton in the antitumorigenic action of <e1>adenosine dialdehyde</e1>.","Regulator"
"Involvement of Src and the <e2>actin</e2> cytoskeleton in the antitumorigenic action of <e1>adenosine dialdehyde</e1>.","Regulator"
"In this study, we examined the effects of transmethylation on tumorigenic responses and its regulatory mechanism using an upregulation strategy of adenosylhomocysteine (<e1>SAH</e1>) <e2>actin</e2>g as a negative feedback inhibitor.","Regulator"
"In agreement with these data, the exogenous treatment of <e1>SAH</e1> or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on <e2>Src</e2>, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.","Regulator"
"Taken together, these results suggest that <e1>SAH</e1>/SAHH-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the actin cytoskeleton and Src <e2>kinase</e2> activity.","Regulator"
"In agreement with these data, the exogenous treatment of <e1>SAH</e1> or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on <e2>Src</e2>, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.","Downregulator"
"Through immunoblotting analysis, it was found that <e1>AdOx</e1> was capable of indirectly diminishing the phosphorylation of oncogenic <e2>Src</e2> and its kinase activity.","Downregulator"
"Through immunoblotting analysis, it was found that <e1>AdOx</e1> was capable of indirectly diminishing the phosphorylation of oncogenic <e2>Src</e2> and its kinase activity.","Downregulator"
"Interestingly, <e1>AdOx</e1> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and <e2>p85</e2>/PI3K, which is linked to various tumorigenic responses.","Downregulator"
"Interestingly, <e1>AdOx</e1> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/<e2>PI3K</e2>, which is linked to various tumorigenic responses.","Downregulator"
"Through immunoblotting analysis, it was found that <e1>AdOx</e1> was capable of indirectly diminishing the phosphorylation of oncogenic Src and its <e2>kinase</e2> activity.","Downregulator"
"Interestingly, <e1>AdOx</e1> disrupted <e2>actin</e2> cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/PI3K, which is linked to various tumorigenic responses.","Downregulator"
"In agreement with these data, the exogenous treatment of SAH or inhibition of <e2>SAHH</e2> by specific siRNA or another type of inhibitor, <e1>3-deazaadenosine</e1> (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.","Downregulator"
"In agreement with these data, the exogenous treatment of SAH or inhibition of <e2>SAHH</e2> by specific siRNA or another type of inhibitor, 3-deazaadenosine (<e1>DAZA</e1>), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.","Downregulator"
"Treatment with <e1>adenosine dialdehyde</e1> (AdOx), an inhibitor of transmethylation-suppressive <e2>adenosylhomocysteine (SAH) hydrolase</e2> (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.","Downregulator"
"Treatment with <e1>adenosine dialdehyde</e1> (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (<e2>SAHH</e2>), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.","Downregulator"
"Treatment with adenosine dialdehyde (<e1>AdOx</e1>), an inhibitor of transmethylation-suppressive <e2>adenosylhomocysteine (SAH) hydrolase</e2> (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.","Downregulator"
"Treatment with adenosine dialdehyde (<e1>AdOx</e1>), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (<e2>SAHH</e2>), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.","Downregulator"
"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (<e1>SAH</e1>) hydrolase (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.","Substrate"
"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (<e1>SAH</e1>) hydrolase (<e2>SAHH</e2>), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.","Substrate"
"Synthesis of derivatives of <e1>methyl rosmarinate</e1> and their inhibitory activities against matrix metalloproteinase-1 (<e2>MMP-1</e2>).","Downregulator"
"Synthesis of derivatives of <e1>methyl rosmarinate</e1> and their inhibitory activities against matrix metalloproteinase-1 (<e2>MMP-1</e2>).","Downregulator"
"Synthesis of derivatives of <e1>methyl rosmarinate</e1> and their inhibitory activities against <e2>matrix metalloproteinase-1</e2> (MMP-1).","Downregulator"
"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as <e2>cyclooxygenase-2</e2> (COX-2)-derived <e1>prostaglandin E2</e1> (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.","Substrate"
"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (<e2>COX-2</e2>)-derived <e1>prostaglandin E2</e1> (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.","Substrate"
"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as <e2>cyclooxygenase-2</e2> (COX-2)-derived prostaglandin E2 (<e1>PGE2</e1>) inhibitory activity of murine macrophage RAW 264.7 cell line.","Substrate"
"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (<e2>COX-2</e2>)-derived prostaglandin E2 (<e1>PGE2</e1>) inhibitory activity of murine macrophage RAW 264.7 cell line.","Substrate"
"It had higher levels of <e1>oleocanthal</e1> (p-HPEA-EDA), a nutraceutical compound exerting actions against <e2>COX1</e2> and COX2 (cycloxygenases).","Regulator"
"It had higher levels of <e1>oleocanthal</e1> (p-HPEA-EDA), a nutraceutical compound exerting actions against COX1 and <e2>COX2</e2> (cycloxygenases).","Regulator"
"It had higher levels of <e1>oleocanthal</e1> (p-HPEA-EDA), a nutraceutical compound exerting actions against COX1 and COX2 (<e2>cycloxygenases</e2>).","Regulator"
"It had higher levels of oleocanthal (<e1>p-HPEA-EDA</e1>), a nutraceutical compound exerting actions against <e2>COX1</e2> and COX2 (cycloxygenases).","Regulator"
"It had higher levels of oleocanthal (<e1>p-HPEA-EDA</e1>), a nutraceutical compound exerting actions against COX1 and <e2>COX2</e2> (cycloxygenases).","Regulator"
"It had higher levels of oleocanthal (<e1>p-HPEA-EDA</e1>), a nutraceutical compound exerting actions against COX1 and COX2 (<e2>cycloxygenases</e2>).","Regulator"
"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the <e2>lipoxygenase</e2> (LOX)-pathway (one having as precursors the <e1>polyunsaturated fatty acids</e1> containing a cis-cis-1,4-pentadiene system).","Substrate"
"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (<e2>LOX</e2>)-pathway (one having as precursors the <e1>polyunsaturated fatty acids</e1> containing a cis-cis-1,4-pentadiene system).","Substrate"
"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the <e2>lipoxygenase</e2> (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a <e1>cis-cis-1,4-pentadiene</e1> system).","Substrate"
"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (<e2>LOX</e2>)-pathway (one having as precursors the polyunsaturated fatty acids containing a <e1>cis-cis-1,4-pentadiene</e1> system).","Substrate"
"The contrasting activity of <e1>iodido</e1> versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, <e2>p53</e2> dependence, and apoptosis pathway.","Regulator"
"The contrasting activity of iodido versus <e1>chlorido ruthenium</e1> and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, <e2>p53</e2> dependence, and apoptosis pathway.","Regulator"
"The contrasting activity of iodido versus chlorido ruthenium and <e1>osmium arene azo- and imino-pyridine</e1> anticancer complexes: control of cell selectivity, cross-resistance, <e2>p53</e2> dependence, and apoptosis pathway.","Regulator"
"The contrasting activity of <e1>iodido</e1> versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, <e2>p53</e2> dependence, and apoptosis pathway.","Regulator"
"In general, antiproliferative activity is greatly enhanced by low levels of the <e2>glutathione synthase</e2> inhibitor <e1>l-buthionine sulfoxime</e1>.","Downregulator"
"The recent identification of <e1>zinc</e1> permeability of the lysosomal ion channel <e2>TRPML1</e2> (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.","Substrate"
"The recent identification of <e1>zinc</e1> permeability of the lysosomal ion channel TRPML1 (<e2>transient receptor potential mucolipin 1</e2>), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.","Substrate"
"The recent identification of <e1>zinc</e1> permeability of the lysosomal ion channel <e2>TRPML1</e2> (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.","Substrate"
"Cellular <e1>zinc</e1> is controlled by <e2>zinc-chelating proteins</e2> and by zinc transporters.","Substrate"
"Cellular <e1>zinc</e1> is controlled by zinc-chelating proteins and by <e2>zinc transporters</e2>.","Substrate"
"The recent identification of <e1>zinc</e1> permeability of the lysosomal ion channel <e2>TRPML1</e2> (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.","Substrate"
"The recent identification of <e1>zinc</e1> permeability of the lysosomal ion channel <e2>TRPML1</e2> (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.","Substrate"
"We now show that lysosomal enlargement and <e1>zinc</e1> build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the zinc transporter <e2>ZnT4</e2>.","Substrate"
"Similarly, intraperitoneal administration of <e1>α-santalol</e1> (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, <e2>catalase</e2>, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.","Regulator"
"Similarly, intraperitoneal administration of <e1>α-santalol</e1> (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum <e2>aminotransferases</e2>, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.","Regulator"
"Similarly, intraperitoneal administration of <e1>α-santalol</e1> (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, <e2>alkaline phosphatase</e2>, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.","Regulator"
"Similarly, intraperitoneal administration of <e1>α-santalol</e1> (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, <e2>superoxide dismutase</e2>, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.","Regulator"
"The increase in <e2>SAA</e2> expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as <e1>acetaminophen</e1>, valproic acid, or metformin.","Not"
"The increase in <e2>SAA</e2> expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, <e1>valproic acid</e1>, or metformin.","Not"
"The increase in <e2>SAA</e2> expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or <e1>metformin</e1>.","Not"
"Our in vitro studies showed that <e1>cyclic adenosine 3',5'-monophosphate</e1> (cAMP) accumulation was not a primary cause of the ritodrine-induced <e2>SAA</e2> increase.","Not"
"Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (<e1>cAMP</e1>) accumulation was not a primary cause of the ritodrine-induced <e2>SAA</e2> increase.","Not"
"The tocolytic agent <e1>ritodrine</e1> acts on the <e2>β2-adrenoceptor</e2> and is an effective treatment option for preterm labor.","Regulator"
"Importantly, expression of the acute-phase reactant <e2>serum amyloid A</e2> (SAA) significantly increased after <e1>ritodrine</e1> injection, with values indicating the largest fold-change.","Upregulator"
"Importantly, expression of the acute-phase reactant serum amyloid A (<e2>SAA</e2>) significantly increased after <e1>ritodrine</e1> injection, with values indicating the largest fold-change.","Upregulator"
"<e2>Serum amyloid A</e2> upsurge precedes standard biomarkers of hepatotoxicity in <e1>ritodrine</e1>-injected mice.","Upregulator"
"Importantly, expression of the acute-phase reactant serum amyloid A (<e2>SAA</e2>) significantly increased after <e1>ritodrine</e1> injection, with values indicating the largest fold-change.","Upregulator"
"Importantly, expression of the acute-phase reactant serum amyloid A (<e2>SAA</e2>) significantly increased after <e1>ritodrine</e1> injection, with values indicating the largest fold-change.","Upregulator"
"The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of <e1>ceftazidime</e1> versus most species of Enterobacteriaceae depending on the presence or absence of <e2>β-lactamase</e2> enzyme(s).","Not"
"Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the <e1>cephem</e1> bicyclic ring system, and avibactam has been shown to bond covalently to <e2>β-lactamases</e2>.","Regulator"
"Although not a β-lactam, the chemical structure of <e1>avibactam</e1> closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to <e2>β-lactamases</e2>.","Regulator"
"Potential future roles for <e1>ceftazidime</e1>-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing <e2>extended-spectrum ß-lactamase</e2> (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.","Regulator"
"Potential future roles for <e1>ceftazidime</e1>-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (<e2>ESBL</e2>), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.","Regulator"
"Potential future roles for <e1>ceftazidime</e1>-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), <e2>Klebsiella pneumoniae carbapenemases</e2> (KPCs) and/or AmpC ß-lactamases.","Regulator"
"Potential future roles for <e1>ceftazidime</e1>-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (<e2>KPCs</e2>) and/or AmpC ß-lactamases.","Regulator"
"Potential future roles for <e1>ceftazidime</e1>-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or <e2>AmpC ß-lactamases</e2>.","Regulator"
"Potential future roles for ceftazidime-<e1>avibactam</e1> include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing <e2>extended-spectrum ß-lactamase</e2> (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.","Regulator"
"Potential future roles for ceftazidime-<e1>avibactam</e1> include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (<e2>ESBL</e2>), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.","Regulator"
"Potential future roles for ceftazidime-<e1>avibactam</e1> include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), <e2>Klebsiella pneumoniae carbapenemases</e2> (KPCs) and/or AmpC ß-lactamases.","Regulator"
"Potential future roles for ceftazidime-<e1>avibactam</e1> include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (<e2>KPCs</e2>) and/or AmpC ß-lactamases.","Regulator"
"Potential future roles for ceftazidime-<e1>avibactam</e1> include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or <e2>AmpC ß-lactamases</e2>.","Regulator"
"The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of <e1>ceftazidime</e1> versus most species of Enterobacteriaceae depending on the presence or absence of <e2>β-lactamase</e2> enzyme(s).","Downregulator"
"Ceftazidime-<e1>avibactam</e1>: a novel cephalosporin/<e2>β-lactamase</e2> inhibitor combination.","Downregulator"
"Avibactam (formerly <e1>NXL104</e1>, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some <e2>Ambler class D</e2> enzymes.","Downregulator"
"Avibactam (formerly <e1>NXL104</e1>, AVE1330A) is a synthetic non-β-lactam, <e2>β-lactamase</e2> inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.","Downregulator"
"<e1>Avibactam</e1> (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some <e2>Ambler class D</e2> enzymes.","Downregulator"
"<e1>Avibactam</e1> (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, <e2>β-lactamase</e2> inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.","Downregulator"
"Ceftazidime-<e1>avibactam</e1> appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus <e2>ß-lactamase</e2>-producing Gram-negative bacilli.","Downregulator"
"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of <e1>ceftazidime</e1> versus <e2>ß-lactamase</e2>-producing Gram-negative bacilli.","Downregulator"
"Avibactam (formerly NXL104, <e1>AVE1330A</e1>) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some <e2>Ambler class D</e2> enzymes.","Downregulator"
"Avibactam (formerly NXL104, <e1>AVE1330A</e1>) is a synthetic non-β-lactam, <e2>β-lactamase</e2> inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.","Downregulator"
"Ceftazidime-<e1>avibactam</e1>: a novel cephalosporin/<e2>β-lactamase</e2> inhibitor combination.","Downregulator"
"The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of <e1>ceftazidime</e1> versus most species of Enterobacteriaceae depending on the presence or absence of <e2>β-lactamase</e2> enzyme(s).","Downregulator"
"<e1>Ceftazidime</e1>-avibactam: a novel cephalosporin/<e2>β-lactamase</e2> inhibitor combination.","Downregulator"
"Ceftazidime-<e1>avibactam</e1>: a novel cephalosporin/<e2>β-lactamase</e2> inhibitor combination.","Downregulator"
"Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective <e2>cyclooxygenase-2</e2> inhibitor, <e1>celecoxib</e1>, improved vascular function, and also attenuated obesity.","Downregulator"
"<e1>Upamostat</e1> (Mesupron®) is a new small molecule <e2>serine protease</e2> inhibitor.","Downregulator"
"Upamostat (<e1>Mesupron</e1>®) is a new small molecule <e2>serine protease</e2> inhibitor.","Downregulator"
"Moreover, we show that <e2>USP22</e2> is acetylated on multiple <e1>lysine</e1> residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex.","Part_of"
"Moreover, we show that USP22 is acetylated on multiple <e1>lysine</e1> residues and that alteration of a single lysine (K129) within the <e2>ZnF-UBP domain</e2> is sufficient to alter interaction of the DUBm with the core SAGA complex.","Part_of"
"Transcripts of GPx4 genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the <e2>GPx1</e2> genes were more responsive to <e1>selenium</e1> exposure in vitro, especially to the organic form.","Regulator"
"Interestingly, <e2>GPx1a</e2> was the most sensitive to <e1>selenium</e1> availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells.","Regulator"
"Transcripts of GPx4 genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the <e2>GPx1</e2> genes were more responsive to <e1>selenium</e1> exposure in vitro, especially to the organic form.","Regulator"
"Characterization of <e2>cytosolic glutathione peroxidase</e2> and phospholipid-hydroperoxide glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro <e1>selenium</e1> exposure.","Regulator"
"Characterization of cytosolic glutathione peroxidase and <e2>phospholipid-hydroperoxide glutathione peroxidase</e2> genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro <e1>selenium</e1> exposure.","Regulator"
"Interestingly, GPx1a was the most sensitive to <e1>selenium</e1> availability in non stressful conditions, whereas <e2>GPx1b1</e2> and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells.","Upregulator"
"Interestingly, GPx1a was the most sensitive to <e1>selenium</e1> availability in non stressful conditions, whereas GPx1b1 and <e2>GPx1b2</e2> were highly induced by exposure to selenium levels that had some toxic effects on the cells.","Upregulator"
"<e1>Mn</e1> exposure (20 mg/kg) increased <e2>p38</e2>(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.","Upregulator"
"<e1>Mn</e1> exposure (20 mg/kg) increased p38(<e2>MAPK</e2>) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.","Upregulator"
"<e1>Mn</e1> (10 and 20 mg/kg) increased <e2>caspase</e2> activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).","Upregulator"
"<e1>Mn</e1> exposure (20 mg/kg) increased <e2>p38</e2>(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.","Upregulator"
"<e1>Mn</e1> exposure (20 mg/kg) increased p38(<e2>MAPK</e2>) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.","Upregulator"
"<e1>Mn</e1> exposure (20 mg/kg) increased p38(MAPK) and <e2>Akt</e2> phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.","Upregulator"
"<e1>Mn</e1> (10 and 20 mg/kg) increased <e2>caspase</e2> activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).","Upregulator"
"<e1>Mn</e1> exposure (20 mg/kg) increased <e2>p38</e2>(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.","Upregulator"
"<e1>Mn</e1> exposure (20 mg/kg) increased p38(<e2>MAPK</e2>) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.","Upregulator"
"<e1>Mn</e1> (10 and 20 mg/kg) increased <e2>caspase</e2> activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).","Upregulator"
"<e1>Mn</e1> exposure (20 mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased <e2>DARPP-32</e2>-Thr-34 phosphorylation.","Downregulator"
"Notably, the antioxidant <e1>Trolox</e1>™ reversed the Mn (20 mg/kg)-dependent augmentation in <e2>p38</e2>(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.","Downregulator"
"Notably, the antioxidant <e1>Trolox</e1>™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(<e2>MAPK</e2>) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.","Downregulator"
"Notably, the antioxidant <e1>Trolox</e1>™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced <e2>caspase</e2> activity and F(2)-isoprostane production.","Downregulator"
"<e1>Nocapyrone H</e1> (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and <e2>interleukin-1β</e2> (IL-1β).","Downregulator"
"<e1>Nocapyrone H</e1> (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1β (<e2>IL-1β</e2>).","Downregulator"
"Investigating the enteroenteric recirculation of <e1>apixaban</e1>, a <e2>factor Xa</e2> inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.","Downregulator"
"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with <e1>GF-120918</e1>, a dual <e2>BCRP</e2> and P-gp inhibitor).","Downregulator"
"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with <e1>GF-120918</e1>, a dual BCRP and <e2>P-gp</e2> inhibitor).","Downregulator"
"Additionally, the role of P-gp (P-glycoprotein; abcb1) and <e2>BCRP</e2> (breast cancer resistance protein; abcg2) in <e1>apixaban</e1> disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.","Substrate"
"Additionally, the role of <e2>P-gp</e2> (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in <e1>apixaban</e1> disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.","Substrate"
"The enzyme (TcCA) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform <e2>hCA II</e2>, although it is devoid of the <e1>His</e1>64 proton shuttle.","Part_of"
"A large number of <e1>aromatic/heterocyclic sulfonamides</e1> and some 5-mercapto-1,3,4-thiadiazoles were investigated as <e2>TcCA</e2> inhibitors.","Downregulator"
"A large number of aromatic/heterocyclic sulfonamides and some <e1>5-mercapto-1,3,4-thiadiazoles</e1> were investigated as <e2>TcCA</e2> inhibitors.","Downregulator"
"Cloning, Characterization, and <e1>Sulfonamide</e1> and Thiol Inhibition Studies of an <e2>α-Carbonic Anhydrase</e2> from Trypanosoma cruzi, the Causative Agent of Chagas Disease.","Downregulator"
"Cloning, Characterization, and Sulfonamide and <e1>Thiol</e1> Inhibition Studies of an <e2>α-Carbonic Anhydrase</e2> from Trypanosoma cruzi, the Causative Agent of Chagas Disease.","Downregulator"
"The enzyme (TcCA) has a very high catalytic activity for the <e1>CO(2)</e1> hydration reaction, being similar kinetically to the human (h) isoform <e2>hCA II</e2>, although it is devoid of the His64 proton shuttle.","Substrate"
"The enzyme (<e2>TcCA</e2>) has a very high catalytic activity for the <e1>CO(2)</e1> hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle.","Substrate"
"However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of <e2>Insl3</e2>, Hsd17b3 and Hsd11b1 in the <e1>DEHP</e1>-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.","Not"
"However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, <e2>Hsd17b3</e2> and Hsd11b1 in the <e1>DEHP</e1>-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.","Not"
"However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and <e2>Hsd11b1</e2> in the <e1>DEHP</e1>-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.","Not"
"The mRNA level for <e2>nestin</e2> (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the <e1>DEHP</e1> treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.","Not"
"The mRNA level for nestin (<e2>Nes</e2>, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the <e1>DEHP</e1> treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.","Not"
"However, there were detectable concentrations of <e2>Lhcgr</e2>, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the <e1>DEHP</e1>-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.","Regulator"
"However, there were detectable concentrations of Lhcgr, <e2>Cyp11a1</e2> and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the <e1>DEHP</e1>-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.","Regulator"
"However, there were detectable concentrations of Lhcgr, Cyp11a1 and <e2>Cyp17a1</e2> mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the <e1>DEHP</e1>-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.","Regulator"
"The mRNA level for <e2>nestin</e2> (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-<e1>EDS</e1>, but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.","Upregulator"
"The mRNA level for nestin (<e2>Nes</e2>, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-<e1>EDS</e1>, but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSH</e2>β transcription is mediated via activation of PKA and CREB.","Regulator"
"Expression of pituitary FSH and <e2>LH</e2>, under the control of pulsatile <e1>GnRH</e1>, is essential for fertility.","Regulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Regulator"
"A dominant negative PKA (DNPKA) reduced <e1>GnRH</e1>-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on <e2>LHβ</e2>LUC activity, indicating relative specificity of this pathway.","Regulator"
"<e1>GnRH</e1> stimulation of CREB phosphorylation (<e2>pCREB</e2>) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and <e2>CREB</e2>.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of <e2>PKA</e2> and CREB.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of <e2>PKA</e2> and CREB.","Upregulator"
"<e1>GnRH</e1> stimulation of CREB phosphorylation (<e2>pCREB</e2>) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and <e2>CREB</e2>.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and <e2>CREB</e2>.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and <e2>CREB</e2>.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and <e2>CREB</e2>.","Upregulator"
"<e1>GnRH</e1> stimulation of CREB phosphorylation (<e2>pCREB</e2>) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Upregulator"
"<e1>GnRH</e1> pulse frequency-dependent stimulation of <e2>FSHβ</e2> transcription is mediated via activation of PKA and CREB.","Upregulator"
"<e1>GnRH</e1> stimulation of CREB phosphorylation (<e2>pCREB</e2>) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.","Upregulator"
"GnRH stimulation of <e2>CREB</e2> phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, <e1>H89</e1>.","Downregulator"
"GnRH stimulation of CREB phosphorylation (<e2>pCREB</e2>) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, <e1>H89</e1>.","Downregulator"
"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a <e2>protein kinase A</e2> (PKA) inhibitor, <e1>H89</e1>.","Downregulator"
"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (<e2>PKA</e2>) inhibitor, <e1>H89</e1>.","Downregulator"
"<e1>Sophocarpine</e1>, an effective compound derived from foxtail-like sophora herb and seed, has been reported that it can alleviate non-alcoholic steatohepatitis (NASH) in rats and affect <e2>adipocytokine</e2> synthesis.","Regulator"
"Moreover, compared with the model group, <e1>sophocarpine</e1> could significantly increase P-<e2>AMPK</e2>α (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.","Upregulator"
"<e1>Sophocarpine</e1> alleviates hepatocyte steatosis through activating <e2>AMPK</e2> signaling pathway.","Upregulator"
"Moreover, compared with the model group, <e1>sophocarpine</e1> could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and <e2>ACC</e2> (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.","Upregulator"
"Moreover, compared with the model group, <e1>sophocarpine</e1> could significantly increase <e2>P-AMPKα</e2> (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.","Upregulator"
"Moreover, compared with the model group, <e1>sophocarpine</e1> could significantly increase P-<e2>AMPKα</e2> (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.","Upregulator"
"While <e1>sophocarpine</e1> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of <e2>adiponectin</e2> expression (>1.48-fold).","Upregulator"
"Moreover, compared with the model group, <e1>sophocarpine</e1> could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce <e2>P-ACC</e2> (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.","Downregulator"
"Moreover, compared with the model group, <e1>sophocarpine</e1> could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and <e2>HNF-4α</e2> (<0.20-fold) protein expression.","Downregulator"
"While <e1>sophocarpine</e1> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of <e2>leptin</e2> expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold).","Downregulator"
"The involvement of <e2>P-gp</e2> in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor <e1>zosuquidar</e1>.","Downregulator"
"Upon studying the drug-drug interaction of darunavir with <e1>ketoconazole</e1>, data were indicative for an inhibitory effect of ketoconazole on <e2>P-gp</e2> as the main mechanism for the increased transport of darunavir across the small intestine.","Downregulator"
"To evaluate to what extent the regional differences in expression of <e2>P-gp</e2> and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of <e1>darunavir</e1> across different small intestinal segments (duodenum, proximal jejunum and ileum).","Substrate"
"To evaluate to what extent the regional differences in expression of P-gp and <e2>P450</e2> enzymes affect the absorption of a dual substrate, we investigated the transport of <e1>darunavir</e1> across different small intestinal segments (duodenum, proximal jejunum and ileum).","Substrate"
"To evaluate to what extent the regional differences in expression of <e2>P-gp</e2> and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of <e1>darunavir</e1> across different small intestinal segments (duodenum, proximal jejunum and ileum).","Substrate"
"To evaluate to what extent the regional differences in expression of <e2>P-gp</e2> and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of <e1>darunavir</e1> across different small intestinal segments (duodenum, proximal jejunum and ileum).","Substrate"
"To evaluate to what extent the regional differences in expression of P-gp and <e2>P450 enzymes</e2> affect the absorption of a dual substrate, we investigated the transport of <e1>darunavir</e1> across different small intestinal segments (duodenum, proximal jejunum and ileum).","Substrate"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS</e1>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>COX-2</e2>), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS</e1>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>iNOS</e2>), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In another experiment, topical application of CFB, CFE or <e1>CLS</e1> prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and <e2>TNF-α</e2>.","Downregulator"
"In HaCaT cells, <e1>buthanol</e1> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>cyclooxygenase-2</e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, <e1>buthanol</e1> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>COX-2</e2>), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, <e1>buthanol</e1> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>inducible nitric oxide synthase</e2> (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, <e1>buthanol</e1> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>iNOS</e2>), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, <e1>buthanol</e1> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>tumor necrosis factor-α</e2> (TNF- α).","Downregulator"
"In HaCaT cells, <e1>buthanol</e1> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (<e2>TNF- α</e2>).","Downregulator"
"In HaCaT cells, buthanol and <e1>ethylacetate</e1> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>cyclooxygenase-2</e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and <e1>ethylacetate</e1> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>COX-2</e2>), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and <e1>ethylacetate</e1> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>inducible nitric oxide synthase</e2> (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and <e1>ethylacetate</e1> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>iNOS</e2>), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and <e1>ethylacetate</e1> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>tumor necrosis factor-α</e2> (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and <e1>ethylacetate</e1> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (<e2>TNF- α</e2>).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% <e1>methanol</e1> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>cyclooxygenase-2</e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% <e1>methanol</e1> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>COX-2</e2>), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% <e1>methanol</e1> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>inducible nitric oxide synthase</e2> (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% <e1>methanol</e1> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>iNOS</e2>), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% <e1>methanol</e1> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>tumor necrosis factor-α</e2> (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% <e1>methanol</e1> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (<e2>TNF- α</e2>).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, <e1>clerosterol</e1> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>cyclooxygenase-2</e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, <e1>clerosterol</e1> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>COX-2</e2>), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, <e1>clerosterol</e1> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>inducible nitric oxide synthase</e2> (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, <e1>clerosterol</e1> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>iNOS</e2>), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, <e1>clerosterol</e1> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>tumor necrosis factor-α</e2> (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, <e1>clerosterol</e1> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (<e2>TNF- α</e2>).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS</e1>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>cyclooxygenase-2</e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS</e1>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>COX-2</e2>), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS</e1>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>inducible nitric oxide synthase</e2> (iNOS), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS</e1>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>iNOS</e2>), and tumor necrosis factor-α (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS</e1>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>tumor necrosis factor-α</e2> (TNF- α).","Downregulator"
"In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS</e1>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (<e2>TNF- α</e2>).","Downregulator"
"Interaction of silymarin <e1>flavonolignans</e1> with <e2>organic anion-transporting polypeptides</e2>.","Regulator"
"The present study examined the effect of silymarin <e1>flavonolignans</e1> on <e2>OATP</e2>1B1-, OATP1B3-, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes.","Regulator"
"The present study examined the effect of silymarin <e1>flavonolignans</e1> on <e2>OATP1B1</e2>-, OATP1B3-, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes.","Downregulator"
"The present study examined the effect of silymarin <e1>flavonolignans</e1> on OATP1B1-, <e2>OATP1B3</e2>-, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes.","Downregulator"
"The present study examined the effect of silymarin <e1>flavonolignans</e1> on OATP1B1-, OATP1B3-, and <e2>OATP2B1</e2>-mediated transport in cell lines stably expressing these transporters and in human hepatocytes.","Downregulator"
"<e2>OATP1B1</e2>-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), <e1>silybin A</e1> (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"OATP1B1-, <e2>OATP1B3</e2>-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), <e1>silybin A</e1> (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"OATP1B1-, OATP1B3-, and <e2>OATP2B1</e2>-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), <e1>silybin A</e1> (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"<e2>OATP1B1</e2>-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), <e1>silybin B</e1> (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"OATP1B1-, <e2>OATP1B3</e2>-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), <e1>silybin B</e1> (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"OATP1B1-, OATP1B3-, and <e2>OATP2B1</e2>-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), <e1>silybin B</e1> (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"<e2>OATP1B1</e2>-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and <e1>silychristin</e1> (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"OATP1B1-, <e2>OATP1B3</e2>-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and <e1>silychristin</e1> (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"OATP1B1-, OATP1B3-, and <e2>OATP2B1</e2>-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and <e1>silychristin</e1> (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"<e2>OATP</e2>1B1-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), <e1>silybin A</e1> (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"<e2>OATP</e2>1B1-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), <e1>silybin B</e1> (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).","Downregulator"
"In overexpressing cell lines, <e2>OATP1B1</e2>- and OATP1B3-mediated <e1>estradiol-17β-glucuronide</e1> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.","Substrate"
"In overexpressing cell lines, OATP1B1- and <e2>OATP1B3</e2>-mediated <e1>estradiol-17β-glucuronide</e1> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.","Substrate"
"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17β-glucuronide uptake and <e2>OATP2B1</e2>-mediated <e1>estrone-3-sulfate</e1> uptake were inhibited by most of the silymarin flavonolignans investigated.","Substrate"
"In overexpressing cell lines, <e2>OATP</e2>1B1- and OATP1B3-mediated <e1>estradiol-17β-glucuronide</e1> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.","Substrate"
"Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited <e2>OATP</e2>-mediated estradiol-17β-glucuronide and <e1>rosuvastatin</e1> uptake into human hepatocytes.","Substrate"
"Selective oxidation of ω-tertiary amine self-assembled thiol monolayers to <e1>tertiary amine N-oxides</e1> is shown to transform the adhesion of model proteins <e2>lysozyme</e2> and fibrinogen upon them.","Regulator"
"Selective oxidation of ω-tertiary amine self-assembled thiol monolayers to <e1>tertiary amine N-oxides</e1> is shown to transform the adhesion of model proteins lysozyme and <e2>fibrinogen</e2> upon them.","Regulator"
"Selective oxidation of ω-tertiary amine self-assembled thiol monolayers to <e1>tertiary amine N-oxides</e1> is shown to transform the adhesion of model proteins <e2>lysozyme</e2> and fibrinogen upon them.","Regulator"
"Tertiary amine-functionalized sensors adsorbed multilayers of aggregated <e2>lysozyme</e2>, whereas tertiary amine N-oxides and <e1>triethylene glycol</e1>-terminated monolayers are consistent with small protein aggregates.","Regulator"
"Selective oxidation of <e1>ω-tertiary amine</e1> self-assembled thiol monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins <e2>lysozyme</e2> and fibrinogen upon them.","Regulator"
"Selective oxidation of <e1>ω-tertiary amine</e1> self-assembled thiol monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins lysozyme and <e2>fibrinogen</e2> upon them.","Regulator"
"Selective oxidation of ω-tertiary amine self-assembled <e1>thiol</e1> monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins <e2>lysozyme</e2> and fibrinogen upon them.","Regulator"
"Selective oxidation of ω-tertiary amine self-assembled <e1>thiol</e1> monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins lysozyme and <e2>fibrinogen</e2> upon them.","Regulator"
"Oxidation with <e1>hydrogen peroxide</e1> was similarly assessed, and adhesion of <e2>lysozyme</e2> and fibrinogen from phosphate buffered saline was then assayed by QCM and imaged by AFM.","Regulator"
"Oxidation with <e1>hydrogen peroxide</e1> was similarly assessed, and adhesion of lysozyme and <e2>fibrinogen</e2> from phosphate buffered saline was then assayed by QCM and imaged by AFM.","Regulator"
"Further investigation demonstrated that 8k reduced <e1>H2O2</e1>-induced activation of mitochondrial apoptosis by inhibiting the expression of <e2>Bax</e2> and elevating the expression of Bcl-2.","Upregulator"
"Further investigation demonstrated that 8k reduced <e1>H2O2</e1>-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of <e2>Bcl-2</e2>.","Downregulator"
"<e2>Insulin</e2> levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, GLP-1 first and second phases, and <e1>arginine</e1>).","Regulator"
"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin</e2> (achieved by administering insulin plus <e1>glucose</e1>, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).","Upregulator"
"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin</e2> (achieved by administering insulin plus <e1>glucose</e1>, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).","Upregulator"
"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin</e2> (achieved by administering insulin plus <e1>glucose</e1>, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).","Upregulator"
"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin</e2> (achieved by administering insulin plus <e1>glucose</e1>, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).","Upregulator"
"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin</e2> (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with <e1>arginine</e1>).","Upregulator"
"<e2>VEGF-D</e2> is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of N- and <e1>C</e1>-terminal propeptides.","Part_of"
"<e2>VEGF-D</e2> is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of N- and <e1>C</e1>-terminal propeptides.","Part_of"
"<e2>VEGF-D</e2> is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of <e1>N</e1>- and C-terminal propeptides.","Part_of"
"<e2>VEGF-D</e2> is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of N- and <e1>C</e1>-terminal propeptides.","Part_of"
"The <e2>CRF(1) receptor</e2> antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with <e1>paroxetine</e1> and D-cycloserine.","Regulator"
"The <e2>CRF(1) receptor</e2> antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and <e1>D-cycloserine</e1>.","Regulator"
"Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial <e2>N-methyl-D-aspartate (NMDA) receptor</e2> agonist, <e1>D-cycloserine</e1> (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.","Agonist"
"RATIONALE: The selective <e2>CRF(1) (corticotropin releasing factor type 1) receptor</e2> antagonist <e1>SSR125543</e1> has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure.","Antagonist"
"The <e2>CRF(1) receptor</e2> antagonist <e1>SSR125543</e1> prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.","Antagonist"
"The <e2>CRF(1) receptor</e2> antagonist <e1>SSR125543</e1> prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.","Antagonist"
"<e1>Aryl sulfonamide</e1> antagonists bind to <e2>CCR4</e2> at an intracellular allosteric site denoted site II.","Regulator"
"A series of <e1>indazole arylsulfonamides</e1> were synthesized and examined as <e2>human CCR4</e2> antagonists.","Antagonist"
"Synthesis and structure-activity relationships of <e1>indazole arylsulfonamides</e1> as allosteric CC-chemokine receptor 4 (<e2>CCR4</e2>) antagonists.","Modulator"
"Synthesis and structure-activity relationships of <e1>indazole arylsulfonamides</e1> as allosteric <e2>CC-chemokine receptor 4</e2> (CCR4) antagonists.","Modulator"
"Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased <e2>CB(1)</e2> receptor density and function in brain, as assessed in <e1>[(3)H]SR141716A</e1> binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively.","Regulator"
"Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased <e2>CB(1)</e2> receptor density and function in brain, as assessed in [(3)H]SR141716A binding and <e1>CP55,940</e1>-stimulated [(35)S]GTPγS binding assays, respectively.","Regulator"
"Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased <e2>CB(1)</e2> receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [<e1>(35)S</e1>]GTPγS binding assays, respectively.","Regulator"
"However, repeated administration of high dose <e1>JZL184</e1> (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacological effects of cannabinoid receptor agonists, and <e2>CB(1)</e2> receptor downregulation and desensitization.","Regulator"
"Repeated Low Dose Administration of the Monoacylglycerol Lipase Inhibitor <e1>JZL184</e1> Retains <e2>CB1</e2> Receptor Mediated Antinociceptive and Gastroprotective Effects.","Regulator"
"However, repeated administration of high dose <e1>JZL184</e1> (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacological effects of cannabinoid receptor agonists, and <e2>CB(1)</e2> receptor downregulation and desensitization.","Regulator"
"However, repeated administration of high dose <e1>JZL184</e1> (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacological effects of cannabinoid receptor agonists, and <e2>CB(1)</e2> receptor downregulation and desensitization.","Downregulator"
"The monoacylglycerol lipase (<e2>MAGL</e2>) inhibitor <e1>JZL184</e1> produces antinociceptive and anti-inflammatory effects.","Downregulator"
"The <e2>monoacylglycerol lipase</e2> (MAGL) inhibitor <e1>JZL184</e1> produces antinociceptive and anti-inflammatory effects.","Downregulator"
"Repeated Low Dose Administration of the <e2>Monoacylglycerol Lipase</e2> Inhibitor <e1>JZL184</e1> Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.","Downregulator"
"<e1>Bicyclic pyrazinone and pyrimidinone amides</e1> were designed and synthesized as potent TF-<e2>FVIIa</e2> inhibitors.","Downregulator"
"<e1>Bicyclic pyrazinone and pyrimidinone amides</e1> were designed and synthesized as potent <e2>TF</e2>-FVIIa inhibitors.","Downregulator"
"Design and synthesis of <e1>bicyclic pyrazinone and pyrimidinone amides</e1> as potent <e2>TF</e2>-FVIIa inhibitors.","Downregulator"
"Design and synthesis of <e1>bicyclic pyrazinone and pyrimidinone amides</e1> as potent TF-<e2>FVIIa</e2> inhibitors.","Downregulator"
"While <e2>HIF-1α</e2> in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its <e1>proline</e1> hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex.","Part_of"
"The most potent compound 5 (<e1>HJC0123</e1>) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved <e2>caspase-3</e2>, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.","Upregulator"
"The most potent compound 5 (<e1>HJC0123</e1>) has demonstrated to inhibit <e2>STAT3 promoter</e2> activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.","Downregulator"
"Fragment-based drug design and identification of <e1>HJC0123</e1>, a novel orally bioavailable <e2>STAT3</e2> inhibitor for cancer therapy.","Downregulator"
"Fragment-based drug design and identification of <e1>HJC0123</e1>, a novel orally bioavailable <e2>STAT3</e2> inhibitor for cancer therapy.","Downregulator"
"To map supercoiling, we used <e1>biotinylated trimethylpsoralen</e1> as a DNA structure probe to show that the human genome is organized into <e2>supercoiling domains</e2>.","Regulator"
"Therefore, we examined whether the <e2>PDE5</e2>-I <e1>vardenafil</e1> improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.","Downregulator"
"The effects of the <e2>phosphodiesterase type 5</e2> inhibitor <e1>vardenafil</e1> on cognitive performance in healthy adults: a behavioral- electroencephalography study.","Downregulator"
"<e2>Catalase</e2>, glutathione-S-transferase and xanthine oxidase activities were not altered by <e1>atorvastatin</e1> treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.","Not"
"Catalase, <e2>glutathione-S-transferase</e2> and xanthine oxidase activities were not altered by <e1>atorvastatin</e1> treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.","Not"
"Catalase, glutathione-S-transferase and <e2>xanthine oxidase</e2> activities were not altered by <e1>atorvastatin</e1> treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.","Not"
"We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased <e2>NADPH oxidase</e2> activity and immunoreactivity for the protein nitration marker <e1>3-nitrotyrosine</e1> in the cerebral cortex.","Upregulator"
"Statins are inhibitors of the enzyme <e2>3-hydroxy-3-methylglutaryl coenzyme A reductase</e2>, the rate-limiting step in <e1>cholesterol</e1> biosynthesis.","Substrate"
"Hyperthyroidism-induced oxidative stress, reduction in <e2>cytochrome c oxidase</e2> activity, and myocardial ATP concentration were also significantly checked by <e1>Bzf</e1>.","Regulator"
"for 15 days or along with a <e2>peroxisome proliferator-activated receptor alpha</e2> agonist <e1>bezafibrate</e1> (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition.","Agonist"
"for 15 days or along with a <e2>peroxisome proliferator-activated receptor alpha</e2> agonist bezafibrate (<e1>Bzf</e1>; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition.","Agonist"
"The serum or <e1>dexamethasone</e1>-induced oscillation in the expression of <e2>DRD3</e2> in cells was abrogated by the downregulation or overexpression of REV-ERBα, suggesting that REV-ERBα functions as a regulator of DRD3 oscillations in the cellular autonomous clock.","Regulator"
"The serum or <e1>dexamethasone</e1>-induced oscillation in the expression of DRD3 in cells was abrogated by the downregulation or overexpression of <e2>REV-ERBα</e2>, suggesting that REV-ERBα functions as a regulator of DRD3 oscillations in the cellular autonomous clock.","Regulator"
"Moreover, the effects of the <e2>DRD3</e2> agonist <e1>7-hydroxy-N,N-dipropyl-2-aminotetralin</e1> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.","Agonist"
"Moreover, the effects of the <e2>DRD3</e2> agonist <e1>7-hydroxy-N,N-dipropyl-2-aminotetralin</e1> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.","Agonist"
"Moreover, the effects of the <e2>DRD3</e2> agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<e1>7-OH-DPAT</e1>)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.","Agonist"
"Moreover, the effects of the <e2>DRD3</e2> agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<e1>7-OH-DPAT</e1>)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.","Agonist"
"Racemic IKM-159 was crystallized with the ligand-binding domain of <e2>GluA2</e2>, and the structure revealed a complex containing <e1>(2R)-IKM-159</e1> at the glutamate binding site.","Regulator"
"<e1>Racemic IKM-159</e1> was crystallized with the ligand-binding domain of <e2>GluA2</e2>, and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site.","Regulator"
"Racemic IKM-159 was crystallized with the ligand-binding domain of <e2>GluA2</e2>, and the structure revealed a complex containing <e1>(2R)-IKM-159</e1> at the glutamate binding site.","Downregulator"
"<e1>(2R)-IKM-159</e1> locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of <e2>AMPA receptors</e2>.","Antagonist"
"Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid <e2>(AMPA) receptor</e2> antagonist <e1>IKM-159</e1>: asymmetric synthesis, neuroactivity, and structural characterization.","Antagonist"
"<e1>IKM-159</e1> was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as <e2>AMPA receptor</e2>-selective antagonists.","Antagonist"
"IKM-159 was developed and identified as a member of a new class of heterotricyclic <e1>glutamate</e1> analogues that act as <e2>AMPA receptor</e2>-selective antagonists.","Antagonist"
"In addition, benzo[c]phenanthrene, <e1>fluoranthene</e1>, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, <e1>2,3-dihydroxy-2,3-dihydrofluoranthene</e1>, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, <e1>pyrene</e1>, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, <e1>1-hydroxypyrene</e1>, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, <e1>1-nitropyrene</e1>, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, <e1>1-acetylpyrene</e1>, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, <e1>2-acetylpyrene</e1>, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, <e1>2,5,2',5'-tetrachlorobiphenyl</e1>, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, <e1>7-hydroxyflavone</e1>, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, <e1>chrysin</e1>, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and <e1>galangin</e1> were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"In addition, <e1>benzo[c]phenanthrene</e1>, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Regulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, <e1>flavanone</e1>, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by <e1>2'-methoxy-5,7-dihydroxyflavone</e1>, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, <e1>2-ethynylnaphthalene</e1>, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, <e1>2'-methoxyflavone</e1>, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, <e1>2-naphththalene propargyl ether</e1>, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, <e1>acenaphthene</e1>, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, <e1>chrysin</e1>, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Downregulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, <e1>acenaphthylene</e1>, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynyl<e1>naphthalene</e1>, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, <e1>1-acetylpyrene</e1>, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Downregulator"
"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, <e1>3-ethynylphenanthrene</e1>, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Downregulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxy<e1>flavone</e1>, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Downregulator"
"In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, <e1>7-hydroxyflavone</e1>, chrysin, and galangin were found to induce a Type I spectral change only with <e2>P450 2A13</e2>.","Downregulator"
"<e1>Coumarin</e1> 7-hydroxylation, catalyzed by <e2>P450 2A13</e2>, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.","Substrate"
"Full agonists to the <e2>peroxisome proliferator-activated receptor (PPAR)γ</e2>, such as <e1>Rosiglitazone</e1>, have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity.","Agonist"
"The loop was embedded between two helices that assemble into a coiled-coil, which served as a receptor-mimetic folding constraint (LPA(1)-<e1>C</e1>C-<e2>EL2</e2> peptide).","Part_of"
"PURPOSE: <e1>Omeprazole</e1> has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with <e2>cytochrome P450 (CYP) 2C19</e2> genotype groups.","Substrate"
"The <e1>(R)-omeprazole</e1> hydroxylation index reflects <e2>CYP2C19</e2> activity in healthy Japanese volunteers.","Substrate"
"Additionally, there was a significant difference in plasma concentrations of <e1>(R)-5-hydroxyomeprazole</e1> among <e2>CYP2C19</e2> genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.","Substrate"
"Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among <e2>CYP2C19</e2> genotype groups, whereas no significant differences were observed in that of <e1>(S)-5-hydroxyomeprazole</e1>.","Substrate"
"The <e1>(R)-omeprazole</e1> hydroxylation index reflects <e2>CYP2C19</e2> activity in healthy Japanese volunteers.","Substrate"
"CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with <e2>CYP2C19</e2> genotype groups than <e1>racemic-omeprazole</e1> HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.","Substrate"
"Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of <e2>PXR</e2>, CAR, or AhR by <e1>oxycodone</e1> or its major metabolites (noroxycodone and oxymorphone).","Not"
"Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, <e2>CAR</e2>, or AhR by <e1>oxycodone</e1> or its major metabolites (noroxycodone and oxymorphone).","Not"
"Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or <e2>AhR</e2> by <e1>oxycodone</e1> or its major metabolites (noroxycodone and oxymorphone).","Not"
"Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of <e2>PXR</e2>, CAR, or AhR by <e1>oxycodone</e1> or its major metabolites (noroxycodone and oxymorphone).","Regulator"
"Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, <e2>CAR</e2>, or AhR by <e1>oxycodone</e1> or its major metabolites (noroxycodone and oxymorphone).","Regulator"
"Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or <e2>AhR</e2> by <e1>oxycodone</e1> or its major metabolites (noroxycodone and oxymorphone).","Regulator"
"Induction of <e2>xenobiotic receptors</e2>, transporters, and drug metabolizing enzymes by <e1>oxycodone</e1>.","Regulator"
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>all-trans retinoic acid</e1> (atRA), which regulates the expression of a battery of target genes through several families of <e2>nuclear receptors</e2> (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.","Upregulator"
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>all-trans retinoic acid</e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (<e2>RARs</e2>, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.","Upregulator"
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>all-trans retinoic acid</e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, <e2>RXRs</e2> and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.","Upregulator"
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>all-trans retinoic acid</e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), <e2>polymorphic retinoic acid (RA) response elements</e2> and multiple coregulators.","Upregulator"
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>atRA</e1>), which regulates the expression of a battery of target genes through several families of <e2>nuclear receptors</e2> (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.","Upregulator"
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>atRA</e1>), which regulates the expression of a battery of target genes through several families of nuclear receptors (<e2>RARs</e2>, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.","Upregulator"
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>atRA</e1>), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, <e2>RXRs</e2> and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.","Upregulator"
"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>atRA</e1>), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), <e2>polymorphic retinoic acid (RA) response elements</e2> and multiple coregulators.","Upregulator"
"Interestingly, <e2>miR-21</e2> expression positively correlated with urine albumin <e1>creatine</e1> ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.","Upregulator"
"Interestingly, <e2>miR-21</e2> expression positively correlated with urine albumin <e1>creatine</e1> ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.","Downregulator"
"We have examined the hypothesis that the formation of <e1>disulfide</e1> bonds in <e2>hSULT2A1</e2> can reversibly regulate the catalytic function of the enzyme.","Part_of"
"Modification of the Catalytic Function of <e2>Human Hydroxysteroid Sulfotransferase hSULT2A1</e2> by Formation of <e1>Disulfide</e1> Bonds.","Part_of"
"Studies on the kinetics of the <e2>hSULT2A1</e2>-catalyzed sulfation of <e1>dehydroepiandrosterone</e1> (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.","Substrate"
"Studies on the kinetics of the <e2>hSULT2A1</e2>-catalyzed sulfation of dehydroepiandrosterone (<e1>DHEA</e1>) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.","Substrate"
"The <e2>human cytosolic sulfotransferase hSULT2A1</e2> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous <e1>hydroxysteroids</e1> and bile acids.","Substrate"
"The <e2>human cytosolic sulfotransferase hSULT2A1</e2> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and <e1>bile acids</e1>.","Substrate"
"Computational docking analysis was conducted to model the interaction of these antagonists with the human <e2>ER</e2>α and showed that they could tightly bind to the ERα in a manner similar to that of <e1>ICI-182,780</e1>, a pure ER antagonist.","Regulator"
"Computational docking analysis was conducted to model the interaction of these antagonists with the human <e2>ER</e2>α and showed that they could tightly bind to the ERα in a manner similar to that of <e1>ICI-182,780</e1>, a pure ER antagonist.","Antagonist"
"Computational docking analysis was conducted to model the interaction of these antagonists with the human <e2>ER</e2>α and showed that they could tightly bind to the ERα in a manner similar to that of <e1>ICI-182,780</e1>, a pure ER antagonist.","Antagonist"
"<e1>7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole</e1> 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as <e2>activin receptor-like kinase 5</e2> or ALK5) inhibitor.","Downregulator"
"<e1>7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole</e1> 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or <e2>ALK5</e2>) inhibitor.","Downregulator"
"<e1>7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole</e1> 11 (TASP0382088) was synthesized and evaluated as <e2>transforming growth factor-β (TGF-β) type I receptor</e2> (also known as activin receptor-like kinase 5 or ALK5) inhibitor.","Downregulator"
"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>TASP0382088</e1>) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as <e2>activin receptor-like kinase 5</e2> or ALK5) inhibitor.","Downregulator"
"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>TASP0382088</e1>) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or <e2>ALK5</e2>) inhibitor.","Downregulator"
"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>TASP0382088</e1>) was synthesized and evaluated as <e2>transforming growth factor-β (TGF-β) type I receptor</e2> (also known as activin receptor-like kinase 5 or ALK5) inhibitor.","Downregulator"
"Discovery of <e1>7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole</e1> (TASP0382088): a potent and selective <e2>transforming growth factor-β type I receptor</e2> inhibitor as a topical drug for alopecia.","Downregulator"
"Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (<e1>TASP0382088</e1>): a potent and selective <e2>transforming growth factor-β type I receptor</e2> inhibitor as a topical drug for alopecia.","Downregulator"
"<e2>AR</e2>F represses <e1>androgen</e1> receptor transactivation in prostate cancer.","Not"
"The forced expression of p14<e2>AR</e2>F in cells resulted in a suppression of PSA and <e1>N</e1>K transcription factor locus 1 (NKX3.1) expression.","Part_of"
"The forced expression of p14<e2>AR</e2>F in cells resulted in a suppression of PSA and <e1>N</e1>K transcription factor locus 1 (NKX3.1) expression.","Part_of"
"Androgen receptor (<e2>AR</e2>) signaling is essential for prostate cancer (P<e1>C</e1>a) development in humans.","Part_of"
"<e2>AR</e2>F represses <e1>androgen</e1> receptor transactivation in prostate cancer.","Regulator"
"<e2>AR</e2>F represses <e1>androgen</e1> receptor transactivation in prostate cancer.","Regulator"
"This study evaluates the production of inflammatory biomarkers (<e2>IL-1β</e2>, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, <e2>IL-8</e2>, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, <e2>IL-10</e2>, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, <e2>TNFα</e2>) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (<e2>NPC1L1</e2>, ABCG5/8, HMGCoA, ACAT) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, <e2>ABCG5/8</e2>, HMGCoA, ACAT) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, <e2>HMGCoA</e2>, ACAT) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, <e2>ACAT</e2>) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (<e2>IL-1β</e2>, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (<e1>stigmasterol</e1>/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, <e2>IL-8</e2>, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (<e1>stigmasterol</e1>/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, <e2>IL-10</e2>, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (<e1>stigmasterol</e1>/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, <e2>TNFα</e2>) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (<e1>stigmasterol</e1>/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (<e2>NPC1L1</e2>, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (<e1>stigmasterol</e1>/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, <e2>ABCG5/8</e2>, HMGCoA, ACAT) produced by 7-ketosterols (<e1>stigmasterol</e1>/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, <e2>HMGCoA</e2>, ACAT) produced by 7-ketosterols (<e1>stigmasterol</e1>/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, <e2>ACAT</e2>) produced by 7-ketosterols (<e1>stigmasterol</e1>/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (<e2>IL-1β</e2>, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to <e1>cholesterol</e1> absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, <e2>IL-8</e2>, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to <e1>cholesterol</e1> absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, <e2>IL-10</e2>, TNFα) and the influence of gene expression transporters and enzymes related to <e1>cholesterol</e1> absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, <e2>TNFα</e2>) and the influence of gene expression transporters and enzymes related to <e1>cholesterol</e1> absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to <e1>cholesterol</e1> absorption and metabolism (<e2>NPC1L1</e2>, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to <e1>cholesterol</e1> absorption and metabolism (NPC1L1, <e2>ABCG5/8</e2>, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to <e1>cholesterol</e1> absorption and metabolism (NPC1L1, ABCG5/8, <e2>HMGCoA</e2>, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to <e1>cholesterol</e1> absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, <e2>ACAT</e2>) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, <e2>ABCG5</e2>/8, HMGCoA, ACAT) produced by <e1>7-ketosterols</e1> (stigmasterol/cholesterol) in Caco-2 cells.","Regulator"
"Cell-pre-incubation with <e2>bradykinin</e2> induced changes in ABCG expression levels after <e1>7-ketostigmasterol</e1>-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells.","Regulator"
"Cell-pre-incubation with bradykinin induced changes in <e2>ABCG</e2> expression levels after <e1>7-ketostigmasterol</e1>-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells.","Regulator"
"Relative expression of c<e2>holesterol transport-related proteins</e2> and inflammation markers through the induction of <e1>7-ketosterol</e1>-mediated stress in Caco-2 cells.","Regulator"
"This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, <e2>HMGCoA</e2>, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in <e1>Ca</e1>co-2 cells.","Regulator"
"In non-pre-treated cells, <e2>HMG-CoA</e2> was up-regulated by both <e1>7-ketosterols</e1>.","Upregulator"
"In non-pre-treated cells, only <e2>efflux transporters</e2> were down-regulated by <e1>7-ketosterols</e1>, showing a greater influence upon ABCG5 expression.","Downregulator"
"Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced <e2>NPC1L1</e2> expression only in <e1>7-ketocholesterol</e1>-incubated cells.","Downregulator"
"This study evaluated the effects of <e1>caffeic acid</e1> on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (<e2>ADA</e2>) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.","Upregulator"
"This study evaluated the effects of <e1>caffeic acid</e1> on ectonucleotidase activities such as <e2>NTPDase</e2> (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.","Upregulator"
"We demonstrate that activation of <e2>STAT3</e2> <e1>serine</e1>-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.","Part_of"
"We demonstrate that activation of <e2>STAT3</e2> serine-727 and <e1>tyrosine</e1>-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.","Part_of"
"When mice were treated ip with the major neonicotinoid <e1>imidacloprid</e1> (IMI), metabolism by <e2>CYP</e2> oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.","Not"
"When mice were treated ip with the major neonicotinoid imidacloprid (<e1>IMI</e1>), metabolism by <e2>CYP</e2> oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.","Not"
"The procedure was to reduce liver <e2>AOX</e2> activity by providing <e1>tungsten</e1> or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.","Downregulator"
"The procedure was to reduce liver <e2>AOX</e2> activity by providing tungsten or <e1>hydralazine</e1> in the drinking water or to use the AOX-deficient DBA/2 mouse strain.","Downregulator"
"The procedure was to reduce liver <e2>AOX</e2> activity by providing <e1>tungsten</e1> or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.","Downregulator"
"The procedure was to reduce liver <e2>AOX</e2> activity by providing tungsten or <e1>hydralazine</e1> in the drinking water or to use the AOX-deficient DBA/2 mouse strain.","Downregulator"
"The procedure was to reduce liver <e2>AOX</e2> activity by providing <e1>tungsten</e1> or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.","Downregulator"
"The procedure was to reduce liver <e2>AOX</e2> activity by providing tungsten or <e1>hydralazine</e1> in the drinking water or to use the AOX-deficient DBA/2 mouse strain.","Downregulator"
"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>AOX</e2>-generated <e1>nitrosoguanidine</e1> metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.","Substrate"
"When mice were treated ip with the major neonicotinoid imidacloprid (<e1>IMI</e1>), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>AOX</e2>-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.","Substrate"
"When mice were treated ip with the major neonicotinoid imidacloprid (<e1>IMI</e1>), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>AOX</e2>-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.","Substrate"
"Currently, the most important insecticides are <e1>neonicotinoid</e1>s, which are metabolized in vitro by <e2>AOX</e2> on reduction of the nitroimino group and by CYPs via oxidation reactions.","Substrate"
"Currently, the most important insecticides are <e1>neonicotinoids</e1>, which are metabolized in vitro by <e2>AOX</e2> on reduction of the nitroimino group and by CYPs via oxidation reactions.","Substrate"
"Currently, the most important insecticides are <e1>neonicotinoids</e1>, which are metabolized in vitro by AOX on reduction of the nitroimino group and by <e2>CYPs</e2> via oxidation reactions.","Substrate"
"Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by <e2>AOX</e2> on reduction of the <e1>nitroimino</e1> group and by CYPs via oxidation reactions.","Substrate"
"When mice were treated ip with the major neonicotinoid imidacloprid (<e1>IMI</e1>), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>AOX</e2>-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.","Substrate"
"Of the compounds active in the present assay system, the most potent compound 7, <e1>platyphyllonol-5-O-β-d-xylopyranoside</e1>, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and <e2>CCAAT/enhancer binding protein α</e2> (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.","Downregulator"
"Of the compounds active in the present assay system, the most potent compound 7, <e1>platyphyllonol-5-O-β-d-xylopyranoside</e1>, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (<e2>C/EBPα</e2>) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.","Downregulator"
"Of the compounds active in the present assay system, the most potent compound 7, <e1>platyphyllonol-5-O-β-d-xylopyranoside</e1>, significantly suppressed the induction of <e2>peroxisome proliferator activated receptor γ</e2> (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.","Downregulator"
"Of the compounds active in the present assay system, the most potent compound 7, <e1>platyphyllonol-5-O-β-d-xylopyranoside</e1>, significantly suppressed the induction of peroxisome proliferator activated receptor γ (<e2>PPARγ</e2> and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.","Downregulator"
"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (<e2>PPARγ</e2> and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by <e1>troglitazone</e1>, a PPARγ agonist.","Agonist"
"Based on our previously published work on <e2>CXCR4</e2> antagonists, we have synthesized a series of <e1>aryl sulfonamides</e1> that inhibit the CXCR4/CXCL12 interaction.","Downregulator"
"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of <e1>aryl sulfonamides</e1> that inhibit the CXCR4/<e2>CXCL12</e2> interaction.","Downregulator"
"These data demonstrate that <e1>benzenesulfonamides</e1> are a unique class of <e2>CXCR4</e2> inhibitors with high potency.","Downregulator"
"<e1>Benzenesulfonamides</e1>: a unique class of <e2>chemokine receptor type 4</e2> inhibitors.","Downregulator"
"Measurement of Transport Activities of <e1>3β-Hydroxy-Δ(5)-bile Acids</e1> in <e2>Bile Salt Export Pump</e2> and Multidrug Resistance-Associated Proteins Using LC-MS/MS.","Substrate"
"Measurement of Transport Activities of <e1>3β-Hydroxy-Δ(5)-bile Acids</e1> in Bile Salt Export Pump and <e2>Multidrug Resistance-Associated Proteins</e2> Using LC-MS/MS.","Substrate"
"The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and <e2>human bile salt export pump</e2>-expressing Sf9 cells for conjugated <e1>3β-hydroxy-Δ(5)-bile acids</e1>.","Substrate"
"The present study demonstrated that <e2>human multidrug resistance-associated protein 3</e2> vesicles accepted conjugated <e1>3β-hydroxy-Δ(5)-bile acids</e1> along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.","Substrate"
"The present study demonstrated that <e2>human multidrug resistance-associated protein 3</e2> vesicles accepted conjugated 3β-hydroxy-Δ(5)-<e1>bile acids</e1> along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.","Substrate"
"The present study demonstrated that <e2>human multidrug resistance-associated protein 3</e2> vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common bile acids such as <e1>glycocholic acid</e1> and taurolithocholic acid 3-sulfate.","Substrate"
"The present study demonstrated that <e2>human multidrug resistance-associated protein 3</e2> vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common bile acids such as glycocholic acid and <e1>taurolithocholic acid 3-sulfate</e1>.","Substrate"
"Here, we report that a specific 29-<e1>amino acid</e1> peptide derived from the intracellular domain fragment of <e2>p75(NTR)</e2> interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling.","Part_of"
"An endogenous intracellular domain fragment of <e2>p75(NTR)</e2> (p75(ICD)) containing these 29 <e1>amino acids</e1> is produced by regulated proteolysis of the full-length receptor.","Part_of"
"An endogenous intracellular domain fragment of p75(NTR) (<e2>p75(ICD)</e2>) containing these 29 <e1>amino acids</e1> is produced by regulated proteolysis of the full-length receptor.","Part_of"
"A series of substituted <e1>3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines</e1> has been synthesised and tested in vitro as potential pro-apoptotic <e2>Bcl-2</e2>-inhibitory anticancer agents.","Downregulator"
"Active compounds, such as the <e1>nitrobenzyl</e1> analogue 6c, were found to exhibit sub-micromolar IC50 values in <e2>Bcl-2</e2> expressing human cancer cell lines.","Downregulator"
"Synthesis and evaluation of <e1>3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines</e1> as <e2>Bcl-2</e2> inhibitory anticancer agents.","Downregulator"
"<e2>Glutathione-S-transferase</e2>, a phase II enzyme, was inhibited by both arsenic and <e1>nicotine</e1> but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.","Not"
"<e2>Glutathione-S-transferase</e2>, a phase II enzyme, was inhibited by both <e1>arsenic</e1> and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.","Not"
"Upon <e1>nicotine</e1> pre-exposure, brain <e2>acetylcholinesterase</e2> increased, while monoamine oxidase (MAO) decreased.","Upregulator"
"Upon <e1>nicotine</e1> pre-exposure, brain acetylcholinesterase increased, while <e2>monoamine oxidase</e2> (MAO) decreased.","Downregulator"
"Upon <e1>nicotine</e1> pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (<e2>MAO</e2>) decreased.","Downregulator"
"Upon <e1>nicotine</e1> pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (<e2>MAO</e2>) decreased.","Downregulator"
"<e2>Glutathione-S-transferase</e2>, a phase II enzyme, was inhibited by both <e1>arsenic</e1> and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.","Downregulator"
"<e2>Glutathione-S-transferase</e2>, a phase II enzyme, was inhibited by both arsenic and <e1>nicotine</e1> but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.","Downregulator"
"The model accurately predicted <e2>CYP19A</e2> mRNA fold changes for controls and three <e1>FAD</e1> doses (0, 0.5, and 3 µg/l) and plasma E2 dose response from the 4-day study.","Regulator"
"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the <e2>aromatase</e2> inhibitor, <e1>fadrozole</e1> (FAD).","Downregulator"
"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the <e2>aromatase</e2> inhibitor, fadrozole (<e1>FAD</e1>).","Downregulator"
"Electrophilic chemicals activate both insect and vertebrate <e2>TRPA1</e2> via covalent modification of <e1>cysteine</e1> residues in the amino-terminal region.","Part_of"
"Electrophilic chemicals activate both insect and vertebrate <e2>TRPA1</e2> via covalent modification of <e1>cysteine</e1> residues in the amino-terminal region.","Part_of"
"Electrophilic chemicals activate both insect and vertebrate <e2>TRPA1</e2> via covalent modification of cysteine residues in the <e1>amino</e1>-terminal region.","Part_of"
"We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type <e2>TRPA1</e2> or TRPA1 with three <e1>serine</e1>-substituted cysteines crucial for electrophile activation (C621S, C641S, C665S).","Part_of"
"We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three <e1>serine</e1>-substituted cysteines crucial for electrophile activation (<e2>C621S</e2>, C641S, C665S).","Part_of"
"We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three <e1>serine</e1>-substituted cysteines crucial for electrophile activation (C621S, <e2>C641S</e2>, C665S).","Part_of"
"We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three <e1>serine</e1>-substituted cysteines crucial for electrophile activation (C621S, C641S, <e2>C665S</e2>).","Part_of"
"We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type <e2>TRPA1</e2> or TRPA1 with three serine-substituted <e1>cysteines</e1> crucial for electrophile activation (C621S, C641S, C665S).","Part_of"
"We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted <e1>cysteines</e1> crucial for electrophile activation (<e2>C621S</e2>, C641S, C665S).","Part_of"
"We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted <e1>cysteines</e1> crucial for electrophile activation (C621S, <e2>C641S</e2>, C665S).","Part_of"
"We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted <e1>cysteines</e1> crucial for electrophile activation (C621S, C641S, <e2>C665S</e2>).","Part_of"
"Benzoquinone Reveals a <e1>Cysteine</e1>-Dependent Desensitization Mechanism of <e2>TRPA1</e2>.","Part_of"
"Electrophilic chemicals activate both insect and vertebrate <e2>TRPA1</e2> via covalent modification of <e1>cysteine</e1> residues in the amino-terminal region.","Part_of"
"<e1>Benzoquinone</e1> Reveals a Cysteine-Dependent Desensitization Mechanism of <e2>TRPA1</e2>.","Regulator"
"We characterized the effects of the electrophilic arthropod defensive compound para-benzoquinone (<e1>pBQN</e1>) on the human <e2>TRPA1</e2> channel.","Regulator"
"We characterized the effects of the electrophilic arthropod defensive compound para-benzoquinone (<e1>pBQN</e1>) on the human <e2>TRPA1</e2> channel.","Regulator"
"We characterized the effects of the electrophilic arthropod defensive compound para-benzoquinone (<e1>pBQN</e1>) on the human <e2>TRPA1</e2> channel.","Upregulator"
"Interestingly, following pBQN desensitization, wild-type <e2>TRPA1</e2> had dramatically reduced response to the nonelectrophile agonist <e1>carvacrol</e1>, whereas the triple cysteine mutant TRPA1 retained its full response.","Agonist"
"Although naturally occurring electrophilic plant compounds, such as mustard oil and <e1>cinnamaldehyde</e1>, are <e2>TRPA1</e2> agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1.","Agonist"
"Interestingly, following pBQN desensitization, wild-type <e2>TRPA1</e2> had dramatically reduced response to the nonelectrophile agonist <e1>carvacrol</e1>, whereas the triple cysteine mutant TRPA1 retained its full response.","Agonist"
"Synthesis and in-silico studies of some <e1>diaryltriazole</e1> derivatives as potential <e2>cyclooxygenase</e2> inhibitors.","Downregulator"
"In this study we investigated how NO/<e1>S</e1>NO may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx1</e2>), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Part_of"
"In particular, nitrosylation promoted disulfide formation involving the pair of catalytic <e1>cysteines</e1> (Cys-52 and Cys-173) and disrupted the oligomeric structure of <e2>Prx1</e2>, leading to loss of peroxidase activity.","Part_of"
"In particular, nitrosylation promoted disulfide formation involving the pair of catalytic <e1>cysteines</e1> (Cys-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of <e2>peroxidase</e2> activity.","Part_of"
"In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx1</e2>), a representative of the 2-<e1>Cys</e1> Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Part_of"
"In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-<e1>Cys</e1> Prxs, a group of thioredoxin (Trx)-dependent <e2>peroxidase</e2>s.","Part_of"
"In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx1</e2>), a representative of the 2-<e1>Cys</e1> Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Part_of"
"In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-<e1>Cys</e1> Prxs, a group of thioredoxin (Trx)-dependent <e2>peroxidase</e2>s.","Part_of"
"In this study we investigated how NO/<e1>SNO</e1> may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx</e2>1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Regulator"
"Our findings that NO/<e1>SNO</e1> target both Prx and <e2>Trx reductase</e2> may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.","Regulator"
"In this study we investigated how <e1>NO</e1>/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx1</e2>), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Regulator"
"In this study we investigated how NO/<e1>SNO</e1> may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx1</e2>), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Regulator"
"We found that, both in a cell-free system and in cells, NO/SNO donors such as <e1>S-nitrosocysteine</e1> and S-nitrosoglutathione readily induced the S-nitrosylation of <e2>Prx1</e2>, causing structural and functional alterations.","Regulator"
"We found that, both in a cell-free system and in cells, NO/SNO donors such as S-nitrosocysteine and <e1>S-nitrosoglutathione</e1> readily induced the S-nitrosylation of <e2>Prx1</e2>, causing structural and functional alterations.","Regulator"
"In this study we investigated how <e1>NO</e1>/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx</e2>1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Regulator"
"In this study we investigated how <e1>NO</e1>/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (<e2>Trx</e2>)-dependent peroxidases.","Regulator"
"In this study we investigated how NO/<e1>SNO</e1> may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx</e2>1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Regulator"
"In this study we investigated how NO/<e1>SNO</e1> may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (<e2>Trx</e2>)-dependent peroxidases.","Regulator"
"In this setting, <e1>S-nitrosocysteine</e1> (10 μm) effectively blocked the <e2>Trx</e2>-mediated regeneration of oxidized Prx1.","Regulator"
"This effect appeared to be due to both competition between <e1>S-nitrosocysteine</e1> and Prx1 for the Trx system and direct modulation by S-nitrosocysteine of <e2>Trx reductase</e2> activity.","Regulator"
"In this study we investigated how <e1>NO</e1>/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (<e2>Prx</e2>1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.","Regulator"
"Our findings that <e1>NO</e1>/SNO target both Prx and <e2>Trx reductase</e2> may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.","Regulator"
"In this study we investigated how <e1>NO</e1>/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent <e2>peroxidase</e2>s.","Downregulator"
"In this study we investigated how NO/<e1>SNO</e1> may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent <e2>peroxidase</e2>s.","Downregulator"
"In this setting, <e1>S-nitrosocysteine</e1> (10 μm) effectively blocked the <e2>Trx</e2>-mediated regeneration of oxidized Prx1.","Downregulator"
"In this setting, <e1>S-nitrosocysteine</e1> (10 μm) effectively blocked the Trx-mediated regeneration of <e2>oxidized Prx1</e2>.","Downregulator"
"<e1>DMN</e1> treatment for 4weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and <e2>collagen</e2> content.","Regulator"
"CK significantly inhibited <e1>DMN</e1>-induced increases in serum <e2>alanine aminotransferase</e2> (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.","Upregulator"
"CK significantly inhibited <e1>DMN</e1>-induced increases in serum alanine aminotransferase (<e2>ALT</e2>) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.","Upregulator"
"CK significantly inhibited <e1>DMN</e1>-induced increases in serum alanine aminotransferase (ALT) and <e2>aspartate aminotransferase</e2> (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.","Upregulator"
"CK significantly inhibited <e1>DMN</e1>-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (<e2>AST</e2>) activities, fibrosis score, and hepatic malondialdehyde and collagen content.","Upregulator"
"<e1>DMN</e1>-induced cyclooxygenase-2 (COX-2) expression and <e2>nuclear factor-kappa B</e2> (NF-κB) activation was reduced by CK treatment.","Upregulator"
"<e1>DMN</e1>-induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (<e2>NF-κB</e2>) activation was reduced by CK treatment.","Upregulator"
"<e1>DMN</e1> treatment for 4weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and <e2>collagen</e2> content.","Upregulator"
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN</e1>-induced increases in <e2>matrix metalloproteinase-13</e2> (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.","Upregulator"
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN</e1>-induced increases in matrix metalloproteinase-13 (<e2>MMP-13</e2>), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.","Upregulator"
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN</e1>-induced increases in matrix metalloproteinase-13 (MMP-13), <e2>tissue inhibitor of metalloproteinase-1</e2> (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.","Upregulator"
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN</e1>-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (<e2>TIMP-1</e2>), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.","Upregulator"
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN</e1>-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and <e2>tumor necrosis factor-α</e2> (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.","Upregulator"
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN</e1>-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (<e2>TNF-α</e2>) mRNA, and collagen type I and α-smooth muscle actin protein.","Upregulator"
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN</e1>-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and <e2>collagen type I</e2> and α-smooth muscle actin protein.","Upregulator"
"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN</e1>-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and <e2>α-smooth muscle actin</e2> protein.","Upregulator"
"<e1>DMN</e1>-induced <e2>cyclooxygenase-2</e2> (COX-2) expression and nuclear factor-kappa B (NF-κB) activation was reduced by CK treatment.","Upregulator"
"<e1>DMN</e1>-induced cyclooxygenase-2 (<e2>COX-2</e2>) expression and nuclear factor-kappa B (NF-κB) activation was reduced by CK treatment.","Upregulator"
"Further analyses revealed that <e1>CdTe</e1>-QD exposure resulted in apoptosis, indicated by changes in levels of <e2>caspase-3</e2> activity, poly ADP-ribose polymerase (PARP) cleavage and phosphatidylserine externalization.","Regulator"
"Further analyses revealed that <e1>CdTe</e1>-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, <e2>poly ADP-ribose polymerase</e2> (PARP) cleavage and phosphatidylserine externalization.","Regulator"
"Further analyses revealed that <e1>CdTe</e1>-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (<e2>PARP</e2>) cleavage and phosphatidylserine externalization.","Regulator"
"Extrinsic apoptotic pathway markers such as Fas levels and <e2>caspase-8</e2> activity increased as a result of <e1>CdTe</e1>-QD exposure.","Upregulator"
"Our findings reveal that <e1>CdTe</e1>-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein <e2>kinases</e2>, leading to apoptosis via both extrinsic and intrinsic pathways.","Upregulator"
"Extrinsic apoptotic pathway markers such as <e2>Fas</e2> levels and caspase-8 activity increased as a result of <e1>CdTe</e1>-QD exposure.","Upregulator"
"Anti-apoptotic cardioprotective effects of <e2>SHP-1</e2> gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight <e1>polyethyleneimine</e1> as a cardiac siRNA-carrier.","Regulator"
"Anti-apoptotic cardioprotective effects of <e2>SHP-1</e2> gene silencing against ischemia-reperfusion injury: Use of <e1>deoxycholic acid</e1>-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier.","Regulator"
"Taken together, our data demonstrate that <e1>puerarin</e1> attenuates MPTP-induced dopaminergic neuronal degeneration via modulating <e2>GDNF</e2> expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.","Regulator"
"Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (<e2>GDNF</e2>) expression and PI3K/Akt pathway activation, which might ameliorate <e1>MPTP</e1> injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.","Regulator"
"Taken together, our data demonstrate that <e1>puerarin</e1> attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, <e2>PI3K</e2>/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.","Regulator"
"Taken together, our data demonstrate that <e1>puerarin</e1> attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/<e2>Akt</e2> pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.","Regulator"
"Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and <e2>PI3K</e2>/Akt pathway activation, which might ameliorate <e1>MPTP</e1> injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.","Regulator"
"Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/<e2>Akt</e2> pathway activation, which might ameliorate <e1>MPTP</e1> injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.","Regulator"
"<e1>Puerarin</e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and <e2>PI3K</e2>/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.","Upregulator"
"<e1>Puerarin</e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/<e2>Akt</e2> pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.","Upregulator"
"<e1>Puerarin</e1> administration enhanced glutathione (GSH) activity, <e2>glial cell line-derived neurotrophic factor</e2> (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.","Upregulator"
"<e1>Puerarin</e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (<e2>GDNF</e2>) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.","Upregulator"
"In addition to the effect on ROS, <e1>puerarin</e1> ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (<e2>Lamp 2A</e2>) expression.","Downregulator"
"In addition to the effect on ROS, puerarin ameliorated <e1>MPTP</e1>-reduced <e2>lysosome-associated membrane protein type 2A</e2> (Lamp 2A) expression.","Downregulator"
"In addition to the effect on ROS, puerarin ameliorated <e1>MPTP</e1>-reduced lysosome-associated membrane protein type 2A (<e2>Lamp 2A</e2>) expression.","Downregulator"
"In addition to the effect on ROS, <e1>puerarin</e1> ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (<e2>Lamp 2A</e2>) expression.","Downregulator"
"In addition to the effect on ROS, puerarin ameliorated <e1>MPTP</e1>-reduced lysosome-associated membrane protein type 2A (<e2>Lamp 2A</e2>) expression.","Downregulator"
"After 18 h incubation with 0.5 μM <e1>Py3MeO-TBPo</e1> and subsequent red light irradiation (3.6 J/cm(2)), a high number of cells die by apoptosis, as evaluated by morphological alterations, immunofluorescent relocalization of <e2>Bax</e2> from cytosol to mitochondria, and TUNEL assay.","Regulator"
"The <e2>gp41</e2> subunit contains several functional domains: the <e1>N</e1>-terminal heptad repeat (NHR) domains fold a triple stranded coiled-coil forming a meta-stable prefusion intermediate.","Part_of"
"Our results revealed an important role of base excision repair (BER) as the <e2>ntg1</e2>, ntg2, apn1 and apn2 mutants showed pronounced sensitivity to essential oil and <e1>nerolidol</e1>.","Regulator"
"Our results revealed an important role of base excision repair (BER) as the ntg1, <e2>ntg2</e2>, apn1 and apn2 mutants showed pronounced sensitivity to essential oil and <e1>nerolidol</e1>.","Regulator"
"Our results revealed an important role of base excision repair (BER) as the ntg1, ntg2, <e2>apn1</e2> and apn2 mutants showed pronounced sensitivity to essential oil and <e1>nerolidol</e1>.","Regulator"
"Our results revealed an important role of base excision repair (BER) as the ntg1, ntg2, apn1 and <e2>apn2</e2> mutants showed pronounced sensitivity to essential oil and <e1>nerolidol</e1>.","Regulator"
"The radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [<e1>(3)H</e1>]-<e2>MRP4</e2> and [(3)H]-SSB siRNA, respectively).","Regulator"
"Instead, radiolabeled <e1>nucleosides</e1> resulting from <e2>nuclease</e2> hydrolysis were observed.","Substrate"
"We rescued cells lethally depleted of endogenous <e2>Cdk1</e2> with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (<e1>RO3306</e1>).","Not"
"We rescued cells lethally depleted of endogenous <e2>Cdk1</e2> with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (<e1>RO3306</e1>).","Not"
"We rescued cells lethally depleted of endogenous <e2>Cdk1</e2> with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (<e1>1NMPP1</e1>) and resistance to another (RO3306).","Regulator"
"We rescued cells lethally depleted of endogenous <e2>Cdk1</e2> with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (<e1>1NMPP1</e1>) and resistance to another (RO3306).","Regulator"
"A series of <e1>N</e1>-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the <e2>vesicular monoamine transporter</e2> and for their inhibition of vesicular [(3)H]dopamine uptake.","Regulator"
"A series of N-substituted <e1>lobelane</e1> analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the <e2>vesicular monoamine transporter</e2> and for their inhibition of vesicular [(3)H]dopamine uptake.","Regulator"
"A series of N-substituted lobelane analogues was synthesized and evaluated for their <e1>[(3)H]dihydrotetrabenazine</e1> binding affinity at the <e2>vesicular monoamine transporter</e2> and for their inhibition of vesicular [(3)H]dopamine uptake.","Regulator"
"Exploring the effect of N-substitution in <e1>nor-lobelane</e1> on the interaction with <e2>VMAT2</e2>: discovery of a potential clinical candidate for treatment of methamphetamine abuse.","Regulator"
"Exploring the effect of <e1>N</e1>-substitution in nor-lobelane on the interaction with <e2>VMAT2</e2>: discovery of a potential clinical candidate for treatment of methamphetamine abuse.","Regulator"
"A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the <e2>vesicular monoamine transporter</e2> and for their inhibition of vesicular <e1>[(3)H]dopamine</e1> uptake.","Substrate"
"<e1>IPI-926</e1> is highly bound to plasma proteins and has minimal interaction with <e2>human α-1-acid glycoprotein</e2>.","Regulator"
"<e1>IPI-926</e1> is both a substrate and inhibitor (IC50 = 1.9 µM) of <e2>P-glycoprotein</e2>.","Downregulator"
"<e1>IPI-926</e1> is both a substrate and inhibitor (IC50 = 1.9 µM) of <e2>P-glycoprotein</e2>.","Substrate"
"Oral <e1>lorcaserin</e1> (BELVIQ(®)), a selective serotonin <e2>5-HT2C</e2> receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g.","Agonist"
"Oral lorcaserin (<e1>BELVIQ</e1>(®)), a selective serotonin <e2>5-HT2C</e2> receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g.","Agonist"
"Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (<e2>DPP-4</e2>) inhibitors, among them, the <e1>cyclopropyl-substituted phenylalanine</e1> derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247 μM.","Downregulator"
"Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a <e1>2-Cyanopyrrolidine</e1> Moiety as Potent <e2>Dipeptidyl Peptidase 4</e2> Inhibitors.","Downregulator"
"Design, Synthesis, Biological Evaluation, and Docking Studies of <e1>(S)-Phenylalanine</e1> Derivatives with a 2-Cyanopyrrolidine Moiety as Potent <e2>Dipeptidyl Peptidase 4</e2> Inhibitors.","Downregulator"
"<e1>TCPOBOP</e1>, a <e2>CAR</e2> ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.","Regulator"
"In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with <e1>pregnenolone-16α-carbonitrile</e1> (PCN), a strong <e2>PXR</e2> ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.","Regulator"
"In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (<e1>PCN</e1>), a strong <e2>PXR</e2> ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.","Regulator"
"In the current study, we crossed <e2>mdr1a</e2>.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (<e1>PCN</e1>), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.","Regulator"
"In the current study, we crossed <e2>mdr1a</e2>.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and <e1>docetaxel</e1>.","Regulator"
"<e1>TCPOBOP</e1>, a CAR ligand, modestly induced <e2>mdr1a</e2>.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.","Regulator"
"In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (<e1>PCN</e1>), a strong <e2>PXR</e2> ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.","Regulator"
"In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong <e2>PXR</e2> ligand, and two therapeutically relevant taxanes, paclitaxel and <e1>docetaxel</e1>.","Regulator"
"<e1>TCPOBOP</e1>, a <e2>CAR</e2> ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.","Regulator"
"<e1>TCPOBOP</e1>, a CAR ligand, modestly induced <e2>mdr1a</e2>.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.","Upregulator"
"The inhibitory effect of <e1>galangin</e1> on theses pro-inflammatory cytokines was related with <e2>c-Jun</e2> N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.","Regulator"
"The inhibitory effect of <e1>galangin</e1> on theses pro-inflammatory cytokines was related with c-Jun <e2>N-terminal kinases</e2>, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.","Regulator"
"The inhibitory effect of <e1>galangin</e1> on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and <e2>p38</e2> mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.","Regulator"
"The inhibitory effect of <e1>galangin</e1> on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 <e2>mitogen-activated protein kinase</e2>, nuclear factor-κB, and caspase-1.","Regulator"
"The inhibitory effect of <e1>galangin</e1> on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, <e2>nuclear factor-κB</e2>, and caspase-1.","Regulator"
"The inhibitory effect of <e1>galangin</e1> on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and <e2>caspase-1</e2>.","Regulator"
"Furthermore, <e1>galangin</e1> attenuated <e2>IgE</e2>-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.","Downregulator"
"<e1>Galangin</e1> decreased expression of pro-inflammatory <e2>cytokines</e2>, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and IL-8.","Downregulator"
"<e1>Galangin</e1> decreased expression of pro-inflammatory cytokines, such as <e2>tumor necrosis factor (TNF)-α</e2>, interleukin (IL)-6, IL-1β, and IL-8.","Downregulator"
"<e1>Galangin</e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, <e2>interleukin</e2> (IL)-6, IL-1β, and IL-8.","Downregulator"
"<e1>Galangin</e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin <e2>(IL)-6</e2>, IL-1β, and IL-8.","Downregulator"
"<e1>Galangin</e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, <e2>IL-1β</e2>, and IL-8.","Downregulator"
"<e1>Galangin</e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and <e2>IL-8</e2>.","Downregulator"
"The inhibitory effect of <e1>galangin</e1> on theses pro-inflammatory <e2>cytokines</e2> was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.","Downregulator"
"Furthermore, <e1>galangin</e1> attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of <e2>histamine receptor 1</e2> at the inflamed tissue.","Downregulator"
"The inhibitory effect of <e1>galangin</e1> on theses pro-inflammatory <e2>cytokines</e2> was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.","Downregulator"
"<e2>HP1α</e2> responded only to <e1>BHA</e1>.","Regulator"
"Furthermore, <e1>nobiletin</e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and <e2>p38</e2>.","Not"
"Next, <e1>nobiletin</e1> significantly decreased the levels of <e2>phospho-ERK2</e2> and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.","Downregulator"
"Next, <e1>nobiletin</e1> significantly decreased the levels of phospho-ERK2 and <e2>phospho-Akt</e2> in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.","Downregulator"
"Furthermore, <e1>nobiletin</e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, <e2>ERK2</e2>, and Akt, but not phosphorylated JNK1/2 and p38.","Downregulator"
"Furthermore, <e1>nobiletin</e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and <e2>Akt</e2>, but not phosphorylated JNK1/2 and p38.","Downregulator"
"<e1>Nobiletin</e1> attenuates metastasis via both <e2>ERK</e2> and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.","Downregulator"
"<e1>Nobiletin</e1> attenuates metastasis via both ERK and <e2>PI3K</e2>/Akt pathways in HGF-treated liver cancer HepG2 cells.","Downregulator"
"<e1>Nobiletin</e1> attenuates metastasis via both ERK and PI3K/<e2>Akt</e2> pathways in HGF-treated liver cancer HepG2 cells.","Downregulator"
"We use <e2>HGF</e2> as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and <e1>nobiletin</e1> on HGF/c-Met-mediated tumor invasion and metastasis.","Downregulator"
"Furthermore, <e1>nobiletin</e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, <e2>ERK</e2>2, and Akt, but not phosphorylated JNK1/2 and p38.","Downregulator"
"In conclusion, <e1>nobiletin</e1> attenuates HGF-induced HepG2 cells metastasis involving both ERK and <e2>PI3K</e2>/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","Downregulator"
"Furthermore, <e1>nobiletin</e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and <e2>Akt</e2>, but not phosphorylated JNK1/2 and p38.","Downregulator"
"We use <e2>HGF</e2> as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and <e1>nobiletin</e1> on HGF/c-Met-mediated tumor invasion and metastasis.","Downregulator"
"We use <e2>HGF</e2> as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and <e1>nobiletin</e1> on HGF/c-Met-mediated tumor invasion and metastasis.","Downregulator"
"We use <e2>HGF</e2> as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and <e1>nobiletin</e1> on HGF/c-Met-mediated tumor invasion and metastasis.","Downregulator"
"We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and <e1>nobiletin</e1> on HGF/<e2>c-Met</e2>-mediated tumor invasion and metastasis.","Downregulator"
"Furthermore, <e1>nobiletin</e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, <e2>ERK2</e2>, and Akt, but not phosphorylated JNK1/2 and p38.","Downregulator"
"Furthermore, <e1>nobiletin</e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and <e2>Akt</e2>, but not phosphorylated JNK1/2 and p38.","Downregulator"
"These data suggest that T-cells can be activated by <e1>abacavir</e1> through a direct interaction with surface and intracellular major histocompatibility complex (<e2>MHC</e2>) molecules.","Not"
"These data suggest that T-cells can be activated by <e1>abacavir</e1> through a direct interaction with surface and intracellular <e2>major histocompatibility complex</e2> (MHC) molecules.","Regulator"
"These data suggest that T-cells can be activated by <e1>abacavir</e1> through a direct interaction with surface and intracellular major histocompatibility complex (<e2>MHC</e2>) molecules.","Regulator"
"These data suggest that T-cells can be activated by <e1>abacavir</e1> through a direct interaction with surface and intracellular major histocompatibility complex (<e2>MHC</e2>) molecules.","Regulator"
"With the former, <e1>abacavir</e1> seemingly participates in the MHC <e2>T-cell receptor</e2> binding interaction.","Regulator"
"These data suggest that T-cells can be activated by <e1>abacavir</e1> through a direct interaction with surface and intracellular major histocompatibility complex (<e2>MHC</e2>) molecules.","Regulator"
"Seventy-four CD8+ clones expressing different <e2>Vβ receptors</e2> were shown to proliferate and kill target cells via different mechanisms when exposed to <e1>abacavir</e1>.","Regulator"
"Excess of <e1>cholesterol</e1> converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for <e2>Aβ</e2> and Tau.","Regulator"
"Excess of <e1>cholesterol</e1> converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for Aβ and <e2>Tau</e2>.","Regulator"
"The neurospecific <e1>cholesterol</e1> 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte <e2>ApoE</e2>.","Upregulator"
"The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (<e1>24OHC</e1>) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte <e2>ApoE</e2>.","Upregulator"
"<e1>Cholesterol</e1> also increases <e2>Amyloid β</e2> (Aβ) deposition and tau pathology.","Downregulator"
"<e1>Cholesterol</e1> also increases Amyloid β (<e2>Aβ</e2>) deposition and tau pathology.","Downregulator"
"<e1>Cholesterol</e1> also increases Amyloid β (Aβ) deposition and <e2>tau</e2> pathology.","Downregulator"
"While the function of N-type <e1>calcium</e1> channels within astrocytes is controversial, these voltage-gated calcium channels have been linked to calcium-dependent vesicular gliotransmitter release.","Regulator"
"While the function of N-type <e1>calcium</e1> channels within astrocytes is controversial, these <e2>voltage-gated calcium channels</e2> have been linked to calcium-dependent vesicular gliotransmitter release.","Regulator"
"We have previously shown that a loss of <e2>CaMKII</e2> activity in neurons is detrimental to neuronal viability by inducing excitotoxic <e1>glutamate</e1> release.","Substrate"
"Remarkably, <e1>3-HPT</e1> gives no inhibition of <e2>HDAC 1</e2>.","Not"
"We have identified <e1>3-hydroxypyridin-2-thione</e1> (3-HPT) as a novel ZBG that is compatible with <e2>HDAC</e2> inhibition.","Downregulator"
"We have identified 3-hydroxypyridin-2-thione (<e1>3-HPT</e1>) as a novel ZBG that is compatible with <e2>HDAC</e2> inhibition.","Downregulator"
"<e1>3-HPT</e1> inhibits <e2>HDAC 6</e2> and HDAC 8 with an IC50 of 681 and 3675 nM, respectively.","Downregulator"
"<e1>3-HPT</e1> inhibits HDAC 6 and <e2>HDAC 8</e2> with an IC50 of 681 and 3675 nM, respectively.","Downregulator"
"Small molecules bearing hydroxamic acid as the <e1>zinc</e1> binding group (ZBG) have been the most effective <e2>histone deacetylase</e2> inhibitors (HDACi) to date.","Downregulator"
"Small molecules bearing hydroxamic acid as the <e1>zinc</e1> binding group (ZBG) have been the most effective histone deacetylase inhibitors (<e2>HDAC</e2>i) to date.","Downregulator"
"Subsequent optimization led to several novel <e1>3HPT</e1>-based <e2>HDAC</e2>i that are selective for HDAC 6 and HDAC 8.","Downregulator"
"Subsequent optimization led to several novel <e1>3HPT</e1>-based HDACi that are selective for <e2>HDAC 6</e2> and HDAC 8.","Downregulator"
"Subsequent optimization led to several novel <e1>3HPT</e1>-based HDACi that are selective for HDAC 6 and <e2>HDAC 8</e2>.","Downregulator"
"<e1>3-Hydroxypyridin-2-thione</e1> as Novel Zinc Binding Group for Selective <e2>Histone Deacetylase</e2> Inhibition.","Downregulator"
"3-Hydroxypyridin-2-thione as Novel <e1>Zinc</e1> Binding Group for Selective <e2>Histone Deacetylase</e2> Inhibition.","Downregulator"
"Native GLP-1 stimulates <e2>insulin</e2> secretion in a <e1>glucose</e1>-dependent manner, as well as suppressing glucagon production and slowing gastric emptying.","Regulator"
"Maqui berry (Aristotelia chilensis) and the constituent <e1>delphinidin glycoside</e1> inhibit <e2>photoreceptor</e2> cell death induced by visible light.","Upregulator"
"These findings indicate that MBE and its <e1>anthocyanidins</e1> suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of <e2>phosphorylated-p38</e2> may be involved in the underlying mechanism.","Downregulator"
"Moreover, <e1>curcumin</e1> could also down-regulate the expression and activity of <e2>matrix metalloproteinase-9</e2> (MMP-9).","Downregulator"
"Moreover, <e1>curcumin</e1> could also down-regulate the expression and activity of matrix metalloproteinase-9 (<e2>MMP-9</e2>).","Downregulator"
"Moreover, <e1>curcumin</e1> could also down-regulate the expression and activity of <e2>matrix metalloproteinase-9</e2> (MMP-9).","Downregulator"
"Moreover, <e1>curcumin</e1> could also down-regulate the expression and activity of matrix metalloproteinase-9 (<e2>MMP-9</e2>).","Downregulator"
"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of <e2>Histone 3</e2> at <e1>Ser</e1>10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.","Part_of"
"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of <e2>Cdk1</e2> at <e1>Tyr</e1>15, expression of cyclin B1, and decreased expression of Cdc25c.","Part_of"
"Treatment with <e1>EVn-50</e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of <e2>Histone 3</e2> at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.","Upregulator"
"Treatment with <e1>EVn-50</e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of <e2>Cdk1</e2> at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.","Upregulator"
"Treatment with EVn-50 or <e1>VB1</e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of <e2>Histone 3</e2> at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.","Upregulator"
"Treatment with EVn-50 or <e1>VB1</e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of <e2>Cdk1</e2> at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.","Upregulator"
"Treatment with <e1>EVn-50</e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of <e2>cyclin B1</e2>, and decreased expression of Cdc25c.","Upregulator"
"Treatment with EVn-50 or <e1>VB1</e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of <e2>cyclin B1</e2>, and decreased expression of Cdc25c.","Upregulator"
"Treatment with <e1>EVn-50</e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of <e2>Cdc25c</e2>.","Downregulator"
"Treatment with EVn-50 or <e1>VB1</e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of <e2>Cdc25c</e2>.","Downregulator"
"Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of <e1>CAT</e1> and to determine the involvement of <e2>PKC</e2>, PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.","Regulator"
"Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of <e1>CAT</e1> and to determine the involvement of PKC, <e2>PKA</e2>, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.","Regulator"
"Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of <e1>CAT</e1> and to determine the involvement of PKC, PKA, <e2>TRPV1</e2>, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.","Regulator"
"Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of <e1>CAT</e1> and to determine the involvement of PKC, PKA, TRPV1, TRPA1, <e2>TRPM8</e2> and ASIC in its antinociceptive mechanism.","Regulator"
"Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of <e1>CAT</e1> and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and <e2>ASIC</e2> in its antinociceptive mechanism.","Regulator"
"Conclusion The results of this work contribute information regarding the antinociceptive properties of <e1>CAT</e1> on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, <e2>glutamate receptors</e2>, PKC and PKA participate in CAT's antinociceptive mechanism.","Regulator"
"Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of <e1>CAT</e1> and to determine the involvement of <e2>PKC</e2>, PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.","Regulator"
"Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of <e1>CAT</e1> and to determine the involvement of PKC, <e2>PKA</e2>, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.","Regulator"
"In an investigation into the participation of <e2>TRP channels</e2> and ASICs in <e1>CAT</e1>'s antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).","Regulator"
"In an investigation into the participation of TRP channels and <e2>ASICs</e2> in <e1>CAT</e1>'s antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).","Regulator"
"In an investigation into the participation of <e2>TRP channels</e2> and ASICs in CAT's antinociceptive mechanism, we used <e1>capsaicin</e1> (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).","Regulator"
"In an investigation into the participation of TRP channels and <e2>ASICs</e2> in CAT's antinociceptive mechanism, we used <e1>capsaicin</e1> (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).","Regulator"
"In an investigation into the participation of <e2>TRP channels</e2> and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), <e1>cinnamaldehyde</e1> (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).","Regulator"
"In an investigation into the participation of TRP channels and <e2>ASICs</e2> in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), <e1>cinnamaldehyde</e1> (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).","Regulator"
"In an investigation into the participation of <e2>TRP channels</e2> and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), <e1>menthol</e1> (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).","Regulator"
"In an investigation into the participation of TRP channels and <e2>ASICs</e2> in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), <e1>menthol</e1> (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).","Regulator"
"In an investigation into the participation of <e2>TRP channels</e2> and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% <e1>acetic acid</e1>, pH 1.98).","Regulator"
"In an investigation into the participation of TRP channels and <e2>ASICs</e2> in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% <e1>acetic acid</e1>, pH 1.98).","Regulator"
"Importantly, 2-hydroxy<e1>chalcone</e1> and xanthohumol exerted more potent inhibitory effects on the proliferation, <e2>MMP-9</e2> expression and invasive phenotype of MDA-MB-231 than chalcone.","Regulator"
"<e1>Xanthohumol</e1> and 2-hydroxychalcone induced apoptosis by <e2>Bcl-2</e2> downregulation.","Downregulator"
"Xanthohumol and <e1>2-hydroxychalcone</e1> induced apoptosis by <e2>Bcl-2</e2> downregulation.","Downregulator"
"Importantly, <e1>2-hydroxychalcone</e1> and xanthohumol exerted more potent inhibitory effects on the proliferation, <e2>MMP-9</e2> expression and invasive phenotype of MDA-MB-231 than chalcone.","Downregulator"
"Importantly, 2-hydroxychalcone and <e1>xanthohumol</e1> exerted more potent inhibitory effects on the proliferation, <e2>MMP-9</e2> expression and invasive phenotype of MDA-MB-231 than chalcone.","Downregulator"
"<e1>3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one</e1> exhibited the predicted binding mode and demonstrated high inhibitory activity for <e2>human DAAO</e2> in enzyme- and cell-based assays.","Regulator"
"<e1>3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one</e1> exhibited the predicted binding mode and demonstrated high inhibitory activity for <e2>human DAAO</e2> in enzyme- and cell-based assays.","Downregulator"
"<e1>4-Hydroxypyridazin-3(2H)-one</e1> Derivatives as Novel <e2>d-Amino Acid Oxidase</e2> Inhibitors.","Downregulator"
"We identified a series of <e1>4-hydroxypyridazin-3(2H)-one</e1> derivatives as novel <e2>DAAO</e2> inhibitors with high potency and substantial cell permeability using fragment-based drug design.","Downregulator"
"d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including <e1>d-serine</e1>, a coagonist of the <e2>N-methyl-d-aspartate receptor</e2>.","Agonist"
"<e2>d-Amino acid oxidase</e2> (DAAO) catalyzes the oxidation of d-amino acids including <e1>d-serine</e1>, a coagonist of the N-methyl-d-aspartate receptor.","Substrate"
"d-Amino acid oxidase (<e2>DAAO</e2>) catalyzes the oxidation of d-amino acids including <e1>d-serine</e1>, a coagonist of the N-methyl-d-aspartate receptor.","Substrate"
"<e2>d-Amino acid oxidase</e2> (DAAO) catalyzes the oxidation of <e1>d-amino acids</e1> including d-serine, a coagonist of the N-methyl-d-aspartate receptor.","Substrate"
"d-Amino acid oxidase (<e2>DAAO</e2>) catalyzes the oxidation of <e1>d-amino acids</e1> including d-serine, a coagonist of the N-methyl-d-aspartate receptor.","Substrate"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and androgen receptor (h<e2>AR</e2>) were investigated.","Not"
"Comparative study on transcriptional activity of 17 <e1>parabens</e1> mediated by estrogen receptor α and β and <e2>androgen receptor</e2>.","Regulator"
"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, <e1>heptylparaben</e1> (C7) and pentylparaben (C5) showed the most potent <e2>ERα</e2> and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.","Agonist"
"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, <e1>heptylparaben</e1> (C7) and pentylparaben (C5) showed the most potent ERα and <e2>ERβ</e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.","Agonist"
"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and <e1>pentylparaben</e1> (C5) showed the most potent <e2>ERα</e2> and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.","Agonist"
"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and <e1>pentylparaben</e1> (C5) showed the most potent ERα and <e2>ERβ</e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.","Agonist"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), h<e2>ERβ</e2> and androgen receptor (hAR) were investigated.","Agonist"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (h<e2>ERα</e2>), hERβ and androgen receptor (hAR) were investigated.","Agonist"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), h<e2>ERβ</e2> and androgen receptor (hAR) were investigated.","Agonist"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (h<e2>ERα</e2>), hERβ and androgen receptor (hAR) were investigated.","Agonist"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (<e2>hERα</e2>), hERβ and androgen receptor (hAR) were investigated.","Agonist"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), <e2>hERβ</e2> and androgen receptor (hAR) were investigated.","Agonist"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (h<e2>ERα</e2>), hERβ and androgen receptor (hAR) were investigated.","Agonist"
"The structure-activity relationships of <e1>parabens</e1> which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), h<e2>ERβ</e2> and androgen receptor (hAR) were investigated.","Agonist"
"Among 12 parabens with linear <e1>alkyl</e1> chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent <e2>ERα</e2> and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.","Agonist"
"Among 12 parabens with linear <e1>alkyl</e1> chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ERα and <e2>ERβ</e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.","Agonist"
"These results indicate that <e1>parabens</e1> are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by <e2>carboxylesterases</e2>, leading to attenuation of their estrogenic activity.","Substrate"
"Wattakaka volubilis <e1>steroidal glycoside</e1> mixture (WVSM) and PPG (1-50μM) significantly inhibited the <e2>COX-2</e2> and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.","Downregulator"
"Wattakaka volubilis <e1>steroidal glycoside</e1> mixture (WVSM) and PPG (1-50μM) significantly inhibited the COX-2 and <e2>iNOS</e2> enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.","Downregulator"
"Wattakaka volubilis steroidal glycoside mixture (WVSM) and <e1>PPG</e1> (1-50μM) significantly inhibited the <e2>COX-2</e2> and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.","Downregulator"
"Wattakaka volubilis steroidal glycoside mixture (WVSM) and <e1>PPG</e1> (1-50μM) significantly inhibited the COX-2 and <e2>iNOS</e2> enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.","Downregulator"
"<e2>E-cadherin</e2> is a transmembrane glycoprotein that mediates <e1>calcium</e1>-dependent interactions between adjacent epithelial cells.","Regulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent <e1>ethanol</e1> hepatotoxicity via depleting heme pool and releasing CO.","Regulator"
"However, the precise mechanism by which <e1>quercetin</e1> counteracts <e2>CYP2E1</e2>-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.","Regulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent <e1>ethanol</e1> hepatotoxicity via depleting heme pool and releasing CO.","Regulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent <e1>ethanol</e1> hepatotoxicity via depleting heme pool and releasing CO.","Regulator"
"Naturally occuring <e1>quercetin</e1> protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (<e2>HO-1</e2>) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.","Regulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent <e1>ethanol</e1> hepatotoxicity via depleting heme pool and releasing CO.","Upregulator"
"<e1>Quercetin</e1> (100μM) induced <e2>HO-1</e2> and depleted heme pool when incubated to human hepatocytes.","Upregulator"
"<e1>Ethanol</e1>-stimulated (100mM) <e2>CYP2E1</e2> upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.","Upregulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent <e1>ethanol</e1> hepatotoxicity via depleting heme pool and releasing CO.","Upregulator"
"Naturally occuring <e1>quercetin</e1> protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (<e2>HO-1</e2>) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.","Upregulator"
"Naturally occuring quercetin protects hepatocytes from <e1>ethanol</e1>-induced oxidative stress, and heme oxygenase-1 (<e2>HO-1</e2>) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.","Downregulator"
"However, the precise mechanism by which <e1>quercetin</e1> counteracts <e2>CYP2E1</e2>-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.","Downregulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent ethanol hepatotoxicity via depleting heme pool and releasing <e1>CO</e1>.","Downregulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent ethanol hepatotoxicity via depleting heme pool and releasing <e1>CO</e1>.","Downregulator"
"<e1>Quercetin</e1> suppressed <e2>CYP2E1</e2>-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.","Downregulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent ethanol hepatotoxicity via depleting heme pool and releasing <e1>CO</e1>.","Downregulator"
"However, the precise mechanism by which <e1>quercetin</e1> counteracts <e2>CYP2E1</e2>-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.","Downregulator"
"<e1>Ethanol</e1>-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by <e2>HO-1</e2> inhibition with resultant heme accumulation.","Downregulator"
"Quercetin suppressed <e2>CYP2E1</e2>-dependent ethanol hepatotoxicity via depleting heme pool and releasing <e1>CO</e1>.","Downregulator"
"Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and <e1>heme</e1> oxygenase-1 (<e2>HO-1</e2>) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.","Substrate"
"Novel racemic <e1>tetrahydrocurcuminoid dihydropyrimidinone</e1> analogues as potent <e2>acetylcholinesterase</e2> inhibitors.","Downregulator"
"Both <e1>ICI</e1> treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine <e2>progesterone receptor</e2> (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.","Not"
"Both <e1>ICI</e1> treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (<e2>PR</e2>) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.","Not"
"We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of <e2>Akt</e2> phosphorylation at <e1>Ser</e1> 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.","Part_of"
"Both <e1>ICI</e1> treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of <e2>cyclin D1</e2>, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.","Regulator"
"Both <e1>ICI</e1> treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of <e2>cyclin D1</e2>, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.","Regulator"
"Furthermore, we detected that <e1>ICI</e1> treatment induced <e2>glycogen synthase kinase</e2> (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.","Upregulator"
"Furthermore, we detected that <e1>ICI</e1> treatment induced glycogen synthase kinase (<e2>Gsk3-β</e2>) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.","Upregulator"
"Agonistic activity of <e1>ICI 182 780</e1> on activation of GSK 3β/<e2>AKT</e2> pathway in the rat uterus during the estrous cycle.","Upregulator"
"We observed that the administration of <e1>ICI</e1> at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of <e2>Akt</e2> phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.","Upregulator"
"Both <e1>ICI</e1> treatments, induced a significant decrease (p<0.01) in uterine <e2>estrogen receptor alpha</e2> (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.","Downregulator"
"Both <e1>ICI</e1> treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (<e2>ERα</e2>) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.","Downregulator"
"We observed that the administration of <e1>ICI</e1> at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of <e2>Akt</e2> phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.","Downregulator"
"Agonistic activity of <e1>ICI 182 780</e1> on activation of <e2>GSK 3β</e2>/AKT pathway in the rat uterus during the estrous cycle.","Agonist"
"A series of <e1>aminopropylindenes</e1>, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<e2>OSC</e2>)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone.","Regulator"
"A series of <e1>aminopropylindenes</e1>, designed as mimics of a cationic high energy intermediate in the <e2>oxidosqualene cyclase(1)</e2> (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone.","Regulator"
"A <e1>N,N-dimethylaminopropyl</e1> derivative showed promising inhibition of <e2>Trypanosoma cruzi OSC</e2> in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.","Downregulator"
"<e1>Aminopropylindenes</e1> derived from Grundmann's ketone as a novel chemotype of <e2>oxidosqualene cyclase</e2> inhibitors.","Downregulator"
"Aminopropylindenes derived from <e1>Grundmann's ketone</e1> as a novel chemotype of <e2>oxidosqualene cyclase</e2> inhibitors.","Downregulator"
"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<e2>OSC</e2>)-mediated cyclization of 2,3-oxidosqualen to <e1>lanosterol</e1> was prepared from Grundmann's ketone.","Substrate"
"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the <e2>oxidosqualene cyclase(1)</e2> (OSC)-mediated cyclization of 2,3-oxidosqualen to <e1>lanosterol</e1> was prepared from Grundmann's ketone.","Substrate"
"A N,N-dimethylaminopropyl derivative showed promising inhibition of <e2>Trypanosoma cruzi OSC</e2> in combination with low cytotoxicity, and showed significant reduction of <e1>cholesterol</e1> biosynthesis in a human cell line.","Substrate"
"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<e2>OSC</e2>)-mediated cyclization of <e1>2,3-oxidosqualen</e1> to lanosterol was prepared from Grundmann's ketone.","Substrate"
"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the <e2>oxidosqualene cyclase(1)</e2> (OSC)-mediated cyclization of <e1>2,3-oxidosqualen</e1> to lanosterol was prepared from Grundmann's ketone.","Substrate"
"MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles <e1>ATP</e1> activates P2Y1 but not <e2>P2X receptors</e2>.","Not"
"Phosphorylation on <e1>Ser</e1> and Thr residues of <e2>pannexin1</e2> was increased during potentiation, possibly mediating HC opening.","Part_of"
"Phosphorylation on Ser and <e1>Thr</e1> residues of <e2>pannexin1</e2> was increased during potentiation, possibly mediating HC opening.","Part_of"
"Immunocytochemical analyses and function were consistent with <e2>pannexin1</e2> localization to T-tubules intercalated with <e1>dihydropyridine</e1> and ryanodine receptors in slow (soleus) and fast (extensor digitorum longus, EDL) muscles.","Regulator"
"During repetitive stimulation of skeletal muscle, extracellular <e1>ATP</e1> levels raise, activating <e2>purinergic receptors</e2>, increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation.","Upregulator"
"MRS2179, a <e2>P2Y1</e2>R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles <e1>ATP</e1> activates P2Y1 but not P2X receptors.","Upregulator"
"Consistent with two <e1>glucose</e1> uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or <e2>glucose transporter</e2> (GLUT4), and blocked by dual blockade.","Substrate"
"Consistent with two <e1>glucose</e1> uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (<e2>GLUT4</e2>), and blocked by dual blockade.","Substrate"
"Consistent with two glucose uptake pathways, induced uptake of <e1>2-NBDG</e1>, a fluorescent glucose derivative, was decreased by inhibition of HCs or <e2>glucose transporter</e2> (GLUT4), and blocked by dual blockade.","Substrate"
"Consistent with two glucose uptake pathways, induced uptake of <e1>2-NBDG</e1>, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (<e2>GLUT4</e2>), and blocked by dual blockade.","Substrate"
"The <e1>ATP</e1> required for potentiation of skeletal muscle contraction is released via <e2>pannexin</e2> hemichannels.","Substrate"
"We found that <e1>ATP</e1> appears to be released through pannexin1 hemichannels (<e2>Panx1</e2> HCs).","Substrate"
"Opening of <e2>Panx1</e2> HCs during repetitive activation allows efflux of ATP, influx of <e1>glucose</e1> and possibly Ca(2+) too, which are required for potentiation of contraction.","Substrate"
"Opening of <e2>Panx1</e2> HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly <e1>Ca(2+)</e1> too, which are required for potentiation of contraction.","Substrate"
"The rate limiting enzyme of beta-oxidation (<e2>ACOX1</e2>) was significantly over-expressed in the liver with <e1>tBHQ</e1> treatment.","Upregulator"
"The rate limiting enzyme of beta-oxidation (<e2>ACOX1</e2>) was significantly over-expressed in the liver with <e1>tBHQ</e1> treatment.","Upregulator"
"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (<e2>VEGF</e2>), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core <e1>PLGA</e1> and more than 45% with HMW core PLGA.","Upregulator"
"When dual angiogenic growth factors (GFs), such as platelet-derived GF (<e2>PDGF</e2>) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core <e1>PLGA</e1> and more than 45% with HMW core PLGA.","Upregulator"
"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (<e2>VEGF</e2>), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core <e1>PLGA</e1> and more than 45% with HMW core PLGA.","Upregulator"
"When dual angiogenic growth factors (GFs), such as platelet-derived GF (<e2>PDGF</e2>) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core <e1>PLGA</e1> and more than 45% with HMW core PLGA.","Upregulator"
"Potency switch between CHK1 and <e2>MK2</e2>: Discovery of <e1>imidazo[1,2-a]pyrazine</e1>- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.","Downregulator"
"Potency switch between CHK1 and MK2: Discovery of <e1>imidazo[1,2-a]pyrazine</e1>- and imidazo[1,2-c]pyrimidine-based <e2>kinase</e2> inhibitors.","Downregulator"
"Potency switch between <e2>CHK1</e2> and MK2: Discovery of <e1>imidazo[1,2-a]pyrazine</e1>- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.","Downregulator"
"Potency switch between CHK1 and <e2>MK2</e2>: Discovery of imidazo[1,2-a]pyrazine- and <e1>imidazo[1,2-c]pyrimidine</e1>-based kinase inhibitors.","Downregulator"
"Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and <e1>imidazo[1,2-c]pyrimidine</e1>-based <e2>kinase</e2> inhibitors.","Downregulator"
"Potency switch between <e2>CHK1</e2> and MK2: Discovery of imidazo[1,2-a]pyrazine- and <e1>imidazo[1,2-c]pyrimidine</e1>-based kinase inhibitors.","Downregulator"
"Discovery of <e1>aryl ureas</e1> and aryl amides as potent and selective <e2>histamine H3 receptor</e2> antagonists for the treatment of obesity (Part I).","Antagonist"
"A series of structurally novel <e1>aryl ureas</e1> was derived from optimization of the HTS lead as selective histamine H3 receptor (<e2>H3R</e2>) antagonists.","Antagonist"
"Discovery of <e1>aryl ureas</e1> and aryl amides as potent and selective <e2>histamine H3 receptor</e2> antagonists for the treatment of obesity (Part I).","Antagonist"
"Discovery of aryl ureas and <e1>aryl amides</e1> as potent and selective <e2>histamine H3 receptor</e2> antagonists for the treatment of obesity (Part I).","Antagonist"
"An increase in the energy required to remove the same anion from the <e2>tridentate receptor</e2> when compared to the bidentate and monodentate receptors is explained as being due to the increase in <e1>halogen</e1> bonding interactions.","Regulator"
"In terms of the mechanisms, we found that fatty acid amide hydrolase (<e2>FAAH</e2>) which degrades <e1>anandamide</e1>, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.","Substrate"
"In terms of the mechanisms, we found that <e2>fatty acid amide hydrolase</e2> (FAAH) which degrades <e1>anandamide</e1>, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.","Substrate"
"However, enzymes contributing to oxidative metabolism of <e1>anandamide</e1>, namely <e2>cyclooxygenase-1</e2> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.","Substrate"
"However, enzymes contributing to oxidative metabolism of <e1>anandamide</e1>, namely cyclooxygenase-1 and <e2>Cyp2D6</e2>, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.","Substrate"
"However, enzymes contributing to oxidative metabolism of <e1>anandamide</e1>, namely <e2>cyclooxygenase-1</e2> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.","Substrate"
"However, enzymes contributing to oxidative metabolism of <e1>anandamide</e1>, namely cyclooxygenase-1 and <e2>Cyp2D6</e2>, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.","Substrate"
"When the expression of ABCA1 and ABCG1 was induced, <e1>24-OHC</e1> efflux was stimulated in the presence of high density lipoprotein (HDL), whereas <e2>apolipoprotein A-I</e2> was not an efficient acceptor.","Not"
"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and <e1>retinoic acid</e1>, which are ligands of the <e2>nuclear receptors</e2> LXR/RXR.","Regulator"
"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and <e1>retinoic acid</e1>, which are ligands of the nuclear receptors <e2>LXR</e2>/RXR.","Regulator"
"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and <e1>retinoic acid</e1>, which are ligands of the nuclear receptors LXR/<e2>RXR</e2>.","Regulator"
"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as <e1>TO901317</e1> and retinoic acid, which are ligands of the <e2>nuclear receptors</e2> LXR/RXR.","Regulator"
"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as <e1>TO901317</e1> and retinoic acid, which are ligands of the nuclear receptors <e2>LXR</e2>/RXR.","Regulator"
"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as <e1>TO901317</e1> and retinoic acid, which are ligands of the nuclear receptors LXR/<e2>RXR</e2>.","Regulator"
"When the expression of ABCA1 and ABCG1 was induced, <e1>24-OHC</e1> efflux was stimulated in the presence of <e2>high density lipoprotein</e2> (HDL), whereas apolipoprotein A-I was not an efficient acceptor.","Regulator"
"When the expression of ABCA1 and ABCG1 was induced, <e1>24-OHC</e1> efflux was stimulated in the presence of high density lipoprotein (<e2>HDL</e2>), whereas apolipoprotein A-I was not an efficient acceptor.","Regulator"
"When the expression of ABCA1 and ABCG1 was induced, <e1>24-OHC</e1> efflux was stimulated in the presence of high density lipoprotein (<e2>HDL</e2>), whereas apolipoprotein A-I was not an efficient acceptor.","Regulator"
"When the expression of ABCA1 and ABCG1 was induced, <e1>24-OHC</e1> efflux was stimulated in the presence of high density lipoprotein (HDL), whereas <e2>apolipoprotein A-I</e2> was not an efficient acceptor.","Regulator"
"When the expression of ABCA1 and ABCG1 was induced, <e1>24-OHC</e1> efflux was stimulated in the presence of high density lipoprotein (<e2>HDL</e2>), whereas apolipoprotein A-I was not an efficient acceptor.","Regulator"
"The expression of <e2>ABCA1</e2> and ABCG1 was induced by 24-OHC, as well as TO901317 and <e1>retinoic acid</e1>, which are ligands of the nuclear receptors LXR/RXR.","Upregulator"
"The expression of ABCA1 and <e2>ABCG1</e2> was induced by 24-OHC, as well as TO901317 and <e1>retinoic acid</e1>, which are ligands of the nuclear receptors LXR/RXR.","Upregulator"
"The expression of <e2>ABCA1</e2> and ABCG1 was induced by <e1>24-OHC</e1>, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.","Upregulator"
"The expression of ABCA1 and <e2>ABCG1</e2> was induced by <e1>24-OHC</e1>, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.","Upregulator"
"The expression of <e2>ABCA1</e2> and ABCG1 was induced by 24-OHC, as well as <e1>TO901317</e1> and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.","Upregulator"
"The expression of ABCA1 and <e2>ABCG1</e2> was induced by 24-OHC, as well as <e1>TO901317</e1> and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.","Upregulator"
"Because <e1>24(S)-hydroxycholesterol</e1> (24-OHC), produced by <e2>24-hydroxylase</e2>, induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.","Substrate"
"Because 24(S)-hydroxycholesterol (<e1>24-OHC</e1>), produced by <e2>24-hydroxylase</e2>, induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.","Substrate"
"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing <e2>human ABCA1</e2> or ABCG1; we clearly observed <e1>24-OHC</e1> efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.","Substrate"
"The expression of ABCA1 and <e2>ABCG1</e2> was induced by <e1>24-OHC</e1>, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.","Substrate"
"<e1>24(S)-hydroxycholesterol</e1> is actively eliminated from neuronal cells by <e2>ABCA1</e2>.","Substrate"
"The expression of <e2>ABCA1</e2> and ABCG1 was induced by <e1>24-OHC</e1>, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.","Substrate"
"High <e1>cholesterol</e1> turnover catalyzed by <e2>cholesterol 24-hydroxylase</e2> is essential for neural functions, especially learning.","Substrate"
"Molecular docking studies were performed with <e2>Human Serum Albumin</e2> (HSA: PDB 1E78), showing binding pattern with <e1>amino acid</e1> residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.","Part_of"
"Molecular docking studies were performed with Human Serum Albumin (<e2>HSA</e2>: PDB 1E78), showing binding pattern with <e1>amino acid</e1> residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.","Part_of"
"Molecular docking studies were performed with <e2>Human Serum Albumin</e2> (HSA: PDB 1E78), showing binding pattern with amino acid residues <e1>Arg</e1>218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.","Part_of"
"Molecular docking studies were performed with Human Serum Albumin (<e2>HSA</e2>: PDB 1E78), showing binding pattern with amino acid residues <e1>Arg</e1>218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.","Part_of"
"Molecular docking studies were performed with <e2>Human Serum Albumin</e2> (HSA: PDB 1E78), showing binding pattern with amino acid residues <e1>Arg</e1>218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.","Part_of"
"Molecular docking studies were performed with Human Serum Albumin (<e2>HSA</e2>: PDB 1E78), showing binding pattern with amino acid residues <e1>Arg</e1>218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.","Part_of"
"Molecular docking studies were performed with <e2>Human Serum Albumin</e2> (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and <e1>Lys</e1>444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.","Part_of"
"Molecular docking studies were performed with Human Serum Albumin (<e2>HSA</e2>: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and <e1>Lys</e1>444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.","Part_of"
"Presynaptic <e2>CaMKIIα</e2> modulates dopamine D3 receptor activation in striatonigral terminals of the rat brain in a <e1>Ca(2+)</e1> dependent manner.","Regulator"
"These experiments show that in striatonigral projections, CaMKIIα inhibits the action of <e2>D3 receptors</e2> in a <e1>Ca(2+)</e1> dependent manner blocking their modulatory effects on GABA release.","Regulator"
"The selective <e2>CaMKIIα</e2> inhibitor <e1>KN-62</e1> reversed the blockade produced by ionomycin and K(+)-depolarization.","Regulator"
"Immunoblot studies showed that K(+)-depolarization increased CaMKIIα phosphorylation in a <e1>KN-62</e1> sensitive manner and promoted CaMKIIα binding to <e2>D3 receptors</e2>.","Regulator"
"The selective <e2>CaMKIIα</e2> inhibitor <e1>KN-62</e1> reversed the blockade produced by ionomycin and K(+)-depolarization.","Regulator"
"The selective <e2>CaMKIIα</e2> inhibitor KN-62 reversed the blockade produced by ionomycin and <e1>K(+)</e1>-depolarization.","Regulator"
"Presynaptic <e2>CaMKIIα</e2> modulates dopamine D3 receptor activation in striatonigral terminals of the rat brain in a <e1>Ca(2+)</e1> dependent manner.","Regulator"
"Presynaptic CaMKIIα modulates <e2>dopamine D3 receptor</e2> activation in striatonigral terminals of the rat brain in a <e1>Ca(2+)</e1> dependent manner.","Regulator"
"The selective <e2>CaMKIIα</e2> inhibitor <e1>KN-62</e1> reversed the blockade produced by ionomycin and K(+)-depolarization.","Downregulator"
"The selective <e2>CaMKIIα</e2> inhibitor KN-62 reversed the blockade produced by <e1>ionomycin</e1> and K(+)-depolarization.","Downregulator"
"The selective <e2>CaMKIIα</e2> inhibitor <e1>KN-62</e1> reversed the blockade produced by ionomycin and K(+)-depolarization.","Downregulator"
"In the presence of this inhibitor, the selective <e2>D3</e2> agonist <e1>PD 128,907</e1> reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4 nM.","Agonist"
"In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the <e2>D1</e2> agonist <e1>SKF 38393</e1> from 56 to 4 nM.","Agonist"
"Additionally, treatment with <e1>glucose</e1>/iron showed a higher <e2>HO</e2> activity.","Upregulator"
"Heme oxygenase (<e2>HO</e2>) activity, <e1>iron</e1> uptake, superoxide dismutase activity, and glutathione content were also determined.","Upregulator"
"The purpose of this study was to describe the effect of different iron and/or <e1>glucose</e1> concentrations over Mfn2, Bax, and <e2>Bcl2</e2> expressions in a β-pancreatic cell line (MIN6 cells).","Upregulator"
"The purpose of this study was to describe the effect of different iron and/or <e1>glucose</e1> concentrations over Mfn2, <e2>Bax</e2>, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells).","Upregulator"
"The purpose of this study was to describe the effect of different iron and/or <e1>glucose</e1> concentrations over Mfn2, Bax, and <e2>Bcl2</e2> expressions in a β-pancreatic cell line (MIN6 cells).","Upregulator"
"The purpose of this study was to describe the effect of different iron and/or <e1>glucose</e1> concentrations over Mfn2, <e2>Bax</e2>, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells).","Upregulator"
"Our study revealed that high glucose/<e1>Fe</e1> concentrations in MIN6 cells induced an increase of the <e2>Bcl2</e2>/Bax ratio, an indicator of increased cell apoptosis.","Upregulator"
"Our study revealed that high glucose/<e1>Fe</e1> concentrations in MIN6 cells induced an increase of the Bcl2/<e2>Bax</e2> ratio, an indicator of increased cell apoptosis.","Upregulator"
"The purpose of this study was to describe the effect of different iron and/or <e1>glucose</e1> concentrations over <e2>Mfn2</e2>, Bax, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells).","Downregulator"
"Targeted disruption of the gene encoding the <e2>N-glycosyltransferase</e2>, prlH, abolished <e1>pyralomicin</e1> production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.","Substrate"
"Targeted disruption of the gene encoding the N-glycosyltransferase, <e2>prlH</e2>, abolished <e1>pyralomicin</e1> production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.","Substrate"
"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of <e2>PrlA</e2> confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the <e1>C7</e1>-cyclitol moiety.","Substrate"
"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a <e2>sugar phosphate cyclase</e2> involved in the formation of the <e1>C7</e1>-cyclitol moiety.","Substrate"
"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of <e2>PrlA</e2> confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-<e1>cyclitol</e1> moiety.","Substrate"
"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a <e2>sugar phosphate cyclase</e2> involved in the formation of the C7-<e1>cyclitol</e1> moiety.","Substrate"
"This includes <e2>nonribosomal peptide synthetases</e2> (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole</e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.","Substrate"
"This includes nonribosomal peptide synthetases (<e2>NRPS</e2>) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole</e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.","Substrate"
"This includes nonribosomal peptide synthetases (NRPS) and <e2>polyketide synthases</e2> (PKS) required for the formation of the <e1>benzopyranopyrrole</e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.","Substrate"
"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (<e2>PKS</e2>) required for the formation of the <e1>benzopyranopyrrole</e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.","Substrate"
"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole</e1> core unit, as well as a suite of tailoring enzymes (e.g., four <e2>halogenases</e2>, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.","Substrate"
"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole</e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an <e2>O-methyltransferase</e2>, and an N-glycosyltransferase) necessary for further modifications of the core structure.","Substrate"
"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole</e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an <e2>N-glycosyltransferase</e2>) necessary for further modifications of the core structure.","Substrate"
"Here, we report that <e2>synaptotagmin-1</e2> is necessary for expression of the vesicular <e1>Ca(2+)</e1> /H(+) -antiport.","Regulator"
"Here, we report that <e2>synaptotagmin-1</e2> is necessary for expression of the vesicular Ca(2+) /<e1>H(+)</e1> -antiport.","Regulator"
"Here, we report that <e2>synaptotagmin-1</e2> is necessary for expression of the vesicular <e1>Ca(2+)</e1> /H(+) -antiport.","Regulator"
"Here, we report that <e2>synaptotagmin-1</e2> is necessary for expression of the vesicular Ca(2+) /<e1>H(+)</e1> -antiport.","Regulator"
"<e2>Synaptotagmin 1</e2> is required for vesicular <e1>Ca(2+)</e1> /H(+) -antiport activity.","Regulator"
"<e2>Synaptotagmin 1</e2> is required for vesicular Ca(2+) /<e1>H(+)</e1> -antiport activity.","Regulator"
"Here, we report that <e2>synaptotagmin-1</e2> is necessary for expression of the vesicular <e1>Ca(2+)</e1> /H(+) -antiport.","Regulator"
"Here, we report that <e2>synaptotagmin-1</e2> is necessary for expression of the vesicular <e1>Ca(2+)</e1> /H(+) -antiport.","Regulator"
"Here, we report that <e2>synaptotagmin-1</e2> is necessary for expression of the vesicular Ca(2+) /<e1>H(+)</e1> -antiport.","Regulator"
"<e2>Synaptotagmin-1</e2>, a vesicular protein interacting with membranes upon low-affinity <e1>Ca(2+)</e1> -binding, plays a major role in excitation-release coupling, by synchronizing calcium entry with fast neurotransmitter release.","Regulator"
"<e2>Synaptotagmin-1</e2>, a vesicular protein interacting with membranes upon low-affinity Ca(2+) -binding, plays a major role in excitation-release coupling, by synchronizing <e1>calcium</e1> entry with fast neurotransmitter release.","Regulator"
"Estradiol replacement enhances <e1>cocaine</e1>-stimulated locomotion in female C57BL/6 mice through <e2>estrogen receptor alpha</e2>.","Regulator"
"These results suggest that E2 enhances <e1>cocaine</e1>-stimulated locomotion in mice predominantly through <e2>ERα</e2>.","Regulator"
"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the <e2>ERα</e2>-selective agonist <e1>PPT</e1> or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.","Agonist"
"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the <e2>ERβ</e2>-selective agonist <e1>DPN</e1> were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.","Agonist"
"The Intermediate-conductance <e1>Calcium</e1>-activated Potassium Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling.","Substrate"
"The current study examined the bioactivation potential of <e2>ghrelin receptor</e2> inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and <e1>1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone</e1> (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure.","Agonist"
"The current study examined the bioactivation potential of <e2>ghrelin receptor</e2> inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused <e1>imidazo[2,1-b]thiazole</e1> motif in the core structure.","Agonist"
"The current study examined the bioactivation potential of <e2>ghrelin receptor</e2> inverse agonists, <e1>1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone</e1> (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure.","Agonist"
"Reactive Metabolite Trapping Studies on <e1>Imidazo- and 2-Methylimidazo[2,1-b]thiazole</e1>-based Inverse Agonists of the <e2>Ghrelin Receptor</e2>.","Agonist"
"Moreover, the active permethylated <e1>vancomycin</e1> aglycon derivatives examined exhibit <e2>VanB</e2> VRE antimicrobial activity at levels that approach (typically within 2-fold) their activity against sensitive bacteria.","Regulator"
"To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (<e2>mPPARα</e2>), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% <e1>DEHP</e1>.","Regulator"
"To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (<e2>mPPARα</e2>), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% <e1>DEHP</e1>.","Regulator"
"Posttranslational modification of the neural cell adhesion molecule (<e2>NCAM</e2>) by polysialic acid (<e1>polySia</e1>) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.","Regulator"
"In mature lung tissue of healthy donors, <e1>polySia</e1> was exclusively attached to the transmembrane isoform <e2>NCAM-140</e2> and located to intracellular compartments of epithelial cells.","Regulator"
"In mature lung tissue of healthy donors, <e1>polySia</e1> was exclusively attached to the transmembrane isoform <e2>NCAM-140</e2> and located to intracellular compartments of epithelial cells.","Regulator"
"Interestingly, <e1>polySia</e1> chains of secreted NCAM neutralized the cytotoxic activity of extracellular <e2>histones</e2> as well as DNA/histone-network-containing ""neutrophil extracellular traps"", which are formed during invasion of microorganisms.","Regulator"
"Interestingly, <e1>polySia</e1> chains of secreted NCAM neutralized the cytotoxic activity of extracellular <e2>histone</e2>s as well as DNA/histone-network-containing ""neutrophil extracellular traps"", which are formed during invasion of microorganisms.","Regulator"
"Processing of <e2>polysialylated NCAM</e2> was reproduced in a mouse model by <e1>bleomycin</e1> administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1β.","Regulator"
"Posttranslational modification of the <e2>neural cell adhesion molecule</e2> (NCAM) by polysialic acid (<e1>polySia</e1>) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.","Regulator"
"Posttranslational modification of the neural cell adhesion molecule (<e2>NCAM</e2>) by polysialic acid (<e1>polySia</e1>) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.","Regulator"
"Posttranslational modification of the <e2>neural cell adhesion molecule</e2> (NCAM) by <e1>polysialic acid</e1> (polySia) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.","Regulator"
"Posttranslational modification of the neural cell adhesion molecule (<e2>NCAM</e2>) by <e1>polysialic acid</e1> (polySia) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.","Regulator"
"Processing of polysialylated NCAM was reproduced in a mouse model by <e1>bleomycin</e1> administration leading to an activation of the inflammasome and secretion of <e2>interleukin (IL)-1β</e2>.","Upregulator"
"<e1>Vildagliptin</e1>+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, <e2>glucagon</e2> and insulin resistance measurements.","Regulator"
"<e1>Vildagliptin</e1>+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and <e2>insulin</e2> resistance measurements.","Regulator"
"Vildagliptin+<e1>metformin</e1> were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, <e2>glucagon</e2> and insulin resistance measurements.","Regulator"
"Evaluation of the positive effects on <e2>insulin</e2>-resistance and β-cell measurements of vildagliptin in addition to <e1>metformin</e1> in type 2 diabetic patients.","Regulator"
"Vildagliptin+<e1>metformin</e1> were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, <e2>glucagon</e2> and insulin resistance measurements.","Regulator"
"Evaluation of the positive effects on <e2>insulin</e2>-resistance and β-cell measurements of vildagliptin in addition to <e1>metformin</e1> in type 2 diabetic patients.","Regulator"
"We also recorded a significant correlation between M value increase and the decrease of <e2>vaspin</e2>, visfatin, and omentin-1 obtained with <e1>vildagliptin</e1>+metformin.","Regulator"
"We also recorded a significant correlation between M value increase and the decrease of vaspin, <e2>visfatin</e2>, and omentin-1 obtained with <e1>vildagliptin</e1>+metformin.","Regulator"
"We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and <e2>omentin-1</e2> obtained with <e1>vildagliptin</e1>+metformin.","Regulator"
"We also recorded a significant correlation between M value increase and the decrease of <e2>vaspin</e2>, visfatin, and omentin-1 obtained with vildagliptin+<e1>metformin</e1>.","Regulator"
"We also recorded a significant correlation between M value increase and the decrease of vaspin, <e2>visfatin</e2>, and omentin-1 obtained with vildagliptin+<e1>metformin</e1>.","Regulator"
"We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and <e2>omentin-1</e2> obtained with vildagliptin+<e1>metformin</e1>.","Regulator"
"<e1>Vildagliptin</e1>+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and <e2>insulin</e2> resistance measurements.","Regulator"
"Evaluation of the positive effects on <e2>insulin</e2>-resistance and β-cell measurements of vildagliptin in addition to <e1>metformin</e1> in type 2 diabetic patients.","Regulator"
"<e1>4-Hydroxytamoxifen</e1>-stimulated processing of <e2>cyclin E</e2> is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.","Not"
"4-Hydroxytamoxifen (<e1>OHT</e1>, tamoxifen's active form) failed to prevent E2-induced proteolysis of <e2>cyclin E</e2> and migration, but rather triggered cyclin E cleavage coincident with augmented migration.","Not"
"4-Hydroxy<e1>tamoxifen</e1>-stimulated processing of <e2>cyclin E</e2> is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.","Not"
"<e1>4-Hydroxytamoxifen</e1>-stimulated processing of <e2>cyclin E</e2> is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.","Regulator"
"4-Hydroxytamoxifen (<e1>OHT</e1>, tamoxifen's active form) failed to prevent E2-induced proteolysis of <e2>cyclin E</e2> and migration, but rather triggered cyclin E cleavage coincident with augmented migration.","Regulator"
"4-Hydroxy<e1>tamoxifen</e1>-stimulated processing of <e2>cyclin E</e2> is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.","Regulator"
"4-Hydroxytamoxifen (<e1>OHT</e1>, tamoxifen's active form) failed to prevent E2-induced proteolysis of <e2>cyclin E</e2> and migration, but rather triggered cyclin E cleavage coincident with augmented migration.","Regulator"
"4-Hydroxytamoxifen (<e1>OHT</e1>, tamoxifen's active form) failed to prevent E2-induced proteolysis of <e2>cyclin E</e2> and migration, but rather triggered cyclin E cleavage coincident with augmented migration.","Regulator"
"4-Hydroxytamoxifen (<e1>OHT</e1>, tamoxifen's active form) failed to prevent E2-induced proteolysis of <e2>cyclin E</e2> and migration, but rather triggered cyclin E cleavage coincident with augmented migration.","Regulator"
"In addition, inhibitors for <e2>EGFR</e2> or ERK1/2 remarkably suppressed <e1>OHT</e1>-induced truncation of cyclin E, suggesting involvement of EGFR signaling.","Regulator"
"<e1>OHT</e1>-induced cyclin E truncation also occurred in SK-BR-3 cells that express <e2>GPR30</e2> and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor ERα.","Regulator"
"<e1>4-Hydroxytamoxifen</e1>-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (<e2>GPR30)</e2> and accompanied by enhanced migration in MCF-7 breast cancer cells.","Regulator"
"<e1>4-Hydroxytamoxifen</e1>-stimulated processing of cyclin E is mediated via <e2>G protein-coupled receptor 30</e2> (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.","Regulator"
"<e1>OHT</e1>-induced cyclin E truncation also occurred in SK-BR-3 cells that express <e2>GPR30</e2> and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor ERα.","Regulator"
"<e1>4-Hydroxytamoxifen</e1>-stimulated processing of <e2>cyclin E</e2> is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.","Upregulator"
"<e1>17β-Estradiol</e1> (E2) has been recently shown to induce <e2>cyclin E</e2> processing in breast cancer cells.","Upregulator"
"4-Hydroxytamoxifen (<e1>OHT</e1>, tamoxifen's active form) failed to prevent E2-induced proteolysis of <e2>cyclin E</e2> and migration, but rather triggered cyclin E cleavage coincident with augmented migration.","Upregulator"
"NMR spectroscopy was also used to examine the <e2>hSOD1</e2> mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these <e1>cysteines</e1> during hSOD1 copper acquisition.","Part_of"
"We recently showed that the first domain of <e2>human CCS</e2> (hCCSD1) is responsible for <e1>copper</e1> transfer to its protein partner, human SOD1 (hSOD1).","Regulator"
"We recently showed that the first domain of human CCS (<e2>hCCSD1</e2>) is responsible for <e1>copper</e1> transfer to its protein partner, human SOD1 (hSOD1).","Regulator"
"We recently showed that the first domain of human CCS (hCCSD1) is responsible for <e1>copper</e1> transfer to its protein partner, <e2>human SOD1</e2> (hSOD1).","Regulator"
"We recently showed that the first domain of human CCS (hCCSD1) is responsible for <e1>copper</e1> transfer to its protein partner, human SOD1 (<e2>hSOD1</e2>).","Regulator"
"The NMR solution structure of the <e1>copper(I)</e1>-loaded form of <e2>hCCSD1</e2> reported here contributes further to characterization of the copper-transfer mechanism to hSOD1.","Regulator"
"We recently showed that the first domain of human CCS (<e2>hCCS</e2>D1) is responsible for <e1>copper</e1> transfer to its protein partner, human SOD1 (hSOD1).","Regulator"
"We recently showed that the first domain of human CCS (hCCSD1) is responsible for <e1>copper</e1> transfer to its protein partner, human SOD1 (<e2>hSOD1</e2>).","Regulator"
"Mechanistic Aspects of <e2>hSOD1</e2> Maturation from the Solution Structure of <e1>Cu(I)</e1> -Loaded hCCS Domain 1 and Analysis of Disulfide-Free hSOD1 Mutants.","Regulator"
"Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of <e1>Cu(I)</e1> -Loaded <e2>hCCS Domain 1</e2> and Analysis of Disulfide-Free hSOD1 Mutants.","Regulator"
"Design, Synthesis and Biological Evaluation of <e1>Aminoalkylindole</e1> Derivatives as <e2>Cannabinoid Receptor</e2> Ligands with Potential for Treatment of Alcohol Abuse.","Regulator"
"In the current study, we show that systematic modification of an <e1>aminoalkylindole</e1> scaffold identifies two new compounds with dual CB1R antagonist/<e2>CB2R</e2> agonist activity.","Agonist"
"Collectively, these initial findings suggest that design and systematic modification of <e1>aminoalkylindoles</e1> such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/<e2>CB2R</e2> agonist activity with potential for use as treatments of alcohol abuse.","Agonist"
"We have recently reported that a mono-hydroxylated metabolite of the synthetic <e1>aminoalkylindole</e1> cannabinoid JHW-073 (3) exhibits neutral antagonist activity at <e2>CB1Rs</e2> and thus may serve as a promising lead for the development of novel alcohol abuse therapies.","Antagonist"
"We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid <e1>JHW-073</e1> (3) exhibits neutral antagonist activity at <e2>CB1Rs</e2> and thus may serve as a promising lead for the development of novel alcohol abuse therapies.","Antagonist"
"We have recently reported that a mono-hydroxylated metabolite of the synthetic <e1>aminoalkylindole</e1> cannabinoid JHW-073 (3) exhibits neutral antagonist activity at <e2>CB1R</e2>s and thus may serve as a promising lead for the development of novel alcohol abuse therapies.","Antagonist"
"Collectively, these initial findings suggest that design and systematic modification of <e1>aminoalkylindoles</e1> such as 3 may lead to development of novel cannabinoid ligands with dual <e2>CB1R</e2> antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.","Antagonist"
"Immunoregulatory effects of <e1>Glycyrrhizic acid</e1> exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in <e2>ovalbumin</e2>-sensitized mice.","Regulator"
"Immunoregulatory effects of <e1>Glycyrrhizic acid</e1> exerts anti-asthmatic effects via modulation of Th1/Th2 <e2>cytokines</e2> and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in ovalbumin-sensitized mice.","Regulator"
"METHODS: After 1 month of HFD alone, the mice were given the <e2>DPP4</e2> inhibitor <e1>vildagliptin</e1> for a further 11 months.","Downregulator"
"METHODS: After 1 month of HFD alone, the mice were given the <e2>DPP4</e2> inhibitor <e1>vildagliptin</e1> for a further 11 months.","Downregulator"
"Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the <e2>dipeptidyl peptidase-4</e2> inhibitor <e1>vildagliptin</e1> in an advanced-aged diet-induced obesity mouse model.","Downregulator"
"Protein levels of the <e1>glucose</e1> transporter (GLUT4) involved in glucose transport via these two pathways were also increased.","Substrate"
"Protein levels of the <e1>glucose</e1> transporter (<e2>GLUT4</e2>) involved in glucose transport via these two pathways were also increased.","Substrate"
"Using small interfering double-stranded RNA technology, we further demonstrate that the effects of <e1>puerarin</e1> on proliferation, differentiation and survival are mediated by both <e2>ERα</e2> and ERβ.","Regulator"
"Using small interfering double-stranded RNA technology, we further demonstrate that the effects of <e1>puerarin</e1> on proliferation, differentiation and survival are mediated by both ERα and <e2>ERβ</e2>.","Regulator"
"Here we show that puerarin increases proliferation and differentiation and opposes <e1>cisplatin</e1>-induced apoptosis in human osteoblastic MG-63 cells containing two <e2>estrogen receptor</e2> (ER) isoforms.","Regulator"
"Here we show that puerarin increases proliferation and differentiation and opposes <e1>cisplatin</e1>-induced apoptosis in human osteoblastic MG-63 cells containing two estrogen receptor (<e2>ER</e2>) isoforms.","Regulator"
"Here we show that <e1>puerarin</e1> increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two estrogen receptor (<e2>ER</e2>) isoforms.","Regulator"
"<e1>Puerarin</e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via <e2>ER</e2>-dependent MEK/ERK and PI3K/Akt activation.","Regulator"
"Here we show that <e1>puerarin</e1> increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two <e2>estrogen receptor</e2> (ER) isoforms.","Regulator"
"Here we show that <e1>puerarin</e1> increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two estrogen receptor (<e2>ER</e2>) isoforms.","Regulator"
"<e1>Puerarin</e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent <e2>MEK</e2>/ERK and PI3K/Akt activation.","Upregulator"
"<e1>Puerarin</e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/<e2>ERK</e2> and PI3K/Akt activation.","Upregulator"
"<e1>Puerarin</e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and <e2>PI3K</e2>/Akt activation.","Upregulator"
"<e1>Puerarin</e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/<e2>Akt</e2> activation.","Upregulator"
"Moreover, we also demonstrate that <e1>puerarin</e1> functions at least partially through activation of <e2>MEK</e2>/ERK and PI3K/Akt signaling.","Upregulator"
"Moreover, we also demonstrate that <e1>puerarin</e1> functions at least partially through activation of MEK/<e2>ERK</e2> and PI3K/Akt signaling.","Upregulator"
"Puerarin promotes proliferation by altering cell cycle distribution whereas <e1>puerarin</e1>-mediated survival may be associated with up-regulation of <e2>Bcl-xL</e2> expression.","Upregulator"
"Moreover, we also demonstrate that <e1>puerarin</e1> functions at least partially through activation of MEK/ERK and <e2>PI3K</e2>/Akt signaling.","Upregulator"
"Moreover, we also demonstrate that <e1>puerarin</e1> functions at least partially through activation of MEK/ERK and PI3K/<e2>Akt</e2> signaling.","Upregulator"
"Treatment with the <e2>ER</e2> antagonist <e1>ICI 182,780</e1> abolishes the above actions of puerarin on osteoblast-derived cells.","Antagonist"
"The preventive effect of uncarboxylated osteocalcin against <e1>free fatty acid</e1>-induced endothelial apoptosis through the activation of <e2>phosphatidylinositol 3-kinase</e2>/Akt signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.","Regulator"
"The preventive effect of uncarboxylated osteocalcin against <e1>free fatty acid</e1>-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/<e2>Akt</e2> signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.","Regulator"
"RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the <e2>phosphatidylinositol 3-kinase</e2> (PI3-kinase) inhibitor, <e1>wortmannin</e1>.","Downregulator"
"RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (<e2>PI3-kinase</e2>) inhibitor, <e1>wortmannin</e1>.","Downregulator"
"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) <e1>oxyfluorfen</e1> showed a higher <e2>CAT</e2> activity than controls.","Regulator"
"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) <e1>oxyfluorfen</e1> showed a higher <e2>CAT</e2> activity than controls.","Upregulator"
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using <e2>D1</e2>/D5 (<e1>SCH23390</e1>), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.","Antagonist"
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/<e2>D5</e2> (<e1>SCH23390</e1>), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.","Antagonist"
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), <e2>D2</e2>/D3 (<e1>raclopride</e1>, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.","Antagonist"
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/<e2>D3</e2> (<e1>raclopride</e1>, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.","Antagonist"
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), <e2>D2</e2>/D3 (raclopride, <e1>amisulpride</e1>) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.","Antagonist"
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/<e2>D3</e2> (raclopride, <e1>amisulpride</e1>) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.","Antagonist"
"The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/<e2>D3</e2> (raclopride, amisulpride) and D3 (<e1>S33084</e1>) receptor antagonists, and by using D2 receptor knockout mice.","Antagonist"
"Here, we examined the effects produced by haloperidol, a typical antipsychotic drug, on the phosphorylation of <e2>rpS6</e2> at <e1>Ser</e1>240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders.","Part_of"
"<e1>Haloperidol</e1> promotes <e2>mTORC1</e2>-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.","Regulator"
"<e1>Haloperidol</e1> promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via <e2>dopamine- and cAMP-regulated phosphoprotein of 32 kDa</e2> and inhibition of protein phosphatase-1.","Regulator"
"These results show that <e1>haloperidol</e1> promotes <e2>mTORC1</e2>- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.","Regulator"
"These results show that <e1>haloperidol</e1> promotes mTORC1- and <e2>S6K1</e2>-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.","Regulator"
"Administration of <e1>haloperidol</e1> increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors (<e2>D2Rs</e2>).","Regulator"
"Administration of <e1>haloperidol</e1> increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express <e2>dopamine D2 receptors</e2> (D2Rs).","Regulator"
"Administration of <e1>haloperidol</e1> increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors (<e2>D2Rs</e2>).","Regulator"
"<e1>Haloperidol</e1> promotes mTORC1-dependent phosphorylation of <e2>ribosomal protein S6</e2> via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.","Upregulator"
"Here, we examined the effects produced by <e1>haloperidol</e1>, a typical antipsychotic drug, on the phosphorylation of <e2>rpS6</e2> at Ser240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders.","Upregulator"
"This effect was prevented by <e1>rapamycin</e1>, an inhibitor of the <e2>mammalian target of rapamycin complex 1</e2> (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).","Downregulator"
"This effect was prevented by <e1>rapamycin</e1>, an inhibitor of the mammalian target of rapamycin complex 1 (<e2>mTORC1</e2>), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).","Downregulator"
"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by <e1>PF470867</e1>, a selective inhibitor of the <e2>p70 ribosomal S6 kinase 1</e2> (S6K1).","Downregulator"
"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by <e1>PF470867</e1>, a selective inhibitor of the p70 ribosomal S6 kinase 1 (<e2>S6K1</e2>).","Downregulator"
"In line with this observation, incubation of striatal slices with <e1>okadaic acid</e1> and calyculin A, two inhibitors of <e2>PP-1</e2>, increased Ser240/244 phosphorylation.","Downregulator"
"<e1>Haloperidol</e1> promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of <e2>protein phosphatase-1</e2>.","Downregulator"
"In line with this observation, incubation of striatal slices with okadaic acid and <e1>calyculin A</e1>, two inhibitors of <e2>PP-1</e2>, increased Ser240/244 phosphorylation.","Downregulator"
"These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the <e1>Arg-Gly-Asp</e1> (RGD) sequence of <e2>fibrinogen</e2> to obtain designed multiple ligands with potential antithrombotic activity.","Part_of"
"These compounds resulted from our efforts to merge the pharmacophores of selective <e2>factor Xa</e2> inhibitor <e1>rivaroxaban</e1> with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.","Downregulator"
"Resulting from this study, a structurally novel class of submicromolar fibrinogen <e2>GPIIb/IIIa</e2> binding inhibitor bearing <e1>1,2,4-oxadiazol-5(4H)-one</e1> moiety is also described.","Downregulator"
"The <e2>caspase-3</e2> immunopositivity was increased in degenerating neurons of the <e1>Cd</e1> group.","Upregulator"
"Rats intoxicated with <e1>Cd</e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants <e2>superoxide dismutase</e2>, glutathione peroxidase and catalase in the frontal cortex tissue.","Downregulator"
"Rats intoxicated with <e1>Cd</e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, <e2>glutathione peroxidase</e2> and catalase in the frontal cortex tissue.","Downregulator"
"Rats intoxicated with <e1>Cd</e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and <e2>catalase</e2> in the frontal cortex tissue.","Downregulator"
"In thyroid stem/progenitor cells derived from nodular goitres the ability of <e1>17beta-oestradiol</e1> to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, <e2>sodium iodide symporter</e2> expression) were analysed.","Downregulator"
"The editing of <e2>ndhD-2</e2> is also completely lost in albino mutants and <e1>norflurazon</e1>-treated seedlings.","Regulator"
"In addition, the expression of nucleus-encoded <e2>RNA polymerase</e2> dependent transcripts is specifically induced by <e1>lincomycin</e1>, and the splicing of ndhB transcripts is significantly reduced in the albino mutants and inhibitor-treated seedlings.","Regulator"
"By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of <e2>ndhB</e2>-149, ndhB-1255, and ndhD-2 is completely lost in roots and in <e1>lincomycin</e1>-treated seedlings.","Regulator"
"By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of <e2>ndhB-149</e2>, ndhB-1255, and ndhD-2 is completely lost in roots and in <e1>lincomycin</e1>-treated seedlings.","Regulator"
"By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of ndhB-149, <e2>ndhB-1255</e2>, and ndhD-2 is completely lost in roots and in <e1>lincomycin</e1>-treated seedlings.","Regulator"
"By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of ndhB-149, ndhB-1255, and <e2>ndhD-2</e2> is completely lost in roots and in <e1>lincomycin</e1>-treated seedlings.","Regulator"
"The HCV-PIs <e1>boceprevir</e1> and telaprevir are both, to different extents, inhibitors of <e2>CYP3A</e2>.","Downregulator"
"All HIV PIs except nelfinavir are coadministered with a low dose of <e1>ritonavir</e1>, a potent <e2>CYP3A</e2> inhibitor to improve their pharmacokinetic properties.","Downregulator"
"The HCV-PIs <e1>boceprevir</e1> and telaprevir are both, to different extents, inhibitors of <e2>CYP3A</e2>.","Downregulator"
"The HCV-PIs boceprevir and <e1>telaprevir</e1> are both, to different extents, inhibitors of <e2>CYP3A</e2>.","Downregulator"
"All HIV PIs except nelfinavir are coadministered with a low dose of <e1>ritonavir</e1>, a potent <e2>CYP3A</e2> inhibitor to improve their pharmacokinetic properties.","Downregulator"
"Simvastatin and lovastatin metabolized through <e2>CYP3A</e2> have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or <e1>cobicistat</e1>-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.","Downregulator"
"The HCV-PIs boceprevir and <e1>telaprevir</e1> are both, to different extents, inhibitors of <e2>CYP3A</e2>.","Downregulator"
"<e1>Atorvastatin</e1> is also a <e2>CYP3A</e2> substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.","Substrate"
"Drug-drug interactions are dependent on statins' pharmacokinetic profile: <e1>simvastatin</e1>, lovastatin and atorvastatin are metabolized through <e2>cytochrome P450 (CYP) 3A</e2>, while the metabolism of the other statins is independent of this CYP.","Substrate"
"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, <e1>lovastatin</e1> and atorvastatin are metabolized through <e2>cytochrome P450 (CYP) 3A</e2>, while the metabolism of the other statins is independent of this CYP.","Substrate"
"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and <e1>atorvastatin</e1> are metabolized through <e2>cytochrome P450 (CYP) 3A</e2>, while the metabolism of the other statins is independent of this CYP.","Substrate"
"<e1>Simvastatin</e1> and lovastatin metabolized through <e2>CYP3A</e2> have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.","Substrate"
"Simvastatin and <e1>lovastatin</e1> metabolized through <e2>CYP3A</e2> have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.","Substrate"
"Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective <e2>anaplastic lymphoma kinase</e2> (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (<e1>LDK378</e1>) currently in phase 1 and phase 2 clinical trials.","Downregulator"
"In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation <e2>ALK</e2> inhibitor 4 (<e1>TAE684</e1>).","Downregulator"
"Limitation of SRF was produced by the anticonvulsant <e1>BDZ</e1>s (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity <e2>BDZ receptors</e2> (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.","Not"
"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity <e2>BDZ receptors</e2> (<e1>Ro 5-4864</e1>) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.","Not"
"These findings suggest that limitation of SRF was produced by binding of BDZs, but not <e1>beta CCs</e1>, to <e2>voltage-dependent sodium channels</e2> and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.","Not"
"These findings suggest that limitation of SRF was produced by binding of BDZs, but not <e1>beta CCs</e1>, to voltage-dependent sodium channels and not to high affinity central <e2>BDZ receptors</e2>, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.","Not"
"These findings suggest that limitation of SRF was produced by binding of <e1>BDZs</e1>, but not beta CCs, to <e2>voltage-dependent sodium channels</e2> and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.","Regulator"
"Limitation of SRF was produced by the anticonvulsant <e1>BDZs</e1> (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity <e2>BDZ receptors</e2> (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.","Regulator"
"Limitation of SRF was produced by the anticonvulsant BDZs (<e1>diazepam</e1>, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity <e2>BDZ receptor</e2>s (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.","Regulator"
"These findings suggest that limitation of SRF was produced by binding of <e1>BDZs</e1>, but not beta CCs, to voltage-dependent <e2>sodium channels</e2> and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.","Upregulator"
"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity <e2>BDZ receptor</e2>s (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (<e1>Ro 15-1788</e1>) at micromolar concentrations.","Agonist"
"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity <e2>BDZ receptor</e2>s (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (<e1>Ro 15-1788</e1>) at micromolar concentrations.","Agonist"
"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>BDZ receptor</e2>, including Ro 15-1788 and the <e1>beta CCs</e1>.","Agonist"
"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity <e2>BDZ receptor</e2>s (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (<e1>Ro 15-1788</e1>) at micromolar concentrations.","Agonist"
"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>BDZ receptor</e2>, including Ro 15-1788 and the <e1>beta CCs</e1>.","Agonist"
"The mitogenic effect of <e1>DHT</e1> on bone cells was inhibited by antiandrogens (hydroxyflutamide and cyproterone acetate) which compete for binding to the <e2>androgen receptor</e2>.","Regulator"
"The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (<e1>hydroxyflutamide</e1> and cyproterone acetate) which compete for binding to the <e2>androgen receptor</e2>.","Regulator"
"The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (hydroxyflutamide and <e1>cyproterone acetate</e1>) which compete for binding to the <e2>androgen receptor</e2>.","Regulator"
"The mitogenic effect of DHT on bone cells was inhibited by anti<e1>androgens</e1> (hydroxyflutamide and cyproterone acetate) which compete for binding to the <e2>androgen receptor</e2>.","Regulator"
"In addition to effects on cell proliferation, <e1>DHT</e1> increased the percentage of <e2>alkaline phosphatase</e2> (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.","Upregulator"
"In addition to effects on cell proliferation, <e1>DHT</e1> increased the percentage of alkaline phosphatase (<e2>ALP</e2>) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.","Upregulator"
"We conclude that <e1>androgens</e1> can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the <e2>osteoblast-line differentiation marker</e2> ALP, presumably by an androgen receptor mediated mechanism.","Upregulator"
"In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (<e2>ALP</e2>) positive cells in all three bone cell systems tested, and this effect was inhibited by anti<e1>androgens</e1>.","Upregulator"
"The effect of <e2>histamine-H1 receptor</e2> antagonism with <e1>terfenadine</e1> on concentration-related AMP-induced bronchoconstriction in asthma.","Antagonist"
"Oral <e1>ibrutinib</e1> is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or <e2>TP53</e2> mutation.","Regulator"
"Oral <e1>ibrutinib</e1> is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or <e2>TP53</e2> mutation.","Regulator"
"<e1>Ibrutinib</e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits <e2>B-cell antigen receptor</e2> signalling downstream of BTK.","Downregulator"
"Ibrutinib (<e1>Imbruvica(R)</e1>) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits <e2>B-cell antigen receptor</e2> signalling downstream of BTK.","Downregulator"
"<e1>Ibrutinib</e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (<e2>BTK</e2>) that inhibits B-cell antigen receptor signalling downstream of BTK.","Downregulator"
"<e1>Ibrutinib</e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (<e2>BTK</e2>) that inhibits B-cell antigen receptor signalling downstream of BTK.","Downregulator"
"<e1>Ibrutinib</e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of <e2>Bruton's tyrosine kinase</e2> (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.","Downregulator"
"Ibrutinib (<e1>Imbruvica(R)</e1>) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (<e2>BTK</e2>) that inhibits B-cell antigen receptor signalling downstream of BTK.","Downregulator"
"Ibrutinib (<e1>Imbruvica(R)</e1>) is a first-in-class, potent, orally administered, covalent inhibitor of <e2>Bruton's tyrosine kinase</e2> (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.","Downregulator"
"<e1>Alprenolol</e1> treatment (4 X 100 mg/day) led to a rapid fall in PRA, but did not significantly affect <e2>beta 2-adrenoceptor</e2> density.","Not"
"Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h. The affinity of <e1>ICYP</e1> to <e2>beta 2-adrenoceptors</e2> was not changed during or after treatment.","Regulator"
"<e1>Propranolol</e1> treatment (4 X 40 mg/day) increased the density of <e2>beta 2-adrenoceptors</e2> by 25% after 2 days; concomitantly PRA and heart rate were reduced.","Upregulator"
"<e1>Mepindolol</e1> treatment (2 X 5 mg/day) caused a 30% decrease of <e2>beta 2-adrenoceptor</e2> density and PRA after 2 days; both parameters remained reduced during treatment.","Downregulator"
"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>beta-adrenoceptor</e2> antagonists <e1>propranolol</e1> [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.","Antagonist"
"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>beta-adrenoceptor</e2> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], <e1>alprenolol</e1> (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.","Antagonist"
"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>beta-adrenoceptor</e2> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and <e1>mepindolol</e1> (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.","Antagonist"
"Inhibition of <e2>5-lipoxygenase</e2> pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and <e1>5-aminosalicylic acid</e1>.","Downregulator"
"Inhibition of <e2>5-lipoxygenase</e2> pathway of arachidonic acid metabolism in human neutrophils by <e1>sulfasalazine</e1> and 5-aminosalicylic acid.","Downregulator"
"Interference with <e2>lipoxygenase</e2> enzymes, rather than a <e1>steroid</e1>-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.","Downregulator"
"Inhibition of <e2>5-lipoxygenase</e2> pathway of <e1>arachidonic acid</e1> metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.","Substrate"
"Inhibition of 5-<e2>lipoxygenase</e2> pathway of <e1>arachidonic acid</e1> metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.","Substrate"
"This new data is consistent with the proposal put forward a couple of years ago that <e1>bevantolol</e1> interacts with <e2>alpha-adrenoceptors</e2>.","Regulator"
"This new data is consistent with the proposal put forward a couple of years ago that <e1>bevantolol</e1> interacts with <e2>alpha-adrenoceptors</e2>.","Agonist"
"<e1>Bevantolol</e1>: a <e2>beta-1 adrenoceptor</e2> antagonist with unique additional actions.","Antagonist"
"<e1>Bevantolol</e1>: a <e2>beta-1 adrenoceptor</e2> antagonist with unique additional actions.","Antagonist"
"<e2>Benzodiazepine receptor</e2> binding of <e1>triazolobenzodiazepines</e1> in vivo: increased receptor number with low-dose alprazolam.","Regulator"
"The apparent affinity of <e2>benzodiazepine receptors</e2> for <e1>clonazepam</e1> in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.","Regulator"
"<e2>Benzodiazepine receptor</e2> binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose <e1>alprazolam</e1>.","Regulator"
"The apparent affinity of <e2>benzodiazepine receptors</e2> for clonazepam in mice receiving <e1>alprazolam</e1> (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.","Regulator"
"The apparent affinity of <e2>benzodiazepine receptors</e2> for clonazepam in mice receiving <e1>alprazolam</e1> (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.","Upregulator"
"In vitro binding affinities of chlorpromazine, <e1>fluphenazine</e1>, levomepromazine, perphenazine and some of their metabolites for <e2>dopamine D2 receptors</e2>, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.","Regulator"
"Chlorpromazine, <e1>levomepromazine</e1>, and their metabolites had 5-30 times higher binding affinities for <e2>muscarinic cholinergic receptors</e2> than fluphenazine, perphenazine and their metabolites.","Regulator"
"Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for <e2>muscarinic cholinergic receptors</e2> than <e1>fluphenazine</e1>, perphenazine and their metabolites.","Regulator"
"In vitro binding affinities of chlorpromazine, fluphenazine, <e1>levomepromazine</e1>, perphenazine and some of their metabolites for <e2>dopamine D2 receptors</e2>, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.","Regulator"
"Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for <e2>muscarinic cholinergic receptors</e2> than fluphenazine, <e1>perphenazine</e1> and their metabolites.","Regulator"
"<e1>Levomepromazine</e1> was the most potent and fluphenazine the least potent of the four drugs in <e2>histamine H1 receptor</e2> binding.","Regulator"
"Levomepromazine was the most potent and <e1>fluphenazine</e1> the least potent of the four drugs in <e2>histamine H1 receptor</e2> binding.","Regulator"
"<e1>7-Hydroxy levomepromazine</e1>, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in <e2>histamine H1 receptor</e2> binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.","Regulator"
"In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, <e1>perphenazine</e1> and some of their metabolites for <e2>dopamine D2 receptors</e2>, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.","Regulator"
"7-Hydroxy levomepromazine, <e1>3-hydroxy levomepromazine</e1> and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in <e2>histamine H1 receptor</e2> binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.","Regulator"
"7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and <e1>7-hydroxy fluphenazine</e1> had only 10% of the potency of the parent drug in <e2>histamine H1 receptor</e2> binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.","Regulator"
"7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and <e1>7-hydroxy</e1> fluphenazine had only 10% of the potency of the parent drug in <e2>histamine H1 receptor</e2> binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.","Regulator"
"7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in <e2>histamine H1 receptor</e2> binding, while the 7-hydroxy-metabolites of <e1>chlorpromazine</e1> and perphenazine had about 75% of the potency of the parent drug in this binding system.","Regulator"
"7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in <e2>histamine H1 receptor</e2> binding, while the 7-hydroxy-metabolites of chlorpromazine and <e1>perphenazine</e1> had about 75% of the potency of the parent drug in this binding system.","Regulator"
"Muscarinic cholinergic and <e2>histamine H1 receptor</e2> binding of <e1>phenothiazine</e1> drug metabolites.","Regulator"
"7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in <e2>histamine H1 receptor</e2> binding, while the 7-hydroxy-metabolites of <e1>chlorpromazine</e1> and perphenazine had about 75% of the potency of the parent drug in this binding system.","Regulator"
"7-Hydroxy <e1>levomepromazine</e1>, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in <e2>histamine H1 receptor</e2> binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.","Regulator"
"In vitro binding affinities of <e1>chlorpromazine</e1>, fluphenazine, levomepromazine, perphenazine and some of their metabolites for <e2>dopamine D2 receptors</e2>, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.","Regulator"
"The present study reports the in vitro binding affinities of the same compounds for <e2>muscarinic cholinergic receptors</e2> and for histamine H1 receptors in rat brain, using <e1>3H-quinuclidinyl benzilate</e1> and 3H-mepyramine as radioligands.","Regulator"
"The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for <e2>histamine H1 receptors</e2> in rat brain, using <e1>3H-quinuclidinyl benzilate</e1> and 3H-mepyramine as radioligands.","Regulator"
"The present study reports the in vitro binding affinities of the same compounds for <e2>muscarinic cholinergic receptors</e2> and for histamine H1 receptors in rat brain, using 3H-quinuclidinyl benzilate and <e1>3H-mepyramine</e1> as radioligands.","Regulator"
"The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for <e2>histamine H1 receptors</e2> in rat brain, using 3H-quinuclidinyl benzilate and <e1>3H-mepyramine</e1> as radioligands.","Regulator"
"<e1>Chlorpromazine</e1>, levomepromazine, and their metabolites had 5-30 times higher binding affinities for <e2>muscarinic cholinergic receptors</e2> than fluphenazine, perphenazine and their metabolites.","Regulator"
"In contrast, serum <e2>alkaline phosphatase</e2> was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with <e1>ROAc</e1>.","Not"
"Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The <e1>retinoids</e1> had no effect on <e2>prothrombin</e2> times of animals fed the supplemented diet.","Not"
"Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (<e1>13cisRA</e1>), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on <e2>prothrombin</e2> times of animals fed the supplemented diet.","Not"
"13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma <e2>osteocalcin</e2>, an effect that correlated with <e1>retinoid</e1>-induced bone effects.","Regulator"
"13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma <e2>osteocalcin</e2>, an effect that correlated with <e1>retinoid</e1>-induced bone effects.","Regulator"
"Hence, plasma osteocalcin is a better predictor of <e1>retinoid</e1>-induced bone effects than serum <e2>alkaline phosphatase</e2>.","Regulator"
"Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The <e1>retinoid</e1>s had no effect on <e2>prothrombin</e2> times of animals fed the supplemented diet.","Regulator"
"In contrast, serum <e2>alkaline phosphatase</e2> was elevated in animals dosed with <e1>13cisRA</e1> or 4HPR but not in those dose with ROAc.","Upregulator"
"In contrast, serum <e2>alkaline phosphatase</e2> was elevated in animals dosed with 13cisRA or <e1>4HPR</e1> but not in those dose with ROAc.","Upregulator"
"Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (<e1>4HPR</e1>) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on <e2>prothrombin</e2> times of animals fed the supplemented diet.","Upregulator"
"Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (<e1>ROAc</e1>), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on <e2>prothrombin</e2> times of animals fed the supplemented diet.","Upregulator"
"Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (<e1>4HPR</e1>) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on <e2>prothrombin</e2> times of animals fed the supplemented diet.","Upregulator"
"Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (<e1>ROAc</e1>), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on <e2>prothrombin</e2> times of animals fed the supplemented diet.","Upregulator"
"Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (<e1>13cisRA</e1>), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on <e2>prothrombin</e2> times of animals fed the supplemented diet.","Upregulator"
"<e1>13cisRA</e1> and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma <e2>osteocalcin</e2>, an effect that correlated with retinoid-induced bone effects.","Downregulator"
"13cisRA and <e1>ROAc</e1>, but not 4HPR, caused a dose-dependent reduction in plasma <e2>osteocalcin</e2>, an effect that correlated with retinoid-induced bone effects.","Downregulator"
"13cisRA and ROAc, but not <e1>4HPR</e1>, caused a dose-dependent reduction in plasma <e2>osteocalcin</e2>, an effect that correlated with retinoid-induced bone effects.","Downregulator"
"Multiple affinity states of <e2>opiate receptor</e2> can be demonstrated further by Scatchard analysis of saturation binding studies with <e1>[3H]DADLE</e1>.","Regulator"
"These multiple affinity states of receptor in the hybrid cells are agonist-specific, and the percentage of total <e2>opiate receptor</e2> in high affinity state is relatively constant in various concentrations of <e1>Na+</e1>.","Regulator"
"However, in the presence of 100 mM <e1>Na+</e1>, which is required for opiate inhibition of <e2>adenylate cyclase</e2> activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.","Downregulator"
"Inhibition of the <e2>leukotriene synthetase</e2> of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and <e1>piriprost</e1>, a 5-lipoxygenase inhibitor.","Not"
"In contrast to diethylcarbamazine, piriprost (<e1>U-60,257</e1>; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the <e2>leukotriene synthetase</e2> of these cells.","Not"
"In contrast to diethylcarbamazine, piriprost (U-60,257; <e1>6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1</e1>), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the <e2>leukotriene synthetase</e2> of these cells.","Not"
"The EC50 for inhibition of the <e2>leukotriene C synthetase</e2> of RBL cells was directly proportional to the <e1>LTA4</e1> concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.","Regulator"
"Kinetic analysis revealed that the inhibition of the <e2>leukotriene C synthetase</e2> reaction by <e1>diethylcarbamazine</e1> was competitive with respect to LTA4.","Downregulator"
"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by <e1>diethylcarbamazine</e1>, and synergism between diethylcarbamazine and piriprost, a <e2>5-lipoxygenase</e2> inhibitor.","Downregulator"
"Inhibition of the <e2>leukotriene synthetase</e2> of rat basophil leukemia cells by <e1>diethylcarbamazine</e1>, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor.","Downregulator"
"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and <e1>piriprost</e1>, a <e2>5-lipoxygenase</e2> inhibitor.","Downregulator"
"In contrast to diethylcarbamazine, piriprost (<e1>U-60,257</e1>; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>5-lipoxygenase</e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.","Downregulator"
"In contrast to diethylcarbamazine, piriprost (U-60,257; <e1>6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1</e1>), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>5-lipoxygenase</e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.","Downregulator"
"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by <e1>diethylcarbamazine</e1>, and synergism between diethylcarbamazine and piriprost, a <e2>5-lipoxygenase</e2> inhibitor.","Downregulator"
"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and <e1>piriprost</e1>, a <e2>5-lipoxygenase</e2> inhibitor.","Downregulator"
"Inhibition of the <e2>leukotriene synthetase</e2> of rat basophil leukemia cells by <e1>diethylcarbamazine</e1>, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor.","Downregulator"
"Similar concentrations also inhibited the formation of <e1>leukotriene C4</e1> (LTC4) by <e2>LTC synthetase</e2>, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.","Substrate"
"Similar concentrations also inhibited the formation of leukotriene C4 (<e1>LTC4</e1>) by <e2>LTC synthetase</e2>, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.","Substrate"
"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of <e1>sulfidopeptide leuktrienes</e1> in RBL cells at the <e2>5-lipoxygenase</e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.","Substrate"
"The EC50 for inhibition of the <e2>leukotriene C synthetase</e2> of RBL cells was directly proportional to the <e1>LTA4</e1> concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.","Substrate"
"Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by <e2>LTC synthetase</e2>, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling <e1>LTA4</e1> to glutathione.","Substrate"
"The EC50 for inhibition of the <e2>leukotriene C synthetase</e2> of RBL cells was directly proportional to the <e1>LTA4</e1> concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.","Substrate"
"The test procedure was verified with respect to intestinal <e1>lactose</e1> hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal <e2>lactase</e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects.","Substrate"
"The test procedure was verified with respect to intestinal <e1>lactose</e1> hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal <e2>lactase</e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects.","Substrate"
"The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/<e1>lactulose</e1> excretion and log jejunal mucosal <e2>lactase</e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects.","Substrate"
"The test procedure was verified with respect to intestinal <e1>lactose</e1> hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal <e2>lactase</e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects.","Substrate"
"The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/<e1>lactulose</e1> excretion and log jejunal mucosal <e2>lactase</e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects.","Substrate"
"Differential lactose/lactulose/<e1>L-rhamnose</e1> absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <e2>lactase</e2> deficiency.","Substrate"
"The binding of phenoxybenzamine to <e2>calmodulin</e2> was fairly selective in that other alpha-adrenergic agents such as <e1>prazosin</e1>, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.","Not"
"The binding of phenoxybenzamine to <e2>calmodulin</e2> was fairly selective in that other alpha-adrenergic agents such as prazosin, <e1>yohimbine</e1> and clonidine failed to bind to calmodulin when examined under the same experimental conditions.","Not"
"The binding of phenoxybenzamine to <e2>calmodulin</e2> was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and <e1>clonidine</e1> failed to bind to calmodulin when examined under the same experimental conditions.","Not"
"In addition, <e1>phenoxybenzamine</e1> showed little or no calcium-dependent binding to the <e2>S-100 protein</e2>, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.","Not"
"In addition, <e1>phenoxybenzamine</e1> showed little or no calcium-dependent binding to the S-100 protein, <e2>bovine serum albumin</e2> or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.","Not"
"In addition, <e1>phenoxybenzamine</e1> showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or <e2>cytochrome c</e2>. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.","Not"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Regulator"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Regulator"
"The site at which phenoxybenzamine bound to <e2>calmodulin</e2> appears to be similar to that at which certain antipsychotic agents bind, since several of them, including <e1>penfluridol</e1>, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.","Regulator"
"The site at which phenoxybenzamine bound to <e2>calmodulin</e2> appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, <e1>pimozide</e1> and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.","Regulator"
"The site at which phenoxybenzamine bound to <e2>calmodulin</e2> appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and <e1>spiroperidol</e1>, prevented the binding of phenoxybenzamine to calmodulin.","Regulator"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Regulator"
"This interaction was found to be similar in some respects to the interaction between <e1>phenothiazines</e1> and <e2>calmodulin</e2>.","Regulator"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Regulator"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Regulator"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Regulator"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Regulator"
"In addition, phenoxybenzamine showed little or no <e1>calcium</e1>-dependent binding to the S-100 protein, bovine serum albumin or <e2>cytochrome c</e2>. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.","Regulator"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Regulator"
"This interaction was found to be similar in some respects to the interaction between <e1>phenothiazines</e1> and <e2>calmodulin</e2>.","Regulator"
"The binding of phenoxybenzamine to calmodulin was fairly selective in that other <e2>alpha-adrenergic</e2> agents such as <e1>prazosin</e1>, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.","Regulator"
"The binding of phenoxybenzamine to calmodulin was fairly selective in that other <e2>alpha-adrenergic</e2> agents such as prazosin, <e1>yohimbine</e1> and clonidine failed to bind to calmodulin when examined under the same experimental conditions.","Regulator"
"The binding of phenoxybenzamine to calmodulin was fairly selective in that other <e2>alpha-adrenergic</e2> agents such as prazosin, yohimbine and <e1>clonidine</e1> failed to bind to calmodulin when examined under the same experimental conditions.","Regulator"
"In addition, phenoxybenzamine showed little or no <e1>calcium</e1>-dependent binding to the <e2>S-100 protein</e2>, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.","Regulator"
"In addition, phenoxybenzamine showed little or no <e1>calcium</e1>-dependent binding to the S-100 protein, <e2>bovine serum albumin</e2> or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.","Regulator"
"Characteristics of the binding of <e1>phenoxybenzamine</e1> to <e2>calmodulin</e2>.","Downregulator"
"The following was demonstrated in the rat and confirmed in man: interaction of <e1>Anandron</e1> with the <e2>prostatic androgen receptor</e2>, antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens.","Regulator"
"Replacement of the methyl groups of theophylline with <e1>n-propyl</e1> or larger alkyl groups yields xanthines with selectivity for <e2>A1 receptors</e2>, particularly when combined with an 8-phenyl moiety.","Regulator"
"Replacement of the methyl groups of theophylline with n-propyl or larger <e1>alkyl</e1> groups yields xanthines with selectivity for <e2>A1 receptors</e2>, particularly when combined with an 8-phenyl moiety.","Regulator"
"Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields <e1>xanthines</e1> with selectivity for <e2>A1 receptors</e2>, particularly when combined with an 8-phenyl moiety.","Regulator"
"Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for <e2>A1 receptors</e2>, particularly when combined with an <e1>8-phenyl</e1> moiety.","Regulator"
"Certain analogs of <e1>caffeine</e1> in which the methyl group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for <e2>A2 receptors</e2>.","Regulator"
"Certain analogs of caffeine in which the <e1>methyl</e1> group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for <e2>A2 receptors</e2>.","Regulator"
"Certain analogs of caffeine in which the methyl group at the 1- or 7-position is replaced with a propargyl or <e1>propyl</e1> group display selectivity for <e2>A2 receptors</e2>.","Regulator"
"Adenosine modulates a variety of physiological functions through interaction with A1 and A2 <e1>adenosine</e1> receptors, where agonists mediate inhibition and stimulation, respectively, of adenylate cyclase.","Regulator"
"The profile of a series of adenosine analogs or of <e1>xanthine</e1> antagonists can be used to define the nature of <e2>adenosine receptors</e2>.","Regulator"
"<e1>Adenosine</e1> analogs in particular the N6-substituted compounds are more potent at <e2>A1 receptors</e2> than at A2 receptors.","Regulator"
"<e1>Adenosine</e1> analogs in particular the N6-substituted compounds are more potent at A1 receptors than at <e2>A2 receptors</e2>.","Regulator"
"Adenosine analogs in particular the <e1>N6</e1>-substituted compounds are more potent at <e2>A1 receptors</e2> than at A2 receptors.","Regulator"
"Adenosine analogs in particular the <e1>N6</e1>-substituted compounds are more potent at A1 receptors than at <e2>A2 receptors</e2>.","Regulator"
"Certain of the <e1>adenosine</e1> conjugates are highly selective for <e2>A1 receptors</e2>.","Regulator"
"The subregion of the <e2>adenosine receptor</e2> that interacts with the <e1>N6</e1>-substituent is different for A1 and A2 receptors, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity.","Regulator"
"The subregion of the <e2>adenosine receptor</e2> that interacts with the N6-substituent is different for A1 and A2 receptors, particularly with respect to <e1>phenyl</e1> interactions, bulk tolerance and stereoselectivity.","Regulator"
"Replacement of the <e1>methyl</e1> groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for <e2>A1 receptors</e2>, particularly when combined with an 8-phenyl moiety.","Regulator"
"Replacement of the methyl groups of <e1>theophylline</e1> with n-propyl or larger alkyl groups yields xanthines with selectivity for <e2>A1 receptors</e2>, particularly when combined with an 8-phenyl moiety.","Regulator"
"<e1>Xanthines</e1> are classical antagonists for <e2>adenosine receptors</e2> for many of their pharmacological actions may be due to blockade of adenosine receptors.","Downregulator"
"<e1>Xanthines</e1> are classical antagonists for <e2>adenosine receptors</e2> for many of their pharmacological actions may be due to blockade of adenosine receptors.","Antagonist"
"Co-incubation with human serum albumin or poly-L-lysine but not lysine protected <e2>human and hamster LDH-X</e2> from <e1>gossypol</e1>.","Not"
"Co-incubation with human serum albumin or poly-L-<e1>lysine</e1> but not lysine protected <e2>human and hamster LDH-X</e2> from gossypol.","Not"
"Co-incubation with human serum albumin or <e1>poly-L-lysine</e1> but not lysine protected <e2>human and hamster LDH-X</e2> from gossypol.","Regulator"
"Inhibition of testicular <e2>LDH-X</e2> from laboratory animals and man by <e1>gossypol</e1> and its isomers.","Downregulator"
"<e1>Gossypol acetic acid</e1> (0-100 mumol/l) inhibited <e2>LDH-X</e2> prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.","Downregulator"
"The inhibitory effect of <e1>(+)-, (-)-, (+/-)-gossypol</e1> and (+/-)-gossypol acetic acid upon testicular cytosolic <e2>LDH-X</e2> was measured in vitro.","Downregulator"
"<e1>Gossypol</e1> and its isomers were non-competitive inhibitors of <e2>human and hamster LDH-X</e2> with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.","Downregulator"
"The inhibitory effect of (+)-, (-)-, (+/-)-gossypol and <e1>(+/-)-gossypol acetic acid</e1> upon testicular cytosolic <e2>LDH-X</e2> was measured in vitro.","Downregulator"
"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme <e1>NADH</e1>, competitive inhibitors of <e2>human LDH-X</e2> and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.","Downregulator"
"Gossypol and its isomers were non-competitive inhibitors of human and <e2>hamster LDH-X</e2> with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate <e1>alpha-ketobutyrate</e1>.","Substrate"
"Most reducing cofactors for the peroxidase protect <e2>PHS</e2> and prostacyclin synthase from inactivation by <e1>hydroperoxides</e1>.","Downregulator"
"Most reducing cofactors for the peroxidase protect PHS and <e2>prostacyclin synthase</e2> from inactivation by <e1>hydroperoxides</e1>.","Downregulator"
"Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of <e2>PHS</e2> is markedly increased in the presence of 100 microM <e1>H2O2</e1>.","Downregulator"
"Inactivation of <e2>prostaglandin H synthase</e2> and prostacyclin synthase by <e1>phenylbutazone</e1>.","Downregulator"
"Inactivation of prostaglandin H synthase and <e2>prostacyclin synthase</e2> by <e1>phenylbutazone</e1>.","Downregulator"
"Phenylbutazone (<e1>PB</e1>), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of <e2>prostaglandin H synthase</e2> (PHS).","Cofactor"
"Phenylbutazone (<e1>PB</e1>), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (<e2>PHS</e2>).","Cofactor"
"<e1>Phenylbutazone</e1> (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of <e2>prostaglandin H synthase</e2> (PHS).","Cofactor"
"<e1>Phenylbutazone</e1> (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (<e2>PHS</e2>).","Cofactor"
"Phenylbutazone (<e1>PB</e1>), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (<e2>PHS</e2>).","Cofactor"
"Chromatographic analysis of the metabolism of <e1>14C-labeled arachidonic acid</e1> in this system revealed that PB-dependent inactivation of <e2>PHS</e2> is markedly increased in the presence of 100 microM H2O2.","Substrate"
"Isolation and characterization of labeled peptides from <e1>phenoxybenzamine</e1>-modified <e2>calmodulins</e2> indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained phenoxybenzamine label.","Regulator"
"Isolation and characterization of labeled peptides from <e1>phenoxybenzamine</e1>-modified <e2>calmodulins</e2> indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained phenoxybenzamine label.","Regulator"
"Drug-protein interactions: isolation and characterization of covalent adducts of <e1>phenoxybenzamine</e1> and <e2>calmodulin</e2>.","Regulator"
"<e1>Phenoxybenzamine</e1>, an alpha-adrenergic antagonist containing a (chloroethyl)amine group, labels <e2>calmodulin</e2> in the presence of calcium.","Regulator"
"Drug-protein interactions: isolation and characterization of covalent adducts of <e1>phenoxybenzamine</e1> and <e2>calmodulin</e2>.","Regulator"
"Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the <e1>chlorpromazine</e1> binding capacities of the phenoxybenzamine-<e2>calmodulin</e2> adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.","Regulator"
"Phenoxybenzamine, an alpha-adrenergic antagonist containing a <e1>(chloroethyl)amine</e1> group, labels <e2>calmodulin</e2> in the presence of calcium.","Regulator"
"Drug-protein interactions: isolation and characterization of covalent adducts of <e1>phenoxybenzamine</e1> and <e2>calmodulin</e2>.","Regulator"
"In plasma membranes prepared from these isolated brown fat cells by <e1>borate</e1> extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme, <e2>phosphodiesterase I</e2>.","Regulator"
"<e2>Amine oxidase</e2> activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (<e1>clorgyline</e1>-resistant) activity at the fat cell membrane.","Regulator"
"<e2>Amine oxidase</e2> activities in brown adipose tissue of the rat: identification of <e1>semicarbazide</e1>-sensitive (clorgyline-resistant) activity at the fat cell membrane.","Regulator"
"In plasma membranes prepared from these isolated brown fat cells by <e1>borate</e1> extraction there was a similar enrichment of activity of <e2>SSAO</e2> and of the plasma membrane marker enzyme, phosphodiesterase I.","Upregulator"
"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible <e2>SSAO</e2> inhibitor, <e1>hydralazine</e1> and the slowly reversible inhibitor, semicarbazide.","Downregulator"
"It was found that the specific activities of both monoamine oxidase A (MAO) and of the <e1>semicarbazide</e1>-sensitive clorgyline-resistant amine oxidase (<e2>SSAO</e2>) were higher in isolated fat cells than in the original whole tissue.","Downregulator"
"Positive staining of mitochondria was achieved in the presence of the <e2>MAO</e2> substrate, <e1>tryptamine</e1>.","Substrate"
"Staining around the edges of the brown fat cells was observed with the <e2>SSAO</e2> substrates, <e1>tyramine</e1> and benzylamine.","Substrate"
"Staining around the edges of the brown fat cells was observed with the <e2>SSAO</e2> substrates, tyramine and <e1>benzylamine</e1>.","Substrate"
"Binding of <e1>penicillins</e1> to penicillin-binding protein 1Bs produces lysis, binding to <e2>penicillin-binding protein 2</e2> produces round cells, and binding to penicillin-binding protein 3 produces long filaments.","Regulator"
"Binding of <e1>penicillins</e1> to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to <e2>penicillin-binding protein 3</e2> produces long filaments.","Regulator"
"Binding of <e1>penicillins</e1> to <e2>penicillin-binding protein 1Bs</e2> produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments.","Regulator"
"<e1>Amdinocillin</e1> is a beta-amidino penicillanic acid derivative that binds specifically to <e2>penicillin-binding protein 2</e2>.","Regulator"
"Amdinocillin is a <e1>beta-amidino penicillanic acid</e1> derivative that binds specifically to <e2>penicillin-binding protein 2</e2>.","Regulator"
"<e2>Penicillin-binding proteins</e2> and role of <e1>amdinocillin</e1> in causing bacterial cell death.","Regulator"
"The compound is more <e2>beta-lactamase</e2> stable than <e1>ampicillin</e1> and has no major delay in entry into the periplasmic space as do some penicillins.","Regulator"
"This agent acts synergistically with many <e1>penicillins</e1>, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan</e2> of the bacterial cell wall.","Upregulator"
"This agent acts synergistically with many penicillins, such as <e1>ampicillin</e1>, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan</e2> of the bacterial cell wall.","Upregulator"
"This agent acts synergistically with many penicillins, such as ampicillin, <e1>carbenicillin</e1>, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan</e2> of the bacterial cell wall.","Upregulator"
"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with <e1>cephalosporins</e1>, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan</e2> of the bacterial cell wall.","Upregulator"
"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, <e1>cefazolin</e1>, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan</e2> of the bacterial cell wall.","Upregulator"
"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, <e1>cefamandole</e1>, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan</e2> of the bacterial cell wall.","Upregulator"
"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or <e1>cefoxitin</e1> to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan</e2> of the bacterial cell wall.","Upregulator"
"<e1>W-7</e1> did not induce a loss of cell surface <e2>beta 2-microglobulin</e2>, a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of W-7 was specific for membrane receptors and not a result of bulk depletion of plasma membrane.","Not"
"We have found that certain <e1>naphthalenesulfonamides</e1> [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for <e2>alpha 2-macroglobulin</e2>, and epidermal growth factor (EGF) in fibroblasts.","Regulator"
"We have found that certain <e1>naphthalenesulfonamides</e1> [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and <e2>epidermal growth factor</e2> (EGF) in fibroblasts.","Regulator"
"We have found that certain <e1>naphthalenesulfonamides</e1> [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (<e2>EGF</e2>) in fibroblasts.","Regulator"
"The extent of <e2>EGF receptor</e2> loss is less than for alpha 2-macroglobulin, and the EGF receptors do not reappear at the surface when <e1>W-7</e1> is removed.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., <e1>N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide</e1> (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for <e2>alpha 2-macroglobulin</e2>, and epidermal growth factor (EGF) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., <e1>N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide</e1> (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and <e2>epidermal growth factor</e2> (EGF) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., <e1>N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide</e1> (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (<e2>EGF</e2>) in fibroblasts.","Regulator"
"Loss of alpha 2-macroglobulin and <e2>epidermal growth factor</e2> surface binding induced by phenothiazines and <e1>naphthalene sulfonamides</e1>.","Regulator"
"Loss of <e2>alpha 2-macroglobulin</e2> and epidermal growth factor surface binding induced by phenothiazines and <e1>naphthalene sulfonamides</e1>.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (<e1>W-7</e1>)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for <e2>alpha 2-macroglobulin</e2>, and epidermal growth factor (EGF) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (<e1>W-7</e1>)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and <e2>epidermal growth factor</e2> (EGF) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (<e1>W-7</e1>)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (<e2>EGF</e2>) in fibroblasts.","Regulator"
"Loss of alpha 2-macroglobulin and <e2>epidermal growth factor</e2> surface binding induced by <e1>phenothiazines</e1> and naphthalene sulfonamides.","Regulator"
"Loss of <e2>alpha 2-macroglobulin</e2> and epidermal growth factor surface binding induced by <e1>phenothiazines</e1> and naphthalene sulfonamides.","Regulator"
"Loss of <e2>alpha 2-macroglobulin</e2> and epidermal growth factor surface binding induced by <e1>phenothiazines</e1> and naphthalene sulfonamides.","Regulator"
"Loss of alpha 2-macroglobulin and <e2>epidermal growth factor</e2> surface binding induced by <e1>phenothiazines</e1> and naphthalene sulfonamides.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and <e1>phenothiazines</e1> [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (<e2>EGF</e2>) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., <e1>trifluoperazine</e1> (TFP)] induce a loss of cell-surface receptors for <e2>alpha 2-macroglobulin</e2>, and epidermal growth factor (EGF) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., <e1>trifluoperazine</e1> (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and <e2>epidermal growth factor</e2> (EGF) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., <e1>trifluoperazine</e1> (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (<e2>EGF</e2>) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (<e1>TFP</e1>)] induce a loss of cell-surface receptors for <e2>alpha 2-macroglobulin</e2>, and epidermal growth factor (EGF) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (<e1>TFP</e1>)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and <e2>epidermal growth factor</e2> (EGF) in fibroblasts.","Regulator"
"We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (<e1>TFP</e1>)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (<e2>EGF</e2>) in fibroblasts.","Regulator"
"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using <e1>rhodamine</e1>-labeled <e2>alpha 2-macroglobulin</e2>, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.","Regulator"
"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using <e1>rhodamine</e1>-labeled <e2>alpha 2-macroglobulin</e2>, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.","Regulator"
"Since both <e1>TFP</e1> and W-7 are potent inhibitors of <e2>calmodulin</e2>, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.","Downregulator"
"Since both TFP and <e1>W-7</e1> are potent inhibitors of <e2>calmodulin</e2>, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.","Downregulator"
"Three lines of evidence suggest that <e2>calmodulin</e2> inhibition is not responsible for the inhibition of binding and endocytosis: 1) <e1>Promethazine</e1>, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.","Downregulator"
"Three lines of evidence suggest that <e2>calmodulin</e2> inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a <e1>phenothiazine</e1> that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.","Downregulator"
"Since both <e1>TFP</e1> and W-7 are potent inhibitors of <e2>calmodulin</e2>, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.","Downregulator"
"From these results, it is proposed that <e2>tyrosine hydroxylase</e2> activity determines <e1>p-HPAA</e1> concentrations by regulating p-tyrosine availability.","Regulator"
"From these results, it is proposed that <e2>tyrosine hydroxylase</e2> activity determines p-HPAA concentrations by regulating <e1>p-tyrosine</e1> availability.","Substrate"
"The binding of <e2>FHA</e2>-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists <e1>diphenhydramine</e1> and clemastine.","Downregulator"
"The binding of <e2>FHA</e2>-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and <e1>clemastine</e1>.","Downregulator"
"The histamine H2 receptor antagonist <e1>cimetidine</e1> blocked the <e2>FHA</e2>-HIS binding on 14-37% of the platelets.","Downregulator"
"The binding of FHA-HIS was inhibited on 35-79% of the platelets by the <e2>histamine H1 receptor</e2> antagonists <e1>diphenhydramine</e1> and clemastine.","Antagonist"
"The binding of FHA-HIS was inhibited on 35-79% of the platelets by the <e2>histamine H1 receptor</e2> antagonists diphenhydramine and <e1>clemastine</e1>.","Antagonist"
"The <e2>histamine H2 receptor</e2> antagonist <e1>cimetidine</e1> blocked the FHA-HIS binding on 14-37% of the platelets.","Antagonist"
"Alanine:<e1>glyoxylate</e1> aminotransferase (AGT) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.","Substrate"
"Alanine:<e1>glyoxylate</e1> aminotransferase (<e2>AGT</e2>) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.","Substrate"
"The holo activity of combined peroxisomal and mitochondrial <e2>AGT 1</e2> with a low Km for <e1>L-alanine</e1> rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).","Substrate"
"The holo activity of combined peroxisomal and mitochondrial <e2>AGT 1</e2> with a low Km for <e1>L-alanine</e1> rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).","Substrate"
"The holo activity of <e2>AGT 2</e2> with a high Km for <e1>L-alanine</e1> decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days).","Substrate"
"<e1>Triclosan</e1> inhibited both <e2>cyclooxygenase 1</e2> and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively.","Downregulator"
"<e1>Triclosan</e1> inhibited both cyclooxygenase 1 and <e2>cyclo-oxygenase 2</e2> with IC-50 values of 43 microM and 227 microM, respectively.","Downregulator"
"<e1>Triclosan</e1> also inhibited <e2>5-lipoxygenase</e2> with an IC-50 of 43 microM.","Downregulator"
"Several in vitro studies were conducted to evaluate the effect of <e1>triclosan</e1> on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, 5-lipoxygenase and <e2>15-lipoxygenase</e2>.","Downregulator"
"Several in vitro studies were conducted to evaluate the effect of <e1>triclosan</e1> on 4 primary enzymes of the pathways of arachidonic acid metabolism, <e2>cyclo-oxygenase</e2> 1, cyclo-oxygenase 2, 5-lipoxygenase and 15-lipoxygenase.","Downregulator"
"Several in vitro studies were conducted to evaluate the effect of <e1>triclosan</e1> on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, 5-<e2>lipoxygenase</e2> and 15-lipoxygenase.","Downregulator"
"In cell culture experiments, it was found that <e1>triclosan</e1> inhibited <e2>IL-1 beta</e2> induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.","Downregulator"
"In cell culture experiments, it was found that triclosan inhibited <e2>IL-1 beta</e2> induced <e1>prostaglandin E2</e1> production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.","Substrate"
"Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of <e1>arachidonic acid</e1> metabolism, <e2>cyclo-oxygenase</e2> 1, cyclo-oxygenase 2, 5-lipoxygenase and 15-lipoxygenase.","Substrate"
"Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of <e1>arachidonic acid</e1> metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, 5-<e2>lipoxygenase</e2> and 15-lipoxygenase.","Substrate"
"Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (<e1>CN-Cbl</e1>) bound to <e2>transcobalamin II</e2> (transcobalamin, TC).","Regulator"
"Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (<e1>CN-Cbl</e1>) bound to <e2>transcobalamin</e2> II (transcobalamin, TC).","Regulator"
"Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (<e1>CN-Cbl</e1>) bound to transcobalamin II (transcobalamin, <e2>TC</e2>).","Regulator"
"Intracellular protein-bound <e1>[57Co]Cbl</e1> fractionated with <e2>methionine synthase</e2> (MS) and methylmalonyl-CoA mutase (MU) activity.","Regulator"
"Intracellular protein-bound <e1>[57Co]Cbl</e1> fractionated with methionine synthase (<e2>MS</e2>) and methylmalonyl-CoA mutase (MU) activity.","Regulator"
"Intracellular protein-bound <e1>[57Co]Cbl</e1> fractionated with methionine synthase (MS) and <e2>methylmalonyl-CoA mutase</e2> (MU) activity.","Regulator"
"Intracellular protein-bound <e1>[57Co]Cbl</e1> fractionated with methionine synthase (MS) and methylmalonyl-CoA mutase (<e2>MU</e2>) activity.","Regulator"
"Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of <e1>[57Co]cyanocobalamin</e1> (CN-Cbl) bound to <e2>transcobalamin II</e2> (transcobalamin, TC).","Regulator"
"Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of <e1>[57Co]cyanocobalamin</e1> (CN-Cbl) bound to <e2>transcobalamin</e2> II (transcobalamin, TC).","Regulator"
"Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of <e1>[57Co]cyanocobalamin</e1> (CN-Cbl) bound to transcobalamin II (transcobalamin, <e2>TC</e2>).","Regulator"
"Cells propagated in medium containing <e1>N5-methyltetrahydrofolate</e1> and homocysteine showed a substantial increase in <e2>MS</e2> activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.","Upregulator"
"Cells propagated in medium containing N5-methyltetrahydrofolate and <e1>homocysteine</e1> showed a substantial increase in <e2>MS</e2> activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.","Upregulator"
"<e1>Ergovaline</e1> binding and activation of <e2>D2 dopamine receptor</e2>s in GH4ZR7 cells.","Regulator"
"Our results indicate that ergot compounds, especially <e1>ergovaline</e1>, bind to <e2>D2 dopamine receptors</e2> and elicit second messenger responses similar to that of dopamine.","Regulator"
"Ergovaline binding and activation of D2 <e1>dopamine</e1> receptors in GH4ZR7 cells.","Regulator"
"<e1>Ergovaline</e1> binding and activation of <e2>D2 dopamine receptors</e2> in GH4ZR7 cells.","Regulator"
"<e1>Ergovaline</e1> binding and activation of <e2>D2</e2> dopamine receptors in GH4ZR7 cells.","Regulator"
"Ergovaline inhibition of the binding of the <e2>D2</e2>-specific radioligand, <e1>[3H]YM-09151-2</e1>, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM).","Regulator"
"Ergovaline binding and activation of <e2>D2</e2> <e1>dopamine</e1> receptors in GH4ZR7 cells.","Regulator"
"<e1>Ergovaline</e1> binding and activation of <e2>D2 dopamine receptors</e2> in GH4ZR7 cells.","Upregulator"
"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several <e1>ergot alkaloids</e1> including ergovaline, may be due to <e2>D2 dopamine receptor</e2> activation.","Upregulator"
"Our results indicate that ergot compounds, especially <e1>ergovaline</e1>, bind to <e2>D2 dopamine receptor</e2>s and elicit second messenger responses similar to that of dopamine.","Upregulator"
"<e1>Ergot alkaloids</e1> were also effective in inhibiting <e2>VIP</e2>-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.","Downregulator"
"Ergot alkaloids were also effective in inhibiting <e2>VIP</e2>-stimulated cyclic AMP production, with EC50 values for <e1>ergovaline</e1>, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.","Downregulator"
"Ergot alkaloids were also effective in inhibiting <e2>VIP</e2>-stimulated cyclic AMP production, with EC50 values for ergovaline, <e1>ergonovine</e1>, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.","Downregulator"
"Ergot alkaloids were also effective in inhibiting <e2>VIP</e2>-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, <e1>alpha-ergocryptine</e1>, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.","Downregulator"
"Ergot alkaloids were also effective in inhibiting <e2>VIP</e2>-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, <e1>ergotamine</e1>, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.","Downregulator"
"Ergovaline inhibition of radioligand binding to the D2 <e1>dopamine</e1> receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (<e2>VIP</e2>)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Downregulator"
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and <e1>ergot alkaloid</e1> inhibition of <e2>vasoactive intestinal peptide</e2> (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Downregulator"
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and <e1>ergot alkaloid</e1> inhibition of vasoactive intestinal peptide (<e2>VIP</e2>)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Downregulator"
"Inhibition of cyclic AMP production by ergovaline was blocked by the <e2>dopamine receptor</e2> antagonist, <e1>(-)-sulpiride</e1> (IC50, 300 +/- 150 nM).","Antagonist"
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (<e2>VIP</e2>)-stimulated <e1>cyclic AMP</e1> production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Substrate"
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of <e2>vasoactive intestinal peptide</e2> (VIP)-stimulated <e1>cyclic AMP</e1> production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Substrate"
"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (<e2>VIP</e2>)-stimulated <e1>cyclic AMP</e1> production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.","Substrate"
"Saturation experiments showed that <e1>[3H]prazosin</e1> labelled a single population of binding sites in the spleen (<e2>alpha 1B</e2>) and hippocampus (alpha 1A and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).","Regulator"
"Saturation experiments showed that <e1>[3H]prazosin</e1> labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus (<e2>alpha 1A</e2> and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).","Regulator"
"Saturation experiments showed that <e1>[3H]prazosin</e1> labelled a single population of binding sites in the spleen (<e2>alpha 1B</e2>) and hippocampus (alpha 1A and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).","Regulator"
"The binding of the antipsychotic drugs risperidone, (+)-butaclamol, <e1>clozapine</e1>, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the <e2>alpha 1-adrenoceptor</e2>.","Regulator"
"The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, <e1>haloperidol</e1>, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the <e2>alpha 1-adrenoceptor</e2>.","Regulator"
"The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, <e1>spiperone</e1>, thioridazine and YM-09151-2 was studied at the subtypes of the <e2>alpha 1-adrenoceptor</e2>.","Regulator"
"Binding of antipsychotic drugs at alpha 1A- and <e2>alpha 1B-adrenoceptors</e2>: <e1>risperidone</e1> is selective for the alpha 1B-adrenoceptors.","Regulator"
"The binding of the antipsychotic drugs <e1>risperidone</e1>, (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the <e2>alpha 1-adrenoceptor</e2>.","Regulator"
"The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone, <e1>thioridazine</e1> and YM-09151-2 was studied at the subtypes of the <e2>alpha 1-adrenoceptor</e2>.","Regulator"
"<e1>Risperidone</e1> was 120-fold more selective for the <e2>alpha 1B-adrenoceptor</e2> with respect to the alpha 1A-adrenoceptor (Ki values: 2.3 +/- 1.2 nM and 283.6 +/- 174.1 nM respectively).","Regulator"
"<e1>Risperidone</e1> was 120-fold more selective for the alpha 1B-adrenoceptor with respect to the <e2>alpha 1A-adrenoceptor</e2> (Ki values: 2.3 +/- 1.2 nM and 283.6 +/- 174.1 nM respectively).","Regulator"
"The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and <e1>YM-09151-2</e1> was studied at the subtypes of the <e2>alpha 1-adrenoceptor</e2>.","Regulator"
"The binding of the antipsychotic drugs <e1>risperidone</e1>, (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the <e2>alpha 1-adrenoceptor</e2>.","Regulator"
"The binding of the antipsychotic drugs risperidone, <e1>(+)-butaclamol</e1>, clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the <e2>alpha 1-adrenoceptor</e2>.","Regulator"
"Incubation of rat aortic membranes with the irreversible <e2>alpha 1B-adrenoceptor</e2> antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of <e1>[3H]-prazosin</e1> binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).","Regulator"
"The subtypes of <e2>alpha 1-adrenoceptor</e2> mediating contractions to exogenous <e1>noradrenaline</e1> (NA) in rat aorta have been examined in both biochemical and functional studies.","Regulator"
"The subtypes of <e2>alpha 1-adrenoceptor</e2> mediating contractions to exogenous noradrenaline (<e1>NA</e1>) in rat aorta have been examined in both biochemical and functional studies.","Regulator"
"Mediation of <e1>noradrenaline</e1>-induced contractions of rat aorta by the <e2>alpha 1B-adrenoceptor</e2> subtype.","Regulator"
"<e1>5-Methylurapidil</e1> and phentolamine were confirmed as selective for the <e2>alpha 1A-adrenoceptors</e2>, whereas spiperone was alpha 1B-selective.","Regulator"
"5-Methylurapidil and <e1>phentolamine</e1> were confirmed as selective for the <e2>alpha 1A-adrenoceptors</e2>, whereas spiperone was alpha 1B-selective.","Regulator"
"Incubation of rat aortic membranes with the irreversible <e2>alpha 1B-adrenoceptor</e2> antagonist, <e1>chloroethylclonidine</e1> (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).","Antagonist"
"Incubation of rat aortic membranes with the irreversible <e2>alpha 1B-adrenoceptor</e2> antagonist, chloroethylclonidine (<e1>CEC</e1>: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).","Antagonist"
"Beta 2- but not <e2>beta 1-adrenoceptors</e2> are involved in <e1>desipramine</e1> enhancement of aggressive behavior in long-term isolated mice.","Not"
"ICI118,551 HCl (1.25-5 mg/kg, IP), a selective <e2>beta 2-adrenoceptor</e2> antagonist, also blocked the <e1>desipramine</e1>-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.","Regulator"
"Moreover, <e1>clenbuterol HCl</e1> (0.1-0.5 mg/kg, IP), a lipophilic <e2>beta 2-adrenoceptor</e2> agonist, significantly increased the duration of basal aggressive behavior.","Agonist"
"Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by <e1>yohimbine</e1>, an <e2>alpha 2-adrenoceptor</e2> antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.","Antagonist"
"Intraperitoneal administration of <e1>(+/- )propranolol HCl</e1> (2.5-10 mg/kg), a nonselective <e2>beta-adrenoceptor</e2> antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.","Antagonist"
"<e1>ICI118,551 HCl</e1> (1.25-5 mg/kg, IP), a selective <e2>beta 2-adrenoceptor</e2> antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.","Antagonist"
"ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas <e1>metoprolol tartrate</e1> (5-20 mg/kg, IP), a selective <e2>beta 1-adrenoceptor</e2> antagonist, did not affect it.","Antagonist"
"Furthermore, the phosphorylation of <e2>myosin light chain</e2> produced by <e1>norepinephrine</e1> was greater than that produced by clonidine.","Upregulator"
"Furthermore, the phosphorylation of <e2>myosin light chain</e2> produced by norepinephrine was greater than that produced by <e1>clonidine</e1>.","Upregulator"
"In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective <e2>alpha 1A-adrenoceptor</e2> antagonist <e1>WB 4101</e1> (100 nM).","Antagonist"
"In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or <e2>GLUT1</e2> to investigate the role of glucose transporter isoforms in mediating <e1>STZ</e1> cytotoxicity.","Not"
"In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of <e2>GLUT2</e2> or GLUT1 to investigate the role of <e1>glucose</e1> transporter isoforms in mediating STZ cytotoxicity.","Substrate"
"In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of <e2>GLUT2</e2> or GLUT1 to investigate the role of glucose transporter isoforms in mediating <e1>STZ</e1> cytotoxicity.","Substrate"
"In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of <e2>GLUT2</e2> or GLUT1 to investigate the role of glucose transporter isoforms in mediating <e1>STZ</e1> cytotoxicity.","Substrate"
"In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of <e2>GLUT2</e2> or GLUT1 to investigate the role of glucose transporter isoforms in mediating <e1>STZ</e1> cytotoxicity.","Substrate"
"The present study utilized blood from normal volunteers and <e1>125I</e1>-<e2>fibrinogen</e2> in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.","Regulator"
"Inhibitory effects of <e1>lysine</e1> analogues on <e2>t-PA</e2> induced whole blood clot lysis.","Downregulator"
"The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (<e1>AMCA</e1>) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (<e2>t-PA</e2>).","Downregulator"
"The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (<e1>AMCA</e1>) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (<e2>t-PA</e2>).","Downregulator"
"The lysine analogues epsilon-aminocaproic acid (<e1>EACA</e1>) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (<e2>t-PA</e2>).","Downregulator"
"The lysine analogues epsilon-aminocaproic acid (<e1>EACA</e1>) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (<e2>t-PA</e2>).","Downregulator"
"Inhibitory effects of <e1>lysine</e1> analogues on <e2>t-PA</e2> induced whole blood clot lysis.","Downregulator"
"Inhibitory effects of <e1>lysine</e1> analogues on <e2>t-PA</e2> induced whole blood clot lysis.","Downregulator"
"Inhibitory effects of <e1>lysine</e1> analogues on <e2>t-PA</e2> induced whole blood clot lysis.","Downregulator"
"<e1>Histamine</e1> enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via <e2>H1-receptor</e2> activation.","Upregulator"
"The enhancement of the depolarizing afterpotential by <e1>histamine</e1> was mimicked by the histamine <e2>H1-receptor</e2> agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.","Upregulator"
"The enhancement of the depolarizing afterpotential by histamine was mimicked by the <e2>histamine H1-receptor</e2> agonist <e1>2-thiazolylethylamine</e1> and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.","Agonist"
"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine <e2>H1-receptor</e2> agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist <e1>promethazine</e1>, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.","Antagonist"
"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the <e2>histamine H2-receptor</e2> antagonist, <e1>cimetidine</e1>.","Antagonist"
"Furthermore, <e1>adapalene</e1> does not bind to members of the cellular <e2>retinoic acid binding protein</e2> family.","Not"
"Finally, the three drugs were compared with the <e2>angiotensin converting enzyme</e2> inhibitor <e1>cilazapril</e1>.","Downregulator"
"The goal of the present study was to compare the effects of three potent reference <e2>renin</e2> inhibitors (<e1>remikiren</e1>, CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys.","Downregulator"
"The goal of the present study was to compare the effects of three potent reference <e2>renin</e2> inhibitors (remikiren, <e1>CGP 38560A</e1>, and enalkiren) in sodium-depleted normotensive squirrel monkeys.","Downregulator"
"The goal of the present study was to compare the effects of three potent reference <e2>renin</e2> inhibitors (remikiren, CGP 38560A, and <e1>enalkiren</e1>) in sodium-depleted normotensive squirrel monkeys.","Downregulator"
"The goal of the present study was to compare the effects of three potent reference <e2>renin</e2> inhibitors (<e1>remikiren</e1>, CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys.","Downregulator"
"The goal of the present study was to compare the effects of three potent reference <e2>renin</e2> inhibitors (remikiren, <e1>CGP 38560A</e1>, and enalkiren) in sodium-depleted normotensive squirrel monkeys.","Downregulator"
"The goal of the present study was to compare the effects of three potent reference <e2>renin</e2> inhibitors (remikiren, CGP 38560A, and <e1>enalkiren</e1>) in sodium-depleted normotensive squirrel monkeys.","Downregulator"
"RESULTS: <e1>Nedocromil sodium</e1> inhibited the chemotactic response toward FMLP and NAF/IL-8 of <e2>GM-CSF</e2> primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).","Downregulator"
"Inhibition of <e2>cytokine</e2>-primed eosinophil chemotaxis by <e1>nedocromil sodium</e1>.","Downregulator"
"CONCLUSIONS: The chemotactic responses toward <e2>C5a</e2> were inhibited by <e1>nedocromil sodium</e1> at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L).","Downregulator"
"RESULTS: <e1>Nedocromil sodium</e1> inhibited the chemotactic response toward FMLP and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of <e2>IL-3</e2> primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).","Downregulator"
"RESULTS: <e1>Nedocromil sodium</e1> inhibited the chemotactic response toward FMLP and <e2>NAF</e2>/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).","Downregulator"
"RESULTS: <e1>Nedocromil sodium</e1> inhibited the chemotactic response toward FMLP and NAF/<e2>IL-8</e2> of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).","Downregulator"
"<e1>Glutathione</e1>-independent prostaglandin D synthase [<e2>prostaglandin-H2 D-isomerase</e2>; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.","Not"
"<e1>Glutathione</e1>-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; <e2>(5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase</e2>, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.","Not"
"<e1>Glutathione</e1>-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, <e2>EC 5.3.99.2</e2>] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.","Not"
"<e1>Glutathione</e1>-independent <e2>prostaglandin D synthase</e2> [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.","Not"
"Glutathione-independent prostaglandin D synthase [<e2>prostaglandin-H2 D-isomerase</e2>; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>prostaglandin D2</e1> in the central nervous system.","Substrate"
"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; <e2>(5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase</e2>, EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>prostaglandin D2</e1> in the central nervous system.","Substrate"
"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, <e2>EC 5.3.99.2</e2>] is an enzyme responsible for biosynthesis of <e1>prostaglandin D2</e1> in the central nervous system.","Substrate"
"Glutathione-independent <e2>prostaglandin D synthase</e2> [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>prostaglandin D2</e1> in the central nervous system.","Substrate"
"This cDNA clone, designated <e2>EAA3a</e2>, shares a 90% <e1>nucleotide</e1> identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions.","Part_of"
"This cDNA clone, designated EAA3a, shares a 90% <e1>nucleotide</e1> identity with the previously reported <e2>rat GluR5-2b</e2> cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions.","Part_of"
"This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from <e2>human GluR5-1d</e2> in the <e1>amino</e1> and carboxy terminal regions.","Part_of"
"This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from <e2>human GluR5-1d</e2> in the amino and <e1>carboxy</e1> terminal regions.","Part_of"
"The relative potency of compounds in displacing [3H]-kainate binding to <e2>EAA3a</e2> receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > <e1>dihydrokainate</e1> > NMDA.","Regulator"
"The relative potency of compounds in displacing [3H]-kainate binding to <e2>EAA3a</e2> receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > <e1>NMDA</e1>.","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, <e1>kainate</e1>, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, <e1>L-glutamate</e1> and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and <e1>(RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate</e1> (AMPA).","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (<e1>AMPA</e1>).","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, <e1>kainate</e1>, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).","Regulator"
"<e1>Kainate</e1> and AMPA activated the heteromeric channel with significantly higher affinities than observed for <e2>EAA3a</e2> alone.","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (<e1>AMPA</e1>).","Regulator"
"The relative potency of compounds in displacing <e1>[3H]-kainate</e1> binding to <e2>EAA3a</e2> receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, <e1>kainate</e1>, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, <e1>L-glutamate</e1> and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).","Regulator"
"The relative potency of compounds in displacing [3H]-kainate binding to <e2>EAA3a</e2> receptor was: domoate > kainate > L-glutamate = <e1>quisqualate</e1> > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.","Regulator"
"The relative potency of compounds in displacing [3H]-kainate binding to <e2>EAA3a</e2> receptor was: domoate > kainate > L-glutamate = quisqualate > <e1>6,7-dinitroquinoxaline-2,3-dione</e1> (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.","Regulator"
"The relative potency of compounds in displacing [3H]-kainate binding to <e2>EAA3a</e2> receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (<e1>DNQX</e1>) = CNQX > AMPA > dihydrokainate > NMDA.","Regulator"
"The relative potency of compounds in displacing [3H]-kainate binding to <e2>EAA3a</e2> receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = <e1>CNQX</e1> > AMPA > dihydrokainate > NMDA.","Regulator"
"Cell lines stably expressing <e2>EAA3a</e2> protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (<e1>AMPA</e1>).","Regulator"
"Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist <e1>CNQX</e1> (6-cyano-7-nitro-quinoxalinedione).","Antagonist"
"Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<e2>N-methyl-D-aspartate (NMDA) receptor</e2> antagonist CNQX (<e1>6-cyano-7-nitro-quinoxalinedione</e1>).","Antagonist"
"One group of experimental animals was treated with 5-lipoxygenase (<e2>5-LO</e2>) inhibitor, diethylcarbamazine (<e1>DEC</e1>, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.","Downregulator"
"One group of experimental animals was treated with <e2>5-lipoxygenase</e2> (5-LO) inhibitor, <e1>diethylcarbamazine</e1> (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.","Downregulator"
"One group of experimental animals was treated with 5-lipoxygenase (<e2>5-LO</e2>) inhibitor, <e1>diethylcarbamazine</e1> (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.","Downregulator"
"One group of experimental animals was treated with <e2>5-lipoxygenase</e2> (5-LO) inhibitor, diethylcarbamazine (<e1>DEC</e1>, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.","Downregulator"
"One group of experimental animals was treated with 5-lipoxygenase (<e2>5-LO</e2>) inhibitor, diethylcarbamazine (<e1>DEC</e1>, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.","Downregulator"
"<e1>Tamsulosin</e1>, the first prostate-selective <e2>alpha 1A-adrenoceptor</e2> antagonist.","Antagonist"
"Expressions of insulin and PC3, but not <e2>PC2</e2>, are coordinately regulated by <e1>glucose</e1>, consistent with the important role of PC3 in regulating proinsulin processing.","Not"
"Single-strand conformational analysis and <e1>nucleotide</e1> sequencing of the entire coding region of the <e2>PC3</e2> gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population.","Part_of"
"Single-strand conformational analysis and <e1>nucleotide</e1> sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (<e2>Arg/Gln53</e2>) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population.","Part_of"
"Single-strand conformational analysis and <e1>nucleotide</e1> sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (<e2>Gln/Glu638</e2>), neither of which was associated with NIDDM in this population.","Part_of"
"PC3 is a type I <e2>proinsulin</e2>-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the <e1>COOH</e1>-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.","Part_of"
"PC3 is a type I <e2>proinsulin</e2>-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the <e1>COOH</e1>-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.","Part_of"
"P<e1>C</e1>3 is a type I <e2>proinsulin</e2>-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.","Part_of"
"P<e1>C</e1>3 is a type I <e2>proinsulin</e2>-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.","Part_of"
"Expressions of <e2>insulin</e2> and PC3, but not PC2, are coordinately regulated by <e1>glucose</e1>, consistent with the important role of PC3 in regulating proinsulin processing.","Upregulator"
"Expressions of insulin and <e2>PC3</e2>, but not PC2, are coordinately regulated by <e1>glucose</e1>, consistent with the important role of PC3 in regulating proinsulin processing.","Upregulator"
"After 7 days of <e1>DMI</e1> administration the number of <e2>beta-adrenoceptors</e2> was lower in frontal and occipital cortex and hippocampus.","Not"
"<e1>Desipramine</e1> administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and <e2>5-HT2A</e2> binding sites and their relationship to behaviour.","Regulator"
"<e1>Desipramine</e1> administration in the olfactory bulbectomized rat: changes in brain <e2>beta-adrenoceptor</e2> and 5-HT2A binding sites and their relationship to behaviour.","Regulator"
"After 7 days of <e1>DMI</e1> administration the number of <e2>beta-adrenoceptors</e2> was lower in frontal and occipital cortex and hippocampus.","Downregulator"
"After 7 days of <e1>DMI</e1> administration the number of <e2>beta-adrenoceptors</e2> was lower in frontal and occipital cortex and hippocampus.","Downregulator"
"After 7 days of <e1>DMI</e1> administration the number of <e2>beta-adrenoceptors</e2> was lower in frontal and occipital cortex and hippocampus.","Downregulator"
"The effects of repeated administration of the tricyclic antidepressant drug, desipramine (<e1>DMI</e1>), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and <e2>5-HT2A</e2> receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.","Downregulator"
"The effects of repeated administration of the tricyclic antidepressant drug, desipramine (<e1>DMI</e1>), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and <e2>5-HT2A</e2> receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.","Downregulator"
"After 7 days of <e1>DMI</e1> administration the number of <e2>beta-adrenoceptors</e2> was lower in frontal and occipital cortex and hippocampus.","Downregulator"
"The effects of repeated administration of the tricyclic antidepressant drug, desipramine (<e1>DMI</e1>), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and <e2>5-HT2A</e2> receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.","Downregulator"
"We show that the binding of <e1>thalidomide</e1> photoaffinity label to authentic <e2>human AGP</e2> is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.","Regulator"
"Binding of <e1>thalidomide</e1> to <e2>alpha1-acid glycoprotein</e2> may be involved in its inhibition of tumor necrosis factor alpha production.","Regulator"
"We show that the binding of <e1>thalidomide</e1> photoaffinity label to authentic human <e2>AGP</e2> is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.","Regulator"
"Binding of <e1>thalidomide</e1> to alpha1-acid glycoprotein may be involved in its inhibition of <e2>tumor necrosis factor alpha</e2> production.","Downregulator"
"Binding of <e1>thalidomide</e1> to alpha1-acid glycoprotein may be involved in its inhibition of <e2>tumor necrosis factor alpha</e2> production.","Downregulator"
"Binding of <e1>thalidomide</e1> to alpha1-acid glycoprotein may be involved in its inhibition of <e2>tumor necrosis factor alpha</e2> production.","Downregulator"
"The complex patterns of sensitivity to <e1>cyclothiazide</e1> seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the <e2>GluR-A</e2> and GluR-B subunits.","Regulator"
"Recovery from modulation by <e1>cyclothiazide</e1> was slower for GluR-AiBi and <e2>GluR-AoBi</e2> than for GluR-AiBo and GluR-AoBo.","Regulator"
"Recovery from modulation by <e1>cyclothiazide</e1> was slower for GluR-AiBi and GluR-AoBi than for <e2>GluR-AiBo</e2> and GluR-AoBo.","Regulator"
"The complex patterns of sensitivity to <e1>cyclothiazide</e1> seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and <e2>GluR-B</e2> subunits.","Regulator"
"Recovery from modulation by <e1>cyclothiazide</e1> was slower for <e2>GluR-AiBi</e2> and GluR-AoBi than for GluR-AiBo and GluR-AoBo.","Regulator"
"Recovery from modulation by <e1>cyclothiazide</e1> was slower for <e2>GluR-Ai</e2>Bi and GluR-AoBi than for GluR-AiBo and GluR-AoBo.","Regulator"
"<e2>AMPA receptor</e2> heterogeneity in rat hippocampal neurons revealed by differential sensitivity to <e1>cyclothiazide</e1>.","Regulator"
"<e2>AMPA receptor</e2> heterogeneity in rat hippocampal neurons revealed by differential sensitivity to <e1>cyclothiazide</e1>.","Regulator"
"The complex patterns of sensitivity to <e1>cyclothiazide</e1> seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the <e2>GluR-A</e2> and GluR-B subunits.","Regulator"
"The complex patterns of sensitivity to <e1>cyclothiazide</e1> seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and <e2>GluR-B</e2> subunits.","Regulator"
"<e2>AMPA receptor</e2> heterogeneity in rat hippocampal neurons revealed by differential sensitivity to <e1>cyclothiazide</e1>.","Regulator"
"Recovery from modulation by <e1>cyclothiazide</e1> was slower for <e2>GluR-AiBi</e2> and GluR-AoBi than for GluR-AiBo and GluR-AoBo.","Regulator"
"Recovery from modulation by <e1>cyclothiazide</e1> was slower for GluR-AiBi and <e2>GluR-AoBi</e2> than for GluR-AiBo and GluR-AoBo.","Regulator"
"Recovery from modulation by <e1>cyclothiazide</e1> was slower for GluR-AiBi and GluR-AoBi than for <e2>GluR-AiBo</e2> and GluR-AoBo.","Regulator"
"Recovery from modulation by <e1>cyclothiazide</e1> was slower for GluR-AiBi and GluR-AoBi than for GluR-AiBo and <e2>GluR-AoBo</e2>.","Regulator"
"The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid <e2>(AMPA) receptor</e2> desensitization by <e1>glutamate</e1>, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.","Regulator"
"Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric <e2>AMPA receptors</e2> with intermediate sensitivity to <e1>cyclothiazide</e1>, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.","Regulator"
"The complex patterns of sensitivity to <e1>cyclothiazide</e1> seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the <e2>GluR-A</e2> and GluR-B subunits.","Regulator"
"The complex patterns of sensitivity to <e1>cyclothiazide</e1> seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and <e2>GluR-B</e2> subunits.","Regulator"
"Striatal <e2>DAT</e2> protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas DAT determined by <e1>[3H]WIN 35,428</e1> binding was normal.","Regulator"
"We measured levels of DA, as well as two DA nerve terminal indices, namely, the <e2>DA transporter</e2> (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic <e1>cocaine</e1> users.","Downregulator"
"Both subunits had novel <e1>N</e1>-terminal amino acid sequences, indicating that <e2>PHBP</e2> was a novel hyaluronan-binding protein in human plasma.","Part_of"
"The predicted structure of PHBP showed three <e2>epidermal growth factor (EGF) domains</e2>, a kringle domain and a serine protease domain, from its <e1>N</e1>-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a <e2>kringle domain</e2> and a serine protease domain, from its <e1>N</e1>-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a <e2>serine protease domain</e2>, from its <e1>N</e1>-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"The amino acid sequence deduced from the nucleotide sequence of the cloned PHBP cD<e1>N</e1>A exhibited significant homology to that of hepatocyte growth factor activator (<e2>HGFA</e2>).","Part_of"
"The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its <e1>N</e1>-terminus, although HGFA has a <e2>fibronectin type II domain</e2>, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its <e1>N</e1>-terminus, although HGFA has a fibronectin type II domain, an <e2>EGF domain</e2>, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its <e1>N</e1>-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a <e2>fibronectin type I domain</e2>, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its <e1>N</e1>-terminus, although HGFA has a fibronectin type II domain, an <e2>EGF domain</e2>, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a <e2>kringle domain</e2> and a serine protease domain, from its <e1>N</e1>-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a <e2>serine protease domain</e2>, from its <e1>N</e1>-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.","Part_of"
"Thus, <e2>PHBP</e2> was a heterodimer composed of 50-kDa and 17-kDa subunits, bridged by a <e1>disulfide</e1> linkage.","Part_of"
"Both subunits had novel N-terminal <e1>amino acid</e1> sequences, indicating that <e2>PHBP</e2> was a novel hyaluronan-binding protein in human plasma.","Part_of"
"The amino acid sequence deduced from the <e1>nucleotide</e1> sequence of the cloned <e2>PHBP</e2> cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA).","Part_of"
"It appears likely that the <e2>histamine H2 receptor</e2> blocked by cimetidine obviated the pulmonary vasodilator effect of <e1>tolazoline</e1> therapy.","Regulator"
"It appears likely that the <e2>histamine H2 receptor</e2> blocked by <e1>cimetidine</e1> obviated the pulmonary vasodilator effect of tolazoline therapy.","Downregulator"
"Interactions of 2,3-benzodiazepines and <e1>cyclothiazide</e1> at <e2>AMPA receptors</e2>: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.","Regulator"
"Interactions of <e1>2,3-benzodiazepines</e1> and cyclothiazide at <e2>AMPA receptors</e2>: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.","Regulator"
"<e1>GYKI 52466</e1> decreased the peak amplitude of hippocampal area CA1 <e2>AMPA receptor</e2>-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.","Regulator"
"Interactions of 2,3-benzodiazepines and <e1>cyclothiazide</e1> at <e2>AMPA receptor</e2>s: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.","Regulator"
"<e1>Cyclothiazide</e1> prolonged the decay time constant of <e2>AMPA receptor</e2>-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c.","Regulator"
"<e1>GYKI 52466</e1> decreased the peak amplitude of hippocampal area CA1 <e2>AMPA receptor</e2>-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.","Regulator"
"<e1>GYKI 52466</e1> decreased the peak amplitude of hippocampal area CA1 <e2>AMPA receptor</e2>-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.","Regulator"
"Interactions of 2,3-benzodiazepines and <e1>cyclothiazide</e1> at <e2>AMPA receptor</e2>s: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.","Regulator"
"Interactions of <e1>2,3-benzodiazepines</e1> and cyclothiazide at <e2>AMPA receptors</e2>: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.","Regulator"
"Interactions of 2,3-benzodiazepines and <e1>cyclothiazide</e1> at <e2>AMPA receptors</e2>: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.","Regulator"
"<e1>GYKI 52466</e1> decreased the peak amplitude of hippocampal area CA1 <e2>AMPA receptor</e2>-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.","Downregulator"
"<e1>Cyclothiazide</e1> prolonged the decay time constant of <e2>AMPA receptor</e2>-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c.","Downregulator"
"<e1>Naphazoline</e1> was the most selective compound for the high affinity state of the <e2>alpha-2A adrenoceptor</e2>, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1-midazoline binding sites, respectively.","Regulator"
"To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for <e1>[125I]p-iodoclonidine</e1> binding have been compared at <e2>human platelet I1-imidazoline binding sites</e2> (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.","Regulator"
"Activation of cytoprotective <e2>prostaglandin synthase-1</e2> by <e1>minoxidil</e1> as a possible explanation for its hair growth-stimulating effect.","Upregulator"
"We thus speculated that activation of <e2>PGHS-1</e2> might be a mechanism by which <e1>minoxidil</e1> (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo.","Upregulator"
"We thus speculated that activation of <e2>PGHS-1</e2> might be a mechanism by which minoxidil (<e1>2,4-diamino-6-piperidinopyrimidine-3-oxyde</e1>) stimulates hair growth in vivo.","Upregulator"
"We thus speculated that activation of <e2>PGHS-1</e2> might be a mechanism by which <e1>minoxidil</e1> (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo.","Upregulator"
"Evolution of the <e1>amino</e1>acyl-tRNA synthetase family and the organization of the Drosophila <e2>glutamyl-prolyl-tRNA synthetase</e2> gene.","Part_of"
"In Drosophila, <e2>glutamyl-prolyl-tRNA synthetase</e2> is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and <e1>carboxy</e1>-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.","Part_of"
"In Drosophila, <e2>glutamyl-prolyl-tRNA synthetase</e2> is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of <e1>glutamic acid</e1> and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.","Part_of"
"In Drosophila, <e2>glutamyl-prolyl-tRNA synthetase</e2> is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 <e1>amino acids</e1> repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.","Part_of"
"Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and <e1>tretinoin</e1> for the <e2>nuclear transcription factors</e2>, retinoic acid receptors (RARs).","Regulator"
"Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and <e1>tretinoin</e1> for the nuclear transcription factors, <e2>retinoic acid receptors</e2> (RARs).","Regulator"
"Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and <e1>tretinoin</e1> for the nuclear transcription factors, retinoic acid receptors (<e2>RARs</e2>).","Regulator"
"Binding and transactivation assays were used to compare affinities and transcriptional activities of <e1>adapalene</e1> and tretinoin for the <e2>nuclear transcription factors</e2>, retinoic acid receptors (RARs).","Regulator"
"Binding and transactivation assays were used to compare affinities and transcriptional activities of <e1>adapalene</e1> and tretinoin for the nuclear transcription factors, <e2>retinoic acid receptors</e2> (RARs).","Regulator"
"Binding and transactivation assays were used to compare affinities and transcriptional activities of <e1>adapalene</e1> and tretinoin for the nuclear transcription factors, retinoic acid receptors (<e2>RARs</e2>).","Regulator"
"The <e2>nuclear gene transcription factors</e2> RAR beta and RAR gamma mediate the retinoid activity of <e1>adapalene</e1>.","Regulator"
"The nuclear gene transcription factors <e2>RAR beta</e2> and RAR gamma mediate the retinoid activity of <e1>adapalene</e1>.","Regulator"
"The nuclear gene transcription factors RAR beta and <e2>RAR gamma</e2> mediate the retinoid activity of <e1>adapalene</e1>.","Regulator"
"On the contrary, pretreatment with <e1>5-HT</e1> worsened ethanol-induced erosions, however, did not affect gastric mucus secretion, <e2>glycoprotein</e2> content or PGE2 levels, although the non-protein SH fraction was significantly decreased.","Not"
"On the contrary, pretreatment with 5-HT worsened <e1>ethanol</e1>-induced erosions, however, did not affect gastric mucus secretion, <e2>glycoprotein</e2> content or PGE2 levels, although the non-protein SH fraction was significantly decreased.","Regulator"
"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of <e1>5-HT</e1>4 and 5-HT1 receptors and <e2>5-HT2</e2> antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Regulator"
"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of <e1>5-HT</e1>4 and <e2>5-HT1</e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Regulator"
"This study was designed to determine the gastroprotective properties of <e1>cinitapride</e1> (CNT), a novel prokinetic benzamide derivative agonist of <e2>5-HT4</e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Agonist"
"This study was designed to determine the gastroprotective properties of <e1>cinitapride</e1> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and <e2>5-HT1</e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Agonist"
"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>benzamide</e1> derivative agonist of <e2>5-HT4</e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Agonist"
"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>benzamide</e1> derivative agonist of 5-HT4 and <e2>5-HT1</e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Agonist"
"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CNT</e1>), a novel prokinetic benzamide derivative agonist of <e2>5-HT4</e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Agonist"
"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CNT</e1>), a novel prokinetic benzamide derivative agonist of 5-HT4 and <e2>5-HT1</e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Agonist"
"This study was designed to determine the gastroprotective properties of <e1>cinitapride</e1> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>5-HT2</e2> antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Antagonist"
"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>benzamide</e1> derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>5-HT2</e2> antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Antagonist"
"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CNT</e1>), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>5-HT2</e2> antagonist, on mucosal injury produced by 50% (v/v) ethanol.","Antagonist"
"We have identified <e2>adenosine deaminase</e2>, an enzyme involved in <e1>purine</e1> metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.","Substrate"
"<e1>Alendronate</e1> inhibited PTPmeg1 with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit <e2>PTP epsilon</e2> at concentrations up to 1 mM.","Not"
"<e2>PTP</e2> inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a <e1>cysteine</e1> residue are required for full inhibition.","Part_of"
"Here we report that <e1>alendronate</e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>PTP</e2>meg1).","Regulator"
"The hydrolysis of fluorescein diphosphate by <e2>PTP epsilon</e2> and PTPmeg1 was sensitive to <e1>alendronate</e1>, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.","Regulator"
"Here we report that <e1>alendronate</e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>PTPmeg1</e2>).","Regulator"
"Here we report that <e1>alendronate</e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>PTP</e2>meg1).","Regulator"
"<e2>PTP</e2> inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent <e1>EDTA</e1>, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.","Regulator"
"<e2>PTP</e2> inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent <e1>dithiothreitol</e1>, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.","Regulator"
"Here we report that <e1>alendronate</e1> is a potent inhibitor of the <e2>protein-tyrosine-phosphatase-meg1</e2> (PTPmeg1).","Downregulator"
"Here we report that <e1>alendronate</e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>PTPmeg1</e2>).","Downregulator"
"Here we report that <e1>alendronate</e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>PTPmeg1</e2>).","Downregulator"
"Among the other <e1>bisphosphonates</e1> studied, alendronate was more potent and selective for <e2>PTPmeg1</e2>.","Downregulator"
"Here we report that <e1>alendronate</e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>PTPmeg1</e2>).","Downregulator"
"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to <e1>alendronate</e1>, with IC50 values of less than 1 microM; <e2>PTPsigma</e2>, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.","Downregulator"
"<e1>Alendronate</e1> inhibited <e2>PTPmeg1</e2> with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.","Downregulator"
"<e1>Alendronate</e1> inhibited PTPmeg1 with an IC50 value of 23 microM, <e2>PTPsigma</e2> with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.","Downregulator"
"<e1>Alendronate</e1> inhibition of <e2>protein-tyrosine-phosphatase-meg1</e2>.","Downregulator"
"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to <e1>alendronate</e1>, with IC50 values of less than 1 microM; <e2>PTPs</e2>igma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.","Downregulator"
"<e2>PTP</e2> inhibition by <e1>hisphosphonates</e1> or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.","Downregulator"
"<e2>PTP</e2> inhibition by hisphosphonates or <e1>vanadate</e1> was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.","Downregulator"
"Here we report that <e1>alendronate</e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>PTP</e2>meg1).","Downregulator"
"The hydrolysis of fluorescein <e1>diphosphate</e1> by <e2>PTP epsilon</e2> and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.","Substrate"
"The hydrolysis of fluorescein <e1>diphosphate</e1> by PTP epsilon and <e2>PTPmeg1</e2> was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.","Substrate"
"The two receptors were discriminated by <e1>butaprost</e1>, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the <e2>EP4</e2> receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.","Not"
"The two receptors were discriminated by butaprost, <e1>AH-13205</e1> and AH-6809 that bound to the EP2 receptor but not to the <e2>EP4</e2> receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.","Not"
"The two receptors were discriminated by butaprost, AH-13205 and <e1>AH-6809</e1> that bound to the EP2 receptor but not to the <e2>EP4</e2> receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.","Not"
"The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the <e2>EP2</e2> receptor but not to the EP4 receptor, and by <e1>1-OH-PGE1</e1> that bound to the EP4 but not to the EP2 receptor.","Not"
"<e1>16,16-dimethyl-PGE2</e1> and two putative <e2>EP1</e2> antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor.","Not"
"16,16-dimethyl-PGE2 and two putative <e2>EP1</e2> antagonists, <e1>AH6809</e1> and SC-19220, did not show any significant binding to this receptor.","Not"
"16,16-dimethyl-PGE2 and two putative <e2>EP1</e2> antagonists, AH6809 and <e1>SC-19220</e1>, did not show any significant binding to this receptor.","Not"
"The two receptors were discriminated by <e1>butaprost</e1>, AH-13205 and AH-6809 that bound to the <e2>EP2</e2> receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.","Regulator"
"The two receptors were discriminated by butaprost, <e1>AH-13205</e1> and AH-6809 that bound to the <e2>EP2</e2> receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.","Regulator"
"The two receptors were discriminated by butaprost, AH-13205 and <e1>AH-6809</e1> that bound to the <e2>EP2</e2> receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.","Regulator"
"The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the <e2>EP4</e2> receptor, and by <e1>1-OH-PGE1</e1> that bound to the EP4 but not to the EP2 receptor.","Regulator"
"The <e2>EP3</e2> receptor showed the broadest binding profile, and bound <e1>sulprostone</e1>, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.","Regulator"
"<e1>M&B-28767</e1>, a putative <e2>EP3</e2> agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.","Regulator"
"The <e2>EP3</e2> receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, <e1>GR63799X</e1>, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.","Regulator"
"The <e2>EP3</e2> receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, <e1>11-deoxy-PGE1</e1>, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.","Regulator"
"The <e2>EP3</e2> receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, <e1>16,16-dimethyl-PGE2</e1> and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.","Regulator"
"The <e2>EP3</e2> receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and <e1>17-phenyl-PGE2</e1>, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.","Regulator"
"The <e2>EP1</e2> receptor bound <e1>17-phenyl-PGE2</e1>, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM.","Regulator"
"The <e2>EP3</e2> receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-<e1>PGE2</e1> and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.","Regulator"
"The <e2>EP3</e2> receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-<e1>PGE1</e1>, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.","Regulator"
"The DP, <e2>IP</e2> and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, <e1>iloprost</e1> and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.","Regulator"
"In addition, three <e2>IP</e2> ligands, iloprost, <e1>carbacyclin</e1> and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.","Regulator"
"In addition, three <e2>IP</e2> ligands, iloprost, carbacyclin and <e1>isocarbacyclin</e1>, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.","Regulator"
"In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one <e2>TP</e2> ligand, <e1>STA2</e1>, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.","Regulator"
"The <e2>EP1</e2> receptor bound 17-phenyl-PGE2, <e1>sulprostone</e1> and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM.","Regulator"
"The <e2>EP1</e2> receptor bound 17-phenyl-PGE2, sulprostone and <e1>iloprost</e1> in addition to PGE2 and PGE1, with Ki values of 14-36 nM.","Regulator"
"The <e2>DP</e2>, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as <e1>PGD2</e1>, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.","Regulator"
"The <e2>DP</e2>, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, <e1>BW245C</e1> and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.","Regulator"
"The <e2>DP</e2>, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and <e1>BW868C</e1> for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.","Regulator"
"The DP, <e2>IP</e2> and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, <e1>cicaprost</e1>, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.","Regulator"
"The DP, <e2>IP</e2> and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, <e1>iloprost</e1> and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.","Regulator"
"The DP, <e2>IP</e2> and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and <e1>isocabacyclin</e1> for IP, and S-145, I-BOP and GR 32191 for TP.","Regulator"
"The <e2>EP1</e2> receptor bound 17-phenyl-<e1>PGE2</e1>, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM.","Regulator"
"The DP, IP and <e2>TP</e2> receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and <e1>S-145</e1>, I-BOP and GR 32191 for TP.","Regulator"
"The DP, IP and <e2>TP</e2> receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, <e1>I-BOP</e1> and GR 32191 for TP.","Regulator"
"The DP, IP and <e2>TP</e2> receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and <e1>GR 32191</e1> for TP.","Regulator"
"The <e2>FP receptor</e2> bound <e1>PGF2</e1> alpha and fluprostenol with Ki values of 3-4 nM.","Regulator"
"The <e2>FP receptor</e2> bound PGF2 alpha and <e1>fluprostenol</e1> with Ki values of 3-4 nM.","Regulator"
"The <e2>EP1</e2> receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and <e1>PGE1</e1>, with Ki values of 14-36 nM.","Regulator"
"<e1>M&B-28767</e1>, a putative <e2>EP3</e2> agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.","Agonist"
"M&B-28767, a putative EP3 agonist, and <e1>misoprostol</e1>, a putative <e2>EP2</e2>/EP3 agonist, also bound to this receptor with Ki values of 120 nM.","Agonist"
"M&B-28767, a putative <e2>EP3</e2> agonist, and <e1>misoprostol</e1>, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.","Agonist"
"16,16-dimethyl-PGE2 and two putative <e2>EP1</e2> antagonists, <e1>AH6809</e1> and SC-19220, did not show any significant binding to this receptor.","Antagonist"
"16,16-dimethyl-PGE2 and two putative <e2>EP1</e2> antagonists, AH6809 and <e1>SC-19220</e1>, did not show any significant binding to this receptor.","Antagonist"
"Thymidine kinase from Herpes simplex virus type 1 (<e2>TK</e2>) was crystallized in an <e1>N</e1>-terminally truncated but fully active form.","Part_of"
"The structures of <e2>TK</e2> complexed with <e1>ADP</e1> at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.","Regulator"
"<e2>Thymidine kinase</e2> from Herpes simplex virus type 1 (TK) was crystallized in an <e1>N</e1>-terminally truncated but fully active form.","Regulator"
"The <e2>human ether-a-go-go-related gene</e2> (HERG), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of <e1>cisapride</e1>.","Regulator"
"Blockage of the <e2>HERG</e2> human cardiac K+ channel by the gastrointestinal prokinetic agent <e1>cisapride</e1>.","Regulator"
"Blockage of the <e2>HERG</e2> human cardiac K+ channel by the gastrointestinal prokinetic agent <e1>cisapride</e1>.","Downregulator"
"Blockage of the <e2>HERG</e2> human cardiac K+ channel by the gastrointestinal prokinetic agent <e1>cisapride</e1>.","Downregulator"
"Blockage of the <e2>HERG human cardiac K+ channel</e2> by the gastrointestinal prokinetic agent <e1>cisapride</e1>.","Downregulator"
"Blockage of the <e2>HERG</e2> human cardiac K+ channel by the gastrointestinal prokinetic agent <e1>cisapride</e1>.","Downregulator"
"Blockage of the <e2>HERG</e2> human cardiac K+ channel by the gastrointestinal prokinetic agent <e1>cisapride</e1>.","Downregulator"
"Blockage of the <e2>HERG</e2> human cardiac K+ channel by the gastrointestinal prokinetic agent <e1>cisapride</e1>.","Downregulator"
"<e2>NMDA receptors</e2> in postmortem human spinal cord were analyzed using <e1>[3H]MK-801</e1> ligand binding and immunoblotting with NMDA receptor subunit-specific antibodies.","Regulator"
"<e2>Monoamine transporter</e2> and sodium channel mechanisms in the rapid pressor response to <e1>cocaine</e1>.","Regulator"
"Monoamine transporter and <e2>sodium channel</e2> mechanisms in the rapid pressor response to <e1>cocaine</e1>.","Regulator"
"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter</e2> selectivities (<e1>BTCP</e1>, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.","Downregulator"
"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter</e2> selectivities (BTCP, <e1>indatraline</e1>, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.","Downregulator"
"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter</e2> selectivities (BTCP, indatraline, <e1>GBR 12935</e1>, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.","Downregulator"
"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter</e2> selectivities (BTCP, indatraline, GBR 12935, <e1>mazindol</e1>, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.","Downregulator"
"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter</e2> selectivities (BTCP, indatraline, GBR 12935, mazindol, <e1>nomifensine</e1>, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.","Downregulator"
"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter</e2> selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and <e1>zimeldine</e1>) either did not produce a rapid pressor response or produced only a small pressor response.","Downregulator"
"At nonconvulsant doses, the <e2>sodium channel</e2> blockers <e1>acetylprocainamide</e1>, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.","Downregulator"
"At nonconvulsant doses, the <e2>sodium channel</e2> blockers acetylprocainamide, <e1>dibucaine</e1>, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.","Downregulator"
"At nonconvulsant doses, the <e2>sodium channel</e2> blockers acetylprocainamide, dibucaine, <e1>dyclonine</e1>, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.","Downregulator"
"At nonconvulsant doses, the <e2>sodium channel</e2> blockers acetylprocainamide, dibucaine, dyclonine, <e1>prilocaine</e1>, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.","Downregulator"
"At nonconvulsant doses, the <e2>sodium channel</e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, <e1>proparacaine</e1>, quinidine, and tetracaine produced a small pressor response or no increase in BP.","Downregulator"
"At nonconvulsant doses, the <e2>sodium channel</e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, <e1>quinidine</e1>, and tetracaine produced a small pressor response or no increase in BP.","Downregulator"
"At nonconvulsant doses, the <e2>sodium channel</e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and <e1>tetracaine</e1> produced a small pressor response or no increase in BP.","Downregulator"
"Monoamine transporter and <e2>sodium channel</e2> mechanisms in the rapid pressor response to <e1>cocaine</e1>.","Downregulator"
"cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the <e2>dopamine receptor</e2> antagonist, <e1>SCH 23390</e1>.","Antagonist"
"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, <e1>levocabastine</e1>, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive <e2>neurotensin NT1 receptors</e2> (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Not"
"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that <e1>[3H]SR 142948A</e1> bound with similar affinities to both the levocabastine-insensitive <e2>neurotensin NT1</e2> receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Regulator"
"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that <e1>[3H]SR 142948A</e1> bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin <e2>NT2 receptors</e2> (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Regulator"
"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that <e1>[3H]SR 142948A</e1> bound with similar affinities to both the levocabastine-insensitive <e2>neurotensin NT1 receptors</e2> (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Regulator"
"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that <e1>[3H]SR 142948A</e1> bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive <e2>neurotensin NT2 receptors</e2> (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Regulator"
"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <e2>neurotensin receptors</e2>, <e1>[3H]SR 142948A</e1> (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.","Regulator"
"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, <e1>levocabastine</e1>, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive <e2>neurotensin NT2 receptors</e2> (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Regulator"
"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that <e1>[3H]SR 142948A</e1> bound with similar affinities to both the levocabastine-insensitive <e2>neurotensin NT1</e2> receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Antagonist"
"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that <e1>[3H]SR 142948A</e1> bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin <e2>NT2 receptors</e2> (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Antagonist"
"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <e2>neurotensin receptors</e2>, <e1>[3H]SR 142948A</e1> (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.","Antagonist"
"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <e2>neurotensin receptors</e2>, [3H]SR 142948A (<e1>2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride</e1>), in the rat brain.","Antagonist"
"Characterization of binding sites of a new <e2>neurotensin receptor</e2> antagonist, <e1>[3H]SR 142948A</e1>, in the rat brain.","Antagonist"
"Saturation and competition studies in the presence or absence of the <e2>histamine H1 receptor</e2> antagonist, <e1>levocabastine</e1>, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).","Antagonist"
"The <e1>retinoid</e1> action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors <e2>RAR beta</e2> and RAR gamma.","Regulator"
"The <e1>retinoid</e1> action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and <e2>RAR gamma</e2>.","Regulator"
"The <e1>retinoid</e1> action of adapalene are mediated by the <e2>ligand-activated gene transcription factors</e2> retinoic acid receptors RAR beta and RAR gamma.","Regulator"
"The retinoid action of <e1>adapalene</e1> are mediated by the ligand-activated gene transcription factors retinoic acid receptors <e2>RAR beta</e2> and RAR gamma.","Regulator"
"The retinoid action of <e1>adapalene</e1> are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and <e2>RAR gamma</e2>.","Regulator"
"The retinoid action of <e1>adapalene</e1> are mediated by the <e2>ligand-activated gene transcription factors</e2> retinoic acid receptors RAR beta and RAR gamma.","Regulator"
"Intrinsic, gating-independent <e1>DHP</e1> receptor binding affinity differences must be invoked to explain the isoform-specific sensitivity of the DHP block.","Regulator"
"We expressed cardiac or <e2>smooth muscle alpha1C</e2> subunits in combination with beta2a and alpha2/delta subunits in human embryonic kidney cells, and used 2 mM <e1>Ca2+</e1> as the permeant ion.","Regulator"
"Isoform-specific inhibition of <e2>L-type calcium channels</e2> by <e1>dihydropyridines</e1> is independent of isoform-specific gating properties.","Downregulator"
"<e1>Dihydropyridines</e1> (DHPs) block <e2>L-type Ca2+ channels</e2> more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.","Downregulator"
"We thus conclude that the more potent <e1>nisoldipine</e1> inhibition of smooth muscle versus <e2>cardiac L-type Ca2+ channels</e2> is not attributable to differences in channel inactivation or activation.","Downregulator"
"<e1>Nisoldipine</e1> (a DHP antagonist) blocks the <e2>smooth muscle channel</e2> more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.","Downregulator"
"Nisoldipine (a <e1>DHP</e1> antagonist) blocks the <e2>smooth muscle channel</e2> more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.","Downregulator"
"Dihydropyridines (<e1>DHPs</e1>) block <e2>L-type Ca2+ channels</e2> more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.","Downregulator"
"<e2>Methylenetetrahydrofolate reductase</e2> deficiency impairs <e1>methyltetrahydrofolate</e1> synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.","Substrate"
"Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of <e2>methionine synthase</e2> (CblE/G) are associated with defective <e1>methyl cobalamin</e1> synthesis.","Substrate"
"These results suggest that <e2>Cat3</e2> compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity <e1>arginine</e1> transport.","Substrate"
"The majority of <e1>L-Arg</e1> transport is mediated by <e2>System y+</e2>, although several other carriers have been kinetically defined.","Substrate"
"<e2>System y+</e2> cationic <e1>amino acid</e1> transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.","Substrate"
"Increased Cat3-mediated cationic <e1>amino acid</e1> transport functionally compensates in <e2>Cat1</e2> knockout cell lines.","Substrate"
"System y+ cationic <e1>amino acid</e1> transport is mediated by proteins encoded by a family of genes, Cat1, <e2>Cat2</e2>, and Cat3.","Substrate"
"Increased <e2>Cat3</e2>-mediated cationic <e1>amino acid</e1> transport functionally compensates in Cat1 knockout cell lines.","Substrate"
"However, the apparent affinity for <e1>lysine</e1> transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of <e2>Cat3</e2>-mediated transport.","Substrate"
"Increased <e2>Cat3</e2>-mediated cationic <e1>amino acid</e1> transport functionally compensates in Cat1 knockout cell lines.","Substrate"
"<e1>Lintitript</e1> markedly increased postprandial plasma <e2>CCK</e2> release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.","Upregulator"
"<e1>Lintitript</e1> markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial <e2>PP</e2> levels (P<0.01) as compared to placebo.","Downregulator"
"Effect of <e1>lintitript</e1>, a new <e2>CCK-A receptor</e2> antagonist, on gastric emptying of a solid-liquid meal in humans.","Antagonist"
"Effect of <e1>lintitript</e1>, a new <e2>CCK-A receptor</e2> antagonist, on gastric emptying of a solid-liquid meal in humans.","Antagonist"
"Effect of <e1>lintitript</e1>, a new <e2>CCK-A receptor</e2> antagonist, on gastric emptying of a solid-liquid meal in humans.","Antagonist"
"In addition, the betaAR-mediated inhibition of <e2>IFN-gamma</e2>, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular <e1>cyclic adenosine monophosphate</e1> (cAMP) levels.","Regulator"
"In addition, the betaAR-mediated inhibition of IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular <e1>cyclic adenosine monophosphate</e1> (cAMP) levels.","Regulator"
"In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and <e2>IL-3</e2> mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular <e1>cyclic adenosine monophosphate</e1> (cAMP) levels.","Regulator"
"In addition, the betaAR-mediated inhibition of IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular <e1>cyclic adenosine monophosphate</e1> (cAMP) levels.","Regulator"
"In addition, the betaAR-mediated inhibition of <e2>IFN-gamma</e2>, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (<e1>cAMP</e1>) levels.","Regulator"
"In addition, the betaAR-mediated inhibition of IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (<e1>cAMP</e1>) levels.","Regulator"
"In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and <e2>IL-3</e2> mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (<e1>cAMP</e1>) levels.","Regulator"
"In addition, the betaAR-mediated inhibition of IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (<e1>cAMP</e1>) levels.","Regulator"
"In addition, the <e2>betaAR</e2>-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular <e1>cyclic adenosine monophosphate</e1> (cAMP) levels.","Regulator"
"In addition, the <e2>betaAR</e2>-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (<e1>cAMP</e1>) levels.","Regulator"
"<e2>Concanavalin A</e2> (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol</e1> and by the selective beta2AR agonist fenoterol.","Regulator"
"Concanavalin A (<e2>Con A</e2>)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol</e1> and by the selective beta2AR agonist fenoterol.","Regulator"
"<e2>Concanavalin A</e2> (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>fenoterol</e1>.","Regulator"
"Concanavalin A (<e2>Con A</e2>)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>fenoterol</e1>.","Regulator"
"The observed inhibition on <e2>IFN-gamma</e2>, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist <e1>ICI 118,551</e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.","Upregulator"
"The observed inhibition on IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNA was blocked by the selective beta2AR antagonist <e1>ICI 118,551</e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.","Upregulator"
"The observed inhibition on IFN-gamma, GM-CSF, and <e2>IL-3</e2> mRNA was blocked by the selective beta2AR antagonist <e1>ICI 118,551</e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.","Upregulator"
"The observed inhibition on <e2>IFN-gamma</e2>, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>timolol</e1> (10(-6) M), a nonselective antagonist.","Upregulator"
"The observed inhibition on IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>timolol</e1> (10(-6) M), a nonselective antagonist.","Upregulator"
"The observed inhibition on IFN-gamma, GM-CSF, and <e2>IL-3</e2> mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>timolol</e1> (10(-6) M), a nonselective antagonist.","Upregulator"
"Concanavalin A (Con A)-induced IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol</e1> and by the selective beta2AR agonist fenoterol.","Upregulator"
"Concanavalin A (Con A)-induced IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol</e1> and by the selective beta2AR agonist fenoterol.","Upregulator"
"Concanavalin A (Con A)-induced <e2>IFN-gamma</e2>, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol</e1> and by the selective beta2AR agonist fenoterol.","Downregulator"
"Concanavalin A (Con A)-induced IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol</e1> and by the selective beta2AR agonist fenoterol.","Downregulator"
"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and <e2>IL-3</e2> mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol</e1> and by the selective beta2AR agonist fenoterol.","Downregulator"
"Concanavalin A (Con A)-induced <e2>IFN-gamma</e2>, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>fenoterol</e1>.","Downregulator"
"Concanavalin A (Con A)-induced IFN-gamma, <e2>GM-CSF</e2>, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>fenoterol</e1>.","Downregulator"
"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and <e2>IL-3</e2> mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>fenoterol</e1>.","Downregulator"
"Although <e2>beta3AR</e2> mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist <e1>BRL 37344</e1> had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.","Agonist"
"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective <e2>betaAR</e2> agonist <e1>isoproterenol</e1> and by the selective beta2AR agonist fenoterol.","Agonist"
"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective <e2>beta2AR</e2> agonist <e1>fenoterol</e1>.","Agonist"
"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective <e2>beta2AR</e2> antagonist <e1>ICI 118,551</e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.","Antagonist"
"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective <e2>beta2AR</e2> antagonist ICI 118,551 (10(-6) M) and by <e1>timolol</e1> (10(-6) M), a nonselective antagonist.","Antagonist"
"The selective <e2>beta1AR</e2> antagonist <e1>atenolol</e1> (0.3 x 10(-6) M) did not have any effect.","Antagonist"
"Only <e1>carbetocin</e1> bound to the renal <e2>vasopressin V2 receptor</e2> though the binding affinity was very low (61.3 +/- 14.6 nM).","Regulator"
"Both <e1>carbetocin</e1>, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial <e2>oxytocin receptor</e2> of a similar magnitude as oxytocin.","Regulator"
"Both <e1>carbetocin</e1>, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial <e2>oxytocin receptor</e2> of a similar magnitude as oxytocin.","Regulator"
"Both <e1>carbetocin</e1>, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial <e2>oxytocin receptor</e2> of a similar magnitude as oxytocin.","Regulator"
"Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial <e1>oxytocin</e1> receptor of a similar magnitude as oxytocin.","Regulator"
"<e2>Oxytocin receptor</e2> binding and uterotonic activity of <e1>carbetocin</e1> and its metabolites following enzymatic degradation.","Regulator"
"Metabolites of the analogue 1-deamino-1-carba-2-tyrosine(O-methyl)-<e2>oxytocin</e2> (<e1>carbetocin</e1>) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated.","Downregulator"
"Metabolites of the analogue 1-deamino-1-carba-2-tyrosine(O-methyl)-<e2>oxytocin</e2> (<e1>carbetocin</e1>) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated.","Downregulator"
"Metabolites of the analogue 1-deamino-1-carba-2-tyrosine(O-methyl)-<e2>oxytocin</e2> (<e1>carbetocin</e1>) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated.","Downregulator"
"Both <e1>carbetocin</e1>, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial <e2>oxytocin receptor</e2> of a similar magnitude as oxytocin.","Agonist"
"Both <e1>carbetocin</e1>, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial <e2>oxytocin receptor</e2> of a similar magnitude as oxytocin.","Antagonist"
"Both <e1>carbetocin</e1>, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial <e2>oxytocin receptor</e2> of a similar magnitude as oxytocin.","Antagonist"
"Both <e1>carbetocin</e1>, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial <e2>oxytocin receptor</e2> of a similar magnitude as oxytocin.","Antagonist"
"Crystallographic comparison with the structurally related <e2>rat tyrosine hydroxylase</e2> binary complex with the oxidized cofactor <e1>7,8-dihydrobiopterin</e1> revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.","Regulator"
"Crystallographic comparison with the structurally related <e2>rat tyrosine hydroxylase</e2> binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the <e1>catechols</e1> and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.","Regulator"
"Crystallographic analysis of the <e2>human phenylalanine hydroxylase catalytic domain</e2> with bound <e1>catechol</e1> inhibitors at 2.0 A resolution.","Downregulator"
"The <e2>aromatic amino acid hydroxylases</e2> represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by <e1>catechol</e1> derivatives.","Downregulator"
"Crystallographic comparison with the structurally related <e2>rat tyrosine hydroxylase</e2> binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the <e1>catechols</e1> and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.","Downregulator"
"Crystallographic analysis of the <e2>human phenylalanine hydroxylase</e2> catalytic domain with bound <e1>catechol</e1> inhibitors at 2.0 A resolution.","Downregulator"
"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (<e2>hPheOH</e2>), cocrystallized with various potent and well-known <e1>catechol</e1> inhibitors and refined at a resolution of 2.0 A.","Downregulator"
"Crystallographic comparison with the structurally related <e2>rat tyrosine hydroxylase</e2> binary complex with the oxidized cofactor <e1>7,8-dihydrobiopterin</e1> revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.","Cofactor"
"All GCs including the antagonistic compound <e1>RU486</e1> efficiently reduced NF-kappaB-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the <e2>GR</e2> is sufficient for transrepression.","Regulator"
"All GCs including the antagonistic compound <e1>RU486</e1> efficiently reduced <e2>NF-kappaB</e2>-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression.","Downregulator"
"Here, we report that <e1>Mg</e1>ATP and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to <e2>SUR1</e2>.","Not"
"Here, we report that MgATP and MgADP, but not the Mg salt of <e1>gamma-thio-ATP</e1>, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to <e2>SUR1</e2>.","Not"
"Mutation in the <e2>Walker A and B motifs</e2> of NBF2 of SUR1 abolished this stabilizing effect of <e1>MgADP</e1>.","Not"
"Mutation in the Walker A and B motifs of <e2>NBF2</e2> of SUR1 abolished this stabilizing effect of <e1>MgADP</e1>.","Not"
"Here, we report that MgATP and <e1>MgADP</e1>, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to <e2>SUR1</e2>.","Not"
"The K<e1>ATP</e1> channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two <e2>nucleotide-binding folds</e2> (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.","Regulator"
"The K<e1>ATP</e1> channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two nucleotide-binding folds (<e2>NBF1</e2> and NBF2) and the pore-forming Kir6.2 subunits.","Regulator"
"The K<e1>ATP</e1> channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and <e2>NBF2</e2>) and the pore-forming Kir6.2 subunits.","Regulator"
"Here, we report that MgATP and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound <e1>8-azido-[alpha-32P]ATP</e1> to <e2>SUR1</e2>.","Regulator"
"These results suggest that <e2>SUR1</e2> binds <e1>8-azido-ATP</e1> strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.","Regulator"
"These results suggest that SUR1 binds <e1>8-azido-ATP</e1> strongly at <e2>NBF1</e2> and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.","Regulator"
"Mutation in the Walker A and B motifs of <e2>NBF2</e2> of SUR1 abolished this stabilizing effect of <e1>MgADP</e1>.","Regulator"
"These results suggest that SUR1 binds <e1>8-azido-ATP</e1> strongly at <e2>NBF1</e2> and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.","Regulator"
"The <e1>sulfonylurea glibenclamide</e1> caused release of prebound 8-azido-[alpha-32P]ATP from <e2>SUR1</e2> in the presence of MgADP or MgATP in a concentration-dependent manner.","Regulator"
"Cooperative binding of <e1>ATP</e1> and MgADP in the <e2>sulfonylurea receptor</e2> is modulated by glibenclamide.","Regulator"
"Cooperative binding of ATP and <e1>MgADP</e1> in the <e2>sulfonylurea receptor</e2> is modulated by glibenclamide.","Regulator"
"Here, we report that MgATP and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound <e1>8-azido-[alpha-32P]ATP</e1> to <e2>SUR1</e2>.","Regulator"
"This direct biochemical evidence of cooperative interaction in <e1>nucleotide</e1> binding of the two <e2>NBFs</e2> of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.","Regulator"
"The KATP channel is a heterooligomeric complex of <e2>SUR1</e2> subunits of the ATP-binding-cassette superfamily with two <e1>nucleotide</e1>-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.","Regulator"
"This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that <e1>glibenclamide</e1> both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at <e2>NBF2</e2>, causes ATP to be released from NBF1.","Regulator"
"This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that <e1>glibenclamide</e1> both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from <e2>NBF1</e2>.","Regulator"
"The K<e1>ATP</e1> channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and <e2>NBF2</e2>) and the pore-forming Kir6.2 subunits.","Regulator"
"Mutation in the Walker A and B motifs of <e2>NBF2</e2> of SUR1 abolished this stabilizing effect of <e1>MgADP</e1>.","Regulator"
"Mutation in the Walker A and B motifs of <e2>NBF2</e2> of SUR1 abolished this stabilizing effect of <e1>MgADP</e1>.","Regulator"
"Although electrophysiological studies provide clues to the complex control of K<e1>ATP</e1> channels by ATP, MgADP, and pharmacological agents, the molecular mechanism of KATP-channel regulation remains unclear.","Regulator"
"Although electrophysiological studies provide clues to the complex control of <e2>KATP channels</e2> by ATP, <e1>MgADP</e1>, and pharmacological agents, the molecular mechanism of KATP-channel regulation remains unclear.","Regulator"
"Here, we report that <e1>MgATP</e1> and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to <e2>SUR1</e2>.","Regulator"
"Here, we report that MgATP and <e1>MgADP</e1>, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to <e2>SUR1</e2>.","Regulator"
"These results suggest that SUR1 binds 8-azido-ATP strongly at <e2>NBF1</e2> and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound <e1>MgATP</e1> at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.","Regulator"
"Cooperative binding of ATP and MgADP in the <e2>sulfonylurea receptor</e2> is modulated by <e1>glibenclamide</e1>.","Regulator"
"Here, we report that MgATP and <e1>MgADP</e1>, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to <e2>SUR1</e2>.","Regulator"
"Here, we report that <e1>MgATP</e1> and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to <e2>SUR1</e2>.","Regulator"
"The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of <e1>glucose</e1>-induced <e2>insulin</e2> secretion.","Upregulator"
"These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to <e2>NBF2</e2> or by hydrolysis of bound <e1>MgATP</e1> at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.","Substrate"
